<SEC-DOCUMENT>0001628280-23-009899.txt : 20230330
<SEC-HEADER>0001628280-23-009899.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330161149
ACCESSION NUMBER:		0001628280-23-009899
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		23780810

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>advm-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae,d:236e9599e5b144f29c9957366d735162--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:advm="http://www.adverum.com/20221231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-32">2022</ix:nonNumeric><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-34">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="i8bed3625ee4841a68ac96bda8ebe9177_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-278">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i45ec54c04d84453db0e4212c80ec2572_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="f-355">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab69acf8f9d429db4ac4733cd22a9d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i20aeecfa68cd4530b60c59a0f8477a8f_I20230317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e11c662ebe9427c840584ca1263d906_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia98f4b7178d44744a308df9113fa922c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82144f9591444e5dbe1046063aa7edbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0774ed7dc54340939b85fedaa67a5b8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee79c44eada9499d85b633f2d5c0e83f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd24dd771e86438c83b29d1f07868719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059429eb76cc4061a0c3fccafcd267c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i479b3dfe4e2b48c183d1c440a675b09f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60d5479647d45e18ebbb413a5d2f359_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4683d59050a46d488a4d745d0c261c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8533e6aac0c44366b466a894286f4fc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706bda682f144a76bbd7a778fd5eeafb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9ff81f454d4f60b51fbf6f6ce9d7dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d1a5fb7eac442c8bf23792e4bf1523_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>advm:segment</xbrli:measure></xbrli:unit><xbrli:context id="i684e262e9ebe4220803a5cdb770ac920_D20230101-20230313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42221aeca784751a0a89d6fafe201f0_I20230324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bed3625ee4841a68ac96bda8ebe9177_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810c20822d984eb08cf7c2a6a817d1df_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e8cdee9ec14b64b91e938377f4a543_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380b7914c06249359dda444f9905896a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54eacdfb353484d994e873fc23548a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82902a75a654473385cd736e75401243_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c540347f7d480aa180db7886e8a3cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd0467e9ac642549c95ec745a488287_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefcd45e58edd4850af86dc9fc5d90f70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icca48fc57d1d479e846c4f02530d15c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5bc35453d4b4041a9df0764848a0f84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib472aed618b34a9fb10288ae7ec8a856_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ec54c04d84453db0e4212c80ec2572_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0937b54576e43eab4b908ba3f5c3b29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472587f29eaa49539627aa26bffabf1a_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b54e278e394f4fbc12c82e6a092b94_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc976ddcd5540e0a8d7e01edfab9bdb_D20211101-20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2458438fba324e4195415ece6f14528d_I20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61a03128ef774adc862263af15bd7c04_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304bc2ab93974910a0151644d3112b48_I20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de68338a8dd4a03a318de90290ec9e5_I20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c92305224cd4ce19a716d33e9ed1949_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib049dd87d3c6476abb81eef9b3a27fff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib005f5973c44406db5dfb1279f382aab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06eefc307c154ccf97e8da306731dc67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28cb0293c25243c98f7ef6c87cf0e73d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7f5d6fc3404c4cb3ab45ed824eed4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95de8a0988824a368b39856bb0aae046_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5dd88652db04bfd85227e3af36299d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0015aff2417c4443ad4e068d9de3e0a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73428454c6a240dfba85f104a15e8855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d00999723f1430587e349be9d8235cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1498b295afbf4a4490855b8a8cdbb3cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f3cdcaa5c74c348159656932b0209d_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ac711d969d4dbfb2019544f7853129_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if279653acc6e4cd2badab9c5d64df217_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f60854b5a5740ef83803c7983ca8de5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970fe692f1ab49b9a0589b0c713af515_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eebdf1a70334e0bbfac1cd4e13e54d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a6c23a548c4172830b509bf8547103_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8538e8736e164287a7a89d9e822ddfd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8691ff06ffc1432cab9667187afd1df3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898f06f98a6748bab720765be614526a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a88b50331e3498db3de301a5215fd47_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f966046784044f3987ed481b7a376f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c7d5d67f5143b6ad282485c7c83751_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5777a3c4cf644a5aa6e2876e0e3e845_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28339715955e48b08119618310a60857_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i156af0396aec4513abe4f372a8df3dbb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7855e85faff848b484bde07a79723de6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18307b729fb84369a1680d708830e51b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7438ee3072e41e794bdd9191b73a3cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9a1719e37e4f70a2a084ceacc62892_I20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>advm:employee</xbrli:measure></xbrli:unit><xbrli:context id="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2fd438f1564243a91086e75afa936f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bfdbc3193a412788e21e1810c123f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f2b20caf244f849a37d4c8e8327f84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85786b5c81d343789ff2c120dd964eb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a146e7e34f3411f8b40f1773b7e8c0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c8589134e324d12b0bbaf1468c0b43a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f072761559d486f92055c7cfb714341_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96823e332fad42d4a1f4b9064d27f17e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada4fca2d20a473abfe9c9eaec73a105_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d6a4e6dcbf4891bbb8bcd22b37a13c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib724c14cbcfe4412b6c1ae8d4c5cc41f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaaa273c85484c7b8335ccf796b65072_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c09039c3df4bae937a95e6a7634f2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i236e9599e5b144f29c9957366d735162_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-36579</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">Adverum Biotechnologies, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">100 Cardinal Way</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">94063</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:CityAreaCode" id="f-14">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">656-9323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:TradingSymbol" id="f-17">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i4ab69acf8f9d429db4ac4733cd22a9d1_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-28">114.9</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market on June 30, 2022 of $1.20 per share.&#160;Shares of the registrant&#8217;s common stock held by each officer and director and each person known to the registrant to be affiliated with an officer or director have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;17, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i20aeecfa68cd4530b60c59a0f8477a8f_I20230317" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">100,559,291</ix:nonFraction>&#160;shares of common stock, par value $0.0001&#160;par value, outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-30" escape="true">Portions of the definitive proxy statement (the Proxy Statement) for the 2023 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 1, 2023, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_19">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_22">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_22">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_52">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_52">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_55">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_55">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_55">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_58">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_58">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_58">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_61">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_61">74</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_64">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_64">75</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_67">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_67">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_79">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_76">Reserved</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">]</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_76">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_82">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_82">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_112">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_112">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_115">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_115">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_115">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_190">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_190">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_190">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_193">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_193">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_193">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_196">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_196">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_196">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_199">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_199">105</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_202">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_202">106</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_205">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_205">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_205">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_208">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_208">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_208">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_211">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_211">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_211">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_214">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_214">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_214">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_217">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_217">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_217">106</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_220">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_220">107</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_223">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_223">Exhibit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_223"> and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_223">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_226">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_226">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_226">110</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_229">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_229">111</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, unless otherwise stated or the context otherwise indicates, references to &#8220;Adverum,&#8221; &#8220;Adverum Biotechnologies,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Adverum Biotechnologies, Inc., a Delaware corporation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum, the Adverum logo and other trademarks or service marks of Adverum that may appear in this Annual Report on Form 10-K are the property of Adverum. This Annual Report on Form 10-K contains additional trade names, trademarks, and service marks of other companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum does not intend its use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of Adverum by, these other companies, and all such third-party trade names, trademarks, and service marks are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to advance our viral vector manufacturing and delivery capabilities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our research and development expenses could fluctuate and may increase;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing or likelihood of regulatory submissions, designations and approvals;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to explore potential applications of our gene therapy platform in other indications in highly prevalent diseases;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the clinical effectiveness of our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the pricing and reimbursement of our product candidates, if approved;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectation regarding the potential market sizes for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intellectual property position;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding expenses, future revenue, our financial position, capital requirements, uses of cash and needs for additional financing and the period for which our cash resources will be sufficient to meet our operating requirements; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety, efficacy and projected development timeline and commercial potential of any product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in &#8220;Risk Factors Summary&#8221; below and under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not currently in compliance with Nasdaq&#8217;s continued listing standards, and if we are not able to regain compliance with Nasdaq&#8217;s continued listing standards our common stock may be delisted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 1.</span></div><div id="i236e9599e5b144f29c9957366d735162_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector evaluation, cassette engineering, and ocular IND-enabling nonclinical and clinical development. In addition, we have in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec (ADVM-022)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) IVT injections. Ixo-vec utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. Ixo-vec is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;) who are responsive to anti-VEGF therapy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of Ixo-vec in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. We completed enrollment for OPTIC in July 2020 and will continue to present updated efficacy, aflibercept protein levels and safety data from the trial through two years and into the extension study as we continue to follow our subjects for an additional three years for a total of five years.  To date, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#94;11 vg/eye (&#8220;2E11&#8221;) doses, including continuous stable aflibercept protein levels from 10 weeks to three years, maintenance to improvement in best-corrected visual acuity and central subfield thickness (&#8220;CST&#8221;), a measure of fluid in and beneath the retina, as well as a reduction in CST fluctuations. Ixo-vec has been generally well tolerated, with the most common adverse events being</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies have indicated that a 6 x 10&#94;10 vg/eye (&#8220;6E10&#8221;) dose has the potential to achieve therapeutic levels of aflibercept. In April 2022, we announced we received feedback from the FDA via a Type C meeting written response related to our planned Phase 2 trial of Ixo-vec in wet AMD. We requested the FDA&#8217;s feedback to ensure alignment with the regulatory agency ahead of filing the Investigational New Drug (&#8220;IND&#8221;) amendment for our Phase 2 trial, which IND amendment was submitted on May 26, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our Phase 2 LUNA (&#8220;LUNA&#8221;) trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec - 2E11, the lower dose used in the OPTIC trial, and a new, lower 6E10 dose - in up to 72 subjects with wet AMD. The LUNA trial will assess four new enhanced prophylactic corticosteroid regimens, including local corticosteroids and combinations of local and systemic corticosteroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (&#8220;Durezol&#174;&#8221;), dexamethasone intravitreal implant (&#8220;Ozurdex&#174;&#8221;), and a combination of either topical Durezol&#174; or IVT Ozurdex&#174; with oral prednisone.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses and will be conducted at approximately 40 sites in the U.S. and Europe. Four prophylactic corticosteroid regimens will be studied. The primary endpoints will be similar to the OPTIC trial and focus on mean change in best-corrected visual acuity and CST from baseline to one year, and incidence and severity of adverse events. Other endpoints will include aflibercept protein levels starting at 14 weeks, an interim efficacy and safety analysis at 26 weeks and will include a reduction in fluctuations in CST and in treatment burden. The study will also evaluate the effectiveness and tolerability of the prophylactic corticosteroid regimens.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we announced that the European Medicines Agency (&#8220;EMA&#8221;) has granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need and bring a major therapeutic advantage to patients.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. In November 2022, a PRIME kickoff meeting was held to initiate interaction with the EMA experts and to familiarize EMA with the product, development program, and planned regulatory strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and ocular gene therapies, regardless of route of administration, and is generally understood to be dose-related. Based on an extensive evaluation of data from all of our subjects treated with Ixo-vec and all of our nonclinical data by internal and external experts, we believe that utilizing the 2E11 and 6E10 doses, along with the new enhanced prophylactic corticosteroid regimens, which include local corticosteroids and a combination of local and systemic corticosteroids, will allow us to minimize post-prophylaxis inflammation in our trial subjects going forward. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of Ixo-vec in subjects with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this population with poorly controlled diabetes and micro vascular complications was identified in April of 2021. Consequently, we are no longer pursuing Ixo-vec for DME, nor are we evaluating the 6E11 dose in wet AMD. We have not seen similar subject safety concerns in any of our subjects at either the 2E11 dose in the INFINITY or OPTIC trials or the 6E11 dose in the OPTIC trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADVM-062</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8. In January 2022, we announced that the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by the absence of function in the L and the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. We are collaborating with the families of patients affected with BCM (BCM Families Foundation) to help advance our therapies. In an effort to prioritize Ixo-vec clinical development and focus on establishing gene therapy as a new standard of care for highly prevalent ocular diseases, we are in the process of identifying a suitable partner to further develop this product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Restructuring</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we announced we had taken measures to restructure our operations, including reductions in both headcount and expenses to prioritize Ixo-vec&#8217;s clinical development, and focus our pipeline strategy on certain highly prevalent ocular diseases. The restructuring was completed in the fourth quarter of 2022. We expect these restructuring measures will be sufficient to extend our cash runway into 2025. See, however, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy program into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations and financial condition for the year ended December&#160;31, 2022 were not significantly impacted by the COVID-19 pandemic. We are actively monitoring and managing our response to the COVID-19 pandemic and assessing actual and potential impacts to these areas. Please refer to the &#8220;Risk Factors&#8221; section for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations, and are committed to the health and safety of our employees and their families. We have reopened our offices to allow our employees more flexibility to mix virtual and in-person work and to advance our culture and corporate goals. We believe this will also enable greater balance and well-being of our employees. We continue to update our policies and implement new practices to align with the current guidance from state and federal governments and health authorities. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. To date, we believe we have experienced limited impact due to COVID-19 on our ongoing clinical programs, including the OPTIC and LUNA clinical trials. We are working closely with our clinical trial sites to monitor and attempt to address or limit the potential negative impacts of the evolving COVID-19 outbreak and the emergence of COVID-19 variants on subject safety, trial enrollment, continued participation and follow-up of subjects already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact future trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Supply Chain and Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously. The COVID-19 pandemic and other factors have adversely impacted the global supply chain for other supplies and materials which could impact our future operations. To mitigate against future potential delays in supplies and materials we use in our operations, including product supply, we are continuously implementing additional measures to address potential risks as we identify them, including securing additional supplies and manufacturing capacity reserve, which have resulted in additional expenses and may result in other additional expenses in the future. Given the uncertainty regarding the impact delays and disruption in the global supply chain may have on our operations, we are unable to quantify the ultimate impact on our future results at this time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strengths</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have the capabilities, resources, and expertise to enable Adverum to become a leading gene therapy company. These strengths include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry-leading development capabilities in AAV ocular gene therapy and AAV product optimization, including cassette engineering and vectorizing therapeutic biologics;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deep understanding of how immunogenicity impacts ocular gene therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a pipeline of gene therapy product candidates targeting the treatment of highly prevalent ocular diseases;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deep expertise developing and administering clinical trials with a focus on regulatory compliance in the U.S and Europe;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-house gene therapy manufacturing expertise, specifically in scalable process development, assay development, and GMP quality control;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maturing a portfolio of proprietary vectors with specific ocular cell tropism;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a robust patent portfolio; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an experienced leadership team with expertise in ophthalmology, gene therapy, drug development, regulatory approval and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to discover, develop, and commercialize novel gene therapies with the potential to treat patients living with highly prevalent ocular diseases. The key elements of our strategy to achieve this goal are to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Target large patient populations impacted by wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  There are approximately 20 million individuals worldwide living with wet AMD, and the incidence of new cases is expected to continue to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Develop a single intravitreal injection gene therapy treatment to relieve the burden of frequent, chronic injections and improve real-world vision and quality of life outcomes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our gene therapies are designed as a single, in-office IVT injection therapy to address the unmet needs of patients with highly prevalent ocular diseases. The current standards of care for wet AMD and other VEGF-mediated chronic retinal diseases require frequent injections for the duration of the disease. As an example, for wet AMD, a current standard-of-care treatment requires patients to receive IVT injections of anti-VEGF protein every 4-16 weeks. We believe that durable treatment to reduce injection frequency and improve long term visual outcomes is the largest unmet need for wet AMD patients and their caregivers. Lifetime need for frequent injections burdens patients, caregivers, healthcare providers and healthcare systems. Real world evidence shows reduction in patients&#8217; vision over time associated with insufficient treatment, and the persistence of macular fluid between anti-VEGF injections, including as a result of poor adherence to the frequent injection regimen. Furthermore, bolus anti-VEGF injections may result in fluctuations in macular fluid that have been shown to have negative impacts on visual outcomes over time. A gene therapy administered as a single, in-office IVT injection has the potential to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, minimize macular fluid and macular fluid fluctuation and improve vision outcomes for patients. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursue indications with well-defined clinical and regulatory paths where possible, to mitigate the development risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In wet AMD, we have selected an indication that has prior clinical validation, including established endpoints, standard-of-care administration methods, and defined regulatory paths. In wet AMD, aflibercept is an approved standard-of-care IVT injection treatment, and ADVM&#8209;022 utilizes our proprietary vector, AAV.7m8, designed to provide a codon optimized cassette of aflibercept through a single IVT injection.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advance our pipeline by moving our early-stage research assets into our development pipeline and leverage our industry-leading capabilities in AAV vector and cassette optimization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Integrating our AAV engineering, cassette optimization and innovation together with our manufacturing expertise, we have the capability to generate high-quality recombinant AAV products. By expanding our understanding of AAV-induced inflammation and the intersection of ocular and systemic inflammatory responses, we are better able to generate optimal prophylaxis strategies and best in class IVT products. We believe that this knowledge, together with ongoing discovery of improved ubiquitous and cell-specific promoters will improve our ability to create optimized AAV cassettes for ocular gene therapy. We plan to use this expertise to expand our pipeline and manage the life cycle of our novel gene therapies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Collaborate with partners to leverage our industry-leading AAV vector expertise and ocular vector development and product delivery capabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We explore opportunities to work collaboratively with potential new partners that may benefit from our capabilities and expertise in AAV vector development or may be interested in licensing our rare disease programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand our process development capabilities to support late-stage clinical trials and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing process is based on the Baculovirus/Sf9 production system, which has been used for a number of vaccines and recombinant protein therapies approved by the FDA and EMA, and is capable of producing large quantities of AAVs. Our strategy is to develop scalable processes to transfer to our global GMP contract manufacturers, providing a flexible manufacturing strategy to support a potential global supply. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gene Therapy Background</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy is a powerful treatment modality to address disease biology in a targeted and efficient way. With gene therapy, patients receive vectors encoding therapeutic genes, expressing a therapeutic protein or the functional version of a mutated protein. Instead of dosing patients with proteins or other therapies repeatedly over a long period, gene therapy offers the possibility of dosing once to achieve long-term, durable benefits. Once a patient&#8217;s cells are transduced with a gene, the cells are potentially able to continue to produce the therapeutic protein for years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to existing classes of protein or biologic therapies such as monoclonal antibodies and drug-antibody conjugates, gene therapy has taken a number of years to evolve from a research tool into a viable and compelling treatment modality. There have been several recent advances in gene therapy, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Substantial clinical data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Positive data from gene therapy clinical trials have been reported in a variety of indications, including hemophilia, spinal muscular atrophy, Sanfilippo syndrome, ornithine transcarbamylase deficiency, glycogen storage disease type 1a, sickle cell disease, Parkinson&#8217;s disease, and Duchenne muscular dystrophy, as well as several ocular diseases including biallelic RPE65 mutation-associated retinal dystrophy, choroideremia, Leber&#8217;s hereditary optic neuropathy, and X&#8209;linked retinitis pigmentosa.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Significant investment by biopharmaceutical companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The modality of gene therapy has received significant interest and investments by biopharmaceutical companies. Large, global biopharmaceutical companies, such as Astellas Pharma Inc., Biogen Idec Inc., Bristol-Myers Squib, CSL Behring, Daiichi Sankyo, Hoffmann-La Roche Ltd., Johnson &amp; Johnson, Novartis, and Regeneron have increased their investment in the gene therapy field. Additionally, pure-play gene therapy companies, such as 4D Molecular Therapeutics, Passage Bio, REGENXBIO Inc., Rocket Pharmaceuticals, Sangamo Therapeutics, Sarepta Therapeutics, Sio Gene Therapies, Solid Biosciences, and uniQure N.V. have attracted recent investment in this growing field.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Approval of cell and gene therapy products by regulatory authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FDA and EC have approved several cell and gene therapy products, including AAV vector-based gene therapy products, several of which are currently being marketed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Novel AAV Vector Optimization System</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next-generation discovery platform is based on vectors derived from AAV, which is a small, non-pathogenic virus, which carry a therapeutic DNA instead of the viral genes. The resulting vector is used to deliver a gene into a desired cell population, which when expressed, can provide sustained protein production. We believe AAV vectors offer numerous advantages over other viral and non-viral vector technologies used for gene therapy. These advantages, highlighted below, have the potential to allow AAVs to be safe, to be applicable for a variety of indications, and to exhibit long-term efficacy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Highly-efficient transfer of DNA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV vectors offer highly-efficient transfer of DNA to the patient.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-pathogenic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Naturally occurring and recombinant AAV are not known to cause disease in humans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-replicating.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Naturally occurring AAV is incapable of replication without co-infection of a helper virus such as adenovirus, herpes virus, or others. Recombinant AAV vectors used in our product candidates lack additional genes making them even less capable of replication.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Long-term expression.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Once incorporated into the host cell, AAV vectors can continue to drive expression of a therapeutic protein for years, making AAV-based gene therapy a compelling treatment modality for diseases requiring frequent chronic treatment regimens.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Low-integrating potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Recombinant AAV vector genomes remain mainly as stable non-integrating episomes, mitigating safety concerns associated with genomic integration.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Low inflammatory potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compared to other vectors used in direct gene therapy approaches, AAV vectors elicit relatively mild inflammatory reactions that may be mitigated with adequate corticosteroid prophylaxis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ability to transduce non-dividing cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV vectors can efficiently transduce non-dividing cells or slow-dividing cells such as retinal cells and hepatocytes, which allow production of the therapeutic protein at the site of the disease (e.g., wet AMD).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Approval of cell and gene therapy products by regulatory authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The FDA and EC have approved several cell and gene therapy products, including AAV vector-based gene therapy products, several of which are currently being marketed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAV-derived vectors are a leading vector used in gene therapy. According to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Gene Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AAV has been used in over 260 clinical trials as of January 2021. As effective as existing AAV vectors are in gene therapy, we believe there are opportunities for improvement. Naturally occurring AAV variants have evolved with particular characteristics, some of which remain and pose limitations to their use in gene therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To create next-generation vectors, we use a multi-step process known as directed evolution. Our directed evolution technology uses a library of engineered AAV capsid genes, which exhibit different properties and capabilities than naturally occurring AAVs. Once we have created an initial pool of millions of different AAVs, we screen the AAVs in the pool for novel properties, e.g., specific transduction of a particular cell type. Once capsids with desirable properties are identified, those capsids are screened to create a smaller pool of optimized vectors which are further screened until we have identified a select number of engineered AAVs with the characteristics we seek.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ixo-vec, Our Single Intravitreal Injection Gene Therapy Candidate for Treating &#8220;Wet AMD&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ixo-vec, formerly referred to as ADVM-022, is our lead gene therapy product candidate being developed for the treatment of patients with wet AMD who are responsive to anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) therapy of wet AMD.  Ixo-vec is designed to deliver long-term, durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-VEGF IVT injections. Ixo-vec utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach), or a medical device to deliver the gene therapy (supra-choroidal approach), Ixo-vec has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AAV.7m8 capsid was engineered from AAV2 by directed evolution to efficiently transduce retinal cells following a routine intravitreal injection. The vector carries a vector genome (&#8220;vg&#8221;) encoding a codon-optimized cDNA of the aflibercept protein, a current standard of care in wet AMD, under the control of a strong, ubiquitous expression cassette.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="advm-20221231_g1.gif" alt="advm-20221231_g1.gif" style="height:394px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe IVT injection of gene therapy offers substantial advantages compared to subretinal surgical administration of gene therapy, for the treatment of wet AMD:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IVT injection is a simple procedure performed during an office visit, and is the mode of administration for current standard-of-care therapies to treat patients with wet AMD; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In comparison, a surgical setting is required for subretinal injections, with the attendant risks associated with intraocular surgery and vitrectomy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Treating Patients with Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Age-related macular degeneration is a progressive disease affecting the retinal cells in the macula, the region of the retina at the back of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. In patients with wet AMD, the growth of abnormal blood vessels begin to invade the space between layers of cells in the retina. These new blood vessels are often leaky, which results in fluid and blood in the retina and causes vision loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. The incidence of new cases of wet AMD is expected to grow significantly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current standard of care therapy for wet AMD is chronic and requires frequent anti-VEGF injections for the duration of the disease. These are effective, but typically require eye injections every 4-16 weeks in order to maintain vision. Real-world evidence shows that this regimen can be difficult to adhere to for patients, caregivers, and healthcare systems, leading to undertreatment associated with persistent macular fluid as well as fluctuations of macular fluid, all resulting in loss of vision over time. We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advancing the Clinical Development of Ixo-vec for Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the Ixo-vec phase 1 clinical trial entitled &#8220;An Open Label Phase 1 Study of Ixo-vec (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration" (&#8220;OPTIC&#8221;) with the first subject dosed in November 2018. We received Fast Track designation from the FDA for Ixo-vec for wet AMD in September&#160;2018. The last subject completed the two-year OPTIC trial in June 2022. Most of the subjects have enrolled in a three-year extension study to continue to monitor safety and efficacy out to a total of five years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OPTIC trial was designed as a multi-center, open-label, Phase 1, dose-ranging safety trial of Ixo-vec in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment-experienced, and previously required frequent anti&#8209;VEGF injections to manage their wet AMD and to maintain functional vision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In OPTIC, subjects were dosed with a single IVT injection of Ixo-vec. Subjects in cohort 1 (n=6) were treated with a 6E11 dose of Ixo-vec. Subjects in cohort 2 (n=6) were treated with a three-fold 2E11 dose of Ixo-vec. Subjects in cohorts 1 and 2 received a 13-day tapering course of prophylactic oral corticosteroids following Ixo-vec administration. Subjects in cohort 3 (n=9) were treated with a 2E11 dose of Ixo-vec, and subjects in cohort 4 (n=9) were treated with a 6E11 dose of Ixo-vec. Subjects in cohorts 3 and 4 received a 6&#8209;week tapering course of prophylactic topical corticosteroids in place of the oral corticosteroids.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial was the safety and tolerability of Ixo-vec after a single IVT administration. Secondary endpoints include changes in best-corrected visual acuity (BCVA), measurement of central subfield thickness (&#8220;CST&#8221;, a measure of retinal thickness), as well as mean number of anti-VEGF supplemental injections and percentage of subjects needing anti-VEGF supplemental injections. Each subject enrolled was followed for a total of two years in OPTIC.</span></div><div style="text-align:center"><img src="advm-20221231_g2.gif" alt="advm-20221231_g2.gif" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Final 2-Year Analysis. *Subjects received prophylaxis of 60 mg oral prednisone for 6 days starting at Day &#8211;3 followed by 7-day taper. **Subjects received prophylaxis of QID difluprednate eye drops for 3 weeks starting at Day 1 followed by a 3-week taper. Final analysis includes all participants regardless of baseline neutralizing antibody titer. AAV, adeno-associated virus; AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IVT, intravitreal therapy; QID, four times daily; SD-OCT, spectral domain optical coherence tomography; NCT03748784.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In OPTIC, Ixo-vec showed a robust treatment response from both doses through 104 weeks. Subjects who received 6E11 of Ixo-vec, Cohorts 1 and 4, experienced a 98% reduction in annualized anti-VEGF injections and 80% remained supplemental anti-VEGF injection free. Subjects who received 2E11 of Ixo-vec, Cohorts 2 and 3, experienced an 80% reduction in annualized anti-VEGF injections and 53% remained supplemental anti-VEGF injection free. The last subject completed the OPTIC study in June 2022. We have initiated an extension study to continue to follow our subjects for an additional three years for a total of five years. Ixo-vec continues to be well tolerated with a favorable safety profile at both doses. We will continue to present updated efficacy, aflibercept protein levels and safety data as the subjects progress through the extension study. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphics below show selected data from OPTIC and the OPTIC long-term extension trial, including the 80% to 98% reduction in annualized anti-VEGF injections observed following Ixo-vec IVT injection; maintenance of continued aflibercept protein levels through three years post Ixo-vec injection; and maintenance of BCVA and CST through two years post Ixo-vec injection. We also present a case study showing that in a subject who had experienced high or fluctuating fluid and CST prior to receiving Ixo-vec, a single Ixo-vec IVT injection reduced absolute levels and fluctuations in fluid and CST through two years post injection.</span></div><div style="margin-top:6pt;text-align:center"><img src="advm-20221231_g3.gif" alt="advm-20221231_g3.gif" style="height:335px;margin-bottom:5pt;vertical-align:text-bottom;width:675px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Final 2-Year Analysis 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Annualized rate (Prior) = (number of IVTs in 12 months prior to Ixo-vec) / (days from the first IVT in the past 12 months to Ixo-vec / 365.25). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Annualized rate (Post) = (numbers of aflibercept IVTs since Ixo-vec) / (days from Ixo-vec to the last study follow-up / 365.25). </span></div><div style="margin-bottom:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NAb, neutralizing antibody; VEGF, vascular endothelial growth factor. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20221231_g4.gif" alt="advm-20221231_g4.gif" style="height:348px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Final 2-Year Analysis 2022. *Modeled based on Do et al. Retina 2020; 40:643-647.  ** Participant received supplemental aflibercept injections. Protocol amendment for aqueous sample collection for participants that consented. To isolate the effect of ADVM-022, samples that were collected within 2 months of supplemental aflibercept are not shown. </span></div><div style="margin-top:6pt;text-align:center"><img src="advm-20221231_g5.gif" alt="advm-20221231_g5.gif" style="height:386px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20221231_g6.gif" alt="advm-20221231_g6.gif" style="height:362px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:15pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data Cut: Feb 24, 2022. *No CST reading available at week 104. BCVA at week 104 was 58 letters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our Phase 2 LUNA trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec - 2E11, the lower dose used in the OPTIC trial, and a new, lower 6E10 dose - in up to 72 subjects with wet AMD. The LUNA trial will assess four new enhanced prophylactic corticosteroid regimens, including local corticosteroids and combinations of local and systemic corticosteroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (&#8220;Durezol&#174;&#8221;), dexamethasone intravitreal implant (&#8220;Ozurdex&#174;&#8221;), and a combination of either topical Durezol&#174; or IVT Ozurdex&#174; with oral prednisone.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses and will be conducted at approximately 40 sites in the U.S. and Europe. Four prophylactic corticosteroid regimens will be studied. The primary endpoints will be similar to the OPTIC trial and focus on mean change in best-corrected visual acuity and CST from baseline to one year, and incidence and severity of adverse events. Other endpoints will include aflibercept protein levels starting at 14 weeks, an interim efficacy and safety analysis at 26 weeks and will include a reduction in fluctuations in CST and in treatment burden. The study will also evaluate the effectiveness and tolerability of the prophylactic corticosteroid regimens.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Additional Programs</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonclinical Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVM-062 (AAV.7m8-L-opsin) is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8. In January 2022, we announced the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by the absence of function in the L and the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Ixo-vec and ADMV-062, we are currently conducting nonclinical studies on additional product candidates that we may advance in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Program Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to GenSight rights to use AAV.7m8 for GS030 gene therapy encoding channelrhodopsin protein. GenSight is conducting a phase I/II trial in retinitis pigmentosa in the U.S., France, and U.K., which began in October 2018. In October 2021, GenSight announced it had been granted Fast Track Designation by the FDA for GS030 and in February 2023, announced one-year safety data and efficacy signals from its PIONEER Phase I/II clinical trial for retinitis pigmentosa. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV vector manufacturing process is based on the Baculovirus Expression Vector System (&#8220;BEVS&#8221;), which has been used in a number of FDA- and EC-approved products. This approach is well suited for the production of large quantities of AAVs, as it takes advantage of the efficiency of viral infection coupled with the high density and scalability of insect cells grown in serum-free suspension cultures. Compared to the mammalian cell-based approaches commonly used in the field, our manufacturing process is designed to produce higher yields of vectors per manufacturing campaign in a cost-effective manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV manufacturing method is industrialized, highly scalable and ready for adaptation for commercial stage. We believe our process provides the following advantages over competing systems:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Industrial-scale biologics production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system can produce quantities of product required at commercial stage by incorporating scalable, well-established process steps used throughout the industry for biologic products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Safety advantages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system does not use mammalian cell cultures or tumorigenic cell lines, and the DNA sequences used to allow AAV vector production are inactive in mammalian cells, which lowers the risk of off-target expression from our products in humans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High yield and low cost.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because of its scalability, our BEVS system may allow the production of large quantities of AAV vectors, up to the 2000-liter scale. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High purity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system coupled with our proprietary downstream purification process produces a highly pure drug substance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:12.53pt">Precedent regulatory framework.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Several other vaccines and recombinant protein therapies have been approved using a manufacturing process similar to our BEVS technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products are manufactured using cell banks and a scalable process developed internally and externally that are transferred to approved Contract Manufacturing Organizations (&#8220;CMOs&#8221;). These CMOs produce investigational drugs under GMP conditions to support our clinical trials. High quality raw materials are purchased from various suppliers and are used throughout the manufacturing process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate new raw material suppliers, as well as additional CMOs, in order to provide manufacturing flexibility. As we prepare for larger, late-stage clinical trials and potential commercialization, we have in-house process development capabilities, allowing us to develop larger-scale processes for transfer to our global GMP contract manufacturers. We leverage GMP contract manufacturer partnerships for flexible clinical and future commercial supply. This strategy capitalizes on our internal AAV manufacturing expertise while providing both security, expandability and flexibility as we prepare to potentially deliver one of the first gene therapies for large indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new proprietary technologies and therapies and a strong emphasis on intellectual property. We believe that our single administration, intravitreal approach for the treatment of wet AMD, our AAV-based directed evolution platform, our nonclinical and clinical development experience, our gene therapy manufacturing experience and our expertise in the field of gene therapy provide us with competitive advantages. However, we face actual or potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as from academic institutions, governmental agencies, and public and private research institutions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gene therapy Ixo-vec for wet AMD utilizes a proprietary vector and is administered through a single intravitreal injection and will compete with a variety of therapies currently marketed and in development, including biologics, small molecules, long-acting delivery devices and gene therapy. The key factors that contribute to success of any approved product include safety profile, efficacy, durability, mode of administration and cost of goods. Existing anti-VEGF therapies are well-established therapies and are widely accepted by physicians, patients and third-party payers as the standard-of-care treatment of patients with wet AMD. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of a significant number of product candidates in development or recently approved for chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD, and we group them into five main categories:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar anti-VEGFs (e.g., FYB201);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bispecific / combination / add-on therapy for efficacy or durability improvement (e.g., Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (faricimab) and OPT-302);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation anti-VEGF for durability improvement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-acting delivery device / gene therapy to lower treatment frequency (e.g., RGX-314); and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other molecules that inhibit neovascularization in wet AMD (e.g., tyrosine kinase inhibitors).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several other companies with marketed products or products in development for the treatment of chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD. These companies include 4D Molecular Therapeutics, Bayer, Clearside Biomedical, EyePoint Pharmaceuticals, Hoffmann-La Roche Ltd., Novartis, Ocular Therapeutix, Regeneron and REGENXBIO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies, as well as competitors we may face, either alone or with their partners, for our other product candidates, may have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments, and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effective, or more effectively marketed and sold, than any treatment we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAV.7m8 License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In June 2013, we entered into an exclusive worldwide sublicensable license agreement with the Regents of University of California (&#8220;Regents&#8221;) to certain intellectual property related to improved AAV vectors, including the AAV.7m8 capsid. Under this license agreement, we are obligated to make certain de minimis license payments, certain milestone payments totaling up to $1.0 million upon reaching certain stages of development of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the licensed products for a first indication, and totaling up to $0.5 million for each subsequent indication for which licensed products are developed, for up to a maximum of two additional indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are obligated to pay Regents royalties on sales of licensed products in the low single-digits, subject to adjustments and minimum thresholds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, this agreement will be in effect on a country-by-country, licensed product-by-licensed product basis until the expiration of the last claim of the licensed intellectual property covering the manufacture, use, or sale of such product in such country. We may terminate this agreement in whole or in party by giving Regents 30 days&#8217; prior written notice. Regents may terminate this agreement for breach by us that remains uncured for 60 days, if we become insolvent, if we directly or through a third-party file a claim that a licensed patent right is invalid or unenforceable, or if we fail to meet or extend the date for meeting certain diligence milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GenSight Biologics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we entered into an agreement with GenSight Biologics (&#8220;GenSight&#8221;), in which we granted GenSight a non-exclusive license to our proprietary AAV.7m8 vector to develop gene therapy products to deliver certain therapeutic transgenes. Under the agreement, we are eligible to receive development, regulatory and commercial milestones. Also, we are eligible to receive low to mid-single digit royalties on sales of GenSight&#8217;s licensed products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GenSight is currently developing GS030, a gene therapy encoding channelrhodopsin protein which incorporates the AAV.7m8 capsid. GenSight is conducting a phase I/II trial with GS030 to treat retinitis pigmentosa in the U.S., France, and the U.K., which began in October 2018. In October 2021, GenSight announced it had been granted Fast Track Designation by the FDA for GS030 and in February 2023, announced one-year safety data and efficacy signals from its PIONEER Phase I/II clinical trial for retinitis pigmentosa. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo Therapeutics </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into an agreement with Lexeo Therapeutics (&#8220;Lexeo&#8221;), pursuant to which we granted Lexeo an exclusive license to the intellectual property rights, pre-clinical data and know how associated with our Friedrich&#8217;s Ataxia program. Under the agreement, we are eligible to receive development and commercial milestones and royalties related to sales of a product containing our licensed rights. Lexeo is currently developing LX2006, an adeno-associated virus mediated treatment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Virovek</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2011, we entered into an agreement with Virovek, Inc. (&#8220;Virovek&#8221;), in which we received a non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing AAV. Under the agreement, Virovek is entitled to certain license payments and low-single digit royalty payments. This license with Virovek continues in effect until expiration of the last-to-expire patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business. Additionally, we may rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity, and patent term extensions where available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; obtain regulatory exclusivity and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. In some cases, these rights may need to be enforced by third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2023, we own or license more than 365 issued patents that are still in force, including more than 35 issued U.S. patents and 11 European patents validated cumulatively in more than 245 countries, as well as more than 210 patent applications pending in the U.S. and foreign jurisdictions, three of which have been allowed. These numbers include more than 50 patents and 35 pending applications filed by or on behalf of universities which have granted us exclusive license rights to the technology. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business. We seek patent protection in the U.S. and abroad for a variety of technologies, including research tools and methods, AAV-based biological products, methods for treating diseases of interest and methods for manufacturing our AAV-based products. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel biological products. We seek protection, in part, through confidentiality and proprietary information agreements. We are a party to various other license agreements that give us rights to use specific technologies in our research and development.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company-owned Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own at least four patent families that are directed to AAV-based compositions and methods for treating or preventing eye diseases associated with neovascularization. Patents and applications in the first of these families relate to compositions and methods for the AAV-based delivery of anti-VEGF proteins, for use in treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, in patients who respond to anti-VEGF protein therapy. Nineteen patents in this family have issued in the U.S., elsewhere in North America, Europe and the Asia/Pacific region, and nine corresponding applications are pending in the U.S., elsewhere in North America, Europe, and the Asia/Pacific region. Patents in this family are generally expected to expire in 2033, subject to possible patent term adjustments and patent term extensions. Patents and applications in the second of these families relate to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver aflibercept. One issued European patent is validated in thirty-seven countries, seven patents are issued in North America, the Asia/Pacific region, Israel and South Africa, and at least thirteen corresponding applications are pending in the U.S., elsewhere in North America, Europe, and Asia/Pacific region.  Patents in this family are generally expected to expire in 2037, subject to possible patent term adjustment and patent term extensions. The third of these families contains granted applications in Europe (validated in 37 countries), Japan, and pending U.S. and corresponding foreign applications directed to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver ranibizumab. Patents that may eventually issue from this patent family, if any, are generally expected to expire in 2037, subject to possible patent term adjustments and patent term extensions.  The fourth family contains 27 pending applications, and is directed to methods of treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, with AAV.7m8-aflibercept. Patents that may eventually issue from this family, if any, are generally expected to expire in 2039 to 2041 subject to possible patent term adjustments and patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own eleven patent families that are directed to various aspects of our proprietary technology platform. Fourteen patents in these families have issued patents in the U.S., Europe, and the Asia/Pacific region, including one issued European patent validated in six countries, as well as at least forty-nine pending applications, including PCT applications or national phase applications in the U.S., elsewhere in North America, Europe, and the Asia/Pacific region. Patents that may eventually issue from these families, if any, are generally expected to expire between 2035 and 2041, subject to possible patent term extensions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both exclusive and non-exclusive licenses to patents directed to both compositions of matter and methods of use and to other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have exclusively licensed several families of patents and patent applications that relate to variant rAAV virions having desirable characteristics, such as increased infectivity, as well as novel methods to screen for such variants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One patent family directed to improved rAAV virions that we have exclusively licensed in the ocular field includes ten granted patents in the U.S., elsewhere in North America and Europe, including one European patent validated in three countries, as well as two pending patent applications in the U.S. The patents in this family are projected to expire between 2024 and 2029 in the U.S. and in 2024 elsewhere, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another patent family directed to improved rAAV virions that we have exclusively licensed includes three granted U.S. patents that are expected to expire in 2031, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third patent family that we have exclusively licensed includes claims directed to the novel AAV.7m8 vector, which allows delivery of transgenes to the retina via intravitreal injection, and which we utilize in our product candidate ADVM&#8209;022. This family includes at least fifty issued patents in the U.S., elsewhere in North America, Europe, Asia, and the Pacific, including a European patent validated in thirty-seven countries.  Seventeen corresponding applications are pending in the U.S. and elsewhere in North America, Europe, Asia and the Pacific. Patents that issue from this patent family are generally expected to expire in 2032, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also non-exclusively licensed rights to a patent family related to the Baculovirus/SF9 production system that includes eight issued patents in the U.S., Europe, and Asia, including a European patent validated in three countries. These patents are expected to expire in 2027.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively licensed a family of patents and applications related to the treatment of cardiomyopathy associated with Friedreich&#8217;s Ataxia. This family includes two patents granted in the U.S., one in New Zealand and fourteen pending applications in the U.S. and elsewhere in North America, Europe, Asia, and the Pacific. Patents that grant from this patent family are generally expected to expire in 2033, subject to possible patent term extensions and adjustments.  In January 2021, we granted an exclusive (even as to us) sublicense to this patent family, which does not relate to ADVM-022, to Lexeo Therapeutics.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secret Protection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some circumstances we may rely on trade secrets to protect aspects of our technology and product candidates, including aspects for which we do not obtain patent protection. We seek to protect our trade secrets and confidential information, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our confidential information and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. However, trade secrets can be difficult to protect. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Relating to Our Intellectual Property.&#8221; of this Annual Report on Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., biological products, including gene therapy products, are primarily regulated under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and the Public Health Service Act (&#8220;PHSA&#8221;), as well as corresponding implementing regulations promulgated by the FDA. These laws and regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, distribution, record keeping, reporting, advertising and promotion, export and import of biologics products. Prior to conducting human clinical testing of our gene therapy products, we must submit an investigational new drug application (&#8220;IND&#8221;) to the FDA, and the IND must be cleared by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies (&#8220;OTAT&#8221;). The FDA has also established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has published a growing body of guidance documents on topics relevant to the development of our product candidates, including, among other things: gene therapy products developed for retinal disorders and rare diseases; patient-focused drug development and nonclinical testing of gene therapy products; CMC information requirements for gene therapy; and observation of subjects involved in gene therapy studies for delayed adverse events. All of these guidance documents are intended to facilitate the industry&#8217;s development of gene therapy products. Guidance documents provide the FDA&#8217;s current thinking about a particular subject, but are not legally binding on either the FDA or the regulated industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before our product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of nonclinical laboratory tests, including evaluations of product chemistry, formulations, and toxicity and animal studies in accordance with current Good Laboratory Practice (&#8220;GLP&#8221;), regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission of an IND to the FDA, which must be cleared before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the independent institutional review board (&#8220;IRB&#8221;) of each clinical protocol and each clinical trial site before the trial may be initiated at that site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the institutional biosafety committee (&#8220;IBC&#8221;) of each clinical trial site, which assesses the safety of research involving, among other things, recombinant DNA, and identifies any potential risks to public health or the environment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generation of substantial evidence from human clinical trials, conducted in accordance with Good Clinical Practice (&#8220;GCP&#8221;) regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and potency of the biologic product for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a BLA for marketing approval that demonstrates adequate efficacy and acceptable safety profile of the biological product based on results of nonclinical testing and clinical trials, as well as providing information on the chemistry, manufacturing and controls to ensure product identity, purity, potency and quality, as well as proposed labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of each manufacturing facility at which the biologic product is produced, to assure that the product is produced in compliance with GMP, regulations, and any additional requirements made by the agency to assure that the methods and controls used during manufacturing are adequate to preserve the biological product&#8217;s safety, identity, strength, quality, purity, and potency;Successful completion of FDA audit(s) of the nonclinical and clinical trial sites and the clinical study sponsor that generated the data in support of the BLA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successful completion of the advisory committee review, if the FDA convenes an advisory committee; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment of user fees and FDA review and licensure of the BLA prior to any commercial marketing, sale or shipment of the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the nonclinical testing stage. Nonclinical tests include animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal regulations and requirements, including GLPs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical tests, together with manufacturing information, such as laboratory evaluation of product chemistry, formulation, and stability, as well as any available clinical data or literature and a proposed clinical trial protocol, are submitted as part of an IND to the FDA. Some nonclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions relating to the content of the IND during the review period or places the clinical study on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND goes into effect and the clinical trial begins. The FDA can impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold on an IND, clinical trials may not commence or proceed without FDA authorization, and then only under terms authorized by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve administering of the investigational biological product candidate to human subjects under the supervision of qualified investigators, who are generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur, and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. An independent IRB, and IBC, at each institution where the clinical trial will be conducted must also review and approve the plan for any clinical trial before it can begin at that institution, and the IRB must monitor the clinical trial until it is completed. For certain types of research, including research involving recombinant DNA, the IBC will also assess the safety of the research and identify any potential risk to public health or the environment, until the research is completed. Clinical testing also must satisfy GCP requirements, including the requirements for informed consent from all subjects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical research performed in the United States (&#8220;U.S.&#8221;) in support of a BLA must be authorized in advance by the FDA as described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the FDA will accept a well-designed, well-conducted, non-IND foreign clinical trial as support for a BLA if (i) the clinical trial was conducted in accordance with GCP as further detailed in the regulation, including review and approval by an independent ethics committee, and (ii) if the FDA is able to validate the data from the clinical trial through an onsite inspection, if necessary. In addition, when an applicant submits data from a foreign clinical trial not conducted under an IND to support a BLA, the FDA requires a description of the actions the applicant took to ensure that the research conformed to GCP. Further, additional requirements apply when a sponsor intends to base marketing approval of a new drug solely on foreign clinical data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or healthy volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. In the case of some product candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients. Phase 1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials are typically conducted in a larger subject population than Phase 1 trials to evaluate dosage tolerance and appropriate dosage, identify possible adverse effects and safety risks, and to preliminarily evaluate the efficacy of the product candidate for specific targeted indications. For Phase 2 clinical trials in gene therapy, although the subject population may be larger than the Phase 1 trials, the subject population may still remain relatively limited.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials are typically conducted when Phase 2 clinical trials demonstrate that a dose range of the biological product candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken with large numbers of subjects, to provide substantial evidence of clinical efficacy, and to further test for safety in an expanded and diverse subject population at multiple, geographically-dispersed clinical trial sites. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product candidate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional data from the treatment of patients in the intended therapeutic indication, particularly for long-term safety.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for any serious and unexpected adverse event that occurs during the study, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the clinical protocol or Investigator&#8217;s Brochure, as well as any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects from the product candidate. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor's initial receipt of the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the biological product has been associated with unexpected serious harm to patients. Similar rules govern the conduct of clinical trials in the European Economic Area (&#8220;EEA&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the U.S., the various phases of nonclinical and clinical research in the European Union (&#8220;EU&#8221;) are subject to significant regulatory controls. Previously, in the EU, pursuant to the EU Clinical Trials Directive 2001/20/EC, a clinical trial application had to be submitted to each country&#8217;s national regulatory authority in which the clinical trial was to take place, together with an independent ethics committee, much like the FDA and IRB, respectively. Although the Directive sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive in a manner that is often not uniform. This led to variations in the rules governing the conduct of clinical trials in the individual EU Member States. In 2014, a new Clinical Trials Regulation 536/2014, replacing the current Directive, was adopted. The new Regulation is directly applicable in all EU Member States (without national implementation) and entered into application on 31 January 2022. The new Regulation seeks to simplify and streamline the approval of clinical trials in the EU. Pursuant to the Regulation, the sponsor shall submit a single application for approval of a clinical trial via the EMA's Clinical Trials Information System, or CTIS, which will cover all regulatory and ethics assessments from the member states concerned. Any submissions made from January 31, 2023 onwards must be made through CTIS and all trials authorized pursuant to the Directive that are still ongoing on January 31, 2025 must be made through CTIS. Once the CTA is approved in accordance with a member state's requirements, clinical trial development may proceed. Approval and monitoring of clinical trials in the EU is, as it was under the Directive, the responsibility of individual member states, but compared to the position prior to the applicability of the Clinical Trials Regulation there is likely to be more collaboration, information-sharing, and decision-making between member states. The new Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements, such as mandatory submission of a summary of the clinical trial results to a new EU database. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the National Institutes of Health (&#8220;NIH&#8221;) developed a publicly accessible database, the Genetic Modification Clinical Research Information System, designed to facilitate safety reporting. The database includes information on gene transfer studies and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper nonclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for up to 5-years for nonintegrating vectors such as AAV vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The responsible party for an applicable clinical trial must register the clinical trial in Phase 2 or later on the ClinicalTrials.gov website, including the registry of new, on-going, and completed clinical trials of drugs, biologics, and device products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics License Applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical studies and clinical trial(s), together with detailed information on the quality of the product, are submitted to the FDA in the form of a BLA requesting approval to market the product for one or more specified indications. The submission of a BLA must be accompanied by a substantial user fee unless a waiver applies, and is subject to a sixty-day filing review period to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA has a performance goal to review applications within 6 months from successful filing of the application for priority reviews or 10 months for standard reviews. The review timeline begins upon the FDA&#8217;s acceptance of the original application submission for filing, no later than 60 calendar days from the date the FDA receives the application. In some instances, the review process and the PDUFA goal date may be extended depending on the information required in order for the FDA reviewers to complete their review of the BLA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny licensure of a BLA by issuing a complete response letter if the applicable statutory and regulatory criteria are not satisfied, and may require additional clinical data or an additional Phase 3 clinical trial. Even if a product receives licensure, the licensure may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited or subject to Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;), which could restrict the commercial value of the product. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA licenses a BLA, or supplement thereto, the FDA may withdraw the licensure if ongoing regulatory requirements are not met or if safety problems are identified after the product reaches the market. Even where a withdrawal is not required, the FDA still may seize existing inventory of such product or require a recall of product already on the market. In addition, the FDA may require testing, including Phase 4 clinical trials and surveillance programs to monitor the effect of licensed biologics that have been commercialized. The FDA has the authority to prevent or limit further marketing of a biologic based on the results of these post-marketing programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the sponsor to develop additional data or conduct additional nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before licensing a BLA, the FDA will inspect the facilities at which the biologic is manufactured and will not license the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements. The FDA may also inspect the site(s) at which the clinical trials were conducted to assess their GCP compliance and will not approve the product unless compliance with the IND study requirements and GCP requirements is satisfactory. The FDA may also inspect the facilities of the sponsor to ensure that processes and procedures are in compliance with GMP/GCP requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, certain changes to the approved product, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval. Depending on the nature of the change proposed, a BLA supplement must be filed and approved before the change may be implemented. For many proposed post-approval changes to a BLA that include new efficacy data, the FDA intends to review and act on the supplemental application within 10 months of receipt. As with new BLAs, the review process is often significantly extended by FDA requests for additional information or clarification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product approved under section 351(a) of the PHSA (a &#8220;reference product&#8221;) can receive 12 years of marketing exclusivity, four years of which constitute data exclusivity. In other words, no biosimilar application that cites the reference product can be submitted to the FDA until four years after approval of the reference product, and no biosimilar application that cites the reference product can be approved during the full 12-year period. These exclusivity provisions only apply to biosimilars&#8212;companies that rely on their own data and file a full BLA may be approved earlier than 12 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA (which is comprised of 27 Member States of the EU plus Norway, Iceland, and Liechtenstein), medicinal products can only be commercialized after a related Marketing Authorization, or MA, has been granted. Marketing authorization for medicinal products can be obtained through several different procedures. These are through a centralized, mutual recognition procedure, decentralized procedure, or national procedure (if marketing authorization is sought for a single EU Member State). The centralized procedure allows a company to submit a single application to the EMA. If a related positive opinion is provided by the EMA, the EC will grant a centralized marketing authorization that is valid in all 27 EU Member States and three of the four European Free Trade Associations, or EFTA, countries (Norway, Iceland, and Liechtenstein) all of whom make up the EEA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, advance therapy medicinal products such as gene therapy, orphan medicinal products, regenerative medicinal products, and medicinal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance that is not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or for which grant of centralized marketing authorization is in the interest of patients at EU level in the EU.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized authorization procedure permits companies to file identical applications for authorization to several EU Member States simultaneously for a medicinal product that has not yet been authorized in any EU Member State. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant marketing authorization for their territories on the basis of this assessment. The only exception to this is where an EU Member State considers that there are concerns of potential serious risk to public health related to authorization of the product. In these circumstances, the matter is submitted to the Heads of Medicines Agencies, or Co-ordination Group for Mutual Recognition and Decentralised procedures - Human, for review. The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biological products authorized according to the centralized authorization procedure are entitled to eight years&#8217; data exclusivity and 10 years&#8217; market exclusivity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure for approval of biosimilars following expiry of exclusivity differs from that for generic medicinal products. Developers of biosimilars must demonstrate through comprehensive comparability studies with the &#8220;reference&#8221; biological medicine that their biosimilar product is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines and that there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has provided guidance to sponsors developing regenerative medicine therapies for serious or life-threatening diseases or conditions, with recommendations on the expedited development and review of these therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast track designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for fast track designation, a product candidate must be intended to treat a serious condition and address an unmet medical need. Advantages of fast track designation include the possibility for a rolling review, eligibility for priority review, and the ability to have greater interactions with the FDA. In addition, under the Fast Track program and the FDA&#8217;s accelerated approval regulations, the FDA may approve a biologic product based on a surrogate endpoint. A surrogate endpoint is a measurement of laboratory or clinical signs of a disease or conditions that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more easily or more rapidly than clinical endpoints. A biologic product candidate approved using a surrogate endpoint is subject to rigorous post-marketing compliance requirements, including the completion of post-approval clinical trials to confirm the beneficial effect on a clinical endpoint. Failure to conduct or to confirm a clinical benefit during these required trials may result in FDA withdrawal of the approved biologic product from the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for marketing approval, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation, priority review designation, and accelerated approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for the breakthrough therapy program, a product candidate must be intended to treat a serious condition, and have preliminary clinical data indicating that it provides a substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross&#8209;disciplinary review; and rolling review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To qualify for the RMAT designation, a product candidate must be a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and there must be preliminary clinical evidence that the candidate has the potential to address the unmet medical need. The FDA has indicated that gene therapies may qualify as regenerative medicine therapies. Advantages of RMAT designation include early interactions with the FDA to discuss any potential surrogate or intermediate endpoints and address potential ways to support accelerated approval and satisfy post-approval requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority review. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product, including those that receive fast track, breakthrough therapy, or RMAT designations, may be eligible for priority review, if the product meets the criteria for priority review at the time the BLA is submitted. If priority review is granted, the FDA has a 6-month goal for reviewing the marketing application or efficacy supplement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug or biologic products with evidence showing that they provide meaningful therapeutic benefit over existing treatments for serious or life&#8209;threatening illnesses may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of clinical data establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit. As a condition of approval, the FDA may require that a sponsor conduct post&#8209;marketing clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation (&#8220;ODD&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biological product intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or if there is no reasonable expectation that the cost of developing and making the product available in the U.S. will be recovered from sales of the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ODD must be requested before submitting a BLA. ODD does not affect the regulatory review and approval process. However, if a product that has orphan designation subsequently receives the first BLA applicant to receive FDA approval for that product for the disease or condition for which it has such designation, that product is entitled to a seven-year exclusive marketing period in the U.S. for that product in the approved indication. During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market the same drug or biological product for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Among the other benefits of ODD are tax credits for certain research and a waiver of the user fee. In September 2021, the FDA finalized Guidance For Industry on determining &#8220;sameness&#8221; for gene therapy products for purposes of orphan drug exclusivity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan drug designation may be granted to products that can be used to treat life-threatening diseases or chronically debilitating conditions with an incidence of no more than five in 10,000 people or that, for economic reasons, would be unlikely to be developed without incentives. Medicinal products for which orphan designation has been granted are entitled to a range of benefits during the development and regulatory review process and to ten years of exclusivity in all EU member states upon approval. As in the U.S., a similar medicinal product with the same orphan indication may be approved, notwithstanding orphan product exclusivity, if the exclusivity holder gives consent or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if the similar product is deemed safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity granted in relation to the original orphan medicinal product may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA or EU and other governmental authorities&#8217; approvals would be subject to continuing regulation by the FDA, the EMA and other governmental authorities, including recordkeeping requirements and reporting of adverse experiences associated with the product. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, or equivalent EU and other governmental authorities and are subject to periodic unannounced inspections by the FDA, certain state agencies and EU and other governmental authorities for compliance with ongoing regulatory requirements, including GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the GMP regulations and other ongoing FDA, EU or other governmental authorities&#8217; regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA, EMA, EU Member State or other governmental authorities may halt our clinical trials, require us to recall a product from distribution or withdraw approval of the BLA for that biologic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. For example, under the FDA&#8217;s current interpretation of the relevant laws, in proactively promoting a biologic, a company generally can make only those substantiated claims relating to safety and efficacy that are for indications approved by the FDA and that are otherwise consistent with the FDA-approved label for the biologic. Claims must be truthful and non-misleading. Failure to comply with these requirements can result in fines, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may prescribe legally available biologics for uses that are not described in the product&#8217;s labeling and that differ from those tested by the sponsor and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. If the FDA finds that we have promoted off-label use of any product that is eventually approved, sanctions could include refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of pharmaceutical products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. Other relevant laws at EU level and in the individual EU member states also apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may process confidential, sensitive, and proprietary information, including personal information.  Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards governing data privacy and security. Such obligations may include, without limitation, the Federal Trade Commission Act, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, (collectively, &#8220;CCPA&#8221;), the EU General Data Protection Regulation (&#8220;EU GDPR&#8221;), the EU GDPR as it forms part of United Kingdom (&#8220;UK&#8221;), law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (&#8220;UK GDPR&#8221;), and The Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations (collectively, &#8220;HIPAA&#8221;). In addition to the CCPA, several other states within the U.S., such as Virginia and Colorado, passed comprehensive privacy laws and similar laws are being considered in several other states, as well as at the federal and local levels. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR and CCPA are examples of the increasingly stringent and evolving regulatory frameworks related to personal information processing that may increase our compliance obligations and exposure for any actual or perceived noncompliance.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, European data privacy and security laws (including the EU GDPR, and UK GDPR) impose significant and complex compliance obligations on entities that are subject to those laws. These obligations may include limiting personal information processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal information processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal information; increasing rights for data subjects; formalizing a heightened and codified standard of data subject consents; requiring the implementation and maintenance of technical and organizational safeguards for personal information; mandating notice of certain personal information breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the UK and/or the EU in certain circumstances. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA imposes obligations on covered businesses to provide specific disclosures related to a business&#8217;s collecting, using, and disclosing personal information and to respond to certain requests from California residents related to their personal information (for example, requests to know of the business&#8217;s personal information processing activities, to correct or delete the individual&#8217;s personal information, and to opt out of certain personal information disclosures). Also, the CCPA provides for administrative fines and a private right of action for certain data breaches which may include an award of statutory damages. In addition, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, expanded the CCPA. The CPRA&#8217;s recent amendments to the CCPA established a new regulatory agency to implement and enforce the law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations (collectively, &#8220;HIPAA&#8221;) imposes requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain and transmit individually identifiable health information for or on behalf of a covered entity relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For more information regarding the risks to our business related to laws and regulations to which we are or may become subject, see &#8220;Risk Factors&#8212;Risks Related to Our Business Operations.&#8221; </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for any of our product candidates, we may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws may impact, among other things, our research activities, as well as our proposed sales, marketing, and education programs. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any health care item or service for which payment may be made, in whole or in part, by federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor, or for which no exception or safe harbor is available, may be subject to scrutiny;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the U.S. Attorney General or as a qui tam action by a private individual (a whistleblower) in the name of the government and the individual, and the whistleblower may share in any monetary recovery. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe the company&#8217;s products; and inflating prices reported to private price publication services, which are used to set drug payment rates under government healthcare programs. In addition, the government has pursued civil False Claims Act cases against a number of pharmaceutical companies for causing false claims to be submitted as a result of the marketing of their products for unapproved, and thus non-reimbursable, uses. Because of the threat of treble damages and mandatory penalties per false or fraudulent claim or statement, healthcare and pharmaceutical companies often resolve allegations without admissions of liability for significant and material amounts. Pharmaceutical and other healthcare companies also are subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which also, prohibits, among other things, executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false, fictitious, or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to direct and indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Outside the U.S., interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products, which is prohibited in the EU, is governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. Certain EU member states, or industry codes of conduct, require that payments made to physicians be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her competent professional organization, and/or the competent authorities of the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, and fraud laws may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the pharmaceutical and biotechnology industry have received increased public and governmental scrutiny for the cost of drugs. In particular, U.S. federal prosecutors have issued subpoenas to pharmaceutical companies seeking information about drug pricing practices and the U.S. Senate is investigating several pharmaceutical companies relating to drug price increases and pricing practices. If we obtain regulatory approval of any of our product candidates, our revenue and future profitability could be negatively affected if these inquiries were to result in legislative or regulatory proposals that limit our ability to increase the prices of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement and Healthcare Reform Legislation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of gene therapy products. In the U.S. and other countries, sales of any products for which we receive marketing approval will depend in part on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. A number of gene or cell therapy products have been approved over the past several years by the FDA. For example, although CMS has approved coverage for Chimeric Antigen Receptor T-cell therapies, such as Yescarta and Kymriah, and has established reimbursement methods for these therapies, these policies could be changed in the future. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the U.S., even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, contains provisions that may reduce the profitability of drug products, including, for example, by increasing the minimum rebates owed by manufacturers under the Medicaid Drug Rebate Program, extending the rebate program to individuals enrolled in Medicaid managed care plans, addressing a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and imposing annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of government controls and other measures, and tightening of restrictive policies in jurisdictions with existing controls and other measures, could limit coverage of or payments for pharmaceuticals, or affect rebates or other price concessions owed on such products. Certain provisions of the Affordable Care Act have been subject to judicial challenges as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act, enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the individual mandate, effective January 1, 2019. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argue the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 &#8220;Inflation Reduction Act&#8221; into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, it is unclear whether such legislative changes, regulatory changes, or judicial challenges related to the Affordable Care Act, or other health care reform measures will also have an impact on biologic product exclusivity, or the biosimilar product licensure pathway established under the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which was enacted as part of the Affordable Care Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect through 2031 unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been increasing legislative, regulatory, and enforcement interest in the U.S. with respect to drug pricing practices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. The Inflation Reduction Act also, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022 directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future. It is possible that the Affordable Care Act, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare financing, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from commercial payers. Coverage policies and reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to what is occurring in the U.S., political, economic and regulatory developments outside of the U.S. are also subjecting the healthcare industry to fundamental changes and challenges. Pressure by governments and other stakeholders on prices and reimbursement levels continue to exist. In various EU member states, we expect to be subject to continuous cost-cutting measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative. Health technology assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states, including countries representing major markets. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally compares attributes of individual medicinal products, as compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU member states. On January 31, 2018, the EC adopted a proposal for an HTA regulation intended to boost cooperation among EU member states in assessing health technologies, including new medicinal products. The HTA regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January 12, 2025. The HTA regulation provides that EU member states will be able to use common HTA tools, methodologies, and procedures across the EU. Individual EU member states will continue to be responsible for assessing nonclinical (e.g., economic, social and ethical) aspects of health technologies, and making decisions on pricing and reimbursement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The making available or placing on the EU market of unauthorized medicinal products is generally prohibited. However, the competent authorities of the EU member states may exceptionally and temporarily allow and reimburse the supply of such unauthorized products, either on a named patient basis or through a compassionate use process, to individual patients or a group of patients with a chronically or seriously debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorized medicinal product. Such reimbursement may no longer be available if authorization for named patient or compassionate use programs expire or is terminated or if marketing authorization is granted for the product. In some EU member states, authorization and reimbursement policies may also delay commercialization of our products, or may adversely affect our ability to sell our products on a profitable basis. After initial price and reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including reference pricing systems and publication of discounts by third party payers or authorities in other countries. In the EU, prices can be reduced further by parallel distribution and parallel trade, or arbitrage between low-priced and high-priced EU member states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of adequate government reimbursement for our products may also be subject to regulatory changes and controls.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval from the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. Many countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. To obtain regulatory approval of a biological medicinal product under EU regulatory systems, we must submit a marketing authorization application. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the EU and the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of our future products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Testing and Approval of Pharmaceutical Products in the EU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The EU and many individual countries have regulatory structures similar to the U.S. for conducting nonclinical and clinical testing and applying for marketing approval or authorization, although specifics may vary widely from country to country. Clinical trials in the EU must be conducted in accordance with the requirements of the EU Clinical Trials Directive, as implemented in national law by individual EU member states, or in accordance with the EU Clinical Trials Regulation which became applicable on January 13, 2022, and applicable good clinical practice standards. In the EU, there are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a country-by-country basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency, or EMA. If the EMA issues a positive opinion, the EC will grant a centralized marketing authorization that is valid in all EU member states and three of the four European Free Trade Association countries (Iceland, Liechtenstein and Norway). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and biotechnology-derived medicinal products, and optional for others. There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EU member states simultaneously for product candidates that have not yet been authorized in any EU member state and a &#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EU member state to apply for that authorization to be recognized by the competent authorities in other EU member states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum timeframe for the evaluation of an application in the EU under the centralized procedure is 210 days, subject to certain exceptions and clock stops. An initial marketing authorization granted in the EU is valid for five years, with renewal subject to reevaluation of the risk-benefit profile of the product. Once renewed, the authorization is usually valid for an unlimited period unless the national competent authority or the EC decides on justified grounds to proceed with one additional five-year renewal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, if an applicant can demonstrate that comprehensive data on the efficacy and safety of the product under normal conditions of use cannot be provided due to certain specified objective and verifiable reasons, products may be granted marketing authorization &#8220;under exceptional circumstances.&#8221; A marketing authorization granted under exceptional circumstances is valid for five years, subject to an annual reassessment of conditions imposed by the EC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The UK&#8217;s withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has led to diversion between the UK and EU regulatory environments, and there is significant uncertainty concerning the extent to which the UK and the EU regulatory environments may diverge further in the future. Any further divergence may lead to increased costs and administrative burden. On December 24, 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement. The Agreement formally entered into force on May 1, 2021. The Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Although the body of the Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extend to procedures such as batch release certification and Great Britain (England, Scotland and Wales) is treated as a third country. Northern Ireland, with regard to EU regulations, continues to follow the EU regulatory rules. As part of the Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK continues to accept EU batch testing and batch release, but has recently conducted a consultation as to the future strategy for batch testing policy; two years notice will be provided of any changes to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland is, however, covered by centralized marketing authorizations granted by the EC. The UK Medicines and Healthcare products Regulatory Agency is the UK competent authority for the regulation and authorizations or medicinal products in the UK. Some diversion has already taken place, most notably the EU&#8217;s regulatory environment for clinical trials has been harmonized as part of the Clinical Trials Regulation. It is currently unclear as to what extent the UK will seek to align its regulations with the EU. Failure of the UK to closely align its regulations with the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization for our product candidates on the basis of clinical trials conducted in the UK. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Manufacture of Medicinal Products in the EU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the EU, a manufacturing authorization from the national regulatory authority of the member state in which the manufacturing of medicinal products is carried out is required to manufacture medicinal products. The manufacturing authorization holder must comply with various requirements set out in applicable EU laws, regulations and guidance. These requirements include compliance with EU GMP standards when manufacturing products and their APIs, including APIs manufactured outside of the EU with the intention of importing them into the EU. In addition to inspection reports, manufacturers and marketing authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in cases of non-compliance with the EU or EU member states&#8217; requirements applicable to manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Data and Marketing Exclusivity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the EU, innovative medicinal products that are subject to marketing authorization on the basis of a full dossier qualify for eight years&#8217; data exclusivity upon marketing authorization and an additional two years&#8217; market exclusivity. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. However, the generic product or biosimilar products cannot be marketed in the EU for a further two years thereafter. The overall ten-year period may be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Data exclusivity periods are currently the same in Great Britain as in the EU. However, following Brexit, the UK could change the duration of data exclusivity periods under its national legislation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, Health and Safety Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state and local environmental, health and safety (&#8220;EHS&#8221;) laws and regulations relating to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials. Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct our operations. Certain of our development and manufacturing activities involve use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. Although the costs to comply with applicable laws and regulations, including requirements in the EU relating to the restriction of use of hazardous substances in products, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, we had approximately 123 full-time employees. Of these employees, 25 hold Ph.D. or M.D. degrees, 89 are engaged in research and development, and 34 are engaged in business development, finance, legal, human resources, facilities, information technology, and general management and administration. We also engage temporary employees and consultants. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our employee engagement is highly favorable, which we attribute to our shared mission of transforming the lives of those affected by highly prevalent ocular diseases and has led to our being named a Top Workplace for each of 2021 and 2022 by Bay Area News Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our employees are one of our most valuable assets and are essential to our success. We have been purposeful in our efforts to hire, develop and retain diverse talent as well as create an inclusive culture. We are investing in the creation of a work environment that values the health, safety and wellness of our team, and where our employees are inspired to deliver their best every day. All employees are responsible for upholding the Adverum Code of Business Conduct and Ethics, as well as complying with our Employee Handbook, which together form the foundation of our policies and practices. We continue to expand our systems to track key human capital metrics such as demographics, diversity, compensation and benefits, and engagement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are committed to diversity, equity and inclusion (&#8220;DEI&#8221;) across all aspects of our company, including hiring, promotion and development practices. As of December 31, 2022, racial and ethnic minorities represented 65.9% of our employee base.  52% of our workforce were women and 50% of our positions at director-level and above were held by women.  Our employees bring diversity to our workplace across many critical categories, and we believe our company is stronger as a result of our diverse experiences and backgrounds. We are committed to creating and maintaining a diverse, inclusive and safe work environment where our employees can bring their best selves to work each day. We continue to implement employee-led resource groups (&#8220;ERGs&#8221;) and to assemble DEI-related resources for our employees.  We currently have two ERGs that represent and support two diverse communities in our workforce: SOAR (Supporting Women of All Ranks ERG), providing support and mentorship for our female workforce, including guidance on career advancement and the LGBTQ+ (Pride ERG), working to foster an inclusive workplace culture that supports our LGBTQ+ workforce. These ERGs mentor, foster, encourage and inspire employees in all stages of their careers by providing access to senior leadership, peer groups, mentoring and other valuable resources to help them pursue their career ambitions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to our employees starts with benefit and compensation programs that value their contributions and offer physical, financial and personal health programs to them and their families. We strive to provide pay, benefits and services that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, broad-based stock grants and bonuses, healthcare and retirement benefits, and paid time off. We also offer an Employee Stock Purchase Program through which employees can purchase company stock at a discounted price and offer stipends to cover expenses associated with working from home and the use of personal devices for work purposes. Additionally, we continue to advance transparency in our pay and representation data by complying with all applicable statutory filing requirements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Communication and Engagement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe that Adverum&#8217;s success depends on our employees understanding how their work contributes to the company&#8217;s overall strategy. We strive to foster open and direct communication and seek to empower our employees to be our greatest ambassadors. We use a variety of channels to facilitate this exchange of information, including quarterly business updates from the senior management team; regular all hands meetings, open forums and company-wide written communications; postings on our company intranet; and employee engagement surveys. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Wellness and Safety</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee safety and well-being is of paramount importance to us, particularly in light of COVID-19. In response to the pandemic, we have taken extra precautions to reduce the risk of virus exposure for our employees. We provide protective equipment for our employees working on site, have implemented new safety protocols and procedures, and provide access to COVID-19 rapid testing. We have also established a governance structure to ensure timely communication and decision making. For our remote employees, we provide productivity and collaboration tools and resources, allow flexible schedules and support their information technology needs. We also regularly promote employee assistance programs to support our employees&#8217; physical, financial and mental well-being.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Available Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in 2006 under the name &#8220;Avalanche Biotechnologies, Inc.&#8221; We completed the initial public offering of our common stock in August 2014. On May 11, 2016, upon the completion of our acquisition of Annapurna Therapeutics SAS, we changed our name to &#8220;Adverum Biotechnologies, Inc.&#8221; Our common stock is currently listed on The Nasdaq Global Market under the symbol &#8220;ADVM.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063, and our telephone number is (650) 656&#8209;9323. Our website address is www.adverum.com. We make available on our website, free of charge, our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov. The information found on our website is not incorporated by reference into this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_22"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects. Further, the current coronavirus (&#8220;COVID-19&#8221;) pandemic and actions taken to address the pandemic may exacerbate the risks described below.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales, marketing and other activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2025. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials, investments into our manufacturing capabilities, the scope of our research and development activities, continued compliance with and receipt of rent under our sublease, and changing circumstances beyond our control, that may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates that we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the United States Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities outside the United States (&#8220;U.S.&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability and cost of acquiring and shipping of supplies necessary for manufacturing and clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales, marketing, distribution and other commercial capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing enhanced internal controls over financial reporting; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. General market conditions resulting from rising interest rates, inflation, global supply chain issues, Russia&#8217;s invasion of Ukraine, the COVID-19 pandemic, as well as other market conditions, as well as our ability to maintain our Nasdaq listing, may make it difficult for us to obtain adequate additional financing when needed or on attractive terms, or at all. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be unable to complete any current or future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not currently in compliance with Nasdaq&#8217;s continued listing standards, and if we are not able to regain compliance with Nasdaq&#8217;s continued listing standards our common stock may be delisted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ADVM.&#8221; On November 18, 2022, we received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying us that we were out of compliance with the Nasdaq $1.00 per share minimum closing bid price rule. We have until May 17, 2023, to regain compliance with the minimum bid price rule. If we do not achieve compliance by May 17, 2023, we may be eligible for an additional 180-day period to regain compliance if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that we will not be able to cure the deficiency, or if we do not meet the other listing standards, Nasdaq could provide notice that our common stock will become subject to delisting. In the event Adverum receives notice that its common stock is being delisted, Nasdaq rules permit Adverum to appeal any delisting determination by the Nasdaq staff to a Hearings Panel. Accordingly, our common stock is subject to the risk of being delisted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions could adversely affect our current financial condition and projected business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;), where we hold a small portion of our cash and cash equivalents, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), as receiver.  On March 12, 2023, the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those funds in excess of the standard FDIC insurance limits, under a systemic risk exception.  As of March 13, 2023, we had access to our cash and cash equivalents at SVB; however, there is uncertainty in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. The ultimate outcome of these events cannot be predicted, but these events could have a material adverse effect on our business operations if our ability to access funds at SVB or any other banks we use is compromised.</span></div><div id="i236e9599e5b144f29c9957366d735162_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials, and if that product candidate is not successful our business could be materially impacted. Our other product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, clinical studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers, partnering with a pharmaceutical licensee with manufacturing capabilities, or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;), and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution, or be conditional on future development activities and clinical results. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;), uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may generate unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) subjects. Although we will be bound by the generally applicable laws governing approval, the fact that our product is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors is safe and effective for use in its target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and human subjects may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In addition, subjects may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that are then attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subjects resulted in our announcement on July 22, 2021 that we were discontinuing development of Ixo-vec for the DME indication. It is possible that as we test Ixo-vec and other product candidates, in current and future clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. In some cases, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to understand the safety of our product candidates, when a subject experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate. The subjects we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the subjects enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a subject in any of these or subsequent trials was related to Ixo-vec, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of Ixo-vec will agree with our determination. If a subject in one of our clinical trials experiences a negative health event, and that event is misattributed to Ixo-vec, the trial and other trials of Ixo-vec may be placed on clinical hold, and regulatory approval of Ixo-vec may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a subject enrolled in one of our clinical trials experiences a negative health event, the subject may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because subjects we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of subjects, this risk is increased.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, dose-related ocular inflammation is a known side effect of Ixo-vec administration, but the duration of inflammation caused by Ixo-vec, our ability to prevent or manage that inflammation using corticosteroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. The primary purpose of our LUNA trial is to identify the best combination of a prophylactic corticosteroid regimen and dose of Ixo-vec that minimizes post-prophylactic inflammation while at the same time providing efficacy. If we are unable to manage this inflammation appropriately, we may not be able to further develop Ixo-vec and the FDA or other regulatory authorities outside the U.S. may not approve Ixo-vec. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, Ixo-vec or our other product candidates if they deem the levels or risk of inflammation to be unacceptable or if they are unwilling or unable to use the required prophylactic corticosteroid regimen. Further, patients treated with Ixo-vec could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of Ixo-vec or could cause unanticipated adverse reactions to Ixo-vec. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any therapeutic protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, Ixo-vec, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though EYLEA&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed via a gene therapy treatment modality. If such side effects are serious or life threatening, the development of our product candidate and future product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology or product candidates. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may become apparent only when the product candidate is tested in human subjects suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. We will still need to conduct Phase 3 pivotal trials in which we anticipate Ixo-vec will be compared to available therapies and utilize longer term endpoints in order to support submission and approval of a BLA or equivalent outside of the U.S. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and the time, cost and probability of subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and in product candidates based on this platform, and our future success depends on the successful development of such product candidates. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EMA and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other treatment modalities, which are better known or more extensively studied to date. In 2017 and 2019, the FDA approved the first two products in vivo gene therapy. To date, approvals for gene therapy products by the FDA have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, for which there is an approved and widely adopted standard of care, the benefit-risk profile of Ixo-vec may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience, including, for example, reevaluating whether to require a companion diagnostic for gene therapy products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a clinical trial can begin to enroll at a clinical site, the site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee must review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory agencies, review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial, including during a pandemic. We will be required to identify and enroll a sufficient number of patients for any clinical trial for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA, the EMA or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, or because of negative publicity from other adverse events in the biotechnology or gene therapy sector or inadequate results in our nonclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in our manufacturing processes, analytical testing, or facilities or the manufacturing processes, analytical testing or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues or further subject follow up occurs and more subject data become available. For example, although we have periodically announced interim data from subjects in our OPTIC trial, which showed all Ixo-vec related adverse events as mild to moderate in severity, there is no guarantee that in the future, we will not have more severe drug- or treatment-related adverse events in subjects treated with Ixo-vec, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of subjects were enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation by the FDA and PRIME designation by the EMA for Ixo-vec may not lead to a faster development, regulatory review or approval, and it does not increase the likelihood that Ixo-vec will receive marketing approval in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for Ixo-vec in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Medicines Agency EMA granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation in June 2022 for the treatment of wet AMD. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need and bring a major therapeutic advantage to patients.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue with the EMA and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track and PRIME designations for Ixo-vec may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA or the EMA. In addition, the FDA may rescind the Fast Track designation for Ixo-vec if FDA later determines that Ixo-vec no longer meets the qualifying criteria for Fast Track designation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the Ixo-vec manufacturing process, internally or through third parties, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we use to manufacture Ixo-vec for clinical trials. Before we use a revised process in clinical trials, we must submit analytical comparability data to the FDA and comparable regulatory authorities outside the U.S. to demonstrate that the process changes have not altered Ixo-vec in a manner that undermines the applicability of the clinical data from our clinical trials. If the FDA and comparable regulatory authorities outside the U.S. do not find our analytical comparability data sufficient, the FDA and comparable regulatory authorities outside the U.S. could place our IND or equivalent on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the Ixo-vec manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process, equipment or facilities of Ixo-vec in the future, the FDA and comparable regulatory authorities outside the U.S. may require us to demonstrate comparability between Ixo-vec manufactured before and after the change. For example, the FDA and comparable regulatory authorities outside the U.S. could require comparability studies to demonstrate that Ixo-vec manufactured in its current facilities is comparable to Ixo-vec manufactured at future commercial supply sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for Ixo-vec or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products and product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the Ixo-vec manufacturing process internally or through third parties, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commercializing Ixo-vec, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our contracted slots are cancelled or delayed in order to prioritize other projects, we may be unable to produce sufficient quantities of our product candidates for our development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect any manufacturing facility we may have or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the United Kingdom (&#8220;UK&#8221;) withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Agreement, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK further diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extend to procedures such as batch release certification, and Great Britain (England, Scotland and Wales) is treated as a third country. Northern Ireland, with regard to EU regulations, continues to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK continues to accept EU batch testing and batch release, but has recently conducted a consultation as to the future strategy for batch testing policy; two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland is, however, covered by centralized marketing authorizations granted by the European Commission (&#8220;EC&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the arrangements. We and our contract vendors currently rely on other contractors based in the UK. The implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect any manufacturing facility we may have or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div id="i236e9599e5b144f29c9957366d735162_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements or partnerships with these third parties and if we do enter into agreements with these third parties, we cannot be assured these agreements will be on favorable economic terms or that any of these third parties will be successful at fulfilling their contractual obligations, and it is possible they may choose to terminate their engagements with us. If we need to enter into alternative arrangements, it could delay or jeopardize our product development activities or be more costly. Our reliance on these third parties for vector production, process development, assay development, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies,  research and related activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product and product candidate manufacturing and testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers and suppliers, and may enter into partnerships and other business development arrangements, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing, supplier agreements, partnerships or other agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers or partners for some or all aspects of manufacturing activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements, partnerships, or supplier agreements with third parties in a manner or at a time that is costly or damaging to us; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer, supplier or partner, or their commitments to other vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div id="i236e9599e5b144f29c9957366d735162_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institutions that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, including through breach of our agreements with third parties, failure of our security measures or publication of information by any of our third-party collaborators, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, in 2019 we received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. Although no further action has been taken in that matter, it illustrates that if one of our licenses were to be terminated, we may be unable to obtain a new license to that technology on commercially reasonable terms, if at all.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Further, following Russia&#8217;s invasion of Ukraine in February 2022, the U.S. government has levied sanctions against Russia and Belarus, Russia has issued a decree that removes protections for some patent holders who are registered in unfriendly countries, including the U.S., and the USPTO has terminated its engagement with officials from intellectual property agencies in Russia, Belarus and Eurasia, so we are not currently maintaining certain intellectual property filings in these jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer a patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the U.S., patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed or may in-license may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control, such as the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials. Before we can initiate clinical trials for other product candidates in the U.S., we need to submit the results of nonclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA or other regulatory authorities may require us to conduct additional nonclinical testing for any of our product candidates before they allow us to initiate clinical testing under any IND or equivalent, or at any stage of clinical development of Ixo-vec or other new product candidates based on concerns that arise as the clinical program progresses or if significant manufacturing process changes are made to the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S. to temporarily or permanently shut down due to violations of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for the clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for manufacturing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses, permits or resources necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection, sample testing or analysis in a timely and accurate manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB that requires us to undertake corrective action resulting in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or that prohibits us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have amended our protocol and from time to time may further amend our protocol based on a variety of factors, and these changes may have unanticipated consequences on our clinical trial outcomes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from product sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our products by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S. alerting health care providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidence of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to the product candidate; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as Ixo-vec. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS and EYLEA are currently available in the U.S. for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, Ixo-vec for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy. LUCENTIS and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including 4D Molecular Therapeutics, Bayer, Hoffmann-La Roche Ltd., Novartis, Regeneron and REGENXBIO. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the U.S., private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for gene therapy products, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the U.S., even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow the company to sell its products at a profit. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act of 2017 included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect until 2031 unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the Inflation Reduction Act, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022 directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional governmental action could be taken in response to the COVID-19 pandemic, and that such action could affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market for Ixo-vec, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, or if this occurs for any of our other product candidates, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of Ixo-vec for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate, we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with Ixo-vec or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages.  We cannot accurately predict the number of patients for whom treatment for wet AMD using Ixo-vec or any of our other product candidates might be possible or whether the FDA or other regulatory authorities may approve indications for Ixo-vec or any of our other product candidates that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from Ixo-vec. If this patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic corticosteroid treatment will be required to manage inflammation associated with treatment with Ixo-vec, and certain patients cannot be treated with prophylactic corticosteroids. If this proportion of the patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing, distribution, or market access and reimbursement capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, distribution, or market access and reimbursement capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, marketing, distribution, or market access and reimbursement capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing, distribution, or market access and reimbursement functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing, distribution, or market access and reimbursement functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department, sales force, or distribution capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, Ixo-vec, expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment or consulting agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize expected operational efficiencies and the cost savings from the restructuring, our operating results and financial condition would be adversely affected. Due to our restructuring, we may not be able to effectively manage our operations or retain qualified personnel, which may result in weaknesses to our infrastructure and operations, increased risk that we may be unable to comply with legal and regulatory requirements, increased risks to our internal controls and disclosure controls, and loss of employees and reduced productivity among remaining employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring resulted in the loss of institutional knowledge and expertise and the reallocation of and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Further, the restructuring and possible additional cost-containment measures may yield unintended consequences, such as attrition beyond our intended workforce reduction and reduced employee morale. We may be required to rely more heavily on temporary or part-time employees, third party contractors and consultants to assist with managing our operations. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We will have only limited control over the activities of these consultants and in many instances can expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our business could harm our business. Employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to successfully manage this transition and these restructuring activities, our expenses may be more than expected and we may be unable to fund our Ixo-vec development plan or implement our business strategy. As a result, our business, prospects, financial condition and results of operations could be negatively affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia&#8217;s invasion of Ukraine and current adverse economic conditions could adversely affect our revenue, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global disruption to, and potential impacts on, the health of the global economy arising from, related to, or resulting from Russia&#8217;s invasion of Ukraine in February 2022 could affect our business and operations. For example, the credit and financial markets have been adversely affected by the war and measures taken in response thereto, potentially impacting our ability to raise adequate additional capital when needed or on favorable terms. In addition, current economic conditions, such as recent global supply chain disruptions, labor shortages, rising interest rates and inflation, may adversely impact our operations, for example by increasing our costs, disrupting our suppliers&#8217; ability to provide us with materials and supplies needed for both our manufacturing and clinical trials, or causing delays to our clinical trial and manufacturing timelines, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the emergence of new variants have caused us to modify our business practices, including the adoption of a hybrid mix of virtual and in-person work, updating our policies and implementing new practices to align with guidance from state and federal governments and health authorities. We may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. We are uncertain that such measures will be sufficient to mitigate future risks posed by the virus and its variants or otherwise be satisfactory to government authorities and how long we will be required to continue these measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, an increased reliance by us and the companies with which we do business on information technology systems to support a hybrid workforce may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also affect our current and planned trials, development programs and our timelines for commercialization. We and our CROs, clinical sites and contract manufacturing organizations (&#8220;CMOs&#8221;) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials, nonclinical studies, obtain clinical supplies, and conduct other research and development activities. The response to the COVID-19 pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our relationships with our manufacturers, service providers, suppliers, or other vendors are terminated, materially altered, or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative manufacturers, service providers, suppliers, or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health regulatory authorities outside the U.S., which could result in delays of meetings, reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, the recent recession or market correction, which has been attributed in part to the COVID-19 pandemic, could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread or any future resurgence of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and other third parties on which we rely collect, receive, use, process, generate, transfer, make accessible, protect, secure, dispose of, transmit, share, and store sensitive, confidential, and proprietary information, including personal information (such as health-related information and medical information), intellectual property, trade secrets, research and development information, financial information, and other business information.  As a result, we and the third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our confidential, sensitive, and proprietary data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent, continue to rise, are becoming increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivist,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products and services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and data and those of third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruptions of clinical trials, loss of confidential, sensitive, or proprietary data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations.  Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations.  We rely on third-party service providers and technologies to operate critical business systems to process confidential, sensitive, or proprietary data in a variety of contexts, including, without limitation, CROs, CMOs, collaborators, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions.  We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business.  Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.  If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.  In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our confidential, sensitive, or proprietary information or our information technology systems, or those of third parties upon which we rely. A security incident or other interruption could result in delays to the development and commercialization of our product candidates, disruption of our programs, negative publicity and financial loss. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and confidential, sensitive, or proprietary information. For example, the loss of clinical trial information from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.  Furthermore, because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, such as governmental authorities, partners, and affected individuals, of security incidents. Such disclosures may involve inconsistent requirements and are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing confidential, sensitive, or proprietary information (including personal information); litigation (including class-action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer confidential, sensitive, or proprietary information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products or product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; interruption of our clinical trials; and other adverse business consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share sensitive, proprietary, and confidential information, including personal information, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our processing activities may subject us to numerous data privacy and security obligations, such as laws, regulations, guidance, industry standards, external and internal policies, contractual requirements, and other obligations relating to data privacy and security and that govern processing of confidential, sensitive, or proprietary data (including personal information ) by us or on our behalf, including information that we collect or will collect about subjects and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including those relating to data breach notification, personal information privacy, consumer protection (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information, as well as their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or the CPRA (collectively, "CCPA") applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain rights related to their personal information.  The CCPA provides for administrative fines for noncompliance (up to $7,500 per violation) and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Additionally, the CPRA&#8217;s recent amendments expand the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive data privacy and security laws, and similar laws are being considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the EU GDPR, the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal information, including health-related information. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing; other corrective actions; private litigation related to processing of personal information brought by classes of data subjects or consumer protection organizations authorized by law to represent their interests; and/or fines up to the greater of &#8364;20 million or 4% of annual global revenue, and separately &#163;17.5 million or 4% of annual global revenue under the UK GDPR. EU member states are also able to legislate separately on health and genetic information, and we must comply with these local laws where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, we may be unable to transfer personal information from Europe and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal information to other countries.  In particular, the European Economic Area (&#8220;EEA&#8221;) and the United Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal information to the U.S. and other countries whose data privacy and security laws they believe are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal information from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal information to the U.S.  If there is no lawful manner for us to transfer personal information from the EEA and the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal information necessary to operate our business.  Additionally, companies that transfer personal information out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal information out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process confidential, sensitive, or proprietary information on our behalf.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) to in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials (for example, under HIPAA). Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law in March 2020. The CARES Act modifies certain of the changes made by the TCJA. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the TCJA, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. For example, the recently enacted Inflation Reduction Act of 2022 includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. In addition, it is uncertain if and to what extent various states will conform to the TCJA, as amended by the CARES Act, the Inflation Reduction Act, or other newly enacted federal tax legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TCJA, federal NOLs incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2022 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. We may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to enroll and dose subjects in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials of our product candidates and the results of trials of competing product candidates or of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial results, variations in our financial results and the adequacy of our cash runway to achieve key milestones, or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to gene therapy and to biotechnology generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our Nasdaq listing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing effects of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants, debt and other financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting. If we fail to remediate this material weakness or if we discover or develop additional material weaknesses or otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected and our financial statements may need to be restated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. During the year ended December 31, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the magnitude of the potential errors that could arise from the operating deficiency as potentially material. As a result, we are unable to assert that our internal control over financial reporting is effective as of December 31, 2022. For so long as we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to securities class action lawsuits in the past and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants, who are no longer at Adverum, made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which we contributed $1.0 million to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detract from our ability to focus fully on our business activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, which may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition, termination or modification of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America. will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Redwood City, California, consisting of approximately 120,000 square feet of office, laboratory, and process development space under a lease that will expire in December 2031, which space is currently not fully utilized. Accordingly, on March 24, 2023, we entered into an amendment to the lease pursuant to which we are relinquishing approximately one third of the space back to the landlord effective on September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we lease a manufacturing facility in North Carolina, consisting of approximately 173,820 square feet, which facility is subleased through the lease term of October 2037.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our properties are adequate and suitable for our current needs; however, we are continuing to evaluate our real estate strategy in response to the changing needs of our in-office, hybrid and remote workforce.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, Lyudmila Pazyuk (&#8220;Plaintiff&#8221;) filed a derivative complaint (Pazyuk v. Machado et al. C.A. No. 2022-1062-MTZ) in the Delaware Court of Chancery (the &#8220;Complaint&#8221;) on behalf of Adverum against Adverum&#8217;s nine current directors and four former directors (the &#8220;Individual Defendants&#8221;).  The Complaint asserts five counts (breach of fiduciary duty, unjust enrichment, aiding and abetting breaches of fiduciary duty, waste of corporate assets and breach of fiduciary duty of disclosure) against each of the Individual Defendants related to Adverum&#8217;s non-employee director compensation.  Plaintiff seeks unspecified damages, restitution and that Adverum make changes to its corporate governance practices surrounding non-employee director compensation.  Adverum and the Individual Defendants filed a motion to dismiss the Complaint on February 24, 2023.  The motion is pending.</span></div><div id="i236e9599e5b144f29c9957366d735162_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i236e9599e5b144f29c9957366d735162_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;ADVM&#8221;.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;17, 2023, we had approximately 17 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. [Reserved]</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></div><div id="i236e9599e5b144f29c9957366d735162_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and, as of December&#160;31, 2022, we had an accumulated deficit of $802.6 million. We expect to incur substantial expenses and continuing losses from operations in the foreseeable future as we conduct our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CROs&#8221;) to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $185.6 million in cash, cash equivalents and short-term investments. We believe that our cash, cash equivalents and short-term investments are sufficient to fund operations into 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will need to adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We may require increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize our clinical development of Ixo-vec and focus our pipeline strategy on certain highly prevalent ocular diseases, which included a reduction in our workforce by approximately 37%. The restructuring was completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div id="i236e9599e5b144f29c9957366d735162_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our accrued and prepaid research and development expenses as of each balance sheet date. This process involves reviewing contracts and purchase orders, reviewing the terms of our license agreements, communicating with our applicable personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. Expenses that are paid in advance of performance are deferred as a prepaid expense and expensed as the services are provided.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of estimated accrued research and development expenses include fees to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">contract manufacturers in connection with the production of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CROs and other service providers in connection with clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">investigative sites in connection with clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">vendors in connection with nonclinical development activities; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">services providers for professional service fees such as consulting and related services.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding of the status and timing of services performed relative to the actual status and timing may vary and may result in our reporting changes in estimates in any particular period. To date, there have been no material differences from our estimates to the amount actually incurred. However, due to the nature of these estimates, we cannot assure you that we will not adjust our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies or other research activities. For the years ended December&#160;31, 2022 and 2021, there were no material changes from our estimates of accrued research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) effective January 1, 2019. For our long-term operating leases, we recognize a right-of-use asset and a lease liability on our consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, we estimate our credit rating, adjust the credit rating for the nature of the collateral, and benchmark the borrowing rate against observable yields on comparable securities with a similar term. We base the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. We determine the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses.  The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable.  During the year ended December&#160;31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and we recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. The deferred rent receivable as of December&#160;31, 2022 and 2021 was zero and $0.8 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of amortizable long&#8209;lived assets, whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values. For example, in 2022 we identified impairment indicators in certain laboratory equipment and tested the recoverability of the carrying amount of the asset group. The carrying amount of the asset group exceeded our anticipated undiscounted cash flows.  As a result of our evaluation, we recorded an impairment charge of $2.1 million for the year ended December&#160;31, 2022. The assets indicated as impaired were written down to the estimated fair value, which was determined using a market approach. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs related to stock-based awards granted to employees based on the estimated fair value of the awards on the date of grant. We estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black&#8209;Scholes valuation model for stock options, and using intrinsic value, which is the closing price of our common stock on the grant date for the restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSU&#8221;). Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the grant-date fair value of stock-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expected volatility on our historical stock price volatility. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derive the expected term using the &#8220;simplified&#8221; method that determines the expected term as the average of the time-to-vesting and the contractual life of the options. The expected term of the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) rights equals to the six-month look-back period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We base the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have never paid any dividends and do not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation model.</span></div><div id="i236e9599e5b144f29c9957366d735162_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. We periodically evaluate the positive and negative evidence bearing upon realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets as of December&#160;31, 2022 and 2021 of approximately $188.1&#160;million and $148.4&#160;million, respectively. We intend to maintain a full valuation allowance on the federal, state and foreign deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $418.9&#160;million to offset future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2022, we also had U.S. state NOL carryforwards of approximately $239.9&#160;million to offset future state income. U.S. state NOLs expire in various years beginning with 2037. At December&#160;31, 2022, we also had approximately $49.0&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to our ability to utilize before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record unrecognized tax benefits as liabilities and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&#160;31, 2022, the total amount of unrecognized tax benefits that would affect our effective tax rate, if recognized, is $1.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize interest and penalties related to income taxes and to uncertain tax positions as a component of  income tax expense. As of December&#160;31, 2022 and 2021, we accrued $0.3&#160;million interest and penalties related to uncertain tax positions. There are no ongoing examinations by tax authorities at this time. </span></div><div id="i236e9599e5b144f29c9957366d735162_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Results of Operations for the Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,922)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,536)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,996)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no revenue for the year ended December&#160;31, 2022. The $7.5 million license revenue for the year ended December&#160;31, 2021 was related to an upfront payment received in January 2021 upon execution of a license agreement with Lexeo Therapeutics, Inc. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $10.1 million to $99.3 million for the year ended December&#160;31, 2022 from $89.2&#160;million for the year ended December&#160;31, 2021. This overall increase was primarily related to a $7.7 million increase in clinical trials-related expenses primarily related to the initiation of the LUNA trial, $3.7 million in restructuring costs incurred, a $2.5 million increase in license fees, and $2.1&#160;million in impairment of laboratory equipment, partially offset by a decrease of $2.4 million in spending on outside research and development services, a $2.4 million decrease in spending on consultants and contractors, and a $1.8 million decrease in material production and bioanalytics. Stock-based compensation expense included in research and development expenses was $7.1 million for the year ended December&#160;31, 2022, compared to $8.9 million for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development activities were attributable to our wet AMD, diabetic macular edema, and earlier-stage research programs. We expect that research and development expenses will fluctuate in future periods as we focus on advancing Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased $6.6 million to $57.9 million for the year ended December&#160;31, 2022 from $64.4&#160;million for the year ended December&#160;31, 2021, primarily related to a decrease of $6.1 million in personnel-associated costs including lower salary and wage expenses and stock-based compensation expense as a result of lower headcount during 2022, and a $5.3&#160;million decrease in professional services mainly for investor relations and legal fees in connection with our proxy contest which ended in May 2021, partially offset by a $6.0&#160;million increase in facilities costs as we recognized a full year expense for lease that we entered into in 2021, and $1.0 million in restructuring costs incurred in the July 2022 restructuring. Stock-based compensation expense included in general and administrative expenses was $13.0 million for the year ended December&#160;31, 2022, compared to $16.3 million for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will decrease in future periods as we streamline our operations. We anticipate decreased expenses related to the human resources, legal, and finance functions brought about by the restructuring measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.1 million in net other income for the year ended December&#160;31, 2022 as compared to 2021 was primarily due higher average yields in investments and unrealized foreign currency gains.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an income tax provision of $0.1&#160;million for the year ended December&#160;31, 2022 related to foreign operations. We recognized no income tax provision for the year ended December&#160;31, 2021. </span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Plan of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of December&#160;31, 2022, we had an accumulated deficit of $802.6 million. As of December&#160;31, 2022, we had $185.6 million in cash, cash equivalents and short-term investments. compared to $305.2 million as of December&#160;31, 2021. We believe that our existing cash and cash equivalents and short-term investments as of December&#160;31, 2022 will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of our commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div id="i236e9599e5b144f29c9957366d735162_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,709&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,236&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,725)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash used in operating activities was $108.1&#160;million, primarily as a result of net loss of $154.5&#160;million due to the continued activities developing our product candidates, partially offset by $26.6&#160;million of non-cash charges mainly related to $20.1&#160;million of stock-based compensation expense, $6.5&#160;million of depreciation and amortization expenses, and a $2.1&#160;million of impairment of long-lived assets, and $19.9&#160;million of net increase in cash from changes in operating assets and liabilities, resulting primarily from $17.6&#160;million in changes of lease liabilities and right-of-use  and $2.2&#160;million due to timing of expenses and payments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, net cash used in operating activities was $107.8 million, primarily as a result of net loss of $145.5 million due to the continued activities developing our product candidates, partially offset by $33.6 million of non-cash charges mainly related to $25.2 million of stock-based compensation expense, $4.6 million of depreciation and amortization expenses, $2.8 million of amortization of premium on marketable securities, and $1.1 million of impairment of long-lived assets, and $4.1 million of net increase in cash from changes in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December&#160;31, 2022 consisted of $153.5&#160;million of net maturities of marketable securities, partially offset by $11.8&#160;million of purchases of property and equipment primarily related to the new facilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2021 consisted of $93.8 million of net maturities and sales of marketable securities, partially offset by $15.1 million of purchases of property and equipment primarily related to the new facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2022 consisted of $0.6&#160;million in proceeds from employee stock purchase plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2021 consisted of $1.7 million of net proceeds from the sale of our common stock, and $0.9 million in proceeds from employee stock purchase plan, partially offset by $0.2 million repayment of loans.</span></div><div id="i236e9599e5b144f29c9957366d735162_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div id="i236e9599e5b144f29c9957366d735162_118"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_121">Report of Independent Registered Public Accounting Firm (PCAOB ID No. </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:AuditorFirmId" id="f-35">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_121">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_121">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_124">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_124">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_127">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_127">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_130">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_130">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_133">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_133">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i236e9599e5b144f29c9957366d735162_136">90</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stockholders and Board of Directors of Adverum Biotechnologies, Inc. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued research and development expenses &#8211; clinical and manufacturing costs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded research and development expenses of $99.3 million for the year ended December 31, 2022. As described in Note 2, research and development costs are expensed as incurred. Research and development costs include fees paid to contract research organizations that conduct certain research and development activities on the Company&#8217;s behalf and contract manufacturing organizations in connection with the production of materials for clinical trials.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the Company&#8217;s research and development expenses for contract research organizations and contract manufacturing organizations and related accruals was challenging due to the complex nature of evaluating the completeness and accuracy of the expenses and accruals.  Research and development expenses are recognized as the services are being performed by the vendors, which requires management to accurately monitor the activity at the vendors to determine the extent of unbilled services performed during the reporting period.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the completeness and accuracy of the contract research organization and contract manufacturing organization expenses and related accruals, our audit procedures included, among others, confirming with a sample of vendors the progress of activities under research and development contracts at period end, testing a sample of cash disbursements after period end to assess the completeness of the expense recognition, and testing a sample of research and development expenses recorded during the period and evaluating the timing, amount and project coding of the expense recognition.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:AuditorName" id="f-36">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="dei:AuditorLocation" id="f-37">San Jose, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;30, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-38">68,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-40">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-41">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:fixed-zero" scale="3" id="f-42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:num-dot-decimal" scale="3" id="f-43">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">190,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">317,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-48">78,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-49">86,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-50">34,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-51">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" scale="3" id="f-55">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-57">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-58">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-59">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">13,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">32,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">93,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">101,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">126,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">123,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-74"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-75"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-76"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-77">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-78"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-79">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-83">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-86"><ix:nonFraction unitRef="usdPerShare" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-87">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-88"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-89">300,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022: <ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-90"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-91">100,117</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-92"><ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-93">98,381</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-94">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-95">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-96">985,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-97">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-98">1,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-99">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-100">802,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-101">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">181,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-103">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-104">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-105">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-107">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">99,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">89,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">57,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">64,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">157,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-113">153,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">157,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">146,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-117">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-118">154,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-119">145,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-120">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">154,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">145,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-124">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-125">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-126">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-127">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-128">155,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-129">145,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130"><ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-131">1.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-132"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-133">1.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-134"><ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-135">99,251</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-136"><ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-137">98,039</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-138">97,549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-139">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98f4b7178d44744a308df9113fa922c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-140">937,134</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82144f9591444e5dbe1046063aa7edbb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-141">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0774ed7dc54340939b85fedaa67a5b8a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">502,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-143">434,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-144">9</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-145">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-147">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-148">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-149">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-150">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-151">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-152">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-153">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-154">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-155">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-156">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-157">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-158">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-159">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-160">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-161">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee79c44eada9499d85b633f2d5c0e83f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd24dd771e86438c83b29d1f07868719_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-164">98,381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd24dd771e86438c83b29d1f07868719_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-165">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059429eb76cc4061a0c3fccafcd267c8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">964,965</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i479b3dfe4e2b48c183d1c440a675b09f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-167">714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie60d5479647d45e18ebbb413a5d2f359_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">316,185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-170">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-171">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-172">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-173">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-174">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-175">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-176">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-177">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-178">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-179">788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-180">788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-181">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-182">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4683d59050a46d488a4d745d0c261c8_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">154,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">154,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8533e6aac0c44366b466a894286f4fc5_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-185">100,117</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8533e6aac0c44366b466a894286f4fc5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-186">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706bda682f144a76bbd7a778fd5eeafb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">985,651</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d9ff81f454d4f60b51fbf6f6ce9d7dd_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">1,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d1a5fb7eac442c8bf23792e4bf1523_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">802,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">181,518</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">154,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-193">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-194">4,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-195">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-196">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (accretion) amortization of (discount) premium on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-197">880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-198">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-199">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-201">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-202">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-203">1,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-204">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-205">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-206">2,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposit and other long-term assets and deferred rent receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="f-207">394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="f-208">990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-209">4,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-210">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-211">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-212">1,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, other current and non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-213">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-214">3,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-215">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-217">13,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-218">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-219">108,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-220">107,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-221">104,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-222">407,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-223">257,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-224">492,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-226">8,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-227">11,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-228">15,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">141,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">78,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-232">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-233">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-234">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-235">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-236">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of BPI loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="f-238">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-239">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-240">2,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-241">34,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-242">26,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-243">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-244">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-246">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-247">68,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-248">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-249">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-250">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-251">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-252">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-254">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in right-of-use asset and lease liability due to termination</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" format="ixt:num-dot-decimal" scale="3" id="f-256">15,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of right-of-use asset on lease modification</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="advm:RemeasurementOfRightOfUseAssetOnLeaseModification" format="ixt:num-dot-decimal" scale="3" id="f-257">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="advm:RemeasurementOfRightOfUseAssetOnLeaseModification" format="ixt:num-dot-decimal" scale="3" id="f-258">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets in accounts payable and current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-259">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-260">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i236e9599e5b144f29c9957366d735162_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-261" continuedAt="i24e861498a4243b48b8b1029d783d124" escape="true">Description of the business </ix:nonNumeric></span></div><ix:continuation id="i24e861498a4243b48b8b1029d783d124"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-262">802.6</ix:nonFraction> million as of December&#160;31, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-263">185.6</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations into 2025.</span></div></ix:continuation><div id="i236e9599e5b144f29c9957366d735162_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-264" continuedAt="ib58824f4b11c4c358cf747468ff49133" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ib58824f4b11c4c358cf747468ff49133" continuedAt="icaa57039d3624f9ab3ddf3f5284d639c"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-265" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-266" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-267" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-268" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-269" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="icaa57039d3624f9ab3ddf3f5284d639c" continuedAt="ib557d6863a4249a2bdceefca3479fb32"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="f-270" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-271" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-272"><ix:nonFraction unitRef="segment" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-273">one</ix:nonFraction></ix:nonFraction> reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="f-274" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company held cash deposits at Silicon Valley Bank (&#8220;SVB&#8221;) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) was appointed as receiver. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its deposits with SVB. As such, <ix:nonFraction unitRef="usd" contextRef="i684e262e9ebe4220803a5cdb770ac920_D20230101-20230313" decimals="-5" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="0" id="f-275">no</ix:nonFraction> losses have been incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the  Company&#8217;s investments are held in custody at a third-party financial institution. Subsequent to March 13, 2023, the Company transferred most of the cash in SVB to a third-party financial institution. As of March 24, 2023, the Company has a remaining $<ix:nonFraction unitRef="usd" contextRef="if42221aeca784751a0a89d6fafe201f0_I20230324" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-276">2.5</ix:nonFraction>&#160;million deposit with SVB, which secures a letter of credit on a lease.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-277" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-278">three</span> to <ix:nonNumeric contextRef="i810c20822d984eb08cf7c2a6a817d1df_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-279">five years</ix:nonNumeric>. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="ib557d6863a4249a2bdceefca3479fb32" continuedAt="i603f4aac3ac14fcfbd6ede9a7af783af"><div style="margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-280" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss an impairment charge of  $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-281">2.1</ix:nonFraction>&#160;million as result of an impairment analysis (see&#160;Note 6) for the year ended December&#160;31, 2022.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-282" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. It bases the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the year ended December&#160;31, 2022 was a negative $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-283">0.3</ix:nonFraction>&#160;million. The deferred rent receivable as of December&#160;31, 2022 and 2021 was <ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="0" id="f-284">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="f-285">0.8</ix:nonFraction>&#160;million, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-286" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-287" continuedAt="i8bc41dfc8f8c4f929021308a2004c1c6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bc41dfc8f8c4f929021308a2004c1c6">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i603f4aac3ac14fcfbd6ede9a7af783af" continuedAt="if2147bd94a054507aa793b4012eb5df0"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-288" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-289" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-290" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2022 and 2021, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-291" continuedAt="i4e9160b5c10d402e97d67fa722a9aada" escape="true">Comprehensive Loss</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e9160b5c10d402e97d67fa722a9aada">&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized loss on marketable securities.</ix:continuation> </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-292" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></ix:nonNumeric></div></ix:continuation><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-293" continuedAt="ic298fe92e95b45409a1b387facefc025" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="if2147bd94a054507aa793b4012eb5df0"><ix:continuation id="ic298fe92e95b45409a1b387facefc025"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted Topic 326 on January 1, 2023, which had no material impact on the Company&#8217;s financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="f-294" continuedAt="i669e22b3ceb34d1f87a4ee17d5761f31" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i669e22b3ceb34d1f87a4ee17d5761f31" continuedAt="i2e92b4fad34b425daa936a24b8a5a34f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bonds and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-295" continuedAt="i6697b6c5c875436b97c8c40f17d57f3a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-296">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-299">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380b7914c06249359dda444f9905896a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-300">59,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380b7914c06249359dda444f9905896a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i380b7914c06249359dda444f9905896a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-302">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380b7914c06249359dda444f9905896a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-303">58,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-304">102,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-306">246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-307">102,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82902a75a654473385cd736e75401243_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-308">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82902a75a654473385cd736e75401243_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82902a75a654473385cd736e75401243_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-310">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82902a75a654473385cd736e75401243_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-312">174,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-314">1,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-315">173,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-316">56,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="f-318">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-319">56,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-320">118,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-322">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-323">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i2e92b4fad34b425daa936a24b8a5a34f"><div><ix:continuation id="i6697b6c5c875436b97c8c40f17d57f3a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd0467e9ac642549c95ec745a488287_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-324">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd0467e9ac642549c95ec745a488287_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd0467e9ac642549c95ec745a488287_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd0467e9ac642549c95ec745a488287_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-327">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-328">62,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-330">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-331">62,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-332">177,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-333">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-334">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-335">177,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-336">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-338">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-339">47,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-340">297,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-341">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-342">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-343">296,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-344">25,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="f-346">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-347">25,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-348">271,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-349">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-350">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-351">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-352">155.5</ix:nonFraction>&#160;million, which are highly liquid securities with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of December&#160;31, 2022 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that <ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" format="ixt:fixed-zero" scale="6" id="f-353">none</ix:nonFraction> of the Company&#8217;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" format="ixt:num-dot-decimal" scale="6" id="f-354">5.0</ix:nonFraction> million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:f-355">one</span> and <ix:nonNumeric contextRef="ie0937b54576e43eab4b908ba3f5c3b29_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-356">two years</ix:nonNumeric>. The remainder of the marketable securities have a remaining maturity of one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. See Note 6, Balance Sheet Components for additional information.</span></div></ix:continuation><div id="i236e9599e5b144f29c9957366d735162_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-357" continuedAt="i8e651049764640bfb2132e98ed94eec4" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i8e651049764640bfb2132e98ed94eec4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i472587f29eaa49539627aa26bffabf1a_D20210125-20210125" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-358">7.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the initial transaction price is the $<ix:nonFraction unitRef="usd" contextRef="i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-359">7.5</ix:nonFraction>&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-360">7.5</ix:nonFraction>&#160;million of license revenue during the year ended December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-361" continuedAt="i7d6faa8b60a047c7b15491a8c2de0010" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i7d6faa8b60a047c7b15491a8c2de0010" continuedAt="ic7ed07565fae40048653698aabd13efc"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has a lease for facilities in Redwood City, which provided a total of tenant improvement allowances of $<ix:nonFraction unitRef="usd" contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-362">6.8</ix:nonFraction>&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-363">2.5</ix:nonFraction>&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of <ix:nonNumeric contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-364">eight years</ix:nonNumeric>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="ic7ed07565fae40048653698aabd13efc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $<ix:nonFraction unitRef="usd" contextRef="i0bc976ddcd5540e0a8d7e01edfab9bdb_D20211101-20211101" decimals="-5" name="advm:LesseeOperatingLeaseLeaseTerminationFee" format="ixt:num-dot-decimal" scale="6" id="f-365">0.4</ix:nonFraction>&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $<ix:nonFraction unitRef="usd" contextRef="i2458438fba324e4195415ece6f14528d_I20211101" decimals="-5" name="advm:LesseeSubLeaseMonthlyBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-366">0.1</ix:nonFraction>&#160;million monthly base rent through June 30, 2022. For short-term leases the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with <ix:nonFraction unitRef="segment" contextRef="i61a03128ef774adc862263af15bd7c04_D20210108-20210108" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfRenewalContracts" format="ixt-sec:numwordsen" scale="0" id="f-367">two</ix:nonFraction> options to extend the lease term for a period of <ix:nonNumeric contextRef="i304bc2ab93974910a0151644d3112b48_I20210108" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-368">five years</ix:nonNumeric> each. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $<ix:nonFraction unitRef="usd" contextRef="i4de68338a8dd4a03a318de90290ec9e5_I20211026" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-369">22.7</ix:nonFraction>&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable as of December 31, 2022 and 2021 was <ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="0" id="f-370">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:num-dot-decimal" scale="6" id="f-371">0.8</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted-average remaining lease term was <ix:nonNumeric contextRef="i6c92305224cd4ce19a716d33e9ed1949_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-372">10.2</ix:nonNumeric> years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was <ix:nonFraction unitRef="number" contextRef="i6c92305224cd4ce19a716d33e9ed1949_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-373">9.9</ix:nonFraction>%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2023, the Company entered into an agreement to terminate the lease of one of its Redwood City premises, which will be effective September 30, 2023. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-374" continuedAt="if7451a23089049f69833f146607e65b4" escape="true">As of December&#160;31, 2022, including the effect of this subsequent event, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="if7451a23089049f69833f146607e65b4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-375">11,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-376">5,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-377">11,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-378">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-379">12,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="f-380">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-381">12,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="f-382">6,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-383">13,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="3" id="f-384">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-385">104,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" format="ixt:num-dot-decimal" scale="3" id="f-386">76,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-387">165,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="f-388">107,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-389">74,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-390">90,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rent expense for the years ended December&#160;31, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-391">17.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-392">12.8</ix:nonFraction>&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-393">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-394">1.8</ix:nonFraction> million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-395">6.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-396">5.2</ix:nonFraction>&#160;million, respectively. Sublease income was $(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:SubleaseIncome" scale="6" id="f-397">0.3</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-398">1.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, which was classified as a general and administrative expense or reduction in general and administrative expense, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-399" continuedAt="ic87f2db58dcf4cd293a9274c1f02089c" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ic87f2db58dcf4cd293a9274c1f02089c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-400" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib049dd87d3c6476abb81eef9b3a27fff_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-401">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib005f5973c44406db5dfb1279f382aab_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-402">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06eefc307c154ccf97e8da306731dc67_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-403">14,382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28cb0293c25243c98f7ef6c87cf0e73d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-404">12,778</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7f5d6fc3404c4cb3ab45ed824eed4f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-405">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95de8a0988824a368b39856bb0aae046_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-406">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dd88652db04bfd85227e3af36299d5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-407">34,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0015aff2417c4443ad4e068d9de3e0a2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-408">26,701</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73428454c6a240dfba85f104a15e8855_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-409">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d00999723f1430587e349be9d8235cb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-410">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-411">51,921</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-412">46,234</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-413">16,994</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-414">13,174</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-415">34,927</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-416">33,060</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the year ended December&#160;31, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-417">2.1</ix:nonFraction>&#160;million was recognized for the year ended December&#160;31, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-418" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-419">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-420">9,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-421">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-422">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:AccruedNonclinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-423">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:AccruedNonclinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-424">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:AccruedClinicalAndDevelopmentProcessCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-425">5,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:AccruedClinicalAndDevelopmentProcessCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-426">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-427">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-428">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-429">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-430">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-431">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-432">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-433" continuedAt="i7ff89c3cad3740a99153ab05db842c60" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i7ff89c3cad3740a99153ab05db842c60"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2022, none of the goals had been achieved under the license agreements and <ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="INF" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:fixed-zero" scale="0" id="f-434">no</ix:nonFraction> milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#8217;s consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-435" continuedAt="id8d1efafc5ac49e9a08bd22bd5bc0884" escape="true">Stock Plans</ix:nonNumeric></span></div><ix:continuation id="id8d1efafc5ac49e9a08bd22bd5bc0884" continuedAt="i1de4911236c34d93adfeb6f5a7f5821a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (<ix:nonFraction unitRef="number" contextRef="i1498b295afbf4a4490855b8a8cdbb3cf_D20220101-20221231" decimals="INF" name="advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" scale="-2" id="f-436">4</ix:nonFraction>%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="ie0f3cdcaa5c74c348159656932b0209d_I20171031" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-437">600,000</ix:nonFraction> shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="id7ac711d969d4dbfb2019544f7853129_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-438">37,900,792</ix:nonFraction> shares of common stock were reserved for issuance and <ix:nonFraction unitRef="shares" contextRef="id7ac711d969d4dbfb2019544f7853129_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-439">3,202,937</ix:nonFraction> shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to <ix:nonNumeric contextRef="if279653acc6e4cd2badab9c5d64df217_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-440">10</ix:nonNumeric> years and at prices no less than <ix:nonFraction unitRef="number" contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="f-441">100</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a <ix:nonFraction unitRef="number" contextRef="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" scale="-2" id="f-442">10</ix:nonFraction>% stockholder may not be less than <ix:nonFraction unitRef="number" contextRef="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="f-443">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over <ix:nonNumeric contextRef="i6f60854b5a5740ef83803c7983ca8de5_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-444">four years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-445" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-446">10,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-447">7.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i970fe692f1ab49b9a0589b0c713af515_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-448">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-449">31,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-450">8,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-451">7.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-452">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-453">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-454">5,366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-455">10.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-456">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-457">5.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-458">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-459">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-460">10,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-461">1.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-462">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-463">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-464">4,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-465">5.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-466">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-467">3.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-468">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-469">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-470">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-471">5.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-472">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-473">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-474">6,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-475">11.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-476">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-477">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-478">18,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-479">0.1</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i1de4911236c34d93adfeb6f5a7f5821a" continuedAt="i93fbf2cbd32841d2aebce3888f5f0069"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the year ended December&#160;31, 2022 include <ix:nonFraction unitRef="shares" contextRef="i3eebdf1a70334e0bbfac1cd4e13e54d5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-480">2.5</ix:nonFraction>&#160;million shares of performance-based stock options with both performance and service vesting conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-481" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-482">89</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-483">91</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-484">77</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-485">122</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-486">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-487">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-488">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-489">1.2</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-494">2.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-495">1.0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-496">3.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-497">0.1</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2022 and 2021 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-498">0.93</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-499">5.18</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-500">30.4</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-501">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a <ix:nonNumeric contextRef="i8538e8736e164287a7a89d9e822ddfd4_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-502">2</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i8691ff06ffc1432cab9667187afd1df3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-503">4</ix:nonNumeric> year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-504" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i898f06f98a6748bab720765be614526a_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-505">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i898f06f98a6748bab720765be614526a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-506">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a88b50331e3498db3de301a5215fd47_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-507">0.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-508">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-509">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="f-510">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-511">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-512">694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-513">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f966046784044f3987ed481b7a376f1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-514">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f966046784044f3987ed481b7a376f1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-515">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-516">1.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-517">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-518">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="f-519">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-520">3.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-521">455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-522">3.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-523">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-524">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-525">1.2</ix:nonNumeric></span></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December&#160;31, 2022 include <ix:nonFraction unitRef="shares" contextRef="ie5777a3c4cf644a5aa6e2876e0e3e845_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-526">0.4</ix:nonFraction>&#160;million shares of performance stock units with both performance and service vesting conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, total fair value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-527">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-528">1.6</ix:nonFraction>&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-529">1.6</ix:nonFraction>&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-530">1.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="i28339715955e48b08119618310a60857_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-531">208,833</ix:nonFraction>&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (<ix:nonFraction unitRef="number" contextRef="i28339715955e48b08119618310a60857_I20221231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" scale="-2" id="f-532">1</ix:nonFraction>%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i156af0396aec4513abe4f372a8df3dbb_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-533">887,061</ix:nonFraction> shares were issued under the ESPP. As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i28339715955e48b08119618310a60857_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-534">7,043,481</ix:nonFraction> shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i28339715955e48b08119618310a60857_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-535">0.6</ix:nonFraction>&#160;million of unrecognized compensation cost related to the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i93fbf2cbd32841d2aebce3888f5f0069" continuedAt="ifec23706e926456a929fc0d77a7988c2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-536" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7855e85faff848b484bde07a79723de6_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-537">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18307b729fb84369a1680d708830e51b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-538">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-539">12,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7438ee3072e41e794bdd9191b73a3cc_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-540">16,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-541">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-542">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifec23706e926456a929fc0d77a7988c2">During the year ended December&#160;31, 2021, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="6" id="f-543">1.6</ix:nonFraction>&#160;million of stock&#8209;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of certain of its executives and directors.</ix:continuation> </span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="f-544" continuedAt="i6aafc102b2544eaea57f1349c04f5f32" escape="true">401(k) Savings Plan</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6aafc102b2544eaea57f1349c04f5f32">The Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-545">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-546">1.0</ix:nonFraction> million, respectively.</ix:continuation></span></div><div id="i236e9599e5b144f29c9957366d735162_1804"></div><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-547" escape="true"><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Restructuring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by <ix:nonFraction unitRef="employee" contextRef="idd9a1719e37e4f70a2a084ceacc62892_I20220706" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" scale="0" id="f-548">75</ix:nonFraction> employees (approximately <ix:nonFraction unitRef="number" contextRef="idd9a1719e37e4f70a2a084ceacc62892_I20220706" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="f-549">37</ix:nonFraction>%) as of July 6, 2022. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-550" continuedAt="if29b04705a1e4acf8c7c2983f45672b6" escape="true">Below is a summary of restructuring costs during the year ended December&#160;31, 2022:</ix:nonNumeric></span></div><div><ix:continuation id="if29b04705a1e4acf8c7c2983f45672b6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-551">4,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-552">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-553">4,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-554">4,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-556">4,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-558">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-559">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2fd438f1564243a91086e75afa936f_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bfdbc3193a412788e21e1810c123f9_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the year ended December&#160;31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-563">4.7</ix:nonFraction>&#160;million of restructuring costs, of which $<ix:nonFraction unitRef="usd" contextRef="i7855e85faff848b484bde07a79723de6_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-564">3.7</ix:nonFraction>&#160;million was classified as research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-565">1.0</ix:nonFraction>&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.</span></div></ix:nonNumeric><div id="i236e9599e5b144f29c9957366d735162_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-566" continuedAt="i27f867ee91ee441abb39050f4d939273" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i27f867ee91ee441abb39050f4d939273" continuedAt="i1060bd3957794128b2b614081e454b15"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-567" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-568">154,002</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-569">145,375</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-570">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-571">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-572">154,462</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-573">145,540</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i1060bd3957794128b2b614081e454b15" continuedAt="ia4928c0143874964b3471662b72a9cf5"><div style="margin-top:6pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-574" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-575">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-577">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-583">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:12pt"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-585" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2022 and 2021 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-586">32,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-587">30,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-588">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-589">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-590">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-591">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-592">2,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-593">2,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-594">31,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-595">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-596">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-597">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="3" id="f-598">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-599">9,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-600">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-601">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-602">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:continuation id="ia4928c0143874964b3471662b72a9cf5" continuedAt="i44a99c5866b84275af9a3190e809e57f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-604" continuedAt="ib50a92bf080b4c768a6fe8a21700fced" escape="true">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</ix:nonNumeric></span><ix:continuation id="ib50a92bf080b4c768a6fe8a21700fced"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-605">111,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-606">105,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-607">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-608">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-609">21,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-610">16,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-611">10,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-612">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="f-613">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-615">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-616">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-617">26,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-618">24,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-619">9,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-620">9,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:num-dot-decimal" scale="3" id="f-621">23,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-623">207,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-624">170,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-625">188,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-626">148,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-627">19,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-628">21,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-629">19,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-630">20,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-632">1,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-633">19,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-634">21,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased approximately $<ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-637">39.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-638">53.8</ix:nonFraction>&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had U.S. federal net operating losses (&#8220;NOLs&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i48f2b20caf244f849a37d4c8e8327f84_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-639">418.9</ix:nonFraction>&#160;million to offset any future federal income. Approximately $<ix:nonFraction unitRef="usd" contextRef="i48f2b20caf244f849a37d4c8e8327f84_I20221231" decimals="-5" name="advm:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-640">57.3</ix:nonFraction>&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2022, the Company also had U.S. state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i85786b5c81d343789ff2c120dd964eb8_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-641">239.9</ix:nonFraction>&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2022, the Company also had approximately $<ix:nonFraction unitRef="usd" contextRef="i9a146e7e34f3411f8b40f1773b7e8c0a_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-642">49.0</ix:nonFraction>&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i4c8589134e324d12b0bbaf1468c0b43a_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-643">17.5</ix:nonFraction>&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2022, the Company had state credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i5f072761559d486f92055c7cfb714341_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-644">15.5</ix:nonFraction>&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased by $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:num-dot-decimal" scale="6" id="f-645">23.7</ix:nonFraction>&#160;million, net of amortization on research expenses capitalized in current year.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><ix:continuation id="i44a99c5866b84275af9a3190e809e57f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2022 and 2021 of approximately $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-646">24.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-647">21.9</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2022, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $<ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-648">1.0</ix:nonFraction>&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-649" continuedAt="ia9588863df414263890e64d7ee526709" escape="true">A&#160;reconciliation of the unrecognized tax benefits is as follows:</ix:nonNumeric></span><ix:continuation id="ia9588863df414263890e64d7ee526709"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-650">21,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-651">8,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-652">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-653">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-654">2,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-655">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-656">24,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-657">21,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2022 and 2021, the Company accrued interest and penalties related to uncertain tax positions of $<ix:nonFraction unitRef="usd" contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-658"><ix:nonFraction unitRef="usd" contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-659">0.3</ix:nonFraction></ix:nonFraction> million. There are no ongoing examinations by taxing authorities at this time.</span></div></ix:continuation><div id="i236e9599e5b144f29c9957366d735162_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="f-660" continuedAt="i95794e427d7049d9a995c73262f305bc" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i95794e427d7049d9a995c73262f305bc"><ix:nonNumeric contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-661" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96823e332fad42d4a1f4b9064d27f17e_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-662">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iada4fca2d20a473abfe9c9eaec73a105_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-663">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90d6a4e6dcbf4891bbb8bcd22b37a13c_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-664">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib724c14cbcfe4412b6c1ae8d4c5cc41f_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-665">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaaa273c85484c7b8335ccf796b65072_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-666">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80c09039c3df4bae937a95e6a7634f2d_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-667">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-668">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-669">15,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_190"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including Laurent Fisher, our Chief Executive Officer and Linda Rubinstein, our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December&#160;31, 2022. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Annual Report on Form 10-K. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the potential magnitude of the error(s) that could arise from the operating deficiency as potentially material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discussed these matters with our independent registered public accounting firm and our Audit Committee. Our remediation activities are not complete and we continue to seek ways to strengthen the operation of our controls over our financial statement close process, and we may need to continue effective operation of these controls for one or more quarters before we can conclude that the material weakness has been corrected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the existence of the material weakness, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed our internal control over financial reporting as of December&#160;31, 2022, the end of our fiscal year. Management based its assessment on criteria established in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management's assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. This assessment is supported by testing and monitoring performed by our internal accounting and finance organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management has concluded that our internal control over financial reporting was not effective as of December&#160;31, 2022 as a result of the material weakness described above. The results of management's assessment were reviewed with the Audit Committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address our material weaknesses, we have implemented and continue to implement increased rigor to ensure controls operate with regard to material non-routine transactions. Consistent with past practice, preparation of technical accounting memos should operate for all material non-routine transactions, including modifications of existing agreements. Management will consider whether it is appropriate to engage additional outside financial reporting and technical accounting expertise to assist in the determination and analysis of potential accounting and statutory reporting impacts taking into consideration complexity of transactions and to ensure we bridge and improve the knowledge and expertise within Finance on such specific non-routine transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that these efforts will improve our internal control over financial reporting, the implementation of our remediation is ongoing and will require validation and testing of the design and operating effectiveness of our internal controls over a sustained period of financial reporting cycles. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate the material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described under the Remediation Plan above, we have implemented increased rigor to ensure controls operated over material non-routine transactions during the quarter ended December&#160;31, 2022. Such remediation actions were changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_196"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our corporate headquarters are located in Redwood City, California, consisting of approximately 120,000 square feet of office, laboratory, and process development space under a lease that will expire in December 2031, which space is currently not fully utilized. Accordingly, on March 24, 2023, we entered into a Third Amendment to Lease (Partial Lease Termination) (the &#8220;Third Amendment&#8221;), between us and HCP LS Redwood City, LLC (the &#8220;Landlord&#8221;), pursuant to which we are relinquishing approximately one third of the space back to the landlord effective on September 30, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, on March 24, 2023, we entered into a Fourth Amendment to Lease (the &#8220;Fourth Amendment&#8221;), between us and the Landlord, pursuant to which the Landlord is providing to us additional tenant improvement allowance funds in connection with our potential construction of tenant improvements at the portion of our corporate headquarters located in Redwood City, California, that we are not relinquishing back to the landlord.  </span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_199"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not applicable</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i236e9599e5b144f29c9957366d735162_205"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with our 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2022, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; and, if applicable, &#8220;Delinquent Section 16(a) Reports,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the Corporate Governance section of our website, which is located at www.adverum.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for our principal executive officer, principal financial officer, principal accounting officer, controller or persons performing similar functions, or any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K. </span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation&#8221; and &#8220;Non-employee Director Compensation,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_211"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_214"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Corporate Governance,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_217"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the proposal titled, &#8220;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i236e9599e5b144f29c9957366d735162_223"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibit and Financial Statement Schedules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K. No financial statement schedules are provided because the information called for is not required or is shown in the consolidated financial statements or related notes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The following exhibits are included herein or incorporated by reference:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312516588027/d130217dex32.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Description of Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1A&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex109_293.htm">License Agreement between AAVLife and Inserm Transfert, dated as of July 4, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1B&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex1010_292.htm">Amendment No. 1 to License Agreement between AAVLife and Inserm Transfert, dated as of October&#160;5,&#160;2015.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm">Exclusive License Agreement between Avalanche Biotechnologies, Inc. and the Regents of the University of California, dated as of June 17, 2013.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm">License Agreement between Avalanche</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> Biotechnologies, Inc. and Virovek, Inc., dated as of October 12, 2011.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Lease Agreement between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">dated as of June 28, 2018</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex101firstamendment-health.htm">First Lease Amendment between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of April 19, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xex104c.htm">Second Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of November 1, 2021. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx104d.htm">Third Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4E</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx104e.htm">Fourth Amendment to Lease between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex105leasenor.htm">Lease Agreement between Adverum NC, LLC (a wholly owned subsidiary of the Company) and ARE-NC REGION NO. 21, LLC, dated as of January 8, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx105b.htm">Sublease Agreement between Adverum NC, LLC and Jaguar Gene Therapy, LLC, dated as of October 26, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312521063725/d61904dex993.htm">2017 Inducement Plan, as amended and restated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-253727</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex992.htm">Form of Stock Option Grant Notice and Option Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex993.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex1042014esppplanamended.htm">Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit1082014eip.htm">Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1014_1087.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1016_1089.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2014 Equity Incentive </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8D(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312514280644/d729335dex1018.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-197133</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 25, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8E(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx108e.htm">Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8E</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx109.htm">Form of Change in Control and Severance Agreement for executive officers other than the chief executive officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020008534/advm-20200331xex101.htm">Form of Indemnification Agreement for directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex107nonxempl.htm">Non-Employee Director Compensation Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex107nonxempl.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Laurent Fischer, dated as of June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">Change</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> in Control and Severance Agreement between Adverum Biotechnologies, Inc. and Laure</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">n</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">t Fischer, dated </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">as</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> of June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Peter Soparkar, dated as of October 11, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 7, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx1019.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Brigit Riley, dated as of May 21, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx1021.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Setareh Seyedkazemi, dated as of December 3, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.16(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx1022.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Richard Beckman, dated as of December 30, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex101ajrakowofferletter.htm">Employment Agreement between Adverum Biotechnologies, Inc. and John Rakow, dated as of January 20, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex101bjrakowpromotionlette.htm">Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of July 15, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex101cjrakowpromotionsvp.htm">Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of June 4, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.18(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex103consultingagreementnp.htm">Consulting Agreement between Adverum Biotechnologies, Inc. and Nancy E. Pecota, dated as of June 29, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.19A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx1020.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of November 12, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.19B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex102dsouzaseparationagree.htm">Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of June 7, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx10lgxadve.htm">Confidential Consulting Agreement between Adverum Biotechnologies, Inc. and FLG Partners, LLC, dated as of November 22, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx211.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_229">Power of Attorney (included on signature page hereto)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx321.htm">Certification of Principal Executive Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20221231xexx322.htm">Certification of Principal Financial and Accounting Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of the Company's Annual Report on Form 10-K has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification attached to this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div style="padding-left:54pt"><span><br/></span></div><div id="i236e9599e5b144f29c9957366d735162_226"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i236e9599e5b144f29c9957366d735162_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i236e9599e5b144f29c9957366d735162_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;30, 2023 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Laurent Fischer, M.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Rubinstein</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Linda Rubinstein</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Laurent Fischer and Linda Rubinstein, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this annual report on Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Soo Hong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soo Hong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Lupher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Lupher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rabia Gurses Ozden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rabia Gurses Ozden, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Scopa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Scopa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Reed Tuckson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reed Tuckson, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Whitcup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Whitcup, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4D
<SEQUENCE>2
<FILENAME>advm-20221231xexx104d.htm
<DESCRIPTION>EX-10.4D
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib2f4157df2f045db863fa61faeb18316_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.4D</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">THIRD AMENDMENT TO LEASE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">(PARTIAL LEASE TERMINATION)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Third Amendment to Lease (Partial Lease Termination) (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the 24th day of March, 2023, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HCP LS REDWOOD CITY, LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Landlord and Tenant are parties to that certain Lease dated June 28, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by that certain First Amendment to Lease dated April 19, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;,) and that certain Second Amendment to Lease (Partial Lease Termination) dated November 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together with the Original Lease and the First Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whereby Tenant leases approximately 119,642 rentable square feet of space (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RSF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), consisting of (i) all of the rentable area (containing 39,967 RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">900 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the building located at 900 Saginaw Drive, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">900 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) all of the rentable area (containing 79,675 RSF RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">100 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the building located at 100 Cardinal Way, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">100 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">Tenant and Landlord desire to enter into this Third Amendment in order to terminate the Lease with respect to the 900 Premises only and to release one another from their respective obligations thereunder, except as otherwise provided herein.</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing recitals and the conditions and the covenants hereinafter contained, and for other consideration hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Third Amendment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of the Lease of 900 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby agree that conditioned upon the performance by the parties of the provisions of this Third Amendment, the Lease, with respect to the 900 Premises only, shall terminate and be of no further force or effect as of 11&#58;59 P.M. on September 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">900 Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Accordingly, effective as of 11&#58;59 P.M. Pacific Daylight Time on the 900 Termination Date, (i) the 900 Premises shall no longer be considered a part of the Premises, and Landlord and Tenant shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Third Amendment to Lease</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(Partial Lease Termination)&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relieved of their respective obligations under the Lease with respect to the 900 Premises, except those obligations under the Lease which relate to the term of Tenant's lease of the 900 Premises prior to the 900 Termination Date and which specifically survive the expiration of the Lease (unless otherwise set forth elsewhere in this Third Amendment) (including, without limitation, Tenant&#8217;s payment of reconciliation of Direct Expenses) and Landlord shall have all the rights and remedies with respect to such obligations as set forth in the Lease, and (ii) the &#8220;Premises&#8221; shall consist only of the 100 Premises, and the &#8220;Building&#8221; shall mean only the 100 Building.  Nothing contained herein shall relieve Landlord or Tenant of their respective obligations with respect to the 100 Premises.  In the event that Tenant retains possession of the 900 Premises or any part thereof after the 900 Termination Date, then the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Original Lease shall apply. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Surrender of 900 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Tenant hereby agrees to vacate the 900 Premises and surrender and deliver exclusive possession of the 900 Premises to Landlord on or before the 900 Termination Date and Landlord hereby agrees to accept the 900 Premises, in its condition as of the date hereof as full satisfaction of Tenant&#8217;s repair, maintenance and surrender obligations under the Lease except that the 900 Premises shall be in vacant broom clean condition, and holes patched and painted to match nearby areas.  Landlord hereby acknowledges that Tenant shall not be required to remove or restore any of the alterations and improvements existing in or serving the 900 Premises as of the date of this Third Amendment (including the Pad, Pad Equipment, Rooftop Equipment, or Lines serving the 900 Premises).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby acknowledge that, in accordance with the Lease, Tenant has previously delivered to Landlord an L-C in the amount of $2,502,813.54.  Provided that Tenant is not in default of this Lease as of the 900 Termination Date, then in connection with the termination of the Lease with respect to the 900 Premises, the L-C shall be subject to reduction following the 900 Termination Date to a new total of $1,881,586.10.  Such reduction shall be accomplished by means of an amendment to the L&#8209;C issued following the 900 Termination Date (which amendment shall be in form and content reasonably acceptable to Landlord) or a new L-C in such reduced amount (which amendment shall be in form and content reasonably acceptable to Landlord and in compliance with the terms of the Lease).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations of Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Tenant represents and warrants to Landlord that (a) Tenant has not heretofore assigned or sublet all or any portion of its interest in the 900 Premises&#59; (b) no other person, firm or entity has any right, title or interest in the 900 Premises through Tenant&#59; (c) Tenant has the full right, legal power and actual authority to enter into this Third Amendment and to terminate the Lease with respect to the 900 Premises without the consent of any person, firm or entity&#59; and (d) Tenant has the full right, legal power and actual authority to bind Tenant to the terms and conditions hereof.  Tenant further represents and warrants to Landlord that as of the date hereof there are no, and as of the 900 Termination Date there shall not be any, mechanic's liens or other liens encumbering all or any portion of the 900 Premises, by virtue of any act or omission on the part of Tenant, its predecessors, contractors, agents, employees, successors or assigns.  Notwithstanding the termination of the Lease with respect to the 900 Premises and the release of liability provided for herein, the representations and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-2-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Third Amendment to Lease</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(Partial Lease Termination)&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">warranties set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the 900 Termination Date and Tenant shall be liable to Landlord for any inaccuracy or any breach thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of Landlord and Tenant represents and warrants to the other that it has (a) the full right, legal power and actual authority to enter into this Third Amendment and to terminate the Lease with respect to the 900 Premises without the consent of any person, firm or entity&#59; and (b) the full right, legal power and actual authority to bind itself to the terms and conditions hereof.  Landlord represents and warrants that there is no mortgage or deed of trust encumbering the 900 Premises and Landlord has the full right, legal power and actual authority to enter into this Third Amendment and to terminate the Lease with respect to the 900 Premises without the consent of any person, firm or entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Remainder of Premises&#59; Notice Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary herein, and for the avoidance of doubt, all terms of the Lease with respect to the 100 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall (i) not be affected by this Third Amendment or the termination of the Lease with respect to the 900 Premises, and (ii) shall remain in full force and effect, including but not limited to Tenant&#8217;s extension rights set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. of the Original Lease and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the First Amendment with respect to the 100 Premises and Tenant&#8217;s right to use of any EV Spaces serving the 100 Premises pursuant to the terms of the Lease.  Effective as of the 900 Termination Date, Tenant&#8217;s address for Notices shall be amended to&#58;</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. </font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">100 Cardinal Way </font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Redwood City, California 94063 </font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Chief Financial Officer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Disposition of Personal Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except for any Personal Property (defined below) that Tenant and Landlord and&#47;or Landlord&#8217;s successor tenant may agree can remain in the 900 Premises, in the event that Tenant does not remove any of its personal property, equipment and signage (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Personal Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from the 900 Premises prior to the 900 Termination Date, Tenant acknowledges that Landlord shall be entitled, but shall not be obligated, to dispose of said Personal Property in any manner it deems fit, and charge the cost of such disposal to Tenant.  Tenant hereby waives any rights it may have to notice under California Civil Code sections 1980 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">et</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  with respect to such Personal Property.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Attorneys' Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Should any dispute arise between the parties hereto or their legal representatives, successors and assigns concerning any provision of this Third Amendment or the rights and duties of any person in relation thereto, the party prevailing in such dispute shall be entitled, in addition to such other relief that may be granted, to recover reasonable attorneys' fees and legal costs in connection with such dispute.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Third Amendment shall be governed and construed under the laws of the State of California.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-3-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Third Amendment to Lease</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(Partial Lease Termination)&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Third Amendment may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement.  The parties hereto consent and agree that this Third Amendment may be signed and&#47;or transmitted by facsimile, e-mail of a .pdf document or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party's handwritten signature. The parties further consent and agree that (1) to the extent a party signs this Third Amendment using electronic signature technology, by clicking &#8220;SIGN&#8221;, such party is signing this Third Amendment electronically, and (2) the electronic signatures appearing on this Third Amendment shall be treated, for purposes of validity, enforceability and admissibility, the same as handwritten signatures.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Third Amendment shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective legal representatives, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Time of the Essence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Time is of the essence of this Third Amendment and the provisions contained herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby agree to execute such further documents or instruments as may be necessary or appropriate to carry out the intention of this Third Amendment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties have read this Third Amendment and mutual release as contained herein, and on the advice of counsel they have freely and voluntarily entered into this Third Amendment.  </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;SIGNATURES APPEAR ON THE FOLLOWING PAGE&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Third Amendment to Lease</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(Partial Lease Termination)&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Third Amendment as of the day and year first above written.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">HCP LS REDWOOD CITY, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:0.6pt"><font><br></font></div><div style="text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,</font></div><div style="text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware corporation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Scott Bohn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Peter Soparkar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Scott Bohn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Peter Soparkar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Development Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Reviewed by ADVM Legal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">JR</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-5-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Third Amendment to Lease</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(Partial Lease Termination)&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4E
<SEQUENCE>3
<FILENAME>advm-20221231xexx104e.htm
<DESCRIPTION>EX-10.4E
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1316acfbbb284ca3913e2872e68c4ec4_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.4E</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FOURTH AMENDMENT TO LEASE </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Fourth Amendment to Lease (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the 24th day of March, 2023, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HCP LS REDWOOD CITY, LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Landlord and Tenant are parties to that certain Lease dated June 28, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by that certain First Amendment to Lease dated April 19, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;,) and that certain Second Amendment to Lease (Partial Lease Termination) dated November 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and that certain Third Amendment to Lease (Partial Lease Termination) dated March 24, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together with the Original Lease, the First Amendment and the Second Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whereby Tenant leases (subject to Recital B below) approximately 119,642 rentable square feet of space (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RSF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), consisting of (i) all of the rentable area (containing 39,967 RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">900 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the building located at 900 Saginaw Drive, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">900 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) all of the rentable area (containing 79,675 RSF RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">100 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expansion Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the building located at 100 Cardinal Way, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">100 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">Landlord and Tenant are concurrently entering into the Third Amendment in order to provide for the termination of the Lease with respect to the 900 Premises pursuant to the terms thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">Tenant and Landlord desire to enter into this Fourth Amendment in order to provide for additional tenant improvement allowance funds in connection with Tenant&#8217;s ongoing construction of Tenant Improvements in the 100 Premises pursuant to the terms of the Tenant Work Letter attached to the First Amendment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Amendment Tenant Work Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and otherwise amend the Lease pursuant to the terms hereof.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing recitals and the conditions and the covenants hereinafter contained, and for other consideration hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Fourth Amendment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Fourth Amendment to Lease&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Second Additional Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Pursuant to the terms of the First Amendment Tenant Work Letter, Tenant received an Expansion Premises Tenant Improvement Allowance and an Additional TI Allowance in connection with Tenant&#8217;s construction of Expansion Tenant Improvements in the 100 Premises (referred to therein as the Expansion Premises).  In addition to the foregoing allowances, from and after the date of this Fourth Amendment, Tenant shall have the right, by written notice to Landlord given on or before the Second Additional TI Allowance Outside Date, to cause Landlord to provide up to $2,000,000.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) towards the payment of the costs of the Tenant Improvement Allowance Items for the 100 Premises only (referred to in the First Amendment Tenant Work Letter as the Expansion Premises) as additional Expansion Tenant Improvements, and accordingly the construction of such Expansion Tenant Improvements and corresponding disbursement of the Second Additional TI Allowance shall be pursuant to the terms of the First Amendment Tenant Work Letter, and accordingly the terms of such First Amendment Tenant Work Letter are incorporated herein by reference.  In the event Tenant timely exercises its right to use all or any portion of the Second Additional TI Allowance, Tenant shall be required to pay Landlord, commencing on the first day of the calendar month following the month during which Landlord makes the first disbursement of the Second Additional TI Allowance that Tenant has elected to use (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Payment Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the &#8220;Second Additional TI Allowance Payment,&#8221; as that term is defined below, in consideration of Landlord&#8217;s provision of the Second Additional TI Allowance.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Additional TI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Allowance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be determined as the missing component of an annuity, which annuity shall have (i) the amount of the Second Additional TI Allowance utilized by Tenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Utilized Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as the present value amount, (ii) a number equal to the number of full calendar months then remaining in the Lease Term as the number of payments, (iii) a monthly interest factor equal to seventy-five one-hundredths percent (0.75%), which is equal to nine percent (9%) divided by twelve (12) months per year, and (iv) the Second Additional TI Allowance Payment as the missing component of the annuity.  For the avoidance of doubt, such amounts shall not be subject to annual increase.  Following the calculation of the Second Additional TI Allowance Payment, Landlord and Tenant will enter into a lease amendment to confirm the amount thereof.  Provided that Tenant has timely elected to cause Landlord to provide all or any portion of the Second Additional TI Allowance, any portion of the Second Additional TI Allowance as to which Tenant has not properly requested disbursement by September 30, 2026 (as such date may be extended by one (1) day for each day of delay by Tenant in completing the Expansion Tenant Improvements due to an event that qualifies as a Landlord Caused Delay or Coronavirus Delay (as such terms are defined in the First Amendment Tenant Work Letter)) (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Second Additional TI Allowance Outside Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), shall revert to Landlord and Tenant shall have no further rights with respect thereto.  For the avoidance of doubt, Tenant is not required to expend the Second Additional TI Allowance equally across the 100 Premises (or Expansion Premises).  The terms of Section 2.3 of the First Amendment Tenant Work Letter shall also apply to the Second Additional TI Allowance.  Landlord hereby approves DGA or CAS as the Architect and Landmark Builders, XL, Hathaway Dinwiddie, Novo Construction or Dome Construction as the Contractor.  A fee payable to PMA in the amount of $1.83 per RSF of the portion of the 100 Premises (or Expansion Premises) that are subject to the construction of the Expansion Tenant Improvements paid for with the Second Additional TI Allowance (rather than the amount set forth in Section 4.1.1 of the First Amendment Tenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-2-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Fourth Amendment to Lease&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Work Letter), shall be payable to Landlord from the Second Additional TI Allowance.  Landlord generally approves the construction of laboratory space on the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor of the 100 Premises, provided that the implementation of the same remains subject to Landlord&#8217;s review and approval pursuant to the terms of the Lease and the First Amendment Tenant Work Letter.  In connection with the foregoing, Landlord may require removal and restoration of the Expansion Tenant Improvements that utilize the Second Additional TI Allowance only if Landlord has not agreed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the First Amendment that such Tenant Improvements do not need to be restored and provides written notice to Tenant at the time Landlord provides consent to the proposed Expansion Tenant Improvements and the same constitute &#8220;Specialty Improvements&#8221; (as hereinafter defined).  As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Specialty Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, any alterations, additions or improvements made to the 100 Premises which are not typical alterations, additions or improvements found in the premises of tenants of similar, First Class Life Sciences Projects.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Pursuant to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Third Amendment, following the reduction of the L-C due to the termination of the Lease with respect to the 900 Premises, the L-C to be held by Landlord shall be in the amount of $1,881,586.10 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Current L-C Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In the event Tenant exercises its right to use all or any portion of the Second Additional TI Allowance, then notwithstanding anything in the Lease to the contrary, Tenant shall be required to increase such Current L-C Amount by an amount equal to ten percent (10%) of the Utilized Amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">L-C Increase Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Accordingly, within ten (10) business days of Tenant&#8217;s election to utilize all or any portion of the Second Additional TI Allowance, Tenant shall provide an L-C (via delivery of a new L-C in an amount equal to the sum of the Current L-C Amount and the L-C Increase Amount or an amendment to the existing L-C increasing the L-C by the L-C Increase Amount) which shall in either event be in a form reasonably acceptable to Landlord and in conformance with the terms of the Lease.  To the extent that Tenant delivers a new, replacement L-C (rather than an amendment to the existing L-C), Landlord shall return the existing L-C within ten (10) business days following receipt of such new, replacement L-C.  To the extent that the total amount held by Landlord at any time as security for the Lease, as hereby amended, is less than the amount required, Tenant shall provide the difference to Landlord pursuant to the terms of the Lease.  Landlord and Tenant will enter into a lease amendment to confirm the terms of this Section 3 in the event Tenant elects to utilize all or any portion of the Second Additional TI Allowance.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord represents and warrants that there is no mortgage or deed of trust encumbering the 100 Building.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Counterparts&#59; Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Fourth Amendment may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement.  The parties hereto consent and agree that this Fourth Amendment may be signed and&#47;or transmitted by facsimile, e-mail of a .pdf document or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party's handwritten signature. The parties further consent and agree that (1) to the extent a party signs this Fourth Amendment using electronic signature technology, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-3-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Fourth Amendment to Lease&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by clicking &#8220;SIGN&#8221;, such party is signing this Fourth Amendment electronically, and (2) the electronic signatures appearing on this Fourth Amendment shall be treated, for purposes of validity, enforceability and admissibility, the same as handwritten signatures.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Fourth Amendment shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective legal representatives, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Time of the Essence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Time is of the essence of this Fourth Amendment and the provisions contained herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby agree to execute such further documents or instruments as may be necessary or appropriate to carry out the intention of this Fourth Amendment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties have read this Fourth Amendment and mutual release as contained herein, and on the advice of counsel they have freely and voluntarily entered into this Fourth Amendment.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Further Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in this Fourth Amendment, all of the terms and provisions of the Lease shall remain unmodified and in full force and effect.  </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;SIGNATURES APPEAR ON THE FOLLOWING PAGE&#93;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Fourth Amendment to Lease&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Fourth Amendment as of the day and year first above written.  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">HCP LS REDWOOD CITY, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware limited liability company</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:0.6pt"><font><br></font></div><div style="text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,</font></div><div style="text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware corporation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Scott Bohn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Peter Soparkar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Scott Bohn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Peter Soparkar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Development Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Reviewed by ADVM Legal&#58; JR</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-5-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">HCP LS REDWOOD CITY, LLC</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Fourth Amendment to Lease&#93;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#91;Adverum Biotechnologies, Inc.&#93;</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>4
<FILENAME>advm-20221231xexx10lgxadve.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iafb99f51e2ed4a4fa18beb114452e1a0_33"></div><div style="min-height:108pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Exhibit 10.20</font></div><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Confidential Consulting Agreement (the &#8220;Agreement&#8221;) is executed as of the date shown on the signature page (the &#8220;Effective Date&#8221;), by and between FLG Partners, LLC, a California limited liability company (&#8220;FLG&#8221;), and the entity identified on the signature page (&#8220;Client&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, FLG is in the business of providing certain financial services&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.454%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt;text-decoration:underline">Services.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Commencing on the Effective Date, FLG will perform those services (the &#8220;Services&#8221;) described in one or more exhibits attached hereto.  Such services shall be performed by the member or members of FLG identified in Exhibit A (collectively, the &#8220;FLG Member&#8221;).</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Client acknowledges and agrees that FLG&#8217;s success in performing the Services hereunder will depend upon the participation, cooperation and support of Client&#8217;s most senior management.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Notwithstanding anything in Exhibit A or elsewhere in this Agreement to the contrary, neither FLG nor any of its members shall serve as an employee, an appointed officer, or an elected director of Client.  Consistent with the preceding&#58; (i) Client shall not appoint FLG Member as a corporate officer in Client&#8217;s corporate minutes&#59; (ii) Client shall not elect FLG Member to its board of directors or equivalent governing body&#59; and (iii) the FLG Member shall have no authority to sign any documents on behalf of Client, including, but not limited to, federal or state securities filings, tax filings, or representations and warranties on behalf of Client </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as pursuant to a specific resolution(s) of Client&#8217;s board of directors or equivalent governing body granting such authority to FLG Member as a non-employee consultant to Client.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">The Services provided by FLG and FLG Member hereunder shall not constitute an audit, attestation, review, compilation, or any other type of financial statement reporting engagement (historical or prospective) that is subject to the rules of the California Board of Accountancy, the AICPA, or other similar state or national licensing or professional bodies.  Client agrees that any such services, if required, will be performed separately by its independent public accountants or other qualified consultants.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.12pt">During the term of this Agreement, Client shall not hire or retain the FLG Member as an employee, consultant or independent contractor except pursuant to this Agreement.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Compensation&#59; Payment&#59; Deposit&#59; Expenses.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">As compensation for Services rendered by FLG hereunder, Client shall pay FLG the amounts set forth in Exhibit A for Services performed by FLG hereunder (the &#8220;Fees&#8221;).  The Fees shall be net of any and all taxes, withholdings, duties, customs, bank fees, social contributions or other reductions imposed by any and all authorities which are required to be withheld or collected by Client or FLG, including ad valorem, sales, gross receipts or similar taxes, but excluding US income taxes based upon FLG&#8217;s or FLG Member&#8217;s net taxable income.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Consistent with common practice in professional services, FLG reserves the right to increase the Fee set forth in Exhibit A no more frequently than on the annual anniversary of the Effective Date, and no sooner than the first anniversary of the Effective Date. Notice of any such increase will be made no less than thirty (30) days in advance of such of Fee increase.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">As additional compensation to FLG, Client will pay FLG the incentive bonus or warrants or options, if any, set forth in Exhibit A.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Client shall pay FLG all amounts owed to FLG under this Agreement upon Client&#8217;s receipt of invoice, with no purchase order required.  Invoices should be addressed to Adverum Biotechnologies, Inc., Attn&#58; Accounts Payable via e-mail at&#58; invoices&#64;adverum.coupahost.com, with a copy to Laurent Fischer via email at&#58; lfischer&#64;adverum.com and must include detail supporting the amounts that are billed. Upon execution of this Agreement, an authorized Purchase Order will be issued.  The Purchase Order number should be included on each invoice.  Any invoices more than thirty (30) days overdue will accrue a late payment fee at the rate of one and 50&#47;100 percent (1.5%) per month.  FLG shall be entitled to recover all costs and expenses (including, without limitation, attorneys&#8217; fees) incurred by it in collecting any amounts overdue under this Agreement.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Client hereby agrees to pay FLG a deposit as set forth on Exhibit A (the &#8220;Deposit&#8221;) to be held in its entirety as security for Client&#8217;s future payment obligations to FLG under this Agreement.  Upon termination of this Agreement, all amounts then owing to FLG under this Agreement shall be charged against the Deposit and the balance thereof, if any, shall be refunded to Client.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.12pt">Within ten (10) days of Client&#8217;s receipt of an expense report from FLG&#8217;s personnel performing Services hereunder, Client shall immediately reimburse FLG personnel directly for reasonable travel and out-of-pocket business expenses detailed in such expense report.  Any required air travel, overnight accommodation and resulting per diem expenses shall be consistent with Client&#8217;s travel &#38; expense policies for Client&#8217;s employed executive staff.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Relationship of the Parties.  </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">FLG&#8217;s relationship with Client will be that of an independent contractor and nothing in this Agreement shall be construed to create a partnership, joint venture, or employer-employee relationship.  FLG is not the agent of Client and is not authorized to make any presentation, contract, or commitment on behalf of Client unless specifically requested or authorized to do so by Client in writing.  FLG agrees that all taxes payable as a result of compensation payable to FLG hereunder shall be FLG&#8217;s sole liability.  FLG shall defend, indemnify and hold harmless Client, Client&#8217;s officers, directors, employees and agents, and the administrators of Client&#8217;s benefit plans from and against any claims, liabilities or expenses relating to such taxes or compensation.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Term and Termination.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">The term of this Agreement shall be for the period set forth in Exhibit A.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Either party may terminate this Agreement upon thirty (30) calendar days advance written notice to the other party.</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Initial&#58; Client  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"> PS  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">  </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">FLG  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"> UHO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Page 1 of 5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="iafb99f51e2ed4a4fa18beb114452e1a0_64"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:48.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.261%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Either party may terminate this Agreement immediately upon a material breach of this Agreement by the other party and a failure by the other party to cure such breach within ten (10) days of written notice thereof by the non-breaching party to the breaching party.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">FLG shall have the right to terminate this Agreement immediately without advance written notice (i) if Client is engaged in, or requests that FLG or the FLG Member undertake or ignore any illegal or unethical activity, or (ii) upon the death or disability of the FLG Member.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.12pt">This Agreement shall be deemed terminated if during any six month period no billable hours occur, with the termination date effective on the date of the last billable hour therein.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.56pt">If at any time during the one (1) year period following termination of this Agreement Client shall hire or retain the FLG Member as an employee, consultant or independent contractor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AND in so doing induce, compel or cause FLG Member to leave FLG as a precondition to commencing or continuing employment or consultancy with Client</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Client shall immediately pay to FLG in readily available funds a recruiting fee equal to the annualized amount of Fees payable hereunder, which shall equal either (i) 260 multiplied by the daily rate, if this Agreement provides for Fees payable by daily rate, or (ii) 2,100 multiplied by the hourly rate, if this Agreement provides for Fees payable by hourly rate, multiplied by thirty percent (30%).</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Disclosures</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">IRS Circular 230.  To ensure compliance with requirements imposed by the IRS effective June 20, 2005, FLG hereby informs Client that any tax advice offered during the course of providing, or arising out of, the Services rendered pursuant to this Agreement, unless expressly stated otherwise, is not intended or written to be used, and cannot be used, for the purpose of&#58; (i) avoiding tax-related penalties under the Internal Revenue Code, or (ii) promoting, marketing or recommending to another party any tax-related matter(s) said tax advice address(es).</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Attorney-Client Privilege.  Privileged communication disclosed to FLG or FLG Member may waive the privilege through no fault of FLG.  FLG strongly recommends that Client consult with legal counsel before disclosing privileged information to FLG or FLG Member.  Pursuant to Paragraph 6, neither FLG nor FLG Member will be responsible for damages caused through Client&#8217;s waiver of privilege, whether deliberate or inadvertent, by disclosing such information to FLG or FLG Member.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:12pt;text-decoration:underline">DISCLAIMERS AND LIMITATION OF LIABILITY.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EXCEPT AS EXPRESSLY SET FORTH HEREIN, ALL SERVICES TO BE PROVIDED BY FLG AND FLG MEMBER (FOR PURPOSES OF THIS PARAGRAPH 6, COLLECTIVELY &#8220;FLG&#8221;) HEREUNDER ARE PROVIDED &#8220;AS IS&#8221; WITHOUT ANY WARRANTY WHATSOEVER.  CLIENT RECOGNIZES THAT THE &#8220;AS IS&#8221; CLAUSE OF THIS AGREEMENT IS AN IMPORTANT PART OF THE BASIS OF THIS AGREEMENT, WITHOUT WHICH FLG WOULD NOT HAVE AGREED TO ENTER INTO THIS AGREEMENT.  FLG EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, TERMS OR CONDITIONS, WHETHER EXPRESS, IMPLIED, OR STATUTORY, REGARDING THE PROFESSIONAL SERVICES, INCLUDING ANY, WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR A PARTICULAR PURPOSE AND INFRINGEMENT.  NO REPRESENTATION OR OTHER AFFIRMATION OF FACT REGARDING THE SERVICES PROVIDED HEREUNDER SHALL BE DEEMED A WARRANTY FOR ANY PURPOSE OR GIVE RISE TO ANY LIABILITY OF FLG WHATSOEVER.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IN NO EVENT SHALL FLG BE LIABLE FOR ANY INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, UNDER ANY CIRCUMSTANCES, INCLUDING, BUT NOT LIMITED TO&#58; LOST PROFITS&#59; REVENUE OR SAVINGS&#59; WAIVER BY CLIENT, WHETHER INADVERTENT OR INTENTIONAL, OF CLIENT&#8217;S ATTORNEY-CLIENT PRIVILEGE THROUGH CLIENT&#8217;S DISCLOSURE OF LEGALLY PRIVILEGED INFORMATION  TO FLG&#59; OR THE LOSS, THEFT, TRANSMISSION OR USE, AUTHORIZED OR OTHERWISE, OF ANY DATA, EVEN IF CLIENT OR FLG HAVE BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN, OF THE POSSIBILITY THEREOF.  NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, FLG&#8217;S AGGREGATE CUMULATIVE LIABILITY HEREUNDER, WHETHER IN CONTRACT, TORT, NEGLIGENCE, MISREPRESENTATION, STRICT LIABILITY OR OTHERWISE, SHALL NOT EXCEED AN AMOUNT EQUAL TO THE LAST TWO (2) MONTHS OF FEES PAYABLE BY CLIENT UNDER PARAGRAPH 2(A) OF THIS AGREEMENT.  CLIENT ACKNOWLEDGES THAT THE COMPENSATION PAID BY IT UNDER THIS AGREEMENT REFLECTS THE ALLOCATION OF RISK SET FORTH IN THIS AGREEMENT AND THAT  FLG WOULD NOT ENTER INTO THIS AGREEMENT WITHOUT THESE LIMITATIONS ON ITS LIABILITY. THIS PARAGRAPH SHALL NOT APPLY TO EITHER PARTY WITH RESPECT TO A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS. </font></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:1.23pt">&#160;As a condition for recovery of any amount by Client against FLG, Client shall give FLG written notice of the alleged basis for liability within ninety (90) days of discovering the circumstances giving rise thereto, in order that FLG will have the opportunity to investigate in a timely manner and, where possible, correct or rectify the alleged basis for liability&#59; provided that the failure of Client to give such notice will only affect the rights of Client to the extent that FLG is actually prejudiced by such failure.  Notwithstanding anything herein to the contrary, Client must assert any claim against FLG by the sooner of&#58; (i) ninety (90) days after discovery&#59; (ii) ninety (90) days after the termination of this Agreement&#59; (iii) ninety (90) days after the last date on which the Services were performed&#59; or, (iv) sixty (60) days after completion of a financial or accounting audit for the period(s) to which a claim pertains. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:1.23pt">FLG and FLG Member acting in relation to any of the affairs of Client shall, to the fullest extent permitted by law, as now or hereafter in effect, be indemnified and held harmless, and such right to indemnification shall continue to apply to FLG and FLG Member following the term of this Agreement out of the assets and profits of the Client from and against all actions, costs, charges, losses, damages, liabilities and expenses which FLG or FLG Member, or FLG&#8217;s or FLG Member&#8217;s heirs, executors or administrators, shall or may incur or sustain by or by reason for any act done, concurred in or omitted in or about the execution of FLG&#8217;s or FLG Member&#8217;s duty or services performed on behalf of Client&#59; and Client shall advance the reasonable attorney&#8217;s fees, costs and expenses incurred by FLG or FLG&#8217;s Member in connection with litigation related to the foregoing on the same basis as such advancement would be available to the Client&#8217;s officers and directors, PROVIDED THAT Client shall not be obligated to make payments to or on behalf of any person (i) in connection with services provided  by such person outside the scope of Services contemplated by this Agreement, and not authorized or consented to by Client&#8217;s CEO or Board of Directors, or (ii) in respect of any (a) gross negligence or willful misconduct of such person, or (b) negligence of such person, but only to the </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initial&#58; Client </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"> PS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;FLG </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">  UHO </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 2 of 5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:48.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.261%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">extent that FLG&#8217;s errors and omissions liability insurance would cover such person for such negligence without regard to Client&#8217;s obligation to indemnify FLG hereunder. </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">FLG and FLG Member shall have no liability to Client relating to the performance of its duties under this Agreement except in the event of FLG&#8217;s or FLG Member&#8217;s gross negligence or willful misconduct.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">FLG and FLG Member agree to waive any claim or right of action FLG or FLG Member might have whether individually or by or in the right of Client, against any director, secretary and other officers of Client and the liquidator or trustees (if any) acting in relation to any of the affairs of Client and every one of them on account of any action taken by such director, officer, liquidator or trustee or the failure of such director, officer, liquidator or trustee to take any action in the performance of his duties with or for Client&#59; PROVIDED THAT such waiver shall not extend to any matter in respect of any gross negligence or willful misconduct which may attach to any such persons.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Representations and Warranties.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Each party represents and warrants to the other that it is authorized to enter into this Agreement and can fulfill all of its obligations hereunder.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">FLG and FLG Member warrant that they shall perform the Services diligently, with due care, and in accordance with prevailing industry standards for comparable engagements and the requirements of this Agreement.  FLG and FLG Member warrant that FLG Member has sufficient professional experience to perform the Services in a timely and competent manner.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Each party represents and warrants that it has and will maintain a policy or policies of insurance with reputable insurance companies providing the members, officers and directors, as the case may be, of itself with coverage for losses from wrongful acts. FLG covenants that it has an error and omissions insurance policy in place in the form provided to Client prior to or contemporaneously with the date of execution of this Agreement and will continue to maintain such policy or equivalent policy provided that such policy or equivalent policy shall be available at commercially reasonable rates.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Work Product License.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The parties do not anticipate that FLG or FLG Member will create any intellectual property for Client in performing the Services pursuant to this Agreement.  However, FLG and FLG Member grant to Client a world-wide, perpetual, exclusive, royalty-free, irrevocable license to use and create derivative works from all tangible and electronic documents, spreadsheets, and financial models (collectively, &#8220;Work Product&#8221;) produced or authored by FLG Member in the course of performing the Services pursuant to this Agreement. Any patent rights arising out of the Services will be assigned to and owned by Client and not FLG or FLG Member. All other rights, including, but not limited to, the residual memory of any methods, discoveries, developments, improvements, know-how, ideas, insights, analytical concepts and skills directly inherent to, or reasonably required for, the competent execution of FLG Member&#8217;s profession as a chief financial officer are reserved in their entirety by FLG and FLG Member.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Any notice required or permitted to be given by either party hereto under this Agreement shall be in writing and shall be personally delivered or sent by a reputable courier mail service (e.g., Federal Express) or by facsimile confirmed by reputable courier mail service, to the other party as set forth in this Paragraph 10(A).  Notices will be deemed effective two (2) days after deposit with a</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">reputable courier service or upon confirmation of receipt by the recipient from such courier service or the same day if sent by facsimile and confirmed as set forth above.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If to FLG&#58;</font></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U. Heather Ogan</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FLG Partners, LLC</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">228 Hamilton Ave., 3rd Floor, </font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Palo Alto, CA 94301</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PO BOX 192304</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">San Francisco, CA  94119</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; 707-373-0837</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fax&#58; 415-456-1191</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:40.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E-mail&#58; accounting&#64;flgpartners.com</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If to Client&#58;  the address, telephone numbers and email address shown below Client&#8217;s signature on the signature page.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">This Agreement will be governed by and construed in accordance with the laws of California without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.67pt">Any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement (including any other agreement(s) contemplated hereunder), including, without limitation, any action or claim based on tort, contract, or statute (including any claims of breach or violation of statutory or common law protections from discrimination, harassment and hostile working environment), or concerning the interpretation, effect, termination, validity, performance and&#47;or breach of this Agreement (&#8220;Claim&#8221;), shall be resolved by final and binding arbitration before a single arbitrator (&#8220;Arbitrator&#8221;) selected from and administered by the San Francisco office of JAMS (the &#8220;Administrator&#8221;) in accordance with its then existing commercial arbitration rules and procedures.  The arbitration shall be held in San Francisco, California.  The Arbitrator shall, within fifteen (15) calendar days after the conclusion of the Arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded.  The Arbitrator also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief he or she deems just and equitable and within the scope of this Agreement, including, without limitation, an injunction or order for specific performance.  Each party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the Administrator and the Arbitrator&#59; provided, however, the Arbitrator shall be authorized to determine whether a party is the prevailing party, and if so, to award to that prevailing party reimbursement for its reasonable attorneys&#8217; fees, costs and disbursements, and&#47;or the fees and costs of the Administrator and the Arbitrator. The Arbitrator's award may be enforced in any court of competent jurisdiction.  Notwithstanding the foregoing, nothing in this Paragraph 10(C) will restrict either party from applying to any court of competent jurisdiction for injunctive relief.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Neither party may assign its rights or delegate its obligations hereunder, either in whole or in part, whether by operation of law or otherwise, without the prior written consent of the other party&#59; provided, however, that FLG may assign its rights and delegate its obligations hereunder to any affiliate of FLG.  The rights and liabilities of the parties under this Agreement will bind and inure to the benefit of the parties&#8217; respective successors and permitted assigns.</font></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.12pt">If any provision of this Agreement, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, the remainder of this Agreement and application of such provision to other persons or circumstances shall be interpreted so as best to </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initial&#58; Client </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"> PS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;FLG </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">  UHO </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 3 of 5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:48.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.261%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">reasonably effect the intent of the parties.  The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provision.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.56pt">This Agreement, the Exhibits, and any executed Non-Disclosure Agreements specified herein and thus incorporated by reference constitute the entire understanding and agreement of the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous agreements or understandings, express or implied, written or oral, between the parties with respect hereto.  The express terms hereof control and supersede any course of performance or usage of the trade inconsistent with any of the terms hereof.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Any term or provision of this Agreement may be amended, and the observance of any term of this Agreement may be waived, only by a writing signed by the parties.  The waiver by a party of any breach hereof for default in payment of any amount due hereunder or default in the performance hereof shall not be deemed to constitute a waiver of any other default or succeeding breach or default.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">Upon completion of the engagement hereunder FLG may place customary &#8220;tombstone&#8221; advertisements using Client&#8217;s logo and name in publications of FLG&#8217;s choice at its own expense, and&#47;or cite the engagement in similar fashion on FLG&#8217;s website.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.34pt">If Client discloses FLG Member&#8217;s name on Client&#8217;s website (such as in an executive biography, for example), press releases, SEC filings and other public documents and media, then Client shall include in the description of FLG Member a sentence substantially the same as &#8220;&#91;FLG Member&#93; is also a partner at FLG Partners, a leading CFO services firm in Silicon Valley.&#8221;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.89pt">If and to the extent that a party&#8217;s performance of any of its obligations pursuant to this Agreement is prevented, hindered or delayed by fire, flood, earthquake, elements of nature or acts of God, acts of war, terrorism, riots, civil disorders, rebellions or revolutions, or any other similar cause beyond the reasonable control of such party (each, a &#8220;Force Majeure Event&#8221;), and such non-performance, hindrance or delay could not have been prevented by reasonable precautions of the non-performing party, then the non-performing, hindered or delayed party shall be excused for such non-performance, hindrance or delay, as applicable, of those obligations affected by the Force Majeure Event for as long as such Force Majeure Event continues and such party continues to use its best efforts to recommence performance whenever and to whatever extent possible without delay, including through the use of alternate sources, workaround plans or other means.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.23pt">This Agreement may be executed in any number of counterparts and by the parties on separate counterparts, each of which when executed and delivered shall constitute an original, but all the counterparts together constitute one and the same instrument.</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.12pt">This Agreement may be executed by facsimile signatures (including electronic versions of this document in Adobe Acrobat Portable Document Format form which contain scanned or secure, digitally signed signatures) by any party hereto and such signatures shall be deemed binding for all purposes hereof, without delivery of an original signature being thereafter required.</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.39pt">Survivability. The following Paragraphs shall survive the termination of this Agreement&#58; 6 (&#8220;Disclaimers and Limitation of Liability&#8221;)&#59; 7 (&#8220;Indemnification&#8221;)&#59; 8 (&#8220;Representations and Warranties&#8221;)&#59; 9 (&#8220;Work Product License&#8221;)&#59; and 10 (&#8220;Miscellaneous&#8221;).</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:28.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, the parties hereto have executed this Agreement as of the Effective Date.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.250%"><tr><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLIENT&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc.,</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a Delaware C corporation.</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58; Peter Soparkar</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FLG&#58;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FLG Partners, LLC,</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a California limited liability company.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58; U. Heather Ogan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Signed&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#47;s&#47; Peter Soparkar</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Signed&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#47;s&#47;  Ugadie Heather Ogan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COO</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Administrative Partner</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Address&#58; 100 Cardinal Way</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Redwood City, CA 94063</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Email&#58; psoparkar&#64;adverum.com</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effective Date&#58; November 22, 2022</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">REMAINDER OF THIS PAGE LEFT BLANK</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initial&#58; Client </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"> PS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;FLG </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">  UHO </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 4 of 5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="iafb99f51e2ed4a4fa18beb114452e1a0_119"></div><hr style="page-break-after:always"><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Description of Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;  CFO level services typical for a publicly held corporation.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">FLG Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;  Linda Rubinstein.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;  $650 per hour, subject to any hourly maximums that Client may establish from time to time.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58; None.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58; $10,000.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;  Indefinite, and terminable pursuant to Paragraph 4 of the Agreement.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58; FLG-Client Mutual Non-Disclosure Agreement dated November 8, 2022 (the &#8220;NDA&#8221;). FLG hereby expressly consents to the public disclosure of the existence of FLG&#8217;s relationship with Client, by Client, provided that the terms and conditions herein shall remain confidential pursuant to the terms of the NDA.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">REMAINDER OF THIS PAGE LEFT BLANK</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initial&#58; Client </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"> PS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;FLG </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">  UHO </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 5 of 5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>advm-20221231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i37dd74e074944e66a2bec88504f7ed18_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBSIDIARIES OF ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country of Incorporation</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avalanche Australia PTY LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annapurna Therapeutics, LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adverum NC, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina, USA</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>advm-20221231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iccd97a2a4e134959b0cbf099de03997c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit  23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-199296) pertaining to the Amended and Restated 2016 Equity Incentive Plan, as amended, the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-203398) pertaining to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-211439) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-218465) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Restricted Stock Unit and Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-220894) pertaining to the 2017 Inducement Plan and Inducement Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-223894) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Restricted Stock Unit Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-230138) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, the 2014 Employee Stock Purchase Plan, as amended and restated, and the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-233135) pertaining to the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-237136) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, and the 2014 Employee Stock Purchase Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-243761) pertaining to the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-253727) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, the 2014 Employee Stock Purchase Plan, as amended and restated, and the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-263954) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, and</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-266794) pertaining to the Amended and Restated 2014 Employee Stock Purchase Plan&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March 30, 2023, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. included in this Annual Report (Form 10-K) of Adverum Biotechnologies Inc. for the year ended December 31, 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">San Jose, California </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 30, 2023</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>advm-20221231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i79b83fddf9cd4e36a827ee0bbcbab527_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;30, 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>advm-20221231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5d26642657034620a923116e5dda8bfe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Linda Rubinstein, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;30, 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>advm-20221231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6a2caccf59fc4900a8e45564dea9d9b0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, as President and Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;30, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>advm-20221231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i92fed3201309460e858c319b8856ba66_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Linda Rubinstein, as Chief Financial Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;30, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>advm-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.adverum.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Descriptionofthebusiness" roleURI="http://www.adverum.com/role/Descriptionofthebusiness">
        <link:definition>0000009 - Disclosure - Description of the business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>0000011 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.adverum.com/role/Revenue">
        <link:definition>0000012 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.adverum.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>0000014 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.adverum.com/role/CommitmentsandContingencies">
        <link:definition>0000015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlans" roleURI="http://www.adverum.com/role/StockPlans">
        <link:definition>0000016 - Disclosure - Stock Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlan" roleURI="http://www.adverum.com/role/A401kSavingsPlan">
        <link:definition>0000017 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.adverum.com/role/Restructuring">
        <link:definition>0000018 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.adverum.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>0000020 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.adverum.com/role/LeasesTables">
        <link:definition>0000023 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>0000024 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansTables" roleURI="http://www.adverum.com/role/StockPlansTables">
        <link:definition>0000025 - Disclosure - Stock Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.adverum.com/role/RestructuringTables">
        <link:definition>0000026 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.adverum.com/role/IncomeTaxesTables">
        <link:definition>0000027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>0000028 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofthebusinessAdditionalInformationDetails" roleURI="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails">
        <link:definition>0000029 - Disclosure - Description of the business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails">
        <link:definition>0000031 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000032 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails">
        <link:definition>0000034 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails">
        <link:definition>0000035 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000036 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000037 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000038 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansAdditionalInformationDetails" roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Stock Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofStockOptionsActivityDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails">
        <link:definition>0000040 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails">
        <link:definition>0000041 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>0000042 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>0000043 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlanAdditionalInformationDetails" roleURI="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails">
        <link:definition>0000044 - Disclosure - 401(k) Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringAdditionalinformationDetails" roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails">
        <link:definition>0000045 - Disclosure - Restructuring - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringCostsDetails" roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails">
        <link:definition>0000046 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>0000047 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails">
        <link:definition>0000048 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails">
        <link:definition>0000049 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails">
        <link:definition>0000050 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000051 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000052 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>0000053 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_LesseeSubLeaseMonthlyBaseRent" abstract="false" name="LesseeSubLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" abstract="false" name="IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LexeoTherapeuticsIncMember" abstract="true" name="LexeoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_AccruedNonclinicalCostsCurrent" abstract="false" name="AccruedNonclinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" abstract="false" name="ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfRenewalContracts" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonQualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLeaseholdImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TerminatedLeaseMember" abstract="true" name="TerminatedLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_DeferredTaxAssetsCapitalizedCosts" abstract="false" name="DeferredTaxAssetsCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" abstract="false" name="AccruedClinicalAndDevelopmentProcessCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" abstract="false" name="DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_SiliconValleyBankMember" abstract="true" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_TwoThousandFourteenPlanAndInducementPlanMember" abstract="true" name="TwoThousandFourteenPlanAndInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_TwoThousandSeventeenInducementPlanMember" abstract="true" name="TwoThousandSeventeenInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_DeferredTaxAssetsLeaseObligation" abstract="false" name="DeferredTaxAssetsLeaseObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLeaseTerminationFee" abstract="false" name="LesseeOperatingLeaseLeaseTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" abstract="false" name="OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_RemeasurementOfRightOfUseAssetOnLeaseModification" abstract="false" name="RemeasurementOfRightOfUseAssetOnLeaseModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>advm-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_74fcbcdb-ced1-45d3-9a27-60c2dbc8b793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4b40c44d-3146-4ee7-b0d0-75d0caf2ce03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74fcbcdb-ced1-45d3-9a27-60c2dbc8b793" xlink:to="loc_us-gaap_AccountsPayableCurrent_4b40c44d-3146-4ee7-b0d0-75d0caf2ce03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_3b44cb68-e24d-47dd-be0f-b687b122b84c" xlink:href="advm-20221231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74fcbcdb-ced1-45d3-9a27-60c2dbc8b793" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_3b44cb68-e24d-47dd-be0f-b687b122b84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fbe6b8e9-c4d2-40cd-9cf2-d17792692cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74fcbcdb-ced1-45d3-9a27-60c2dbc8b793" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fbe6b8e9-c4d2-40cd-9cf2-d17792692cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_173172a0-98bd-477e-8883-c17fe4671fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_PreferredStockValue_173172a0-98bd-477e-8883-c17fe4671fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d97a92c4-4495-41e4-92d5-29c8b32cf6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_CommonStockValue_d97a92c4-4495-41e4-92d5-29c8b32cf6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d6b71368-35fa-44e3-b25e-85ed74ac5fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d6b71368-35fa-44e3-b25e-85ed74ac5fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9896d3af-93dc-4d36-b8e6-6d7a840c1012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9896d3af-93dc-4d36-b8e6-6d7a840c1012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3ba3d5f-15d9-40ce-a9c8-2ce6a57a6cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3ba3d5f-15d9-40ce-a9c8-2ce6a57a6cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d453fbf3-037d-44e0-a3a5-31425354a8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_888d517c-39e8-4e24-807f-fb7b73e150bf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d453fbf3-037d-44e0-a3a5-31425354a8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_69985880-a905-44d0-83c8-02538b0d20f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b24ee730-50c2-4dc0-b4c2-0f4777df63d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69985880-a905-44d0-83c8-02538b0d20f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b24ee730-50c2-4dc0-b4c2-0f4777df63d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_45670ce5-9768-4ff4-9566-a98450b6b943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69985880-a905-44d0-83c8-02538b0d20f3" xlink:to="loc_us-gaap_ShortTermInvestments_45670ce5-9768-4ff4-9566-a98450b6b943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_f902f298-5271-4ac7-bed8-eb931a6bf886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69985880-a905-44d0-83c8-02538b0d20f3" xlink:to="loc_us-gaap_IncentiveToLessee_f902f298-5271-4ac7-bed8-eb931a6bf886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aee31ec1-7ec9-4af7-9642-1af004d3b6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69985880-a905-44d0-83c8-02538b0d20f3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aee31ec1-7ec9-4af7-9642-1af004d3b6d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de8b6508-1f10-4080-ab08-4a26651949b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_48297e86-9d02-4ba7-b296-bf1dffdf0779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de8b6508-1f10-4080-ab08-4a26651949b8" xlink:to="loc_us-gaap_Liabilities_48297e86-9d02-4ba7-b296-bf1dffdf0779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_933e8fea-c95a-4fc2-9594-52a03451587c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de8b6508-1f10-4080-ab08-4a26651949b8" xlink:to="loc_us-gaap_StockholdersEquity_933e8fea-c95a-4fc2-9594-52a03451587c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90888260-61ba-41f9-9222-795f0d46b344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_46f2006a-f469-4c04-a48e-6de47e3f8f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_90888260-61ba-41f9-9222-795f0d46b344" xlink:to="loc_us-gaap_LiabilitiesCurrent_46f2006a-f469-4c04-a48e-6de47e3f8f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_59f631ba-9384-4b78-8dab-e9f29fe3e112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_90888260-61ba-41f9-9222-795f0d46b344" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_59f631ba-9384-4b78-8dab-e9f29fe3e112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_943b9094-43dd-4dd2-9ce5-6e9974575d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_90888260-61ba-41f9-9222-795f0d46b344" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_943b9094-43dd-4dd2-9ce5-6e9974575d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_db20b1ac-9711-44fb-ab4f-7ca907a35ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_AssetsCurrent_db20b1ac-9711-44fb-ab4f-7ca907a35ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6305826-04c3-40e6-94ee-b5497796ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6305826-04c3-40e6-94ee-b5497796ac4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2fcac333-1d23-4d0b-8831-0e15f364e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2fcac333-1d23-4d0b-8831-0e15f364e08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6242c94a-d9f2-4f30-b427-1b56c6ecb060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6242c94a-d9f2-4f30-b427-1b56c6ecb060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_4457e9a0-1f7c-41f3-b30b-ebeb76794c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_4457e9a0-1f7c-41f3-b30b-ebeb76794c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_340c241a-aacd-4bc3-95f1-7e111a9b33c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26dff162-f7ee-4614-890b-1f0d25db7269" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_340c241a-aacd-4bc3-95f1-7e111a9b33c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432825c9-8559-417a-8e68-30eb43066ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f0abafa-791a-4bd4-9c0a-a7053c8007a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432825c9-8559-417a-8e68-30eb43066ed6" xlink:to="loc_us-gaap_OperatingIncomeLoss_9f0abafa-791a-4bd4-9c0a-a7053c8007a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7fb4f235-33ae-4357-8cfd-2fa914faa5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432825c9-8559-417a-8e68-30eb43066ed6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7fb4f235-33ae-4357-8cfd-2fa914faa5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5405f09e-c961-4bbd-a0f1-06f7e0dae02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b4b18822-5ebe-445f-b722-4477f9a3f3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5405f09e-c961-4bbd-a0f1-06f7e0dae02a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b4b18822-5ebe-445f-b722-4477f9a3f3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_06c9c019-c467-4d73-9565-631850caca75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5405f09e-c961-4bbd-a0f1-06f7e0dae02a" xlink:to="loc_us-gaap_OperatingExpenses_06c9c019-c467-4d73-9565-631850caca75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_edb5973f-5163-4940-a3dc-6363743b803e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_78de8d75-74c4-4a4d-a693-850ad0c87818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_edb5973f-5163-4940-a3dc-6363743b803e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_78de8d75-74c4-4a4d-a693-850ad0c87818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a96c9de0-e084-47e0-8995-4f760d12af94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_edb5973f-5163-4940-a3dc-6363743b803e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a96c9de0-e084-47e0-8995-4f760d12af94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cadad7ae-dd28-47bf-ae34-b00cbf3e712a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05a66380-9ce9-487f-b1ca-56f924f229bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cadad7ae-dd28-47bf-ae34-b00cbf3e712a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05a66380-9ce9-487f-b1ca-56f924f229bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_717b7638-aae9-4947-8e60-fe7fd0d93182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cadad7ae-dd28-47bf-ae34-b00cbf3e712a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_717b7638-aae9-4947-8e60-fe7fd0d93182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c3521-c4a2-4ad1-b5dd-b33560cc1980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5a8f403-cc0b-4da6-b60c-c7e15e15fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c3521-c4a2-4ad1-b5dd-b33560cc1980" xlink:to="loc_us-gaap_NetIncomeLoss_e5a8f403-cc0b-4da6-b60c-c7e15e15fd1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_cd48e9b9-f715-4c37-8243-c6869d38bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c3521-c4a2-4ad1-b5dd-b33560cc1980" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_cd48e9b9-f715-4c37-8243-c6869d38bd20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2b526412-8883-46a9-8b23-3b46115d488e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499c3521-c4a2-4ad1-b5dd-b33560cc1980" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2b526412-8883-46a9-8b23-3b46115d488e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e77f5d93-a212-4270-b6b0-010c4d95e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd112711-71cd-4e2f-9314-ba3e5d4e206e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e77f5d93-a212-4270-b6b0-010c4d95e76b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd112711-71cd-4e2f-9314-ba3e5d4e206e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48c8dc54-cca8-465a-89df-a20b499c6f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e77f5d93-a212-4270-b6b0-010c4d95e76b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48c8dc54-cca8-465a-89df-a20b499c6f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_accfebae-d9ad-4cef-aaac-cf3c3108d821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e77f5d93-a212-4270-b6b0-010c4d95e76b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_accfebae-d9ad-4cef-aaac-cf3c3108d821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_b5622b26-0103-4b04-a6bc-e3416c272447" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_b5622b26-0103-4b04-a6bc-e3416c272447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_18d0e907-08e8-43b7-8d19-093f6fc84b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_AssetImpairmentCharges_18d0e907-08e8-43b7-8d19-093f6fc84b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_390d1e8a-a134-461b-b63a-c57c7d0316c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_390d1e8a-a134-461b-b63a-c57c7d0316c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4290fff7-77e3-4031-8d3c-522011833d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4290fff7-77e3-4031-8d3c-522011833d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7a7a07ca-ea11-4387-bd60-d1a927957422" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7a7a07ca-ea11-4387-bd60-d1a927957422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_02cbab43-5588-4577-91ef-bc7bc78dea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_DepreciationAndAmortization_02cbab43-5588-4577-91ef-bc7bc78dea0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dbc4567a-9122-467f-85e6-1e39a4219433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dbc4567a-9122-467f-85e6-1e39a4219433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_95636b80-1ab5-465d-9a6b-67abeb808cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_95636b80-1ab5-465d-9a6b-67abeb808cbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2243f979-dd7a-4eab-9224-9fad5c2a38cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2243f979-dd7a-4eab-9224-9fad5c2a38cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a456f661-f931-4dbc-a839-93f8e5309a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_ShareBasedCompensation_a456f661-f931-4dbc-a839-93f8e5309a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be634ca1-2299-4239-b0b7-68a0576d7700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be634ca1-2299-4239-b0b7-68a0576d7700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_27491d6e-304a-46aa-af00-d1fd2f12c4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_NetIncomeLoss_27491d6e-304a-46aa-af00-d1fd2f12c4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6774ee55-e515-4358-84a0-ae68b49fc61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6774ee55-e515-4358-84a0-ae68b49fc61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_89445853-94b4-44a6-9b92-69218e622059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efdb5e6f-2334-4b8f-a101-22f887202520" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_89445853-94b4-44a6-9b92-69218e622059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ccfb684-6345-4876-915a-f586f3f53fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4632928b-2413-422a-9d48-04812a53b5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ccfb684-6345-4876-915a-f586f3f53fa8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4632928b-2413-422a-9d48-04812a53b5be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5edbca25-a140-48bf-9fea-d5f24a137316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ccfb684-6345-4876-915a-f586f3f53fa8" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5edbca25-a140-48bf-9fea-d5f24a137316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df63bafa-64f4-49da-8618-d7da14c72358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ccfb684-6345-4876-915a-f586f3f53fa8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df63bafa-64f4-49da-8618-d7da14c72358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e67f357-7636-4ebe-ad33-64d86386826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ccfb684-6345-4876-915a-f586f3f53fa8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e67f357-7636-4ebe-ad33-64d86386826e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7975764-4fd5-4604-9972-6a5c33d43777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c496bc0f-2f65-4f7d-a7fd-3564d523eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7975764-4fd5-4604-9972-6a5c33d43777" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c496bc0f-2f65-4f7d-a7fd-3564d523eef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_729468c6-9337-49ee-a8f1-dd82b3ac4532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7975764-4fd5-4604-9972-6a5c33d43777" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_729468c6-9337-49ee-a8f1-dd82b3ac4532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79abaf60-1462-4300-af00-47b377578e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fef6310d-f21f-4130-800d-2da425082515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79abaf60-1462-4300-af00-47b377578e29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fef6310d-f21f-4130-800d-2da425082515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e08154aa-b3bc-45d7-a847-0cd421a3718d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79abaf60-1462-4300-af00-47b377578e29" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e08154aa-b3bc-45d7-a847-0cd421a3718d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d82503c5-d0d1-4e04-b3e7-78a55610e57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79abaf60-1462-4300-af00-47b377578e29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d82503c5-d0d1-4e04-b3e7-78a55610e57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_930766fa-7630-4452-95bb-403fe227dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79abaf60-1462-4300-af00-47b377578e29" xlink:to="loc_us-gaap_RepaymentsOfDebt_930766fa-7630-4452-95bb-403fe227dcac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_334a04bc-0cd1-470a-aa06-ea2c479d6467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_92173ae8-2d8b-432d-978f-c679a3cfe8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_334a04bc-0cd1-470a-aa06-ea2c479d6467" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_92173ae8-2d8b-432d-978f-c679a3cfe8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bdde5b04-2bb5-43e2-ab6c-be48e22b1a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_334a04bc-0cd1-470a-aa06-ea2c479d6467" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bdde5b04-2bb5-43e2-ab6c-be48e22b1a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79de2163-9b10-482f-8b7e-647ccc01aa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_334a04bc-0cd1-470a-aa06-ea2c479d6467" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79de2163-9b10-482f-8b7e-647ccc01aa6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_44199154-0a64-4884-8d41-acb39730a554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_44199154-0a64-4884-8d41-acb39730a554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2a6d4725-c18d-4978-b7f3-fc71a7917c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2a6d4725-c18d-4978-b7f3-fc71a7917c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6eb40a49-c9c8-4472-b411-0ef1b822a028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6eb40a49-c9c8-4472-b411-0ef1b822a028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_95badb14-71ca-4889-8a63-1475b7d2c4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_95badb14-71ca-4889-8a63-1475b7d2c4d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8fd1b194-69ff-4ab3-b239-5de8a4e9f3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8fd1b194-69ff-4ab3-b239-5de8a4e9f3e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ac704a5b-bb75-40fa-a26f-78e4061032cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d2b4880-c0a6-410b-8532-b64cc427546e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ac704a5b-bb75-40fa-a26f-78e4061032cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_0739023a-d41c-4eb2-8ee8-17b3681ea12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_0739023a-d41c-4eb2-8ee8-17b3681ea12e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_d5d2cbaf-b1f0-42ef-a799-08290f53ee17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_d5d2cbaf-b1f0-42ef-a799-08290f53ee17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_9c9b6dbf-cec0-40d8-a729-85ffeafb4f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_9c9b6dbf-cec0-40d8-a729-85ffeafb4f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e19f3a53-6aa6-4250-9e84-da3811256cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e19f3a53-6aa6-4250-9e84-da3811256cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_120e9b7b-d34d-4e5f-aec8-7e5a5cf65dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_120e9b7b-d34d-4e5f-aec8-7e5a5cf65dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_4f8d4d5b-5278-4007-9602-2b0af7d53c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eabb2003-5d20-4509-ac2d-295ece02a586" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_4f8d4d5b-5278-4007-9602-2b0af7d53c72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c1a7ca85-fccd-41c0-9fca-5ac873bb803b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b6851c57-74f6-4c41-94e3-5974110e4ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c1a7ca85-fccd-41c0-9fca-5ac873bb803b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b6851c57-74f6-4c41-94e3-5974110e4ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8b9f42f-541f-4105-a88d-b84f2c52d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c1a7ca85-fccd-41c0-9fca-5ac873bb803b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8b9f42f-541f-4105-a88d-b84f2c52d70e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:href="advm-20221231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f7de8127-8625-4700-95fe-537c129a7de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f7de8127-8625-4700-95fe-537c129a7de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7405c34a-142f-425c-b8c3-2b82c32b04ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_us-gaap_TaxesPayableCurrent_7405c34a-142f-425c-b8c3-2b82c32b04ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_533bc8c5-5818-4cf4-82ae-25d1afce8087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_533bc8c5-5818-4cf4-82ae-25d1afce8087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent_efc7a462-d1f9-4a29-8daa-800a21d3a710" xlink:href="advm-20221231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_advm_AccruedNonclinicalCostsCurrent_efc7a462-d1f9-4a29-8daa-800a21d3a710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_f31593a1-2182-4e68-a47b-322dceeb82aa" xlink:href="advm-20221231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_f31593a1-2182-4e68-a47b-322dceeb82aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43ba941e-969f-4830-808c-f890cd26e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ae4dfe4b-1a88-41d4-87a3-f2f620bf5cd1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43ba941e-969f-4830-808c-f890cd26e09d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49db075f-235b-4261-8a90-e9f01c588994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f6dfd214-a35a-4697-99b2-82ee1019ef6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49db075f-235b-4261-8a90-e9f01c588994" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f6dfd214-a35a-4697-99b2-82ee1019ef6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b1a68ad0-a3f8-4ff0-b086-bee643b91a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49db075f-235b-4261-8a90-e9f01c588994" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b1a68ad0-a3f8-4ff0-b086-bee643b91a4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bd7b0dc8-4990-4758-ad5e-d2d3a204f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eb1ba40e-1ff6-4f10-bfb3-45874e70e948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bd7b0dc8-4990-4758-ad5e-d2d3a204f7e0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eb1ba40e-1ff6-4f10-bfb3-45874e70e948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7479607-b6c8-40af-b123-762f39367c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bd7b0dc8-4990-4758-ad5e-d2d3a204f7e0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7479607-b6c8-40af-b123-762f39367c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fd6cfdb4-aa57-49d7-9fc9-79c82c117bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cbe9888e-6670-4718-b424-756fc78f10a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fd6cfdb4-aa57-49d7-9fc9-79c82c117bef" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cbe9888e-6670-4718-b424-756fc78f10a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7036ab58-2e19-424a-b92c-2a55982dc951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_85b0dc1c-1959-46ea-973d-ed86f012644b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7036ab58-2e19-424a-b92c-2a55982dc951" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_85b0dc1c-1959-46ea-973d-ed86f012644b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7511003d-4089-4c60-9ea0-c72e3eb86d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7511003d-4089-4c60-9ea0-c72e3eb86d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_212960e3-92b1-48a0-b5a1-2d126c67c1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_212960e3-92b1-48a0-b5a1-2d126c67c1a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_96e404a4-32c9-4ea6-85fa-3e8dbb24945a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_96e404a4-32c9-4ea6-85fa-3e8dbb24945a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_288dcccd-1fd2-4757-98b3-619106a1f072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_288dcccd-1fd2-4757-98b3-619106a1f072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_53a48738-74f2-49fd-bfac-b2a7aa9fb6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_53a48738-74f2-49fd-bfac-b2a7aa9fb6a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ac14a423-72bb-431f-950c-66de451f191e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ac14a423-72bb-431f-950c-66de451f191e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_561fe666-87b6-43b9-a4f1-bee7b7d727e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_561fe666-87b6-43b9-a4f1-bee7b7d727e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_7b68bbfb-9196-4d68-b816-83f77ddff89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9aa85062-1089-4bc5-8b8a-db06a7525948" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_7b68bbfb-9196-4d68-b816-83f77ddff89a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8768d097-971c-4a6b-8d69-9419cfe73151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e60e05e0-c183-41c6-8a5c-ddbd6b005cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8768d097-971c-4a6b-8d69-9419cfe73151" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e60e05e0-c183-41c6-8a5c-ddbd6b005cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8f710c71-30c9-49ea-9773-8326db9d9406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8768d097-971c-4a6b-8d69-9419cfe73151" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8f710c71-30c9-49ea-9773-8326db9d9406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d8fbdced-5d87-4f6c-96c3-eb24c93009b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_45de982c-7218-4eb9-8023-06a8d5db617d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d8fbdced-5d87-4f6c-96c3-eb24c93009b9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_45de982c-7218-4eb9-8023-06a8d5db617d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a8042f4d-a824-4707-a34b-93df8833639a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d8fbdced-5d87-4f6c-96c3-eb24c93009b9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a8042f4d-a824-4707-a34b-93df8833639a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e2274ea1-92aa-48ab-8fdd-e104643dc76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e2274ea1-92aa-48ab-8fdd-e104643dc76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f7b5b9ab-3499-404d-9997-07824c43c5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f7b5b9ab-3499-404d-9997-07824c43c5c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a87f6f3f-4724-49b3-ba8a-735b4725d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a87f6f3f-4724-49b3-ba8a-735b4725d10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de93b212-b9fb-4548-81a3-ede17f8a1faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de93b212-b9fb-4548-81a3-ede17f8a1faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6692c5b3-e4a2-4fdf-92cf-0b923499e970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6692c5b3-e4a2-4fdf-92cf-0b923499e970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f9577899-c1e0-4210-acdc-f840f1e4b7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f9577899-c1e0-4210-acdc-f840f1e4b7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_fe6ee4ab-fe1e-4425-8417-a9633730c467" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_fe6ee4ab-fe1e-4425-8417-a9633730c467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_4c1c793f-fdb9-4eb0-bb7e-16369aa17721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_4c1c793f-fdb9-4eb0-bb7e-16369aa17721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_6a287bd2-f45b-458c-87ee-488ea2fa28e6" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1d9d573e-021f-4276-add3-8492c0d49354" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_6a287bd2-f45b-458c-87ee-488ea2fa28e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b91632f9-1b3f-4e24-8265-3365a898e147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8252c43b-e237-4897-a1ce-fbafe1bc85ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b91632f9-1b3f-4e24-8265-3365a898e147" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8252c43b-e237-4897-a1ce-fbafe1bc85ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c97c3d13-1958-4419-8de8-3b521291c7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b91632f9-1b3f-4e24-8265-3365a898e147" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c97c3d13-1958-4419-8de8-3b521291c7c6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>advm-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="id565cbad282246c785c25f69bc7bac69_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_03c01a87-72f8-483e-8b73-0cfff8af5a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_03c01a87-72f8-483e-8b73-0cfff8af5a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8558e279-fc65-45d8-b8f9-09120baa8283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockholdersEquity_8558e279-fc65-45d8-b8f9-09120baa8283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b7e96942-b9eb-48ce-96bb-273afeda994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b7e96942-b9eb-48ce-96bb-273afeda994e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e2a547d-8844-402f-93bc-a986c360803e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e2a547d-8844-402f-93bc-a986c360803e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aa3f0745-b805-4def-9222-3d1ef55394dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aa3f0745-b805-4def-9222-3d1ef55394dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d188497-99f0-41da-b318-c670ee49bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d188497-99f0-41da-b318-c670ee49bad8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d461e96f-7c94-4514-be37-8320ee6999b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d461e96f-7c94-4514-be37-8320ee6999b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913af89b-6635-42a3-8707-55c32cd3c489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913af89b-6635-42a3-8707-55c32cd3c489" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef95a0eb-134a-49fe-830a-3a63c1bc8dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef95a0eb-134a-49fe-830a-3a63c1bc8dc4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_784417f2-cd02-474c-abfe-436a94ecddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_784417f2-cd02-474c-abfe-436a94ecddd2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_36fc2e37-64f7-4ec9-8c26-2cce4f39007c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_36fc2e37-64f7-4ec9-8c26-2cce4f39007c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_93ed4ff0-920b-4073-b447-453a2ffa903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_93ed4ff0-920b-4073-b447-453a2ffa903e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3ca55ee-4598-4023-bd6e-65bf03c0202b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_NetIncomeLoss_f3ca55ee-4598-4023-bd6e-65bf03c0202b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_222fa75a-2553-4467-80be-1f509a05453e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73ba8fb7-d7c4-4770-b92c-b28a285d92e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:to="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29c0efc0-b006-4a7b-9dd3-6ebb109e6386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:to="loc_us-gaap_EquityComponentDomain_29c0efc0-b006-4a7b-9dd3-6ebb109e6386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:to="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a6044b8-f75b-4be9-977f-99ce2a7d512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_CommonStockMember_4a6044b8-f75b-4be9-977f-99ce2a7d512e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c7c6933e-1a40-4de5-adcf-2e39e196bd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c7c6933e-1a40-4de5-adcf-2e39e196bd06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10e71a15-70de-4853-b9c3-3293da0c35d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10e71a15-70de-4853-b9c3-3293da0c35d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_024a4031-cf59-47bf-96b1-cb13067e0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_RetainedEarningsMember_024a4031-cf59-47bf-96b1-cb13067e0c02" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="if407504a2b4041a39002cf588a5f6cf5_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2a409622-09bc-4cbb-bb5f-37398e75d673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_NumberOfReportableSegments_2a409622-09bc-4cbb-bb5f-37398e75d673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_036083b5-1744-41e8-8a66-7bcb15dd2bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_036083b5-1744-41e8-8a66-7bcb15dd2bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6392dcc1-7ce6-4150-877b-c76732701748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_GainLossOnInvestments_6392dcc1-7ce6-4150-877b-c76732701748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a90ae24e-74ff-414a-bb0e-9bc25e515df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a90ae24e-74ff-414a-bb0e-9bc25e515df0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f86b339-c038-4a4c-b5c3-4c9293dab927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f86b339-c038-4a4c-b5c3-4c9293dab927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6139095a-f2ef-4e23-8819-3e07d4b9cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_AssetImpairmentCharges_6139095a-f2ef-4e23-8819-3e07d4b9cc7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_47c1bf2c-5219-485c-af53-7849c519696c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_SubleaseIncome_47c1bf2c-5219-485c-af53-7849c519696c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_f189af4e-d73b-49db-8807-1cfeb83c6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_f189af4e-d73b-49db-8807-1cfeb83c6602" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:to="loc_srt_RangeMember_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:to="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07725f80-13bd-42c5-b7e6-cf7759ee6bc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:to="loc_srt_MinimumMember_07725f80-13bd-42c5-b7e6-cf7759ee6bc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c56b880-3654-4247-8ffa-02e244e34ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:to="loc_srt_MaximumMember_9c56b880-3654-4247-8ffa-02e244e34ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a19a5962-3011-4405-898b-64a898f386d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a19a5962-3011-4405-898b-64a898f386d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59978136-acfb-4b12-8a5b-257693218a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:to="loc_us-gaap_SubsequentEventMember_59978136-acfb-4b12-8a5b-257693218a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502fa132-14be-4a6f-977a-a4c354897dcb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502fa132-14be-4a6f-977a-a4c354897dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SiliconValleyBankMember_f3f357fd-10b8-4a39-a3b2-74633c38b0cd" xlink:href="advm-20221231.xsd#advm_SiliconValleyBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:to="loc_advm_SiliconValleyBankMember_f3f357fd-10b8-4a39-a3b2-74633c38b0cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended" id="i320018ec5e6745d085c4fedd6f9f17f6_FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c07759b-1701-4be2-a8bc-261cc27d1ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c07759b-1701-4be2-a8bc-261cc27d1ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44a61d30-f89d-44d4-859d-70e99160a869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44a61d30-f89d-44d4-859d-70e99160a869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725db606-611e-4bd1-9487-bbf02cc91234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725db606-611e-4bd1-9487-bbf02cc91234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8b1c80a-faa9-445a-808c-e3b62c8b7a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8b1c80a-faa9-445a-808c-e3b62c8b7a4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_4ba77496-687f-4a14-bede-70be04ebd7fd" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_4ba77496-687f-4a14-bede-70be04ebd7fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_6b899157-0619-423a-a692-de53944f0ae7" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_6b899157-0619-423a-a692-de53944f0ae7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_c8182b3b-6c3b-4893-999e-ab73ecea62fa" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_c8182b3b-6c3b-4893-999e-ab73ecea62fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97d0b4ce-7e91-4e59-a3db-173bdefbb7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97d0b4ce-7e91-4e59-a3db-173bdefbb7c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bc21037-8576-41cf-830d-12e699d341ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bc21037-8576-41cf-830d-12e699d341ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_202f4482-2110-4f6a-8a48-74b4ce531b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_202f4482-2110-4f6a-8a48-74b4ce531b52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ddf7a5ea-0982-43e3-ad17-ee0aece78b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ddf7a5ea-0982-43e3-ad17-ee0aece78b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_721fc145-560b-44cc-a0d8-3894ff7598fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_721fc145-560b-44cc-a0d8-3894ff7598fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a0956bbb-0fe1-45fe-9ddb-e0e3fe8dde28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a0956bbb-0fe1-45fe-9ddb-e0e3fe8dde28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_66847678-b243-46e5-a01e-5562a3a70679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_66847678-b243-46e5-a01e-5562a3a70679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e16dd7b9-9e35-4ef3-a1f7-30a3f3a5490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_CommercialPaperMember_e16dd7b9-9e35-4ef3-a1f7-30a3f3a5490e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6dce26ce-f240-4d3a-8ae3-cd4729f5267f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6dce26ce-f240-4d3a-8ae3-cd4729f5267f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_eecb956d-cd32-4e75-a54b-1137100145b3" xlink:href="advm-20221231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_eecb956d-cd32-4e75-a54b-1137100145b3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i0c44580664fe4485b0058d0d3a80d05f_FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfb74e66-53cf-4ccf-ae23-891b39a01e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfb74e66-53cf-4ccf-ae23-891b39a01e3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_d2677c7f-da70-4508-a3f4-add2f44c5330" xlink:href="advm-20221231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_d2677c7f-da70-4508-a3f4-add2f44c5330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_7b7ef6a1-5542-45e1-831b-8ae899d2b1e4" xlink:href="advm-20221231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_7b7ef6a1-5542-45e1-831b-8ae899d2b1e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_fded9b92-1665-4aa3-9806-3a4f163e53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_fded9b92-1665-4aa3-9806-3a4f163e53a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:to="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a66a85c-7e07-4fd2-b14a-993d11f30196_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:to="loc_srt_RangeMember_7a66a85c-7e07-4fd2-b14a-993d11f30196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:to="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_11a263f1-9e39-49fa-8c9f-d03abb3941d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:to="loc_srt_MinimumMember_11a263f1-9e39-49fa-8c9f-d03abb3941d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce0f2582-91c4-4fa2-be22-16d52338a989" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:to="loc_srt_MaximumMember_ce0f2582-91c4-4fa2-be22-16d52338a989" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RevenueAdditionalInformationDetails" xlink:type="extended" id="i8c79d1241d284b30bb13a4a6eec9df8e_RevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d296a4dd-85f1-448b-a5c5-fc20a1af0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d296a4dd-85f1-448b-a5c5-fc20a1af0c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:to="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d6f339b-564a-41bc-8691-eddbd1558109_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d6f339b-564a-41bc-8691-eddbd1558109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_af016910-222b-4235-b352-e3beae90dfcd" xlink:href="advm-20221231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:to="loc_advm_LexeoTherapeuticsIncMember_af016910-222b-4235-b352-e3beae90dfcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="ife16449a61d541e5994329e20e5704dc_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_887fd961-28b1-4b2b-8755-c6c0c27c46e7" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_887fd961-28b1-4b2b-8755-c6c0c27c46e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8ba31e9c-cfa9-49dc-aa2d-82273dd89d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8ba31e9c-cfa9-49dc-aa2d-82273dd89d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37970b86-accf-4837-be4e-b96fce817372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37970b86-accf-4837-be4e-b96fce817372" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_d1911b9a-1f27-4875-aba4-29c16c01b31a" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_d1911b9a-1f27-4875-aba4-29c16c01b31a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeSubLeaseMonthlyBaseRent_f2ea403c-e47a-4e41-890f-71febaecd6db" xlink:href="advm-20221231.xsd#advm_LesseeSubLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeSubLeaseMonthlyBaseRent_f2ea403c-e47a-4e41-890f-71febaecd6db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_5be82b4e-f88a-455f-b747-5868bbb3fa68" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_5be82b4e-f88a-455f-b747-5868bbb3fa68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_c4490b7d-4aea-484b-acac-44e2c0fb8907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_c4490b7d-4aea-484b-acac-44e2c0fb8907" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4683af1e-61fb-4ca6-aa90-7d9408b8772d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4683af1e-61fb-4ca6-aa90-7d9408b8772d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa3d7fb3-dd5a-4bf6-be81-7a53fcad4fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa3d7fb3-dd5a-4bf6-be81-7a53fcad4fb4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9ea8ae34-8e35-47bf-93ce-c65a9cd889c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseExpense_9ea8ae34-8e35-47bf-93ce-c65a9cd889c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0c87967e-711f-4535-a321-05b9fb605e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_VariableLeaseCost_0c87967e-711f-4535-a321-05b9fb605e70" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_072f3688-b857-4fcd-a2af-55391826b287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeasePayments_072f3688-b857-4fcd-a2af-55391826b287" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_7da9d34b-a1ac-4f01-b52f-97042c269db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_SubleaseIncome_7da9d34b-a1ac-4f01-b52f-97042c269db3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e949e629-1c18-49fa-ba15-e24e3b0acd8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e949e629-1c18-49fa-ba15-e24e3b0acd8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f26bab4a-617d-4dd2-a998-e7489e5d2376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:to="loc_us-gaap_BuildingMember_f26bab4a-617d-4dd2-a998-e7489e5d2376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_e699c3b3-a30a-4f3b-9850-b7b4eec0ee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:to="loc_us-gaap_ManufacturingFacilityMember_e699c3b3-a30a-4f3b-9850-b7b4eec0ee0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0be0735e-9e6a-4821-883b-eece24302625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0be0735e-9e6a-4821-883b-eece24302625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:to="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember_40a106d8-6304-4bf6-8128-79a357055449" xlink:href="advm-20221231.xsd#advm_TerminatedLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:to="loc_advm_TerminatedLeaseMember_40a106d8-6304-4bf6-8128-79a357055449" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="ifafdf419617945249ada94da60534169_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f99f590f-8347-4ef4-a5ad-f366cdde7d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f99f590f-8347-4ef4-a5ad-f366cdde7d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6d8cf5ab-5989-4a3f-b0d1-a607eaddc7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6d8cf5ab-5989-4a3f-b0d1-a607eaddc7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c9ccdae2-17cf-4336-8d64-a6ca5d19b03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c9ccdae2-17cf-4336-8d64-a6ca5d19b03c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_540b7fda-e1dd-4b4f-80fd-39a26f079814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_540b7fda-e1dd-4b4f-80fd-39a26f079814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b188fa6d-8ec3-4fa7-8a5d-f128d9231a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_ComputerEquipmentMember_b188fa6d-8ec3-4fa7-8a5d-f128d9231a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_473ec062-112d-49d8-8193-fa2bf6becdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_EquipmentMember_473ec062-112d-49d8-8193-fa2bf6becdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_443e8659-f41d-4fdd-be9b-00ee7b4505a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_443e8659-f41d-4fdd-be9b-00ee7b4505a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_82581b00-52f2-4751-b45d-40efcfe00432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_82581b00-52f2-4751-b45d-40efcfe00432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_81138af5-4599-407d-849c-ffee11915948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_ConstructionInProgressMember_81138af5-4599-407d-849c-ffee11915948" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="extended" id="ie431f7c32c944f7a8f1df459a788eb89_StockPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_8c13b522-0501-4e51-b87c-e3394dbe92cc" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_8c13b522-0501-4e51-b87c-e3394dbe92cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_503a15c1-4832-4c50-8fab-57fee673b828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_503a15c1-4832-4c50-8fab-57fee673b828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_366433e9-ce69-40b1-a47a-decf06e71017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_366433e9-ce69-40b1-a47a-decf06e71017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50c594b3-ea9a-48da-bea5-37aff8cf9dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50c594b3-ea9a-48da-bea5-37aff8cf9dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6695039e-981b-42f1-b664-3354481f4048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6695039e-981b-42f1-b664-3354481f4048" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_1fe55285-1b08-4930-bf48-757317075ac9" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_1fe55285-1b08-4930-bf48-757317075ac9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_3a5d066f-b001-4e6a-860f-32ee200de67a" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_3a5d066f-b001-4e6a-860f-32ee200de67a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58015dac-db9c-49ed-9b4b-28072bf15051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58015dac-db9c-49ed-9b4b-28072bf15051" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e15dbc7b-106b-409f-84db-4993fa213a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e15dbc7b-106b-409f-84db-4993fa213a67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_727fc3fc-02b4-4fc4-8dec-08f9cb83abf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_727fc3fc-02b4-4fc4-8dec-08f9cb83abf8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8fd513ec-8bb8-4f71-b299-a91ce12fc443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8fd513ec-8bb8-4f71-b299-a91ce12fc443" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_65eec6fd-9036-4fd0-95f0-97b1ba2c9e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_65eec6fd-9036-4fd0-95f0-97b1ba2c9e12" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b11e3f80-3a71-4544-8e6d-77b6efb5e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b11e3f80-3a71-4544-8e6d-77b6efb5e975" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_016bfbba-5585-4077-8f3a-712f8303070d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_016bfbba-5585-4077-8f3a-712f8303070d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ac929747-9c43-4b60-b138-041cb59904c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ac929747-9c43-4b60-b138-041cb59904c6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_678a18bc-208a-448d-aad0-50d6ff04f857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_678a18bc-208a-448d-aad0-50d6ff04f857" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_1056360d-94ab-4439-b5b6-19f39ec2fd70" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_1056360d-94ab-4439-b5b6-19f39ec2fd70" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d805d95b-8e20-4ab8-b19a-f1eddaf3b92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d805d95b-8e20-4ab8-b19a-f1eddaf3b92d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_879f9d20-95e1-4d23-a7a2-8d8d65dd8d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_StockOptionPlanExpense_879f9d20-95e1-4d23-a7a2-8d8d65dd8d46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80c99e95-01be-47ce-a893-282288903bcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:to="loc_us-gaap_PlanNameDomain_80c99e95-01be-47ce-a893-282288903bcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:to="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_d03ac62a-601d-474c-bf46-897cda6db8c2" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_d03ac62a-601d-474c-bf46-897cda6db8c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_aa5f9c6e-0d98-40a8-9779-61518b4e82dc" xlink:href="advm-20221231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_aa5f9c6e-0d98-40a8-9779-61518b4e82dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_3d7e69c7-60d8-4d56-bc2c-af5ea76c5594" xlink:href="advm-20221231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_3d7e69c7-60d8-4d56-bc2c-af5ea76c5594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_b31bde74-5547-4de9-bb95-44e36ee2ad05" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_b31bde74-5547-4de9-bb95-44e36ee2ad05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3690a340-4669-4d1e-85cd-91f3685fce4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3690a340-4669-4d1e-85cd-91f3685fce4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_75a167af-7c56-4756-956c-b1dcf34817f6" xlink:href="advm-20221231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_75a167af-7c56-4756-956c-b1dcf34817f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_55cf7991-a008-4ddc-8b84-d9e9cbbbd77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_StockCompensationPlanMember_55cf7991-a008-4ddc-8b84-d9e9cbbbd77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c32a3b97-1bd4-4691-85df-9d748d0b6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c32a3b97-1bd4-4691-85df-9d748d0b6f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_4e07c260-1996-4b2d-8c80-1068f6bbe370" xlink:href="advm-20221231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_4e07c260-1996-4b2d-8c80-1068f6bbe370" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_07f4a037-c528-41f1-a7cf-7d0b57f670fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_PerformanceSharesMember_07f4a037-c528-41f1-a7cf-7d0b57f670fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7c7c8c65-ddd2-4d5c-855e-0183d1ff3ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7c7c8c65-ddd2-4d5c-855e-0183d1ff3ce5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38b82ac5-0a4e-408c-95d1-44bab65bb1eb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:to="loc_srt_RangeMember_38b82ac5-0a4e-408c-95d1-44bab65bb1eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:to="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f831b63f-b5d1-407e-9e11-6b6da311e5c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:to="loc_srt_MinimumMember_f831b63f-b5d1-407e-9e11-6b6da311e5c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_558b23fc-c615-4b85-a8f0-c8d4c3a1bd21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:to="loc_srt_MaximumMember_558b23fc-c615-4b85-a8f0-c8d4c3a1bd21" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="extended" id="i7514c9e737a34ee1a01d47cb25aeef95_StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_77975f5f-6858-4ef1-ab18-215fdbbae522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_77975f5f-6858-4ef1-ab18-215fdbbae522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461e5cdb-9d27-4de7-bb33-eae52bce43af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461e5cdb-9d27-4de7-bb33-eae52bce43af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1915278-b1ab-4520-845a-a27001fac421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1915278-b1ab-4520-845a-a27001fac421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d4addcc9-1d41-4af1-9c6d-0a27f02cdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d4addcc9-1d41-4af1-9c6d-0a27f02cdca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:to="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36118ccc-4b12-4f82-bec4-c019f5a6fb9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36118ccc-4b12-4f82-bec4-c019f5a6fb9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d3e3815f-1cc9-4694-b53a-1daf5bc3bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d3e3815f-1cc9-4694-b53a-1daf5bc3bf6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_087ac367-6634-4a18-8623-08098e2c8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:to="loc_us-gaap_EmployeeStockMember_087ac367-6634-4a18-8623-08098e2c8c2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i1589240151c1429d9c18a08737253ec8_StockPlansScheduleofRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e458dfef-e918-4f33-a61d-301215d520d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e458dfef-e918-4f33-a61d-301215d520d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f09734-5ebb-41cb-b714-e1b934cd7003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f09734-5ebb-41cb-b714-e1b934cd7003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dc40d0ac-c474-417d-b750-207be9c832e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dc40d0ac-c474-417d-b750-207be9c832e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dec6c127-46a8-4290-b1ae-3aacf324898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dec6c127-46a8-4290-b1ae-3aacf324898a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cbbdfbae-82e7-40b1-b651-f1ac57676131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2cf50be9-5b3b-4632-9840-a10b85799b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2cf50be9-5b3b-4632-9840-a10b85799b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad80f0a3-3439-4d46-9a75-08409e714a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad80f0a3-3439-4d46-9a75-08409e714a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_2e03caa3-cf00-4b69-9498-b463801b11f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_2e03caa3-cf00-4b69-9498-b463801b11f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3217a8c7-42b8-4d96-bbbb-22da8f56efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3217a8c7-42b8-4d96-bbbb-22da8f56efa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_629d7379-b6e0-4d2d-b5b4-3f45a85cea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48f8c015-a6b3-4ac2-ae9d-f15d5e798f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48f8c015-a6b3-4ac2-ae9d-f15d5e798f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:to="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8c3063b-9622-40df-9bb4-c7b03937d59b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8c3063b-9622-40df-9bb4-c7b03937d59b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9309756a-883b-4eab-a545-6aeeb2b1d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9309756a-883b-4eab-a545-6aeeb2b1d11a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="iaf554b28e2fd4923a702e69ab08c79c3_StockPlansScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca735db0-7ca5-44ab-bb0b-51720627689f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca735db0-7ca5-44ab-bb0b-51720627689f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a10b79d5-3243-4690-b14a-8af6ca3e6316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a10b79d5-3243-4690-b14a-8af6ca3e6316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c63410a5-bf0b-438e-a13a-85d97f3b4903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c63410a5-bf0b-438e-a13a-85d97f3b4903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a501497f-4032-415b-badf-943ab9edc601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a501497f-4032-415b-badf-943ab9edc601" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RestructuringAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="extended" id="ib99195c5ebd440ecab0d7fc0b91dfcb6_RestructuringAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_5ef9047d-add2-4627-adab-e03661c6eb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_5ef9047d-add2-4627-adab-e03661c6eb3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_e24ecbb7-cc82-4e30-a704-cc4a2a04ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_e24ecbb7-cc82-4e30-a704-cc4a2a04ad01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8fbee944-a7d4-41bc-97dd-127f8c661c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringCharges_8fbee944-a7d4-41bc-97dd-127f8c661c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_90b15f45-0570-40d5-b14a-c0ef03cb610e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_90b15f45-0570-40d5-b14a-c0ef03cb610e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9eb2eeb7-d436-4db0-9818-10e7416bd073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9eb2eeb7-d436-4db0-9818-10e7416bd073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2340ca6f-2613-47f0-909b-181b928c95d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2340ca6f-2613-47f0-909b-181b928c95d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RestructuringScheduleofRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="extended" id="i8809f48d3263492b83c27d0d9e1bfdc3_RestructuringScheduleofRestructuringCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8446f213-3e2d-4915-867e-6574241276c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringCharges_8446f213-3e2d-4915-867e-6574241276c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f03d7986-e23f-421e-91cc-ea153ea34761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_PaymentsForRestructuring_f03d7986-e23f-421e-91cc-ea153ea34761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_fc551120-c8c6-4d1a-8b2b-b5c4e0d02932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_fc551120-c8c6-4d1a-8b2b-b5c4e0d02932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_edf3d3be-eb5e-4e44-a132-0dec667226f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringReserve_edf3d3be-eb5e-4e44-a132-0dec667226f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7b2eddc8-04f5-4974-9e04-a67857f41b17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7b2eddc8-04f5-4974-9e04-a67857f41b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_bef9dc34-e1c0-4517-8b0c-9069e42173f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:to="loc_us-gaap_EmployeeSeveranceMember_bef9dc34-e1c0-4517-8b0c-9069e42173f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8ec7c89a-64af-4094-8509-2873be1cee89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:to="loc_us-gaap_StockCompensationPlanMember_8ec7c89a-64af-4094-8509-2873be1cee89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i79c62455dc7847a3a865a2abd620c5a4_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:href="advm-20221231.xsd#advm_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3b61efae-a5f8-4686-b80a-6619687910d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3b61efae-a5f8-4686-b80a-6619687910d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0c75a8c6-817a-4b0d-9bf6-29b556041228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0c75a8c6-817a-4b0d-9bf6-29b556041228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e02db782-6350-42bb-b2b0-157b0125cb24" xlink:href="advm-20221231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e02db782-6350-42bb-b2b0-157b0125cb24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8d54f26d-d549-42ef-a58a-569380fed702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8d54f26d-d549-42ef-a58a-569380fed702" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_f08860f9-a792-4063-a566-0f6541321173" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_f08860f9-a792-4063-a566-0f6541321173" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ec8f591a-a65a-4943-97cf-9ea036ff93d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ec8f591a-a65a-4943-97cf-9ea036ff93d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a0b6cf42-cfcb-4b7a-b086-a53702a18af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a0b6cf42-cfcb-4b7a-b086-a53702a18af9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d944a0e9-865c-42c0-a4b5-bf600f30ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d944a0e9-865c-42c0-a4b5-bf600f30ec26" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:href="advm-20221231.xsd#advm_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d6a69b50-6496-4f48-a3fe-5e40032cb82a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d6a69b50-6496-4f48-a3fe-5e40032cb82a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bfda4ec6-1cf7-4ebe-a6ae-a4cb9589c593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_DomesticCountryMember_bfda4ec6-1cf7-4ebe-a6ae-a4cb9589c593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c246c79c-0f3f-4742-9fd2-3d35ae35e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c246c79c-0f3f-4742-9fd2-3d35ae35e3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2e2ae1f7-52cf-4000-b044-5abae45076ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_ForeignCountryMember_2e2ae1f7-52cf-4000-b044-5abae45076ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2354181b-fcc8-43b3-a7f9-efc5edcc3179_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2354181b-fcc8-43b3-a7f9-efc5edcc3179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_19bf3f6a-e076-496c-b6b1-c72c58cb62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:to="loc_us-gaap_ResearchMember_19bf3f6a-e076-496c-b6b1-c72c58cb62fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i17f36ed2143849c184e0246fb06a80d9_NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b551d74e-d82e-42b8-9ea7-31e6f686b936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b551d74e-d82e-42b8-9ea7-31e6f686b936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe48e915-63ca-4904-b906-62af1d0b275d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe48e915-63ca-4904-b906-62af1d0b275d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5c0b3a5-0d93-4dc9-8205-97db42a0ec17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5c0b3a5-0d93-4dc9-8205-97db42a0ec17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_253914f9-6605-4a4a-ac84-f329471d6f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_253914f9-6605-4a4a-ac84-f329471d6f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_23c006f5-a0cc-4a39-83dd-0b94e039f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_EmployeeStockMember_23c006f5-a0cc-4a39-83dd-0b94e039f44f" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>advm-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_48e581ac-a07a-4caf-b52d-32fd98a70d53_terseLabel_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_label_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Costs</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_documentation_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DeferredTaxAssetsCapitalizedCosts" xlink:to="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a69a5d2a-d445-4f99-b8ba-c6ab885375c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c9af5e1a-811d-4b8a-ae03-5711accc1998_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17a2f1f9-2b4f-4e31-9b80-4f4725cd795c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c75899f0-f60c-48b2-8d96-0a4766ac80d3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_d3d970b7-72b8-473b-beaf-6eb5b31715e2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Savings Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_954f4dbd-2a7a-48c0-8e0f-cc29011ad07c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4148c9bd-5560-4432-8d3e-249c49686572_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_885cef61-ea9f-480f-842c-b7fe825f2de6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5c651995-cc27-4053-b999-c350908290f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1d96c092-a3c8-4c0d-9141-534f4646e353_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_b3e45107-9a37-45fe-bf9c-5ea7f583582b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses incurred on deposits</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a9185c43-e6a8-4488-83e3-e2e5172d7d20_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_db5bc211-1b13-4893-a457-79a76312fc24_terseLabel_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_label_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_documentation_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:href="advm-20221231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:to="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_490cb9a9-d387-4965-8810-459a7f607e8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2649d0e0-a1b4-43e6-b51b-39ad87b7715b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1e147898-eb95-4adf-ab8b-07443ff95a2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ff664821-4964-4eb3-8ce4-27627a6cfad4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_73b9a7b6-7f6e-4e52-857c-9533400f0dbb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96d7a035-b13d-4d91-8c56-7c3289fe0947_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_afd87b86-cda4-4e11-b3d9-02324b257fa2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_117e5978-7049-4371-b46b-32b10477ef06_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1cec0c9b-5f39-4901-9adb-7195c8b6c9dc_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_d8aa22cd-bae0-4bd0-b819-489503f78aa4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_24221fbb-55f0-431d-9d5f-6edff9834978_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_91752738-d66c-4178-92fa-a27626e1686f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average IBR (as percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_bda97004-947b-4c78-bddd-6aac336bcf0a_terseLabel_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of right-of-use asset on lease modification</link:label>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_label_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Right-Of-Use Asset On Lease Modification</link:label>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_documentation_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Right-Of-Use Asset On Lease Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:href="advm-20221231.xsd#advm_RemeasurementOfRightOfUseAssetOnLeaseModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:to="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3ab64b2e-ab68-44a3-906c-52a10e26e20d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a585526-75ab-4ce7-8174-08bd70194565_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ab6911c7-b4de-40de-8a0b-539be44ca291_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_d2cef7ce-d6ac-4982-bcc1-68ba9a79b8e5_terseLabel_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:href="advm-20221231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:to="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_374b15a8-18f3-4b29-9017-03721d5e013e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_287e9bfa-8d3c-4de8-a54d-aea4ce42df5d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of BPI loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ce2fc4ca-c09b-46bb-a764-5425bb711fcf_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_17c1fc3c-186a-45f2-b3bb-e29f33f60836_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7376bf36-3061-40c0-ad27-64f25c038b0c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_399df7c9-4130-439a-bd9a-b004fc5a2f49_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7fe0fd36-e3fa-454b-95a7-e532e6587484_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ab510fc0-3945-48d2-8f66-4f709ef7beb3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_af9a1fa0-b493-4a94-8e81-3757cf386331_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9e340c11-64dd-4399-b51a-6a24c046ce46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca45f83c-c254-4136-9585-4ceba3c268b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5d49bd3e-7691-4682-8c0f-445cac8c0bda_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c48c7eca-2477-4246-8db9-823f7e23b2eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f0c35b9d-1b1b-4e02-8efc-3b2f2f795b7b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_212f0b59-5af3-4590-b079-3b8c80c43325_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ca557458-6491-4d2a-a9e9-855148b08d23_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year tax provisions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e85d29be-eb02-4850-aa23-cd7f8c6b2292_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5fe3df35-935e-4555-9136-d955f08765f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_75d7d3bb-9e1b-41c8-96a9-17b54b6dba94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f146e581-0d56-4faf-8b0c-51200e81eb7a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01708959-770c-40ea-ab9c-802d3ba73117_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_76bc63c7-e355-4811-b65e-f61821f85f39_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1f46259-6879-4b45-aa1f-eb571d08a9c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ed60965d-e176-4560-b3b6-9438dd72d756_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_667416c5-132b-41d0-8e66-f5372197812a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_50db51fa-15f1-42a3-9991-4f41fdf3fa83_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8c48b34d-988c-4b44-8c84-50b2cfe30677_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4c344990-02bd-4c7a-8e49-c422626c3cc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5932b7e6-411d-4f78-9dbb-a743766fd26e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bf97b11f-5331-46ac-989c-52924fcf531e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e33f4df1-abdd-477b-abe3-ea86733414d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_a5e28b2f-81c9-4dc8-ad78-aa17000fc236_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3ef197e7-ca35-49ff-9b1a-ba49ecd6e701_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contract Life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_bc07096b-4914-4819-a63a-76ae12333818_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b031bddc-0bde-4783-975f-96b2d86a1ce4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b62ebe1f-1171-4704-89d3-ba432edce288_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecd59d71-4cc1-4c68-810c-f4547533317b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_befba3a1-fdce-4a12-8142-4f23ed5a2e92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_d0abade8-1b47-41d1-b2be-5c00219fa35b_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_95f04be1-9be9-4987-a7c8-f8b703dfc51c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_1fd44a4a-7ec8-4a92-bb90-41c5cee06202_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4627bb2f-edcf-4563-9e38-60d68e3bc292_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_59d955e2-a25a-4829-bb74-2d516396a095_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_919645ac-b7a6-42af-9ad1-a0e80d166957_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d8bf1ef-54e1-42bd-8d63-f60af56a346a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a2914e6a-357e-476a-bb48-0ea6adc3d175_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e7d05a0e-bd27-42aa-867a-0b3dbc8ecd4b_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb7cac42-6a67-4ba9-b693-0aff94ec71ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_58170515-05f2-4e34-9125-3756cd5d671c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4fa9f803-dc9a-4eea-904d-df82be3852b0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_85c2bb17-1a79-4f37-aece-509318feceb8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_52385a99-6fe0-4eba-a164-9adace2dccd3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f451248f-d06e-4ce5-ade2-bc4308724d6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2b8fbf28-8383-4501-89a5-c1d434e8f6e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of assets (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c2bfbca9-337e-4e02-b9a5-73189a9550c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_5782dc53-16c4-47d8-a7ae-50711002206d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b628373d-dbea-433d-96bc-fbe972abcc1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bd66584-c62b-4502-bbd3-8a7a9c3d2032_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f689a675-47a4-4a69-a37e-1791a29a34a3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5b88d340-be73-4205-97bd-d27d8f23d2ba_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_091680c8-6f80-4921-b5f8-adb7584720d8_terseLabel_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="advm-20221231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_150a9cca-9b0b-414b-8562-cf3bcb2155b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses, other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_da8dc962-3e3a-4929-8108-444f5fab9e06_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_44402317-0152-4f97-a17e-2c3f07183b39_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_60e73a21-c7fd-48e5-a764-664ed6b2d622_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_4a9ecc4b-4a56-4c9c-a1ea-4b528b50a2b6_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvement allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:to="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7327fd11-f636-4461-a57f-936810bddf5e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7297d038-e1b2-4a64-b8ea-e8659cae69fc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_2069dbff-a640-4610-a39f-20035815ccca_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fa5c3745-e058-4468-8515-9c5433bdb124_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0adf339d-d0a9-41ee-b3f5-763998c8af04_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_07725458-2134-4004-870b-ec3ada26d218_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_096e2969-2453-4331-88a1-45364f60d50b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fef9fbc7-f2a3-48f9-a980-db6be2812a0c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_67b08a73-a699-4424-a20e-6dd09ba1cdc4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_db18ed75-ad97-4fab-ac4a-18557274d9e6_terseLabel_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_label_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options [Member]</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="advm-20221231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:to="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_031dbc9a-2972-43fc-b7d2-24effaf90937_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_5a03e76d-5e7c-478d-8d98-26278a424e47_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in shares issued</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_617e1090-b9ba-4416-b0bf-ce81672fcf16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1a563dbc-1b7c-432b-b917-e6537d3a3b57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_509731a2-f46f-45f0-9cef-cdc16584a177_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_51710412-38cc-4edf-944e-b6547905c886_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_bb312083-6c79-4171-ac05-67d578bde53d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6c5babf3-0c22-442f-b0f2-e3e40b5f15a9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b24f1ad0-2c39-456a-9499-bb061ba21f49_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca363d9a-7c73-40a9-bf80-ddde4764638a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a8763646-81c4-451e-912f-02433eb33a85_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f422f44a-1804-485a-ad92-e67b99e28291_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Option Issued Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveToLessee_7dddab95-8f50-41c2-ae43-ba6155f4b578_verboseLabel_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive receivable</link:label>
    <link:label id="lab_us-gaap_IncentiveToLessee_label_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive to Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveToLessee" xlink:to="lab_us-gaap_IncentiveToLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d9e8f2b7-0937-4793-b21a-1bb3ba2be4ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_36f339f6-c832-4986-b275-0a5012be92fc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f3180714-f4ee-4315-8f37-f41df70ed46a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7d044a8b-a31b-4a42-821f-92df5523f1c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_641577e2-56cb-4eef-acc5-99fb48351277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28a91e18-6f6d-4bf8-b84e-ecde5e3926bd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation, weighted-average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_75a347a9-2de9-4d09-8276-bdaec00fa4fa_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_849ff2fc-4376-4f71-84c0-6f544b64dc79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e94fb910-8429-4117-ad49-2728b1257489_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f49de6d3-7fcc-4baa-8362-ce81d99af7c2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85d9d3b4-5dc2-4b5f-a9bc-ae8ca4964f52_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_f1378ddf-1c67-4e66-b890-6fec7b2fd0bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (as percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b3752fb-8ad4-4842-a0f4-6813f98a95bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_f7537215-e7fd-4131-8e5b-16b23af9324f_terseLabel_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan And Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Plan And Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fourteen plan and inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:href="advm-20221231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:to="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_822c45ad-926c-439e-86eb-4a8d923cfc3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_4edc419f-d40d-44b3-8eb2-4191a2436a7d_terseLabel_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_label_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember" xlink:href="advm-20221231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LexeoTherapeuticsIncMember" xlink:to="lab_advm_LexeoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6110f1a8-cbe0-41f4-9fdb-85e1be60b06b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e97b382c-b38e-4671-b4e3-308db1689d9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cdaa0a9d-27e8-4858-becd-209e01ccf666_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2bc8f3c6-ea04-4e89-ae0f-93c14649ece7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_112907da-0dde-4a9a-b0e1-6d6506e90508_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_14de3804-801c-48e3-85c3-ec5c1cc7dbc0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_95b52ff4-5b46-49dd-8287-d628659f22db_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_8ed90c39-4421-4ccf-a060-1105a4443108_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_3504acab-78dc-4d48-ad50-a3d8d43a89e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5bd5ea6b-3c12-4af5-83d4-e6949d2fcb15_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_8d148937-7c31-4e53-9c68-c4372a249faf_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6c0d0bdb-38e8-4804-a75c-5322a0a568ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_39c99c35-088a-4d4b-9c83-de19877bcfb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fe9031e0-0667-4f88-82fb-15f59c504e9f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6c1d7413-d111-4114-b553-f36b6a057191_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_91ee89b9-1fe9-4beb-90eb-bbe26c15f27e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_67d48c83-4a7f-4c21-bc61-825ac614dc27_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to prior year tax provisions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_b0b04496-78db-43e7-a0e5-7c1256fafadf_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d236b5f0-5b23-42ca-9141-ab7547911750_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_eb3539b8-3525-4e63-9f74-ba00c04e6549_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad56f7d1-3bc2-41eb-b245-6535a5adbadd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of performance units both performance and service vesting conditions (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4a798a5-e442-4c33-bd39-b2d10fed645f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a2f656eb-d35c-4f91-b9da-41dc7eaeca29_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9f9925b2-fd6f-4a11-abdc-8995b312630a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_22ba22cc-17a3-49c9-b4d3-1db6940f1575_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2484be35-f80f-402b-8245-515ff5d8b9eb_negatedLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f5200abe-8a62-47c4-a16b-393baf7a9f21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_91782a32-ed67-4cc4-90b1-1f5dbbe72b4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_99ed729b-2d4f-42c9-9902-65df06501e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4faa18b0-8672-467e-b4c4-edc923284c7c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8d570eb-1c3c-4a80-b38c-5bfa171a6093_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_611a3d52-cc23-43e2-aeba-1fe6f3bc92f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair values of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bb1a9eca-33df-4db6-8b44-814af5089a94_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ae4b0e5e-b52c-4e24-afa9-6b9fc88b4572_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2b9345e2-0f46-494b-8f7e-2ddb367b5d58_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2a613f18-d2e2-4124-b9d2-15d3893801f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_80394566-2ea9-4c50-8433-4d7076bbdb7e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_66166fb5-947b-4846-a4f2-792ba21fb65f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1bc0db2-7474-48a9-ac51-6ec5649dc9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_895647fc-02bf-4913-ac36-0b99f9f87f68_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c39ed633-1b78-4c92-8a5d-b05b090f5b19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_f09c9c34-ec1b-49e1-b736-b4cda04a2ba4_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Award Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_160829b0-6afc-4dbe-bcc6-241c30b6a333_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8002bdaa-0d55-4379-9090-c86d20bfc535_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_b3b478c3-c232-40e5-855e-e0c101632e2b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2fd5f393-f1a7-4664-ab2a-041ab7d45bce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_6b6bf85e-4bf0-4706-8f0d-4a1e1e08eee0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plans</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a30ea8f9-f8ba-4287-901b-8fd7ef12b073_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_df9d2ca4-8f26-4fb0-b54a-b511a43495b7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a2dce2e4-b7a5-473e-b889-afb57ebc81fe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ddea4454-a00d-4e91-9c69-7b2d6f7438d1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_d215d854-ebfb-472a-bdcb-5c2ad7d1ac63_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a10291bc-46c9-40bf-a8e8-ad79fa3801ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4aaafa48-2ae0-4ebb-b01d-a4940f5bc35e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_6abba554-5b0e-4b60-b930-f391059ffa9b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2eeb8aed-28b2-4a55-b300-2be9b43fd5bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f88f7abb-2eee-4519-b094-1017bff20888_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d1a28800-708d-490b-902b-e504946badd1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e4b92667-7438-4a0c-abe2-5d74ccc1cfb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_12c95fe1-9c9f-47ec-bf31-10a83ad02520_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_d71b02a6-36d0-4445-91c5-fd1bddc8ea1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5e93c8e8-1956-4599-b20a-fa3486ece610_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fdc70ec6-f851-42ab-90dd-524db6566a09_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8436b780-062f-4b1f-a7fc-0bdedff7a32b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0afe8459-d4b2-47a2-a24b-e07876a20ee4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_34f2b41b-ab34-42d9-baaf-7d3c8d112212_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued nonclinical costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_label_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Nonclinical Costs, Current</link:label>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent" xlink:href="advm-20221231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalCostsCurrent" xlink:to="lab_advm_AccruedNonclinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e406e8d2-a7c0-4204-b5f3-3d8ecf86f6fc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_05c340e2-5f29-4449-a792-c0d1fe54317d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e6f4636c-8c18-45a3-9628-478f9777ec09_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4ae24f0f-0166-450b-b66d-c900a0a570c6_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d184a877-4f95-43f3-a303-291a64045bc2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_08d4a3af-f16e-4d08-a6eb-c074d183f1a1_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20221231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4fd06d4c-8782-48f2-94ae-a0944d5e8236_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_225be4ab-d7de-4976-9545-f43f2ca5cd30_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e9740c17-4962-4af0-b3e8-b7a08b72f2c9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_536a6d5a-3589-4075-9106-35feb1908d46_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_1fcfbf58-53a2-4b2b-9760-ebb19652777a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a363e4dd-1429-4281-b67d-2f7e9840d95f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_df670501-a69d-40de-bb8e-6463b39b42dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91135639-20d8-46aa-9fee-916365495752_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c388eea-7f9a-499f-8336-3d86d3d4b987_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d9cccb47-68e1-4839-a38b-27606a822db8_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_716bba71-5252-43a5-a95a-d5bdd32b3f72_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_310c35cf-a604-44e5-bb7c-e5dfd16d1c6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5e4d7768-7f6e-467c-9cd5-1f0e9672ef53_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97f49252-ec1e-45ab-bd18-532b584c951b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f0c2517c-ebe2-4c6d-97be-c6e9054c61d5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d8b87d56-b626-40b7-a8c5-fcd67cdafed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6638f91b-bde2-44cd-b0af-4725342572ef_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_2a74774e-18a8-4bc4-81c7-063be8fc7ae5_terseLabel_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in right-of-use asset and lease liability due to termination</link:label>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_label_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</link:label>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_documentation_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:href="advm-20221231.xsd#advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:to="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_483c7855-06f2-40aa-9bd2-1915ec89bc73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_fc3ce34a-a727-4ad9-b6d5-8bcf4c0dfcf0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b02c226f-f1ee-4f67-aa1c-b8825311d988_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_38ded93e-7bc8-456a-9002-dbad14b4a38f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_9c75e6a3-ae92-44a7-b2b7-f0dffa20862b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d3d12450-cb5b-4097-abee-aa1b2c744072_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6d9c3c3b-cffb-4069-a3c9-c77a95a64426_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7315ddec-7e1c-46e5-bbfb-9a108bd1b755_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7a6cf902-c355-44a7-acef-46119daef698_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_694f7eb1-789d-4633-9a4f-014da31de289_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cdf9cf4c-feb3-4f34-8689-b9fd68a2250c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_e8bba631-2af6-4834-a3ef-6c06eda5a078_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State credit carryforwards</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a3294a10-7c7f-4bc4-8d51-4b5fd27838da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_88603ebc-a726-47d7-8d11-9470cd6c1181_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d687fb30-b202-45c4-831a-56d1959e6bf9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeSubLeaseMonthlyBaseRent_9dc952f9-de36-4d3b-ad85-3f1291992d29_terseLabel_en-US" xlink:label="lab_advm_LesseeSubLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease monthly base rent</link:label>
    <link:label id="lab_advm_LesseeSubLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_advm_LesseeSubLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Sub-Lease, Monthly Base Rent</link:label>
    <link:label id="lab_advm_LesseeSubLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_advm_LesseeSubLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Sub-Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeSubLeaseMonthlyBaseRent" xlink:href="advm-20221231.xsd#advm_LesseeSubLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeSubLeaseMonthlyBaseRent" xlink:to="lab_advm_LesseeSubLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_274cafbd-8a5d-4fa7-bb4d-f264e556873e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1545b800-cbe6-4614-90fa-4e46b3b35803_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2045c1fb-ee80-4dea-9dda-db3700538bc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13a6ae9a-df98-4768-999e-cdd3588f183e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ee3f65b0-542c-4d50-9eb2-a42153bfc871_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e7a64255-abc3-4960-97b1-f3c31cbf70b5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d485943b-e974-421d-b6df-cee0739208f2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_26a5e628-755c-4a87-851d-92ac4495aa41_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29501fa5-86df-459f-9b4f-06f06622e633_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9930afbe-10ba-4ebe-8572-ff2786ae41e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_656da70e-2c84-4d71-968a-13f0bfb862fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9ff16df-9b5b-4b66-bcf5-114c9ff386c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_9b74728d-1a3d-4534-8c1c-cd64ef0fc031_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_3c371d6f-80b4-4f79-9a6f-8a02271af150_negatedLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets and deferred rent receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deposits and other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:to="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4b909db6-b259-4884-ab16-b84c4aab27fc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4da76e6e-3d2e-449e-bc5b-444b60e00de0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_e15a0342-99c2-4975-8d89-6795c262779e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d7f63504-7d9f-4de3-bc4e-693024efd929_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_059c7882-6871-4903-a410-dac3ee3b12fa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_092d7655-1971-4961-b231-cc6f5d27a84a_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_b4fe48cc-5a9e-4e94-b24d-b1d127aa3798_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_36ba53e2-9454-4062-97d7-81e564ee677b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_100c9364-1003-477a-a371-107d7129cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f4bad766-fa83-47ca-8687-271ec5beb873_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_8332d2f7-2e61-4b8e-a5dc-baa962e37080_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant stockholder threshold ownership percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_15121293-7120-4805-8139-0ce7110ca78d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2022: 100,117 and 98,381 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_04429ec8-4ebb-4b1c-bb8e-4517b9435947_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_744def94-7054-4e4e-a898-dd37cc1a422e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_81603e3d-874f-4926-b3a4-6b1789b6eff0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cf4da1f2-3a8f-4f0a-9f07-b0393e1ac67c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84f12760-11f3-4130-a35b-50381533a2c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eff446d8-623b-418d-b8cd-0800149bba77_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ac67201-395c-4c9a-aa7b-f46c229d286a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7660fb1b-21e0-4232-a69b-1662b305d8c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_3b4a1e07-d631-44b9-abf4-410390bc833a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of internal reorganization</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c0b6505d-82ae-427c-8e83-18444aac7321_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_75c27697-207b-4633-ba1a-6b219faa061a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d97bcc9a-d9c8-4e6d-b290-dcf38cc3261d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_54895865-5544-4759-ac52-06f31a3ef4d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0fd730d1-5643-444c-a675-970e3cf924ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8357ff87-caf1-442c-a57a-74cf3f2b3bbf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_723aae53-b1ee-4a85-b396-ffa65777a473_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable and current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_7dbcc416-8f45-4190-ab30-1a924810025c_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Payment Receivable</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_099b1769-5dee-4608-a5db-f7e3b5d574cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d06ae5a1-47ab-4ad1-a64d-65f6f60b2a84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e34dddd-eabb-46fc-b532-9d106c66310c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_996dd147-dbdf-41a5-ad8d-43c9eeb54270_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_053449ed-cda3-4fb4-baa5-759a790b2dfe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_130c33a9-d657-42f5-9b1b-7a2763ff4907_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_30f6e539-f5ee-4019-9fee-a7159632d698_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_d5439c86-de33-439e-b2b7-7f13673cae4a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34529907-4937-4197-892a-31d97abd1f49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e9d9809a-bafa-4dcc-b2d7-775dc519ce22_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_208c28ab-b748-4c06-ba20-43d8d330d51e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b456adda-f46a-494b-b973-732dc2d1c336_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5bf4c56f-b7ac-48f7-b340-26b13e1bfb18_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_734cf45a-8a83-4677-99a9-051a8e107d29_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_c703c591-ee46-4d2b-a1f7-ccfdb9898a61_terseLabel_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards subject to expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="advm-20221231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_4a9ecfe8-f9e2-47f9-9120-22a0a8904c5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5afbcf82-bb56-4cbd-9ce3-5a37a82b73be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contract Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_07e5b44b-40ec-41f4-9ab6-0c17fcfa5e66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d9bb3d52-50d3-42b1-a697-3ba52dbd3051_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesTable_87d53eba-b89b-48e0-a107-3c2393cf2b0c_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_label_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_documentation_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable" xlink:href="advm-20221231.xsd#advm_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesTable" xlink:to="lab_advm_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_77d651dc-7ddb-4abd-aa8f-f8899b38fb89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and Benefits Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3a5c6c92-27b0-45cd-900b-be42a60e5e11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a524a916-f59e-444c-9a04-19a5598c2cd9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_199645b5-a7f2-477f-a4d8-d11644478e5e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab28e39e-e60f-4054-b139-5aaca18f3c42_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e0e9de6-9e24-41ef-b3ef-0c70c00d75c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_a7581dd0-0896-426b-a4eb-ec9af4b35790_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_b1b7eefc-5460-4781-a0a9-1cf64d5164e3_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20221231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_54bee903-9a71-4ad9-ba01-0603bcac6bc4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3ea6f4e5-8014-4c91-8f8b-fb5f3a814e15_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_446b71ce-ce1e-4b34-88d5-26adc0abe5a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8cdb63ab-9160-408d-a600-1f497157908f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9156d183-2735-4e28-8368-0e7de654bb4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9ed4bc47-947e-4a0f-aae6-f5d43d47179c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f1398124-1a2b-4e00-b3dc-a9dadc5747ba_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82c5a552-ff58-4382-a61b-29b69552ad89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6200b58e-0d99-4fcd-a572-08330a21467b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57d1dc24-3b49-4ca5-90c2-668b3dd18748_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9ece300c-a7c5-4559-9952-0eb61400a6f5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_42c81f00-5fbc-40fd-857a-da765dd4b399_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ac957d33-eb84-4582-988c-6b48b980e181_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9d8d03ee-a2d3-49f7-8ef0-cbedf8ee4dae_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_7b4a8760-5756-4626-92b7-835b10a22b36_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f3ed6927-94e2-4f6e-8104-449c1207bba0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6abf7f04-7b67-4877-884c-496cc6f72979_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_277b8f0c-378f-42c1-b48f-6fd5b37d9b93_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_76acb5ff-9363-42a3-82f1-efca3c28de19_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d27b2e61-390c-4084-b153-f8585996daa1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_b85b9eca-9277-43c3-a376-782fdb9ee8f3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_41f61874-e02b-43d2-b368-e514f33c3235_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_de3e908a-5a40-4d6b-a304-abd29ac3472a_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_d06e9dba-f8aa-41ac-8c53-b63a53f509c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities term (in years)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8a09882b-83a4-4f0b-801f-d7abfa83396a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d7d7ac62-c072-43c3-945e-bb2c13b5bf95_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_c64259a2-dd5a-48d6-a97c-6368f8cfea46_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ad365aa-b182-452e-aa4e-3c7d543e0bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesLineItems_a66488ce-69cd-49d8-8d19-e817711c2a99_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_label_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems" xlink:href="advm-20221231.xsd#advm_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesLineItems" xlink:to="lab_advm_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_92d379e9-3c40-4abd-a77a-7798bfd8cedb_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3df071b1-0cd0-4ab5-8d29-15c864d422b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bfb30f1-d8da-427e-a653-7cbe152f2070_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2fb7bfdb-8f80-4d2b-b7a5-5b0b1692d566_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5ae18fe0-07f3-47ed-8431-505fbf6ed160_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_7e04689b-d6d3-4900-86f1-59664b765456_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SiliconValleyBankMember_f1d4a3d6-0584-4ca9-8407-f0c4682d2788_terseLabel_en-US" xlink:label="lab_advm_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:label id="lab_advm_SiliconValleyBankMember_label_en-US" xlink:label="lab_advm_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:label id="lab_advm_SiliconValleyBankMember_documentation_en-US" xlink:label="lab_advm_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SiliconValleyBankMember" xlink:href="advm-20221231.xsd#advm_SiliconValleyBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SiliconValleyBankMember" xlink:to="lab_advm_SiliconValleyBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_69b04b32-4684-4196-9818-bc623a72fef6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b64aeaee-6fac-4615-b3bd-19101806dbf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_348f51fe-bfea-4b67-a0a6-0571646b7f97_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c39acf75-4ba7-4c01-8e41-9972639ea43e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_39777daa-6cea-4696-96ba-51acafd754ce_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (accretion) amortization of (discount) premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1f84f250-7a1c-401b-a18c-7c377dba17c7_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9218d9c0-cac5-455d-9c43-3a62feb42b0d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4c9be4b3-c8d5-404b-9812-9046616f25fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07564757-c7cf-49cf-9d47-f2bdcd61eef0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9f0fbdea-fbd8-47ea-aa9b-e0daf1c16575_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_229d5ce3-7158-4286-a206-77ffa51ea49f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_83aec493-9109-422e-8645-1b9d9c42d315_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals, reserve and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_64d1b908-dbbd-4574-94f7-9cbb6cce62e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2461b984-0278-4225-a586-3670c64f87a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d3ef40e0-d0df-4389-bb07-74df578be02c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_948d061c-449c-4489-a555-81d95f022007_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_53f24709-ebde-4a8a-973c-8da11415b0d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_23266414-c977-4793-9148-74b71624527c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_590ac3a5-4e40-4abd-b875-2f2d41c3fe18_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_862d4417-a16a-4023-a1c8-63546ffaf01c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5aee70cb-b579-427d-978c-00b10897965a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b0e9d124-18e7-41ea-aff3-17aabe041a26_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f62b9334-2a84-4af7-8b9f-ff3ec2249292_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9689107d-8417-4096-8248-a146ff4d489f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_bc4f96f7-f03b-454f-94cf-8a6c52fe4901_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3a34ce39-2a71-418d-a294-d82602a4fcb3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4179deb-0b80-429f-b49b-264c1135d471_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_efb3757a-d5c0-49d7-bcd3-02ab101ef1cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_7e713fba-1305-4960-a476-5e96e9c19266_verboseLabel_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_label_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock or Unit Option Plan Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cf528520-4f83-474e-b568-44bb2ce0cef6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cd286414-2a1d-4bcc-83c0-c2d6b181124b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_560eadd1-a0a5-4b4a-af33-101f79e05555_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_fbe7a024-de89-4d82-961b-a8a999aeeb4d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed2f2e67-1b67-4d49-8f14-5f695bd57bfb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3b2aa635-5504-48bf-bbe7-ad275bc10c36_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d90bfb5e-d176-43e5-a751-c0cb79ebbabb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebf415a9-aa82-4297-9039-1851b07f7c48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_adac652d-2f08-464c-aa06-abe3f6de8f3d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_376385f3-bd48-4945-9599-43e5f5b0c650_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f41c7808-6d23-4898-bf97-a9a6a8960031_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0fe28533-6b94-4eeb-b87d-39a3e3281a84_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_2dca65e8-cf01-46e9-bede-cafb47e62904_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6c4da747-db08-474d-ba4a-a58d03832037_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_8b2b7b46-fc39-42a5-8f09-2e86d608059b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_b6002a06-ebb2-410d-9254-02b509452947_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_3d5fd611-9e50-4ec1-b103-0af945a6ce30_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award price as a percentage of grant date fair value, minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4455ce8f-f060-4435-82e4-a6104d791caa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_038516af-abb8-4579-aa43-6d9009377a4d_terseLabel_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_label_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical And Development Process Costs Current</link:label>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_documentation_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and development process costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:href="advm-20221231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:to="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_922d2c15-3603-4066-b3f4-46023377bdc8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2b6957ce-85bb-4b52-8422-48b49395f40b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_dd06348c-ca5c-47f4-8a3f-51c615984abe_terseLabel_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities other-than-temporarily impaired</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_label_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporary Impaired Investments Available For Sale Securities</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:href="advm-20221231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:to="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3ff8ead6-fdff-4cbb-804b-80e615e57540_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f4edbeb1-70ea-4843-bd13-2eb60e5d62f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TerminatedLeaseMember_aee6d938-f89a-4406-9846-75a48bf47197_terseLabel_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease</link:label>
    <link:label id="lab_advm_TerminatedLeaseMember_label_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease [Member]</link:label>
    <link:label id="lab_advm_TerminatedLeaseMember_documentation_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember" xlink:href="advm-20221231.xsd#advm_TerminatedLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TerminatedLeaseMember" xlink:to="lab_advm_TerminatedLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_c21500fa-f4d0-4a98-a89d-f75e47ccc972_terseLabel_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_label_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_documentation_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets lease obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:to="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c79b9e55-0111-4fe7-9943-3c1d5609ad75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1eeb9d20-dd45-4898-b959-a844c910bbb5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a3b88176-8b48-488b-82c2-daf8f83535b4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0d03e01f-0bf6-4123-b7e2-a423ebe7ca36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f9ed087-1c55-4fb8-8565-be4d20cc116d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6dce59dc-2211-4ac3-b371-c1823ee36ac1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_30e94ca7-3016-4cf6-a58f-9f26fdfa1551_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_af053d19-eff2-4a1c-97a6-c4aacc656e02_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1dd1439b-b4bd-4ad5-a3ce-2c9ebcf6e315_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_92694b2a-db82-440b-82d3-79e3c9084ba8_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f3a790b9-ba4e-4ea6-ad38-4e4d04b13886_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f4bca6b6-539b-4e2b-ac96-8c56a51ad073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted to employees and non-employees vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_335bbff6-d8ba-457f-b1d9-063d9e856a22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78e2efd1-6f71-4afe-8663-936199f8c159_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cb48f0a3-adab-41ed-8a11-cc7f81e5a7dd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b71ed1f9-99c0-489a-8e52-1ce4123cb05c_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b9d79beb-60ac-4896-9c92-010ee43cb1be_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_10f8bf09-cb84-4580-8bfb-c6bce68425f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d360d6b5-bbb7-4c16-a1c0-f7da2f32ee28_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a9050b9c-9144-46d7-880f-12da75a6b30c_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits as of the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7e02e11a-1ada-44dd-9142-a6daea3306f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits as of the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_7e499680-2748-438a-b4a5-de6b9bff41e0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_71024370-c0c4-41e0-ad3e-0dfd8e19861c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_38892e39-6a3e-4eab-b026-75963bf5065b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2e187b34-acaa-4599-8d73-23d0b0c0f1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6e4eee8a-678d-4088-ace7-5fab7bfe88fd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, if recognized would effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_69435e6f-e057-483c-a175-137f7dc6849c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_523bbe97-c4e3-4d43-97cf-3bb15723b293_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ac36c95a-f48f-4137-bccf-295df7b78bdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f40ff7e1-72e3-409b-b700-9cdefb5db6cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Future Lease Payments under Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AuditInformationAbstract_label_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_advm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract" xlink:href="advm-20221231.xsd#advm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AuditInformationAbstract" xlink:to="lab_advm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2e7d4036-f366-47e2-a6a5-337dc5ea4673_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3722a6ef-919f-4c23-830d-bd4454100721_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c35266c2-d61f-4417-89c3-b6e70f475052_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance due to net operating loss</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2eafb555-bdef-4600-ab6f-e6468aab5ebc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_205706a4-3a83-402b-bcc6-460a6adc0fad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_172f88bc-ffcb-4ef6-957d-52ebeca0442c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9532c470-39de-4c01-9345-4c3f9fb06b24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_30d747dc-1f52-48b3-bf53-76539d15a5f6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b65d64d0-be51-4e88-b9ac-a831cc4f838b_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7763b2d1-1ba7-4ec2-b4eb-2fdc1fa54219_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution by company</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_156c22e9-f56b-4bed-8f2d-76a2ad06a955_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_0118b64f-91f3-48ca-be7f-2ca90eb806c8_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3f1b58bb-57cc-4d8b-8947-6227ee00cd6c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd73524e-e071-45ec-845f-83793f7c01ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_0656eb83-1288-49a8-ae59-5d017e6d248a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a81f0b7e-adee-48ac-a42b-02e1c97bbc09_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7dbf96b9-1c25-498a-9cc2-ab011a1159f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ede3535b-6ebd-4a1d-8c95-b471436d76f4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_af06f182-76f9-4aad-a99a-480942cf9a25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_fd105f87-3520-4fea-8bb5-47336869428b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets and Purchased Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2155cb9a-ba50-4ba9-902a-ae34be0dc147_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_53a80538-c785-4fe3-a601-eca49b5e41a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_873d9dcd-0591-4b25-bc0f-c2f2ec89c708_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d5dda8c8-266c-4935-88ae-bad43d4abdd2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4123dc9c-4ee8-406e-bcaa-6ed1d205abd6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d88f7528-7eb9-4acc-bae7-00f5d13e0579_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbfcf18a-f2c6-4e10-b24e-4bfc3bf194dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6ff5146a-15b2-413c-8366-f93cb17ba64d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_fe6e6a1c-7f6e-4b06-a7db-00ccaa25f736_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_96728a53-7a60-4983-9413-a2e07bdb519a_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination fees</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Fee</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:to="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_181d540c-372b-4a84-a5a2-754ffd9359fc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_906eab90-ad35-4564-bcb8-fb811aab294e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_66d94d9f-3ec3-4ad6-8179-dcd5e57d7b29_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c4a2f59c-9bf3-4387-a9e4-336f104e06d1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_77bcacd8-956f-4004-8fcd-45db6a966cd6_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6828f258-d46c-4305-97a9-bcda058767b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_00b10c9c-479c-4638-9b0a-95cd27c347c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_51633dea-4468-43d3-a48c-612782a86244_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1988d01c-5b68-476d-9ff3-917546b6022d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a2432ca4-fdaa-468b-a260-76a101990b34_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b790cd9c-078a-42c9-b050-9815ca1156c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e8e12e32-bd1a-406d-b5eb-3d3d7ee34b11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92412d47-1dc8-4a1c-82d0-602b9e24d005_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair values of options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9799bb6b-54a9-4195-bd5a-e113a2acc51b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ae5d7f7-f931-4f26-ac19-6d2e2e052092_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a0d40c4f-1c1a-4961-bcf3-f62aec2f0201_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a1f06bdb-36d5-4f97-a4cb-529cb50cfffa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_466f9d07-950c-4767-89a6-82abdf75d6ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_2e2d5f23-a263-436a-bea8-f64b69648eb8_verboseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future issuance (as percent)</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:to="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_cbf2ec4f-9d26-4a52-b2f6-c6f7e3e882ff_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>advm-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:757626be-73e2-4b39-a587-515e5fd5b38d,g:eed8e054-5400-4ef7-aaaf-6c3fc06598ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_781029d6-3585-4e25-8721-577f573e2865" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentType_781029d6-3585-4e25-8721-577f573e2865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6dac4649-b504-4b06-9e0e-0162451aa917" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentAnnualReport_6dac4649-b504-4b06-9e0e-0162451aa917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_76c7cef0-c3d5-4cce-b3cf-aa7939cfda73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentPeriodEndDate_76c7cef0-c3d5-4cce-b3cf-aa7939cfda73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8951731f-31c5-4990-97d1-346e64adcd39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_CurrentFiscalYearEndDate_8951731f-31c5-4990-97d1-346e64adcd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c3b45b97-4113-4ada-8b75-37761d1789be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentTransitionReport_c3b45b97-4113-4ada-8b75-37761d1789be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5ca441e5-bfff-44ba-a1dd-9891429ae973" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityFileNumber_5ca441e5-bfff-44ba-a1dd-9891429ae973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_27e6d856-fd04-4e84-8528-2c8e9ec37735" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityRegistrantName_27e6d856-fd04-4e84-8528-2c8e9ec37735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bd05c324-3363-4f1d-a072-e861b74e586d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bd05c324-3363-4f1d-a072-e861b74e586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_49893955-fc34-4d69-bc20-6b06eae2522f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityTaxIdentificationNumber_49893955-fc34-4d69-bc20-6b06eae2522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a6563d68-f0c1-40c5-be72-07b882bdf1db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityAddressAddressLine1_a6563d68-f0c1-40c5-be72-07b882bdf1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3a0848db-0fa2-4c26-aa5d-da632a8fcf41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityAddressCityOrTown_3a0848db-0fa2-4c26-aa5d-da632a8fcf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_753b8cad-daae-4fbe-ad66-dc4c28ecb23d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityAddressStateOrProvince_753b8cad-daae-4fbe-ad66-dc4c28ecb23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_acb4d7c8-7022-4a0b-8d33-56ff9eaf2bb3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityAddressPostalZipCode_acb4d7c8-7022-4a0b-8d33-56ff9eaf2bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_77a5d4a7-8e2e-4c7a-b57e-96c8251519d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_CityAreaCode_77a5d4a7-8e2e-4c7a-b57e-96c8251519d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_71fa7deb-6b16-4c5d-8718-291df4b65d0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_LocalPhoneNumber_71fa7deb-6b16-4c5d-8718-291df4b65d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f1c1fc69-9d2e-4e89-98d4-fa7e4c274f97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_Security12bTitle_f1c1fc69-9d2e-4e89-98d4-fa7e4c274f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7e269011-15bc-4269-82ff-180282a0e02b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_TradingSymbol_7e269011-15bc-4269-82ff-180282a0e02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f353e3f2-6804-4597-a1a5-22bf687e98bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_SecurityExchangeName_f353e3f2-6804-4597-a1a5-22bf687e98bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3920b3c0-918e-4c8f-b529-b1f37aad3c3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3920b3c0-918e-4c8f-b529-b1f37aad3c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ae0e4697-06b7-4c68-b1c7-fb671b301b17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityVoluntaryFilers_ae0e4697-06b7-4c68-b1c7-fb671b301b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c469d5b0-256d-4437-8c17-f6aaba56bdce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityCurrentReportingStatus_c469d5b0-256d-4437-8c17-f6aaba56bdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_241f5d23-2982-40d3-8f7d-4d1698e8261a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityInteractiveDataCurrent_241f5d23-2982-40d3-8f7d-4d1698e8261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_516df244-8e20-434c-8de9-893271172acb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityFilerCategory_516df244-8e20-434c-8de9-893271172acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f81b1834-57e2-4b3e-8912-568e28b1b404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntitySmallBusiness_f81b1834-57e2-4b3e-8912-568e28b1b404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c83ce899-e3c3-4329-9df5-eddd81dbec62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityEmergingGrowthCompany_c83ce899-e3c3-4329-9df5-eddd81dbec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b535a048-4f11-4e0a-b943-06ac872b64a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b535a048-4f11-4e0a-b943-06ac872b64a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a07f789a-a110-4ea1-b470-85ddb19cabf2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityShellCompany_a07f789a-a110-4ea1-b470-85ddb19cabf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_62871fbd-d9f1-4f7a-902c-36b91b9a240f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityPublicFloat_62871fbd-d9f1-4f7a-902c-36b91b9a240f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6e6a6c6a-db66-4db5-8705-a083aee80511" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6e6a6c6a-db66-4db5-8705-a083aee80511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cb556fdb-7cab-4ddd-a253-549e2a22bc40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cb556fdb-7cab-4ddd-a253-549e2a22bc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71244056-daec-410c-be0e-0fd7fd81677a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_AmendmentFlag_71244056-daec-410c-be0e-0fd7fd81677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_21b9939a-6863-40ab-b659-2512c7dc04ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentFiscalYearFocus_21b9939a-6863-40ab-b659-2512c7dc04ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0c37443f-411b-43e2-9d72-4e9d54d6f75c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0c37443f-411b-43e2-9d72-4e9d54d6f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_93d1ee61-93b2-4bce-8b59-27edab1d0a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_132dc431-df9b-46f5-8049-faef4e2c92c2" xlink:to="loc_dei_EntityCentralIndexKey_93d1ee61-93b2-4bce-8b59-27edab1d0a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/AuditInformation" xlink:type="simple" xlink:href="advm-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract_3f827054-0d97-4078-84c4-e444a47e4d63" xlink:href="advm-20221231.xsd#advm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_375bc4e8-1af5-4916-96da-6d56073b23f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3f827054-0d97-4078-84c4-e444a47e4d63" xlink:to="loc_dei_AuditorName_375bc4e8-1af5-4916-96da-6d56073b23f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_0e05906d-cd17-4e1f-a9ca-c5e271497f5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3f827054-0d97-4078-84c4-e444a47e4d63" xlink:to="loc_dei_AuditorFirmId_0e05906d-cd17-4e1f-a9ca-c5e271497f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_43821188-6a30-4231-b78d-dab16a03b8ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3f827054-0d97-4078-84c4-e444a47e4d63" xlink:to="loc_dei_AuditorLocation_43821188-6a30-4231-b78d-dab16a03b8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f838d4d8-d3ed-4f6f-b989-8f157a74a899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f838d4d8-d3ed-4f6f-b989-8f157a74a899" xlink:to="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dbf152c7-243a-4541-a999-3a611ccbd913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dbf152c7-243a-4541-a999-3a611ccbd913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_7be5263c-c78d-4188-b1f8-0f50c6d8e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:to="loc_us-gaap_ShortTermInvestments_7be5263c-c78d-4188-b1f8-0f50c6d8e76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_2f4c10df-e8bd-440f-8b03-084da74e1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:to="loc_us-gaap_IncentiveToLessee_2f4c10df-e8bd-440f-8b03-084da74e1b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b07a7be-66d7-41c9-87fd-89e7a30d7bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b07a7be-66d7-41c9-87fd-89e7a30d7bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3ee9f015-ff8f-49d5-aa86-7d3fce4127e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d6010dd-3f3b-40b0-a597-5dbb03daf3bf" xlink:to="loc_us-gaap_AssetsCurrent_3ee9f015-ff8f-49d5-aa86-7d3fce4127e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_48b44eaf-d68d-4c80-a3dc-554eb8213147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_48b44eaf-d68d-4c80-a3dc-554eb8213147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6d135f79-9126-42ea-86ff-7361df23ddfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6d135f79-9126-42ea-86ff-7361df23ddfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3dd223d6-a906-4026-b0d1-ecf699a86682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3dd223d6-a906-4026-b0d1-ecf699a86682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_182f2820-df95-4c60-a88d-3ac01af55bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_182f2820-df95-4c60-a88d-3ac01af55bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f63b9033-e0cf-4db8-8132-a77e4f918c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f63b9033-e0cf-4db8-8132-a77e4f918c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a8ceedc4-2f0a-4622-85e2-565e7295e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e24c400-0858-4c0c-a177-6fc32829d4c9" xlink:to="loc_us-gaap_Assets_a8ceedc4-2f0a-4622-85e2-565e7295e7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f838d4d8-d3ed-4f6f-b989-8f157a74a899" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_37cf125c-2021-4789-95dd-1dc08967e6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:to="loc_us-gaap_AccountsPayableCurrent_37cf125c-2021-4789-95dd-1dc08967e6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_67d8759f-091f-4505-bef9-48ee356048d9" xlink:href="advm-20221231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_67d8759f-091f-4505-bef9-48ee356048d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3d4fc83-d90f-43ad-a0f2-54a2ae38bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3d4fc83-d90f-43ad-a0f2-54a2ae38bc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2aeef846-009d-47cf-83c8-ba196930da65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd8a7d90-459a-49a2-a939-b47dc60eb103" xlink:to="loc_us-gaap_LiabilitiesCurrent_2aeef846-009d-47cf-83c8-ba196930da65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_a2bd8d1c-8cbb-45e0-9400-854bf71a0822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_a2bd8d1c-8cbb-45e0-9400-854bf71a0822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39a0e977-ceaf-4249-a9a1-1e42aea1a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a2bd8d1c-8cbb-45e0-9400-854bf71a0822" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39a0e977-ceaf-4249-a9a1-1e42aea1a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_29cf300d-5509-4e8c-a9cd-2b3a647cfcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a2bd8d1c-8cbb-45e0-9400-854bf71a0822" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_29cf300d-5509-4e8c-a9cd-2b3a647cfcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1e412236-f037-48ab-b8c2-097d7c9757f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a2bd8d1c-8cbb-45e0-9400-854bf71a0822" xlink:to="loc_us-gaap_Liabilities_1e412236-f037-48ab-b8c2-097d7c9757f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d0274791-736b-4814-9cf5-db216e827442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d0274791-736b-4814-9cf5-db216e827442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_26bf32ab-c1ca-4b85-987b-bf32f9afe9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_PreferredStockValue_26bf32ab-c1ca-4b85-987b-bf32f9afe9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c92f6593-670f-41d1-b05c-f497ed77e93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_CommonStockValue_c92f6593-670f-41d1-b05c-f497ed77e93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86e625a5-bdc5-49ca-acde-950e3ce13429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86e625a5-bdc5-49ca-acde-950e3ce13429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d31e4fa2-f0db-4554-8d29-494631d2536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d31e4fa2-f0db-4554-8d29-494631d2536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83137e22-b5d6-4ba1-a395-e95a7edb82c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83137e22-b5d6-4ba1-a395-e95a7edb82c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4b77735-5cb1-499f-866c-2807b538e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8b3acaec-21eb-49ca-85a5-c7674ece9f9d" xlink:to="loc_us-gaap_StockholdersEquity_b4b77735-5cb1-499f-866c-2807b538e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d0c290c5-3699-4251-8fa8-35a6b4cf7f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_169878b4-e843-4440-96d4-7ab3b56d4078" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d0c290c5-3699-4251-8fa8-35a6b4cf7f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_209a4e83-7b43-4dcb-b501-397ae88f338e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_209a4e83-7b43-4dcb-b501-397ae88f338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_35c292e2-6b63-427c-a84e-f418e0508156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_35c292e2-6b63-427c-a84e-f418e0508156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_553dfac3-0b0c-4107-99c4-effd05a537b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_553dfac3-0b0c-4107-99c4-effd05a537b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d122f24e-df36-40de-b876-930325381045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d122f24e-df36-40de-b876-930325381045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5ce60306-e7f4-45ba-8c05-b1070dda4c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5ce60306-e7f4-45ba-8c05-b1070dda4c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c227a81b-0af4-44b2-8740-187b2ca199a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c227a81b-0af4-44b2-8740-187b2ca199a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dcc4ceb6-b150-439b-b16d-3000c051e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_CommonStockSharesIssued_dcc4ceb6-b150-439b-b16d-3000c051e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_34171d1d-b044-444a-9dab-29c3808db614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1087d190-fe83-4666-9b6f-6eba18d758b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_34171d1d-b044-444a-9dab-29c3808db614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0305656b-b89e-498c-8746-83ee9619827f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0305656b-b89e-498c-8746-83ee9619827f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e6a1d97b-1df8-4a12-822b-7eeeb68bf05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e6a1d97b-1df8-4a12-822b-7eeeb68bf05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ce759282-4abb-4751-a4ed-b96b04119b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6a1d97b-1df8-4a12-822b-7eeeb68bf05e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ce759282-4abb-4751-a4ed-b96b04119b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dc4915a5-fd75-46ce-96d8-13b2a869c694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6a1d97b-1df8-4a12-822b-7eeeb68bf05e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dc4915a5-fd75-46ce-96d8-13b2a869c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4e2f6d4a-e057-4541-896c-2e66e5e16afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6a1d97b-1df8-4a12-822b-7eeeb68bf05e" xlink:to="loc_us-gaap_OperatingExpenses_4e2f6d4a-e057-4541-896c-2e66e5e16afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_305fb674-e2a7-49bd-8331-63069604c7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_OperatingIncomeLoss_305fb674-e2a7-49bd-8331-63069604c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c998630a-9aa7-47e1-ac8d-aa4e22f651dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c998630a-9aa7-47e1-ac8d-aa4e22f651dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d061da4-e17f-4b40-b3fb-988bde48d7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d061da4-e17f-4b40-b3fb-988bde48d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4fd323ed-73cf-4914-ad1d-5154f1bdac61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4fd323ed-73cf-4914-ad1d-5154f1bdac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6c870ac0-56aa-47ee-b992-651ce7749f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_NetIncomeLoss_6c870ac0-56aa-47ee-b992-651ce7749f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c3d1672f-ad0f-4b1e-8fb2-03ef806c392b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c3d1672f-ad0f-4b1e-8fb2-03ef806c392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_8b296b51-0f9a-4bb7-9800-52f8c38943f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c3d1672f-ad0f-4b1e-8fb2-03ef806c392b" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_8b296b51-0f9a-4bb7-9800-52f8c38943f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e4dd49e9-a790-464e-aac9-080c6bbb071d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c3d1672f-ad0f-4b1e-8fb2-03ef806c392b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e4dd49e9-a790-464e-aac9-080c6bbb071d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9224f52e-6bff-4b8a-9606-9ec3e64fb6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c3d1672f-ad0f-4b1e-8fb2-03ef806c392b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9224f52e-6bff-4b8a-9606-9ec3e64fb6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_99e03169-331e-402b-9720-337fad88ea7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_EarningsPerShareBasic_99e03169-331e-402b-9720-337fad88ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_69e89b92-38f9-4b72-bf3c-ca13752e6db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_EarningsPerShareDiluted_69e89b92-38f9-4b72-bf3c-ca13752e6db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2cb74fa2-0525-448a-a972-436ba148bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2cb74fa2-0525-448a-a972-436ba148bc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73b9241a-3d41-4c9b-9a40-40890a8e973e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ca0112-3810-454f-8dff-04304bc9b231" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73b9241a-3d41-4c9b-9a40-40890a8e973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2eccf5a7-9b36-4c0d-98a2-81b6595854b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2eccf5a7-9b36-4c0d-98a2-81b6595854b4" xlink:to="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29c0efc0-b006-4a7b-9dd3-6ebb109e6386" xlink:to="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a6044b8-f75b-4be9-977f-99ce2a7d512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_CommonStockMember_4a6044b8-f75b-4be9-977f-99ce2a7d512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c7c6933e-1a40-4de5-adcf-2e39e196bd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c7c6933e-1a40-4de5-adcf-2e39e196bd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10e71a15-70de-4853-b9c3-3293da0c35d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10e71a15-70de-4853-b9c3-3293da0c35d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_024a4031-cf59-47bf-96b1-cb13067e0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fcf018e4-a362-46cd-aa7e-bc42a8656bba" xlink:to="loc_us-gaap_RetainedEarningsMember_024a4031-cf59-47bf-96b1-cb13067e0c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a964271-a64f-41d5-987d-279bee90c7b5" xlink:to="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a38862b9-68dc-47ef-aa57-caae9d8eb398" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_03c01a87-72f8-483e-8b73-0cfff8af5a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_03c01a87-72f8-483e-8b73-0cfff8af5a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8558e279-fc65-45d8-b8f9-09120baa8283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockholdersEquity_8558e279-fc65-45d8-b8f9-09120baa8283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b7e96942-b9eb-48ce-96bb-273afeda994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b7e96942-b9eb-48ce-96bb-273afeda994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e2a547d-8844-402f-93bc-a986c360803e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e2a547d-8844-402f-93bc-a986c360803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aa3f0745-b805-4def-9222-3d1ef55394dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aa3f0745-b805-4def-9222-3d1ef55394dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d188497-99f0-41da-b318-c670ee49bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d188497-99f0-41da-b318-c670ee49bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d461e96f-7c94-4514-be37-8320ee6999b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d461e96f-7c94-4514-be37-8320ee6999b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913af89b-6635-42a3-8707-55c32cd3c489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913af89b-6635-42a3-8707-55c32cd3c489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef95a0eb-134a-49fe-830a-3a63c1bc8dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef95a0eb-134a-49fe-830a-3a63c1bc8dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_784417f2-cd02-474c-abfe-436a94ecddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_784417f2-cd02-474c-abfe-436a94ecddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_36fc2e37-64f7-4ec9-8c26-2cce4f39007c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_36fc2e37-64f7-4ec9-8c26-2cce4f39007c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_93ed4ff0-920b-4073-b447-453a2ffa903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_93ed4ff0-920b-4073-b447-453a2ffa903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3ca55ee-4598-4023-bd6e-65bf03c0202b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_NetIncomeLoss_f3ca55ee-4598-4023-bd6e-65bf03c0202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_222fa75a-2553-4467-80be-1f509a05453e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_222fa75a-2553-4467-80be-1f509a05453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73ba8fb7-d7c4-4770-b92c-b28a285d92e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a8006a9-6d43-4fb9-b249-f93b8bf18d00" xlink:to="loc_us-gaap_StockholdersEquity_73ba8fb7-d7c4-4770-b92c-b28a285d92e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cab0eaca-08a8-4b80-ad8a-a8694b4f8bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_686b838b-a79b-4bb6-ac90-d013f7cd1ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cab0eaca-08a8-4b80-ad8a-a8694b4f8bda" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_686b838b-a79b-4bb6-ac90-d013f7cd1ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="advm-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_834d74ef-d833-4fb4-a7cd-47c2f305679d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:to="loc_us-gaap_NetIncomeLoss_834d74ef-d833-4fb4-a7cd-47c2f305679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_babe5b1e-31b4-4598-9eba-2a0c1dd82b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_DepreciationAndAmortization_babe5b1e-31b4-4598-9eba-2a0c1dd82b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_51113c2c-1379-40cb-acb3-845c63b00f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_ShareBasedCompensation_51113c2c-1379-40cb-acb3-845c63b00f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b8b53156-fa61-43d8-ad3f-0e5f9ad04750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b8b53156-fa61-43d8-ad3f-0e5f9ad04750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cf97a856-6f28-4190-b205-aab34b8a513d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cf97a856-6f28-4190-b205-aab34b8a513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ab961422-b5c5-4e43-ac50-bf84f71716a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_AssetImpairmentCharges_ab961422-b5c5-4e43-ac50-bf84f71716a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9242f627-eb96-4637-a43c-e8e1df6c4dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_369e6d36-8c6f-467b-9fc3-9f4304600a83" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9242f627-eb96-4637-a43c-e8e1df6c4dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f39403f8-a5dc-41d4-84f0-bf481e8a816a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f39403f8-a5dc-41d4-84f0-bf481e8a816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_9f22918e-47c0-4210-90d8-aeb020958c9f" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_9f22918e-47c0-4210-90d8-aeb020958c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_9727962f-e251-4451-83df-fe8bfbadd247" xlink:href="advm-20221231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_9727962f-e251-4451-83df-fe8bfbadd247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_781fd60f-d5fb-44b5-b76c-90d7edf66a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_781fd60f-d5fb-44b5-b76c-90d7edf66a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8c8c7f7-1a76-43cf-b5e0-ad1a2b0bf206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8c8c7f7-1a76-43cf-b5e0-ad1a2b0bf206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ede3465c-0f8d-4bb2-a6dd-1950ac6b9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ede3465c-0f8d-4bb2-a6dd-1950ac6b9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a1b7bc13-81db-465a-b212-9592992cc69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a121cc3-41f5-441c-9b98-e0a796741a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a1b7bc13-81db-465a-b212-9592992cc69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f34ad4f8-5689-4f4e-9ae8-df41917c2576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_094a0460-f110-4e58-af37-cb0f020a4753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f34ad4f8-5689-4f4e-9ae8-df41917c2576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1a65775c-90fe-462b-ad90-78eef92942a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1a65775c-90fe-462b-ad90-78eef92942a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b50f7679-3395-414a-909d-00cc08b16e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b50f7679-3395-414a-909d-00cc08b16e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ec53de4b-2046-4b54-aa34-e9c32916d201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ec53de4b-2046-4b54-aa34-e9c32916d201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0f93888-9d7f-48d1-a067-b684e07ca501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0f93888-9d7f-48d1-a067-b684e07ca501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4bd83f9-6536-4068-893e-eb4f03c92bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_246049de-a7c3-490d-87bf-dd0cabde75a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4bd83f9-6536-4068-893e-eb4f03c92bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_494da7f6-9e34-432b-86bc-53ae431527f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_494da7f6-9e34-432b-86bc-53ae431527f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c4a99bc9-9d21-47a8-a79e-46ba8a096616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c4a99bc9-9d21-47a8-a79e-46ba8a096616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_1d4e257a-5d55-4b6d-a792-9de5d20a116f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_1d4e257a-5d55-4b6d-a792-9de5d20a116f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_b8f8e442-3701-4044-a3e3-2d9f511def70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:to="loc_us-gaap_RepaymentsOfDebt_b8f8e442-3701-4044-a3e3-2d9f511def70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_753ee299-5b79-4581-8e0b-a238c4f9108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_396b70bc-500d-48e0-ba0e-90daf0123cb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_753ee299-5b79-4581-8e0b-a238c4f9108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2a0455e-5a55-428f-b7b8-a59d16a7fa00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2a0455e-5a55-428f-b7b8-a59d16a7fa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfaf51e3-830d-407e-8608-776ee9fa28f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfaf51e3-830d-407e-8608-776ee9fa28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f767d575-d01e-40e7-b144-f8b0d571deee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f767d575-d01e-40e7-b144-f8b0d571deee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20b24d1a-08d6-4614-aed4-915de352c745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20b24d1a-08d6-4614-aed4-915de352c745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a5eff1f6-3563-40e2-ad48-80440ab4fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a5eff1f6-3563-40e2-ad48-80440ab4fba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6052e2ba-8e59-4a16-9213-f7cf700a627a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6052e2ba-8e59-4a16-9213-f7cf700a627a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_12e3a1f6-c111-4307-9827-90d6ac5a73bc" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6477810c-49cb-4773-8a17-a13d9b03a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6477810c-49cb-4773-8a17-a13d9b03a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_c8dd4273-c675-4aa3-bd02-1f7a3f9b4af8" xlink:href="advm-20221231.xsd#advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:to="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_c8dd4273-c675-4aa3-bd02-1f7a3f9b4af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_56a80e1a-8b6f-4299-8de6-2521fc3b8877" xlink:href="advm-20221231.xsd#advm_RemeasurementOfRightOfUseAssetOnLeaseModification"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:to="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_56a80e1a-8b6f-4299-8de6-2521fc3b8877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0231c0f6-1e96-41d9-93a3-ed4a9ee67115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3bc90cab-7680-47e0-bdff-3f3fa42607b1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0231c0f6-1e96-41d9-93a3-ed4a9ee67115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Descriptionofthebusiness" xlink:type="simple" xlink:href="advm-20221231.xsd#Descriptionofthebusiness"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Descriptionofthebusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5eeef94e-9625-43f8-96c4-26033e800b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_36b79177-b0f7-4227-8b09-e5f8ede85d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5eeef94e-9625-43f8-96c4-26033e800b0e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_36b79177-b0f7-4227-8b09-e5f8ede85d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d77035a4-b090-442d-99d9-697bc28f404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fffbbb14-3509-4551-81ee-fb6936636929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d77035a4-b090-442d-99d9-697bc28f404c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fffbbb14-3509-4551-81ee-fb6936636929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fc83ba72-96c9-4736-a34c-8b022908916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8017e296-169c-47ae-a4ca-e7c6a9ad6b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fc83ba72-96c9-4736-a34c-8b022908916d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8017e296-169c-47ae-a4ca-e7c6a9ad6b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Revenue" xlink:type="simple" xlink:href="advm-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7c3f35bd-8842-48d6-999a-a97014a8d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1059f686-3548-4001-9d74-99c7ed82a661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7c3f35bd-8842-48d6-999a-a97014a8d6db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1059f686-3548-4001-9d74-99c7ed82a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Leases" xlink:type="simple" xlink:href="advm-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7c4636eb-e88e-4cd3-95a1-aae7f5b14f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4309e2bc-555d-4ee9-9207-6f771bc78748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7c4636eb-e88e-4cd3-95a1-aae7f5b14f4d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4309e2bc-555d-4ee9-9207-6f771bc78748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_22068728-74f2-4323-bbe1-24220d94bbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_36c09f4b-6803-4e97-ba51-759f325bf515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_22068728-74f2-4323-bbe1-24220d94bbf9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_36c09f4b-6803-4e97-ba51-759f325bf515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="advm-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53aef20e-b5e7-4d24-a223-2cfd684f50b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_166db196-15f1-4700-ad8c-f5aa0b9befc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53aef20e-b5e7-4d24-a223-2cfd684f50b6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_166db196-15f1-4700-ad8c-f5aa0b9befc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlans" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlans"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0d0d1165-ccd3-4c04-9ff1-89c77b455e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_807aee56-f708-48aa-9305-fd97cfb1941f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0d0d1165-ccd3-4c04-9ff1-89c77b455e1d" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_807aee56-f708-48aa-9305-fd97cfb1941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="simple" xlink:href="advm-20221231.xsd#A401kSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd540d81-1a02-46cc-8a04-a28f7eee2bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_9ab6b90a-bce3-46f9-ac61-ec2136dbc689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd540d81-1a02-46cc-8a04-a28f7eee2bb3" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_9ab6b90a-bce3-46f9-ac61-ec2136dbc689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Restructuring" xlink:type="simple" xlink:href="advm-20221231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_34d00cea-da50-41b8-88c8-d3651659b61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3320676a-cd15-4f19-8849-ee5bde4e3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_34d00cea-da50-41b8-88c8-d3651659b61f" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3320676a-cd15-4f19-8849-ee5bde4e3b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxes" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_97f3fb58-7a63-4c9a-a40b-b2de120e588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5ea0f80e-23a3-4c6d-86ac-219bf8cfc160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97f3fb58-7a63-4c9a-a40b-b2de120e588d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5ea0f80e-23a3-4c6d-86ac-219bf8cfc160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20221231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db01a80c-00e5-43ba-8184-5016f4dd5ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7416c8e2-a9c7-408f-935d-a4ab7d58bfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db01a80c-00e5-43ba-8184-5016f4dd5ca7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7416c8e2-a9c7-408f-935d-a4ab7d58bfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b907aec3-5901-4463-b3dd-6a29bff78d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b907aec3-5901-4463-b3dd-6a29bff78d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3ab14190-eca6-49a3-bd43-cde9756476bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_UseOfEstimates_3ab14190-eca6-49a3-bd43-cde9756476bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b988b909-275f-475c-b331-aacaf41d7712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b988b909-275f-475c-b331-aacaf41d7712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32944bd4-77be-44c1-9988-7113042e3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32944bd4-77be-44c1-9988-7113042e3bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_98df6c47-d8fd-4032-9e0a-c24bbf4998ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_98df6c47-d8fd-4032-9e0a-c24bbf4998ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_4e3f747c-c1d3-4301-b296-2de3e233f8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_4e3f747c-c1d3-4301-b296-2de3e233f8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_17429896-9c00-46cb-af89-2e8e024c2feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_17429896-9c00-46cb-af89-2e8e024c2feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_17c6c4ed-a282-43e7-81b0-6d25070f7687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_17c6c4ed-a282-43e7-81b0-6d25070f7687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4a194ae1-3e35-4e6e-b0a6-dda5232cf56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4a194ae1-3e35-4e6e-b0a6-dda5232cf56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_09c5cf4a-02a5-4e66-8cd3-17f1a70dd903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_09c5cf4a-02a5-4e66-8cd3-17f1a70dd903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a8d9b011-4155-4d47-b3ab-4b09e0c07d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a8d9b011-4155-4d47-b3ab-4b09e0c07d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ec7801e8-29a9-44cc-8b7e-15fee36c8275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ec7801e8-29a9-44cc-8b7e-15fee36c8275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0d63b3af-7c13-45c9-9096-8dfac6f3d05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0d63b3af-7c13-45c9-9096-8dfac6f3d05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fb38423-9b89-4917-8cc0-325b386ee3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fb38423-9b89-4917-8cc0-325b386ee3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5ad06f64-3d6d-430c-b73e-14114e089a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5ad06f64-3d6d-430c-b73e-14114e089a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6fa0e491-1ef1-4cbe-a235-5345b7c9f4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6fa0e491-1ef1-4cbe-a235-5345b7c9f4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_042b6f26-a32c-42ea-952a-a1b2f2699699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_042b6f26-a32c-42ea-952a-a1b2f2699699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5af6edf3-7fce-4669-a640-fe71d9cdb8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5af6edf3-7fce-4669-a640-fe71d9cdb8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8b306057-194e-4d34-a47b-95cff747eb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5db0b91a-b012-48b6-b451-f6d16f422cfb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8b306057-194e-4d34-a47b-95cff747eb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d9a660e1-3004-4fa7-9ca5-9b9c65e4fc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7263692f-7802-4c2a-a255-569cb834c96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d9a660e1-3004-4fa7-9ca5-9b9c65e4fc49" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7263692f-7802-4c2a-a255-569cb834c96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesTables" xlink:type="simple" xlink:href="advm-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_01f0f028-2726-4fc6-993e-93982b30a8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e88595eb-2e13-4966-9459-c0f40c74243b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_01f0f028-2726-4fc6-993e-93982b30a8f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e88595eb-2e13-4966-9459-c0f40c74243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e5e5e2cb-fc7f-4f8a-a02a-7053bc6f71df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_824ce0e8-65ca-47c3-8760-c5e509694145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e5e5e2cb-fc7f-4f8a-a02a-7053bc6f71df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_824ce0e8-65ca-47c3-8760-c5e509694145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ece23632-06f5-4b69-8706-d9fb81772868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e5e5e2cb-fc7f-4f8a-a02a-7053bc6f71df" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ece23632-06f5-4b69-8706-d9fb81772868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansTables" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9c7178b-0907-42e0-a3ab-6aceb3de4f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_931dde8a-b885-43a0-990b-8fe9bc33d458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9c7178b-0907-42e0-a3ab-6aceb3de4f4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_931dde8a-b885-43a0-990b-8fe9bc33d458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2ec9b4f1-2eb0-4f6c-906f-b1b58cd617cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9c7178b-0907-42e0-a3ab-6aceb3de4f4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2ec9b4f1-2eb0-4f6c-906f-b1b58cd617cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4be4baf8-6340-4004-82a8-150327628cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9c7178b-0907-42e0-a3ab-6aceb3de4f4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4be4baf8-6340-4004-82a8-150327628cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c2f44f97-29a6-4906-b95c-3f14d865e9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9c7178b-0907-42e0-a3ab-6aceb3de4f4c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c2f44f97-29a6-4906-b95c-3f14d865e9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringTables" xlink:type="simple" xlink:href="advm-20221231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ce4ffa5-9584-4f79-b753-9a51c368f44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f89fbb0d-d536-4d4b-b6d5-b66df9875c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ce4ffa5-9584-4f79-b753-9a51c368f44a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f89fbb0d-d536-4d4b-b6d5-b66df9875c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_550cc09e-d613-4753-ab95-f389e048e4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_550cc09e-d613-4753-ab95-f389e048e4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d4f1e149-65d6-4520-b1bf-eabc7072caf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d4f1e149-65d6-4520-b1bf-eabc7072caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5aae86dd-82bb-4ade-a32b-acafad5e9c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5aae86dd-82bb-4ade-a32b-acafad5e9c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cb2d1078-896d-41d2-966a-3aaa4f86791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cb2d1078-896d-41d2-966a-3aaa4f86791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_dd8286c9-c7ec-4fc4-95db-37371add5f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa28c88c-22c8-4a1e-a7d6-08cddbea5e2b" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_dd8286c9-c7ec-4fc4-95db-37371add5f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20221231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30e99a17-a242-487c-a3f9-44baed72897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_df1ee30a-2925-48aa-90c3-fdc2fef3bc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30e99a17-a242-487c-a3f9-44baed72897f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_df1ee30a-2925-48aa-90c3-fdc2fef3bc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#DescriptionofthebusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d6dabc5-2f99-4216-89a8-771449184b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7b4e678-c921-42a2-b2ce-09deca678caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d6dabc5-2f99-4216-89a8-771449184b54" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7b4e678-c921-42a2-b2ce-09deca678caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75b554d8-a4bc-4428-ace0-4cac9abbbb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d6dabc5-2f99-4216-89a8-771449184b54" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75b554d8-a4bc-4428-ace0-4cac9abbbb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22c3fd04-3514-4663-bb46-f520514cc6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22c3fd04-3514-4663-bb46-f520514cc6c1" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1cac9ed3-c75d-40ea-9a6a-4e494578f8c1" xlink:to="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07725f80-13bd-42c5-b7e6-cf7759ee6bc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:to="loc_srt_MinimumMember_07725f80-13bd-42c5-b7e6-cf7759ee6bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c56b880-3654-4247-8ffa-02e244e34ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0090ca7a-ed68-46b8-9b9b-4f3669e6c22c" xlink:to="loc_srt_MaximumMember_9c56b880-3654-4247-8ffa-02e244e34ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a19a5962-3011-4405-898b-64a898f386d9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59978136-acfb-4b12-8a5b-257693218a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_473cf97b-e52f-4c07-b1a0-1b8ae7b06d68" xlink:to="loc_us-gaap_SubsequentEventMember_59978136-acfb-4b12-8a5b-257693218a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_502fa132-14be-4a6f-977a-a4c354897dcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SiliconValleyBankMember_f3f357fd-10b8-4a39-a3b2-74633c38b0cd" xlink:href="advm-20221231.xsd#advm_SiliconValleyBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1e789cd-475e-4cf2-8d84-d22e81e1f56e" xlink:to="loc_advm_SiliconValleyBankMember_f3f357fd-10b8-4a39-a3b2-74633c38b0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:href="advm-20221231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_d92b45b8-8fca-4623-829c-485466ca6190" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2a409622-09bc-4cbb-bb5f-37398e75d673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_NumberOfReportableSegments_2a409622-09bc-4cbb-bb5f-37398e75d673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_036083b5-1744-41e8-8a66-7bcb15dd2bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_036083b5-1744-41e8-8a66-7bcb15dd2bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6392dcc1-7ce6-4150-877b-c76732701748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_GainLossOnInvestments_6392dcc1-7ce6-4150-877b-c76732701748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a90ae24e-74ff-414a-bb0e-9bc25e515df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a90ae24e-74ff-414a-bb0e-9bc25e515df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f86b339-c038-4a4c-b5c3-4c9293dab927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f86b339-c038-4a4c-b5c3-4c9293dab927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6139095a-f2ef-4e23-8819-3e07d4b9cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_AssetImpairmentCharges_6139095a-f2ef-4e23-8819-3e07d4b9cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_47c1bf2c-5219-485c-af53-7849c519696c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_SubleaseIncome_47c1bf2c-5219-485c-af53-7849c519696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_f189af4e-d73b-49db-8807-1cfeb83c6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_bcc68ea4-b06e-467f-a267-f3a60e6c045f" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_f189af4e-d73b-49db-8807-1cfeb83c6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a418d195-6e4f-4ee3-8456-f41a18260321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a418d195-6e4f-4ee3-8456-f41a18260321" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bc21037-8576-41cf-830d-12e699d341ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_202f4482-2110-4f6a-8a48-74b4ce531b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_202f4482-2110-4f6a-8a48-74b4ce531b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ddf7a5ea-0982-43e3-ad17-ee0aece78b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61532480-063c-448c-9f2c-91e261d49ff9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ddf7a5ea-0982-43e3-ad17-ee0aece78b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc145-560b-44cc-a0d8-3894ff7598fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a0956bbb-0fe1-45fe-9ddb-e0e3fe8dde28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a0956bbb-0fe1-45fe-9ddb-e0e3fe8dde28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_66847678-b243-46e5-a01e-5562a3a70679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_66847678-b243-46e5-a01e-5562a3a70679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e16dd7b9-9e35-4ef3-a1f7-30a3f3a5490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_CommercialPaperMember_e16dd7b9-9e35-4ef3-a1f7-30a3f3a5490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6dce26ce-f240-4d3a-8ae3-cd4729f5267f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6dce26ce-f240-4d3a-8ae3-cd4729f5267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_eecb956d-cd32-4e75-a54b-1137100145b3" xlink:href="advm-20221231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a54619b4-8888-475d-b395-4e09771b7be0" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_eecb956d-cd32-4e75-a54b-1137100145b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9066060e-2563-46c4-b380-8645cbecf74e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c07759b-1701-4be2-a8bc-261cc27d1ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c07759b-1701-4be2-a8bc-261cc27d1ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44a61d30-f89d-44d4-859d-70e99160a869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44a61d30-f89d-44d4-859d-70e99160a869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725db606-611e-4bd1-9487-bbf02cc91234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725db606-611e-4bd1-9487-bbf02cc91234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8b1c80a-faa9-445a-808c-e3b62c8b7a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8b1c80a-faa9-445a-808c-e3b62c8b7a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_4ba77496-687f-4a14-bede-70be04ebd7fd" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_4ba77496-687f-4a14-bede-70be04ebd7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_6b899157-0619-423a-a692-de53944f0ae7" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_6b899157-0619-423a-a692-de53944f0ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_c8182b3b-6c3b-4893-999e-ab73ecea62fa" xlink:href="advm-20221231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_c8182b3b-6c3b-4893-999e-ab73ecea62fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97d0b4ce-7e91-4e59-a3db-173bdefbb7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2282bf9-ff4d-45ec-a685-18de8df7d563" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97d0b4ce-7e91-4e59-a3db-173bdefbb7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5da8b25-d96f-42f4-a999-7faed85afb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5da8b25-d96f-42f4-a999-7faed85afb19" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:to="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7a66a85c-7e07-4fd2-b14a-993d11f30196" xlink:to="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_11a263f1-9e39-49fa-8c9f-d03abb3941d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:to="loc_srt_MinimumMember_11a263f1-9e39-49fa-8c9f-d03abb3941d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce0f2582-91c4-4fa2-be22-16d52338a989" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dccb37fc-d1ec-4408-8718-0c9e96b2a405" xlink:to="loc_srt_MaximumMember_ce0f2582-91c4-4fa2-be22-16d52338a989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b107702-d20a-46ac-bcc7-31b05eaf2829" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfb74e66-53cf-4ccf-ae23-891b39a01e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfb74e66-53cf-4ccf-ae23-891b39a01e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_d2677c7f-da70-4508-a3f4-add2f44c5330" xlink:href="advm-20221231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_d2677c7f-da70-4508-a3f4-add2f44c5330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_7b7ef6a1-5542-45e1-831b-8ae899d2b1e4" xlink:href="advm-20221231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_7b7ef6a1-5542-45e1-831b-8ae899d2b1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_fded9b92-1665-4aa3-9806-3a4f163e53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0bfdaf-e4c2-4365-927c-ac3b792ed3a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_fded9b92-1665-4aa3-9806-3a4f163e53a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3b578893-31e2-4b69-ad7d-1fc54770a3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3b578893-31e2-4b69-ad7d-1fc54770a3f6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:to="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4d6f339b-564a-41bc-8691-eddbd1558109" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_af016910-222b-4235-b352-e3beae90dfcd" xlink:href="advm-20221231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36c9d833-45d2-4ef6-a434-301f3eac0c4e" xlink:to="loc_advm_LexeoTherapeuticsIncMember_af016910-222b-4235-b352-e3beae90dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1906e384-21f0-4326-93e0-45948801dbb6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d296a4dd-85f1-448b-a5c5-fc20a1af0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ed123a21-d2d7-4655-ae3a-3201e65f5190" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d296a4dd-85f1-448b-a5c5-fc20a1af0c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef2cf59b-b179-499f-8e2f-392a56093559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef2cf59b-b179-499f-8e2f-392a56093559" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e949e629-1c18-49fa-ba15-e24e3b0acd8c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f26bab4a-617d-4dd2-a998-e7489e5d2376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:to="loc_us-gaap_BuildingMember_f26bab4a-617d-4dd2-a998-e7489e5d2376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_e699c3b3-a30a-4f3b-9850-b7b4eec0ee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83f1b009-35a2-4991-942f-4c936ef7d9c1" xlink:to="loc_us-gaap_ManufacturingFacilityMember_e699c3b3-a30a-4f3b-9850-b7b4eec0ee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0be0735e-9e6a-4821-883b-eece24302625" xlink:to="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember_40a106d8-6304-4bf6-8128-79a357055449" xlink:href="advm-20221231.xsd#advm_TerminatedLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_6fe006b7-f5b7-4de1-b29a-5d1bce48cd81" xlink:to="loc_advm_TerminatedLeaseMember_40a106d8-6304-4bf6-8128-79a357055449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b90bd81d-d06a-4518-bbbc-7970db4d2ef9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_887fd961-28b1-4b2b-8755-c6c0c27c46e7" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_887fd961-28b1-4b2b-8755-c6c0c27c46e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8ba31e9c-cfa9-49dc-aa2d-82273dd89d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8ba31e9c-cfa9-49dc-aa2d-82273dd89d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37970b86-accf-4837-be4e-b96fce817372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37970b86-accf-4837-be4e-b96fce817372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_d1911b9a-1f27-4875-aba4-29c16c01b31a" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_d1911b9a-1f27-4875-aba4-29c16c01b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeSubLeaseMonthlyBaseRent_f2ea403c-e47a-4e41-890f-71febaecd6db" xlink:href="advm-20221231.xsd#advm_LesseeSubLeaseMonthlyBaseRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeSubLeaseMonthlyBaseRent_f2ea403c-e47a-4e41-890f-71febaecd6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_5be82b4e-f88a-455f-b747-5868bbb3fa68" xlink:href="advm-20221231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_5be82b4e-f88a-455f-b747-5868bbb3fa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_c4490b7d-4aea-484b-acac-44e2c0fb8907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_c4490b7d-4aea-484b-acac-44e2c0fb8907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4683af1e-61fb-4ca6-aa90-7d9408b8772d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4683af1e-61fb-4ca6-aa90-7d9408b8772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa3d7fb3-dd5a-4bf6-be81-7a53fcad4fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa3d7fb3-dd5a-4bf6-be81-7a53fcad4fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9ea8ae34-8e35-47bf-93ce-c65a9cd889c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeaseExpense_9ea8ae34-8e35-47bf-93ce-c65a9cd889c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0c87967e-711f-4535-a321-05b9fb605e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_VariableLeaseCost_0c87967e-711f-4535-a321-05b9fb605e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_072f3688-b857-4fcd-a2af-55391826b287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_OperatingLeasePayments_072f3688-b857-4fcd-a2af-55391826b287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_7da9d34b-a1ac-4f01-b52f-97042c269db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca188e58-5a1c-4510-b443-0ae4c9c5454d" xlink:to="loc_us-gaap_SubleaseIncome_7da9d34b-a1ac-4f01-b52f-97042c269db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e0c278fc-ca82-4554-a1c4-834c87d16666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e0c278fc-ca82-4554-a1c4-834c87d16666" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bfed6baf-f592-4060-9f78-2589f5bf972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bfed6baf-f592-4060-9f78-2589f5bf972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f81a274f-f711-482e-943c-f1b750cccfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f81a274f-f711-482e-943c-f1b750cccfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37a56c7f-da4d-441d-9e1b-990cbfda4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37a56c7f-da4d-441d-9e1b-990cbfda4d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca66a1a-648f-444c-a83c-e7ef92ccb322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca66a1a-648f-444c-a83c-e7ef92ccb322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cc9cdb38-d617-49c6-bae1-5f4892d1dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cc9cdb38-d617-49c6-bae1-5f4892d1dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cbe909e0-ff48-4579-a740-b5c1b4807e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cbe909e0-ff48-4579-a740-b5c1b4807e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_702c8788-4eb5-428b-a945-c83939d88162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_702c8788-4eb5-428b-a945-c83939d88162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_be7143e9-3c36-4d21-9ac3-43926caf7dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_be7143e9-3c36-4d21-9ac3-43926caf7dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_91a4aeb3-33d3-47fb-92b4-3a86bcbddbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a52aeb15-5ed6-4811-96d3-4aad520d8547" xlink:to="loc_us-gaap_OperatingLeaseLiability_91a4aeb3-33d3-47fb-92b4-3a86bcbddbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e0c278fc-ca82-4554-a1c4-834c87d16666" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_eb30d7c1-8d9d-4282-b085-d0617ca60b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_eb30d7c1-8d9d-4282-b085-d0617ca60b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_7ec132ac-b61d-407d-9b9f-da4175816220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_7ec132ac-b61d-407d-9b9f-da4175816220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_31045e65-b5d7-40ac-8799-03b43a188dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_31045e65-b5d7-40ac-8799-03b43a188dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f9ffd42b-8bd5-4567-a246-94f13cc6b29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f9ffd42b-8bd5-4567-a246-94f13cc6b29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_623759f3-10ae-4938-8c06-683f1d4b59c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_623759f3-10ae-4938-8c06-683f1d4b59c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_3df285cd-fec8-4c4d-a164-00d3535163a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_3df285cd-fec8-4c4d-a164-00d3535163a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b975d737-2aa7-487f-9837-d42b5f0140a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_6d141dff-3527-4598-9810-00b87be788cd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b975d737-2aa7-487f-9837-d42b5f0140a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d747ba10-ad03-4ea2-bab8-89107396a1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d747ba10-ad03-4ea2-bab8-89107396a1ad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540b7fda-e1dd-4b4f-80fd-39a26f079814" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b188fa6d-8ec3-4fa7-8a5d-f128d9231a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_ComputerEquipmentMember_b188fa6d-8ec3-4fa7-8a5d-f128d9231a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_473ec062-112d-49d8-8193-fa2bf6becdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_EquipmentMember_473ec062-112d-49d8-8193-fa2bf6becdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_443e8659-f41d-4fdd-be9b-00ee7b4505a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_443e8659-f41d-4fdd-be9b-00ee7b4505a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_82581b00-52f2-4751-b45d-40efcfe00432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_82581b00-52f2-4751-b45d-40efcfe00432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_81138af5-4599-407d-849c-ffee11915948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_111809e7-8fa4-40c0-96c3-4be21120586a" xlink:to="loc_us-gaap_ConstructionInProgressMember_81138af5-4599-407d-849c-ffee11915948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb9e16e-c327-4389-bec2-de8cf240a58f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f99f590f-8347-4ef4-a5ad-f366cdde7d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f99f590f-8347-4ef4-a5ad-f366cdde7d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6d8cf5ab-5989-4a3f-b0d1-a607eaddc7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6d8cf5ab-5989-4a3f-b0d1-a607eaddc7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c9ccdae2-17cf-4336-8d64-a6ca5d19b03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b85d154-a08a-4905-952d-a256d6b71b43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c9ccdae2-17cf-4336-8d64-a6ca5d19b03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0da947e1-a339-41bf-a915-10a2f80dfbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0da947e1-a339-41bf-a915-10a2f80dfbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0f06290e-0084-4a16-b535-07414ef93ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0f06290e-0084-4a16-b535-07414ef93ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent_ee4f27a2-13cc-490d-afb6-4ec16e66feca" xlink:href="advm-20221231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_advm_AccruedNonclinicalCostsCurrent_ee4f27a2-13cc-490d-afb6-4ec16e66feca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_6ed277c1-b548-43e4-bcb5-bd96e22eec0f" xlink:href="advm-20221231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_6ed277c1-b548-43e4-bcb5-bd96e22eec0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a0c3b7d7-c9a8-4919-b56c-0a46102a6d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_us-gaap_TaxesPayableCurrent_a0c3b7d7-c9a8-4919-b56c-0a46102a6d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cafe414c-4280-4ba5-853c-924727198a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cafe414c-4280-4ba5-853c-924727198a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_bfaac3bd-8318-4a2f-963e-b971e0d5e443" xlink:href="advm-20221231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_902b3484-f4b4-4d93-b8d4-c035aa226761" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_bfaac3bd-8318-4a2f-963e-b971e0d5e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be8c61de-70a4-4b97-a117-e4a9a8ecf282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_d0da9cdc-d0d6-4cbb-b90c-14c483a841cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be8c61de-70a4-4b97-a117-e4a9a8ecf282" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_d0da9cdc-d0d6-4cbb-b90c-14c483a841cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f3b414f-3de6-4755-9d4b-2817bc04ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f3b414f-3de6-4755-9d4b-2817bc04ce5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_80c99e95-01be-47ce-a893-282288903bcc" xlink:to="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_d03ac62a-601d-474c-bf46-897cda6db8c2" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_d03ac62a-601d-474c-bf46-897cda6db8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_aa5f9c6e-0d98-40a8-9779-61518b4e82dc" xlink:href="advm-20221231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_aa5f9c6e-0d98-40a8-9779-61518b4e82dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_3d7e69c7-60d8-4d56-bc2c-af5ea76c5594" xlink:href="advm-20221231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_3d7e69c7-60d8-4d56-bc2c-af5ea76c5594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_b31bde74-5547-4de9-bb95-44e36ee2ad05" xlink:href="advm-20221231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5d9676f0-0b10-4dc8-aa49-efdcd3ac296f" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_b31bde74-5547-4de9-bb95-44e36ee2ad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3690a340-4669-4d1e-85cd-91f3685fce4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_75a167af-7c56-4756-956c-b1dcf34817f6" xlink:href="advm-20221231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_75a167af-7c56-4756-956c-b1dcf34817f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_55cf7991-a008-4ddc-8b84-d9e9cbbbd77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_StockCompensationPlanMember_55cf7991-a008-4ddc-8b84-d9e9cbbbd77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c32a3b97-1bd4-4691-85df-9d748d0b6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c32a3b97-1bd4-4691-85df-9d748d0b6f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_4e07c260-1996-4b2d-8c80-1068f6bbe370" xlink:href="advm-20221231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_4e07c260-1996-4b2d-8c80-1068f6bbe370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_07f4a037-c528-41f1-a7cf-7d0b57f670fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_PerformanceSharesMember_07f4a037-c528-41f1-a7cf-7d0b57f670fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7c7c8c65-ddd2-4d5c-855e-0183d1ff3ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ddc378-4d23-42ea-bc1d-3c134aaefd19" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7c7c8c65-ddd2-4d5c-855e-0183d1ff3ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38b82ac5-0a4e-408c-95d1-44bab65bb1eb" xlink:to="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f831b63f-b5d1-407e-9e11-6b6da311e5c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:to="loc_srt_MinimumMember_f831b63f-b5d1-407e-9e11-6b6da311e5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_558b23fc-c615-4b85-a8f0-c8d4c3a1bd21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cadf336c-4fb2-4ffe-95f9-58f89723b327" xlink:to="loc_srt_MaximumMember_558b23fc-c615-4b85-a8f0-c8d4c3a1bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39d085-922f-492d-a839-c1d0e5f96f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_8c13b522-0501-4e51-b87c-e3394dbe92cc" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_8c13b522-0501-4e51-b87c-e3394dbe92cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_503a15c1-4832-4c50-8fab-57fee673b828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_503a15c1-4832-4c50-8fab-57fee673b828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_366433e9-ce69-40b1-a47a-decf06e71017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_366433e9-ce69-40b1-a47a-decf06e71017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50c594b3-ea9a-48da-bea5-37aff8cf9dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50c594b3-ea9a-48da-bea5-37aff8cf9dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6695039e-981b-42f1-b664-3354481f4048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6695039e-981b-42f1-b664-3354481f4048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_1fe55285-1b08-4930-bf48-757317075ac9" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_1fe55285-1b08-4930-bf48-757317075ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_3a5d066f-b001-4e6a-860f-32ee200de67a" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_3a5d066f-b001-4e6a-860f-32ee200de67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58015dac-db9c-49ed-9b4b-28072bf15051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58015dac-db9c-49ed-9b4b-28072bf15051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e15dbc7b-106b-409f-84db-4993fa213a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e15dbc7b-106b-409f-84db-4993fa213a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_727fc3fc-02b4-4fc4-8dec-08f9cb83abf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_727fc3fc-02b4-4fc4-8dec-08f9cb83abf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8fd513ec-8bb8-4f71-b299-a91ce12fc443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8fd513ec-8bb8-4f71-b299-a91ce12fc443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_65eec6fd-9036-4fd0-95f0-97b1ba2c9e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_65eec6fd-9036-4fd0-95f0-97b1ba2c9e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b11e3f80-3a71-4544-8e6d-77b6efb5e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b11e3f80-3a71-4544-8e6d-77b6efb5e975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_016bfbba-5585-4077-8f3a-712f8303070d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_016bfbba-5585-4077-8f3a-712f8303070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ac929747-9c43-4b60-b138-041cb59904c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ac929747-9c43-4b60-b138-041cb59904c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_678a18bc-208a-448d-aad0-50d6ff04f857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_678a18bc-208a-448d-aad0-50d6ff04f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_1056360d-94ab-4439-b5b6-19f39ec2fd70" xlink:href="advm-20221231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_1056360d-94ab-4439-b5b6-19f39ec2fd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d805d95b-8e20-4ab8-b19a-f1eddaf3b92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d805d95b-8e20-4ab8-b19a-f1eddaf3b92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_879f9d20-95e1-4d23-a7a2-8d8d65dd8d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e781d1-64df-4f78-a599-c52a60092f4a" xlink:to="loc_us-gaap_StockOptionPlanExpense_879f9d20-95e1-4d23-a7a2-8d8d65dd8d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d9c5aa9-a0d9-4835-a7ff-aa227f04bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d9c5aa9-a0d9-4835-a7ff-aa227f04bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aa1c6f69-3e7c-4bcf-a6b9-bea2aafa7105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aa1c6f69-3e7c-4bcf-a6b9-bea2aafa7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ce711057-1ec0-4c95-8558-4458eaaaf055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ce711057-1ec0-4c95-8558-4458eaaaf055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bcdad3e7-0be6-4270-a3ed-c1192e487d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bcdad3e7-0be6-4270-a3ed-c1192e487d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a879d87-ac4f-4738-899c-935b94d3d470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cb7a062-6c3c-496e-b90a-1af9fa6a57dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a879d87-ac4f-4738-899c-935b94d3d470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cfd93fc0-3ba2-4bcb-99d5-00dbfb114118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cfd93fc0-3ba2-4bcb-99d5-00dbfb114118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ea7aaf67-ade1-4179-8237-81f71808acc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ea7aaf67-ade1-4179-8237-81f71808acc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b01487f-a9bb-43c1-b313-ea5139a5f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b01487f-a9bb-43c1-b313-ea5139a5f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c085de6a-815c-4465-afda-a204c7d35fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c085de6a-815c-4465-afda-a204c7d35fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_97ac270c-aa5a-453a-aff1-a381ed71b289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_97ac270c-aa5a-453a-aff1-a381ed71b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe39006c-dca0-4ffd-bc4b-e5be598d548e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe39006c-dca0-4ffd-bc4b-e5be598d548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32da5f5e-d1e8-4537-beb9-534aeba53ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2608d979-1761-4e38-8032-4d232bca2269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32da5f5e-d1e8-4537-beb9-534aeba53ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_441e9873-9d1a-49cb-8d70-35774cf90fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_441e9873-9d1a-49cb-8d70-35774cf90fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_58c737ac-dd71-498f-a6da-bdb4970a4bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_58c737ac-dd71-498f-a6da-bdb4970a4bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_659af9f3-c4ba-460b-bbd0-a04504f500a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_659af9f3-c4ba-460b-bbd0-a04504f500a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5601f6f6-bc0a-4f74-a1e8-5582edeb64ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_659af9f3-c4ba-460b-bbd0-a04504f500a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5601f6f6-bc0a-4f74-a1e8-5582edeb64ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6af6e821-83c5-4a75-a2eb-22890469ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_659af9f3-c4ba-460b-bbd0-a04504f500a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6af6e821-83c5-4a75-a2eb-22890469ec51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ff08ca92-0715-4041-8b7a-ef1610d28ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_659af9f3-c4ba-460b-bbd0-a04504f500a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ff08ca92-0715-4041-8b7a-ef1610d28ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e0955f1c-52d2-4e19-98e7-fab15e5d883a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e0955f1c-52d2-4e19-98e7-fab15e5d883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_851d5cbc-80f8-487d-a451-0bc12fac1c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_851d5cbc-80f8-487d-a451-0bc12fac1c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c6937cb5-365a-404a-85e0-eca1901de4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0aeb249-bb98-4ef3-b1b7-56ce459ca9f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c6937cb5-365a-404a-85e0-eca1901de4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d817075-512f-48ab-9f24-43f07bf872ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d817075-512f-48ab-9f24-43f07bf872ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:to="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_36118ccc-4b12-4f82-bec4-c019f5a6fb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d3e3815f-1cc9-4694-b53a-1daf5bc3bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d3e3815f-1cc9-4694-b53a-1daf5bc3bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_087ac367-6634-4a18-8623-08098e2c8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0ed1fe0-6ce9-4425-ab57-1dd69746c583" xlink:to="loc_us-gaap_EmployeeStockMember_087ac367-6634-4a18-8623-08098e2c8c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e4a534-d2e1-4e0f-bb82-96a3f10de434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_77975f5f-6858-4ef1-ab18-215fdbbae522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_77975f5f-6858-4ef1-ab18-215fdbbae522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461e5cdb-9d27-4de7-bb33-eae52bce43af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461e5cdb-9d27-4de7-bb33-eae52bce43af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1915278-b1ab-4520-845a-a27001fac421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1915278-b1ab-4520-845a-a27001fac421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d4addcc9-1d41-4af1-9c6d-0a27f02cdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21a770cd-d742-477f-ac7a-4a991aad2c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d4addcc9-1d41-4af1-9c6d-0a27f02cdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3cc768f2-0a9c-4d29-adfc-9cb0a85027f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3cc768f2-0a9c-4d29-adfc-9cb0a85027f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:to="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a8c3063b-9622-40df-9bb4-c7b03937d59b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9309756a-883b-4eab-a545-6aeeb2b1d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a23feaf-4ffd-45c7-80db-028cc0b94336" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9309756a-883b-4eab-a545-6aeeb2b1d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aef22d0-cfaf-4cd5-9389-635439403347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e458dfef-e918-4f33-a61d-301215d520d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e458dfef-e918-4f33-a61d-301215d520d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f09734-5ebb-41cb-b714-e1b934cd7003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f09734-5ebb-41cb-b714-e1b934cd7003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dc40d0ac-c474-417d-b750-207be9c832e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dc40d0ac-c474-417d-b750-207be9c832e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dec6c127-46a8-4290-b1ae-3aacf324898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dec6c127-46a8-4290-b1ae-3aacf324898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cbbdfbae-82e7-40b1-b651-f1ac57676131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9343cc59-ac8e-4362-90ff-57cb4abed639" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cbbdfbae-82e7-40b1-b651-f1ac57676131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2cf50be9-5b3b-4632-9840-a10b85799b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2cf50be9-5b3b-4632-9840-a10b85799b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad80f0a3-3439-4d46-9a75-08409e714a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad80f0a3-3439-4d46-9a75-08409e714a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_2e03caa3-cf00-4b69-9498-b463801b11f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_2e03caa3-cf00-4b69-9498-b463801b11f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3217a8c7-42b8-4d96-bbbb-22da8f56efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3217a8c7-42b8-4d96-bbbb-22da8f56efa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_629d7379-b6e0-4d2d-b5b4-3f45a85cea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a22efc7-1f9b-4375-aad5-12ccb776699a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_629d7379-b6e0-4d2d-b5b4-3f45a85cea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8419e49-3e7d-4234-8c99-a71fcc7fa724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48f8c015-a6b3-4ac2-ae9d-f15d5e798f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_ed598c93-3be7-429b-aa39-cb5dc18de616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48f8c015-a6b3-4ac2-ae9d-f15d5e798f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#StockPlansScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37b2df87-a363-4ab0-aad1-91d343954daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37b2df87-a363-4ab0-aad1-91d343954daf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a10b79d5-3243-4690-b14a-8af6ca3e6316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c63410a5-bf0b-438e-a13a-85d97f3b4903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c63410a5-bf0b-438e-a13a-85d97f3b4903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a501497f-4032-415b-badf-943ab9edc601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_302dc65f-b817-4479-80a8-556891f3cd7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a501497f-4032-415b-badf-943ab9edc601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b7832185-ee28-4bb4-9030-9d692c15e514" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca735db0-7ca5-44ab-bb0b-51720627689f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc9467e2-d325-47ea-9ef3-f630d3bebc22" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca735db0-7ca5-44ab-bb0b-51720627689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#A401kSavingsPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9462edc-7d34-4482-a22c-73950ac7bff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_5fcfc27a-237a-4dee-b0b7-b90851c9c197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9462edc-7d34-4482-a22c-73950ac7bff8" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_5fcfc27a-237a-4dee-b0b7-b90851c9c197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RestructuringAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f3c1053f-3107-4e45-bd9a-7c1ec046f7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f3c1053f-3107-4e45-bd9a-7c1ec046f7a5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90b15f45-0570-40d5-b14a-c0ef03cb610e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9eb2eeb7-d436-4db0-9818-10e7416bd073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9eb2eeb7-d436-4db0-9818-10e7416bd073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2340ca6f-2613-47f0-909b-181b928c95d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19df4b11-ec21-4a65-bac4-c6a1adf96cdc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2340ca6f-2613-47f0-909b-181b928c95d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b10120b4-afbf-4385-8726-402311749900" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_5ef9047d-add2-4627-adab-e03661c6eb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_5ef9047d-add2-4627-adab-e03661c6eb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_e24ecbb7-cc82-4e30-a704-cc4a2a04ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_e24ecbb7-cc82-4e30-a704-cc4a2a04ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8fbee944-a7d4-41bc-97dd-127f8c661c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8995d064-0fbf-4a59-b773-7ceac98449b4" xlink:to="loc_us-gaap_RestructuringCharges_8fbee944-a7d4-41bc-97dd-127f8c661c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#RestructuringScheduleofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_17d2a988-18fd-41c4-bc4d-92ef16caf940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_17d2a988-18fd-41c4-bc4d-92ef16caf940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7b2eddc8-04f5-4974-9e04-a67857f41b17" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_bef9dc34-e1c0-4517-8b0c-9069e42173f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:to="loc_us-gaap_EmployeeSeveranceMember_bef9dc34-e1c0-4517-8b0c-9069e42173f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8ec7c89a-64af-4094-8509-2873be1cee89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47b221-a377-4cc3-9ad6-fe9c1bc234f6" xlink:to="loc_us-gaap_StockCompensationPlanMember_8ec7c89a-64af-4094-8509-2873be1cee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_22f909ff-b001-4a6d-85c8-e90f4fa019fe" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8446f213-3e2d-4915-867e-6574241276c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringCharges_8446f213-3e2d-4915-867e-6574241276c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f03d7986-e23f-421e-91cc-ea153ea34761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_PaymentsForRestructuring_f03d7986-e23f-421e-91cc-ea153ea34761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_fc551120-c8c6-4d1a-8b2b-b5c4e0d02932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_fc551120-c8c6-4d1a-8b2b-b5c4e0d02932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_edf3d3be-eb5e-4e44-a132-0dec667226f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bea825b7-ab88-4ed1-a5d5-84c45b274233" xlink:to="loc_us-gaap_RestructuringReserve_edf3d3be-eb5e-4e44-a132-0dec667226f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b04b4492-b352-469d-806d-89941cd016c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_15e3dd04-5c45-41af-87d3-33e1cd752d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b04b4492-b352-469d-806d-89941cd016c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_15e3dd04-5c45-41af-87d3-33e1cd752d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b6e3ce3a-dd3a-4536-b69c-d572c8a69e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b04b4492-b352-469d-806d-89941cd016c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b6e3ce3a-dd3a-4536-b69c-d572c8a69e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69a1935a-cb98-4870-a7d5-f1e89ca8807b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b04b4492-b352-469d-806d-89941cd016c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69a1935a-cb98-4870-a7d5-f1e89ca8807b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_abcfcf7d-6e20-4ac0-aa67-7421566b14d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd34df18-2b2c-4f81-bf42-88956dd0a7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_abcfcf7d-6e20-4ac0-aa67-7421566b14d5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd34df18-2b2c-4f81-bf42-88956dd0a7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_2b9b534b-f7e0-4765-b303-2a096e5e4eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd34df18-2b2c-4f81-bf42-88956dd0a7cd" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_2b9b534b-f7e0-4765-b303-2a096e5e4eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6e1c877c-350e-4fad-97fa-eb02d95f4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd34df18-2b2c-4f81-bf42-88956dd0a7cd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6e1c877c-350e-4fad-97fa-eb02d95f4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2d6a567-9a54-4f67-bc1a-34af061e831d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_abcfcf7d-6e20-4ac0-aa67-7421566b14d5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2d6a567-9a54-4f67-bc1a-34af061e831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_76af55fb-0471-4969-8314-fcc0aa0179b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2d6a567-9a54-4f67-bc1a-34af061e831d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_76af55fb-0471-4969-8314-fcc0aa0179b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f624cb94-cc22-41b5-9d9d-6a292df085a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2d6a567-9a54-4f67-bc1a-34af061e831d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f624cb94-cc22-41b5-9d9d-6a292df085a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a0c5ceb-6103-4a47-b46b-f9747cc71b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_abcfcf7d-6e20-4ac0-aa67-7421566b14d5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4a0c5ceb-6103-4a47-b46b-f9747cc71b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_73868bad-f695-461f-ba56-545eda3de0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_73868bad-f695-461f-ba56-545eda3de0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_24fb72fa-5656-4037-a832-82a9fa5549ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_24fb72fa-5656-4037-a832-82a9fa5549ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_bf2bc610-9015-446a-af8f-fb02e4f90460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_bf2bc610-9015-446a-af8f-fb02e4f90460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ea0cc1bd-4ec8-4af7-9591-dec4b734a5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ea0cc1bd-4ec8-4af7-9591-dec4b734a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_cfd324a8-999e-4088-8cfa-05e3dfdd7467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_cfd324a8-999e-4088-8cfa-05e3dfdd7467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_484dbfee-9c3a-4fa9-9c65-20505c17ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_484dbfee-9c3a-4fa9-9c65-20505c17ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_6a647e45-4ff8-4917-9590-1f80e4c85a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_6a647e45-4ff8-4917-9590-1f80e4c85a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_bb1f9c23-44d8-48a6-9bfe-2e0e82ddb4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_bb1f9c23-44d8-48a6-9bfe-2e0e82ddb4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20607e10-412e-47da-bf9c-73abb8ef8db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e0d3b9-e258-4cc3-b2c0-e97ac6a49684" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20607e10-412e-47da-bf9c-73abb8ef8db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_db061ef7-1cc3-4024-8d00-282384e921c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db061ef7-1cc3-4024-8d00-282384e921c2" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d1194a9a-10d2-4993-8411-9e99ebcbf7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d1194a9a-10d2-4993-8411-9e99ebcbf7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3020eb89-d005-4999-a052-b04716315adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3020eb89-d005-4999-a052-b04716315adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c95d6a5a-12f9-4bc1-ba50-ad3d2e4b00d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c95d6a5a-12f9-4bc1-ba50-ad3d2e4b00d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8f9f8d5d-78f5-4bb1-b919-2c4578cf6cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8f9f8d5d-78f5-4bb1-b919-2c4578cf6cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2d217b76-97ce-4960-bc89-87eaa70323c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2d217b76-97ce-4960-bc89-87eaa70323c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3edcdf08-a57e-4088-bb2b-89e6d6e1f386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3edcdf08-a57e-4088-bb2b-89e6d6e1f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_42d37f5b-f094-4b5c-bd15-34cd430dae27" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_42d37f5b-f094-4b5c-bd15-34cd430dae27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ec17196a-e700-4044-b8bf-5e705a3e6f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ec17196a-e700-4044-b8bf-5e705a3e6f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_91724400-b1fd-4743-b6bf-72ee59364806" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_91724400-b1fd-4743-b6bf-72ee59364806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_be5838bc-4aed-4528-b264-1f37ef77ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_be5838bc-4aed-4528-b264-1f37ef77ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa6dac21-2a7b-4e1d-8d15-beacaab068b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa6dac21-2a7b-4e1d-8d15-beacaab068b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_52b283f1-2771-4bae-9b85-ca6594e505ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1b1aae41-9a36-4c3d-a9b3-c7e2d69549a4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_52b283f1-2771-4bae-9b85-ca6594e505ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a4a04d7a-5ad5-410e-ac8e-6ae4c2b2211c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db061ef7-1cc3-4024-8d00-282384e921c2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a4a04d7a-5ad5-410e-ac8e-6ae4c2b2211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1dee7a23-763a-4afe-babd-e9251b6eea19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a4a04d7a-5ad5-410e-ac8e-6ae4c2b2211c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1dee7a23-763a-4afe-babd-e9251b6eea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_48e6b0ae-9f1c-4df3-99d2-c7c5a94287a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a4a04d7a-5ad5-410e-ac8e-6ae4c2b2211c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_48e6b0ae-9f1c-4df3-99d2-c7c5a94287a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ecfff098-aea0-482d-8cff-0cc71d25d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a4a04d7a-5ad5-410e-ac8e-6ae4c2b2211c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ecfff098-aea0-482d-8cff-0cc71d25d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6e3cc17e-81e3-48f5-9ec4-076b546f0a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db061ef7-1cc3-4024-8d00-282384e921c2" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6e3cc17e-81e3-48f5-9ec4-076b546f0a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_14a2612d-0b14-45d2-aa07-b561e1e838f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:href="advm-20221231.xsd#advm_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14a2612d-0b14-45d2-aa07-b561e1e838f3" xlink:to="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6a69b50-6496-4f48-a3fe-5e40032cb82a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bfda4ec6-1cf7-4ebe-a6ae-a4cb9589c593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_DomesticCountryMember_bfda4ec6-1cf7-4ebe-a6ae-a4cb9589c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c246c79c-0f3f-4742-9fd2-3d35ae35e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c246c79c-0f3f-4742-9fd2-3d35ae35e3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2e2ae1f7-52cf-4000-b044-5abae45076ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d36951eb-4607-407a-bb7f-96ce81fbf8e6" xlink:to="loc_us-gaap_ForeignCountryMember_2e2ae1f7-52cf-4000-b044-5abae45076ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2354181b-fcc8-43b3-a7f9-efc5edcc3179" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_19bf3f6a-e076-496c-b6b1-c72c58cb62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_89bb3e6e-ecc0-4ce8-9fb9-b2f9003492ef" xlink:to="loc_us-gaap_ResearchMember_19bf3f6a-e076-496c-b6b1-c72c58cb62fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:href="advm-20221231.xsd#advm_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_1385de6e-ba44-43d7-bbe0-05e3b79c4291" xlink:to="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3b61efae-a5f8-4686-b80a-6619687910d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3b61efae-a5f8-4686-b80a-6619687910d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0c75a8c6-817a-4b0d-9bf6-29b556041228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0c75a8c6-817a-4b0d-9bf6-29b556041228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e02db782-6350-42bb-b2b0-157b0125cb24" xlink:href="advm-20221231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e02db782-6350-42bb-b2b0-157b0125cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8d54f26d-d549-42ef-a58a-569380fed702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8d54f26d-d549-42ef-a58a-569380fed702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_f08860f9-a792-4063-a566-0f6541321173" xlink:href="advm-20221231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_f08860f9-a792-4063-a566-0f6541321173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ec8f591a-a65a-4943-97cf-9ea036ff93d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ec8f591a-a65a-4943-97cf-9ea036ff93d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a0b6cf42-cfcb-4b7a-b086-a53702a18af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a0b6cf42-cfcb-4b7a-b086-a53702a18af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d944a0e9-865c-42c0-a4b5-bf600f30ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_65601f5b-000e-4cd0-a583-27bc148bb122" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d944a0e9-865c-42c0-a4b5-bf600f30ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4b3ae88d-1c44-4f1a-bc60-21cfeb9c18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b3ae88d-1c44-4f1a-bc60-21cfeb9c18a0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6313f7cf-fce3-475e-9228-58dc9f13cfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6313f7cf-fce3-475e-9228-58dc9f13cfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8644dc6b-c5b5-4e8a-ab5b-30f12c5f859f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8644dc6b-c5b5-4e8a-ab5b-30f12c5f859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_cb51492d-125d-45f7-b1b5-7de2a6060ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_cb51492d-125d-45f7-b1b5-7de2a6060ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_823cb811-80be-453d-a871-8bfdedb8a051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c0f52986-581a-45ae-9d1d-7e128cc686a3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_823cb811-80be-453d-a871-8bfdedb8a051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="advm-20221231.xsd#NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30a72cb3-f340-4ff5-8a10-00e791964b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30a72cb3-f340-4ff5-8a10-00e791964b57" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe48e915-63ca-4904-b906-62af1d0b275d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5c0b3a5-0d93-4dc9-8205-97db42a0ec17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5c0b3a5-0d93-4dc9-8205-97db42a0ec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_253914f9-6605-4a4a-ac84-f329471d6f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_253914f9-6605-4a4a-ac84-f329471d6f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_23c006f5-a0cc-4a39-83dd-0b94e039f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0f74aaf3-27cd-41b6-b1e5-7d22b7cc5066" xlink:to="loc_us-gaap_EmployeeStockMember_23c006f5-a0cc-4a39-83dd-0b94e039f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5cd2bd2-24c4-435e-a6ab-b44e812a86ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b551d74e-d82e-42b8-9ea7-31e6f686b936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_39aa28c5-9f24-4f0e-b1a3-39f78caccb93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b551d74e-d82e-42b8-9ea7-31e6f686b936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>advm-20221231_g1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M/=O8+W_\6U0S*\4I;IZ+?_2+2Z]<Y3_6[)!>(SNG.1=%+F4]:YRO.97%DB7
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M8.,>H(@0J-AD<4.02T9E'#@U:*."MU&/F8 B&N@C2F-U.1(WA@1T%ZI7(ZB
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MMJU,R:JYR+*AQ1>V :!,R= *QK",0Z^<Q5-T0Y<L4XZL"5NSR+]HN]%;CY_
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M<?01'*M81YO0&&AYX0$>E\8C3LFETDBSQ))_HY2E(M6A4+CR#S7Q&Y4=S2N
MXSSHEY)45TDFAT8ZV@ %J)*[[S"/>7"H*?R =U=%HDIS/<$1$2RD"6+J!E7[
ML2I.-7+5@PZD22H\D3LO1\S0S$E$5#G3IU (G)I&$E=80O$/SB06./\LZ54#
M AX1J&R03&Q4@FR55!% P<VDR)FY&=& P*J4D$;=U'*?VM"EDB73IMC*3?'=
MQTG"A9P'6:Y%_C6?#WB<7A=NZR$=/$A='ZLU2 W%7$R\5DM>LBX',IC$^*H9
M,2#"1KRB,25NH&=3%&:HLK ZB<R-QF>74^L+RB1A.C&+#]P0E"]R)#!H,?;$
M'NN7C#6FCKRE8U[>>$?$N,&WBNGC8;3]1]QBIF6506XA8X9(Y@*A:!P@C@6@
M:P0=H49GM E.)H?7&T9RA#@PM<T/IBH2Q-V&; <!1< %#@H%*:X]MO1.,''S
MR;>I![W"=!J%V*0).UC$(!',)?"DC)_;C'C_(M7A(D:2*3A=OH:ER2GL0>:S
M'H&#^4[PB\]^[O2A$%D(&H!J9Y-4*K?:\(=\;BK2,OP4\GVN&4(G"C$%?7!F
M"&7IH1@Z*$\6JLHO5;UV ,=5N,(#3^0Q]R"1&Q1-+56D E)SZA)]N4T1AR,3
M8VH?FJB#Q:?\@Y$N W@8BM1-V\JYOCDK6"5A*5?*RI ZY(];#"F@[[+$/#'A
MG4*!%S)/!+[R]0QDWQ<J20\A(J.!#UR"&:R@F)=\$"T[N6Q6,;J9>MCY@'N+
MNRR1(7!.Q?2C_(#I)\Q\ S>%3:_D&O89)-9] OLM<'JI3 )/AL"KA<1/E#(J
MD(W\Y2*K0TDW"B:4235)^"(+BN1S'WR012-," V-+Z(EBBT1$#V^F(QMG66-
M5#JV'#5FECLR&V-U 3<?F^TRWP+F,4HPF93A#&PSKCQJ TQ0#..B@YC_*;?G
M<BYW\S*1,(VI(1$%"1I,689*6KC7* \X"!4/A(,(T:Y>FB8-:0[<.,&X026Q
M"3A-@)JP29RR"0]-, 7;.!$X"!]A$AL[VP=]*+.H 1"%:YHFJ0X>O*K\&!1<
M>A BBZ<T&9 M&90$VH\*\ &G,;CPR++'V1'2P9 6DH[[N2M3**HW.;W^&8GP
M" I% 3  010"$Q:":P_8Z3KILR?! 1.<J"A"V0"!Z2(L)!0U[!_FT@??(3/L
ML3"SZ:'@$9PED9Y,$9%5495P,4,3XP\3>XAQH2D;$1_!,9_Q,*A ,PY;83HL
M.0F3"I?E,1^;"HJ,X))-,060 B *H !IL8HE_\DSQ',6Y.@?:# @'ZC%!](5
MX.FI5*FG2]$ 3T$HO%K$I^C%MR(\^%E"-:L>&F*HRL*IE/ *Y\.KAT@)'6*)
M%'&K1K/&-["*<GR*AX 6N0H+JB@A50$U@U 7,((BB&A$7BRV;;$B<WP*F*"U
MT%J791"MTRJM85N)?P$.C?$9N7 M^?NB.W+(N_"_:(NMP!@9.@(NVW)(_..V
M0F(9SL@,OA@WY$H,YI*-HMF9U2B-+@("W&B-Y4B3E1R-<5$0V;@\(HN-VSC!
MV\@.VK#!VTB2MN$>_4@=G\0.A1./E+(7Z" <Q<FX'S G]VBT]F(OS6$1L6FT
MB>B-#3">'[DZ6NF:Q?_B'HD#H>C@D4^Y#_B!#PQ!1AY1*C!#'$3SB2A9L1,Q
ME' Q'&OJ&SG!%0PYEVB:LLP[0M9ID*G#LPU)1J2JCBSC1L%)CA/)'ODY&+>8
M'X9J-)]8DASLRHS8E8%(PT>\$B/T"5M)BD?Q+P$:%\R1PR61I$VDH!_8.'(4
MJPO!RVMD.RV;.I'(B(2@#=BD"D7DD9*X$DF!G>@SDAH+GA3K%4(YN]"+3'@<
M*EAI$$D,'A.#/=H+K*!P("1)"IWB%S^3OC<#OI((B7J "*4@NG0Y+:I0E]/Z
MB.;$*X51%>*$OO"!S56\/IEXBC5Z@Y'RHKL02-5BL[+8IB\*2+(0K7$YBY'_
M @NS$!C(<@.!@:/[ZR-HDRVTL+]F8XP^>@S@HB-PRS;9 J1M S</W:,!?(R8
M,5'F"AK92(UT>R][&8XRF:50H#>W(SB:0 WM"@^HN4#G2).80S0_T82;$+JL
MM)!E4(\P41"(ZXU#],N#F)LC] X1>8_+,Z508HAZL)N)*H[2A#"FT)3ON(]?
M H5&A) JW!7\PI,0^XXR>0.M2)OS.H\BK(X4@RD2Z:@,*9N D@@_H0FS*8EQ
M24R.8)$14Y3,BM+: $R,L --X ]"_00<Q X*08[WL95 5"5_:LP%"YT'>@BT
M43/\BH8Z&-+G0+*H\)-MXI*Z:[)/[=/S+!_&FYNA_R&>-812^WR1K].2@HHR
MQ7-&@,.21O-3K:J@4-05CR.1W'3/7QH@>E ;"E B+KDK/..Q8:T':(@09Z&1
ME @7&8.B%/J<P90@GGB4!]&'BE.+:Q4?CO P\^E3236*AV Z*!W3"G+/?1H^
M'1(L@:"O$D$)5HN&3-"$+B+')\((4@T*Z!,+Z]D\X&@^B9B1EJ@[A;&UEH#4
M3"!8:\0IH(#8\CL+M" VT=(UHSA/:+ +L<@$QH"M@;RMEA6,B(RCP* V_WL9
MD=%(R\@8$S7 Q\"$$<4,GT71!G0DZ"*.%@,"-FDD>YG)HZT9#[$N^/ NTX@/
M>PF.ZH@-UNC7JCV<F@$%7/\"TD\Z$62]G 7)I0BL&91KCQ]9N^B JK0UVZCP
M"6JB*!Z#@W'"$$R%6+6DCAS3$O+R.A:QI[#KC:O<&ZXLJ/PI@I&2B#G1GYKY
M!+,IQ:@X*%/#J5DT#K"JJ$UY4B,Q5DV=NC:1VTMM0V2:%_%JK <)L$SYP[1+
M3$&YTURID]05B38*EDE+E$5+EW#1$>#;N741N>I+UA/KU93('=N%6#O07!QJ
MVM>9D,/S$><ED<<]M$U)L^\@-#X)GN5IPDP+VZ;EBI]H7I- 5I-"W08K5DGK
MTVY\"?7E3.:BB+ZRL*B@"&HD$=QC5W\4F&0]B3>(-?++S]7JEYIY7[+(7R<4
MHE7_^[55TY[2@@N(/0NQJ /ZTRV9G> *O2WADBT K+:+!(QF$\ _VC;-\"-$
M<@,4':02E0PZ8"Z=(=H5-8*+V!$+" KFP TV,8).DHY+T@26] X<QDGC4!J#
M,(TF79L<AM@(<9KO@%>,L,#RT$$@],KP8+?*00A<(N+X(%3VP"8BAH\# 1##
M'+R^F:8B6&)2:H_UJ:7HM.+O*%6J8([BN(A!)%NOZM?9O9',>;#T 05["5AC
MO<37H#$CC 9-(#J)^H[SC :*2$P'&=,ZE+LOZ]OQ2:@Q 5<^ ZEM52F0PR#^
MH1&.T(2-&Q6WV)#42[)HP%[1<<2_BS*+X.,XX1);:6,E_]LIJ]-&[MBRYQ53
MI)(@0SR)=/(27HEE4W;,<*&@Y'0#'%1<4CHRT+,#I>KCE!@>X6R@L)JS5X4Z
M^-$R0^0);)Z76\8I_R "!:IE(A(\(KB\Q'.6(&J*1][?Y0@B8:ZKNI)DZ4O%
MCP@7Y17@5BF)'6J)ATV34R&^I;@D:("L(UI8XJN#,;TK>R1(61-(2TD8(DAH
MB8 &32 +8>-'M^@B _78,GH-C2FCH(@&NGC@QYH_E;T_NS@,QZ@CB=2+B*PV
MP,A0$/4CY,*C$/;9/9J9.4! PV"N'SBWE42WU!@.TBB"E:RNTXB-)BV/\G"N
M57+J]Y(-IFXDH&X;L,FEZ)BFKO_1ZO;:ZKA)6[$)'/U .&%*6YWTCJW&&_=*
M./WX#F7ZD+LQ:Q"IJ"49Z[F.L!/ADHUR#Q=QGZ:YE!ISFD>L$Q=Q,9IS$]$K
M*A"A("K\0TK^')B+LSJ,LU!L7?X"M-K<L.!YE%:L$S9]%)A#6_VX'DZD*&,-
M%IC;UJ2[NY,XH'4"O0S:$UZ.[$OE5BT!/F)V/"VY[>3$$<GFYI"ZE#\$/<8A
M;E7&;96*-' !5VETO+Q+']T.QDW1UJVZ9Y3 J*WR;'"),TSFY;"BD=\[W\_K
M[7L&;D,C[S<K/?#4[7/1%7E.B9)HQ%B-9^#K*^S^%GEVJ\6\H7C<E(#$:%'[
M%IWH1C+_2H//,IBRB$^!K+5]+ N!T G1\N\&)Z,*K[4=JO#3PF@Y*BW=\E@.
M9T@X$HR5S<C:FBWZFZ/$^)AM^V"6>8S.  QLRPP2'D!,(,F<0<D<)]H*,,FD
ML=K5.#>K'MH5-6K>P&&P&6+5 (_R*!JCQAL8;.LGYF*N;FLA!$H( Q'X.*B$
MP^R$XV*[S9SD\,/%"9&M#FO$99UI0EPN'^W:Q"4IU!(QU^M')',NA# NG<7(
M*8Y_XL*[R]SXR%P]3VVNLTVS^VO>QA%-O5M.!C1;>>5N54/NLCKD-LS-SEQ%
M-.[7M,73#A;&Q&T_' CBW<RMXZ#/_O1KKJE63+,@V^O-U&T*_S+$VC0J%#-6
M_CH)2F_N.BSFY=94T*-UC>.IS\EMMEMN3@G&WL:>XR3FT";L'!OOWE:ZK;)N
M8[<@[E9O4B-F\=Z4,G&6@*0^4,E7D_C741-(#<_M<KDAJQ@UMWHC75%>94X8
MYK$>"=_G@?B7T(+P\S,MT>(*CT"+A]@A"9?P"_='"S=X\XN_E8T_E>68"(W9
M(8!9.HK9_!OQE $9.MB_D?%(;8OQCKR,SD# &._X1%*DZAI:HS[)HEEJ"UA1
M1EK1U7 /[YIJ2(*DE<^.I@$/J!EBK,:E'&6-+IYRJ0P<)0>;_!#KJ?R0B+MR
M.>>-Z&@;N.9JMXVYB7(?%TE+Q_851O^/>KGFRF3:$#C/<D4+*13Z)UI?=E_)
M(!=I536+;$7;%9HJ<QP!J-B9^^2(9% O*C+';>M=9"2!AFU2=JJ_;<KVJM+;
M#YWC>]C#-)P*-$LM=>84[4?,Y,!V>Y4:>TQ&H5-O,E7N,LGO].E]=3VTNE2T
M)Y]J?&970VE$R[T//5UI145<;F?A6[)'H2[S;-B[]F4_=X%8=6@?;VHW[TB;
M*RT2-,%Z"+I1*G6Y9V%;?I8@< )?->P.]PS_(MCT]H]XB8 WB2\J";A0!F50
M)]-"X'H?HP=?-8C8\#<ZOR*0\*%P X^(:'<Y"S%*X(^=OX'T\(VY"VISMC@"
MB"%NV@Q4,G#_(!$W;A*V44*0H,*&$ ]2A&CQ($$Z&"-N?.CFTD!,<P;N*VGR
MY+XB%GX J6#DQ\J8,%7"_&&D I":&W)6L%FA2$X./W2V+()SPX^?0Y'>!&(T
MYP^D2:,NI>JTIU2I0I$:_6&T"%6J7WN.!<M5Z=FN7\4J_4GVIP^S7N&N_4H!
M+!&V>9&FG2L7K :O994.+A+W\(:X1-#Z2)P8+&2O/P('WON#B-G%1>[2Y=MX
MLM>\FCD7,8PTKP:\>*,V-FP4\^707C_GQ4L7].8BM6O?G:V;*N77LS> 0OGF
M1VO0M>-ZO?NXMVC3C>-J,OGF>>G>1=Z8!!7WM?#?KBL0V6#:].[8_ZDO/R8O
M/#IMN*=/DX^-F?ERU_9=QUW/6W=NBGD5F'1%I':8>/?])II]DRWH&H&+P59;
M9>S%=1=MI^VG7&G]Q>9:=!/R]]N!(%YFX'Z(F:@@? \*"!]F1'!7$B@G^L B
M$<6=] :"1(1(A ]OW <C?T#JYH9N,MYHHX^7^7C?0F@D240:3Q:!9%P+Y8B2
M2= (">1"6?JXT)=5$H&&CSYH&:-B2"[T9D)QQ@DGF6<FI&9"1:#YYIM[SCDG
MGW"VD1"=@P9JJ$*!)J211XFZ8=!$"UG$J$(C$=$&'1E=I*D;G52*B1LC93JJ
M1URB9$%+0,1$DU"I1@7$3C\(19,%0/54U/]15\'*DE4[N1166K5&!5:M2E%E
M;%95#<:67\VZ-9>S<IT%[5?,I26?9%SU)IE;D#$&V%R:L2:<A@769VY98FF7
M+6BI.<<N:N/Z=ME/&*[VVD^/\7?:6J.!%]L&_SD&6GN80?<8:N &9V&U^KF&
MHF%O1*.,,J"4YE]HY 7LX(<4COM8<W90#,IU^5DH,<5VK%A@< @^?"%@'>9F
MX\-WY=9BC!N61R^)KFV,\<8X-R<SSB,J5I^$0X/X4WGZ)?PBA"?2K!B((V*&
ML&MWI8=99;8QF-K*]P4]-8!00RV:T&P^^ 8TRD"3"8L+_O"&VQ4+":"1#*J-
MI)5K7JG;86XX>27_D'<O] /?6 (^I9EXBH;F&Z#4/7$F7WY)>%Z"C[DYX5^B
M0>>8-^:)9Y ^HFFG&S=J"3KK?WY.Z)^2*C0G1(3.WE"B"0E4$: "-7KI090R
MY$:F%&TT$J85=;1\&YY@:NI)-0G5ZDHMW=043CW)M&NMW<LZU%$L\3533\?N
MVFI6/(%UT_?27B77J]0F]5*R;7G[%V%DB<5LNESM/VUA_%(?__6%7,T:G__P
MA3^3$:A=')+,OA+V$_T$)F!,\XW&.,:@W"!L7)K!3\S.12 02FUGXFG-N;[S
M'>5D##/NX0R#+-@8# UG.J7!C8 JN,'E!,TQ%(Q97!R#H8+1)3^FH5>\_^36
M-88Y"#\?ZDUEY/.TE37Q05J+RG]NYAL"<7$X+RM-B&C6P18E2(,K:XR"G"B:
MQR"H1_9AH]5.]+6:Q=%@ $+:TEIDM@6E36]RC N:DJ0!M)4-2Y=KDMJDA"!%
M9BY&COQCWH"$MCGI*4E\$])"IO0DT9D.2F!ZTN$R>;K4Q2E)5=+<0LR4R=7)
M*$^Q:V7K_#0[/O5NEK:CTYMVE[M( <HC&KG=00Q"$>3)KE+!2]2FBE>\D8SD
M$ID2"4:@9Q+OK8J:-;G>K[:2*J2LA"8N48JP5O*2;[Y$6%/I"UJ2(I=?'0LL
MW:(*4]*YEK[0LRKHG&>S\)F6S\AE+W$YUP%Y]O_/^S%G9K4A#V$TF$ZD$$@[
M]T.H9A*Z+RP.AV<1PN#.-C:>I&EF+Q\LE[WN4L'IC&VD]S(I'K%X+NCH9VPR
MJ^)J0%8>VGPHBF7\XA4G-*_T/ @[N3&1$N\E(-W@T697!)#.?!,@. (,A'O<
MFM,:E+.9+C5K)"*;#>W51IDF-6 HXMIJQ,;3KE$-K$?3X\K.6#4/335H:DV;
M86*T.!9]Z$4O0B0CXZK))"7I2Y<)DIJ.E*4C(>Y(.#-=7)=T)RQ-\F^4;"65
M-A?9A%R&;W[Z$^%6AR<IR0E.J(L=GEJ'2X$ *DZ(8L@M=9<HAPR/(+!#B/$X
M8JB)C&0C&"$(,6O;*((%8&*W!QG_B31+ I.<6*"<-:D5K%*EO9[@1"7$\LI*
MOD>^Z4K%G6-Y";&R^ZRNO"4LUA6?.I5EO_"^<[S[6TO^>-9.=?H 6$OAY_^2
M4H' ()2?;O&G7!IH%X51I3$I!!E7]FLOPB"&I%3QIWG4>T23-LB'*TQP1X>&
MQ"$*AF;@<@QS#@3'NW#X-11HZF8B2H0.:^R?L*DJS/+S&) !B,0[B_ 1)>28
MA#71/"Y#T!!)*AZ;H;$^5^27B<GSX8[61\-4DUJ)[!BA^MJXAVCLL(0*!#,<
M2X>-/OV.:" ZQI]-9CJ+*;!A*B-3]-",PFY$JH*\>E8RB]4'[FFCB^*<-YJ%
ML<YZO5&2_P:GF*))4DCX :QH#@/9N,KQ3IITTBD1ZR/=? G/@7T3XB2I6-&-
M,F)/^E(G?20DSCI.2U)B993B=$K"D4ZTG[7EGF:I*-=&Q+2[=)1"($6\BQ"!
M40Y!)AV&-TQD$F_7O_T4IB#"S(\\LPW!W4?W: 447RG7"'!X-K1OHCV?%&4E
ML?H54I+[S>_ABKHVP:Y+X& '.-RO6,N.;[+80K^AH%=:T,H*_KY[Q/XU:[U(
M><,;[)")9]?AV6\@=_[<G5\(%L'?-RQXY/J7Y=H,:UR?2:!L7$A!P1AX-S^I
MX!>+S-9QF>;?^7Y#AP9&'QG!(7+XUJA[W//O3Y1\.W#H]V_RO?_O^[Q<$R#G
MX<+#&M,@JA ]=)&S1:7VQ1%A=,4]=PW(G3HS\9 LJ$78=[]O#M2>(Q&F]CI.
M;5:>](T*1A-1%RJC:PZ@E=?<Y#('N8GN@F\[O,'F6\^/UVU.,CBP_ UUT$3$
MZ+XB/'XG$VS'FV_F^*(4E3$U4']['==*5*GC>=%[9I)>#VMIT?B9T6_(!,E$
M0Z:[N9)-,4I<CS0WZB==QG-Q\D$F/N%U+37>1VFH0^K?4"?,A*FSJI.1WS,1
MIM7I)I"7_1(I@?]*?+_IZ;&GI2US1TM6OS90N)34I6RG6CY%JB <N?ZD+J(\
MWGKD(<7K?JC<<.SL*;?\SH6#,E R,3C_8!M7NC+*.+_7%O:MY29J^0$<]@$*
MK%2'1A5 5E6,5SJQQ7<E"S[%6U+DA3RITP+21V2PV(=M0/I)DS*\007PDW:8
M&+MH0/_M QPDAAV8A"9H5;SE&&1P1<*06,-PA8&)!X-]S;BXQX?0A4AU((V0
M(!I%Q026Q#+@U\/LX#Y$ ]N8!&!$ Q%.ADE$@VW\AO]X%&O8V(AT&-$UU(59
MF V-D-%9D(+LAU$507'<'$*5C7A @W!UT-.A!-=YE;V,D,P@R!LL S0X"!$D
MX4]139"<Q,.4B!&6A 4"(?1$0]?<11WX84DH QQ4B ;H2'"!W(Q83 YB!E%A
MQ@[R"(A@!UV)_PW08<:,Z!\)7F*!:*(^>$<:W5G9Q(UBE$Z/A,B>;:+%+!K=
M>,FDZ4F,,-(J1A*;I [FV*%N[&$T7-*=? D9\F&:A(F0>,Z1Z,8.0A:/%-]C
M[5YFN4Z<T(T^S(E)U,,KR=)KE9:J[<[T/<0MR1:L)0]"3$0R78I&Z-(0?)\Z
M#L0R&5,;]!:Q!1M)!!<0"$5Q?9.VM<0R!!<<U,2O% OWO$IV%<7\3)M27,\$
M]B-2Y%])L-^YG==/$.0]A5<]?5<#1DL,(J ^"9 [*:(TD5NS5)  648=6$=4
M;.)UP!.(Y1-$X08$T8Q)-5!&T10')0=LK(<%+0@+,N2.% %?Y$<%;/_B$=H1
M>7CD/BA#$>SC/L1A7DQ@-$S''B(ECX&(<V38&^&0S'1A='P1?FD-9+2&TFV4
M0='+$.Z#!>K44OF CF3"'9E&,%I'5%G<5D*1:^@(*$3'!")EU/S4)"8&;_ D
M-!B(49J*,E3=8**$)J1&7GS"L9DE9NSAVTG5#Y@"$8;-B 2($C$,Y75'#IG(
M@<A57$S@7<K1&;$(H(6-H%$B(FWB)QR&CO3@Y^59)FD:(M$FH'$>Y746D$0E
MCZ0)J1&!4O9B*V%.GX5.0BBB9.U>*9V:9%V6EDP@-,!)$"YE[""?JQ5*\Q53
M["!*$BR?&Z1C,2F$[Q@3]LV:\=26;8$?.R;_#_=UBO@%%_G5A*J(#Q 8I3+L
MH4GT(_K,1$UXTZZ$A5#\"CY5 $]J @'MCSQAA7A!UURLFUITUP%V%P E:#]A
MRUIH1T))8!+>YWVB8=+X#QN."T_: 8;Z) 1IH$\^(D!YBXP]' 0Y%'0475WE
MA@SF1U6:!F.6A!U\Q]+\% 4,9HVP(04$)]K]P%N^!H;AA5+JI7H1B%7QU-$0
ME<^H$$,YB-;4Z%=JD8',FPW)Y6DH(ASH5(FX!F22H%#RX%=QV=807A%TQ]()
M#8CX0 C2""0J!ICZ@%INZ,3LZ7V"0M<8Y9X:AVCP))\6ZAO<1284HE;I2VA:
MAY%%U8/(F=%LP"8F_^:*T-E^5*K<F*:D_@C@<%Z2' 9N%II)(*61W(B9$!HB
MI5(DA>J9_&8E*<8$ZL,Q:LF7S&IO!M^C29;PJ0ZJTF8GV>J-;%HT#NN=F,0R
MQ-(K(=_S$<KND):JH><OZ1)Y\MHX_E+QH%;X502E_%KXR>,RP:,\$I.QT>-.
M^ HVM02A:D)3P($BAL)3W(I!]H3]6<__O<6]6D]24*I)V,'_'0L#&@5S[<K_
MX8];;%?!OL4ZV9MDR!<^?1C"3D5/?%A=8 M].:4[888FO&5A'BAGO)-1Y*A9
M@LN0S9?)E@:V=(M9S!!EO"1E&)@&4$ 85F65LH<&(1%"M6QM) :!6@?/?O\0
M$S;J4BYIR)D&=/X !>1%,/9@#>5D,#YERV)A0;E98'38B7Q8RU:<= A4C+5D
MA?!'RV[& Z%&!QZJEDI(!>B(7J+19NC(Q QEQT"4W/[''-+(840M$@4MOYI$
MU16!/A A9BAB7&&(A B(4&9>Z>&GQ;2MH]XMS+@&7$98E+DM)8K96>64E6)F
MC*@<9]I1#FK C;S9B"EB'?C 9SK:D ".I"'27RU.CR168J7);I8$-.!9[4W2
M9,65).%B(/$-)W%2F"#K[3K)C3AE)G&2["Y)[9$29'E:IGE6J,GNG_A(J7Z2
MG0 *G@S*&1 !M.92] G*FYP6],&:0$#K;!'*+WG_(T<4C_+\VJ9<'TCLEKBN
MYWM*4TRDBDS4BE+JGP5\$T[@IQ%46Q$8 2B  AR&0C]:6U(HPS(L U 8,#0L
M@\70*P-WB003* 3W(X$RL -[(1PNPP=6A>1(L+<8L#*$@G=AL DW'3QYH=N,
MX%Q ,-X%&"A  RA,#"B$Z3M55U3H2#V\@4@&)7ZZVR>$PLB$Z1/R),@%)8>"
M',5(\("Q#<4 ,6B(# ,W'4G1C01'S@M/3,7<"]TH@RF<I1?93%"*S#)0#+E5
M!AQ PUOBL%56R]YZH")2<5Y(SDG (1P,J4F@A@DCY640K29(SA>?BX2@L0UC
MW6NT,<5X8=NT(GD,,@Z3_XQ_/(;D7#(<V!"EIC%21LXC)QVE=F@A"N&.(9UH
M<HQK*&4!=X<=M>W($,$@CPP0&P8>E^KB$G(K>LV"U#&$L*)K.JIJ#)70ZM]7
M;499ID1<)"H?6N'B%$$P^BF=N<8.;@<N"\EEW/ 7?RW%>(E4&7-WV S%5* +
MPR'>02+%)"$T: (1P($II+$77C(E8M[$2' %BDXU;U(1;+,ZAW$TL&4ME\3$
M\ @VD\P3PXUN8%X:I_.4 (X;C# #I[/F(&,?7TFDU<G28E(XRY[D?#)M9H(7
MIX[E$'+;8%UD:<DG/+0R?(+LJ<E)G\1(NT'=)$/L9,(V4XP;] "<T#3%#(%.
MM__-)TA?]95O."K$+XTC;$5$MPJ;.ZXO;I$G\FC$4S>UI[QCN4K3]R!7K B%
M$2!K4N3$56A"-.0P@_[ 84)#4\A*?N(GFO8LES@P3X8P0[XM8L)?!21A>.%G
M6ARFQ2P%*Y[%D2:%#9Y$C8!%;XP/!6 LNVAH0^8%!4@,E^RU42BS!][%6Z>M
M=72+X'J%8Z,$9/]H$B8A/0#T9Z3&!#HP?DF-9W.)$%*VJ8""1D79-0,T+'?'
MT+QE3R[M;SPMO6PH2N@#R''&9@NV?B@B$$*&6@.T(@?)<1.S'P,T(5IJ8-,(
MF64'2@;B=EA'W1YE6!DIC>RO26H ]&"&76^0$RGB7=;_9>1:]E(>1]+.;6YT
MB<X4 5@WW6*(+!6_[!?U7S14B='HAGES"1*C9-G4<9*="&N67G=P"5+>H6HW
M=*G2(1$0(IV2-5QF21W+""M[-W9WB6 #"2%ZB92@"5BW=JA%I=^@KE+2*H:/
M,DIXR9,D8YI(]DE\@F8%]X[(B(0O1)>$UAO\+9?0.$/DJ W_.*+D$JS)CK,B
M1%'SFO:YEO:U+_AU'SSJ%D:,RK%93_EESU;3"%;G"KUF3Q&$@F#O[S(<"TI(
M<!X'Y0TG80'C7WY&!4_R(!"&\ _LH0.[Q0Z"CWSK*;*J17=@A0\HY9UOMA<K
M+H5Z11U[!ECPI&M[11Z_98V _Z!)SO$ALB)=N.E=[*]<'R5EQ+G^5: 2?P@K
MB] 3RK@I[* 0:@#=X.<CM]=7#4VIDL<0VXPFB/)1>@D?+R5@I'B*VG:@5F:0
MO&7;T/8@Q;D79[+?EBH04G$1X"<<BN!K!/:F[T-BKOJ&(G'4;$E)O%3@$F$%
M3&*- >&O[T,/;D"M;^A@YR5>]!!J9'=*A :18HAYFQS;>=S8L7()W<R+S*G^
ME9S=E5R8H@=*(LP+Y3-*N,U)5#MGND8P!N9WY-1F>X>JM[BMJ[,7XN?$J'-@
MNTTFY*ESVW:2E.J".*4FBGQ+V[*04'SF[>"P([>FN73%Q\@TE_0S&F]"J'4:
MGX0RV/_)A;O!)D[,6ZIS)OGX4@*A0ORS%\M>]2X$)K Z$.K>0HAL(=JV1GPO
M,KE:^@XU00C$'"Q*^ J3;LE:.XHC07A*^+%O_-(!2,R!N!Z;3*!/JC!Z?$97
M@.X*H]L?HU^%<./?'D(#<U7J_YE[?BYD$CID!^Z?431\M@2G4O D4O[$X9\D
M;;N3XA<<<E? )B\EWA%&87\[0+,;<#A^#_LLA6][5'3@(?X OX,<=VNWY//A
M3^B(/NRQ%^:GVB6A!6YI=S!4!YZ@$Y5&J>;^)@(R!UYV:@!8UD4N+Y.44R)M
M:01C/>1&\^<%?E;@71Q^8]3QZ</E#TC]=:1&(L*EY=/(94S_8F (;EZ4)%Q2
M *&:AF0?JH*,B+I_KB^O,[ZCB+ ?ZC'SB'E\,T 4(5(DVKY]T 3^*.)CP\(B
M17X0 65PWQL-/]Y0!.5#8 5E%$&&?+-PHD%0$7]H8,C11P4B$1=J"CG3(<>,
M!C]%K)#08<E]T49BI(A0HL%E'6_N@S.0XTND&BD4>5/0H*:!21'Z()(TDX:!
M/H%>'/AIV3YE;Z)^-/B&H]I]1.!RC:N1B-:R9N&^!*ELX5R3 I."B@MM;5VL
M=8G4,ZC,35ZM+^&JK>?79..DRQH341LML]LW6]TV]N$V$Q$WF2@JRZMO<5XW
M5*$U=D/X9VG3M#F;1FU0WYLV;CR[_Q'N9HALTW.$$VECVO1R-\Z'"_\]??AO
MZ=>M8W>#_'GWZ71^([?^O<W,D!6,5 ""7CU[.!K7IY??/CV0'Z$H&OGQP\(/
MG^E_H"J:_3;X8;,?"C1"HPH4>L\@.! ,;"?T-"J"P;N.^F$GMQ2J@*I]+"30
MIS<J>.,N4"J8\"X0*1@1HIT@LO"E A'DJ *?%BK00JDH.JH(Q?9!L:4?:-N(
MQ[5V2HK$#1RL**J2,BP"JB*B.C&J)HV,RC^*B"B0-KZBXHC*(C;P8<0-7M)
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M4^J2^4@<\7L6B"=POJ*&K%Y"^!=_'.>1Z.)KPGOF<^FRL3MIV.EYZ.HCK2_
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M!'J+X0NO+D6L<5T+,82I3%3PTA?(* 8KC_^Q5\$",YEON>LQ)<D7!1=CF"(
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MOALU2*>K.>VT%Q1%44E44A#ET*Q\3!VU.=]#2"(U0(CD2VB(# /5A-Y4!C6
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M>NR-RFYI3C\PUQ9S"3SV QG$':@&DJ]#KMWN8 .!I']+(05$N\[*], 8SC]
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MT(.BV388R4;>Y+7<E\C!I,V$!VW549#*.$IF^'%3[3FF\'Q7%'WJ/X596+@
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M34R%OVB9:H#5RE\['Q*LJT#%5:!SWSYWXAJ0L9,C^).6H+S'3FH=\E@)I=]
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M&Y'.W9HU Q?CI!Y*R>!?@%/AWU#$,6@[[D!D."5B?0I,$[+28:]#FEGF+W/
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MDA9JD_-F^51*DY5OH72(>9$FS9)O'<N #SB#3U KH9=EBU,.\;(^]0>*J;)
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M<PY0\%U%Y VGFT#13)A7CW36:>>=_WCF6=D8]!VUHYZ JH1&0FDV!!E%Y>$
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M2,4JFF:)-.&A%6&RD"UZ\8LUZ=?MP @39:1!08XCHQK7N \LSL2-1X1-EHJ
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MC\\WH 0Q6)@Y/#BD#((*$6^@> OHBC/84\K54(MX;Z\W:,/WH2HE9!!!#)E
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M1&^M=V(6ZVT?AIA>&C%I(+ISF'QB0?F((]/FG5___I*BL>; CS^7@N*(F*B
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MN,(M[G![NUSC,E>YS87N_W.EFUSJ(M>ZOO5J=F.K7>YNU[O=!>]NO4M;KCZ
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M?V47/W^1DM_]\8___?'N_O.+_Y3^ZN<_^EL_DNH[]%._]D/ DL*[!$1 RV+
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MH]4FWVD]6XV0B_:\I[#*TI:U($M9Q\J6N2X3+7@P##4&! 5H9(,_L[QK,</
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M$6,2TS+-9"BHKL[P=X/^W2\QZA'3"FZP+E:IASZ608]H",PJ@#'_(83SD<4
MX0\9Y44A/M8Q#U"1S"MB&(]@QHL=7O'GJ6+ X<Y$]IVN:DP^.<&6?9X8G[/0
M!SX[4P:,TQ!%*>ZG/LW%YQB\JL6VKK&O#7K2D0$[Q@I)TDEUZ]N0DNQ7,R;9
MR4^6))/_RC>]:0AO&*KD58"7O<,-MY-DQJ0[$4?<Z!4%(81#<U*0FY2#$&XA
ME!/SG*?R*9KDN<VXZE*N:L6]V7E2LBK)K*Z6HEHX2T_-W#.SH>7ZXTD'*\%E
M8<OYSF&L8]7%,N(<S+3T,0]D8$(3E"'&)S:3#%,38]6*&>\PL!F,H*9E'=@2
M#"APG8Q8UBM9S%H?+^+Q+M00N()F><<&_Y?1F7<$F!C(3FDQZ!'M:(,*9 SN
M\%7F$;_0B'J%")J4,H8AC_CA8]ST"\L2RQJ>:+#LJ6B(*@[0H!NEQE ,8.U3
MS;8C'W8_<1]'W4YX_%TS\W!'AFC0]WQ@.(GE4AJN]GSK7.WV5R5'.9(5-VR5
MH3SQB2O9R1G7*Y(\+K6/5USD#7)L5N+I2<$AU]"<M.QPBPOS0;\\2T39+*([
M:?.##&24E$V<*&.^<S-#>DO'';.C<=5H79V$LC ';=$9+;BB-KSJ"5(+IS'-
MZ69M(C&8&0T$;1VM;\726;5D+WLS@4WVCL8X ,2U:PA3EWRMSUC8I36Q6\KL
M#';&O\46L+('//_3J'*EA/[CM@J5$R!>E448QPC&.I!AEJA2'2OTH:*_ZT,?
MWJ%!$I.2!!JJ<G!B;"R)F=_850XNY'T,(X9"U@1VT' PE5U5$@"[ZB16;_6A
M(<V*$+?B'24.V+H*%N2&I7C(IVQRQO:-XX6U.)2C#U@PNQ6TB=[DFXTN9TC?
M:NB9-#KXBPLFRQJD_+UMN?6TW^BE_WS-.W=YRY6>V9IOK_[OQ]ZK)+W[_8]E
M&>2+[OE@6K.HER;$ SZ8AK5HPJX-!D"9BR:H!J\Y!K6\77JA"W?QE[&IQKT,
M0R^L$&@06V<$GEHPF[2I"PD6 X!)FS(P&ZAXA<-$!F1 QF=XVU;X!F 3;!BV
M645P?%#9M2#_]<K._. ]_?]>TO3>/84-QET<E8V<8(E<R3UATSR?Q5G9$SHA
M&A'?85WA80T)]6&%#WB2_$E/U'F)KLS<]%C/F!&=&4K=T=$$G<F*FZFATW%6
M]G$/HRD=&>Y$&!)=H<7<F?VA^,G39#&<$!;B5\@,L6B=UA6+75C7GUS7K,7@
M,40+M%2BW"G#)VB+LP@#.T@4:O3@ %*0?HDB=CW&N*6&L5F02AE;@:F%.XC@
M@$4#3V5%,D14#/[/:21#@VG%N$%8_.C>O^"07K@,,1HB@*!!P!FC%DU8^!"A
M^ 3?%A:?QB7?\7&<D24?%AI?-'89-RXA7PF?-S9(%U8?^95AFHDAH@5B'T;%
MTJG_XQR2WU/,X9JQH_H1USG*$Y[Q(2"J7Z#M(QLB7?TQFIK-BOXIHS$:S*4!
M(+%,%TW)1C?%@SI F#!X5T/RAFN4A;3< V1,U+,,$ 7YPKV$Y&8@BSH$0S (
M R^LA@E6$ H2P[2-8%D\VPHV&S!BA3)H&PP&E=N9T/=$U;@AG@EQ!8(%#"$:
MY%@4D5&"CS/R7ELI Q-6H?%)F91!X51FW,=)9?,UV3>"W%4JH1)BY92%)<IQ
MQ1IB'_O!H\W=7\YEG_6@V?N=&<Y15EL"8OO1HZ/%I5DB5_@!Y%T&)#Y>3SZZ
M3E(.YCZP2R(J)%LTBR-^5R9@@N/%6@-V9$6"PMV5!K$%_]3<B2(ZB.*]^,)\
M?=0D4!"SM=2 W8LK$EA+^I=B5)[+K(.X")5Y!= ^S*+#3."[ - \,"-A[B;_
MC8%N%F%;+8TW/F5B@6-85F74%&=R9B$U4N'S4:%7.F%4,L@XIAP8:A/^I9DY
M7I^A358_ZEP=SN-F_:'UL>'XG65=SJ,?ZIS1T=QUYF'W19;2O><Z8DE!\N;N
M^9\R'(LB)B+[:&(E8M-XF9K7O<^?Y$5>>"2XQ$,P,.BU\$;[N-3ZB&0&$H.O
M44)KO%1+]MUH/IL(IJ97\$[_O.9KR@,[$)Y-FE!DV*9QK -^OBC_+:70R&C2
M."46WBCS75Q7,J$6,J>/:B&0,O]?!> HR6&ED4[96';%#WP?FL'E6E867[;G
M7Z)EX&@3/Z9?<:EGENJA)Z%C:]5</&X?E<IA.JI?>C;IRJV?K? $:\)HU5T:
M+O1G8C9B9FCB9L3:8 Q@0R*HMF2",(R7VGT*,!F&2HHB2&K@1HWB*,YD?V5@
MWZF+8ORF#BY#,C3H 99&AB6#_WU/=HE:3H+&"A6EFXXJ/HD$%]&HT;B-54+E
MJK8JJ[ZJJ\8JK$+EK!Z9K%JEE%6G5L16:&&);WV6:3G$)?UJ37Q69]46;W7*
MK_(J<,66LQXK:B$KL/)J]X36:,E):6W69XV6M?XJRSDKMU*KL$+K;2VKL>KA
MMNX6N5+_:VBUZVX-Z[!VCP,@ *D*H7[R)[ZR144Z)(#2:6'(Q+-(9BP)*'N9
M"\!RUV8:"Z+:R_HDK 5A(+*E(F>\CSNHSBNNY)^ A5TD SL<PSK$ X/NFES9
MA3Q<ZG$8A\/49+VN;#,^7)LF330801V\@1&\ 1PL04LP@<W60<W: <V^@<_V
M[,\&+= .;1'  <\"[=&^@<[>;,[:;!$0K1U$+<W6 1Q0K<Q>K=0>;=).+=+V
M+-?6;-)>[=<J;=D&K=52K=,R;=%F+=>N+1SDH%? P42\01K0+=V^ 47<;1KH
MK=WB[=WN;=X*+M_J;=]*!.*FP40L+MWN+45(!-WRK>,N;N)*_P3E*F[B+B[F
M:J[E<N[EUJWG>J[ECN[FBN[FDJ[E-N[I;J[A2N[JMF[D>J[A.J[AVJW?%B[A
M#J[=/N[FLNP/ED6<^L(M""]_*B9-S1U-Z45=6-=B9F8W):]KC"0&)JS#5JC$
M<F99M*2QG:9(_HG<;D4]V,4P"$,R*!"+:$7"D,9K+DP^),=]^B[\_@H6G6K\
MUJ_]WB_^YN^+@LISY6OP^D)A/,MB0F@E)H:G?1JT7&(#(JQJT 5G(NK#.NHH
M4JBTQ91US6)7D I-#:564"I0+4R+:JK^CK" /-S[DC *I[ *KS +?T6_A%2<
M!J_6=9I'&K"Y_&>_[NMDX@5W2>];_/_PH19+PA8+!G*F]G+H9NR=Q)**",FB
MZ52%I.&/,(S4";4O.WAO"V>Q5?@F_6JQ%W\Q&(<QJ89O_[+%\/;"__*&ZE2&
MN00L ANH,EC7IW@:H7K:^_RPIBDL:QSJ]2IJ!#L;:?)=8OS']X*O+"H#,GRL
MN2&#OXBQ"J,JL!BA(T\R)5>R);-56=P")9PQ):!Q+X2F#M^%..WKLWA:UXVR
M119&L30LPZI/ F7@A/*Q!!<Q!M[+:,+'"=?@;(+%^Y2O,*"7.!7R)?NN)+?L
M,!\S,B>S,I-0^&):##LS(R+PGSP+\@84'-_P\9:R*@_#9M)7^M3=*AL+?]5=
MA7*0]7:O#QH+38+AC_(V\C+'+R3_R^\[SS,]US,ERXRQW,(D!.\9NX4RG'(E
MNH\-Q_$ V?% /^+<@62Q3%<W W$M3Q<%)6PYS[)+%C&I"+-7(%A.*<R"<44T
ML'."%68NV[-1,E,7DS1*I[1*VZ_]8!H:3P+Q#F^ST'$!7X8:$W U-V #BW.Q
MT 5]=3-$=X9$7R^%BN2]U!2"U*()Y51V">552.I*$V8\^\I41[557S56-YQ=
M[//PWD(O;+(O3,(M7&1 />)E&.@!GPN_'JQU*6\X]S1/_[!/"_5[_7!#3^C"
M<E#?,5B :-M&@D;[YJ978'16&R,7^UYA)[9B+W9SX44O]((C>+(G[]-AU&FV
MT/3[8$9:_U?D2+K%.0BQW<$U:.MQ$!<J+3_P46,P6 A,;2*><0@;8]=K52=(
M,<>V;=\V;A?(8FA"G'IU3/M"(T3S  EL03<D'#<O/VT:/W%S7+O#0F]F+W1&
ML;1#!96VPA+QPE+7+O['#8H:PX J"^4V?M8V<(JW>9\W>MNDRZS%\#;"2WOR
M\ *PMK3UW*7U\BZP.'73=<_%7?N::+]U=9.VL6WF::>BOXBJ6)@0K4'&!.I4
M>@_F;"-(A#\XA5?X/.-0?3US5[.%>Q?+9O.&)O"P04NS/DD77+P7IYUX-U,W
M2#*W6P@QLS3T:JPR!]G%2&L%@R&#^H(P<FR8A1OC_"+VCP\YD?^G-+3T@C[W
M-EAO.*$^8MJ$,D6BB[&\^&$JB_HL]T(2"XJ+LX7*>'4[=Q'_L($52()IV_KJ
MY+RH;)%3VH0+R(VO.9S'N1?O-BYX=63W-G!S.".V,V8>+ Z/\D@B9F@GB[*$
M=EP#-8#+M6J$\U#;!E2'A3*$R\)8ICQTS9O+N?@$V4EC.J=WNA8SF/C>0F]#
M-I(+KR<'MYYB-H0N>G_RDR]\=I:K3_D8BZ:]>+(X-S%HVC>_%Y@?JCFCZ+?I
M W;9HKC$PR2&D*?_6)L;R,LFN[,_^\I&E5V$]2T$MU?'J;6;,9(_( XGZ/%N
MAIP>IJL3>F+V]"KODY:_.&E+M]V-I)A45YNOR$RD?RP\Q -%@4JS0[O1D/>^
MZ[N__[OO)@9\1_:&WSFIRS"&;@:W+_JQG'&5]^>QH .YHX\0(XN*WSI;X'H>
MK_B=6KJOZ$9B9()\I9>: WQY_PNYR:>\R@]F^)H:P:.Q>\>P6,<T?+>%UG4U
M3(<[Q+_X^22+Q!.+K&]YN>NQNB>ZC0<+XT&H:J_\OC]ZT"P[TT>]U!O-1^/%
M,-R"(WBUJ(LU?,]\AR>Y)W=RP^>K0I)]V9_/IKG7JZ^%<[L%='=&=%MH;Q2F
MT" 8N,7,U"OEP^4]W_=]6Y$,KR6Y>XNZ5UO[;Y]QG-8\)W?U8>Y\E1/Z=!V+
M^OC"B6NYY4?^^GP*/0![L%0%8?N]KQSVD($^Z9?^T+!V8=S"M8OU)O<VUQ-\
MGO.SV$^V,R^B[9N] /KG7/13=(-V=$^0OUPZ@ B_Z8,%U/L'OQ>_\B\_Q(CO
M)C="G?^K/F0SOIV7.JG7_&0[O,Z7?729#[IS&N5/>7*OCV+\"_,;I*FB_/FO
M/_MK!<@<>>$+K]9'=K9C^S._].*WQ3.3O>VS!4 ,\]7+5\&!OMP=[$6,(#%?
M#H<14Z8,VCZ+%S%FU+B18T>/'T&&%#F29$F3)U&F/)E#94F6+6'&E#F39DV;
M-W'FU+F39T^?/X%VG AJ&*5;MQSU<G2K%ZZC32?=&L@4UR1<!*GVZD6)8->K
M5P\J+$CPH,"%8=L9='C.5\2)RO;5"SJ7;EV[.G,L\_GR;E^_?P$'%CR8<&'#
M(>M%HZ>,&+&H1V\]-IKTUM5&OK)>-8H5<].N!Z5^%CU6[-G3@0Q/-YYXF'5K
MURM_YGT]FW9MV[=QYWZ=>"(Q3;T:.37*M#)PJ4<W-^IU?+/FXYA+BY5.5GKJ
MB?04Z]:^?>X8O3WY<A<_GGQY\^<!Z]NWN+=QY+>4%[^<V7/HJIW%/B<[.NQG
MU!&)26:B:- KT,"1PMLIP0,9;-#!!R',C4#V&)O$ET8@<\JJHZQ2KBJIYL.*
ML_D4 BNTZ/@#<*)E])$KPA?+RX% \&"LT<8;<<QQIFCJ>8L8@3 <CJFDG&HJ
MJR&7PVPST/)#L;^V?IP(&A=UK)*V!?]SPM+*+;GLTDOTAE)F&$TXQ 7#IX*$
M[\+.JKKJ.,^L\HQ).3]349EEE$GLRST#RP$N&OD,5-!!"?5KRO7P9"P38IXR
M$S,WCSOJPB1O,6K2JSRC\TDH)9+R(O4*#94G+6^24=1344U5U9$(5.\M3931
MQ)=)EL,P..,N?=--.9GS[*NN?NQT(KFH7-78EKS;Z]AEF6TV4&+U68:],8G)
M9"KX(/TPSODV2XHS@BP<<QA0A)UQ'U"=33<D4FUB5]UWX8UWO!FCI8@Q91;5
MQ-I>K'H,,PP[T[52?GU9-)-[*5JFHO7D;5@C4P%U6.*)*::MGFCU>:NW3W[4
MI-J%>OF-J]^"-!%7(F'?6L_%8BN.UUV:7FY9YIEI[DFO'C7N+59BR"6&XU@1
MSKG'N/8QMV:7OQOUZ*69;IHF>BQ:N,<>H;DNYZM7^W-AI^6-62;9N Y;[+%+
MDHO *=63"VJR*Q[C3Z79CEONL>FUB$JC>9R[Z]CT[MOOOXD&W%B(X1;<\,,1
M3QQ'KW1C8ESQQR&/7'+#P"Y\\LLQSUQSNAQOB?#-00]=]-%+2C9BTE%/7?70
M.U>I]=5ACUUVKG/86L'9<<]==[%?1^GSW8$/7GAX*[]]^..13S[5WE=B6?GG
MH8\>1],ME][ZZ[$OD'F3ML_>^^_!O^OW+,,OW_SS!?_KGJ3QT6_?_?=K\E-9
M^.FOWW[8YB=4S[<QJJ>BQ*)UD3_IY5"#X=]%_+</ NZO, !,FDQ:1* #_N2
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M$"FJC)QR[38A Y-&B!92*E?*.O]P/>M2T=CQ2O_P2E""K:FB#RX,ZSMHKO]
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>advm-20221231_g2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g2.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MU5:#S9K87],5MMECHUWV#V>SG;;;:[?][-Q=UTTW$58WES=>>^/_S=K<6?L
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MV9-C3:Y-.SX.,M:$7#5G$<O'HGQG*)?LR>R Y\D-REO@GO4XUGS4<H*+W.1
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M?&.B,'=ET>8S2Z1&U M*B"22Z ;#V,@><F&1J.MA*@D82IX>,X:,6.DEZ;"
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M:"F@D$GHDE,>)%G'2/\36LJ&O*03Y#BI"(,K$&:<%"7K[4-'^?$+$3*1O2*
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M,,%T9 2S?5@F@1+#,!M06'6#$6^PDA?C,2-3+U$!"G(C:%FQ2PPX4>FT%)J
M-A5P%[.F3$QS%UX&$U@A-T&S@%NV4(DV-$Z&%\HP?_('.5$C% 3T,?/7;Z41
M61LC-TNY4TCQ-)5F/:+S,0RU-C](D]*U%^S3-/WF/$910)ZS.$29:?H##?4
M#34)%J?#4!:A<J\C'?:A,J.A05'B&0&U:LI$.KUF3-9A(B(8%1U8'8JQ.&FU
M.Y0Y;Z!1'OZQ-/'#BN_6$W?Y'02T'ZT$'U&6/\_15VA&FI I_Q5?"7!TN($^
M4VC\AC^0I8B+9FX+-R0ZJ(=O)9?E48JO$W#T45>-P1C0 UA2(1X#,B;9PQW1
M4 ^F@#?<48H#QQV,F)N3=5@ -SA:,QV#@YA$\") 05F5U2(3(B')07)\TQCE
M!T2]42$58A29T".H\7*GZ3._A2!.0E,=,B69P#Z9(!-1TD)70B5+@J ;8D/!
M!4%F0HQ;,AIJ$EQ6PB97TD-@PG174B8(.G1%A(R-TD1/]$10A D,P8QN,"E;
M%R>E^ 97I"AHYW9IY"EM-T;KZ"FC8BCYM:-V-"<J,8T$]BHP@PDZ:BL$=BPJ
M47>]4DB]4BR()V&-ERH,QGC#$GF0Q/]Y_CA*U.(N"$DM 0D$[&)Y"DDN[/)B
MX;)*^T(OUC)*KU18Q+$,&W 0D!0PFR1DT\=D;LID#=,2O20MPY25C%8@>V:2
M2),1*@<7!002C.@0'&%CNO$8%?B$V>=N#N42!\$^0+%H(!%-[,=^(6-KK24>
M15,T[6<2:..:*-.:(.$#?[,,<@,WFW$V<KD7CP$6^JD@%J$V5I4WBHH5 K(3
M =6649&4!%<0""48<GD609D4IND0E"85G_ Q+]%L"@=3*9,)XJ,7"36#\<&&
M^L%-KA,ELQH>J--7+;43%;1R3?."W@081:@3S_$2_ 8*( @VY,=SNB$^^K _
M3R.KMR$Z^U?_J3^A'*VZ4KT!4RN"(OL*5[!1.@R24WL!,[VQ =$W4W YK)O1
M<T&95RY%:9>Z#[*)/X,3/!=K%-"@'!K4'\@'G0V2/_31(6_3-8VQK7_5B'>%
M0"4$6ALR)=\Q-H2C'FS8B<A*$/@Y'1S"GUS1&S(KB:6(B9>8BL#*'SXRM$OG
MBK\(=1CJ<]:57)9%)E;7(U-B)C.47$9'7,@(HK_()D9TC%?T77$K7MS%75,D
M4=>87FTW)Z7(C)!B)@9VM.DU1N\%1F;W=I:2=IQ"$,PH=W)G1I_"*CN*1RF:
M'Y@ *P[FI+_B"8DECGADC[CR*A?V1[8"2'G"8.M2>M[BI=5R8I)T_V+A(I#O
MTB[=(DD+*2^AQ$G_>#"6QTEH2K7!MBP@XV0=^7SZDA&69[Q"0V5% (?"*Q2,
MM@P$$Q)Q*A5P@#3FHGX5\;N(@ZAT Q(DB!7/!)2M%6@(L85ZX90Y(6;[0!48
M Q)CD3FM!0WV-ZB=:JJ5VKX7XQ58PW.UP;_&FE"L:)9H19G(HSBMU3DV)5MX
M80K*L3BD<8=X,5><%A6'PCKC2X",$5@77!FM)6Z7R!;-@1,3N*NR ;Z2PSLK
MA3;_BQ7ZYF0J&S_AJCI%I2"O6B#"2@0GG!7D,:K$\5'F<;Y[86ZTIC]&NZ@6
M"\+D(X;Q86T>)VR'J %+L6T7$;1(R3O N?\<RWF<1B%4\5$@;)$4T4D<4]QL
MRUELYW,BV[MKZA$Z,QLC.XM JXJ)/>>;J7&)TB=RB*E T>=#+N<C-0M$;KC
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M,1 ZJ#\,L9#Y0)!8B[_O63Z)M!"F>DGNV8^J$K5;<Y'_\RF2_@&V!;01(#%
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MJPLU[@O1" OQR.<,<^0&D^.BJR$LB9(RX@O/BU\6R5QFXB L25_JRR(VQB+
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M?!?)OP>WO8>,MZ?)G:D,DX #,!  !A #DQ"_6+O &CC.A5G.1FN(\JK&T0
M,0  R:B8Y!N%%-B19_F4V?\9NMJ, S$  ^XL!IK0EG '  >@ KN'N#=0T)K0
MQVQ7N0SXIOZJ#&B@"7.G @<  )D0GH&<=T<:FJAGR!&(C(4<NKC\G<HJG9EW
ML)8GCXU:F7%)@)7[PN);SA7LI8R9O-<(@LG;API8RX!5A:C;Q=$:>'Z;NP6,
ME=.KFAB[J]BKM63JR[EI@L>)J8_Z@3FZQ<!,M>7;FR-KU>OILKGGB+(X#-X,
M "M@ .X, #<0SATZMW67"6DMOF%-H;77E/=[>9,8INU+@+>7"6)P V8- #C
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M'@_Z1,GU(<:!)072)9A2*=6,)Z-!.XNR[%6]6,%R-=AV8=FV8>OY7/CX[&+
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M)A4PC4&,%R7!5!,<+K\!\6=S4B8 F_#==(5AO8PF$TP/P"ERU2<)-W-D#0]
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MY)"<MNF<G$SI/Y2:G]R>%*47]2<3JH/01<6 DRYI(F XW$<^B760& 0L$_L
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MB+;NXA^NTX0T$#-<V8CUJ#.(<)C<FCD(F4&(H"T?6A.&,!;F<Z?7:#_H^JX
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MR,,ZF3V-"U(Y A:7E BEXZ#NRAYC.9[4LA>#<">N@9?A>4RV.@COPP$]-8F
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MC5--**]B7*])$&S]1<O^+<*:A=K5W N^ECW%$C,>;H]0HB4OG:)0<:1-(J8
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MF="B)+WB!@X#*UWB4 %7LY@TX].(,3 )1F$$0-,R]2ASP TOH0& ;%+Y1%
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MFF8.25A0X:V>1$P:Z6F-$2,49:+_25/$G&Q? &.U61!J#MF&AHBDQ"(+B<:
M:)(BH61N&1J!@1CJ9R85:&(G ]Q;-/ EHTD$  T.HUH O60O3:@ !Z\[   \
M$A50Q*<>H @ AXA!D=.<IC8J&)0F5H"&7&6H36C0!$10$H!!+0Q-T=F'"?45
M1+,$@#@@.0 .,$*0&T0'03$ RXM\$B^SF!!Q P' S'   P6^CH$404,FLL>]
MN?7-+)H0PW0,$,0_500C, C 4@QX (LP*PWQ.HDF1H;$[=6Q33.L8YDB8AT(
MR>0\+E&70&*7AKA53@Q)5,OA%'=)[;0D*VNB&Y?. TJY56D9< A"7^)@A(N
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M/!I-5!C^KDEP !V &R816A,# N@<!M7%4.:J"+$"*I,;5N@^C#2488SZ, X
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MC.@> APHHBBY[A&#@6JDNTB#+9"?& @#<D(_&_LE\'&HILB$">,<''C :-C
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M;(A? JF&V1RST$&63(/T<2:5=,DW4(9Z6/^&AIJ$-,BG!T0L6C$Y'"#*^@,
MDOBECA*#-+"H%(,(,: ?HJ3*ARK*>OM)]//)^C-!C% X?$J#HNR_8)K*$NPX
MB<(*<5(&K&$- ^#""9$H\5FJ\3*(3*BWKF*2^M,>@^F3JWP#%RD2+5P=&#1
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M_RS# &9;FB;Z-+(P9^(SUS&:?UB4&1>)A2V@Z$A-L%[-H<!(8PM)PU6D3F)
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MR"9BUN%"%HN]K&++]9EAJ:54P$>05%A?7EXS^@8Y9J2^1<=W).7TC5Q=?J:
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MTP2>901@-+Q! AK%).! D(V7G"X#VQE,[6GH2)S$P+@/XHD!* !'X*F&)!P
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MZ13'.=:QP_QTGR:^5*;2M4I?1W96U*IQ9892%QFO9^":8/=5B]KA<HKK7?S
M.$LA5IRF2FQER^BUN+#:((H$!"&FNHI46$MMM.C#%\74K%H#V134'@G9HL4F
MQCX+8IFU!"1^&5!Y<_'LSQ3;)6#UIET\Q&+VVI*H_ZT\4F1>&VQP[(J8LQGL
MJS8:'+4R>];$L<AD&+WS"RNUS_H"MEO+Z#'E3'BI)R;1L8CEU53'IL:.9"(
MN#/ &,1*20\QJ&BMVXU:[\DQ+X(HELE<@2:&H\Q3?VHT&;N2?('=IJ?)2BYL
M!<X317*#&##;7 /)1 Q.!^"9 (>"=RR8?BJ<I<8:UF27#3>_PN!07EHYM< 9
M9#7_M4CKB2H:MN0>6Q$#%17HCUS<$_A&#$#0V, YVWK5XZPRA.*O+;&LX&VG
M6Z/519=UY(98,K2_@R:8L,9ZB?OM,V):NV.7OQSFVID.["A.FM->BJF-/>,C
M2=04]'&QM+E*3W*'?6V9YO^(BV6*55LPRSW_T'I0^V.=:%LGR'\I.4R B;>?
M%9WPKTSTJ6 E>LX,%&EWA:HSS1RJ62I5&76RZ'(U5)8<597N^5Q=7X<.5LIV
M1,1>'><Y=5.EE]^B:2$M[KAO.IX(ZSAV:"NW<8=&5ZO^8M;X'O)9E;..C3_Y
M*4P!$8-2.5N O.4B,<! $_6X 0"Z61HQQ& %!B WFEX/@Q7,WK&O5\%YB4&2
M9: A!BH(P W0T/J#O-Z6LX=EP%=P@(9G8KGBU?UYF_D3X)=.#-!WUD[2H )-
MI"$&!P" &'KGDTS@(/BS#ZXF7A_1-'2339I@WOB7P;SH^BZW#3=  ,+@FTF$
M_^#_,D$Q)H%WZBT&,F$V?./U2N<&WN\@-&$%T$!.]B$  . O5N &B $'8""B
MH \CAH_]./  A82YGD,9Q. &=D\,E*$X " #Q4#\1G#<L"]W .7\IN<&)H%&
M"/#[ ! 'X$\3;&G_5( BSF_W O J^*]2-.$(Q:\B8L  -+!T8D 2VFGZQ  4
MBJ.>B $*8P"9E.'_IA 'B($OP$D2-&$+#&#\-*$F0&'W%&WA&H>&-L/ X"+2
M;"/+%FG(\.-MEB*O["OCB*2^*,((3"GF#A$1=4QB)@6U E'/%BE!V"OJ0(DW
M,$;G#*M6ONZH)DE?U(;*8 NW\,,]HJ1Q'$QE3J1(C IF_THQROHP0]0D1 C-
M*V:'*(;$JA8ES(3NB JNE9X(5T+HJ7ZM:7X*\%A)9H(.[-)'Z38B+XPQ3B;M
MXA*->(S#L?#FOD@NK$Y+IA!(< PFJ]@%D9Z&&;\"7JI+-2*H;%YD04IK2KBD
MJ I(U>+@.LRC=?3ES2:Q%DL"=$:M5>I!&0Y HJ)A#,B-390A_,3@#?[OO'Q#
M!LXK#=X@!G0K(\SKO-Z N6( %!)"&;8)(<-0?V[B(-\ _"3RA51C$K8)#28!
M)[P-(!\R_&*@*1J2W,!/O-I"0"3A *0G)3<P!IX"U\0I#3;P!T." &, #=*
MN8;R("8!!@[@*+W-VW(G*=!@#- ,0 S2 /J4008,0 8F ?Q,1R32 "!CP"*/
M)3&V\BH5$KWJ(1,.0 =_1?9&P@4C<IP:*KJ:X^#HDB;OK_Y48#!()W_2  TB
M:IF.8OAN:1)XZ[PJ$@8#DB!V9R8/,B. 3R<G80,/ ">( ==B8!+>0"-P " 3
MLOWN<AFLLKJ@01G SRW3 "%V+R)%LJ'08"(!$@<L,B*932%DX""1\B8:,BTO
M$_[&;9MP(#$!LO7"S\ FP2U7!ZI\B,6D$;_LR&GFY]^FB(S*160FX]^PIZ=&
M0_,2_Q$\PW.%;*PVTBFF/*(9"\7,3-'#A$5"JNY45(S*TC&0PBX?1\5]'B0_
M<R91T$216"<=C61=S*(E?*GF(B6V\G I\*V21D-DKBOP4,Z^6N-9;*Y=DH:J
MA@0W7*02W:S8K(K?3B,KJ*4E9FB*'B?9;.,UR(PYW>C5:A%TVBC1TJ[6&-%1
M4 <<00-#(&-##N]$<V[8_&. QD8916>N6.>Q&NA$6H*FKL/&[$@5[8R*P.OW
M;.G]B#2D@B,3 $ 'DT/@H ("T2!%;@F9,B$"N2<B@2(%)3 Q(@HG@K#<$")-
ME\%,9;,JYG1?<,#[)J(Q/^DV#Z(J5W T4I#9+BX:WJ#YD/\)(<0@ -+ -W8O
MNFQB2\7 -\+/ Z,!URCU)QI**O=A-.4.(4!A!5AS(&!0#&S"(G8GNJ(!)WO2
M8 0D$U2 5.6T)Z.!=.QT))Q03H?/;$J'!7,K?]S,5X_O $ ""D]'/8SS(#@0
MO0XB#9XO)+P- 3'5./-##%3@#0@B#1(5(:)/$HPU@"IB!G\U&D!A^" % T,E
M(TH'3<>O/AH.*M:T*HA!]NAC=] +52?!-!%B'\ /O6PU ,[+)O9!$PS@ ,0U
MUU[F],IO9YYFZ3IE6K3'OIHE.*["S4 *&>$MHV *\]!3YVQ,/$-69!W&/$;(
M\SPMP1Y-FD1$A)ZES6SKPE3$[+C_)".$47Z" WG<$[:F;*KBQUD.!V<<;8PX
M2,I^J2WPT$[(Q^XD]'/HKEAVIJDDK6>GAHM,!M7^YE0P:3$"A<G0Z-6.3.^D
M"&5U%(M Q60;*[)8S$M&#' X8VJ$B67I X'F$XJ0**7X;<""B YMRXL*1T3I
M2S JB/3<D61"9Z]0-!Y=*TN'#N/$924@$\+ [:I,"S20$RIVI_SV 0T.H-R4
MQB+T-4[+#-?JYTL&$_J44TP#(QJ>E375I30V!_UJ<!^D!_I4 B>K4!ELR4*@
M =?$U%26 2?%5#,*=BT'4S8M@B"0\_<83,XT @IQ G73PY:DDDN&P0!T<!GH
M%28-9-QD_V @NJ]UA4HL[;0J,F(8&K5+=B\C=F]'-Q=[=5<K@ ]9M^  ?L),
M_4=W#E CW/0_Z!7A/A< :A?V:G<@_G%[@4]X-8)X0^)+V5)_EP->+<(JD>5+
M;*DWX%<EF*M,AZ]+8'!:I74G7@_^WM1=V1(&'/,@Z-=YM/<_E"$ /M*-?N1Q
M8FN3ZM%@,BN2<DF]%.C%-"M";/04?<0\1I:(BQ@\R)-'B<5@D*;PZF)N#DFC
M[G/?^D)$4%9T3-$7YTOP?L-I^%'TMO:@%HD_/REH]H=;WJ)$H>D_AFDGTL.7
MF@H/1T+)HD-%2>.[= ARN">*!:1'5Z490V6'@4Y9A&=MR6MEN/]JZ;!LB?$0
M0B:WY!H(=N2#C$/,2\)X.ZL19BGC>?8ITRZ)C'\,MCIJ1?REJASI-=#*DD!O
MQKPG([X3(H[ (9!+;92.S^X,_0;**1?ERD;"7)M5W$C25J<G^[(09&P5^U22
M*/R5*-H2O33!]H@3_J""&(19 "FB08^/=X""N31!*MZ@4>M!5'')]P9J9\&W
M3%PX#!:U)JMB=;ETN1Z80=(@ '20MPB8(#90$V8E)L")32&R6<<T@*)!.3OW
MZFSUF3.!& RB*FZ5@MB5( !RJ)@0!Q8"(-L8 L593Y=28(DD"/_5H4>'_WP"
M41UU'PSV5R\"!WBG7P/@6T_#A?\9P5+_)!HT$RDC,ERC807TAVDF2/RNHJ$T
MCE&=QU^Q IPH=;E4VG4U(1-J^@#2>:8WVC# CZ1!DQ@.8DNUCW$>RV.',:0X
MHX[<]EE09N^^1HXO3VK PDA_"I$*T8C;VJU="TIU0FGDUM *=(F([(N)Y.KJ
MCM_>BT(7A90CCW)[ZFZ_S(?O[E:>I9.(@MOL8DI\)]!*"SZHL=(RC1.GBX_+
MAU(6Z&9 ", 69[$<B?" 5.VHA!IEV.E0,9?J"CU)1F*?V(LRJR\Z^V1ZYM]T
MF#9> N0TL9*[RY 01QSU.&?KILJ*JF7,LH?H,*O8*<ZT!L:*RATI1'*N@Z:0
M!''(K!(K! 9W_P_U>,).8.7U],^6QMLG]R_VE"\A$-7Y;N_]Z.G@$C,-)*&F
M<: BE'/WK%0Q-A, ,% "TU@OHG(PF <4>N-V5Y<K!3,Q$Q,*BVT@W)=[,E6"
M8^ JY7LG"1( <BW!!?/T6!-S\6898!"9DL-@Q@U[>>L-FJ@BI*=WNH_9T A2
MQ'+W !*9E:%@L3<C+-@BW-5 -&$AH^'@;HA.SPLAO&TA]!0'XGN<YKLB++@G
MQNTC%6(P,2&8#6"<*'PDF0TGD15AT_DG(DHX_B\ 9&\Q [(>)EB/-X(#A83)
M,T*9EJ'>CER^Y?OT$ X&:_;XCG#X[E4CVE('M4(2 D#*Z516-<+;5O^ECB>W
M?$8KLK2$I=)C;TSMBR2IERPG75SL?EKNK3/=B,GS99@&MZ;$1!>G\)1,8Z-J
MHIYSZ CK-FR%7;:OW826T'0C1-(BJZ-,= #EMP3F/4+"O\*'O"9"WE;&U!C+
MTTLE5E8+ZD /;8Z'#XV64?S&U:"819]1M;$4U]411V;E;7V]D6:#@E).;]E-
MT*C6F](Q>>1X'#UNB:F47^*35.B3BQ:TAG>DPUC9/)&L/%=QBB7-U\URU:H#
M9/_V;V$D.F%G<\D-S4"+5L4 !\2 X5^/<^$K$Q90=T]BX@$2?ANSX2 ,X\5
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MW94F4Y.84+\4D@855&8VP\#/091!G-ML2!ENXQTH3D3_#&9!LT'+>(ML[G(
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M')_K[([H;I[RX/[HYO[F#R_JPIX_,;_R)9_Q8P[FX>[O1K &<;KC_T2?KIL
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MO:U^/^O@8@P0M<4L0P4LS,S]/,.[QTSB # XP-\09H 3?J9D!\B,&&)P@!4
M[V0ZO*$.!S:,''IN,9+XV]-TZ$0A$G%XJANBZN0& X3=,  ^XV(2CS:9LF4L
M!GVSVF-&-CST-682,2B8W.*8&2;VSS&3"$#+R&?'\?6P,<1XW6L"]L#KH.&$
MQ(CC]1Z3.A@2+XJ,$2)G F!$R2Q/CG[$&P"B09D84)(U8B!@=L2 L);]$ 9P
M5%\.8]"_E27O:S$PP-W.5S+.6+$R:.!<%M-'F2K2,C) RYEL;.D?M3UFC(QY
M6P#_5H"_3BYFCIEIFF3RYAA$H@N13MR'!C73+CY:IG%W?.3Y5L RT0P#80
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M<RK '_J$IL)Q5LZL3SNA][AG7@"8,\"-<1?*^%J=$1Z H"I8QF(886+L M3
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M5<L8I4HPO8FUR""W;/(9E+DL]W*C6JL]=EF:E2$?^H(C+CJXNXJEJY&A?=#
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MA!L0J:KJ&Z/:&N:"H\HP.XR)!LQRKA(*)$!R%Q8"2B+4A.1!-W><'*6"(WH
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MX[J(M(S'^A>BY"QXS*7(0 ,TN#RY626@5"&N2L?]FA?Z@[J?8@R=:DUCXYN
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M^T_)<,]O&<"&2<BS M71ZUL0Q9^I@9A8?9N%TU2"@@R),1_T,;G+I"B9*[.
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M?2#5;YF$!JTP2=-,R2B\,),TO.W@P"D^!6NYP3$ BW0:,<"AG'FCSP4Q.#*
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MR*[[%4U!1S+,4-+S$E0ABG+708,!5(,7WSF*+'WR#*#,9)"8]&XC.#%0T@Y
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MF[R:JKQ@#+<S6^'I>8K]X=)HD"R4!A%)FBYT!X^Y[*-W]ZW(,H1 =*1XE\M
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M^?#(@0%H4.(7_SFD:6PIHC()E?@CP&@4542E,%&!-U !&N$.P-BEAP9R33
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MBD@7L]*5Z"1K!@[4&+,'WL @3@&_)6QD5_4TX#ZFN;:4L &/"9.VR:98K9(
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M)#"R48F,6C40'5D$!FB"S(^6M,05+HPOA:K'U'02#24F@VY94DB\Q""? !Q
M!9,[TR3DY*0PZ,5-PHF4DRA%-P.H4"<Z4@K\P"(C(N5I!9HP(TTTPL(^4D4%
M(_\* #TT02.$!&"!&SE &N[8PUCIZ3O#0%.GYE*5T !E*@'0G5>&,:^;4#$-
MFV/5ZAYIRE.F10>HQ(G^?.*]FP1&*'[IX($RT;X2*A) 4XD-=4I6PLZTYG?[
MTI]I(N(RXNR*;_NHS%\RTY"7O<R9VSI-0L(#&9DI$$7]N4N"2,.Q5 E'F3GC
M25S8]DGPU.PZ)6O,82("'6-6$US8P> 'E_F6@@G0-7,SST"PUJQN548[JFG,
M3.!)R[C YRW7(E.S.(A+N+23-]3*YLQJECZ1S>16<BL10/'BE,RL;!\M.]"#
M]I$2BQCF+POE)8!F$L"XA(0O_"-.0'LV,I:T)3#86B7_3\5R-)[HZ:)(:AV/
M_I,),;KM1G\"@*3$("JF$55K3E*JUZR"-#2L:6P#1!9#$=D?C25D>]8DW3 T
M@:.=B)-$KN%J3MJ&$#3(H&\-V1'3"@,=\/1*$WLJB0&408\G8L1M,(E!R@!P
MNQ#V-"QH.$!)8Z)2 X0T,PD)0^D,T(BQJ(Y[H1F)F[YJ@,8F-K2BS<GM>GJK
MB.02)Z.Q3%L^I)>X]"4D'W)6MO#R*_H]Y9O%(\TTAX6@F,PR(JKY[<RP!5M^
M[J8AXBLA^#K3*_9 #B<R=8XO2]B:S%AGMI:1&0:'<YG6X#8S:UIM_/ UV/_,
M!T6V30VZ'%NBX_HKH'B1$418_UM-S_12@O*)5\@"$-N<Y.5W@IHI7D*DDO)T
MDTN6$5I"4N*9ZJU@E@N1RX081P_EJ"D]\6*/F-K"EVY]Z*X?(B&!I\).O(PV
MQ3UY44]<@J0;685+8H(QDMIRN?[$@*C$0)(8194E'-!6B<Q!&CV8 T2US24B
MH'#(%MM:$]<P&&YA>O)U#I>02+4%!ZL*XO56=4D[2LIN'"*J2T(B1C\RF,J3
M>I.-8+ RPPAE85_>QR0;@A&;++:4*M:)4_]T@"V_851UY=_E-,G)W!Y2G=XR
MDMVFH@PQZGG/DN8AK29MZ4MC>BQT#6T,4IOI3X,ZU*)^RD]](JIRO8DFS#D;
M>%@-1_'!4N1R3T32 @TI)-"NY  P6-T2H_(8+_8D4I 3ER.?=(!AXR14"-''
M+',R1_,%0 7L\@K.7 .1*&UEC&8]CKC&*J!CVXFQV8:<V&"\5Z99I;JCAA-3
M"<?7A,3EV&)@R40V?=Z=S'D@GPO594L2JB;%(*3K'OBE2DOP@R.<AQ$1K4L2
M[O"'0]R4/XQX;S"7%C%1?!]\S#C"Z=%DCH-\:*H,.<E+_I5.)38BTS8YRUO.
M\E)'G-4KBA_!-^F0';K<TIE@:\Y[_A2#^SSH0A\ZT8MN=)ZPF.*1ZEE9.@WQ
M=,?QZ*.]@<"E;O5]5/KJ6M\ZU[ON_W71POSK8A\[V<N^$Z";/>UJ7SO;N3[Q
MML,][G(G^<CG;O>[XSWOH Z[WOON][^;$NV 'SSA"V]XG\+H\(I?/.-GE7 :
MYB1$EY)1N\(RW:*!=2R'N258+I\JMK0R.72J=HMISL/E2HWG7C/J.;_B^5<=
MAB6']HGD&Y]SOML^][I7O. CCL\65:\L.2R:><7BU+2(X:X:9)@=3=_6=)H2
ML<$+2_5(O,K,F\KYN\_XV[?O_>_WO>XD#V"+Q$D6U \-^V#A2%INP.#EAYXG
MI.>)]7%WO]6H/HC-;/WUU?T5\H-?QJE!&L !):A! 1Z@ 1;@ E(" SI@ T+@
M RZ@&F@"!?\F8 &^ 01F( 9:8 5.H <VH 4N8!IXX"3 @0B:8 .2H!ILH!ID
MP@6&8 6"X >*8 1V8 W2X SBX IRH S"X GJH Z^X 0.800:X0+Z8!)>( [>
MH!(Z(1,&X0W"00JRH %J0AI8H FJ 25DX %.@@6N(!=NX10FX JZX!BF 002
MH &^( 6FX0E281=>818"(0[&( K6H0-*X1WJX142X07RX!$*X@A6X!FZ(1@6
M8AO.806:H2)B(2,FHAH<(B1*HB,B8B5*XB(.8"1.XB9B8B<V8B8^HB<:HB:&
M(BARHBFFXBB>HBIB(@0V8=817+3 65\T2%\(A'$D!G3AV0JDQ[W_] 5G>$:F
ML(6&.0UQO=)N!(BU,8<OV9=[Y(]%P-1_#0=LD81AD$8SM@1Q;,IQ/<9L"44R
M$AB*35"\*%1S'%?]::-L,80MOI5E) 0VWHHNXI?_-$M?_$8PUDU8/<0RPMFS
MY",^*E PWA=>,)WT3$:$H1CSA4LO\19T%8LM[LN'Q(5-"!<_?<A?L!!OT2/.
M!>"D_= R*(-(CJ0RF&1)GB1*FB1)KN1)DN1+MF1,CN1+TJ1,NF1*JJ1(ZB1*
M[F1/UJ1*YF1,PB1/RB1+ B5+(B5/#F50%N5-(N52,B512B50VF122N50+N53
MKN1/+@-7>N56@N5,AF57CN57BN59&J55_Y;D3MYD4[KE6K8D5^+D4;JD69(E
M6MIE7I;E7N(E7][E7^IE7PHF8/IE8!+F8,*D4:*D+ Y<94@C ( 8$<W+?''(
MB<C><%C$5+Q&L\S/_I$$<\3481C+9H:7:DQ78&A$@@0/ A470\%6+0V'0!S$
M9H+'_+ >2?!%6[P/-!''\'V/R6#0CBS49N*&3?U'M B7HY4CBHS+7#0;9=(0
M=D37^%C7N.P0<WC88=R*^5F;@O1.L[">/.E&0#DGIZ2(MM#F+)U(IF@,:TH3
M.I%'<TA3 *7G7PP9AWSDWD5:?O)G?UI=[WU:M 1G035'L[&)P="2/?D.-[86
MN;P3<3@+B: ?0W*^16"L7+. "P79Q7Y=R72\)PT]S_&-$W/\YD6]RX1RC+:D
MEX%DR.^0V,?(Q7O.S'7L$(CFAX'NX\)@$+7L(_3<1+E4TW$(#6UY!VPZAWEV
MZ$UX#TYET+L,QT.EAC)$Q$[UDK<HQT5%"^HI1\'8:$,\E7__9EKW@>F8DFG1
MB=_ L28&+4P $5-?3$<T <"T*8?XM$_P :"&*9?RL>8 34?Q10< *-^ SBB\
M2.F\9(:<<EN[+->WP)L[XM:)5 Q_/68]8!="5 :J(,]V5&J4(AC\("KS/8^$
M8I-@7-2!\F-T" 2)'.I-B _I4<O]"8SPO,2>#FK=( P)*0=OS51JH &CTL4"
MN58)>4C\O$7PE>F>:4+5'>NR,BO) 6BFT2+T189:&5!?6$2NI-=QV1<!Q>II
M$<=Q%>I<F8MN>0]N)8<_2FM1,!AV[8JV6NN!9LKP/<^(20R*#E=1Q*G-=-"J
M1JGPB,MB2!9 VM-_N6MB ,W"U(U"_U[&CCT,&A20DXR)+]*H=#5H:$2&PA(7
MGT*I>QQ(/3Q/P=8%7Q38KOK6)/!,D/Y2KMY,?G376_A3LZ88'.PGS-)LS7X:
M8ZZ;8X[3AE3;R.R/#B5H=S%0N]BI7'3I=;P?K4ZLN1:';L20--Y-C,Z+T$*9
MHJ[)N]R*PRA:;T4JMNBH7)#>R:9*LA!#P/9K6,D%U8+'PPQ(=QAK3%S/W#C=
MT#ZIM]4-Y]W/V]*-8.@LR:ZMQJAMH^*KE?:JSZZM>,B,#"$3L<Z51]KL(VD"
MTSWNY%+NGJG!XRF'ADYK@>K%RU8G!0F3<E0?A.J%B'P33#4D3'@NB_I?HSZI
M"$'CT.Y*Z/_:5:PFX[?X:C7^K$@,5WSFSWYM[(M^TGX(BY\R%^TR)$'EZ];.
ME#(@C]X:J,^D!M..KL7.Q 71G/?0*E@]Q)@@K_ (!+Y$"Y;FJEXP*9<ZBVG$
M7^72CB:$ OO";_R&%LZN6SEBR^;*DE[44_T@*8K,Q8QTYW!\YIH<4+/A1I[J
M"@Z)9G71T"RQ%%\\)NL-ZZ\U!P##:WX82X4L9$ =AR]!ZDP\<#E.1<#4E))&
MU"U&E'()#6E6<+>$SW0V"VH,T_Q$+V2@!X/EIOY5WH$"ZG?ZZ\:"%6Y<205[
MZ+P(Z&&P9HIJ"XG>8V;.2RQQ)F18G/QF3N12\15C<>T\*Z9%:VC_I,^''6Z7
MQ!;V0%]%&:AP94+!7%3!7*1@O,6$IBQT,"UT^0N'26Q%UB,)P=?)&$>\$K!D
M/IA V&M(W%1LW?'RCICSB:QJ#"1R[0,7P..Y&JCA%D^OK):3*"0!?0=K:"-B
M+,UNI7&\P.HE:TJ>.$OQE4^CCJR"K-<]BH'$>%<[_LR#_0<8Q[)>Z&T6$XTF
M+)DN^_(ONPK] C/\JM_#Y>XP2YH5V^R.59.R(O,SI\7E0K/\SJW#;>?[33/8
MO:]/A KE&!%/G,DGX\HG6PZ1N@O_><6I&5$UWX1A,,?'B07*O8TWAX:9_$<T
M0 [G/%&+A $\7UU4B)$Y^T0<B8$XWX38$U*'-W]ROLFO,&<SS#*'XP[<=CW_
M-+)*+KR)BJS!0-3E!.5<]%/8B,P1A%4@"6AJSY%YA8V$!$=H2*)-RI:)(Z9$
M;QBP7FT0@QAHPG^X,4ZX":RUB)1M'6WNP[&Y1<IH#1J8A$$CDM5TS/)1!5-3
M\197]%13-=GQLOPI$;/(P$9_-$7LLUA<T5=O!!-C577)L_&U!I5A'$RPT4J(
MM%?@@) 0\#>+ ;.LM<9],ZLH-5D &]<YE;+"\4[8W#)  U'@YTXL!',(19#<
M">:,TA4[=%5+]F1WG3++4=3)2#Z"6W] CBUULW"4,XZU(XQM="H[1*ELS.1<
M*"/+1;O-WDKX38V(M61\]7UB)BS!0#3LX^N\VU;4_W'IE,8A102X-?5,A81*
ME\BQ.:R_X$! ?U6[6=G,A-%KSZ*]#80FJ,!$=(J@ (!' !GEK E=U75L[P1&
MV%*JP=*:B$$8#4D,7"C[2C-ER_=\;YW[\D08B?.C78Z0J$"67 Z//<Y X#.
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MMOP2S+U0"Y/,,LT\$\TTU5RSR=_8#&JYULA[D\XZ]<JD/COU!/+%/?W\$]!
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ME &SC1VH79R##!AG1D:P0>,&<#Q(MAHRP0#I$"T=*MJX-A:RP^&D*SW\X%U
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M1@GB)F3 +!%"'QJ#I#*A(+1F35O2?W9R)N8Q/;S_1+"BPOZ"Z1\!,RH69XR
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M/GN3MGWZ\Y\ E4TZ TK0@AI4GIK@VT$7RM!]:K.A$(VH1)<)!U).]*(8Q>9
M,\K1CGK_])WC_*A(1PI+>Y+TI"A-Z9/ZJ=*/G*4I^FBI3-FUT9G:]*8X?4U"
M'5*M , @ "$ER)Z&(IL8$'4G7=N( 2SZ$&(8H%K0B8'"#&( GP)U-I-XJ5JL
MJIZB]"4&5X784=$2@+':!%L+R418B0F-GO[TJ2&#32;V=  5'   6OU-)OST
M%X>@P:[[>LC#S/G0G!KVL(@M2$49,@D#'& %!X#!8[FE$+QJ8C;*"(!1*WL
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MT0! F:-$5,E B/;B:9((&X)P'Q8UFM##@BX4"$8$!^IPH F77%)&AT2<D/_
M_::DDC8#4W0R+0 F,2B&JB8R\$B#8*3(I8S(;(@8DE0D2,0;O!*(0H,RS)(B
M+PW:TD0Q;;JA*CJ7$D-*AM2L$Z<\'S*0RXW43/$@-^$D44B!_CPHT8=$Y(ND
M*C?EE+4,25142TD,"K2B>DY,Z-.)Q( A(U490L. 4_<,U$ G?RR(*HRX^%+)
M'2.:=:=2]Z$T*31Y''&G$A\Z-=2,9@JVH!MBL%4@7 G2%:%L';HSQ!@[!3=<
MT0R@:R:"U%P2)@.71!#="6O"%$E4E?Q2S1J91'#="<]E]U ETXT38$?[Y<O=
M!EF<4%&$_?61710=+@C*"6'R,L.)&T[84@GINF'_"P'S7"% :.;=A]"#%E81
M $E&VI?$=$64<4L8EN27YH$DIG&?&*1<>%1OFXPX64WDC%,,,IE4!D:+ES5(
M8@\E1G7GA;.$^D@FO1VP7T%W;G/)JB06]&8-EQ22953CM3;&JP--L4$F";3T
M1QB9)!KL!#D.V](5*ASY2),/HI3%I8G!6: ;N!"['G$79[RP#2K8 ")[2T:U
MVGU@#M-;E6#VMB:N0X1TH,_WL37SRT=4LT(6941[I#1(_5+3T_>D]-W3%6V4
M6!6Q))WHW#,?MB!*_TQ1=0"@T=U7A$2,1O<-DV_8R3<),K=+ P;*W7:=#_YZ
MQ(0%&JESPQNL_41<>5]&_T[.&\830P"N[UT97,7P$P "T2:H=KK6CS?%JE8_
MG9/BE23VY6Q8E+*<O&!"J? %[4'+:IFE3.<C AU*<*2+%+WV,3*M7 M[Y(L:
MF\0VJ621L$C?0E'HJF<A#\&H0BDBT)_4E*E>-<Z&-UQ+$3:P0S@\9%H:/)U!
M#*0X:0DJ3Z]BFNCJ%2,U$9$@/Q0=74(F+V<9+H8 <*('XQ0J PUC']L"U3[0
M-$.Q*6-RUO*/F=HWD+YMCXTG4I7&#)*M'BFI0AI;7Q@_MB'. 0 '(]19]V+V
MI9&IA&A%TV/O:O)#,F)-+PL95I^PF#Q<=:M8>\-3J&!V.(+DJ8&(Y*22N!0\
M4/]QKGIMA!Z_G'1(.8H/?/M#8?(:Z2/X'0I& F13J9HE1A'J3UY[HF,2B8;'
M6#(L?[%D$?(":)+*+:F*.(1F-,5BA,=MX T.J6/T>F?,("V/;(KLW?/ )Z5J
M=;.3SD+#"E )OE_M0P9A,!S\-*?*3FIBG2@JB:I>M8]9B>@@:%"!0I;&)2CR
M$XX/?"8XQU?&@:Q GG6+Y4':]JU#<@X'\#R=(9T5 S&,S%DS22"):O*C?<YJ
M77MBZ-@621<T'3"6Y"K(WP;63?I13U!.VP=,@Z:2X/%*(#KET(@F&,B=8J\D
MZ0PJ,28XK&5I,6#[BAN;1*0HF>I,4A/,W3+!]] *Y3'_5[T*GDS-A\*L2M.L
M9UW*#HOPD*4Q*51F\]!$J^(N+BV+DV@(&R(%<D:Y;I-N:CL2#)YY@S]^L5=>
M-=#S#F2P)7E%52ASYK%L.M,#[7)ZS*P)FIKU";=BC&Y\,1O23&A5A"RL'CFK
MZ"1C4-@^6@T-L]19#,X8IT6F\:^'ZNS',F&C&]!EK(:K$(R<&(-?)5:(SB21
M5CA*O>OIJZ[*E=0RD>JM>H1TK]_RZB&Q%L7M_76W\ZJ>!=FT)-N"\UH$/-U?
M:PA9[846:-";8J48ML+UA6F7HD1K?O5K%C"B**\7/"9=NJ57$=7#  FM*3,+
ME2$QW)<@#M;9ZZ3EL11VK4ZP_SW04 $IV8'L<R K[*2'.$C+@01+51YE84$^
MQTV^+3:BOTQIA(;QK8[-DV0<1;%1AWJBZ7%8HB2SEA@FD<^]'*Q!4,SC<NGY
MU1#[:$<_!*.<E-PUGLHSN9D(G0(I=Z0ISQ.-_I4O@IBJJ&/E$4TE.M;HM'HW
M)D,X@XJTKMB4^>7M&O2[1P+J?O6\YZ3 =G9=BFZ?WMP[#U'H> <9<,ZD51(#
M]&IZC9:7SPBR6A+.V:F')*-V[X2F/(8I@9^:;E 1--78PCB.QEPS"9-V:.JA
MD*,@MO"'*?JT21)VNZP<491]ZR$R<JW30$YDA\G%I2LACI>OK+3RAA0J0N&:
M8Z&3DSRS23P0<IF,E/1;@1L.\C=<5S&/@BX6S*(%9CU>RX,K4%!4%QI49VG7
MJ[I;]9S3ILS#P;K5!0E>@3$+853_\]G?_^Y)6>E%*4PIVE*?)-()\TK">\7(
MX'E*G:HIIRC7&>2B2H(3_L26J1.16INOXAV)JO*[/*EQ2 TZ59YPT"HEU415
MIVKG)]_(HKQJ;%T)I5Q7+Y9:&>& PJA%5;8\GCNTV:YZ(=?4M8HEKV1I;W[U
M&VYT&5@2A,NI>.NN>H6(]BE36GE=3@RJDS($6BM[F8+@0SG18@ GB\4I0$I'
MU=QZ-TH%94B<NN.+P&4ND)'1_+B*NKE,UBO/OP$O60('>.(5'Q/TMEH9;>4+
MU$*%M-'YN=43,J[D._G>#3KSP 9!%U\,P/F/O2M9^AHOT18FI(4I2A_?>S#E
MJ4Y.5 4IPL<P[M+%##)ZT8G0@?;+'-/T'7J3;<EK09U0Z/25L\MZUD,H*U3O
M/TA$7(7^EM2.;GIEYS+,_["W;8-VDPHJ6D7#_HMEGW3+)%;#.I-V?.;GOM&N
M>#P/KE[<>3J:>G\&@"Q;OKMW=YF&8I.RTJZS\Q9EBA:)R;+%8\ &+(MW<\"Q
M(*6/Z+<(M, +M*'>PL"R&+"/\*<-!,$0[!08$D&Q2#"/@)+H*\$59,$6=,$7
MA,$8E,$9I,$:M,$;Q,$<U,$=Y,$>__3!'P3"(!3"(23"(E2+%!$G@3.G]E.6
M[%L(_U,*-%"8!LD$)VR(I;L(IQ*H*)$(8+LN)F$_C+'"C4 \B)!"A:@J,EPX
MAOA A=# #KL:.,RMD_-"CF@EB5@!%40(U / F*I#(P3$\^@/?!.4*Y&J2>J)
M O0+5(NOB1"NC=#"!'DF,9 T":E#O%H(#0N)@IJ("MPF/12)Z'HQ/_0]?#ND
M9%HW%!G#(+*).X0($9$W-#P4C3N(T4.I0,1%\D 8(2DK:)D7"#2455R+)/HI
M84R54:P('TN(;!J(N9&PTJO#$]S#/^R(YNO$=B*A"0$[,F0_TI.UEK'$0_*7
M^_)$B;,)8O]\141D"!"S1E+1GER$Q_*0FEA2,ZLSMME!KA.R&0L!F'61-= 2
MF!(IEF4QF[E"%8-1HL'YF,E3D>HQFX(QOHX[/FA4D!\1+>Y#H71"F#J!$65:
MOW$BB.M#R+0)1^RZR(&@JZ 2 ^-RI7)LJVP41XN)KKGQEY&,K879$)ND'_?R
M/4S)D%AD.MB#D93\%PJ9P+3!O&.2G_&2$OM)+DF,'S><2":!B:G2O<U+2J0\
ME$2)0Y@LM+;J)H/IP\E"B!DJH7A$2^>H)A^ZGD\JJ ^D%'21D1YY%2UTRC]+
M$HTQ@/N9-7CCKC"(';K('+0)@R,CFNN;M*I8%R?YO :2H/?!H+'_0SL+(;,&
M4;(K8;C3T8H%^Q;)S"FO8$G#NAV29)^/J9 _<3-I23C<*XB1,9N$,AT $KF
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(<[_[.0P( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>advm-20221231_g3.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g3.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MOO-Q[WN=]EZ6YM ].FA/JO;KJE=#;3XN[:](]MM2JI_T/DS@SZQ6C?6HW;!
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MH*BG067%/14<@/.YMT]T#T+3528 7J:A;L*=IF$1B)EF6W@%J@:*/EU-]Q^
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M2Q#_Q=[=$A# 4C!534M$XX+EC$LH!1!PHUG 4H/5CC*HS=6<B% 4TUE\B%R
MQ6,PDUDL%V! TP\806-QCNH5!AQ@!QPT1MM(3CPU$SC5D]:(AS(%EF;$Q8?8
MV \HT9G9QH> 0CREQ1364Q&$0NP(AZH<R.D%"C@QS3) @R:8BZ:U'^U "81L
M69'QAIE4&GAP$PR="$1:U(D86ERH2'U B.!%5(Z8R6/0WUAUV:'A!P0]FOLD
M8;%Y!^RM#^]5"D\*"5':1KCMPPY&I2;@#F(DB&0((%Q<X?P\B R:RDHY2O4
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M/U:OA!!=D'3\D8:C&?&AEHY&7_D6QO2<N8E:%:17LT_23Y0)(BM,C<>E?HD
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M SO_JHHAH"2P_FTJH:=UX++=1%4KK4?=*J!9,R2PPBI]M0,QCZ.R*" YNH-
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M 2F 45K2EJC_- =,?$E*9*JK6_6WI05J24M5@F ;X#1"#@*63Y B% :!H*=
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M^L"TY(@1X,&SQH"&8:LI\*",R*FI(@ T:/@.Y'D/.[B0UO W^H@<?>BTUGC
MQQ@LWPDJ^E T.Q">VM@J>0,J%82,":P>X?DT@A.UV^H0#W2/2F.,::N [^&=
MVS&W#\$X\GDLMNJ/8BDA3-,2=7,U@LNW'[A =JL1-6E!_>.A':'"Q_@$ @K
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M*(4B2ND:4JZ6M3=OA6P)G7-7VB8V.LO9+0E=Z&$PFN>+)$YOARE<8=@B&+@
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MK%2E>>IH])]B_[1!55YE K):5:ZJ!,9&43T@!?J.6$Z5!? 56)[&KK6&[6S
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M2\( 4FS6'!7%6" ]D29^8RYVV-_MG;'8(MN9$AGM2XL]GH1J:#NR[;-$GL=
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M5%&&X,- !3(P0S1"$1$<."(@47"!&;P1D7BT015U,((<#*$;H,2D$0(I2W2
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MDBS+947-15T9-YD.UX76)2T?)RY7V(;^8H9"IT<#<1$"0YGJTB]WJ"V8.1$
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M]W#H-3[NIKP)580>8ZI$/2U-U5C_!HMI00%]C$O(G6C3:)F'A,HLAFCT=!&
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M/#KO\+DZ>"V-B:10"4@D'BZ0>VXL= 4K>"#F]][.[:=_N85 Z8&XHQ7X*<2
M+U>V*[#OTJFO"#HK.L>/G2HO>:_/YFYOU5Z4"KM_>'H_Q^,0B2>OS0X2]WCO
MIF5O8%49;$94_9?;>QA&_WUO/HT;D($(DG1R*_M4BXNLZ1(9YW8+!U/G4PH8
ML/GA1@A]</4D\R15,_D(9OQ3W>=RQB$IECR8,OU0 <1)N($W*F?>3QGY=K"W
MYU(#,0"]#$"SB $5,'^8>_T0%G]2C?ZBO*$Q;HKG>Z>VQWX@I,0$=/-O P@
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M&74#A -*.696]1%')IIIXK><FFU*9)AU/,8Y)X_::8?#C7$22:>>=]:YHX^
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MWK O<WB,;81<:9$)I?(I_WF&3%HS3%91<X<#&[5=\XU_1;:SC%$7]ZK71-)
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ML</4$4K>62?^A!7)KM')3,8?_=HTC;BRKH?.HB,M&GWAI=(5KE*BSCHF<.
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M,9T!S>+.=J22.,TGS=DD*>.41/B%JH@H*YA$VN,\,.YK?BV)S$Z 8LD#J(A
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M,1L*A8@VD7JS&(.SV[.-U*0,GH.-3'+-"EQ$^L#+?5 9P:#-?9@$C/_<2\I
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M!)"98^L!JP[@5DW;[FJM G!/'JP&+\.\/L?'>8N.2NTGE[_EIIDK?XU!YPY
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M;5H$30PJX#!1)@>L ")6!B 9PYOA+7/IRYJM$-X^*BCF$(8P-%7NO9=&JA@
M-P2@0L^J.N>A9C&(>&_/1VJ&T-%,(W0 SEA97?(^FN!,8VD_W-<P3&':5L'
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MJ_^C(PP1$S7$^,TA]+#00_PFQ"@BTB>W*U)%;+=(@@PDD4#9G23+ C;A)5%
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MLUJ*H=&:SCM<L#8W9\AM;E.&2]'HWJV%RF6L8BAT,AAP9DUO*I%WQ[>8S<%
M(FB0$'H14[JN.B>(_[A=<6DRRV**T/7%&>GH2/_Z$;,)R%?2#& G/^H ':/-
M).:LI-P:L[V*!--:C#7?*H\RR^O N)D*F4HF<*G5*/N2R8YMR*+D-S23+;9>
M6EY4>.:W9?OUV(AXI2UKZ0O2NWPR+R46ZS(FIML+;"(UT/!;#D6V)R >=X].
M.\Y.!X65'@DS9V&YV@>QNX\;O DJW[%P0K&:.<LU4YB:X9.@TX"S@^X#!SA[
MD>4^MK5(>8TT],W!_E8;$A\,2[!'Q!(%>"Q8O]K& 6\CLK-X]YBK- 04,I5T
M?(!*$5816M!&/8X^4%8R+4*-9E+37$6!:<A])*8P+A.:HA:'T#-2YE(,)?^:
MMEEF7::Z3L;J_@DQY#:)=]=*3G-.DS*8N=&>Q'C=%0$>CV^SR;T&EHGYR:2:
MIUE86^U:=V%NWPH4^RA<JBHY&Y)>^W!:D- "@"SGPHB9'^V^=JD/:8WZ\VB+
MA"WA>,^TF99$04 MJKO^^+[\ :GO"@[?UM;D?P-[<1S(&8$\(S9#U&H=&J^R
MWZ1>4!E8)%>.<FIH%W('*RGNXT5Z!I6K %-"V\4Z1A W$165%]M4 R2;Q+Q#
MA((Q-4^T<<#=W,2%99.DH40;?<=J6%QAB*(4R8QRB"&6Y([X[#LS=--].A&K
M#]XYP.XZ3P-O8:LU!*MXNXCEHL?<>J$,%.+YH%'_1X/0 #Q3W\K+!*RZPY.<
MSBYV4\[$>&PV29&+WB+5E+NM_;U-CN@8L!^I]3;[=Y*$E_(O^FC,<TQ?<?%
M$B'L 5)QLO6M><5GRM"_TS$[KLPS*R0R(>>6.\.L3(6$)^3A">:NNJ1[E,J&
M[O+U* %I FN#%7R)!I-QSS?6F4-[C<\-J<>E .5'T.]#L_V0((E%R>C#D5#$
MBX27@AF>16 %TC"% 5"()HC1UE0@646:SC#-88S!I2Q)@&%>PRD4N*6&^=%>
M2,7=F]W>;+G:2>3>E<#?:XV)))G2D)$)_E$$!(V15#"69GQ%-%P*HNW#/<&
MU@0-I^T).Y7,1%'+X5&;_]@!@.9]&V=H@N6$GD,8SM==BGM$X%=$"P\:%:)1
M((+%G@%=%G7P!#,9']R,!T.-QQ7.%>R5X42L8'TPS+^Q&?HUD=O9V$P4%G
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M'JWZ[5Z_L<3+JI3C#@:]R(LP,1F=-I9"N$<J/^7&08IUF!E[E% GN@LL4P1
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M'K<ZO^#4(6CXUTQWR9#QPG>?RBGLY*3)N<.*9(NO0>KF7-6Y*XT$C)'CI$.
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MVW567=#!8'#/C%5289$X_2PFJZU6FY-,9],+X;(T3K ]*_8F+B\K 994IE4
M&39.EZ8BQG7GIFW04$-C%U)5!Y/O-E4R82\']1 DZDS\,O9D_Y'T.2SV-BI-
M.)85(I#UHZ0+):&R["C4Y&H5/'&%7QG')DX441$U$Y*V9BTC)T>N(H$,2#^V
M8750-< 5#HS "+KV:[T6;,=6;,LV;+NV:^/@;(\ ;8U ;=,V;-_V;,V6;,/6
M;LD6:C5V3ZV3!_75-?BS/X3R32')&9MH::-V43'#)@-.C2+C!FX@!D@280\O
M,].4";56T^X1%.]RFW2S:<4/2Q%70!C+22NB%J$45Q-2(#\1NBZR,-P6"-0V
M#F(7=F67=F=7=MU6=W,7#MB6;7?W:W^7=X_ =HO7"-:@=H\W>9%W=D47(I:1
M+.WU!D<T9;&G^/KP>38S;YWW-QMSZO]LKSV&\_"DE*((4-IXKEI%@U4![&@)
M#5Q1Q5#;TW"X=TTRU$:I5D9;]U9O=1\GS@&VER'>5GB#%VY[MX#9EG:/0 V.
M@( '6( -6'=U%PAZEX!U%X(?V()_EW[]+2Q[SSA_\F4]D7V!%GH >(-/F#)^
M@V??SV<35%Y8=QM%=#2OUEY9#WN[J-L^]Q51F#+\,ET#-'##,55)<T@3@X!I
M]X(G>(#A( @*.&R1%PZ  ':_%@@0.'D7^("C6&TS.(NYF(<+8FCJM5.KMS2R
M1")8+E[O-72^F(T%!)AR!S)N@ L@=PA;N*'VM&])>"^5%%Z'--3VPX0_Z$1I
MMHT5@WJ/\(6?)=8^(K-YY!1Z\=<!AE4F9A>"?[>)C>!W$3B3T_9V&]B '3AL
M01F*E_B22[EK3=D()!EQSW1HG+0 F;%R"TP[%2N2"]F6+P,SU-&GYC!A]XR,
M/79_9?ET^98OTS0C(&H9Q$\^;YDRC!1,'[8;:5A]YW1,C/B!D5AXE;B+'_AW
MM[F"U58-*OAW1_F;R[EWV;A7JW5!Z71E-<+H+HJ1ZX69_^=YZW@CSPAV!>TX
MH831>G\Y' /3AB52[Z#R#@L7BFQBF>DY,<H5:_]C%N\0T'0/CXET@JIR)]"6
M@2_8"+"8BVEW@;\V",*6=J'XDDFZ:T>9@C6:DI>8I:,8G5>O>N]7FO;N,A7Y
M52HT2RQ:H7?:*/49H8+T!E6V/_D75EUV6GN+D'E:)];9.+O05O^3T"#ZET7M
M,-06I5M:>2LYBWVW:S<Y@@58=[&8=N,6I$^ZK&'7@-EX0^'5^L0Q7S<W5E\S
ML92:KGNZE^GLY$XW3N_59?]KB+$OD.N:N"BI8YGZ7(./F'727L&5K"E9>:<8
MK#^Y@)L8J[FY=\-9HYDXI;UZ@/\CF(U=U>MFV(,-C!G]FGKW0Y4%>Z>5@1A8
MV[67J([O^KBV,8TM,C9/^TE)NTY-0K4Y[U/'L&\=<H1_F=&@F7.K.JPQ6;([
M&IR35VZ9^*R1-ZLWNK(S.)PQ6&VQ60U>.O%L^W.$.T(=3[2YSS-ZV[RKT$MY
MF7*->C3$V#-HFL# NV-7SOC,>^I&%/\XY[ ?,HC+LGH_PHCA%H,A&'FY>HF5
MF(NYV'<].:2S&X-)6<!U-[!--:[E54ZE&F1-L^[DV_$LU+Z5V@7#5[W?3F@Q
M7%UK6YJ&>3L/4)W_\,-#3BPS%&*5<>Y@F%='L!\1PZK)>J0M6)PW.ZP-W(E7
M>FR[.9O_/QF++UEN.?JE*0@Y!U>_/S@1#1&F+^K%Z?I#IH)'^(D(?7J;9M%3
M_UL'F]0_]97X(&EQK]S/?,Z1GPNT6UQ7(;F#91(QR!JK=U>),9NRNYBZDQ=X
MB5S)O59NY59WN5IWWW=1R^XL-;5(5T+&63E,_0/CU'RG%==&B"(Y5)"%99NX
M"INT,2V/F?-/O= _T8[2$4Z/R[QD5W)7R!=$:QR(N4W'DSNR%=C0ESAY+]MM
MC;R L?F;D9BR@_=M.UF#O[B1;:70I-H#TSDSL>W4%5IRD@/K.%WKO#R,^IH0
M9?FO*3HPJ_;[GEWDB%A_D=TX&QJ2M6W"HQAXQ?J:5=K'OSIN*K6YD[%YR 4]
M>*_;QZ\;"-CXG1ETV0G[@A2;4S&3JM/E8?ZB^>CH6 \6W/]Q#R%^PCC(@HYB
M>[W#_#Q+'9'A-!-/+E<:O@Z-$4AA\WK/?+3#^Y(2P] W^X"#O&L[F<B5-W<3
MW'9[%\%Q]ZRY&8N+G8=!T8+H<EV=:QBA7$W3Y5JX!2(^X5@Q0],]'OVNY;WT
MB^+?SGY!QT'U%]N=RW+]_2,FG.DAIYU+>RZ%OO7Z$ ?9/(OJNS#@@).QVPB0
M6,%;'LDSF*PS6^;7]H GV-XIN,F?V1M;-I:QZ<#^F"#Y ]$5HZ>6(W19YUAW
MN.L=GC 2)%P2/_VL'8K*,X0_@LTY*JXWL0R3IO&/:SQ)7M3M<F53P]5;LB50
MGHOWW+HS6H$]6>YU?:7S''CC?GC_;YZYV3BHD1&2)_)E;3ROX]O%4\4[W.):
M[@TBD@,>/Q\#:^3.Q&#I)Y_:>TN@5Y=]F;(02WS0QD2&_9HB"I_YF8E"Y[SO
M1[["99-O/3SM?SQXM;FE#7V+=URR;[VKP_GU);N*M1CV7SZU:Q8@?CC(,;"@
M0((/<"1<2 $A#@<+%4JL(+$@08<1%Q;4>!&BQ(P5H^T;2;*DR9,H4Z:, 0!
MII'Z K14IK*DLI8W:NK<R;.GSY] @PH=2K2HT:-(DRI=RK1GRZ90BV+\6!&D
MU8\6LW8DJ#!KQ()=MSJ@^F#L@ZAHTZI=R[9MT8I<$X(M"]?L0[%?Q7:<:U:K
M@XUA/<XE_QK'R!HC<(+ ,5(8SI'%0!S# 5*8<63#B!4C9KQ9,N+'G#T7!BWZ
M\V8UH$$7=LNZM>N3!0'[G4NV:]7:9?72O@HXM\>$K_?=?$J2)0":.UG&",Z\
MN?/GT(=FFH1F)+'HT8EC;WK0K]C;<@GRQ8I[(N[9#G]WU;>]O?OWV[WW/I\^
M[D..=M7S_A[>:]=Z0Y&FFA&H+5;8@9\9:$1J"B*HV1$%4D;@@),5IEECCTE(
M(6CP=?A>#N?5-556Y<D65U]4-91?7G;UM\QKPP%0DA@M3;(3,2U5Y^&.//;H
M828M$0> CCZJI5V10(U'%XMXE==?>E_U%YA]5SV)Y)589FE21__XB:6B5BI6
M>=^4\W%$@7RU#424@IR%!J& EGE6FF:)*2C9AFIPUAAGJ"6H6F00+JB&EH1"
MI9Y?3/[6%Y4F#J1BD[Y9Y5=@P>%XY TMO:23 4<6ZNFGH*)D:9 C91KJ49V>
M2A)N/N"''WTMDMAEF7<)EFA'+ZJJZZYI"21E?_)1B55<K:9IGV"ZN5HK0= $
M*)EFAXW6X&48%HB9@ALN9IIG I969X88ZFD$K^2JQ&BRY$E:'Z)4[69L;UDY
M$%R,,[8DB4Z9K " &.7VZR]V--XPW$@T+G>J,C$0^5.JNDYUZZ+YG<M71V3)
M*A^\XN7P[\8<[^2DDQ"[Z]NQ#LOW*W@\!:T)J)W7'D&@N&[>*=G*URH&KI]]
M?IO@9A@NQF;'Y9)IVY,M?IPHRF)-3)MWE0+ :4F8!J"I2C0>!_35_U@WU1*
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MQ]_-G+TKIM8"57W7MYC*![:5.HXMIXW*Y]N5#KES'$^.H>@YS+UZL[U*/,
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M L$:8L714Z)SDK]69+KPV<71D[[ J;F'R+ @(L1;)#P3PYH5A,(JBL$@)!;
MF@A>2QK26CUIQ!)J))9V@\9R-,=S1,=T5,=U9,=V=,=WA,=XE,=YI,=ZM,=[
M,<3'?-3'?>3'?O3'?P3(@!3(@23(@C3(@T3(A%3(A63(AG3(AX3(B)3(B:3(
7BK3(B\0/R(S4R(WDR([TR(^\C8   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>advm-20221231_g4.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g4.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M$(+0A5*$.<_ADT/W7-&+9:>$%:VXGT JJ.L&6F,8#0FBMV-1D#PA)!D%#TG
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M>X/Z=+7]B;W6XA4O7*V!J(<:XKAM\X'TG+3YD] T.1D,I L-?(SF HE1 PD
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M@ 6J^[&4!VV8!OH4+=7.?IS C=BR!QH4UI)'2=L?L5#0@L@?1PM+@=0N^PG
M?<@CF.TL4^!1A]T'.- @]1,-O^@)AV0J'.J(E#2_E=C*DQDU-8W T'"TA(N7
M3U@&:'BUMTA3OPB;_1'3AV J5F-0[9K_TCK+":3E1WS4KB4JN0TX+9"(!JL5
MOYUX"JP="-#P0KJ(%TA]*Z01#HQP-.@@"ITK4JZ 2H,97%=1B+HL(T<ZRM7:
M.JOY%/]BV%%]VI=XTI=@&9MPJ]QHKG&1++>%1_\"43;53J2L#M:BFLEEU8'
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MKRD5UR:W&F$.QS 2V@B6I#,__6AGF#H,#)YB8QTNQF8UR]#_VF4,")WH-#%
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M/(VQY*57N.6H+(M67F@6KZB*LLT1B<6JD$+69B_51O&KA.CV0B_S)HM_)(.
M6,712 ,D9*:.;J6FP$+XH#'RB!'Y..NJ#H;6*F.!) G5=H:RH ]G).EH>";Z
MD -G]"@ZSC.UL-$W6LO;%N(Y"/(PINUM3D,[O/&UGF8_X0^V<H.YF.-MX@9L
MB.8[W@/_B&L[-,G<S&:4SB8]!%  _09P_F8A*;)#)M B#40)" 1!DF"8(L1
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M3E6NYZ $"FTP+!M"+5-."ONDP8R.3KQ4&3K,2QDL&M!T'TP!C<]2Y;I6HGY
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MJS;%51I>ZR /[.!!_,S42ZL5K@N!JT7&!>J6[!!=?'T(NTA"AXRDNM2E_HC
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MLL8AQ!13B2[##/-'.L0LLTTWRFS#3"+F=&,.+LULHTT[^\S33CSO%-//.>?
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MV/^+7W$!B1(-XS7J4*=A^G++2BY3%8WI1BQ2E)G10*,2GV61;C8\XW.LLY@
M<<PP7*S+%J5HL3>>!S@QBYA$:-.AJ^'%+W4[8U\"69TA:N9A^JF.V]IEG;!,
M9SHBZ^*_QL.8Q3Q-/9_9V7E@TR&WD$PPYWD9X0[FEMI YF3XZ:3>.!F72)KG
M.G[3BR!#F2!:7C*58?G/?OJVH, 9YVS( 67C #<AT3DH0SH)D6E.A#F_'8DQ
M)#+<ASR4.=TIDW$H.E*%1*<ZS$FI1JE;$8A8%SP@Z:B<Y3Q1EI24I"JM$YTG
MHJ?F9#>E>!Z/1>Q$GO*,]\\Q:8]Y 5W>\RRD)N\5;T[_9>K>$!A5(S[5B4M>
MLM-$,96]0?&)>^"CU*/ 5RE!8=10>)H?GN+'ODL8J@W9DY6H2M4_(^"/51-1
ME:U.]:M/,80AIQH(J?QW*HX(A*<-B4A$#O(KI]"*)16!H5&%Q1"A/.2"S5*)
M"ZO**V])9" N3-=,-@BN>5V5A47<2A&CJJY$J@2'* /8N-H5Q"-&## YO$@@
M29:L+28,8H,L"GF2,[&[O45KOG$CP[#6,:N)3&WS\2+1VI9%?-4K:N#)BMI@
M(YR'#8=M9GL;>"+[FRX69F=T<\O0 'L7G?6L:93ESVA=*S'NB*:2[:D9T^AR
M2_C C&P2RZ1LZB:?__#1.Y&-L Y1Q%.XLD22D:11SM)N,QNXR=:55*O-T(2I
MG[^B;;:]Z24PBWG*82YH0#H1+^>LN<G[>%<U,BH0>0^DN,K%#BP2RM"1V'LA
M\GY3FQ#B)NE:=)W0@7)U&2*0BK@Y&0WUSB[2_*\XD>1.U;WN1[K+W9-\5SIZ
M]E.<8^)P] #JO"]Q.'EA8FB;R-0][UG4H(GR4J#LA+[K/:I\;KAHGC ZO_9A
M=%)SXA3[>,PE1CEJQW<Z_Y2E7(H_@NQO(?U[Z4L+""M5Q>I_$ZE@!9<,98@,
M1".V.M:M&/*2+WN+(1\LR >7"L.!?'DHYL(("&F(DQKN,*S>\J&W5NB2.-?P
M!V/QB5OWDJZ<^)F(=<T)$>.U$BRNZ[9!\8@<4>,4A\G5:%[,6E3$V!A(YR5G
MK#W-0W1#%%!/S#Z3]%>^'+O%KBB&KZG\)=#D J]^L6:-5ZPL=^9#V,JFMI4:
M&V07&<E*K%628G/T)*^S.-SOP*R2K22EUT8-2^2(,MB161IRK'T@Y5CGN,[E
MS]?<B)=46OLY]+%.>7JIG&33=KNV95IH.B9,[Y9-EA+KC7>U(SKSB,A!=L$<
MA__(ZQYM&HYS_ 5XYN(Y&652LT;DE="%/G0Z9HJ(FABJDN7F2:,6S:Z<29)<
MC7)T3]/I;G.ENQSN2L=/)QTIXU3ZDL4MKKR7LV@(:-B2\L#D8>8QU*#1,RA#
M&0H^$*.84'K:*)Q\_+[N86IZ.CYZ]MS7"2YQJGV=PH1)2\HEF>:45#Y]::VH
M?*I:A1U7!)0R3Y6:P"ACN2+-2I6R<BKE$'Y$)2.L:I=?F!$SJP2J52[7#[-J
M%*^^\(.#SW-5R>-W1">^7(N9ZUD5VV<]W^LM$NM,4%*9K*DLY[-;86Y>F)M)
MQ#RL-(;]S\..$\K6Z(=D87RE&)U#:R4N33Y\DX]H;_;_$Z^I3(C\"DW3I*8Q
MW!/6UYF%)="636NMH9:YEX2CJ.M6W?C<;+B&C9HGK:;ID.'ED-E]&:]/KY?'
MEB7YA/&.YFV)2#_Z;6F7Z74OG2C+0!:LV^!N]V_+;Z#<H*UOL.%:&0^'W%Q:
M#_= +L: IF*R-_O@+WXSG9(SG<K9G/SB' O1I@F1+]MQN ;LIM01D73Z/P3S
MG'(Z$MBIN-G9)@CDKP:A)R'9IW:*DB51D'!*,"0Y'I73L ^[P1$3,9NKGH,Z
M,8$J$R* $SM1'J/+GC9YDS7!*"#[DSV9,:9[%*?#E$J9NHM"%"YQE*@+J2R<
M@QVKNE9QJ5FAJ9B2,B=S%5)Y_SLP'" N.Z#_Z:F!6#*H,B!=N2"6L(B7L*HM
MNX@,.A9BR;.M I67X(F_PP@YVQ>O8B(?DB&9<"N;:(S$BRMT88U *[72, H9
MPBQ]D;QX>0A#6PY.W(NRTK4J\B.2H9GT@YHQ.D5IZXJJ@*OJJ(ZH&)LK8@MI
M@P\C:J38$PU:M*'$&)K?4@Z(\2W:TZO ^K23.9CU( RLH3VB6!G:6Z1N>PU@
M5#VW&"_&FJW_RZ3XH"2]D(V2B22,P9CI&Q#>4 [V.P[92"72R(_=HJXL6AC1
MHS]X"[^ZX3;Z4P_K>@W_,!#TNS>\\+^_(20$\0L-D [2B@Y<FI!A:KC\4AP#
M3!P1L?^=\*J2LT$P]DJO%<F*S2FP 7LX]]K &RDY&7E )PDGC/,<'0&2%5DG
MW,$2=_(=QHB2D/RX"4N2?>HG%X0PY-&G"V,>&P0QB9*H+R$Q@_H2(9RH@Z(Q
MH&,HH303C I"/XDQ,5'")FP4.YD?+G&?\/FQ(9.4K#0II(.?*T043W$R)0L@
M5QD5FMH5-(05H;J5*/L487F[MWQ+6-$5-\0@0'P6OGL[.S.S/S26A( 69VFS
M9ED\FABK/X0AC. 6P?NAKIJA0^.J0=,SM-K$G/&A><DKHQ LC%F7EH";*[(9
M7^RKS+@KSRB97!L^I]"_F+$7_FNE] L,::--:70.B!''28+_&NZR/EJLC+&!
MK8XAHL?0S5?CHF\DC-0<+LT@#DI,)"@"/[Y9+&P,1TTSOF 3CG2$KN%T+2?*
M/F 4-ODXI>JKO6HDG/"4O\#:3N,@&5S+HE\[-9SQSGM;FGT,K 29FOZP#+F(
M/R=:F7H1&WF3&O&:MWF+0%;BG/92R"!!D T1'6\JD/MB+[L8N7_#+QL1N8S,
M'!M!L"&!T&7R+QH!' S1G1$DD(WD'89C'=Q)2<W90)6C28^;49X<GN'1)X(*
M,1P,,1-S@R1 ,:8LRH+R$A2#%.N)RD QPCY!'S\!2[#D2BVT0K)$NI7:D_5)
MJ?>Q2EPI%5+A %>Y'R9CLJ-J*3+\_[HJ(Q6# ""%^)2Q8T.\VQ6*&$PJDR#%
M[#*C4A>\4SPF*A<DXB#$!+0WB[/'C$S([%.W<LQY<9>0:,4X4U3 \"M_Z4R8
M "/42%3#V\6@$*1%92/G@XR1 2S=!(VM0"U>:C:_JE1.XCW F(TI0HNLJ1?0
MZ@S=.)FL::*K2,W/LK10K514^C0U@IJX6!N.B3;D/$COJ"-K@R31*[^6Z:WG
MZ"SH> S?6IG2ZRRBB,ZA =!LO<Y>!<?QLD_HVL8#(:VR21#@")QFA)M&8AHM
MNC:R^27;2Z;RJK\";3><^1OU6H]Z R4:0= 'M1$)41R0%!"&-#@474D4B<!K
MBLG)$)+.>?^1DF.2BC,P&,2=#\TPW>$OD7,2S7DPDVS1=,JG=W+!W^$GDMW)
M*OD2(!PH?QH4F_LYWZDH@+(3.2&"0+$QB=*H[7&>.3E*-.F>H9M*-Z@Z(),>
M2'%2]YD?]1G+(!LR+NPHK.-2_?D?M?S2F&H5)2,5,U53K473,JO+BKA+88$6
MJ5JJ*L,(.[RII9J(-'VS.XP5#WH5*Y,6.#O,P6.7O_PJHZ@S'WA;=A&,;V$B
M&?*KM76-NV(KM *8;PD*U?H8<[D\@FFLZKK4.1*9@?&T5OR7_I3.4Y2^FCG-
M7YV91++-R%)&^_C,UG(:S=7-F3$D9*$,.7)6X>R]UZJ.JNB.Q<+_).%#O\4B
MC9\A4)V9S9.Y#N/R/\NM&WK47%+RC%*SCR]JK=MX&5,\1O4,O6ZS35F*KM.(
M)/50-N<+"X'T3TGR#>RPU_SD).&45]E;I;/A3TYZ/9U M[D!7@&S5[PY)GQ#
M6$)ZK\1!6/):6(K3-X,=D<BAT/YRIR+!+]DQL U\,)7$BPS30 O!' 3K-\WI
MV!5QD!A\N91#8"?9V(7CR>,!G@T487]J@YA;$X7JL#R)6: ]DSPQNJ;4$Z&,
M2O1A4CA)4D@A%$P0%/C12A^[%.E1J4PI6JA#E/II@U)A%:IU("1S,BA;LIIJ
M0YORLBAFTT\IEK#=PSS]E3&#"*2Z4\54_XEI"5LZ>TP\(SQ=H2 T^RIJ6:&N
MTE-RZ=-]F=0Y:Q<5HI<7DL3?=(U$TS/&RTQ3+*,_[D;.RQI6_8YD<9?CB$_5
MG2+Z/-58':QDW!G0RK1SQ5U>JJ7.U:R.V;32Z%4]HF1.RL1H6[;/6D^BF37X
MO#2><31:]8^^Q4;"/9J^ BQI)5X!?<=4M"74N!KM=;?MA:->TXS"*3U>#E"=
M$<Y3A:7F>^3KL*Q=:D9NE"W@ (YDCE]A/MV\"8M?*AOL*M=<,HYYV[=C$D@#
M&1$ 4U@&[5<!+KG2 4D%K5^.55 "(TEDDIW\DI $;B<(:5B95)(:S%@%H3 5
M7#@)]% G@1V.D__8WZG8G]Q)B18Q'>0P@6J>[O$=)0 3@GHQB:HHD 9:GI-*
MH",?(RQ:E.:Q'*/2I 4I1!FI(O/A.?%*EZ*I,^S2,$S+)*/B ^*RLQVS5CF@
MKSW380&5@2B(.%4(N;TJ/W7+NUV6M@V*B(#J/B4\-I/,E] 6C'"AO-V70+TJ
MU@@BQ=M$-F,\4+SJ/46C7CY<TF3<O5WFQS.;3K*8._(DT%#&AHF9AP"]J>%&
MVEP9?;'-^'!/Z["KJ4%&2@VV\D47RDBBZNBMOG:CFYE>/V9.;+VD,6+>L(@*
MXBP8W(U>A5DMCDG(:PL96UY>=6LNZ2KFSCI.[C4][/BV:K9%]:"]US[R3U<R
MW]3(MGGLCV'%;5]&-GH-P&*6C@0=T/Z@9GL[+P<U)OSH7Q=9)_@R+_IBP B\
MD0RAX Q-0 Q,G0JE#H UN!]!L- Q$0<)8139IHHKP MI[XR4IXYEP90480S6
MIYBS02U!GANU:)9-2J&L$R*-RI >*#FQ$.[9Z#;8:/)90D!A<*7<X?0I:1<3
M6BO,'@L_%*V\,2O%E$ZX%@__<! /<1$?<1(O<1,_<11/<15?<19O<1=_<1B/
M<1F?<1JO<1N_<1S/<1W?<1[O<1__<2 /<B$?<B(O<B,_<B1/<B5?<B9O<B=_
M<BB/<BF?<BJO<BN_<BR0SW(MWW(N[W(O_W(P#W,Q'W,R+W,S/W,T3W,U7W,V
M;W,W?W,XCW,YGW,ZKW,[OW,\SW,]WW,^[W,__W- #W1!'W1"+W1#/W1$3W1%
M7W1&;W1'?W1(CW1)GW1*KW1+OW1,SW1-WW1.[W1/_W10#W51'W52+W53/W54
M3W557W56;W57?W58CW59GW5:KW5;OW5<_\]U7=]U7N]U7_]U8 ]V81]V8B]V
M8S]V9$]V95]V1D\#!\"!9W> :)]V:*=V::]V;+]V;;=V;L_V;M]V;P]W<!_W
M;R]W<3=W<C]W=4]W=D=W=U_W=V]W>/?V:=]V>Z_V>,_W>9=W?M?W?M]W?P]X
M@ ?X>L=W@V_W@I?VA+]WA3]XAG_XA8]XAY?XAJ]XB)]XC+=XBK]XC<]XB*]W
MA0]YD1]YDB]YDS]YE#=YCQ_X?V]Y@7=YEG]YF8]YFH=YFX]XD$]YC]]XGJ_Y
MF7^#&'_V"H#V'\"!!_ !H\>!'WCV'*" '"#ZI/>!!\"!IJ=Z!RAZ!\@!J<<!
M'!CZ''  '_AZK?_/^J[G^J/_>J4G>Z<W>J2?^J6G^K6_^JB?^JK_>JS7^JDO
M>[1?^J>7^[SW^F?G>ZC_>ZM/^[Z_>QR(^[0W>Z17^\+?>JAG>@HP>QR _*.'
M]J=7_+?_^K;G^J&/>K('>[0O>\SW@=!'_+@?^\/'_,1'^\O/^[>?^K"7_*0G
M_;R_?<JO?=S7_=S??=Q'>[%G_=]G^M!_^N&W^KXW?LH'_N+G?>9/?N<G?N@_
M_N G>^IO_NN??LS'?M9_?N%?_N^W?LH_?KK_?N0'?[('?M[/^^I7_O27_NU_
M^J1_?J:/_OF7?OC/>NX7_Z0G?X# D<.!0 <#"^; 8="@PH0/&N)XB)#_8,*$
M B]>M%@11T:.&SN"_"@2XTB-) M.1 A1XL.# Q,R9(GRY4J.+2DRC&ES9DZ'
M.UWVC/@3)TR?0H$6%7J4:,VE*G4ZI0GUYE.C5*5:Y9DT*->M22/Z*.CCH8^$
M97&<39N0PMJV#LJ^'?C#X%@<<W.PQ5%!(%L'/\#*!>Q7\-\'< L?)DQXX;[&
MCA]#C@PY(I$B12A8+K*A\@_+&BQO*.(C\V;-G2MK+D*D NC*H7]\3DUD0^?2
MH2^#5OW:MN?:NBU7<.VYR(_0LT&/OAT[M(_;O''+=IY\>.KFOX]#YSV[\W+A
MUHMT+Q)<L_#MV&-_+NYZO?C?X)%'_UW<O7'6__%-HVYMVK)P_IWU.]??<P,*
M6&!JY!VX''W]*8C=<PT&F&!N#C(X883*60@@=<9=N.&"$MZGVH29N??>?<_E
M5V)^I676'X4'8F<B@OK1:!R),<;&WXBWI9@CBSKR2&*.(LIVXVU$S@BDCID-
MB9J-+4;(I(084CE<E>]=^5F64UK9I8P_FLBAAF%^B.&)%9X)HI@(FKGF@QFR
MZ>&+;98I9X=DSFGGF!#NF>%Q?XH)*'TE_B <;<>]IB5^N17*:&6/CO=HH:41
MT>AQUETJ)J;,:=KI;Z.)2)!DHY+:&$'0->=#9YAIT)FJE6X6W ^%3@K;#Z,U
MBNMHH.[JJFK%O7I:H?\5T,I9I9CE2ERJEO6*6Z6BT;H9K<6R5FFEM+;ZZ[6K
M/6OMK*UVZRIKM#(K'KF- ML9N;C-^FQRN))KW;3/CC=O<>A"*]ZSHBE+&[_N
MRAKN:L4V&EP%N%HK&FW8SH>9JL19Z^]HJT&LL+ 4\RMOQ 1OL"MQX+K:,<2V
M9GQHM![;ZJ[(#)?,,<H@*XPPR;N:#.O+\:Y<:;8TN\QORKXV]S-NF,FZL\7>
MBCR:P12/1C2W(0<-+FL>!SPUNT]WG+.LN.'::JLB(ZLSL"('/';03P^M[[!I
M#TNQP_H:S*_36V/F]-IU0QSWVTM;+;/18<]\=>" _SURX2PW;;BOA$.M>,O_
M2-^LLM] UPRLSS OB_C1)U^.\^2/<]ZUYX[S#'GGDI.^N<VG-Z[YV:%_C+.Z
MF],>M..WQGJ[V"/#RC'#M/E[+_#J#B]Q[#Z[.S+ROL:KO-(4#U2J]),1JS#$
M6E]Z.7A DZ?W>WR_9[=KJ1YJL=?"?MV<Y+1])OIGX[V;.\VX%9[U^LZNVEZV
M8F?]+VM.\RMK*?L8W"H6'. A#'A,(T[NC'9 Z[A/7WG#C<ABUS]0Q0TV!J38
M 6ME- I&[33_8Q;[)KBST(2-?2)\3W*X91E678]BE<&,M(Z#F<H<\%F?P8QJ
M#LBO]T&*A=U##0PG)4,*1LQ9^I)6^/CCP]$ L8="_XP5$;\G*2%J2S-0E"#%
MVC?$<IGG5TW,HK-*"*O*8*I>:'RA%%VH05[]2EKI6:/"SH@N-#)'C F#7[GV
MARXO^B^+DX*C'8V%*C&"JV(T5%^U--@H'D(1?8KLHR0?2<E?S?&0?LPD)+?7
MPS N4HJ)?" ;PQ:WQ%6-:W![%M[:9C7QC3!^.G3D;""XO1J64);<H>4%;[DQ
M+RXM?Z9<("Q5&4RV<>N5:G,;OXY)-+E=;80>C.&XW!@SXGS2/N13S]J25CZ/
M@2QA;[-6W%BI117F;I'H9*8 _2B:MTPOGOL@B'D<24!U?4UM#+2.U?Z#*^4I
M3U@(Q*;%\HC-KPEKGZ\1(_]KLN4KUFQMA28[Z'S.E3OE=7"-MGJ-L2"J1^'!
ML8!P3%_%-%@V43+/E[.S#@_)E=&1]?)T]S3GOYAGR*V%-&S'HVG7E <SBKG4
M9_K,G[J VDR,"C6B[)K@0Y'Z3Z4BBZE'#>I3GT54J2K-J=A4:E5!.CRK3I5>
M0MUH4Z':'JXRD*II?9\6][.O\;"F?XT$SG90:!F)FI2$^IM/O<Z)38J5\#\T
M%.@2_1F:N990FZ9A8F'+]=>*;H>-_L)87JVW2X[ZBX(K)* V%YK/6DEVLZ -
M8$++UYFM$?"OF8658\O'0,[T)C/?:=1D&9A4L$9U;4U5ZVEQBTW=QI%Y!N7F
M7=/_HU?"HFNXC+6G9>-8TN%F4F.V!94]UY; @LFPH99;6[AHYT=T\LJN)S-H
M"/EE7IF=MUS-,Z_3-A ]>4HO(F%5(TX#Z+&6G8^*VDV? #6Z0]Z-+7G,3!Y)
MN_52]UU,/?6-VO*^9M7>59!G?K19S2QXW_*2BZ3D4B'RM)L\4I(+@ @;88=Q
M4R^M>3)HZQSAUOB+O(DN\&@3M"H3(_DX^\ITD([;F.EFB;H?4BY928N=L7)&
M,AYSSL>- _*-XQ="0TZ.BJGKHN?RN#J=.KEFN?PF@*%Y4I214Y4$0V;S )>\
MY]%-<.8<9M_R1LQE+FZ9L73S".UVPL]E;G=YGIF1[TRZ;#ZW3L\K.Q\TJ553
MD5VK?2+DE2,G1BPT<A-4%$"7^MIUF8LU$H=TO*$(#=E)&6*7O6+,LYJYC.A=
M%GFD%S/UQ%!]/55KR[2>9#*2ZRA0A.DS>7^$*8.QFS\^-G.!O;R;8^<&0KMZ
MKW_&AN-<</\ W_@Z -39ZF]A:XSLCXKQCK[:H':O9U+8+INN'$[.1D=<6,X@
M=(YCDR"Q)SNV-[*QG)<]LH*OUI[^UH:E,*6R.8>M['+%[;L;-;")#?FSW*DL
M6<M#I$VER4QB0YR9:#:A8-N3U?U!E%Z1?;AF<1C-MA9P;=DR\5$QKL\.2C&J
M@_6X*4&>02J?<[MZS'C&W7U4'G80Q14DF:P8J^)_:MIX BTW H7>SGLA5./O
M7MG-AYINI#?UG\C"]U"!JN&E9A7#0+7JU?_I]4.-RZ'9ZCFNR&:QHX4=G[W=
MKMEM=[:T'R]P5WWFQ O*F<V4KX0$S/MWK%/!_K%VY'0/.0<U;C7_:9)\XFO;
MVDL1G_1W%[3LK^,P62D<,K9/GF25-YN%%1JM!993NX->M]U "'!APW%J@=4T
M\Z)H7=,:RZ8E[6ZXVOG.9Y?*('H%L] IK#QFLG@[^00@:D4GU-69MU:Z3K'R
M(FQ Y$UPX5%-GDY#C,W4"YBHR5/S"M%K2YPM_&S.L[GQF?U!R9LLC]&B)<V/
MS6=[T_N0M-REJ'>=87*!&OG/ZYP8.2WC_2=9_N18_EE.L/&?.27<&JF1Y? 4
M[_A4N:F71E'9J4$? *Y. ]J*NFV/T1!;]4&97OD?[2G?3-F7E:W0A,W>-QE4
M",Y5(M$2 4G:)<T2)K$;NAT;_214=AE<_WH TKMX$L&YD0W"&XZYDP[.5 GQ
M4">Y4R?Y0#\%#=7H"KO@"N \8=[0RO/XRA*"T5SE7PT>TB$MT CZH"59GZ&9
M&]50G_*863\M$!86FM(%6QG.X/;AFAK]'G%9X$RI'HY9EV2AEQJ!7<$E%O 1
MXAZBET'@'JGX@%]PH'A-X)F-FV,QF[=($192VP.E7P@-VA*)3@-='A!-D[S]
M6QWME[<YV&4!5@QRV",V$A"EWR.B8B/]6P4-UARM6!S!W 16FA25X'EQ67J)
MFO:T6 $"T,#ESR:FV<HXHD=9GL?5"TFU!R1]50%!6 R>V)$QX[LY([H5((FI
M&';)HN787OLY5/\<,5C-K=<("5#YB&(!]IH%[8L')11G"=^]V=)>>2)'L5MZ
MD-=A_2!A=5 FV4<H^<MWL19<:1HVB4S_<!,345;0,5=(G> \?EM)^15UH908
MT:-%QM1$:B0OX8LO4A03/9/Y>!L[1E9%;I0I2E0O_AHW2LRX?17D02!99>0W
MGM&XJ-0MF>))NN1.?E8]UDH>,60]Q@]IV2*?$5U-\A<$]ISEG5 ?;@VH"8X4
MH5A(>9\D:N7K7581*$0BCHI!0*0+>M'GQ=6N>4^RX2'(=1):.9\<_I8&JLS"
M393,U!@)%=5*P1[]R<SJW-%<V65*Q9A=>I_ZQ9Z1R1C^;5?"I1=?4EW_,0Y?
M 95>K]D1'[(>7G;4J!EFIA'7[BA90OH:-\;:MG':95X@7_)B#+::\PT9&%83
MD37F![Z8[0C,'166"PJ,\=B:I@&F0YJ-N]E/?34/80I57S)EXYR24,T-)78B
MF 59P8V9\;72F>W3*I$,X,0,> E0L!W3Q+U-!U[?*M67]YA;*W$GVDS>-I%4
M5(E?XFA/KL >TQ%@)M';]UG3 NE,2457/^Z++7FF]M6.SYD@?>ZG+_;G@.IG
MQ=RC=,U'>!U:[8G@S(V:5EJF0-&>+*IB3R5GQ[&87\5-AY8D#Y68SKP76$(&
M02"F7YI>LLB=P=4F= I.:8Q'*)%=:&1+MN -_W08&]/8U=FLDSCZZ/-<4""2
M#6^V59%6RQX^DPN=$J=\6T/RJ#Q*RT)"4""25)$>"I*V576!IO[-'FF"' ">
M8L?56_R HSGF$622#(S&57-V7N*MZ$!!((RN7$T.%)UNZ>-!(]3]6UIN7<%Y
MU-$M3Y]"TW8NYKI-G-<EYE\%7Z,VG;%5D_:Q85--)_%$W$MVJ'.>U</I&O")
M&5@%3G(V3Y"!JH8E' =FY[ETGNR@ZC:!57(*Y_*YIXI1G/FL4%01&JT2FTF*
MG-J=4'M$G,,AWG1ZE*U:3PK9$[$"*Z<*ZU(I:YI!*W=Z69BUW.'ID[&%6\#5
MVV0.XDNBI/:%S!U6Y?^+7ABV[8[#K)Y]B(J)3L8#Q-O6K1ZFVF! DIX$=1*J
MU"61)10'$AR836J%FB:8GDLM 106N@L</ 9ZM0HH/(8F1$-C@,)H.$9Q*$-C
M*,,$X1KGE!AZ^65F9B5B<M\FMERK0(/%:J>.JN$^WEJY\%#%[@,H1-0'59]Q
MN:&^MA'G%$S)ONSK@((^. 8H]&%EPHHF6&P-VHICP& E>IO'TN"M46"GGL;/
MVIAM:JJ# 68@-1B.C6BG%:5X4F6$)A)U09G.*D-H_*PZX0]L\1O1-D9.FJLE
M#6)-X:+H"4P1Z.P^1 .K:)#+EJVH_1NW3%8I.F@HE>!]"BX(ANDY&>[V;!K_
MXOZ;UUQ?'NWB&':L*AT/S< 1PC8&LAB-"S+?+@IM9P[A_*'GEH:NYZ[AAZEN
MG/%MC 9F EX>K\DNRVR,8]GF"(YJD<V?UIYAGI9IT:'L.GX;\')N >(+(!;+
M0[ K9%" 7AA2[9P;06$GQ^Y6+EJ-H$[0S);I72'<1.:,/7);54*NKV2-^-7;
MW>Z#;I#,&T#&&_CL/L#!93A&9;CL,M13RB7N2X5B[9EO/1;?8=7>(45#3T6+
MRP[PEWI2$JJ7 QD>-E& 8\"!$ K?)^*3RKK@!H "T";3W!8!^S9&_"H,PT(&
M*+P:,JK&P^X#-&"7OXCP/OA?5,Z1PPU/JJJMHUKM_S(T1AW<2WY^*"PR',F!
MG>_UX2C679Q%5.SY$MW^1RGFE0@/\ _H+ A+I%UERP"'1ATT1C1P(=V>I2!Y
MG-6^+4_BL&-<+$RUK@^F5V;9V(%^X5%B)(=% QO?JQO?%1M]E^FUL>V2D+"-
MEUF*",K]@"EH BU61[Q]0A:G(/%D#ELEJDB%G'5VW+G5F^4IE"JN\"5#I&;P
M+69A<O2^%.&"LLO]*;8ZLI:&&\EH6%-V[%[*;586B_,L\.QYCSE%BU<ZP/(^
MAD*\*Y1>[3&!\2E2J=(.<4[A<3'.I=X:*__FDB3W7\Q9D% =*WM!QC*(FN8>
M<!&@\"<XL+Z,,0GK6\.1W/]0%F;!T2,X%U,G#8L(Z]/.=#,YL^'QA#)"3A(V
M-\8G]),[::']/;//7BQP(HSFUO-X% '2#G1CU''%D<MCD'!]>;!!0YX6UE_M
MVFH1;ANNO*\F.)=B(G%Y$3 ESA0V#FK_HIRH@;$K2]QOM6$[&XTF+LL_B?#H
MO$[XD5QRHA<IUY?.#O+958K.+K2TO@Y"V2KH<>I+OO)+YZIDINPQ@>OJ BJ@
M&I7!5@O&,@L;>G $LUMYF1,JJ4P\%JB#>O4>_T?@A.']QK0UN::$ B'E5&?+
M&=A-N?4&P;6O9=/L/5:,=DLBBV9E>AL'LY.*L:*'IJ+:C-Y%6:-HCH9?X+)C
M4,;_RC9/SNW+]&Y0@UH<9BYFF]:U]N;.P&XQ.2?4>$[P1^VG!MVKK3BQ8SA<
MZW;,&-M!_(DP-/13$F?;##U@]P9CANIC+9]IMLRO8Q:!""O#T)F'-&F@^4KK
ML-!#8V"TOA74>/DT=%2*RWHS[12!RT+PM8BP-U_W(!%R"S?&,I0G"K=MK#JR
M-\K/%_8Q$&4<"MO!VU$RVIJ;'5IM\GPK9U<BH#$=86JG&>(;Q9B"Q3X464<N
ML,ROPU&P=AIGY$7BJ)X/TH87Q3AQZ3@FGDUVK&;<?_^/8R@JA>L3&D9KZ6'G
M<-)9<!FIV\IC-M_S7[(;OAH3V@P>K&[=G/GR#FMCO<DC_V^:T^$)-8YG%+#-
MWW9RM$PJY6 ;7['DMW$]))]VXUMQ'4@Z%%C=M4DGF#FRI7KQG\;2T%<F]CSA
M0.+^FX+[<94V-A[Q4H7J%\,YGU-3<(D5V(R7X.!,]GF?QAAK D^?D614P/MF
M@F4X1L>0;0M#0T"U<#0 ;0]!\,0N[&-<K.6\ 7@KPQNP#]OJ RB@,#7O=&2
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M/#3L2TI.Q:*..*;0.E",;?\*I=+ 4M>FX^#8*7/:;9THQ+_B$J% +#=LQ)D
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M_DN_P:N8W!NUXUN4\_"^_YO "JRD];N7ZCN2R>"FU7N4[/"JKKO &)S!_MG
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MK*V9Z"8.H7\.I1GY\KB9]+A)^% ?L&TM_#B^^[POG4O__>5>GHOKVF&?W&'
M_1X=Z+IO_E*>D:?-P@ A!L"D?<H  -B7:>"^?0<+.DP((,8^- OW&0!0C^%&
MCAT]?@094N1(C@A)GFR(4N5*EBU=JLST4J4\=363R<3)DB8P=3=S_@0:5.A0
MHD6-'D6:5.E2IA\/1MLX"8"8?<L@A@% ;-\- ,KVQ3@8EBJQL >I2B7(L"R
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M;J*#5;EC2E5*NCRFQ#SU@0ET>H<[_ZFEI@VYJ4@2^$2>"$]:A-I3Q9HF33B
MT"77BQJKFL8X32A%'YE3AN9$J-%EHG)]'\V;X]00!XMI48:96VE8Q?JMEK94
M)K&+J5_6-J2U;J6M-VBK3I52M[D)RGAM6L8FELHXB?U36\JHG%^Y(S2HCE&C
M>]/9&D'JM,1-\X64NV#1QCI9RHZJK'R:!!HFD=G,PK2/TF%90S846B>U;%G_
MG^A23PVJ)7L)5$M"Y:(:3%K9P08MJLJ0W BKFEB0^HVQ.],J2<M7C YND+;'
M12YZ+NN<KJUEIRU1QN\T-5=HN;9*<ELM>I9!4:AI0K#)+0]4"DO&O47,HVLT
M7$C/*+E-$",4404K>.4[WVX%Q:R^VVPF-$N:S/83* $RBE:((8:F%D2S&Q%#
M6A(BAL4,V#K*./!K)H&,[T2BP03FW\DDO#387;C (X-3@CG,8(8,^,,:ULTD
MH!*\[6A"# ^.<(H-1&*W8-C "D[PC#W,OP@OHVR*2X,8X( 8%\,8QVG0!T/T
MNQC8&1E$D\!?AQDRC!=G&$XQ7G*)JWSC)QL(#1=V_S)#-,OA+VO90EP6LXJ5
M7.8:AUDWDA@QD\5P9@@K6+-)7K"<W8QE&L..SC&^LY+[3.,Z@T@2K<M$&A93
M9/Y)PC_+0$,:0 B*21!X?$%.@]-R@(8QY T':'C:&,1 N!R(80S14X,8TM!5
M51.#:%)NLY41K&!8.UC6$M:QEA^,XAP+&LRWEK&O=0WL7N=YV&@.=D+8;&MD
M%SO+L6XVK9>]Y4+C>LV_CK:7L5WM9#^;V=QV]K3='.YMQYC<QP:WM,N-8W6C
MV]SMAG:ZM>UN=N<ZWN^V][?Q+>Q[UYO?L/,/B&<=93;KT;[M0BT:Q- @V)%X
M9!HNFW_$\&E!.[QLE.1))/\DOO"*VZYL9XZXVAA>-H_/66T;'[G%PZ"5XND+
M3&5+><DWCO*.%R3D8Z/Y@L6@LQ],/ UP4 8.(,YQG9?<.C>'><7!-N M(YWB
M1:_QT/V#AJ<W?.E(US#54WYUD^/\-54O&]=!#G&P6[SK-U>X;:P>]0*CG>AK
M9_K,Q?QVDK/]Y'-7>]CMOH\P0%SA-1]9&!:#];PS>!D-'Z'0T^"XLN% 9SXH
MF^!^H/ <.*UL.5"#$28N9$T$F<"FQ+K$RR[SN^MF]#:7^M=CCGJYFW[U#V_]
MQ%\?>C&?'O:EUSK@:4\1V^\^]U"_O==Y/_O4#U_WQ?]]PTDO_.37/?AH[SWR
MH]__^N:;G?K3QSWVF:]]Z!/_^M['O=N4C_JCH]BET1$/,3BKV4E\]SQ:\3.Q
MW6#O8:"!SKQV0_ B81W]WC_$\_\W^Y,_>^L_8GL#AF@M90LX7CO  /0_!&M
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MFAY:F;[I;?;BX2;CP[W?R16@ZB:=U$UQCK&B*$?_S+ 6:\J( 8+(+#8Y;91
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M-Z ?1SW(W9<O-X*YF7BX4.ATNHN'^D#DWO72.JZCWJBO!:/#-9$D=,S@^5R
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M'^*,NRBQ(\*EVGPFSAH"=>#B$GB0\0B.?500,[QEI>"J:* #A^3/A&AJ7."
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M#%"Q\_:V09I%=$%"6=HU<&X6OB:588$U2V]W:'576-Y56:;68A,W7.D!  Y
M7'F,NDK-;?<A-B=!=-WS.567#"<!&I8*AR*5<P-W'PP +.06>M?6>)5)=;<6
M  XRF;*PU-9B>_?!>Y-6F2S$=Y4E;4>629>*8I<J>9TE# P7?!-V>>O24=--
MF;X6:U/W;JGK7OLW:5?7<[,V"P>7<->7Q_Q70E 7 #H/;)4W9_E6NH@I=O\;
M$T8]*YG(-F/!UBEVMBKL='.!UCYWMX6'!60S5FX5.!H 0 76MJZ4:EY15C:W
M%[^,KH&IEV---6FIJVW%57Q)5[]D&&N5BKIV-8CO=BW&U8*5(G&D=L^:=CU[
M$CJA.((UD&^UURLT 0#TEW43V,K 8H<'& <@%QJ>]HR?4T(P]HB^M5#"]7)E
M\WKW+(UE4[K>EV_?%!6S$((QUW^9#6NE*SH3QT+T-PL]EI1FEY3.=GF=&+\<
M$$X?5"EZUBI8#4O_IF%=.)07!!4I-H*/[FCG&&V/^"."&(/EV'\7RXA$XH$9
M&&M-SRN2"8EOV9?BV"M0,0R6MO-H63;WU8A>623_$#A I6MII2LR%6>8R8(,
MZ4%T.78? KB:SU5YU5ARERI*;1F9$383@IETS8* R?@CZ-::E0F;K?9[&SAK
MNQ6!;^!I==E_/\)\'Q4D\!EDGY:=B1:$&2MQ;J"9Q!5@??F(1)@I:M<JY%,O
M_V8@IU64)5I! EB ^Y9;O[=RG9:*-]HKR# +D^Z61<*5+U:!1;IE12)Q=*N7
M3?=B99.D+21CJ5=Y04)_#9J=?9=Q5F!78=IY"==Y,_E@]:MS^?B>^=:GI^N-
M2>)QL_8&AK>:(X08-#J7#5ALE6FHB_J=\7E[ZY=ZZWE[#[GS'E>0]P$'>FRF
M_1&@+X1D2R)N2WE@Q36N_^5Z*4Z8*BSTZ0A'*#=THOF:.1 6+"PVE5OV6]<B
M0@;9G[>W"W\8%;F0H[%W+1A;7&O6D$4BG44B@!6WGE]VET/B:*F+K$/BC9TE
MW2[8L2\ZD]]YL]4YD_V57$T:%<T6C,G6GRG[H@>9CB4D8<RYE,,6)&2XG4W:
M=]]9NGQ)0OQ$J;*0N/>!JA,9<@\8MVG[<2+Y*IY5C]-B$@A:68RZ'K1[N<]8
M)#89A6OT<7ZVK\T[+5#:N5?;G<.5AH\W@JNWMGW:B>=7>CNZ+N$[>WE,=;\5
M7C48<?GWFS]B>+,WI<VYI!\UOGF,8L<X"^66JY7)NI#:G0<7&A!X00E:)'I9
M-O\K&L$!@&))FKH@'(*QE\*/^L27RD+BN*6ALV5%6WGU=RWZ.:UQ#$$F83T[
MC,-('#(F 73! A65H;N!7*$'JLB-_,B1/,G-HHO@0AB4_,FA/,JEO,B7 =[(
M:LJQ/,NU?,NYO,N]_,O!/,S%?,S)O,S-_,S1/,W#O)G-HAUS&!K8_%LSD*F2
M"0L9MQV58<=ZLHB<I<T#& W:L1YB,TK?V&L'2HN+'($O=LZ7"<_KP>C:G"XG
MQ(T)5QDJ^LB787#+XLB1NYRG2QG:<="A@1Z65D(,(&&06[>=Y<4W?: >78XQ
M5\X#ZJJ5 <*U[,.17-$!W2Q$]Q3GG N#7( 7G=6/O-(A*_U=H2'5+;UL9?1@
M,\'-*7@#\7R=09TN]SRWU?S(Z^ID_]6:.5Z<Q[J0QPDZH448KA.:KBWS+3PY
M6NS4H<_[W3]+M8=665!;PJ9;0%OWS]AZ*=" 8ZGW+#)A7H<\X)LBO*FBH7.H
MD^%]X4.O G%TW3S8P.Y=0.LZ*S*AE)?70BK$]%2\<8=T.O$::,>;X4F^L^0]
M8A/7Q2:^*C0A-B<[+?I]A#&^A)M"A=FBW1->6$M^YWE^4;N=.H:!##-<8?<!
M%,3 <90A,GT;T/OV%#]"$XY^+I4>G2>!R=4A$F0$ZI%^ZJV9Z>DUZZ->);A^
M$KP^$U#WZ<,^Z1\T#20A)7!>ZZ7^0<F^"\U>1H@A[<>^[,]^N?%>[O7>[OM^
MZ>E^[^]^Z__]?O !W_ %OV\)/_ A]._OV?&['O$C7_$?G_+YWO(GG_$3/^X7
M_^LKW_,OO^D[7^S]_G6=/O-%?_,W+_4+?_7GGO-#W_0_O^YG7^UKO_$U/_9!
M7_5I?_1[__5_G_5MW_=Q'_B+7_B/G_A3?Q@DG^Q1'_#S=?FAG_097_/1H'$S
MP?6?7_M3W^QWW_ME!/QA7_P_POFQW_R-/^^C'^W#O_W7__2M/_Z7'O[A?OBK
MO_5+G_K57_D! LVD?00GH2&X+Q,:900SB2%&4)E A&D.-EQ(D-C#B!,+HJG7
M4 S#?1HA[I,XT"/(A")#9HHHQN(^-&GH71Q)$ #"G3Q[^LSY,ZC_T*$[;P 0
M$Q$  )Q$FSI]VO/3/C%A+#H4 XWDC993Q;R<6C5D2XTXY %3IR[25ZH6)XD9
MNW7DV[5A][F%RW4N0;9B&1(+TU(>6G7(NK9]ZS?N7J][<1S&*Y?Q5,<%$6O-
M*UD,9;N6B2GNNG;SW<280S\F'=ET9<B+57-F#7KOC=.74\NF[;GT[=6H6^]^
MW3OVU-EBL^8VJ7>XU<Z?DXLA#KRV;^6\I0M_CKMY9NBCK3OGSEPW]>BY;8_O
M7GXZ]NKIK_M8CO4R\LSOB\M7CP:^\;?SU_;0?]]U^=EW''X %NC>@?RI]Q^!
M6_6WUQD'/LC@A!M=UR!+\2'HG(0.7NA<_X97&4<AAA9".-6 &AH'&(KK:1C<
M=]F)]Q9\?EDF'%!0":73CC[V),92" 7)U(]&&@F1,F)H E-*^Z0AR3(AF40,
M&DR>U-%4;[ S6"0F*7DE2A1)$DU((U499I90ELG22&!RY"244LZCSEGRD(3&
M5V(2)*>9!"4CQC!PCBEEFW\&.BB?4?JY#Z""8AGGHH8VBBBDA#+J:*)/2NK0
M2)E:JFBAG1[ZZ)Z;BLJ5DE^JR6FJ%YK:YZ2J:AKKJ">]RBJJ5*+QI1B1LNE0
MKZM&JFM&O-)*)J-5#CLFL%PMJZE 64T*+:@S33*MK=6:*JVRQUK;+;7?<HNM
MM\P2)-!(P<)4:M^6X=H*Z+G79NNJGKXB]*ZK\J[)J))ZTH1ON;)*!FNR [?K
M9+YNOGHON@+;^B:X#^N+K+,+RYMOKVDF//'%T78,4Z\<T[OPOR.;6S'*UO([
ML,D!JWNACD?NU./,/A)S5%(WV,SSCB;U_)-9:,T#=-$^":T.T48OS7333C\-
M==123TUUU59?C7766F_-===>:UTSSV%3;9129I_]\]<_204UG77>J790;@,#
M=]QVWXUWWGKOS7???O\->.""2SWVS(5+7?;99Q>9=]I-(ZTTWY /3GGEEE^.
M>>::;\YYYYL?_VXDZ)XSS?C2<]>]=SMHT3UZZZZ_#GOLLL].>^U&B^XC[E K
MDPFV*P7^U=.3]SV\[<8?CWSRRB_/?/.&%ZV[TY.8[9E,?SO.].E^:^]\]]Y_
M#W[XXH_/=?1/F;]T)@#$$,-2[0M>NM%(HZXWTNV0CW_^^N_/?__,H]\4 !;-
M*)X!@$8,"+RHS2UR>^.>_QX(P0A*<((4S)H AW+!GK6O@,I02OP:%S6DL<-O
MR!@, RN(PA2J<(4LG& &@_)"F^',;.V+ ?RBIKHZG3!O0F-="W\(Q" *<8BR
MBZ%/C#BSZ9G- !_,6_"<-K_MF9"(5*RB%:^(1:\AD2=;G)DROD@Y[$F9;G4[
MQ!N7SE*8+*IQC6Q,'BC@\ 90M'%O741('7^4"89,HHEYXR//HMBW>9Q%'?2;
MHR$/B4C*O:$(1"@"!8K0Q!L$+Q,X2.33_^ZX#TP^!1H;W(=1D)) J E&AWX;
M)3#*:,E4JG*568,#(RM0A!\4H0@_R40 ?!6 3+XE!D]DY?. IDFG!"D&QE&*
MX,1HM&0,II!X$R1:1NC+:$ISFCZ*AC*L"8IL:J(.;UBD#V))A HT,G[T.  H
MIW( FU#S2)@,9E."]#,"!LZ/-CNC.I)12C*N<Y_\/.0UOZA-.W1SD47PP0:^
M:= ?$.$'&HCE+!U9A(/&4HX](88!JH24&"PD /3L)\V@AS6C!,^#H7R:,]4!
M3;Z=E)D>;:E+]V=-;&ISH \U:$$W<-.%1E2ALI1E$;H)!SMH(IN@4(8X9?E-
MG';TI3MJ)]8ZN/^^LNTL<,@LFBE1:;>K,G6K7+7=/Y6AS4_ \:>S#"="-Z!0
M<4;4H=_TZ1O@4(>A9O.+T6#34!9Y4+0NM*NW RG6U&<V,?SN;TLUTDK]IDRT
ML)2OC$TE*+I)4<'%%*#:K ,<NSG+M(8SG$70 $,?FE:?SA*H1"VJ,J!AUZ(5
M=):/C&QC?]DS=Q*%&)FHAS*JRK=>,DVK?;,G/E\+W%02M BP+&S/HD&/R8*5
MJ-N\[' UBU2<*A2<LT1K9T4[4#AH,YO06$8T],$U38PVM<']D5.O)D_+X;9G
MAPWD,LOKH\?&$;XH7"1#ITO+H2!7N6!=+BB&^@:!TG2X!OWF43TKT4?H>K:Z
M/.4L=KLI5#O,]8O3HJ_QSFLU]<6G<L;U$6\E=Y936M@IPRWNB%_')BEE91G=
M;?%7^UO4TI96NW'\K(%U.MR:'E2<L$SK6HF[VH9^\Z'$7:A.1?M3",=1KJ:-
MZ8GSA^&JM4]Q" 2<;DTWR)0V<#!:?G)/[.M9G::0367Z;C3J\5T5+T,?DVWS
M/Y5KS1<#=,XQAO%R_2MC&<MUSX_];USMD E  QJN<(3K6[,[T$0GF:PY)K)#
M=?K-1TI:H9(F+D)CB6";2E>B//4L!1II4YT>%:(\C?2C'9WH;HKUC:7M+XNC
M42@O__\PRE0+$I79=KVH<0DMO^5;"<_2:UGSI+.K52LHV'P2-\NYSG/-<VGY
M#(=/:$+0F8"K)@)\Z&QK6]&87:2WR0IN1XO;I[*$-#@/?%_/>MJ1/A G!7[@
M@_MR]I$)72U/5WOI1T*4QVO%Z8]!N^F%ZA6I^"ZH6A7,T%#KM<BQQ.F0==K(
MLOH;I_Z&)9 )WF!X,U*6"'8H?I%,9&^G&JB6+3F?B?H#B5ZW"*!H<5V%O4Y:
M\Z_#.U*FG:2HV#66"1IH;C&+Z8SG[<8QVG 4L'._W>C,>ISA/=TQOB6:UQ];
M_,89K[0&#$J$#0A<IUI/.<3+NM:L]]NG%H^NCR\=[X4BM-/_"U6WUV&YX)3?
MNZV-%"W(Q8UWO"-]Y'SO>]$S4?*@#EW0?AXJDPWO[#S[]\[]_:+CH4'A-S/$
MN_MXN93(2S6"OGOC,&^IS*L&C?7J[<KRFV+/Y'LE^848J[(KD^3C'.,\ _BQ
M G4NH_%>X+S&6Z)G37EFI6MD<>+4R+-\>+\=:F^U!UG>F,9OCO?.=T('FM!O
ME/9_KW_R5L<^]E\,A>,C?UH*LWC\R;ZF=WE>UYY7'B28[WQ/'@U+U[J?FI^7
M6B96H!3/B-YN^Y^9,WUH,P^E=9!D-#E$2%Z39CYW6MO'7'WV5I;%;8XV79)6
M 3ZP8+EG4T76:9^E;]_42/YF=FK'_V\8IW=]9P=$AWW.UGB/-WZH=7EV!6;X
M-7_Z0U!OT'XSZ$OU!S4X8P >9!0W)$JF-S.9P%9 5GK ]A-F)GDPUH"KAFVV
MEV,^A8&PU%8-U6,;EU.P%''X]6-TIU#6-62HEF0#57N"AGB*!U8^QW.H]3=8
M"$NIAX-Q*(>:HX-/0T!W*"16%C4V1Q@\XW +!TG*QH!"]T;8EFV8,!B7X%"3
MYEE'M5D6YXA:IX4$UU!@^'0)I5.HEFI%MV3;I7V.YUW7M'[ZXTI$8(-SB(JI
M6#EUZ#3P9!3*T$F TW]',DKJ<#\!J&^/Q&-')G!$1G<0Q4BK16P;< DA%@G
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MK#PR-@VZ$TI$K"3,,]RXO-'_R\%\L[Q^RD/RV7DH?$Y$P8W6,T, X"29E,&
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E?__]_QY_  Q  1Q  BQ  SQ !$Q !5Q !FQ !WQ ".2_@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>advm-20221231_g5.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g5.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
MS,R _\RJ ,RJ,\RJ9LRJF<RJS,RJ_\S5 ,S5,\S59LS5F<S5S,S5_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\K /\K,_\K9O\KF?\K
MS/\K__]5 /]5,_]59O]5F?]5S/]5__^  /^ ,_^ 9O^ F?^ S/^ __^J /^J
M,_^J9O^JF?^JS/^J___5 /_5,__59O_5F?_5S/_5____ /__,___9O__F?__
MS/___P               "'Y! $  /P +     !>!'<"  C_ (%8$$APH,&"
M" \J_'&P D&'%A@"@2C1H<6)1BYNF ADHT./'3%^9%ADI(62/SC\J% DXH:5
M)6.RG"FS)LT?+U_6Q,ES9\X?/GO>U,E2:!&C2(D>59H4:%&F4)TNE=HT9M6G
M5*/&W,J2:Y&M.)<>+:)3IU<B87UL.$I$IP:@12A\55O$!UF[<>>NM;L!K]RZ
M>^]^_4N7K]^Y@Q'GK9N8\>+#C@DWQDM9<67'E_&B+4*$K>+-G7]T=@S:,VF@
MH3N7UBP:<6K.J$^/MOMZ]5>TLSDS[DQ[M^_>N'4#;\U;=_#BJHG[/KY<^7#5
MS:$_%V[<>77IUZE#WVZ\._?OWL.#_Q\OOCSY\=O3<U;-?KU[(NWAOY</G[W]
M]?;KZ]_/O[___P#"YX9^ PI87X$%$H&@@0HRN." $#88X8025D@AA!@JF*$;
M&':H(8<@ABCBB&ZT$:*)'**H8HHLELBBB3"Z&..,,M9(XXTES@CCCCFZ,<<E
M.2ICD$$4#012!1F)%!*2#JETDI$AJ21E2E1*&1)(1R;))$D6E02$EV Z%.8/
M&0&%T0\<H<D2$#^064&;1_'D%% PO7E443P59=5.>]YDE598_9G5H((6&NBA
M4QF*EDYR =7H6WG] .FCC@)FEUQJV?46$16@M6FGDHHF&JB>CHH;J)N&RBEC
MJ *EEJE':?_ UDN==1KKK*W9*BFNM88FJVBTEN2KL+?J*JNQQ.Z*[++#=OK2
ML6TIVQ9=<O6U5K6OOF5MJ-MJFRU.WW8+[K/CANJMN.?:U2FHUJK+Z:*9"LMN
MO.O"2RM+E$8Z::Q [:LOOT7X^RC D!:6+*2K&G;KJ+#UE1BPHFZP666MV46;
MJ,5=')S%L&U<EZ@6@_PQ6B&3//(/):-\<LHL,\;QRR['[ -N%M-<E\TS8_PR
M;CK?+%K-/_M,!-!#NTS$&S,7@09G/KPQM-,^N%&7TS](W301:1R-]=%7(^UT
MUE]K[?388BM8A-0#.HTVVIVE#9_:G UXMH%.5]B@A79?B/>%&W+_J*&%?;LQ
MA-\H#EZB@H,G+OCB;1!AXN"-HUBCBRVN6",=*,X!HN8^<LBYYFU@WCGHF&/N
M2>AMG$[')9IWXH;KL*<N^^FGQUXB[,1P%!$'!/%ND!$*/21\1 95))#QQ#.D
M?$0<M:2F$<H7,1&9T:>)I/(DK?3EFRKA-!%*9<VY@9TG57 2EQUE[_U,<LI4
M)YQOLH^GG"_1WR91<UI5%%97)8KHJY%RV+R$U9-&%0HN>A(+G<@"%ZF,I2=T
MTLD"A;(J.BU*5 W;3,3P I=&:=!AH0+,!@'V*GB1D%;@.N$(5VA"%J;0A2!L
MX<38XBH:TI!G.,38;BK6L1TBAX<>"V)K_WBXPQX2\6)&+$X1@W/$)'IFB*^!
M(FIJR!@IP@8SGN$8#F.V12WJT(L>TUAK,"6Q$ IL89 ZXZY"^)>_R&HQ;0&,
M;APF,<[82E:>XDP9VY*<[1 'B$"DC2![>)P_RJ<W28O/?,03'ZF9[9&.A-!Z
M1/.VHM&'DH=TY"'UPS3^S$P_,PLE$=!0-%)&;69+B]K0!J3*F;G!E:ZLVBJW
MIJ"H<69I \J:W/3&R[U-B)<=@E#C#N>W8G[H0R1*IH@,1P0Z#"ATAON<YSCD
MS!A-#D<N$EV)5E<B3.!(1S:2D8E<UX8V>/-T)1(2$'QWO($4B2-,$EZ3&)(D
M)RGI(P)IR9<BDO\D+"U)2UIRWD8\PA.5X/,EZ;O>FK;DDNU!KWY,&0M6)"@]
MG9P/@4!Y25?@I%$&VL]0@VK*53;#$KLPS*1[HHI$'ZBH%WJ+7Z3"%UMFLAFY
MQ#0OE\H+IJJHTYA<L&#/\NFX3 HM$ *5536=*5(K=5("1BIA3O5@I3@FU7=A
M<*<YQ1BIINHP2EGU4P!K8V,&ML9?_2I:P\I5:H*UQEXQQF&+P@VM'):75;WK
M5H4I8\ @-JW$V-56:I$K;0"[U\[LU*I]U92H9&6Q/;(DJ:4R+&-2Q=BZJ@JG
MA=U53D^5L8[Q4(R=[:(/>P@SDUW,BZC=86KEPBDPCE9CKR6D(9&#FXS_X0PM
M;O@9TK;6-+ND4FA$VYDL;T:;5RKM;;W-9%WDMK11:@UL7>LMW-QVM[G-[9%Q
MXPS<&G1=ZG)W07=[Y8!(>5SQ[@UPYRWF,S4TA+^I5T$F@B^'##?,P<'WOI&C
M ^3TN\W)G4B^X>Q<Z+9I(M&)3G- ,J>)$BQ@S&$"P0Z>PX-?YZ-+K&YU$I9P
M.2_<ACF8T\/J+%[PW+G.@I!D(.R\"$2DYY"0I(EX6N+(D::WI)!0B7D+9=-
MV]10ZFT)H?IKT_Z.<C[V0=1,1A8?3R*"DCFQCTXPZ9^4 04P/UG9*JL"E;S&
M8M.Q %!/?NK)2A=8TI6B5,M(L4FD;,A:GJ"P_XI #2%*"1,89/'U8+S"\YUU
MM5;-WF4MP#)84 T#Z&D%9M!ZR6)@Y!@<NBHL8C/4,E%K*.DW2S6&92YA4ZN:
M0I/RS&&>'F&H31AJ2YD:9EC=#5Q[6-D^UG$X>"2-:4HCZ]9<,3>ZL;5=/^,9
MY! R.MKQH2%'V\?L%/O8OV;.Q5H-R!_RYMF4C+80:ZO=XG9,.NH1T"(A.1_1
M1-(X\,%DV^13H/64.T#T(25\LM89=;]2:ZI4M[SAT]QYKW)NJA3OV5RIM?/B
M>[RU!*:$?NG>^:J7F2X:># EUTP2(9-P+^H<Y5 D.LNMB$8N(AWJ*DY@&8$N
MG#R"D8;= "0@:5B=$/_))_'T2>(FF7CE*%X>1YQTXAHCZ21I4DE& CJ]\Y7/
M>2K9B/:(\KTWE>FAWJ/2!J"GT#NQV'DHT9_3\923I7SI)4902M5O,N0HXT_J
M42X*I.Q$=CJQ;^IF[U.?*IB7HE2P8%L.5T[95:Z8_(4EFZHK88.SKBVG<#/6
M>BI;5]5FJ!K+5<&R,UKUO'AF/7'Q=XX\Y"<_^,I#\<WQ:BS'+)O'BDF,SYP/
M5F#5.MDA5M:R/20L8#:3]T#[%37(HLP>':T8R3@&8364\U$FC4$?,#74JOK!
M3BFP6)5A*OC#+WY.?<\SS:OJ358EH^\_M7Q;23]@IL[[Z!&[U51A>F(HA+O_
MQO8N[=@&,3O &60?$7DSIK6?9CB;VLRR%ERD?3MIJ.1:W;)VW)^U>VNB87]5
M4S5*<S:R]&X&*""J5("UI!J.5#=ULR!G,S<%@DL.J&T/<C=J$W"^U($1$E_O
ME2$@&#C#5#@#0@>.DW"/8R,I.&!ND 0@HB+5I 24<V IHDW2-&$7YR(FYTTD
MYR,39G(6-H0<1CMM0$Z8TPFHHX3FI P% 3P)T4XOISR\DW+$LT[T=!$P9A%)
MLCPWYH4JD3YE@G-B$A'*LQ%>(B;<\SXO$1$W$79(EU)8]R8\D1$2Y3UQ\G5T
M*$%O4C].)U)ZZ#_^<T%[8D!=)A5:=A-9ME)Z4D!3_T%1@:)28F=!B<A3D:AF
M<(%2J6)W;!95!],3=I5"CX%"1H5X*Q1G,E0N<!=\(L0SJ[B)FE8J(N1]FO9Y
MK+(8W#)8>/87E\=!9_48@A%7'71%K==7<-4OIH=%K =%D7%KR0A;DI%'!A-9
MHE=8:Q$<C'6-JU=8N88=KN9KQ[%JRE9'<@6.UD$=W9B.,7-%O<&,GM9K.%$:
MA219R 9:YK<;ZE=^H@5MR$%_$TAMSU9M-^,TUB4W];$>!/E(JE$SR]5'!SDT
M["$UY'4@B50?GV0@K9$@!HD?Y09P#?ANN:4@LM1*%*B CC1OYG4U*-D@&T@A
MI,0A^;8A'K@A(SA,QA2#Q?\D.2!"@]34(3*X.)438#*X@R:B<73@3=5$8!R'
M.N*4(]XT(P_&8)>P8)B#<E)XA1MA ?4D$;XC$2!!<UB)A<ES//]T$4"G)O"T
M)"M1)E3B/&H()DS&3V+"$VQ2/G;8A]]3)W^HAWD)/O>3/T<F01U%*&0GB$;Q
M*E,V0:M8/R3U0&SG+I%8BJ5H>)_&5#&A+O+BBL''67UG0.U2+([!5+XR1:%8
MBG+D+J)99EKF0:J95+K',*Q)F64F%['9FK-913R#FU-$'6(D;#,4+U6U59@&
M9UH%?IXF:4N55,<)5<N9:3/%G$J5>3&$,0S36=.(,2C46>NX4T?E+C;4G4^$
M,&7_!F<V-$-<]$6^>9YAQ$6VXFR M&SOZ5F\08[-9FK3AH_N9TG384E"@S-0
M@Q]"$S0Y<UM$,V[6A5ORD4IN8TOIMAWZAC8%R&^LI#;>YES_>6XA^6UWPR!J
MDS09*$F0E%XBVDM]8S@(9Y,%AZ*6@W#%- ?RM8(SHB$EZ 8X""+:9(,K(DW=
M]$W<M&! Z*,9!H2:TSJAPSHNXCJMDR.7("102"0E%CPIIX4<@852"#QHPCQD
MN'/XY! WYCQ<HJ5G$H8>428JX3Q%YJ5'QB2%PF1PN#Y3429J-U%_63]==V1@
M=R@A=61"0145I!1RZJ<B]!-!X51@]D 4Y6:(6$4YP1>6_ZE2B=J(H0$P2Z%!
M6896B\HOCH54"U.:RVA'&82,G@H:\0BJN-=7LU(9=.5ZIXH8J9J-@F$M7V5&
MXR)'8D5'F2$86 2,.Q083&2JH[='Q%(9HFJIPOI8H)=7O>H9UI<82!17-X2,
MO?I8ET4JZOE9\NDR>V2MB'6>>4=&U.B=9&1JK&6L>517P&HJ=P:-I"5;B26?
M0/0;ZVI)]1E&"RD<WDB0^,<8S:5(!FJ0!,E<M>5;^L%NTJ%)HJ%N^V9<SP:1
MVL8;=5.A5_,T#7)*X%6!VD9*4).!S?5N=?.2Z562 !>R D=P$)>B!>=>"L*3
M'_)QE/-P/=E?DF."US1Q2>FC,?]B8"9'8479<1L7(PS6!@GF@^,TM$)8E>Z$
M8O*4EE 2<T^B.RF1EOZ4/%=X8EYX)6S"I0HU/1Y!9$16AVJ8=-W3/6G(8HF:
M)WFX$GOJE_D3F?Z3IQ%$F'L)MQ\%9H0(06.7* #4**2(F?GR+6T'?E=UF1+5
M>6_Q*8A5G#319IA5+S:$FJ%XFG8TFI$UJGT5BI4EGO,9BLAAK%>$>G=%>J K
M69BA5^CYG19$18KUFZD7J\.2:HKU*S'C+#S$BG*E5:LGK>*'&+D[1HBQG,&J
MFZG1*L611ACT59KJ1:-X&(?A9XJK,-LW1<=8C*2YF_:H1>HI,]?*?D%$?C^4
MC?/8&I6$M7WPZFSF1QR(%)+O9Q<#$C0)VAX"6S4"&UP0J7Y<XQZT\7_JQAML
MPQGL9FXL&5WT=B#<I8'PH;[9)9((C#;\9B!S,UP1DK!W8X%7 Y+.1:(G"Y07
M7*(8PDR9$Y3#=+(?!X.1 Y0=?(/95,(25V J7$U+"7)(J6 _^&&C8V$]FV$P
M@H0P_[RD!#$\3\BT[201*N>T2_NT&J%R5-(\3V*F])1T2=QC*W<];@@F"54F
M;7B'[D.F:5>'<P*G:VET15$^5&(_<%J82(&G5G&W'[6GG+*VH6(_?9H4F E!
M@@*)C'B+;N=F<0P6#/05++%UO:M4[**HN4B*2G5IPZ@P0@4I/"&+ !1\$G0J
M;?>LG^FWY5(JH+8M2(6<A5LI?0L;LG)]L!='KP)JBL&*?(5Y>L>.?_M66?6Y
MQ8&N'7,O,_17,R16.72YI%<:6U4<YUH;0U1&>%2?G'<:\9IGO6%[FG*/L&5(
ML>$Q\&JML&4PL94J6Y2NP*:NTZ%^@W2_PZ9%]^M^W%Q;V?\V'P0)-1!8D?5V
M7-W!H#E3()347!A3P/7QKQM32TP3(<ZU;@XRSY6$2_D6P*R$SVPSHA6<7E$3
M(6@ (?;5-P47(LBT-SRY@I/CLM-$PA:M@B W<3(BM*73<9KC8#L[I$X)(SY8
M<DZI82!MPRA'8EKY3E':I$JK3R!QA?A$AG5)A4=L$6ZBQ 9UM=!3=%U;%&**
MMF$L=!I%Q6Q247_I/8-)$W+J/GW2$^<#*/D#01#DAU%VF%3FJ *4* ;T95Z]
M%,?)RGN;:&AVJ8OLR,")O:-<=R8E0$HD>\6GK-P'>)-&B-OG=K?I%)S9N+/8
M>X(+RXXKFK#Y0/[25* A4[BYJKW_!ZPEM1>.5D:T9RO'ZC"E2KFDB5?5:&KK
M.'J>%;DWQ"^I@;KDN7G@64*8I3"J2\OHR5F\6]<[1,V^^=K":]GHFHW+9]M]
M55FLE7CDNWVT=QW4:9VO%9#\F)_!UD<5HQK--=N/Y&W@C$/)E37Q',[,#6[V
M:USK6TGDII >"Z&Y%=#C1ET&.5QF4R!(LV_[]I$'$C?]UEWKC= 3RS9N R$Q
M6= R"2(H*TPH:Y,?;''Z;:.&$W&#P[(]V3A)6:,5/6!,J:.@@PD\N*,R(CH)
MEF"J(SM$:CJHLV ?EL-.^#LL_:0\O#OTQ-)<Z2;[=-/NI*4Q5@%BFI;K4R5J
MXCS]A.)]_X@F.U;4;@(44TW4@4DG=A@],,%D=K*G=!QV?VC&7#?'5('&C"*(
MJFF8@@E!;S<H4SY!@/83;WMZ+R1!BCSE/Y&=F7@MGLJW6R9'IO)FGVA"L5V>
M;>49BHM[9O6[Q;*YF]NY?)830G16S/C82%1"Y%)Z>X5%A1?*F1TOGX::JFRY
MT.J<O.MG7<6L!$2\B=TKSPC,E?)IN5EXHZ56O.O9?P[9%Q/9O3G+V(E!AKO8
MZ"E%Q"VJZZI#IO[;ZPI:PZ8:[>E#QQA:U:K<N.%(V@O=B?2PM84Q]/S>]$%O
MZ]&_SG4S(:F@[/'.!;S>-\-_#GF1]CI*G81;"YB2#1A>!A))(__)2@V"L;,T
M[M?5DNG%-P0-@B-HH@$.8#?).,\4(LSD3"U[.-8$X)/#.0!N32*]<0*&3CTK
M8#%<(PFF8!<.81W6!NID3R)&A0)AI5>8/%4H\<A#Q#&&8_N$)E0+ICGM)6V8
M= 15$M #QB"?=&6'$F5Z/4*'=DR^ME%'=4B>F%8AQ\)GF/RC%6=6*&^-F3T_
MY4K%1G5>4KI'RG5B59+MB,N'O32%G!;T9B<ERUY&YD0U%GR'5J8(*:6G5\+H
MJ8(>5Z"G+ UC69^75KR\*[Q(>$\%,:NWF;#7,8 55*,YZ+*(>Y"K1 ,3BZ$-
MOM ZO474K%CDO+O*,>[HC.?76)Y>N<7_2XRP7D2LE42QH7US->NWL:J]D9Y1
ME!OKR7ZQI=KDIQO=6N;9&D; &LV\J1WT*VV?%9 >JD4'69$P4S/L1NTW\W_$
M837'WI#*_H_JNQ_FY3;V)R'^NX'C%NS<-C/VMQON5DD##5[$KS<O*:$$[2'C
M1;(,W2(20E_J1:,0%]$)QR*<H]&B0P0?QW$9=_X,WL)0&2/DY(/D=#I)2L-#
M^F P8M(>-H1N("02,?%1J(4 8<0"D U !E8P^ ,(0@L_."PT@A#A0H(5*PC\
M8:&(A8(5]GW<]^-B!84=C8@$4@2ARH5%()+<4'+A#Y4_?A2,&=$A39@BB]ST
M2=!G4* Q-_Y4__FS0M*B39<"A1IS&4B0;V(:K0"*ZD=0)'_&).+5:U$?'D%F
M OK4:-.O-WVT!:6L+5.D/(NTC4F5I@::?9.^];&!"$VC2:_>'*P!:04BA_F"
M7?IX<)' ;]V"_3&9+^4B8?_^Y&N':A$*I#__>&PY-66C;QG35(T:-FO 7VM7
M!IUY:6V:I6O_),*:\^:WG"$'=]T9*'*WP#F7ILDY<.8-K)5MQ;X/&JCBOJN7
MUJ#I.LAHVV47T:"U:F[/8:&!E!LVN'J0C&FSERVXR(:W_%4&I^XWUP!4K"SI
M.H/LK<&"&V\?N4I;D+39("SB#67JH2H:4/SS(3/GB@!E*O*6J2,SV?^(@",[
M%?=Y"T+[?!!M1>SXHRI"!3F3S\/:;%0.N1X5Y-''"(>D[ TB@CO20R$IFZQ!
M97PP,K,C.YLRR2E]",X-)CMSPTKDM/0!3"K1(.(-+-_J$CDCTT#RQR.%#',P
M-Q3\H<LXNYSS2#*)P/--/O\LHLLB]OP32C[#'/300/FLDX@X_^QS3B.[)#-2
M2BWE$T]-(=T4SR'< #543MO@D]0V0CUU#DW;H(-45.EP8PA8W3B5UE!M!575
M6EG%]=1+;*WU$EB%3=4-76T]]E1E:57UUTN4Q62.:(W]M1-@E1DH6R X0(B#
MC"(RR"",&CI(((@&\O:@A#1JZ"&$,H+7(B#_X*6*W9U6:A?>@FZ:R=N=H +W
M*)*BLNDBFV):RF"U#O9IK)C2.BFGH7CJZV&LYJ(/)%" 2JK!L_;C>&'/ABJB
M03O:"LNN\YX:[*KQHFE.-],8VPTSTJAZ>.:1J[.KQ0-][BM'YTKC;#?@$(O.
MM[M*BVFSU,#2F3+ZH)G-1/^LMFPRZ#R+[>H%C>[M0+"%?FTSI?\S;;H%)T2;
M3N%VI(XFS<(>KC^WLQ91QH^B@;#J-V2$YB[+J*(:P+6)H H4H@/#D*HW3(NP
MLQ=_[A%'N?U;N\"[$N/,Q.!,D^V]C^3R&4?..,L[N\<;JRUC[ KW,!.]M^I1
MQR)DGQVDP?02TG8D_Y6T_/?>A?==R>(=[>PV*C-3$$LN?8@&I,"Q+/,M,NO$
MD0@VJZ^RMC2-/!)(/CM+OLSP$TU33R(J-9_-/L$_LD_S.]L>_$#13-3(/?/L
M<_LTM?P3I *(IT5I*5("[!0"B7"J3#7050L$%01C=:LNM4$)$P16IFX%00W6
M"E6TRM2NNJ0J6K4J5[@R(:YT!2M632M9MOI5&UR(B5-9:P[$\H2OC+7#3K"J
M#;[R81MRV$-LA8LAX=*6O<BU+HH4A%SQVM=#,C(3"X K(N R&+OT,J^&9%$D
M&?G)$X^"$GZ-Q"D_\990(O*5E!@L9 SSUF)T0A>Q-.5B8E'*7"J0NH\L(_^/
M(LE.5RK&,#VV)7H?T40%DK.<I_R'+7_KXV02MAA*LH4J;S$;4CB$F3LFI9&E
M68IMUL*U_4S'/TN!#G\P$YS7=(YUSED*)/?A1\DLI67MV0O2T",W7<ZM.G83
M#&$"8YQAVHU\J%'.+@%D&N$@)I2UH1DSO</,P'!.0)T[W8GLXSH9+4,SG>%F
M=IXCNH\42#^,29'N9B-+^*Q-<I/)&G!L:<M<NE,^Q\R1D##G.<XT:!E$^]J"
M_,/.%;UA-D30Q.SBDYD8Y6X??&F3@AJ:N\S4*$ '.MQ]@G31C,(I>1]%WI4B
M&BC3W6@R1'"2\*C4(STM[TINR P %^2]([&),OS_^VB:>F33B+Y)2C^%*9BX
MM[[XQ>]1>7H3 -' I405=:F4<BJ7'/6_0[V/J ?L$QH2&*E/:0I3$9R@!L%*
M!PW2X5,21!6?S I"4+$05"(L(0.7!:P=+LNN=/7A#E>HP[S>M0VJTE4,W?"L
M'-*A6K2*81&=2)$G+C%;&'D(8[D(+G>M:R</42*\--+$>5&E G$DETI.XB]O
MQ<1?&EE*0Y1RDH98Y(]U3)C*EB*4GZ2EM@BKR<7ZHK#:BG9B%_-8?=I"T(_
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M$:0 0O*(0?GP#QC+C 8)A1ZYKZBS P#)&-(Q':I8!L78 (]Q)Q_ NW[C$/J
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ML9PCDT_2K"ANI1.(*[%([:;SS!U#W!V%HCGE(8*HJU;%(XWB, WBTI#@D5?
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MC<Y$IF&5'(LNWGY#)_$&'5C=&-35S9;.W@/D)<58S/3..\;(&X/BBZC#WKP
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M2KG]LFAM?%G&8+"@R@^\ H*_0BJ<O,D3PRNX H"_PLJWO,JK_'[#?,V;_##
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M,&5E6C7K):UCS5Z:6M9-IS:>VF!J<REH&Z]!Z;JYI R(!2,6^@:V4 0PAQ^
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M1$.@:4.&I$5.!YPDS#9VQSW\3D(&# J_1W0T[,"TS'5$3E5L#N[0Z4R0*DW
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MN2Q8(2VXDWP+WMF=,Q[#P/LO:2I\'R#<,5865Z*KPS&T C8:1H4F5TX6 HM
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M@E<U6A2,=12$093(R69O'6!W.J-3KJ<,TMHR$(,[25\%_MJR A/9&9.TYI[
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M#:AM/;1M#&#;:@.N[S)SHA57+4,#X]Y &9&R:0- ;A-N-,1 #&RR&"R#&-Q
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M\9&MWJ2&1D/?JC8A]^WE^GHC+Y(!"/LR-'+CWN<R2((JWU+;HL$^7&XF+"X
M>-'PHM+K+E*T1[M.]:THIZTV][?MWJTHI_(* #<JZZUS)^XVN=&O9Y<*:(*!
MV[)ZC_:-73;>1L,T/ZYKJU?;=K,LV2XH;RYK-[(!@-%[JZWCSG=O3RXM1;(C
MGW?>HO(F-S(U?Q@.<#8 K,#E3K+:[L/"4WL]A('$@]%J;W=29E/03F>KM9J=
M@R1+9:1:9F27<E<HG7'<CCB6EAPY^Y<%+N]QCET3JG#6;2UQC>\J+BA):\KG
M:/$=4%DAI<?SQ[H7H3*<KCHO1NY5,V]C1 ;;>@V8JK[E]3:T E8Z["VT%"Y>
MWXE="7_HBN>7E_&HP-HZ'\M>?>U35(==W?]GN@7>)9#2.DCIH\N=IP]_8_"!
ME)<N:_,&V$B=NH03IA?17L_5:(RJM-V[Y0\>6N1'>DR7JS8^5P$6]*9]>EEW
M)W)W-29")/\=<.,GI_L6V.RAH_%1J1>*[$_J55K67O..\,\2WH'RX:]>[3BJ
M9O9Y8LS'*$/Q-83B*-&G6#U\^^6"0K17-C.KMQ@,XPI@=BHC^^7NK3W=N]N6
MD2!KPITYDVH[+BEK C:M;=KF-J2=]R,?NR84,RC7ML9#\KP#;#CY^X%2KN "
M!#U- &+4BZ8L6CTT &XLVQ< P*1H  +H&XC#8+UET<1$W+C,(<A, & X3$,P
MVDD#!@$ 6#800+3_92-=TDP8;04 92&A.92Y[R2:91UC1!NHPB@ I/5N !"S
M#)K&F4X'HADH9F",90=T3A6C#, !@QTS+6O9=%+4CS+I+=.W=AF]A B7:41H
M<)FR?3OIUNTI<V[>@Q_7&MQY<!_(GCT%A]QX6&X]A,KPRJ1+5^;;>HM!RC2\
M66-FPG=#[MUK^&#"QR#QODT,.G5DP'TM;Q:,M[-;D*OW;C08.>I?U'4?OTX8
M-5I;XY)_=M[Y%^3>YI<WROWX&Z3USXBK.Z1,U_5AP[L/:DS,7:[LR1GUTCU/
M>F[BU1F+(Y1[N.[-W<BC=S;O^";E<F-,.OMXZH\YO4":;*WT_&JL.L!L_X,J
MO_%"*@^Y_\YK++C_!,RM+]WH4FLGS2RS[+7'4M-00=L&>XTNZU3[R#V_<",P
MKKG^0TTR^62*R[O$<&3O-]4T4RQ'Q:0:3+7$SM/HR.-8DQ"Z(I^C4"/Z0B/.
M-=TF9"NYN>(C+K4DO=.(L^0$H\W!WC SB,FVO&SPPO4 $_!$.0?+J+D?35,P
M1;:Z4W.V)O.CK#S=,/1PS")!3 J'D3() (:!;JBGI4R=^K&IEG9J2::1Q/@Q
MJH4T;6G4& #01+XJ1[H!K ,2$S4A [JZ3M6[)D)UU4D *$L?4"\<21.:TKB0
MGJ#PZLD@8E"*QMD#5!OKUXT62J.>CI3I2)._]/_"H=KT,ANC6ID(6D82 -)(
MR-.1L)4)!@#V\774C52X5:V\:%)W'W S8:DF=4/=%*]]+%VH+  ,\#6-?4ZE
MZN%,',Y4$]%D[$RVPH2C4,:,JFRO.2?;LPW0_5A,K,0*=[H.Q0K5>BNWTJ[<
MD+OL].LI1,]F9%;*T9@D,Z^0H.Q/YZ#?>NM.U59D\$??Q*,P7YR;EBG-!]5R
MTLP'0T)ZM[<PHU#1Q[8\T>G"Q O3.L:6!9'/QCQ;3\6VJ.;S2MQ8EGNGC*&2
M;&\&<49YML3:&B[+$\>3L#B9<0,,I&12%JVN%JGN;V_"*&02T?]HG$VW#'7S
M3:T^N\,Z[FE3P^\C$R__W[*MOV1#D[#7H6.<,R!_/*ZRQH;[FNRY;][R:B0'
M _MTG>\*43K_A"YS,L3Z8NQNQITFM7*YM48<9OVPN_TCX_*B+TP5;><MO[T9
MQQ,VO Y+&>9'#=2/^^ '4VOVH!=??ZV^C@[)V1C R@DK*'E84>Y%C'UPA1B[
M,HBO,-*3Q 0E)&"15T<D<A>=T(570HF&JDXE$479*H$[P4M3E+$0#;9D//N(
M@1@<EH:1$ -LHO)/#,H"EI+D12EK DI$WN(K-$1C)&B B.!4 T' J" 3*8D(
M8I2B1$9L1%7$H)5>(#*5!M:#*SN1CSY.PD((4M!< 4/# C=U)9P0)"9,06/"
M_TYU YAH2BB:JDC,WN*@U;1G2O"QW<K$I#S&0,]/F],;(-57)I&]:$TQ^Y-M
M>!::E#ER'_,KG') ]APKI2Y'?')1YIIG->;H[6TW(E-H>H1'U7@N?'P25^&8
M S2I1<@Z8<M1+$76-ATE34#)@]%T"*.S^ZAL0WG!FHL.!+SRZ<J1HIF0 S\2
M%07UJ6"'\DT$-[(B[TQ./AY+D(^"EB<U>4UI>L(,W K4JO1ELID4:L]K^#/-
M-%FO<]?38=:\Q2@YD8^1E8$=U(AS,?R4\C1-PJ5SO-2SQ&C&F?1!FEV*%CH*
MF>AU:DK1QI@5'-8XLW=%H@_HS%/)Z% F3:#Q#>.XMO_(V_VR-V J9=PVEYO(
M7&YP)]+B@E(*(9G6DG%H6][F$&5'27(/.UCKB8E4J;*I(60D1<G)JBQ5#XCH
MQV ,@9:GS!(3K[PM&HS@UT:<Y1*8)' 9J@K >3I"U:ZVL7SUR!4.7?*_I,1@
M7E(-S4B4,9!,#*1B?&I)#4^BDX'(2AFQ"N9" B"3>Y7%+*JJ%XJZ2HQOH7 D
M8UW&0AJ2KG71 R)U;<FL4$(O3G4%.O?:B:HD$H9J32RJ*SA(4YYB''ITJB'1
M(-=FHW&O/CFK(4_:%4=.JR"X2/1")!/2A3+)GP(I+DP*.I[2'IG<TAP*D8"C
MVY>NXQSN5,9 E"L3V8*;&R+_IK,OW]U8F;9$HS]QKDLAY=YP&4.;SZ&.GS<Q
MT'+P [DD^8DZ,FUEHAY%',X +B0.8DQSH*,;KM5-32,]7@J1E%#FW@1VB]LC
MDH@)N)GV9KA.0XU[Y:,;]728<7S[69,R)[Y"V@TZB]E1TP:LQ2M5Z".QO-$Y
M0813\5&)/C@2YHZU!)7SX:[ !!U,+*64NP&WLI>7 Y)PX*9,ZBV(>,*+L/22
MYSO0P-=U3]89,:?989A-QLOD$8SU[G<XD$1)-P<U$RHCU#;?JIF( MJGA!!E
MW1@)C9#! ]*?P*L??J[O9QI=1O]X&Y/^[<-4F;KKPQ+8DK:,!".8Z>NIQ "-
M0FNJ_RS)@4EKNWBAEA!#:MR22:=:@H;$<+ EDZ"0"I\R$33X"J1!VU>FG@(6
M%6SD*@J2BZ].E9^REB6@&YDTK>%UJIV<1!(;B==.2+U7KVB1@T]1#E?@.)2(
M]*0E=;&5IBHMOKYB"QI=;<@RAKW$9G<EV_^#WE!MU-*S]<>2C*M;G>""&PQ3
MF'H-I3" 9EJ;/D4&(:8I7]\ 9!B!![5\>'/NG6 ,SBXKJ8\.K/-U2L:D_]0-
M9\LK$MYT6[+6E4^FW3/3AA ZNC2#O,[1>(OGF#FATQ38M6#[;HPA_#.,WO>8
M@5(174[,L?!EJ(_"G.G:/O/1$)^)1.%KIE20,SBIL2=YF__[3R.-AF?-/1WH
MZ)-OF6*Y\H(B21_ _=E+;?,EGB.2;*]4"VQBIE%F5OES$M_S@SS3(>"^R9JB
M69\FHS',#GG'?"E+J63H\[4_[;)"A'H:P'_:9B5E&7PY$KS(+^;0*)M=3>L6
M^N0(4^#M#LUZU\6S^*Z9/\!D5')!"Z@FMR;+GKRJ'F]@2#T@O1%>5VNR+4D#
MPJHJ$\^>*=&9:LA<-049>ZWJ(/>JV%TZTK"0!-$\F3H6A:2?(KHFA-?'$IT$
M]VJ9L"2&861;R.V;QVOB@93VFF+51TBMQ>8[)+,. 5=+UD^KO=!D5):1X '
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M(AEX6@Q8"-%^'*-?Q:+U>P72>LC;^L01.\6OG,N[W,M_.@B"( )V(,P[FAX
MH,=QVEGT(:-;(@QD *G_>KR_7*W3_+"WG,[S7,_W/*4W(0AVX +$/ B0?*/-
M0B\,0*D[8A_."J-_A;G_^JR&.M(U&BP<)M'E91+V ;*9&[7_G9O/L3K+[QS*
M/YW42YW4XR "QCS5!3T"@N " !W6+T#56SW5XV#!A_I7Z H:=$+3#>"B)8&\
MQ2#3P4)B4ALLQ-K3,?H&E#K7>9VBQ2 ,*GH2?%VWZSI3*MJT''VE@X^_9\V
MHJBB1:6O 4 2!MO.#1O/35W=USW(7]W5PYS6!1W679W, UW0_WP?@L6K)4AB
M?*6OD=LLM%LO3CNR[7NC_1VO]\JB-WT?W,#3#7ZN,\6KJ<W*4]I7TKK_*#I=
MTIHLQ/W9M9TF*/NN0QW=1YW=3Q[E5SP.8GW>7]W=71[6XST";/W8+=S)F[RO
MN8^OJUP9R)O;,V'.-WHA+OH&N."B)\4 !\(=M2]<KM&(A;BOXE$Z75B%HF/
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M+_PU_<?1X,(E2,'I6BF(/09NX.*U9<']'NKW 2 , -BW[\9 @@0G <B$$
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M*.*())9H8FQ38?>4AB>VJ%*%(+HHXXPTUFCCC1-Q%@,TFNTS((XN_WKX8(Q
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M.$SH71M_"_S@"$\X=6#D;H4[_.'X)OA-T3 )?D\9XABW<P1V$(&.YV3C'8\
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M5:SZ]-&;QXX=5,M/O1$-2HN<?/KS[=>'K]2;,.']7[[=BC'(1.(.,MXV&>E
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M;1"\_B8"3DDV5I3$"YR3VD<C+:35>XGZ2YKT:_^--/.[F*B8M%B7GR$E>&+
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MQ#L2.Y.D(J75(@N.Z$ 1#!Y9J\"**)\&J0O.\BJS<1@2_[S*@AB97"I!SP
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MB;"P!@L?Y&80U8A/.H,0Y'YCXC#L?-$Z5\--*[A,P!M8 175$;HZ"?:YB4P
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M[_TWSI=Z#'*YVHH+Z=8F#QZVN*=27;*CU_'(+:LI1\3RC0/& ,U!F=CLT^>
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M !XM*-N$C.<^[!Z)#5UR.,@%,A>4+1AJ(!(W"=I$N2O#P20YO=1Y4@<^_L:
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M1*5Q4_!Y1N WGTTDGR<4G__XR9_WB1C_69]21)^/H9389Z#V.:#YV9\!VIX
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M9BN\\)L0=XO!.L*@D<I5J3(A3%,<U4/(6VNG6D$_@@*=<2 T:!S* $2OFQ4
ML0032$!1=;J.3:WFHW0?(K5ZTEZ)JGJ-OAH!&/')QI94E"N=#(AI280+JDJL
MT,2*C^%4):J'WHC_FY+2)GK$8!<G2B<Q, :="C*LU,-\8EDA*H>5>6:::Q:6
M'32-98<AZMQC5Z=&V@MMM()<NV&J/ E*VB!M!]I8H!M3;DW7)+TM%+PEV<RI
MT_N<5G2?>_5%#U&&-SXOJ/L$'LC:UT+3S]J(Q!*/("(!C.&^)P^6:E+<]K$V
M)B(_-@K6FC2-(;485!VX2=;V(6^UJLD5KE>;*[?\<LR1HX>==NC1"[RA :MJ
MM*4'4B8&0JGCJI[1_9388,?3%@VP<E4+M^4@/_6K4V7FFQ1'N$GFM]1]Y[LM
M^+D+,TWM?3965^$BE_SNS9?1O;8]W48;F5ZS'8<R*<'[0D-*98A\W:#W_\Y-
M/WV8*<_\??CCEY\R%ZO2[TD_]T7(@+[S1^P[ ($J8/"J$:',E;^! 24^?D*#
M8'R",8+HY@;=*XB^[H,QMU%P?S%A'O/",PF,9:U@8S,0DA %MMUT*A.L\E/X
MB$*XIF1"53[)$Y!JV+7VS4^'.^1A#WV(E)R@L!YN(&!$WN451=V+A?HRC?$(
MJ$1Z%62!]_(>T^#%%:U<9Q+6:H^BZG:00Y5+(D^"FE2<)RH8%L6%*U&&)I0Q
M*SB^$2%]PE\-8Y(G3! J*,+[81_]^$= !K(BA@IBQ@#0+ZWI;Q\KB$B2+%@O
M/^&&D4@ZR*1HB!, 0:PKW./C8;X6(%+YA$AQ8UH3![OR*J*03)7N,TBXTI>N
M<^TC#>I262<%>4M<YE*7N^2E0]:HDFG=()@WX,(-:'F0C2FC<>I99@+WV$MH
M1E.:TZ2FY=*XE#R)C$TN\\GMOO?,:H93G.,D9SG_Z6>4%3I-<@>YCB)WY29G
M@M.<\Z1G/>UY3YY<<R7T.,#7GK2"$:4$ !$(0@1V$ %\)E2A"V5H0Q/RRY0<
M"C?O1 D @K"#"P3A @[E:$<]^E%HZE,E?PH0*T<2D0OL *0K96E+Z2FC2>'0
MDRP;Y538QQN2X>8_?5(.1"OJOIB!)"(%=6E1C7K47=X+8S=(T@K @K]DYJEZ
M! D-8;"(0C;U[S@B%2CE.C52 & 4J6,E:UGG9S_OC88KRI@8FU8H%3'$Y*8%
M<1A"=.,3IB;(IR<A4@P"ZKUXB@2E*C5K80U[V&"%1B<18QC&)H8GL$S5=)\L
M6IL<J!RNI@13B4O>3XF*7UC0AE:TRF$L 9\$0D15552B04-]<*K5@CWPA,C9
M*TI&><J51(2@H^5M;WT;&53E3XN*9=,Z_9(=X%1,3X9I:W(R2YFA(O2WTZ5N
M=<FR)YQF H,$7,]]_ (D@K#-KJ#C_RYMW[*=$>J/HNW;K77=^U[X_J1CZRE2
M6R$X$+]L+!,\-95,E<;<0V+V+1U;@=3PZS(71C>^"V9P@TE26K$8H(O^ZI4,
M\;M?_RK73UELTWV/4]O!Z>8JC$M25ABBVR X6,4K9C%%(-A./6*R( 5VDY&0
MIU/#7-:Y;KE6CBBWOF/N\;,M)G*1BTQ9EN2UIU&28T+VBUX9RCA/M&-OBHU\
M92PS.*XVF2URGKN2VZZS, <656O&^",83 XG0\YRF]WLVYZQA,K) 3%)B';A
M-[)2##I!;T%<^:,@SQ3%;R9TH0W]JR^79+:#T18K555(KQ&CF2>VJ'0/?6E,
M9]HX=1Z)8&Y4H!-BZ,8 X:-.-N_CS6L.6M.K9G6K$Y-HDZ2!4@9>R--&6)_U
M3H[-KN9UK[-$"PH%VT+"K@6Q)?0-"AT[V=!)MK.,A:QGF^E"&9JVM*/-H6AG
M&T/5SK:S:=$A<$LHW-\6=[G)#6QD"_O<S*8%4/\X;1+!Q #6&5&UK^U];P9]
M(V=H(@>__;VA?VNH',X!T\#Y'::#:TA#SU;3L9HS)H9'G$S?$-.&DK6LSE3\
M3,H"D\ ]WJ6/ER/D(^^2P1$.\C0)'"CS%@DT?%2>\@GHW8^I-+YM?O/CT(),
MT"DV9WC^<Y]SQD+(%GHMB.ZLHP]]XMO&>-.5)6TO-1WJ3]\XQBD.\8<CG=RU
M<%;7+>1UKG]=[#UG-M&WCBQW$^5)3ZH/_KK:7IS'7>Z2*8>Q]"TFA1L\[\Y1
M>,<+3G"!.P?P#C=6LYYS>&517=K-8OSB';]PPI,I[P#G.^5%;OF]7U[S!0?X
MR<FQ\E0.A!Z]8OECO/'_'&/-7?6KCXO.&0YQH_-\Z+(WNM;-?GMG7QSJC]=]
MX\]T]<.;">)-MU#='SYQVR<_Z;$O.NX_=/NR.ROM0[G.#0(0Z), X/ 88GWW
MO4^6T_-^X&,*O,G[WG?S>[Y+BD>\T]N_>\.S7_[N5];5!Y]^]-]?_^DW.?Y!
M/Y1Z0 ,N$#.PHKCO.T $5(I:J#B)ZS;GJSUD63YDJ;IGPSAR&+Z+NSK?X[T-
MC+_@P[;<F[T'A#;FRST)7+[I2Y"($),$;$$7_(D+9,#-F#CG,!/U,SB"P[^4
MZXS7<SBL>ST9O+KCL[L@K#@AM+N'T[@;_#O^$SP=Q$'_^XG2"XD;R:G< @ #
M\'Q!+=S"E%C (Z3!'V2^Z"/!H7,V,!03(T3#'_1!&21"K/O"!GR.,]$]$1S#
MY!-!$XR^Y>.,%/R)47(J32' DPH 26B$9>!"1$Q$D"@'.!Q"&BR'O!B(CB,(
M?? [#3$'2NP]6I".8IE!;_"<@6"'9RL(JK._;\@+>@##I8NX2-P'YC"XO- '
M_9..@6".S]N'RH-"2_P_H""IR3(ID4  @L*H35!$8SQ&BRC%R$/"9W.'@M '
M/BP(>ABZ##$(>DB\J-L'?3 Z-=0'@S"3@P#";_#&?: '4US&S:!%@F 'HP-%
M<Z2]G2D(=I2.=F ^/$2[G_^8.:$"*F!DDZN@J%Q#"!TH*(W:@5! 1H1,R(2(
MO"\T15T(Q7;;!YS1QEJ(Q^9 $^G8QHS\AHW;&7J /(KSG';0!>FXQH%X#I%4
MO&=\NO>+/V^<!UKP'),DB%2DN/&+Q9AT17#<!V49//3;$%Z4K[AI(#1@I,#R
MGJE8F:1$L(58A@A(*8*, X6<RJETPXD[$R#$1'TH.UI Q2ST!C&!#F\<R9*L
MA8D3R8M3EH$0ANB@R(%0%L^9!\?;AW)@$7IXOP^TOX$PAUV(RW'D!52T.VRL
MD'+P''-@P7U8AQ*D1J3KPY]H)Y+!/A(1L18!#_4(#70YRF6 @" @R!V02JH,
MS6/_/,-&Y,A:P$10E,A=*$GNVP=>V#[H$!//&8;32SQO% 8WK(56' AH)$>:
MI,#5U$8,9!8AO#IG.\G$RT@T_,!:0$Z4+$=LW+^'E$*CJ ?M J%4HPX3.Y?M
MG*N#("CP#(*#%$WR1$1Q9,/4C$=21$7H.,EDT3>X+,?X&PB=H<F<+,=R-!.B
MB<NIPQ#VM,"+2\^>#$6H0T4>3,OG,%!R\,N)XTJB<\R?@(8W:C*%>+)2R9/6
M<AQ<,2F<$$:"M++R#-$75$5Q3,U:L1!OI(>2Y!!OY+T4=;V'0TYUK$DQ^0QH
MU 4SR<EVL, Q*<F63!;?- <.&8AV4#S6=,.Q+ =>0$Z9_W2X,\G!Z<PGHJ@'
M;HD(03P,;7R3'\&;+54S2I&$,5 #T"2*""C3I[0T$4W3WCI/<43#-=D'#!')
MS]B'BJ3/&611Z&1$-=R%MVR_G+S&L>33NHA(89 _!470IS.6IR-0Q@M,&O2<
M;?Q/_L1*:;L]"+4)(DD- 9D49]JS?5B&4@&RU? -[S0(+>"2;Y $H\BHB[HH
M-7U5WNH,\4/09$G-@:@0WRS'7=@9C32(&X4X;V3'JE//6_W$9_R&-^5+8\E(
M#N'5WA,^6LC5_/02NWR.C8Q(@MA1'95!"PR3H.0)M: DN$$(&% E[:H:K; P
MQSE*GAP_'+75H8 [6'W+"<'6>><UJM?#RCUUR-1,5/O\AGA\4X/ 1AUUNF](
M388CQVW$T9-L#F>DA\Y8T6=MS8*8!V9!Q<V84V7!1"+=!67Q1EZ(.!LT30NY
MU)J("-81BJ]2B)Y1RN8AGC2"V(L#D:/8-5@UEFR\UZ-JR#94163[0(\%VMB\
MNL3[V60I235$0S;$O0O<0#2,R524.--\#E.L5!B]-B\<S#Z=/ZK[UIUX$H>A
M%]Q*"%M#()D8VX2 R>!3TJ.05YU52YT]*H)E3C_]40Z!S^ [O:6UN(VSTR/D
M67Z3-A)]..G@$C=,VC?4N&?MUJO+"VT%4.;_--F:V*S1.*"38$Y:JX@+,%,T
MU0B;':W--5/+>(ZX/2KWF[JH8\FYM4$@]!(V?;AFK8LO1%37]<0?_<#!K+K%
MG3_45=WG],*]'47J+ JVL@D8L#];&-.+V('._-R+<-N,X-R-:BCF[<S.C8R=
M%!9@DQ![+=VFX-JZ'4SF;$1F9,BDG=L>;$!'K$#QQ;O>#=_#JT#'PTMEJ<VH
MT\#=D]R6R%RFR3X5.#Q&N"B#*M.+<-X"OEZ,(*C.)"Q@.5/1-0IRB!!=$-C)
M&%+*X%[NY0B<[0SO'0L/9#^[ T[[[=DUY-DQ*<[!+=]SM,KR96&?3<,3)F'W
M;3QT_$&OY3)&BR-B_\B*H.*(B$B67< HC7)5BI!@;[A%CH#>Z 71R9!>CF#>
MZIW>HI!5TJV,[)6,+OD2"LZ(+(S;[06VIIA?\$5=.EQ%\UW#PTU<AU1CQ)5A
M$V[C-69 ND7=-(X\_64)9:A2DA&#*>25^ 6"0S1@A6#)YNP(0:Z(0YX+!29B
MCDCDG4#,C<!@,%[5'1 3!/Z)+^[>C*#8C8@ #''DT-S@<F@*X#3-#ZY;,TE=
MXTO?X#UCV22(PS/%@D#2NH!DFN2^>3@\Z2C"-R1-,TYC!KSAG5 F'XDK-.#?
MDP( )&2$28B0"+Z(U/,()4Y@)M8()^:(3-;@":8%).[D:C:*+M:(+,X9;/^N
MUR0. C.1XJ*(.D[6B&CFB LPEFE.TW!>BO>%/]UC3FQ[X3<V83#<S7WHP5R]
MQBIVQ7J6R(QTQN;4!Y&D/U3>0/K%N#O&C!\.OC2@XHMH9\^]9(L@!["4D'->
MX(X096R.ND)N9(ZNB&SN"%O."(RB.+&*Y''VB)8FBI02$W7&B(+ZY)2>"(WV
M%0<F8(?Z::3P0/%;W:HC33&)1W*<A^(D5H(8S+$DU*:[U7C4!8X="'=HPVE=
MTG:EA=%03(B>/W]>8:+&XP6)B*I3@W;%B'?6"&?^:(Z@8DVVB(_F9H^X8HZP
MX(Z8YXI@YRW."+VF9F7QZX>X )C.:2Z.THU8:6O_1F=RZ&F'("B*,^R'&!/+
MN&:-@.+.5.P^TNR-..BD$&.'IMU$?6%US%9LG%.#<,,^14MFD<EH_H9UX,E)
M!5*>) =.])PUT8>="=GUQ1  K;KZ]67,SL>TUCY:8,=R& .ZK&N'*&B-J#A9
M[8BS5FF3]@CIYHCKG@ANONN.V.Z-X&ON#FR,V &>INEO\ B29NGU5N^/F&"E
M"%VA?FR1-F3)/FS.%99%9F!K%A-0WHG2)D[A5D8BU&=IBT=SR$EHO,JCKF(.
M0<6-.U+/8<?X?-Q-+,?GV#8T=!;27-O<G=DAC&4W%6:7F!6*.!0:N15XXI4Q
MF0=CJ85H&.R'H'&W%M21=<;QCB#OQA[ECQ!MBSCAYN@(N,WK;@YMQNYQD$"V
MC[!QC #RBX#R(-=QHZC> %^(*V^(E/((*\]OA@!MR;#LPZ[L;SZ*,3YE,K9?
MU$5:@"U'!DQM@GB]6UW0/%66O)!+']^,YPA4N_-&/>>X$!:^/55?LU;CO?^=
M:+":B/3A+I0)"J9<B(C@/FD+A9*%YI,N[X_H[HK0](D0;XW@<7$V;XSP](P
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M(6@HQ6K6>:SR>D,FKS<@$QI&'#5?:40B3RFJIGFP S:?\>$PZCO>;]1W*9M
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M3$ Q&6G,7$Z&TTK6( A.A#Z\Q"@]6.[P&UM@DB1L$N10CI295$2]&,G9CRV
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M_A9([,E7,?=RO#/#]#%C0;G!LU$XL4GNJ):IO.*Q,*$D68&O7K5"4"O$\#,
M06MDI:IM(36LT%:YNU*X_+;\[=ILM]WDO6XS62+3)X94+IX; D#E:5"MV&U3
M,;SD,5R$6ER4E6>:!B&,$A6.]$6U-N8?SA"''-5DDC\VE?_9B*N]*4*#G@2Z
MXT+O YUD.Y&^D8LBA5?YK!Y=_9%C52,='4&AUXLO ![IBD9+76LT.(,2378#
M%VLEOFY1.2<$'=9[^Q2YS+%>9Y2N<]E)MT9BY'U<]W5%[U-:O.-,6%GQZFW
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6,AS#-#S#-ES#.+RH)5RXH;NX 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>advm-20221231_g6.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20221231_g6.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MMVMX>^U#X80'GOC@ARO>..-_+ZZX&\NET> /(F+>]QM]9>Z&:YQC#CH1;_C
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MASF62O-Q@N/:7DX:F,N9%'AXZ2F* @>[C*H4_S8G+8*:*=<Z(ECNSK;S7>^
M9Z(0:?1W#=T=@F9WG13Q^47&LU%-1:3FD\YTJ$V%M(^^Y]3H#:E'E"X?DZ2:
M/>SI*'O=$Q_XZ" ^K8;5?%JR'I50C3\GQ2]^57IUDN:W0+/.[W]88F#_SFK
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MA+1Z*L6N<K*''6IEU^XJUZ[*KH=8/%J+%]PC'&4SOGCISFEF;XKIM+[G/3>
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M+!!C&<O_2'2,89RH5$A2UW,[A[ZJJ+YO2)Q_^+Z^1&!^ 8>)U$W)-(52-V.
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M41'JKII"X)D(9$,$$BE2B[WA#!>U*[KZ*5$_].NFBB@I'TYFA$!\%6$C9<1
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MCMF]'8Y7ZM;IICT*8M%J@J2=Y-!8&0(M0O"[<QWD*"?_<?EITH2:<[_YH.A
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M -V(C\$8L6/02N(8B%#02"H)A@E&4<HDD* )N'-&C9F(6_VRF&FECU$E5:J
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M]=25/;:8&Y< IO1?B1$SVFV>O>8:;*?U9D1MG9G6VVMP;P#$;[,MIQK_:$7
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M'@C5 Z$MP><ZEGS1]QZW/!2AZ#M:O1"!I#.ZK8(/JQ6 5*/BM[[9#>@AXMM
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M<X1N!?M5[->S7*]R5>H6*Z:T6^FZ!7L)JZ<V?3'EO027J."X;>KV==/)S1S
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M#O+V5&@T+V_$1N<PX63%FC(80>W SF>(AR80(G=(%6YX1P50<!&*(/:LAG>
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MJW7Q7<%11?_].[FT:-2FWZIV(SKUZ[^R7P__H3T;MFW<NMN\[NVF#>[>;>@
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M*E,CI*->-PE]HN37QB=-CB39$ 7:]H=]F 2 \BI*Z*J P*38_JJ %F)1B&V
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MLW)>1VHHN5%@(E17A( ZPT,,<OD!8 F2Y\NO[ZE(D\4>(!@K_?L^J$F#:!@
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MFW\EHT8:Z>@%5>II&[QFXV#.U!QQCUKDJ]N8HC*X_^%OU1;=Z* ,O9#?T2!
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M,NC 7>!JGF0^Z>EP58%YSJ3>K8CMUV45JUA0-%ALBV_<C7QBG,<IK=*V 29
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MGDG;.9D3"K6 W3!7J4O<:*/E#HE(0BJPW&C7YC:Z&DO?'VQ33C;7 E9N->:
M# J4831)QE5:DUVR28,T#BG+5_O2J]CK)NINX?J237*@9]5+$EKTEF7(UX42
MZV\ZLCV:J,@Y00E9[KGIOA8EE !NJ[2UTE@-7I:QLK?1%F-^D40Z3!Q<44:I
MHD,)&?TUZZPW=$C#B'R+D&0X-!IA2RC/*[N;& #V6TQ)C0RXTH#OL@0IZXG'
M9CNA _2B'6*&;MT:S+VB]<YAW,>#R/8#U L4JLWCQ?BSXZ150O^P3@-#>XZ8
M,-@$5#<T+HG*Y9;1:-G"JY1H0V8+.T%&TV,HK31]33MQG%\ZBOBAK#?>4'42
MM5:+<)*1E&:006-Q!8.-B*DP#X$:1*X4._Q AB&OTPYB?M>>BZA'=^MI8$+V
M@Y%=77 A"-D)7492-Q&.D'G/N0%0T( #!_U&$I= QE(ND:Y!0:4JZ\I*5J*2
MA!:-Z$5@J4/\0&46-[P!.<AICJI&8[9?U6<\Z1G,8=IS-H:H[6(.F8QU"'.F
MA,GJ8DT;FQ<!4!(QFF2$982>&$7S"3>%(84K- H,$Q45(O@@1'7LBHD:)SX2
M\4M?,BI"#H"@LQ_PJ AIR,1NVD(P(K'_:G3PT:)U;/<J)JJ@/_-1V\(RDAB)
M#.9UYN%BER("P?@T+%?'LAH$![B0Q2!$/"KXSX+,&$M9QM(D.O%<P"0D(55I
MJ T94I1O5C0$Q"'.1(2+2OA6I")%P4@);G!<'> W%B/@* U%N)QN2L86<,D&
M0/X#14.V\\D$[D4[%G1:7Z3HM/184(!H,Q8E*=DVZ620(?AICPK4M(7DP<E-
M,4">&-#(DP3=Z4!IG)-.5"@4-[7%#82RU[J<,@=,S&$.=&C?BAZE%)6I[U(7
M?5R]FFF6'Q+1*)TK3:DR(1K1H01VH)R=*&D''E*&9VVZFD@D([,Z"I*-E.],
M5E]2F9$QM9(P_QWQU7Y8IY>C4>LRLW3J@9[#(&)LP7-L3*1RF'*)2W3O98J2
M2C*C@B)X$8&&RQ1<,W^@+WX5$DB<\QQ;)%$DA!T+=@R#3_ ZJ)ZI+:0Q5+38
M%3E91?,(%DD):96VGII8FM!)I<00$@Y:@X:)3K2A+?-!B:A"(IDQ"D59N0J]
M9B2Y'P#!"$4 P@_4,);5" P-C$"D&$"H$_3X:B+P=)B2$+)7TLD..WK12T7:
M>;OKT/0\ F0/>C"BQ3,%UW5E\XBO3@F ;4U+L=6U[H!$UQ9=VB]5O<R0)]R@
MK@XYLZ(L&M&(=!@5BV*HE^5]41VV,I:RJ.$'-P)"OK"9WR&)@7D[&?_=>(*%
M0< \<+< 4-LCC?HU8KDS(^-4)3D+D],SJ0D';/K3G_[9'(/2)4'/*U#H1I,)
MYBQ4-X)ZR@RW>JX+/>I22T'*I2AEJ4=5U%YT&"80Z5<:WYA&.:3R)M*4QD0F
M@8>)-;7/3G6UF&<1%W94HJLD68D0D!"8KTW3V@*/+-P$]@4^H[G,W:X;YIQ,
MJR35PX'/2B6)3+@P4MAC64/+&B)Y)2I['%K<5F"T5C_*2 D_@4M^36.2NR6$
MMG[Q*6$+/%A03M!I$>.@H7]WUT?NA8L9B18E81"#:2F-H&*N[G2__+D;G%0Y
M;<A>G4\\+SG74691F4/V]AB60LXH1_4-Y&K_?,,6W^SWE=_L4G:>Q1Z(1&LZ
MD;F2Z^)95R4Q>C\Q?>DG*Z*7!R[P.\(C]*U<!US4S?,\>I'>T3P=;G$KZ,MJ
MUM])(X2)#%'6!^]R2J,^9$QXPPN\EE(FI_#\AL?U$0AC,,OG2B:D#R9Q;$.6
M53M+9V0L$OK!=Y7@DQFN$2P;N*?I&:>O!"CM /B3+6&0 6K<I$)L NH_.QDH
M@E3J/Y(\2(5LTHVI72;14[OL7+V<%#+0=Q2=1VI2E\@4^L!KXXH*$W, 6XMK
M)[&W-/2:&'-5&RMW%W'H>D2+/WW8QH;KR(-8,-D<I/8%[](?J"V\R/Z1*O,$
M-.YQ_X?3;CH5FM&P_^9.!,,IA-IJH[0BUG;!\%P-C514.N'JKW3%#7UT0UMX
MS!RD'XVE@6FE?* M8+UF!#_I;.ETE 38R],52KY]Y,&UQ$!<T8YX,3#]#=1D
M>M/G"<QJ=RHC=6*\;(K!#=G#A*E]@(8<BD\J())9#:_R61WN2W(V D(@Z5M(
MY?QYOT8#LJO.H\&!1')A$S\=V:)-<8T\L%<2I_KUJ]\TW35P,CT5Y99FYUO*
MTR=/H7']^ZW;*J2IJBAJR64F+.H).CS%J^]+PHI:Q,969 #7S5+:QYF4@$7@
M*Y!F9+2* )N:#Y'(3+84#3QTAR/0:;8N;W6JXZZTPTH2[3ZR1J>TQ)R8!/\D
MB"W+#()X;@!0,$R%X 0U/*?"U.0&C.0R,J'#$$1I&.D3F@-0 B6\M.K5)BJ&
MW$#%/,%<,"$3=.XHW( )D0(9@@$9A,$I,N1#XNTKDLXT=FWY)H%Y>) "PP9X
MM@YU.D*Y/H*F'N+ K*CT3"_1)@Y*KN2*L".XS$F+%H. O"_CPJ,_FDTD# I
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MJ?\.G(D.U"VC(O(V,.$VCI#&YD );.Q08,0K1$M((% W-@WZT(0#O0X62\G
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M=V1E/>;CR[-/;8;RPX>Z3>R\9'@QQU-/>7.P2P^$PQE+&5+GS-* $4 Q#7Q
M>S8D>TU9$GR[MX';MR\A&'AA%RZ!%QBAMX^!MY%[*>;E1-+@N17VE3YA)%B7
M(4T%EY3NI(;#<*O9-1K!?LZ7(0TIG.D[!FXS49O#*/]:][3C;GU_@R&_&552
MEYOA#JZ&A*$E!.D:OBU:DIQ]?-!1[FXU(3JK.WT;*GO)O9]Y>PJ=G#--'E*:
M@H(U<4,HMT2Z8G-&/6!:)1E&_)'[5M2;KV_%-TADSWB@4S' "9 )^<F$<[>
M%X"G5BA 6L0G.<>56%-3+P88"=PPGC.*FAC8Q%3>@#MI3JM@SGLIY0B/ N?"
M/4Z70HTCLD.XHIE@Q,KC)_<N5\/)3!-F\ 9.6CF!'>_]/3\+34RD)+ FIE#C
M*05CQ=GTD0-3J9(^(O4@&J11 \9-YCD!>+6!<2F+.NVJGJU914TF81B4 1H\
M%QJ4X0WHH-T2L%_!V!/0^+C_/4$2()SG*D480!Z$G:+=0H2'Y'B.Q& &9$]A
M]WOJ'8^'G>6%.^@5D]-I(+1"R08%49R>+C9VVN,$&V*VB=*J_LESUF0+9. T
M@-'I?W=D2.*U"V1Y*L/T4&-/A:)=7,UE^KFX>SO;BYLUNITU(F$7&($1)&$7
M@N%-2UDI  +3I3EMB+09XF.,&#0+Q3A<2$Q3,HF:B(&:E E-)HP;)V'"B&;2
MI) A)4V2]&92FI$LT4A*H_&E1Y OQ=P0(VGCC1@ 5L#@&4-C2)@.0V[4V(@A
MFI"39(31F&:ATH9+'XI)(XFD2#0P6[Y\R32C58>:E)7-9''8OK5LV[I]"S>N
MW+ET_^O:O5LW[5EE,?J&R028H\=+GMIT:E/84[!.F(1=ZG0)#:9@GAX+Z[18
MDIO'GMRT(=QFCILY0XB8MLIPX1A)8M!^LMBP:&RI2I?B"/,P]<C456O?4#I2
M3)@8!G@".!Y Q?'C!XZO6 Y]N7$#RY4?5U$\QDV'V[<+7XH[#(ZQ#V]PV=GW
MYLZ;?6,<^!D#QHK7KS.9Q8L_O_[]_/<1JZ^,?=I=M9%)(;FQ&62B$30'89T@
M,P8FR!R###+!'',))L=,-N$E::31R1QTM$$'$24604011?R0U6Q79541*/\1
MPU%@&V6R4D=+832)&R(!MA%1W+47PW,&!  # ,VM0!T,R?\=H *4 1C@Y'+4
M/0? D4Y2AV1RT649  #PW2">53?=-A::ZVG7EQ@#EG>>FS?81^=]_=V)9YYZ
M[LDG6WNU65& F=03((I*M*$$$7,H.J(GI#B#22848N(&)HQ=:JDGB:$QFF@(
MDN9&$J41X4.*J'DW55J@#%/6<4E:"8!Q63*Y')9B6HD= -8=)RNO6>YJW916
MTNK<K]090"QUNS('@+  ;(?&> S=Q%M5W@DG WI$WK#%#=M)HLDP,I[5IS)\
MBLOJ1&;M--XD#_F0PQ DMF'88Y=L.-DEP0@3S"Z+, *P)+8 S$@MN]0B23#!
M9'A)PQC22]H0;HR1FFP,K5K66<3_^&BC8#=^S%$:-\XTLHV!P20)Q2RMA,8-
M3!+7Y4]B!&?3F[0MY*ZW0.&$U<S R88;0U$]]!5P.Y)DIE22!&B17GT^#374
M]F5L41CL3D),D"IYUB =E]1;62;.4'8O&@UC@G:&E#XF$-J'73+B$'(3,81"
M%=?66HS#U!;<4DLQ$M7=>$_EXHZQ]?907UG"^B5T6"ZK:W3MC>4=M&*,-YMZ
M-GFK\^6XU=S7RT0>X%[3XR83=>JJSS6U61')G%/';A QVH@$C0B9)VAGHB$R
MA#V&(62==(:@&T/,X8EHI97X!A$_4&QQ;$S+",I7JRG%&MY4;>\0;K=-=1L.
M.T6I*W4\_W6I;',J3!GE^N8[B9URN8+I)'S"I2D<FMUSM_GEY&G>'FT1R76G
M6YT!#XA J(DK(F020S*((:BL?:((;TB4$A8E(CH@KT*9\%UE,(&&3KCA,)Y@
M3(,\P2G&T.%3B)H;$32 HA]$ZW#;0T/6S&*682"'?LUR'+(69SY>0:F'SHI.
MF!:WG"D):WU5FA42>PB='RI.26(*$PR4$P.<5.QSN4F->((F0/1XRRHB TS3
MZ$.,/J5Q3S%JFGW$T"VI6.5XH<'$' 2BF&!8:F'!B(0M:F&(@BE,&))@Q"X*
MM@M>+$P@#8,8O>35 [LU9#MAH-Z,RH*SW9 $*SEB"9! PB..8/]B)2>)2HL6
MDI-2#F<G75*!>\B71= %\"JA1$-?7#DYC."L-IN<2E9F.!;HE:<H7$G-#=KX
MFK(D<)G,/!U%'(*#+7S2)6F0UQT/<RD]2NA">CS&4MKF!LD\1F''T&-E(#:W
MTN0@>EQAC6M@DQON,:0FO0G<;FZ&.*/%$W%]25*8=I4L6#4G.LU)SU6J)9MX
MQD9\.MN)3889AFRM( 91VE9ZAE/)&TZ-F1S5$_70!8KT8"1K0$H#$9(0FN.-
M!C&,Z1W:D)&[2_@.&94)IVAHA[PV)&%1IDG1#^0X.!O*J#[NJLI#,*=0A?+2
MF F%YG" $JOC&,!]Y$/65-]3OC!QZ4C_48W5FWC#O>V=27/GP0V9!$BDM :P
M(@#21$??"M>WLI48#[4/28'T@R*4J$1).%1GAC<,"1WC,L%P X@\-1H[<LJ.
MEKH$@AXY*N>92@S0NY92J/::D()I5Z]J7.0\>QU?N<IQ/4R2=:CSJ^I8\4NV
M@@[YK', '!#.-KQT:K;&$\"^G(=:-0+2&9OF5CZ9:T\366 R:Y:;F^3@D9\1
MWB(G,YF#_0N1PM#0(0M6BT74(A*$;"2]Z(72(:!!(?\3PR7-,A&2,"5P^"QJ
M46FCDI3)\:B9%)( MP049+U)6V/,#6O< P/2S8I:N1E)4EH4-);$AI)@U=Y3
M=X)>O04WKA3._],"+9D1\4QB&)Q4R1"\=D*V;4A?]BIGI;[V-<_\SH.2:!A!
MY!;9Z"V$$0S)A-["YR+^/70L8,U-X!HL8_8:DR=-1.UG&Q<SF]W@EZ@I2G<<
M>I,M1/,VL7QH>P(<8(,F=+Q&(6#6*@QFNH0K8V9I#QK"M9%P_4!1HUEI"364
M"6&4$QF268R=,<.8!'EJ7A)+0D]-0]ZI*#A .-3$5&8KST/+9BL\_DZ:9!4#
M]C6G?F$:XI2>0^DDN2>+GZL6410=OB]>KEMJ34]:'7JSC<SHHV%NM:OOM"H9
M^8].'<G$&WY0P1)E4(.::BFF(.,&'YB45*5*X:6\]MB(#4$#IO%!$?_&LTXG
M'V[53<,>3&:IG0:Z23LXF.5ZN$/ET;VJ23U$[7/.1YWF&%E6!C!RXX[$Q<.Y
MBWM6>^A3V82J'XUT&!#,H8PVRJ<UZDG".*R9YJ Y!)3.@2#" S9D&A:)2"QB
MXK$3B"0D'O%(G,TP*145:40E+?64*:,:DQ%3,&*2CXAD*PH.24.*6IO5P 0-
MG=8Q4[L=5:B^*:WV5LU.].O5XFQG/.H9^LXJ1A6_W:P\VW+(]%;]ZJC7A2+H
M"E=4@J*C\=Z.I8WM1(LQ0V*T(<8-(Z*=\,9YXJ\=I#2EN0H-N?Q.4#39BTC=
M\?U$K>/[);7N--]R9='3OAX.E"=8+$Z99L/_9>X47?%.T1_FI+RFB1(GTEI&
M)6!(R1%5L6JX4F^UZ3:_2C%H(C 828,2/JQ2@KQY&,T0!DRUJ;:TK>U2Q6,0
M2NG6TW4">2F8)89E]S?W&J*!QC4,:V^&'#\H%2E]V$&2K@K**^W06-&(NQ^9
MT%0QM(K'6WR'KU$RP:IAV!B' .^\^<^_%@+VW6,_^H$2<DV')(Q&=YVHKH9D
MNA@[KMDTS?N!#T:$.XR%!O1B/'/#;!J =$CW$.0W(S<"031B8V@A@9H #5D3
M%J$42@6B$DN1"3YS.47R1+WR*LKQ0U'T')@V4#D7*V^7=*FQ6U8Q'*1#8$+Q
M(__6;V-6: %2+GP2_VNJXGMMHF,X<#SR@DV/(4(- QD1MPAAP B+$ F#<0E-
M.'%.J'&1@ F<0"]"T'%", 31!DU'-2.9-0S*T$5#<S0EPR.98!(=]A4@04S#
MM!#H41[-IVG[%48[-BU,PB3D,U$V46]$\E!BE&W:UE1R8E$.%1(9LT 2@7Z-
M:#I-@PDU<Q0LL5P,UUSWHC8-XSN,<0:B@2,HX@,C9"F6TF)?0QIK)S>Z!U0O
M]V_*H'2'5EM+5X@YIA5+]8:W.$QG\F#<=GC!1V#7$HC=TVU60R9L0B39$4"=
M=B,5,8;VH0P0U$;_UH@51B=NY#EB$" KXP.+(G\[-1IL(UC!X#L9PBG%P_\I
MOT-[(]0&H>)"@,8]7Y$&-Q0CTN8YXK-]3J4_^[1E791T0-5M/*%NSP$E6J)$
MKQ(#G],5,F85TD(YIX8Y:- (*Q<I8Q9^9?& S\@T;?4?T\B1KO9.EW,#:<@C
M:? #>U4'2J!!(T08LK<A&R)"S@8'/V $;[ B) (WC_$9 ZA3<I,!I'(:8J"*
M0%5CA6810 (8X6>4$L@J1YF4-L))[;1/+8$#/M%55A4FQF$KO;)9C?-[\J9X
MJ,80_]@F%VA&RC"&RO",OM56G*<G I<G5-.*WO900B@OG]$P&;(P";,P_E(+
MA6 (VK4+_')(A:!=M6"8"$-BW\5<.# &FO-%0PG_EYI@=S1T.-170SF#CX78
M%]FQ?0'T9'&B;?BV$,2AAU85*]<W) <9 VJ25C* ;P.R)J]98&:46?+8D9V'
M,<4E=]TV,VIX%9@P!JJ'&"MV"2U63O<2# 61(F^@!KA6! 1A+XZE=HIY$$0P
M7@N1%*@T$F8D:]E#'N0!5C[01<>G=*O88_US/^&3;R71,_PX+<&8BYMS'EF$
M5L8X>9Y)8 1B5VG9E("1D19QFV]5:.H2EF(@?CAB$BCB!HFR('0P/)+@"1A2
M8I)Q& 1!.W9$&/G'-8_44RH"/8K&&A^U*G[HGOV8@*DQ'H>GBS@&C"[R5+0"
M/^KC53/H$OD#GDR5/['Y@FTXP9W)@)']AI8/>*!).0F%MD !BJ1O93IU53*
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MZG&#3:P%6P"1?6,11F!,>XH,9&B,.?@!?!F5(E"EBED.B5"BA8*)-^G 9X-
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MOR"/LB3_Q-\8G&\!(05\VOCJM%7Y6W\-@S:(TYV,$'NK'@SQJM=ZK<C\MU>
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M)1;NB847FXW,!4(:NB::SCB3,_I" X\!?A"'Y/$N(2DD]*BW296-]X\+ Q.
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MT+!F$=U6>)2E:X7?61!IHP*4*X5'-_E &&R.;NV6G&'<&]B!-W[C6SXIQN5
MJ/Z ESJ7FOF2;:5$D"4$ /C,CDA%:78*>.U(D'A7D 0)B9C$!78*:#Z$>(&7
M2&AA=W$2]IQ'D7174VA"IX (]H#;M^6-@1X$W-V$+L:@0@SB74#8$RTJ,<!
M,UI9 !CB?@[C=@+%>Y:K^L@@38QB_U#0A(YF3&"BYS'ZA:JM2=69CTSPA>*@
MFD26VM4=IWNFS\7(X"E.%4Q<W42"1ZG)A"(.$;[N:,$FA"QI"6\NCG!VWS$:
M;)? @#-2'@ <(GVN@#ZQZM,)E*.VVLUT%?=,"JJBWTWVHHI:98:*@0Z%5+O]
M!H@*API"*Q")14JLDZ'5#$HP2?$-!W>DG_(I'T_0+(E,2H(M!U+HV0CV!">"
MTX+EV"IB#+]*Y%[$$FL,HLDVT55]0A2UFT%(25C]1Q)$2CD" 3F^0:+8U;$U
MT$ $X)QYJ1&8(TQZE$<-%?> 3QA(V%VLJ#H1"]Z@A+ \!Y0<AU(PQR?YU(J@
M6^0:Y?$PH/^DM8AS--957$<(+BY*68="WE8T/=ZA'L1JAL3[3 78JF[\^!O;
M>,?;:.-F9("#=@80M"US<<;;KAF%>D;%Y4!>Z@ 2OD'&-:A"X<!6NH3%A %A
M6E.Q%BN0?,1#T-@%MA"0\(Y)Y.F,KM PW$JJ',DGA%M& (G011+);9*$;9>X
M11HB42!CU4VR/)FJHF(83%WF11TK5=.:5)Y^SB?_\B<L!>=U,IZIE2N7C,TH
M2E6U.N2[KNM4.6<4ADC0(.R44=4QQA)0<&UW2O"5X&M>3.2/6IA%CIHT(0YK
M^IVID6OD\47!5F=4Q9)^WF8 Q   8-E^'H *W/!M\E.:K.YL$:+_M=0&H+E)
M6(C@GL63D04Q/T*)/W9(&E"0[@T5]*7!CH""S!PN@\5C;E 'D^B$B7K%7XU@
M$?.I2:!4\Q&'B_P&5[PO@P7>4%"M$)D@$?D=]UFD" ^C0.U(#\L/5XF(5Z7H
MLS*I;D&*[#07'+P!G8'&_\$>E](9'!1!&N#M_[D1LSU)%DL"#M1*B$0'#_V0
M/"6%IT4'B@Q'3?$03V5%4C /<V#;KF :/8(@H")NBD Q]!55JO8&X&&EW;1$
ME=#$58F)'@.SLX3?QB*BT,C2Z*$92<[D&\"!&MQN7YIC[X:J#LR #H0J'/5E
M@^*+:_88JYZN@Z&*9*5,K% %]#KF!L(7_RB$T&Y4Q;#JE/ 0 S0 6/F.5UE
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M4(<> X("?B8$14224< 0+O&$)20@_D1(%(!)!#[]4Z'JV#9 0B%*C%%,(*/
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M;@%25N:12T=$;.ZZ;MA2UGX"FU])XBB.='GT3<(A(KGI!F^=?,!9PA,[!Y>
MJ0(G@B$(BIYPX^3[RA"7!&Y0I70@?AZW(869&Y,0&#1"X&5J0[W[P"+CV +8
M;:1I84!=C#X#86M"6DAD;ASZ*JY5;J2E<[?R3C94KS?#<F0:S=[CR/^34V+_
M_1K LQ*:E1/FR(D7R(Y:&X*1"H_QK-NVS8[(8-NVG=LG+'%FN^AV8 0&:0=O
M("\  ^=?Q7:<H=TI)Y%ZJT^,8R=T]R)KD>*TP>3Q(B7#&FL>#=(A[0-ML-Y#
M( 0]L-Y/V@/1%](HK0'V_0,M78LY,-\N[0-!%9,Q,%A4 <A-^24'_M1"5)KN
M(3-/'4KUY\S-QG[7#)5NK#)$Q$O2DJM> G\(C;2;3G^S\D[J65RB#F-S?N[J
M3AIU[ES% 2*Y>8XW+HJBV 839^,A;($Z'M=NP($P[@GL3 <^,.09^\H>5XO2
MT62/8AW.P<;UY^'M5)0QR\BO6T^"2BVTBZ8N<]2E_Y>KDQV'D@>[Z!;5 6Q:
MZY,FM!M:O<5' 0!LD#0OYGXH(JX,6)8<G0SPC^JPG_@&@V[HMHUQ'8@))8@,
MI$#TNWVV;W#"QUD'>_""=: $X[)%A^L4#I9L%CD11YC00*C-:W<^!TTRJU06
M= @@#I(J&(U Z_X:" L*@?1()8D#'AW2;.#%J?BD)AWK*CT$[VWW=G]]/J!]
M+UT$0/  +OT#_OTY(PE?^D([!] KI9=Y;QJ:_=0KC7]Z 7Q#.<M/T,YR,("&
M*SJ[\ %N N$>E<EYI03:2LUMU"(S8EX0V%D0R613:3]C!.L:M;] .#K[=Z21
M%%1H>>X&Q6?C#6OCHEP$>?^MSA1H?$9Z?)_(<.S8EUXKI4,.^#J!9.4,*L)Q
MUBED(/KA/LKX?XK8OZ4?F2L0; @F..*&P,,HR'AS-\]^>FVX3V5"P/6+X'>&
M\2O :A7\,#.QD "Q3^! @@4-'D28T& F99J&@2*F2=*D26@F94J#"1DF3,<\
M74+VT5,G3&X\C?2$*9-&9,(ZA42V\B0I3W3>T-%#1R<=)77J%'%#)Q.Q3,.(
M$H,(\1,Q $V=/G5JX*E4 "J>!H!J%2I4K%NW:@4 PZE8 %V;DO4*@*K9M&K9
M@DT;0RZ.&V+$-&SX$"DQA7W]_D6HC"]@PH4-'P8\3).RH1!CX-AR(X9=RFC:
M7+[_Y*/-&1]LAK01,D3T:-%M/(.^+)K(:B*B??R _:,";,B2;<N-<8,HXX95
MIY8U8#6&6@ KU X/^U3% :L'  S'.MQY61@!@C==82# <K<&C#<=KL)Z]J;+
MQ:K0SAQK]>H IBL'KM:J ?9EFZX_2[PI5>\PY-X(0[*&DM$$*<0.1#!!!1=D
ML" QT&C0K\$BI/"P2<2H,$,--^2PPX$8(V:II3*9!),T)DE#DC<XND2D2SII
ML0TZD-FHI#=:),G%FE!R PTW?J1C#I3FF&,((MX@XH<T+$*C$33&0$.,"Y.*
M2!FULC-..['&"\XZW[(J3BKTLEMN.=QNV((N,>H2 [<8_P(0:SHO[\O/-^W<
M$RZLKL2[4K_ZR.+.*:W0<\HZ\^0*$(<P<+!K44=QR N481+*!$,/"=*$P $U
MR00-$E,L\1*..@GFHTX\NH04CCP1)A,:G:'Q&!I?]<2-3$ZZB0Y2<-+)ISK>
M*$()A@3+9*@1\6K*.>3:*H^MY+9Z+[DY[?R.6:Y^ZPHKJMPKS]JO]/-*KC7%
M8%2,,,AEJ+&],KGTL"C;A?= 29-Z*(8P9&"SKBC/N.023BR[K W-/ANMC<^$
M,#A@A8UD>+4*B"CBAQR*\('BNB:+@8O;%N.8F.JD6E8\[\3TLDSGNAI..JL^
M)E2\EKFLBJKJP$).N^#NA-,^Y_^T IFXE<^"TSGVL/I.N^'$(NN ]HI[3MRZ
M;BBW7*/HC;=JJ^.%9D(/E;FZ:Z^_!CML@3AN"*F+*#)QHA^1>?%%3#J9XT5D
M.O%DC#0\HKL3DO1^F^Z1,,G!#2+I:,,3&5>C ^(B4EP2#4G0@+PBI!YZZ-S;
M[%)T33?_LVU<NM#,+3=%RZ6L] <?C/(& -\<]#FDN>5VNV>9VUFJG8G[KJOI
MD!,9=MIC\$_T1>VJZUQR*1L^Q+THG:3JO9:"B,1,)K*(HXY< LF34F5UQI,2
M:<3GU;F1Z9Y\7&\B18]/<M*CCE[K,.*-3QPJ5MWHE7GP\8K&G8Q_.)WU5@ +
M199M_>;_*6@A5%NZ(J;I2 4_:?D=FRA3O-&9JTJ9<@A$Q&80941C@V KD*0X
MIKK*8.Y!;;A$&P"6PC.X(36@(9C"V@"C%!JL811;31&*,)L?%($N,EA4Z,*0
M&^4Q1!/!H1UWD @>U\$,/<,9&7)V=@ L2>5.(RM+#-3SG/WLATSW08]6F'.=
MG>4L9?:)BGC0 D7CA!$K9LE2;B1H+M-%R2Z@P*"!/KA'/GY-:WT$9" %&39C
M%5%Z%SFD&U!E.+JUZ",U4LE+CB$,605C;BW"Y(K>T G!!8D.0R@2$1)'A!Q$
M21)B2(,8&O&@22RE8YG@%"(SD8RC#.-$GBK6)&(YE%Q6) V,_TCE*5%7P2B%
M(4JFI RC)!,#FV4G.E79C@&@N)TQALDL4OF.TI@9 Q7(I6D@VQR:H%:ZS#WM
M='1$'MG8]<$,1B1$%TF#](KEAHYHCVX>\0B-6N4J6,DC?+/RB">0H:HWO&%'
MN]H53WP5/TX5BU,BU%1#S];+2;B!(B1BTJ.6>49P$0> 4"D@TZXBJ&U]M%OE
M">E)MW(G1,VQ+A64H/$X%E$"#=*FE\(@7H@AKM29ZY@PLDP*V7"9,Q!A80'[
M3!M<.$.FAC))K*E8$7)0 8IA;%%I>LP6($(V+LI%FR&CRGN6QD6G'(T\6N*6
M&JD#- 0F\3[ @QU9638GMB!Q9G)*&AQZK*,MXOS'='9! Z-(!SERH6$899/4
M315;-:[!_ZNQB_7+4" [6<I^*(1[\9398-DID332<)XXAB530B..7!*TG:#D
MW#Z2AAD"B6YMF$,;DN"&).002BC*'Y/NDM-B*48Q)))E;R5:O_I1)'*$/29@
M3WG,):$RN><D'C<=F#0]#0T&TR$/<F"P@@/\QU% K*#GSF6\OPXO0'\]76#M
MB ;E+6:/6TW&5H5+7).HME2H!6U(6#(,9,@#5K*2E?E4=2M/O($F--E)K^B@
MPZ)H8A+#4-=BAL*XQZ6(21>RB"3B:9&*3$+#D>,?1[-24KC<*2IUHA.*L>,6
MIT3+6MW-#3H9E5P: _9X41)11"(*2&70H[(96A=O[)6Y$EK&A?\U1*H;6B/;
MR_2H1RJ$W(\NTQH<YC!)$9L8U "$KR%'1GFN!.Q%-+PF">( #8P0@X:->R')
MU.<^[>'."N*DE8^1AW9X2A84!=5=)F*E3%Q$8C?E)*:1^3E9PL&-Z?*%.I^B
MSG'IE3"(?CSI!MD%7G^DM$#>E6E.\]&(!'K(18@!85ZF04A"N@0=^';/3%!2
M5I+H2$<N0<E@4!(3:$!)K=[V-L$180ZL&<(/H.2X)T$N11S3"T48QX@+,Z[#
M$Z'(A3!\ND/B%G)02B]P'VU'&]L1-UUMSQ+AS,#@*4I?37KN<TM7XQG;N,CF
M4M.CPK!5QB2D(HPUHF*2,0EB,&8HQ,C_"$KH=E]D',,9PQ"&/EDR*X8W0R4S
M6=&!/3&'G.AD"6XH BQ)/91(+P:ZE-D?Y$CG[CJ64'-PO0K/Z 27:GU+@&#A
MTTAC3-["EFZ.ZT[OFO;2L<3VT=*=5A"HJ?28=Y\0#2F,+9*5>N0?N0%&*)QA
M"GT$6S?XP*BJ84V2*. #R_'O8E1*5Z=D.=&)8D2>TONXN;2X7:ELB8 H6VO*
MEI.S,GESC.1Y#G^04S/L!+J!(G,3@,Z)!F-VV\;-Y7:C<* 8O&@"Z(\'C& <
M"WG*5]YK.NZ8&.8GSTD007"P_6R+C@$25QWC;2GI2# PH?I@J%X2;-O;CV 4
MV]@F80A*)L*3_R2!;0WWOIV90F[.M[U>PGY82A>6WN,>Q&Q6,DF8Y2(A!4]'
MER%Z4RQO\L]7_S/8TGU8F/E+[S$A9\?" U;\QQR=HTK(&\DBQ")5LQ]2)+&8
M85QD&&]P^NG]-CYA),,9 &Z5@AL?@]L(5WD)FB"P':D)G@B*Q8$P^E$>I2"&
M&AL_#TLEU'F<Y&*3]<*Y)]$< QJ+$P.7;.DB--(/_EBI%HNQQ#NF3F$T&SL#
M1@L^VYB<>6$\0(*&Q[(\PN@8Z,F-<ZFQ%D*A?B'"R^";'EF]2PB&MB'"N+D$
M-+@UV)(1I#(2V? !<DF3R&@3G<LIB0@Y)SF^BJ# RI"@&DNF(?(H]O\8&4(Q
ME&U1%O=@#[R3+N,8CCCJLSGC(C.QE^/YN.#SPX\K/&.SBTAYB!TTQ*O!M$-4
MQ$4\$",JFT]@+Z( KC1X@\%)M4Z8(>T9K5AA&V20A$]D!$:0!%&4!"6TI[E)
M@[W!A%^SH2%0@F)SG"5AMHIHO(8(0U-:$A1!M^93-OTAK YC$@H[D;3C0,7[
M0>A*'1S C45ADQD+)D?SI0\#I@I$@\:I"#4SO#^<H+^JH#"X+%#8HYG"H$D@
M%OJ: YWP&[T1*(V0!X#RA)50"3=8D55Y"8%R!DSXA+S9E2+AB06[B(;*!'KA
M&.&S"]Q2/OT9QG2309+C-LF "N0P"ZWH"K3_\ KF* N7*0\7ZZ8-=#?"2A$P
M)$CR(YXU,1[HN:":8L1)PSP0\0ZB2[>C@[K+H#U1Z80QD 12P<DE[!=,O(38
M"IPV4(*$40VKDRIR^2[)&!='9(B1(SGTRKF0,\H9,R<3\J83XRZ)K _NT KI
M(*L&RCOJ6(__$8OL$)ULY$!N:R[&*:;,L2/&L3%'+)"4E,L,T<%.Z[>YQ$O$
MD+#V$H-DR"5)R(0Q<"&=F(/3,Q5/#(;0TI[0N@2;W(7'W#U>2,SMB;6W:2HC
M80TW& ,I2:5J]#W*@8@+TZUKS$71+!$4@39AA+;C(JSPNXC4<<CE6($80T89
M!"9HC,753#///"==_YQ%T:S&G!O)<RK#I_D/W)! Q_L@O2 ;-/"W:$L#55,U
MIQ,H 62)20*P>#R)3@"6DQ@)&E$5@?+.<Q2E!GP#HS@*AT V4#@=,0Q)*>D4
MXQN\]R0V5HHND/**$H,F^<!/$P2/R0A.X3PF,!R_A3R>E[JJE[*+&F2\N.RC
M>H"&O#P(N&R(ZX(!?1%#R/$!VD,J%(H;>N((TZ.AT=-)PME0'Q"-VLHZB)D-
M10&B&+L8W>"Y\#N=0*11;N.P-U"^RN! ];N8[>"K:DH6+OH8LV*B,MF3:M*S
MZZ+-!QD>,:@4\7.TWM.M.K*CIQDB ($4#$))":6T3;N41/Q22_'2,DT( O]Y
M'OQQ"'A"$:>;3L]ZB6!X ],C424,Q5V(!%M8A,=DA-6C))<(!GIZNM2HK398
M#;LYR.;;.0)Q3\\,)@L#Q@X3QM,\KOV9MOS)Q?U9$S6"F><P.1;<40Y$/&[L
MR*+[JS+4U.@*O,E0':6DE'5RK$@;"O;*I1-Y QGI!#KP3KHA+8T L%[UA%'8
MB1\9A9F8%99X$<%1 C=8@L31)>+2BWDABC5+LR5Y'&SSR#&,DDL=P^8ZG:J<
M"KX:4I43( !]D!1)K^4ZOU-*57A3O]:<(+EPI><)$4 "4S/%BT)R$_ALDL!<
MLL]( BF,FQ ]!EC;&Q2"$;UI ]9:.MIJ12*P.HC_!:]'29-SV<NE6"Y'"\F,
M32X=U50S^ZNS=%(<N"ZK"!39$8LH:C&R,!2AF9-JF<URD=+=M,]CNI"T:Y3G
MDJ/0"1T<>#!Z@U4SI2RBF#S(ZR"A1=J"Z+B("(/BPH1)$,RX4364" ;4ZH2;
M-,5@J(5%8(1%J 5>*!%AN 1)J+5+. :K99%4D\+6J"W-#,YH7)(:1 KT"KZF
M%+_&Z4/4 49L'1?)"(!MZBKB.+=NJ\9B6[XH\5;=*M I+<;2B4%J7$C5X5DY
MJJ.53(A[O91"XAA/.1L328.)PP24^%5,2#B0"+"-J F5T(D?.8GQN4>-J,=<
M%24E2!Q.\:T0:M!A."<B_PNS7G0<8/S%\1,_TEPSFPV^93FI/;D/,1G7VFF*
M#;39#*Q6)EDEZ%HT/C0\NG 3 Y!;>@,D8A!3O(P_4) +_ZC&#O-75RP-4*+)
M3%"]T7.#4D38?A%;RTA8@"&8U=  ']C?',"8+30G"DTO8/JP#+V04:5 /Z0Q
M&DO5(>(S\Q@/[.H3JF"FF+L.+]*7-&O/Y+)6"V,^<CH7-\@Y[4VTFW.< G&E
MNDS:%1Z(\&7A%ZZL!@T1-?T4>!K,PMD;RKQ)E]B%K:T%0_!:P'3?8!C%7;"D
M4EE"-ZBAV))"U=C,WK,P*4GA6;4P"[.(YA-94_(P2RW07:2(&V"/,U'5VVB:
M__]02,!BME-"/&8#3N/Z1>.2P2X>U;[=G,>8(T^A'X'<H[V05L",-A*1/2')
MM8(;K="*E5K1B3?(!#CXB3KP!)HH']1]$4X:'#=8UC<H$(:(P @TI^$)+\+#
MN9)S2L"BL&T+.6]#WOGPBH]:@3)D)5_BME,JER=]4HT%938)G6XZ$W4J(ACF
MHXLEBI-+LY!+@]4PDH"=+2GTU;<1%25V,DQ0H<]+(24#)=)8#:N3@;YU44<!
MYLQARI!5+G2], \S7D:+U/"[4F8B$Z4)DPF>33W)N_;0HA4$QL[D8C5./'U!
MO(N(2LF(# ER$C&\J,;K4E]>817.M!XSZ#*50%>2!*+_>!P2B5HZZ,G3DY46
M63U2P00?OM-@:#74DH3'S.@7@;47"9@B844B&(-S-BX^1HK?1!$,0TTWYC"+
M.)&;AF)F$T;"BX%6=DG#B]>4Z1\<+:$E0=<2J@M@K-''2+QM9%5SX;)$"QUT
MZKUB&35E$ R7WB,C>IZSJ<9/F=K]"S!A(.L :T=D"(HZ@(.UM@,XT E[+#CK
MH>0$TXF,<XB(8#S[83YN T(["J_AO-+3,:?,H3F&#.@"_0^3@@K_2"\#KE+,
M4;Z^GEE%NXTZ#IVZV VR<:^%%IM-#LTVJ0N,6*XQ6 W<J^;8"M&$Q80G])%I
M9JVX@:UI3@W5H(!KQ@'PJEA&/5F4"PH1HS2_OAT7DG,ID\-9X6P^P<8^L?P?
M/?&.,;(*E-E#X[U&XZY-\5.^U FG&8MH7I)$]8RH2>'L0(+_G$NCO)\+[[E,
M88XIKMLB;=IS.A@1J-&;!-0*ADC0VD7@VB84%=)5PM%C&R6NH<]S(=M3:8$.
M1DP 9LZ]1MTROFU%KO'3G^D#ZB(3)G@-[MN0H*GD2)NKXYLKER$3; S7&-!^
MZCK*18?J-ZQ6\6,)VH(@VGBY'R/R:FAS U BDCG0FV+5&Z>#O1S'N#IH:SBP
M@R+ B3G( U43UE6\\1M/@B9/ DS6MSR"KV$30[Q5UW+N8KU=X"T?/#.DC"C>
MJ#-9+YNT1A C[G.-$J94)M5A\S"_;,ZI#%X>$7LE4S.E$@RJE#7QV3%#@QQ8
M#27P-5"2D4N@IR5<;:"*K: T$A<J_TRF6JK1L+H?T( ?.)[O.A=%X5*/8Y('
MQ^).WT9RV<!%>YI\IEOD!K28R1D6:QK!V^?'KDT:_?1M5I3'(*]_3'$5%PP5
MWTMP/.\^(I&B?;P<[/6YQ#S*$>W<%,Q!QT2GFZ1308.J74(\K04TPX36^)&,
M:#VV&;UC2 .39N(B"=AEO:WC@K8N5(:Q0]Q2I]O.1!Z9'1<+MSES@1HM!&Q%
MF\\/G.<PQU+*[1_^P9P &7%TJL#Z 5]:PG7P;:B=0VA-J_,P3>_[BYQX2H//
MU=6]T54 :[73I1%Y+(*UA@,C8&1=:5W4I9LYZ*1SQ DB:# T;6BDN'0-3J;J
M;D]S[C8"=O^N"S2AD92,)RVS-!-M4-GTX[K-;22L-E<[HU\=<<F8&^ "IZF-
M)H4<-0,US5YXL&D_H2TDZ*D(I#PN5++V(2 <PNE)^VV;0+7V@BH"B)U)%*KQ
MT;AFV\YF<S(GEQ8[=<M&\.MBXD,WQ3V_ -7 Y2/NR0TG&WLV<1:^5 UL.9IW
M,88,(IL>J\9JO"9XA\K=83=3%[;\S+\:"G6P&K;IH,"DD:!)0R?=UN.%2*@%
M,:C?JEL]6(-V6\/:?E&83S*2E<XPM60OH+T(K':PZW[WXX-7"B0O=5NO1>DI
M-@$ONX!ZXBRZ90J.535.90QNOP9M>#/QX+KU:,AU]>RE& _'?&W_B&C+L(O8
MSET-"5EAE99 AG5XW9I8 K6V@U_1%?(A'])]+9-'^7,LJ*.8I78""%#$-(7!
M$4:,&#1B;BQ$Z/ A0X<*&SHTB.-APHL3;W"YL05'C!L,%2H,<R.&19,7,2(T
MB! -280<9W[DV+(@3HL,0YZD./'-I$F9- U3IHF8P$_$E&;:Y_0IU*A2IU*M
M:O4JUJQ:MW+=:M0H4F*3%L80,Y;D&")#AB2ATV9.&T^7,%VJ&^S8I39NAA3)
ME*9($2)OW;3IU 9-FS9#B&182V&QCXL1=R[4E(RH0)@/"S*,F+ BR\^-$DZ<
M^'*,)(<J&Y:UZ#-A&J&9_$I2F :-I-N:_\6LW%BVL\@;!G?>D'$0.$8TLI41
M4^:<6*9A0S/)SA16*:BNVK=S[^[]._CP5I6)+^^]'C3SZM>S;^^^*M)AEH]B
M$IJ[]A@T<RYU"H;,$S+'!./),<*XX=\ENRS"R"+!U-4&?PXR@DDPPO2'"5V=
MY 57$HK-080/^4F2WUB3X(:9?,\]-QN+D]3'XD#29:*<)":FII!+FNDHQFTR
MY?193 HQI!%%0!JYT H&A%2D9P_!9)J3+,[6''/.6<D<=%*VB,E 8+W7E75*
M::+,;+F9.$D::;C!GR>>.(-/@,(<@\PPPL@C#S*8"(.,,VW2H8<G@+Z1C#-\
M"I.))YUX\M8<;O_,00<=2A!!%*7#"#3?91.M)%-G#8GD4).?X>3903&)$8:0
MO.$4PV^@+M01JSAL$5%)GQUYJDN=MHJ3<;W&$$:K$IE%W6Q"$4/E4LF.N>R7
MS3K[;%1A)OL)63'DIE!N8B1!!%R-:J@A7<$X&$PGF/A !!QCJ/'#&SYT:%A=
MA*TU[[P@0H30<5TNFUI+^&XZF6J2O68:P!AQ]JNG2Y[Z4F>SXAN:DT8*5Y!,
M& D,VD%FN5'=F%=**13(0:$1UIA-07LRRL^:^"PQ*;N'D,LQRSRS5F(:92F:
M]Z51VP]#0)AHH<A<,BZ&XD;22"2+1+)+779%$HPDDMQ5GX"7P)58&V[_)3&$
M#R;NK%NV7Y6\SY7.T:-,/58N0T\T;+.=MMA9*O>DBR**N-NFI"6D\ZF=RF1J
M:;S%L$*H$M5F(DQ!S8;;QE-:1R7:T,#-G(S%\EOC;$DM!1]YT"Y+IE'WX;8S
M&FZ4JZ@SSR 38)QZ'C.),'O*62B I/"9B3!P8K*ZHHT^^KL;?4EK729Q$\LB
M&IE(9&+%GW8:T:8N"8Q&QA15C]"OTH<A W$?X<1;D*JZ%IKT&!4L!FK*:4D4
MY%+J"SI1-$^EO/PT+TNR&*SR6)M#.0PQQQ#< I<V7<(-PA@:A?CC R.D(0<Y
M4(,.BN"&)!#&,(A13 _H-0&NX2 E"UG)?,@$_YTT9$(2Q:*."64SMQWARB04
M\<SS&N(2WF"$)T0RB Q"$I+>S#!\H?$;J2I6O=@XKDIGPY)USH2&G07E#34"
MA:4LU;+Z4;&*5%'.LSIGQ>XP9XM>_.)Z2B:V^I N(8TH'5S*Q3IQ!>-I:*"+
M)!91BUHL8A=/<Y =F38AJ%WB&'3)R_\4LQ8B_$ ,UQI1SB8!Q?E 3AGT6 ;9
ME@$-92S#D<XAFR.=0AZW59(YQ*..XH@ELB %91*YB0ZQTO 2NA%+=+:B&+YV
MA"8828<8EY$/="BI#RM);D59H@X3F0<;D"E+BU)1R,FDN*QAQ.9KRL$0)A0%
M(-HAPS]YXH4D>!&[=?\(@QURDH<SP'D[9&1B=<>0BUO2.0=)N6$H\I&B0(I7
M/+-IDCQDFB=T F>KC9!FA5 B"4EZ-#<9Y@18OS%.;V#9&6#1$";*,])M:K/"
MEXB!1?*9TK&N!)TLG4F>)+N,%ZD#1FA%$8I09-5(5HF&,= AD%C3T%PHY""\
MN,$'/P!"#LB0 QT8@0B.2DP!VR"$(0R57D3(VPP9$I;B=:QLT; GV>I!MH$L
MI83WJEB1;$7155[KJC<PJ/Z.H](=?>])6E6(*=\ N)W!J$H:U42+9K2\-[CO
M?I\8*5[S&IXIZK6O?OUK=U)T%*6P-0V,T(T;3->M3C"V7'5A+$SJDK3)0B+_
M:4I3VB66&,UO=>M_6]L:$>ZC,5/.*"P" 465,II:MS:GM4UMK3)ZB9ZU==*M
M<".&C.23#.8(A!BUA4YNX\,<]L&U.KAQ(E#.))1:JJUL9M.H"#\6&^6HT$FF
MO!1(J8*>DXF1J27\FD3=@"'&MHEUJXO=)!HAC'+PHKW=M-,\Y)$/9.##&4)9
MW>H\\3M(*8$.P<O$9:QD4I*IB#S-J8<^UJ:,:#C%.IZLD8[X]TF0)6]N0F'B
M=(3Y&A)2^$81>Y4'1_F22=1RH\TY"O$@U\B;_=*4.ZOHLBX38$T ML;> <NE
ME'& LARN-&-0@J,<18=..*HN%.J/,((A+R(4P0AO_RC"#[@UAV@2)C'SVN @
M.]C"E-P@A$V];8&OA!ZW[4.21J$.;LRJOHFB@5:C4URJ0@4E54U$E0K)WDN
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M]93&&7V&S!KM6_"',$A"DET"-LF>+41"<&H3)NQ>--&!#_C,UJQ%#QQC!?@
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M2:05.P)9C)12DE'PBF>3K_6"*U^.RO*4.*L.U9NB@Y1A24GF?5+:WP,L.("
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M>^:CY7 L;K@H#&(@TBS&>VY(,L3P-I J)4:19Y9L9(0NJF@M3MX !,5*MRH
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MI?\45"C'Z0#1RY#L8SY,(B<8"3HY+6N\T$(U=$/WX22"2MNT[3ATJ6&4JR%
M(N]81#A+PD[_*,JQ(D@2Z(NXL-$^$P@-L+!P/&*7 ..!0H4:+8@O6FPO>%.C
M>O00A>]@[M.8U";C*,*"[C,S031!I9!4#(:X[N*QWN9ZS F]Y 8F(8.=:((N
M-J:&+.:'KM%4.F.C%(LP,$A SX9JX@B20O/\Y$)L:# 5F<KG1#1+421%#NB
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M3^0:;6E-!1[S-9C=)C@-V$G$K:)@S  E4V+0VIV;N7-E^#5B .:XJ,=B( :
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M<:[EZD"%+<DM^]3H+;O,/!"V7-%?==$/M=2G?0,^N](R$=[33=ZX*Z;0'1/
MBK23/-G2_55D2E=W2@R<ZJ,&@*6C.LLK4<O1[6)1[+<HJ\WG'1-D6AB]^K-
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M-B#AD=I81=N E7K,(W5SB$DD"&-$O&C QT2<O%FI%<>S'%^T&]T,Q77,C/#
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M7KOM\WI^N^Z[\]Z[[[\#'[SHK<<> P#'(X^\:&*(\1HQ -AU/!H)H1$#06(
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M2A=O[HA90A!LJ!XJA<%SG5Y$&@A6 V<OJ2%:_!JT!WV%GT9N']MT0MRK1.1
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M/MV0:T\['MFS!J73NA]-$%S #N![OX^.9B)T#^]V@/G;H<ZW1!2LOU_,)NQ
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M>>A$H7?+V]Y^RQ24@2@Q@*"&/RJD814ZHUE*Z4='+1$DA-*$<8/2L.F:A#1
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MSZ&X*FM:[A7]VM98%TK3R1+NBIL(R#H'W"1RO/,?_WSI>,^[WC6RA@@$8>^
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@XC >>"D>XS1>XTGGXC:>XSI>;S.^XS[^XT=&# $! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
MB5!.1PT*&@H    -24A$4@   3<   !+" ,    B:S .     7-21T( KLX<
MZ0    1G04U!  "QCPO\804   $X4$Q410       "! @&!@8!PY<55552!
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;8XB/&R'^"YY'6F-\>Q-O     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075835040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,559,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the definitive proxy statement (the Proxy Statement) for the 2023 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 1, 2023, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074386272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074508608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,431,000<span></span>
</td>
<td class="nump">$ 34,195,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">117,158,000<span></span>
</td>
<td class="nump">270,993,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Lease incentive receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,709,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,006,000<span></span>
</td>
<td class="nump">6,248,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">190,595,000<span></span>
</td>
<td class="nump">317,145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">78,934,000<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">34,927,000<span></span>
</td>
<td class="nump">33,060,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503,000<span></span>
</td>
<td class="nump">2,503,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">769,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other non-current assets</a></td>
<td class="nump">1,413,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">308,372,000<span></span>
</td>
<td class="nump">439,727,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,238,000<span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">16,767,000<span></span>
</td>
<td class="nump">18,047,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">13,241,000<span></span>
</td>
<td class="nump">1,886,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,246,000<span></span>
</td>
<td class="nump">21,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">93,561,000<span></span>
</td>
<td class="nump">101,108,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,047,000<span></span>
</td>
<td class="nump">1,114,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">126,854,000<span></span>
</td>
<td class="nump">123,542,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2022: 100,117 and 98,381 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">985,651,000<span></span>
</td>
<td class="nump">964,965,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,531,000)<span></span>
</td>
<td class="num">(714,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(802,612,000)<span></span>
</td>
<td class="num">(648,076,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">181,518,000<span></span>
</td>
<td class="nump">316,185,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 308,372,000<span></span>
</td>
<td class="nump">$ 439,727,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075812880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">100,117,000<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">100,117,000<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074479744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">99,277<span></span>
</td>
<td class="nump">89,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">57,858<span></span>
</td>
<td class="nump">64,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">157,135<span></span>
</td>
<td class="nump">153,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(157,135)<span></span>
</td>
<td class="num">(146,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(154,462)<span></span>
</td>
<td class="num">(145,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(154,536)<span></span>
</td>
<td class="num">(145,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(788)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (155,353)<span></span>
</td>
<td class="num">$ (145,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">99,251<span></span>
</td>
<td class="nump">98,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">99,251<span></span>
</td>
<td class="nump">98,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075239568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 937,134<span></span>
</td>
<td class="num">$ (261)<span></span>
</td>
<td class="num">$ (502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock net of issuance costs</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 25,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (145,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">98,381<span></span>
</td>
<td class="nump">98,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (154,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,536)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">100,117<span></span>
</td>
<td class="nump">100,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 181,518<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 985,651<span></span>
</td>
<td class="num">$ (1,531)<span></span>
</td>
<td class="num">$ (802,612)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077678848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075067408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (154,536)<span></span>
</td>
<td class="num">$ (145,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,528<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,079<span></span>
</td>
<td class="nump">25,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion) amortization of (discount) premium on marketable securities, net</a></td>
<td class="num">(880)<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,417)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="num">(2,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable', window );">Deposit and other long-term assets and deferred rent receivable</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">845<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses, other current and non-current liabilities</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">3,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">13,607<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(108,091)<span></span>
</td>
<td class="num">(107,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(104,363)<span></span>
</td>
<td class="num">(407,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">257,899<span></span>
</td>
<td class="nump">492,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,816)<span></span>
</td>
<td class="num">(15,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">141,720<span></span>
</td>
<td class="nump">78,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of BPI loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">34,236<span></span>
</td>
<td class="num">(26,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">36,698<span></span>
</td>
<td class="nump">63,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">70,934<span></span>
</td>
<td class="nump">36,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">68,431<span></span>
</td>
<td class="nump">34,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">70,934<span></span>
</td>
<td class="nump">36,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination', window );">Decrease in right-of-use asset and lease liability due to termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_RemeasurementOfRightOfUseAssetOnLeaseModification', window );">Remeasurement of right-of-use asset on lease modification</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable and current liabilities</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 1,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deposits and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_RemeasurementOfRightOfUseAssetOnLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Right-Of-Use Asset On Lease Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_RemeasurementOfRightOfUseAssetOnLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643079682752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the business <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $802.6 million as of December&#160;31, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of $185.6 million, which the Company believes will be sufficient to fund its operations into 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643078445824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company held cash deposits at Silicon Valley Bank (&#8220;SVB&#8221;) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) was appointed as receiver. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its deposits with SVB. As such, no losses have been incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the  Company&#8217;s investments are held in custody at a third-party financial institution. Subsequent to March 13, 2023, the Company transferred most of the cash in SVB to a third-party financial institution. As of March 24, 2023, the Company has a remaining $2.5&#160;million deposit with SVB, which secures a letter of credit on a lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-278">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss an impairment charge of  $2.1&#160;million as result of an impairment analysis (see&#160;Note 6) for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. It bases the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the year ended December&#160;31, 2022 was a negative $0.3&#160;million. The deferred rent receivable as of December&#160;31, 2022 and 2021 was zero and $0.8&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2022 and 2021, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized loss on marketable securities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted Topic 326 on January 1, 2023, which had no material impact on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643078445824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bonds and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of December&#160;31, 2022 was $155.5&#160;million, which are highly liquid securities with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of December&#160;31, 2022 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that none of the Company&#8217;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $5.0 million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:f-355">one</span> and two years. The remainder of the marketable securities have a remaining maturity of one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. See Note 6, Balance Sheet Components for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074497712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the initial transaction price is the $7.5&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The Company recognized $7.5&#160;million of license revenue during the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643166359456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has a lease for facilities in Redwood City, which provided a total of tenant improvement allowances of $6.8&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $0.4&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $0.1&#160;million monthly base rent through June 30, 2022. For short-term leases the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable as of December 31, 2022 and 2021 was zero and $0.8&#160;million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted-average remaining lease term was 10.2 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was 9.9%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2023, the Company entered into an agreement to terminate the lease of one of its Redwood City premises, which will be effective September 30, 2023. As of December&#160;31, 2022, including the effect of this subsequent event, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,766)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rent expense for the years ended December&#160;31, 2022, and 2021 was $17.2&#160;million and $12.8&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2022 and 2021 were $2.3 million and $1.8 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2022 and 2021 was $6.0&#160;million and $5.2&#160;million, respectively. Sublease income was $(0.3)&#160;million and $1.2&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, which was classified as a general and administrative expense or reduction in general and administrative expense, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643079706960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the year ended December&#160;31, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.1&#160;million was recognized for the year ended December&#160;31, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074634576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2022, none of the goals had been achieved under the license agreements and no milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#8217;s consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077647824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock Plans</a></td>
<td class="text">Stock Plans<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2022, a total of 37,900,792 shares of common stock were reserved for issuance and 3,202,937 shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $18,000 and $0.1&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the year ended December&#160;31, 2022 include 2.5&#160;million shares of performance-based stock options with both performance and service vesting conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2022 and 2021 were $0.93 and $5.18, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $30.4 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.6 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#8211;4 year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December&#160;31, 2022 include 0.4&#160;million shares of performance stock units with both performance and service vesting conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, total fair value of RSUs vested was $2.8&#160;million and $1.6&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2022, there was $1.6&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.5 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2022, 887,061 shares were issued under the ESPP. As of December&#160;31, 2022, a total of 7,043,481 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2022, there was $0.6&#160;million of unrecognized compensation cost related to the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,079&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,194&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>During the year ended December&#160;31, 2021, the Company recorded approximately $1.6&#160;million of stock&#8209;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of certain of its executives and directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077676128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text">401(k) Savings PlanThe Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2022 and 2021 was $1.1 million and $1.0 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643081340080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Restructuring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the year ended December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the year ended December&#160;31, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077611888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,002)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,375)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2022 and 2021 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased approximately $39.7&#160;million and $53.8&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had U.S. federal net operating losses (&#8220;NOLs&#8221;) carryforwards of approximately $418.9&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2022, the Company also had U.S. state NOL carryforwards of approximately $239.9&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2022, the Company also had approximately $49.0&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had federal research and development tax credit carryforwards of approximately $17.5&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2022, the Company had state credit carryforwards of approximately $15.5&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased by $23.7&#160;million, net of amortization on research expenses capitalized in current year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2022 and 2021 of approximately $24.7&#160;million and $21.9&#160;million, respectively. As of December&#160;31, 2022, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $1.0&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. A&#160;reconciliation of the unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2022 and 2021, the Company accrued interest and penalties related to uncertain tax positions of $0.3 million. There are no ongoing examinations by taxing authorities at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074397296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075060208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company held cash deposits at Silicon Valley Bank (&#8220;SVB&#8221;) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) was appointed as receiver. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its deposits with SVB. As such, no losses have been incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the  Company&#8217;s investments are held in custody at a third-party financial institution. Subsequent to March 13, 2023, the Company transferred most of the cash in SVB to a third-party financial institution. As of March 24, 2023, the Company has a remaining $2.5&#160;million deposit with SVB, which secures a letter of credit on a lease.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-278">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Valuation of Long-Lived Assets and Purchased Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss an impairment charge of  $2.1&#160;million as result of an impairment analysis (see&#160;Note 6) for the year ended December&#160;31, 2022.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. It bases the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the year ended December&#160;31, 2022 was a negative $0.3&#160;million. The deferred rent receivable as of December&#160;31, 2022 and 2021 was zero and $0.8&#160;million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span>The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2022 and 2021, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive Loss&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized loss on marketable securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted Topic 326 on January 1, 2023, which had no material impact on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074681232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077602928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Future Lease Payments under Operating Lease</a></td>
<td class="text">As of December&#160;31, 2022, including the effect of this subsequent event, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,766)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077666864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643070428176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Option Issued Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,079&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,194&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077587840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Cost</a></td>
<td class="text">Below is a summary of restructuring costs during the year ended December&#160;31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643253222832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,002)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,375)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2022 and 2021 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">A&#160;reconciliation of the unrecognized tax benefits is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077652416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074374336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 802,612<span></span>
</td>
<td class="nump">$ 648,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 185,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643070412896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 24, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,124,000<span></span>
</td>
<td class="nump">$ 1,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Negative sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Losses incurred on deposits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075336720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 118,247<span></span>
</td>
<td class="nump">$ 271,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">117,158<span></span>
</td>
<td class="nump">270,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: Cash equivalents, amortized cost basis</a></td>
<td class="num">(56,256)<span></span>
</td>
<td class="num">(25,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: Cash equivalents, unrealized losses</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: Cash equivalents, estimated fair value</a></td>
<td class="num">(56,240)<span></span>
</td>
<td class="num">(25,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">174,503<span></span>
</td>
<td class="nump">297,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,105)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">173,398<span></span>
</td>
<td class="nump">296,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,235<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,235<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">59,487<span></span>
</td>
<td class="nump">62,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(824)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">58,663<span></span>
</td>
<td class="nump">62,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">102,722<span></span>
</td>
<td class="nump">177,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">102,476<span></span>
</td>
<td class="nump">177,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">47,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,024<span></span>
</td>
<td class="nump">$ 47,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074470544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of marketable securities in an unrealized loss position</a></td>
<td class="nump">$ 155,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities', window );">Marketable securities other-than-temporarily impaired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears', window );">Marketable securities</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impaired investments available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071674544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember', window );">Lexeo Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071226560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 08, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,503,000<span></span>
</td>
<td class="nump">$ 2,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200,000<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Negative sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember', window );">Terminated Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseTerminationFee', window );">Lease termination fees</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeSubLeaseMonthlyBaseRent', window );">Lease monthly base rent</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts', window );">Number of renewal contracts | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average IBR (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leasehold Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLeaseholdImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfRenewalContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeSubLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Sub-Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeSubLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074677152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 11,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">11,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">12,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">12,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">13,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">104,410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">165,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustments</a></td>
<td class="num">(74,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">90,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Payment Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2023</a></td>
<td class="nump">5,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2024</a></td>
<td class="nump">6,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2025</a></td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2026</a></td>
<td class="nump">6,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2027</a></td>
<td class="nump">6,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="nump">76,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted lease payments</a></td>
<td class="nump">$ 107,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643070373600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 51,921<span></span>
</td>
<td class="nump">$ 46,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(16,994)<span></span>
</td>
<td class="num">(13,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">34,927<span></span>
</td>
<td class="nump">33,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">14,382<span></span>
</td>
<td class="nump">12,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">34,336<span></span>
</td>
<td class="nump">26,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 4,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071762576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation expense</a></td>
<td class="nump">$ 8,710<span></span>
</td>
<td class="nump">$ 9,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedNonclinicalCostsCurrent', window );">Accrued nonclinical costs</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent', window );">Accrued clinical and process development costs</a></td>
<td class="nump">5,692<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State taxes payable</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 16,767<span></span>
</td>
<td class="nump">$ 18,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and development process costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedClinicalAndDevelopmentProcessCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643077643008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074950208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10,933,000<span></span>
</td>
<td class="nump">8,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of options granted (in USD per share)</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to awards</a></td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares authorized for issuance (in shares)</a></td>
<td class="nump">37,900,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">3,202,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember', window );">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold', window );">Significant stockholder threshold ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="nump">857,000<span></span>
</td>
<td class="nump">2,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair values of RSUs vested</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan', window );">Number of shares available for future issuance (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember', window );">2017 Inducement Plan | Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="nump">208,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">7,043,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage', window );">Percentage increase in shares issued</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued (in shares)</a></td>
<td class="nump">887,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071349136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">10,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10,933<span></span>
</td>
<td class="nump">8,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(4,886)<span></span>
</td>
<td class="num">(5,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">19,320<span></span>
</td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">10,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">19,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">6,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">1.24<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="nump">5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in USD per share)</a></td>
<td class="nump">5.29<span></span>
</td>
<td class="nump">10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">3.38<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share)</a></td>
<td class="nump">$ 11.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contract Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contract Life (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 31,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071649360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">122.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071765200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Restricted Stock Units Activity (Details) - Restricted stock units - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares)</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">1.43<span></span>
</td>
<td class="nump">3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share)</a></td>
<td class="nump">3.41<span></span>
</td>
<td class="nump">5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">3.21<span></span>
</td>
<td class="nump">5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted- Average Remaining Contractual Term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071714096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 20,079<span></span>
</td>
<td class="nump">$ 25,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">7,108<span></span>
</td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 12,971<span></span>
</td>
<td class="nump">$ 16,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074496256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution by company</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075271760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Number of employees (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 4,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071775472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 4,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="num">(4,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Total restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and Benefits Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="num">(4,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Total restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Total restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075896496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (154,002)<span></span>
</td>
<td class="num">$ (145,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">$ (154,462)<span></span>
</td>
<td class="num">$ (145,540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075745568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes- Schedule of Components of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax provision</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643076008464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="num">$ (32,437)<span></span>
</td>
<td class="num">$ (30,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,414<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(2,529)<span></span>
</td>
<td class="num">(2,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">31,542<span></span>
</td>
<td class="nump">41,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Impact of internal reorganization</a></td>
<td class="nump">103<span></span>
</td>
<td class="num">(9,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643071743952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 111,709<span></span>
</td>
<td class="nump">$ 105,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals, reserve and other</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">21,439<span></span>
</td>
<td class="nump">16,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10,705<span></span>
</td>
<td class="nump">9,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsLeaseObligation', window );">Lease obligation</a></td>
<td class="nump">26,241<span></span>
</td>
<td class="nump">24,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital losses</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">9,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsCapitalizedCosts', window );">Capitalized costs</a></td>
<td class="nump">23,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">207,535<span></span>
</td>
<td class="nump">170,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(188,141)<span></span>
</td>
<td class="num">(148,440)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">19,394<span></span>
</td>
<td class="nump">21,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(19,394)<span></span>
</td>
<td class="num">(20,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(19,394)<span></span>
</td>
<td class="num">(21,607)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643075016880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance due to net operating loss</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="nump">$ 53,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsCapitalizedCosts', window );">Capitalized costs</a></td>
<td class="nump">23,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">24,745<span></span>
</td>
<td class="nump">21,944<span></span>
</td>
<td class="nump">$ 8,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized would effective annual tax rate</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">418,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OperatingLossCarryforwardsSubjectToExpiration', window );">NOL carryforwards subject to expiration</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">239,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643074561424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the beginning of the year</a></td>
<td class="nump">$ 21,944<span></span>
</td>
<td class="nump">$ 8,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax provisions</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax provisions</a></td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the end of the year</a></td>
<td class="nump">$ 24,745<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140643076012816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">21,320<span></span>
</td>
<td class="nump">15,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">19,320<span></span>
</td>
<td class="nump">13,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>advm-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="advm-20221231.xsd" xlink:type="simple"/>
    <context id="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ab69acf8f9d429db4ac4733cd22a9d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i20aeecfa68cd4530b60c59a0f8477a8f_I20230317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e11c662ebe9427c840584ca1263d906_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia98f4b7178d44744a308df9113fa922c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82144f9591444e5dbe1046063aa7edbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0774ed7dc54340939b85fedaa67a5b8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee79c44eada9499d85b633f2d5c0e83f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd24dd771e86438c83b29d1f07868719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i059429eb76cc4061a0c3fccafcd267c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i479b3dfe4e2b48c183d1c440a675b09f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie60d5479647d45e18ebbb413a5d2f359_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4683d59050a46d488a4d745d0c261c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8533e6aac0c44366b466a894286f4fc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i706bda682f144a76bbd7a778fd5eeafb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d9ff81f454d4f60b51fbf6f6ce9d7dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21d1a5fb7eac442c8bf23792e4bf1523_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i684e262e9ebe4220803a5cdb770ac920_D20230101-20230313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="if42221aeca784751a0a89d6fafe201f0_I20230324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="i8bed3625ee4841a68ac96bda8ebe9177_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i810c20822d984eb08cf7c2a6a817d1df_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9e8cdee9ec14b64b91e938377f4a543_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i380b7914c06249359dda444f9905896a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie54eacdfb353484d994e873fc23548a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82902a75a654473385cd736e75401243_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3c540347f7d480aa180db7886e8a3cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedd0467e9ac642549c95ec745a488287_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefcd45e58edd4850af86dc9fc5d90f70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icca48fc57d1d479e846c4f02530d15c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5bc35453d4b4041a9df0764848a0f84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib472aed618b34a9fb10288ae7ec8a856_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45ec54c04d84453db0e4212c80ec2572_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0937b54576e43eab4b908ba3f5c3b29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i472587f29eaa49539627aa26bffabf1a_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="id5b54e278e394f4fbc12c82e6a092b94_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bc976ddcd5540e0a8d7e01edfab9bdb_D20211101-20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="i2458438fba324e4195415ece6f14528d_I20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="i61a03128ef774adc862263af15bd7c04_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i304bc2ab93974910a0151644d3112b48_I20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-08</instant>
        </period>
    </context>
    <context id="i4de68338a8dd4a03a318de90290ec9e5_I20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-26</instant>
        </period>
    </context>
    <context id="i6c92305224cd4ce19a716d33e9ed1949_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib049dd87d3c6476abb81eef9b3a27fff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib005f5973c44406db5dfb1279f382aab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06eefc307c154ccf97e8da306731dc67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28cb0293c25243c98f7ef6c87cf0e73d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa7f5d6fc3404c4cb3ab45ed824eed4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95de8a0988824a368b39856bb0aae046_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5dd88652db04bfd85227e3af36299d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0015aff2417c4443ad4e068d9de3e0a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73428454c6a240dfba85f104a15e8855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d00999723f1430587e349be9d8235cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1498b295afbf4a4490855b8a8cdbb3cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie0f3cdcaa5c74c348159656932b0209d_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="id7ac711d969d4dbfb2019544f7853129_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if279653acc6e4cd2badab9c5d64df217_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f60854b5a5740ef83803c7983ca8de5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i970fe692f1ab49b9a0589b0c713af515_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3eebdf1a70334e0bbfac1cd4e13e54d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25a6c23a548c4172830b509bf8547103_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8538e8736e164287a7a89d9e822ddfd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8691ff06ffc1432cab9667187afd1df3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i898f06f98a6748bab720765be614526a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a88b50331e3498db3de301a5215fd47_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f966046784044f3987ed481b7a376f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22c7d5d67f5143b6ad282485c7c83751_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5777a3c4cf644a5aa6e2876e0e3e845_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28339715955e48b08119618310a60857_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i156af0396aec4513abe4f372a8df3dbb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7855e85faff848b484bde07a79723de6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18307b729fb84369a1680d708830e51b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie7438ee3072e41e794bdd9191b73a3cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd9a1719e37e4f70a2a084ceacc62892_I20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-07-06</instant>
        </period>
    </context>
    <context id="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e2fd438f1564243a91086e75afa936f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18bfdbc3193a412788e21e1810c123f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48f2b20caf244f849a37d4c8e8327f84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85786b5c81d343789ff2c120dd964eb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a146e7e34f3411f8b40f1773b7e8c0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c8589134e324d12b0bbaf1468c0b43a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f072761559d486f92055c7cfb714341_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96823e332fad42d4a1f4b9064d27f17e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iada4fca2d20a473abfe9c9eaec73a105_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90d6a4e6dcbf4891bbb8bcd22b37a13c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib724c14cbcfe4412b6c1ae8d4c5cc41f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idaaa273c85484c7b8335ccf796b65072_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80c09039c3df4bae937a95e6a7634f2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>advm:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>advm:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-32">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-34">0001501756</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8bed3625ee4841a68ac96bda8ebe9177_D20220101-20221231"
      id="f-278">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i45ec54c04d84453db0e4212c80ec2572_I20221231"
      id="f-355">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <dei:DocumentType
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-4">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-6">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-7">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-9">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-10">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-11">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-13">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-14">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-15">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-16">Common Stock, par value $0.0001&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-17">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i4ab69acf8f9d429db4ac4733cd22a9d1_I20220630"
      decimals="-5"
      id="f-28"
      unitRef="usd">114900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i20aeecfa68cd4530b60c59a0f8477a8f_I20230317"
      decimals="INF"
      id="f-29"
      unitRef="shares">100559291</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-30">Portions of the definitive proxy statement (the Proxy Statement) for the 2023 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 1, 2023, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-35">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-36">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-37">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-38"
      unitRef="usd">68431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-39"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-40"
      unitRef="usd">117158000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-41"
      unitRef="usd">270993000</us-gaap:ShortTermInvestments>
    <us-gaap:IncentiveToLessee
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-42"
      unitRef="usd">0</us-gaap:IncentiveToLessee>
    <us-gaap:IncentiveToLessee
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-43"
      unitRef="usd">5709000</us-gaap:IncentiveToLessee>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-44"
      unitRef="usd">5006000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-45"
      unitRef="usd">6248000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-46"
      unitRef="usd">190595000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-47"
      unitRef="usd">317145000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-48"
      unitRef="usd">78934000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-49"
      unitRef="usd">86000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-50"
      unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-51"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-52"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-53"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-54"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-55"
      unitRef="usd">769000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-56"
      unitRef="usd">1413000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-57"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-58"
      unitRef="usd">308372000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-59"
      unitRef="usd">439727000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-60"
      unitRef="usd">2238000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-61"
      unitRef="usd">1387000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-62"
      unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-63"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-64"
      unitRef="usd">13241000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-65"
      unitRef="usd">1886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-66"
      unitRef="usd">32246000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-67"
      unitRef="usd">21320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-68"
      unitRef="usd">93561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-69"
      unitRef="usd">101108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-70"
      unitRef="usd">1047000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-71"
      unitRef="usd">1114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-72"
      unitRef="usd">126854000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-73"
      unitRef="usd">123542000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      id="f-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      id="f-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-76"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-78"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-79"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="INF"
      id="f-80"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-81"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-82"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="INF"
      id="f-83"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-84"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-85"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="INF"
      id="f-86"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-87"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-88"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-89"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-90"
      unitRef="shares">100117000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-91"
      unitRef="shares">100117000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-92"
      unitRef="shares">98381000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-93"
      unitRef="shares">98381000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-94"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-95"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-96"
      unitRef="usd">985651000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-97"
      unitRef="usd">964965000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-98"
      unitRef="usd">-1531000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-99"
      unitRef="usd">-714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-100"
      unitRef="usd">-802612000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-101"
      unitRef="usd">-648076000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-102"
      unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-103"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-104"
      unitRef="usd">308372000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-105"
      unitRef="usd">439727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-106"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-107"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-108"
      unitRef="usd">99277000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-109"
      unitRef="usd">89181000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-110"
      unitRef="usd">57858000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-111"
      unitRef="usd">64441000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-112"
      unitRef="usd">157135000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-113"
      unitRef="usd">153622000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-114"
      unitRef="usd">-157135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-115"
      unitRef="usd">-146122000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-116"
      unitRef="usd">2673000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-117"
      unitRef="usd">582000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-118"
      unitRef="usd">-154462000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-119"
      unitRef="usd">-145540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-120"
      unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-121"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-122"
      unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-123"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-124"
      unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-125"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-126"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-127"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-128"
      unitRef="usd">-155353000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-129"
      unitRef="usd">-145993000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-133"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-134"
      unitRef="shares">99251000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-135"
      unitRef="shares">99251000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-136"
      unitRef="shares">98039000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-137"
      unitRef="shares">98039000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231"
      decimals="-3"
      id="f-138"
      unitRef="shares">97549000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia2adc237b17e4a0a91ee3139a8e40c15_I20201231"
      decimals="-3"
      id="f-139"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia98f4b7178d44744a308df9113fa922c_I20201231"
      decimals="-3"
      id="f-140"
      unitRef="usd">937134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82144f9591444e5dbe1046063aa7edbb_I20201231"
      decimals="-3"
      id="f-141"
      unitRef="usd">-261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0774ed7dc54340939b85fedaa67a5b8a_I20201231"
      decimals="-3"
      id="f-142"
      unitRef="usd">-502536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="-3"
      id="f-143"
      unitRef="usd">434347000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-144"
      unitRef="usd">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"
      decimals="-3"
      id="f-145"
      unitRef="shares">121000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"
      decimals="-3"
      id="f-146"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231"
      decimals="-3"
      id="f-147"
      unitRef="usd">1685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-148"
      unitRef="usd">1685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231"
      decimals="-3"
      id="f-149"
      unitRef="usd">25194000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-150"
      unitRef="usd">25194000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"
      decimals="-3"
      id="f-151"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231"
      decimals="-3"
      id="f-152"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-153"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"
      decimals="-3"
      id="f-154"
      unitRef="shares">397000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5d67ab47f29a49fb9b0173b0fc4fb23c_D20210101-20211231"
      decimals="-3"
      id="f-155"
      unitRef="usd">901000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-156"
      unitRef="usd">901000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i1111347a3d724cf1aff7344a4d2be0a0_D20210101-20211231"
      decimals="-3"
      id="f-157"
      unitRef="shares">305000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231"
      decimals="-3"
      id="f-158"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-159"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8b105cce479e4bacaadc201e246e1253_D20210101-20211231"
      decimals="-3"
      id="f-160"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-161"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iee79c44eada9499d85b633f2d5c0e83f_D20210101-20211231"
      decimals="-3"
      id="f-162"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-163"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd24dd771e86438c83b29d1f07868719_I20211231"
      decimals="-3"
      id="f-164"
      unitRef="shares">98381000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idd24dd771e86438c83b29d1f07868719_I20211231"
      decimals="-3"
      id="f-165"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i059429eb76cc4061a0c3fccafcd267c8_I20211231"
      decimals="-3"
      id="f-166"
      unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i479b3dfe4e2b48c183d1c440a675b09f_I20211231"
      decimals="-3"
      id="f-167"
      unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie60d5479647d45e18ebbb413a5d2f359_I20211231"
      decimals="-3"
      id="f-168"
      unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-169"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231"
      decimals="-3"
      id="f-170"
      unitRef="usd">20079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-171"
      unitRef="usd">20079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231"
      decimals="-3"
      id="f-172"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231"
      decimals="-3"
      id="f-173"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-174"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231"
      decimals="-3"
      id="f-175"
      unitRef="shares">886000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i040c4d5cfc4947489cd089c8ac852cca_D20220101-20221231"
      decimals="-3"
      id="f-176"
      unitRef="usd">604000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-177"
      unitRef="usd">604000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i83ddd55c3bf44301a225e905139d36d4_D20220101-20221231"
      decimals="-3"
      id="f-178"
      unitRef="shares">835000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231"
      decimals="-3"
      id="f-179"
      unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-180"
      unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3cc3cf4b1d3f40b3a6512dbd1f681f72_D20220101-20221231"
      decimals="-3"
      id="f-181"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-182"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id4683d59050a46d488a4d745d0c261c8_D20220101-20221231"
      decimals="-3"
      id="f-183"
      unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-184"
      unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8533e6aac0c44366b466a894286f4fc5_I20221231"
      decimals="-3"
      id="f-185"
      unitRef="shares">100117000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8533e6aac0c44366b466a894286f4fc5_I20221231"
      decimals="-3"
      id="f-186"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i706bda682f144a76bbd7a778fd5eeafb_I20221231"
      decimals="-3"
      id="f-187"
      unitRef="usd">985651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d9ff81f454d4f60b51fbf6f6ce9d7dd_I20221231"
      decimals="-3"
      id="f-188"
      unitRef="usd">-1531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i21d1a5fb7eac442c8bf23792e4bf1523_I20221231"
      decimals="-3"
      id="f-189"
      unitRef="usd">-802612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-190"
      unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-191"
      unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-192"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-193"
      unitRef="usd">6528000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-194"
      unitRef="usd">4645000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-195"
      unitRef="usd">20079000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-196"
      unitRef="usd">25194000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-197"
      unitRef="usd">880000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-198"
      unitRef="usd">-2770000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-199"
      unitRef="usd">-122000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-200"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AssetImpairmentCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-201"
      unitRef="usd">2124000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-202"
      unitRef="usd">1063000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-203"
      unitRef="usd">1417000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-204"
      unitRef="usd">25000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-205"
      unitRef="usd">-1653000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-206"
      unitRef="usd">2257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-207"
      unitRef="usd">394000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-208"
      unitRef="usd">990000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-209"
      unitRef="usd">4040000</advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-210"
      unitRef="usd">2719000</advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-211"
      unitRef="usd">845000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-212"
      unitRef="usd">-1612000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-213"
      unitRef="usd">64000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-214"
      unitRef="usd">3274000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-215"
      unitRef="usd">74000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-216"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-217"
      unitRef="usd">13607000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-218"
      unitRef="usd">2928000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-219"
      unitRef="usd">-108091000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-220"
      unitRef="usd">-107831000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-221"
      unitRef="usd">104363000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-222"
      unitRef="usd">407514000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-223"
      unitRef="usd">257899000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-224"
      unitRef="usd">492356000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-225"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-226"
      unitRef="usd">8990000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-227"
      unitRef="usd">11816000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-228"
      unitRef="usd">15123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-229"
      unitRef="usd">141720000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-230"
      unitRef="usd">78709000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-231"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-232"
      unitRef="usd">1685000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-233"
      unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-234"
      unitRef="usd">51000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-235"
      unitRef="usd">604000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-236"
      unitRef="usd">901000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-237"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-238"
      unitRef="usd">240000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-239"
      unitRef="usd">607000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-240"
      unitRef="usd">2397000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-241"
      unitRef="usd">34236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-242"
      unitRef="usd">-26725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-243"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="-3"
      id="f-244"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-245"
      unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-246"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-247"
      unitRef="usd">68431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-248"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-249"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-250"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-251"
      unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-252"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-253"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-254"
      unitRef="usd">84005000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-255"
      unitRef="usd">0</advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination>
    <advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-256"
      unitRef="usd">15768000</advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination>
    <advm:RemeasurementOfRightOfUseAssetOnLeaseModification
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-257"
      unitRef="usd">2842000</advm:RemeasurementOfRightOfUseAssetOnLeaseModification>
    <advm:RemeasurementOfRightOfUseAssetOnLeaseModification
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-258"
      unitRef="usd">2052000</advm:RemeasurementOfRightOfUseAssetOnLeaseModification>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-259"
      unitRef="usd">64000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-260"
      unitRef="usd">1402000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-261">Description of the business &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $802.6 million as of December&#160;31, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of $185.6 million, which the Company believes will be sufficient to fund its operations into 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-262"
      unitRef="usd">-802600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-263"
      unitRef="usd">185600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-264">Summary of significant accounting policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#x2019;s original estimates in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support growth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company held cash deposits at Silicon Valley Bank (&#x201c;SVB&#x201d;) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) was appointed as receiver. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#x2019; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its deposits with SVB. As such, no losses have been incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the  Company&#x2019;s investments are held in custody at a third-party financial institution. Subsequent to March 13, 2023, the Company transferred most of the cash in SVB to a third-party financial institution. As of March 24, 2023, the Company has a remaining $2.5&#160;million deposit with SVB, which secures a letter of credit on a lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-278"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets and Purchased Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates the carrying value of amortizable long&#x2011;lived assets whenever events, or changes in business circumstances or the planned use of long&#x2011;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#x2011;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#x2011;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#x2019;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss an impairment charge of  $2.1&#160;million as result of an impairment analysis (see&#160;Note 6) for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. It bases the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the year ended December&#160;31, 2022 was a negative $0.3&#160;million. The deferred rent receivable as of December&#160;31, 2022 and 2021 was zero and $0.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#x201c;RSUs&#x201d;) and performance stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2022 and 2021, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized loss on marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#x201c;ESPP&#x201d;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted Topic 326 on January 1, 2023, which had no material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-265">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:UseOfEstimates
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-266">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#x2019;s original estimates in any periods presented.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-267">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-268">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-269">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-270">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-271">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="INF"
      id="f-272"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="INF"
      id="f-273"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-274">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support growth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company held cash deposits at Silicon Valley Bank (&#x201c;SVB&#x201d;) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) was appointed as receiver. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#x2019; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its deposits with SVB. As such, no losses have been incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the  Company&#x2019;s investments are held in custody at a third-party financial institution. Subsequent to March 13, 2023, the Company transferred most of the cash in SVB to a third-party financial institution. As of March 24, 2023, the Company has a remaining $2.5&#160;million deposit with SVB, which secures a letter of credit on a lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:GainLossOnInvestments
      contextRef="i684e262e9ebe4220803a5cdb770ac920_D20230101-20230313"
      decimals="-5"
      id="f-275"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="if42221aeca784751a0a89d6fafe201f0_I20230324"
      decimals="-5"
      id="f-276"
      unitRef="usd">2500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-277">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-278"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i810c20822d984eb08cf7c2a6a817d1df_D20220101-20221231"
      id="f-279">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-280">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets and Purchased Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates the carrying value of amortizable long&#x2011;lived assets whenever events, or changes in business circumstances or the planned use of long&#x2011;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#x2011;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#x2011;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#x2019;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss an impairment charge of  $2.1&#160;million as result of an impairment analysis (see&#160;Note 6) for the year ended December&#160;31, 2022.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-281"
      unitRef="usd">2100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-282">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. It bases the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. As a result of the adjustment to eliminate the deferred rent receivable, sublease income for the year ended December&#160;31, 2022 was a negative $0.3&#160;million. The deferred rent receivable as of December&#160;31, 2022 and 2021 was zero and $0.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SubleaseIncome
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-283"
      unitRef="usd">-300000</us-gaap:SubleaseIncome>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-284"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-5"
      id="f-285"
      unitRef="usd">800000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-286">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-287">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-288">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-289">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#x201c;RSUs&#x201d;) and performance stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-290">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2022 and 2021, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-291">Comprehensive Loss&#x2014;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized loss on marketable securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-292">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#x201c;ESPP&#x201d;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-293">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted Topic 326 on January 1, 2023, which had no material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-294">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bonds and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#x2019;s consolidated balance sheet. Management regularly reviews all of the Company&#x2019;s investments for other-than-temporary declines in estimated fair value. The aggregate fair value of the marketable securities in an unrealized loss position as of December&#160;31, 2022 was $155.5&#160;million, which are highly liquid securities with high credit ratings that have final maturity of less than two years from date of purchase. Management determined that the gross unrealized losses on the Company&#x2019;s marketable securities as of December&#160;31, 2022 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that none of the Company&#x2019;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $5.0 million of marketable securities had remaining maturities between &lt;span style="-sec-ix-hidden:f-355"&gt;one&lt;/span&gt; and two years. The remainder of the marketable securities have a remaining maturity of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. See Note 6, Balance Sheet Components for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-295">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231"
      decimals="-3"
      id="f-296"
      unitRef="usd">10235000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231"
      decimals="-3"
      id="f-297"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231"
      decimals="-3"
      id="f-298"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9e8cdee9ec14b64b91e938377f4a543_I20221231"
      decimals="-3"
      id="f-299"
      unitRef="usd">10235000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i380b7914c06249359dda444f9905896a_I20221231"
      decimals="-3"
      id="f-300"
      unitRef="usd">59487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i380b7914c06249359dda444f9905896a_I20221231"
      decimals="-3"
      id="f-301"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i380b7914c06249359dda444f9905896a_I20221231"
      decimals="-3"
      id="f-302"
      unitRef="usd">824000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i380b7914c06249359dda444f9905896a_I20221231"
      decimals="-3"
      id="f-303"
      unitRef="usd">58663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231"
      decimals="-3"
      id="f-304"
      unitRef="usd">102722000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231"
      decimals="-3"
      id="f-305"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231"
      decimals="-3"
      id="f-306"
      unitRef="usd">246000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie54eacdfb353484d994e873fc23548a0_I20221231"
      decimals="-3"
      id="f-307"
      unitRef="usd">102476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i82902a75a654473385cd736e75401243_I20221231"
      decimals="-3"
      id="f-308"
      unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i82902a75a654473385cd736e75401243_I20221231"
      decimals="-3"
      id="f-309"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i82902a75a654473385cd736e75401243_I20221231"
      decimals="-3"
      id="f-310"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82902a75a654473385cd736e75401243_I20221231"
      decimals="-3"
      id="f-311"
      unitRef="usd">2024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231"
      decimals="-3"
      id="f-312"
      unitRef="usd">174503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231"
      decimals="-3"
      id="f-313"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231"
      decimals="-3"
      id="f-314"
      unitRef="usd">1105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia3c540347f7d480aa180db7886e8a3cf_I20221231"
      decimals="-3"
      id="f-315"
      unitRef="usd">173398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-316"
      unitRef="usd">56256000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-317"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-318"
      unitRef="usd">16000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-319"
      unitRef="usd">56240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-320"
      unitRef="usd">118247000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-321"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-322"
      unitRef="usd">1089000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-323"
      unitRef="usd">117158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iedd0467e9ac642549c95ec745a488287_I20211231"
      decimals="-3"
      id="f-324"
      unitRef="usd">10311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iedd0467e9ac642549c95ec745a488287_I20211231"
      decimals="-3"
      id="f-325"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iedd0467e9ac642549c95ec745a488287_I20211231"
      decimals="-3"
      id="f-326"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedd0467e9ac642549c95ec745a488287_I20211231"
      decimals="-3"
      id="f-327"
      unitRef="usd">10311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231"
      decimals="-3"
      id="f-328"
      unitRef="usd">62268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231"
      decimals="-3"
      id="f-329"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231"
      decimals="-3"
      id="f-330"
      unitRef="usd">218000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iefcd45e58edd4850af86dc9fc5d90f70_I20211231"
      decimals="-3"
      id="f-331"
      unitRef="usd">62050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231"
      decimals="-3"
      id="f-332"
      unitRef="usd">177215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231"
      decimals="-3"
      id="f-333"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231"
      decimals="-3"
      id="f-334"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icca48fc57d1d479e846c4f02530d15c2_I20211231"
      decimals="-3"
      id="f-335"
      unitRef="usd">177155000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231"
      decimals="-3"
      id="f-336"
      unitRef="usd">47323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231"
      decimals="-3"
      id="f-337"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231"
      decimals="-3"
      id="f-338"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5bc35453d4b4041a9df0764848a0f84_I20211231"
      decimals="-3"
      id="f-339"
      unitRef="usd">47284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231"
      decimals="-3"
      id="f-340"
      unitRef="usd">297117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231"
      decimals="-3"
      id="f-341"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231"
      decimals="-3"
      id="f-342"
      unitRef="usd">318000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib472aed618b34a9fb10288ae7ec8a856_I20211231"
      decimals="-3"
      id="f-343"
      unitRef="usd">296800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-344"
      unitRef="usd">25808000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-345"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-346"
      unitRef="usd">1000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-347"
      unitRef="usd">25807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-348"
      unitRef="usd">271309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-349"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-350"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-351"
      unitRef="usd">270993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-352"
      unitRef="usd">155500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-353"
      unitRef="usd">0</advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities>
    <advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-354"
      unitRef="usd">5000000</advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ie0937b54576e43eab4b908ba3f5c3b29_I20221231"
      id="f-356">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-357">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lexeo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#x201c;Lexeo&#x201d;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the initial transaction price is the $7.5&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The Company recognized $7.5&#160;million of license revenue during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i472587f29eaa49539627aa26bffabf1a_D20210125-20210125"
      decimals="-5"
      id="f-358"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125"
      decimals="-5"
      id="f-359"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-360"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-361">Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redwood City&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company has a lease for facilities in Redwood City, which provided a total of tenant improvement allowances of $6.8&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $0.4&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $0.1&#160;million monthly base rent through June 30, 2022. For short-term leases the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;North Carolina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#x201c;NC Premises&#x201d;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#x2019;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable as of December 31, 2022 and 2021 was zero and $0.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the weighted-average remaining lease term was 10.2 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#x201c;IBR&#x201d;) was 9.9%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2023, the Company entered into an agreement to terminate the lease of one of its Redwood City premises, which will be effective September 30, 2023. As of December&#160;31, 2022, including the effect of this subsequent event, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rent expense for the years ended December&#160;31, 2022, and 2021 was $17.2&#160;million and $12.8&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2022 and 2021 were $2.3 million and $1.8 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2022 and 2021 was $6.0&#160;million and $5.2&#160;million, respectively. Sublease income was $(0.3)&#160;million and $1.2&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, which was classified as a general and administrative expense or reduction in general and administrative expense, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance
      contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231"
      decimals="-5"
      id="f-362"
      unitRef="usd">6800000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231"
      decimals="-5"
      id="f-363"
      unitRef="usd">2500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id5b54e278e394f4fbc12c82e6a092b94_I20221231"
      id="f-364">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseLeaseTerminationFee
      contextRef="i0bc976ddcd5540e0a8d7e01edfab9bdb_D20211101-20211101"
      decimals="-5"
      id="f-365"
      unitRef="usd">400000</advm:LesseeOperatingLeaseLeaseTerminationFee>
    <advm:LesseeSubLeaseMonthlyBaseRent
      contextRef="i2458438fba324e4195415ece6f14528d_I20211101"
      decimals="-5"
      id="f-366"
      unitRef="usd">100000</advm:LesseeSubLeaseMonthlyBaseRent>
    <advm:LesseeOperatingLeaseNumberOfRenewalContracts
      contextRef="i61a03128ef774adc862263af15bd7c04_D20210108-20210108"
      decimals="INF"
      id="f-367"
      unitRef="segment">2</advm:LesseeOperatingLeaseNumberOfRenewalContracts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i304bc2ab93974910a0151644d3112b48_I20210108"
      id="f-368">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance
      contextRef="i4de68338a8dd4a03a318de90290ec9e5_I20211026"
      decimals="-5"
      id="f-369"
      unitRef="usd">22700000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-370"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-5"
      id="f-371"
      unitRef="usd">800000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6c92305224cd4ce19a716d33e9ed1949_I20221231"
      id="f-372">P10Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6c92305224cd4ce19a716d33e9ed1949_I20221231"
      decimals="3"
      id="f-373"
      unitRef="number">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-374">As of December&#160;31, 2022, including the effect of this subsequent event, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-375"
      unitRef="usd">11484000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-376"
      unitRef="usd">5844000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-377"
      unitRef="usd">11857000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-378"
      unitRef="usd">6019000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-379"
      unitRef="usd">12242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-380"
      unitRef="usd">6200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-381"
      unitRef="usd">12639000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-382"
      unitRef="usd">6385000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-383"
      unitRef="usd">13050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-384"
      unitRef="usd">6577000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-385"
      unitRef="usd">104410000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-386"
      unitRef="usd">76174000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-387"
      unitRef="usd">165682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-388"
      unitRef="usd">107199000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-389"
      unitRef="usd">74766000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-390"
      unitRef="usd">90916000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-391"
      unitRef="usd">17200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-392"
      unitRef="usd">12800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-393"
      unitRef="usd">2300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-394"
      unitRef="usd">1800000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-395"
      unitRef="usd">6000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-396"
      unitRef="usd">5200000</us-gaap:OperatingLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-397"
      unitRef="usd">-300000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-398"
      unitRef="usd">1200000</us-gaap:SubleaseIncome>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-399">Balance Sheet Components&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the year ended December&#160;31, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.1&#160;million was recognized for the year ended December&#160;31, 2022. The assets indicated as impaired were written down to their estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-400">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib049dd87d3c6476abb81eef9b3a27fff_I20221231"
      decimals="-3"
      id="f-401"
      unitRef="usd">1325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib005f5973c44406db5dfb1279f382aab_I20211231"
      decimals="-3"
      id="f-402"
      unitRef="usd">1224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06eefc307c154ccf97e8da306731dc67_I20221231"
      decimals="-3"
      id="f-403"
      unitRef="usd">14382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i28cb0293c25243c98f7ef6c87cf0e73d_I20211231"
      decimals="-3"
      id="f-404"
      unitRef="usd">12778000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifa7f5d6fc3404c4cb3ab45ed824eed4f_I20221231"
      decimals="-3"
      id="f-405"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i95de8a0988824a368b39856bb0aae046_I20211231"
      decimals="-3"
      id="f-406"
      unitRef="usd">1136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic5dd88652db04bfd85227e3af36299d5_I20221231"
      decimals="-3"
      id="f-407"
      unitRef="usd">34336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0015aff2417c4443ad4e068d9de3e0a2_I20211231"
      decimals="-3"
      id="f-408"
      unitRef="usd">26701000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i73428454c6a240dfba85f104a15e8855_I20221231"
      decimals="-3"
      id="f-409"
      unitRef="usd">1010000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d00999723f1430587e349be9d8235cb_I20211231"
      decimals="-3"
      id="f-410"
      unitRef="usd">4395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-411"
      unitRef="usd">51921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-412"
      unitRef="usd">46234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-413"
      unitRef="usd">16994000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-414"
      unitRef="usd">13174000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-415"
      unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-416"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetImpairmentCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-417"
      unitRef="usd">2100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-418">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-419"
      unitRef="usd">8710000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-420"
      unitRef="usd">9209000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-421"
      unitRef="usd">532000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-422"
      unitRef="usd">550000</us-gaap:AccruedProfessionalFeesCurrent>
    <advm:AccruedNonclinicalCostsCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-423"
      unitRef="usd">1162000</advm:AccruedNonclinicalCostsCurrent>
    <advm:AccruedNonclinicalCostsCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-424"
      unitRef="usd">2895000</advm:AccruedNonclinicalCostsCurrent>
    <advm:AccruedClinicalAndDevelopmentProcessCostsCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-425"
      unitRef="usd">5692000</advm:AccruedClinicalAndDevelopmentProcessCostsCurrent>
    <advm:AccruedClinicalAndDevelopmentProcessCostsCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-426"
      unitRef="usd">2058000</advm:AccruedClinicalAndDevelopmentProcessCostsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-427"
      unitRef="usd">254000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-428"
      unitRef="usd">1318000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-429"
      unitRef="usd">417000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-430"
      unitRef="usd">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-431"
      unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-432"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-433">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2022, none of the goals had been achieved under the license agreements and no milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="INF"
      id="f-434"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-435">Stock Plans&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#x201c;2006 Plan&#x201d;). The 2006 Plan allowed for the granting of incentive stock options (&#x201c;ISOs&#x201d;) and non-qualified stock options (&#x201c;NSOs&#x201d;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#x2019;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#x2019;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#x201c;2014 Plan&#x201d;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company adopted the 2017 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2022, a total of 37,900,792 shares of common stock were reserved for issuance and 3,202,937 shares were available for future grants under the Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $18,000 and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the year ended December&#160;31, 2022 include 2.5&#160;million shares of performance-based stock options with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of options granted during the years ended December&#160;31, 2022 and 2021 were $0.93 and $5.18, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $30.4 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#x2019;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#x2019;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#x2013;4 year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted during the year ended December&#160;31, 2022 include 0.4&#160;million shares of performance stock units with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, total fair value of RSUs vested was $2.8&#160;million and $1.6&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2022, there was $1.6&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#x2019;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#x2019;s board of directors. During the year ended December&#160;31, 2022, 887,061 shares were issued under the ESPP. As of December&#160;31, 2022, a total of 7,043,481 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2022, there was $0.6&#160;million of unrecognized compensation cost related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the year ended December&#160;31, 2021, the Company recorded approximately $1.6&#160;million of stock&#x2011;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of certain of its executives and directors.</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan
      contextRef="i1498b295afbf4a4490855b8a8cdbb3cf_D20220101-20221231"
      decimals="INF"
      id="f-436"
      unitRef="number">0.04</advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie0f3cdcaa5c74c348159656932b0209d_I20171031"
      decimals="INF"
      id="f-437"
      unitRef="shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id7ac711d969d4dbfb2019544f7853129_I20221231"
      decimals="INF"
      id="f-438"
      unitRef="shares">37900792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id7ac711d969d4dbfb2019544f7853129_I20221231"
      decimals="INF"
      id="f-439"
      unitRef="shares">3202937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if279653acc6e4cd2badab9c5d64df217_D20220101-20221231"
      id="f-440">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"
      decimals="INF"
      id="f-441"
      unitRef="number">1</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold
      contextRef="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231"
      decimals="INF"
      id="f-442"
      unitRef="number">0.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="i7e8f5fca025e419b9c107a346d8ccb42_D20220101-20221231"
      decimals="INF"
      id="f-443"
      unitRef="number">1.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6f60854b5a5740ef83803c7983ca8de5_D20220101-20221231"
      id="f-444">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-445">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="-3"
      id="f-446"
      unitRef="shares">10432000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="2"
      id="f-447"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i970fe692f1ab49b9a0589b0c713af515_D20200101-20201231"
      id="f-448">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="-3"
      id="f-449"
      unitRef="usd">31626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-450"
      unitRef="shares">8231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-451"
      unitRef="usdPerShare">7.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-452"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-453"
      unitRef="usdPerShare">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-454"
      unitRef="shares">5366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">10.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-456"
      unitRef="shares">13288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      id="f-458">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-459"
      unitRef="usd">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-460"
      unitRef="shares">10933000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-462"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-464"
      unitRef="shares">4886000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-465"
      unitRef="usdPerShare">5.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-466"
      unitRef="shares">19320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-468">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-469"
      unitRef="usd">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-470"
      unitRef="shares">19320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="2"
      id="f-471"
      unitRef="usdPerShare">5.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-472">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-473"
      unitRef="usd">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-474"
      unitRef="shares">6102000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="2"
      id="f-475"
      unitRef="usdPerShare">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-476">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-477"
      unitRef="usd">29000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-478"
      unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-479"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3eebdf1a70334e0bbfac1cd4e13e54d5_D20220101-20221231"
      decimals="-5"
      id="f-480"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-481">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"
      decimals="2"
      id="f-482"
      unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231"
      decimals="2"
      id="f-483"
      unitRef="number">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231"
      decimals="2"
      id="f-484"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231"
      decimals="2"
      id="f-485"
      unitRef="number">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"
      id="f-486">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231"
      id="f-487">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231"
      id="f-488">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231"
      id="f-489">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"
      decimals="INF"
      id="f-490"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231"
      decimals="INF"
      id="f-491"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231"
      decimals="INF"
      id="f-492"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231"
      decimals="INF"
      id="f-493"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231"
      decimals="3"
      id="f-494"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0884ecfec23e44ed8b1ae896b9fa3ace_D20210101-20211231"
      decimals="3"
      id="f-495"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4e9c27c2ff9c499e82d3e4866000bf5b_D20220101-20221231"
      decimals="3"
      id="f-496"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i25a6c23a548c4172830b509bf8547103_D20210101-20211231"
      decimals="3"
      id="f-497"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="2"
      id="f-499"
      unitRef="usdPerShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-500"
      unitRef="usd">30400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-501">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8538e8736e164287a7a89d9e822ddfd4_D20220101-20221231"
      id="f-502">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8691ff06ffc1432cab9667187afd1df3_D20220101-20221231"
      id="f-503">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-504">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i898f06f98a6748bab720765be614526a_I20201231"
      decimals="-3"
      id="f-505"
      unitRef="shares">540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i898f06f98a6748bab720765be614526a_I20201231"
      decimals="2"
      id="f-506"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i2a88b50331e3498db3de301a5215fd47_D20200101-20201231"
      id="f-507">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="-3"
      id="f-508"
      unitRef="shares">2585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">3.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="-3"
      id="f-510"
      unitRef="shares">305000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="2"
      id="f-511"
      unitRef="usdPerShare">5.26</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="-3"
      id="f-512"
      unitRef="shares">694000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="2"
      id="f-513"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5f966046784044f3987ed481b7a376f1_I20211231"
      decimals="-3"
      id="f-514"
      unitRef="shares">2126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5f966046784044f3987ed481b7a376f1_I20211231"
      decimals="2"
      id="f-515"
      unitRef="usdPerShare">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      id="f-516">P1Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="-3"
      id="f-517"
      unitRef="shares">857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="-3"
      id="f-519"
      unitRef="shares">835000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="2"
      id="f-520"
      unitRef="usdPerShare">3.41</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="-3"
      id="f-521"
      unitRef="shares">455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231"
      decimals="-3"
      id="f-523"
      unitRef="shares">1693000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231"
      decimals="2"
      id="f-524"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      id="f-525">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie5777a3c4cf644a5aa6e2876e0e3e845_D20220101-20221231"
      decimals="-5"
      id="f-526"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      decimals="-5"
      id="f-527"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9cdb0a3d38584e5ca9c4f3e46767bc6a_D20210101-20211231"
      decimals="-5"
      id="f-528"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i22c7d5d67f5143b6ad282485c7c83751_I20221231"
      decimals="-5"
      id="f-529"
      unitRef="usd">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231"
      id="f-530">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i28339715955e48b08119618310a60857_I20221231"
      decimals="INF"
      id="f-531"
      unitRef="shares">208833</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage
      contextRef="i28339715955e48b08119618310a60857_I20221231"
      decimals="INF"
      id="f-532"
      unitRef="number">0.01</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i156af0396aec4513abe4f372a8df3dbb_D20220101-20221231"
      decimals="INF"
      id="f-533"
      unitRef="shares">887061</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i28339715955e48b08119618310a60857_I20221231"
      decimals="INF"
      id="f-534"
      unitRef="shares">7043481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i28339715955e48b08119618310a60857_I20221231"
      decimals="-5"
      id="f-535"
      unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-536">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7855e85faff848b484bde07a79723de6_D20220101-20221231"
      decimals="-3"
      id="f-537"
      unitRef="usd">7108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i18307b729fb84369a1680d708830e51b_D20210101-20211231"
      decimals="-3"
      id="f-538"
      unitRef="usd">8875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231"
      decimals="-3"
      id="f-539"
      unitRef="usd">12971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7438ee3072e41e794bdd9191b73a3cc_D20210101-20211231"
      decimals="-3"
      id="f-540"
      unitRef="usd">16319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-541"
      unitRef="usd">20079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-542"
      unitRef="usd">25194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-543"
      unitRef="usd">1600000</us-gaap:StockOptionPlanExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-544">401(k) Savings PlanThe Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2022 and 2021 was $1.1 million and $1.0 million, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-545"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-546"
      unitRef="usd">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-547">&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10. Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#x201c;Ixo-vec&#x201d;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the year ended December&#160;31, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
      contextRef="idd9a1719e37e4f70a2a084ceacc62892_I20220706"
      decimals="INF"
      id="f-548"
      unitRef="employee">75</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
      contextRef="idd9a1719e37e4f70a2a084ceacc62892_I20220706"
      decimals="2"
      id="f-549"
      unitRef="number">0.37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-550">Below is a summary of restructuring costs during the year ended December&#160;31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231"
      decimals="-3"
      id="f-551"
      unitRef="usd">4632000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231"
      decimals="-3"
      id="f-552"
      unitRef="usd">53000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-553"
      unitRef="usd">4685000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231"
      decimals="-3"
      id="f-554"
      unitRef="usd">4632000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231"
      decimals="-3"
      id="f-555"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-556"
      unitRef="usd">4632000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i4f4b83fb892241c2b8a6099f9648e856_D20220101-20221231"
      decimals="-3"
      id="f-557"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i6c2a257cab854b379328d0e6dd7676f4_D20220101-20221231"
      decimals="-3"
      id="f-558"
      unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-559"
      unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i1e2fd438f1564243a91086e75afa936f_I20221231"
      decimals="-3"
      id="f-560"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i18bfdbc3193a412788e21e1810c123f9_I20221231"
      decimals="-3"
      id="f-561"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-562"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-563"
      unitRef="usd">4700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7855e85faff848b484bde07a79723de6_D20220101-20221231"
      decimals="-5"
      id="f-564"
      unitRef="usd">3700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i46127e0f6a5f48739b0017319ee38920_D20220101-20221231"
      decimals="-5"
      id="f-565"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-566">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax provision were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision for the years ended December&#160;31, 2022 and 2021 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#x2019;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased approximately $39.7&#160;million and $53.8&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had U.S. federal net operating losses (&#x201c;NOLs&#x201d;) carryforwards of approximately $418.9&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2022, the Company also had U.S. state NOL carryforwards of approximately $239.9&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2022, the Company also had approximately $49.0&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had federal research and development tax credit carryforwards of approximately $17.5&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2022, the Company had state credit carryforwards of approximately $15.5&#160;million available to reduce future tax liabilities which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, the Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased by $23.7&#160;million, net of amortization on research expenses capitalized in current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#x201c;ownership change.&#x201d; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#x2019;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has total unrecognized tax benefits as of December&#160;31, 2022 and 2021 of approximately $24.7&#160;million and $21.9&#160;million, respectively. As of December&#160;31, 2022, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $1.0&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to prior year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2022 and 2021, the Company accrued interest and penalties related to uncertain tax positions of $0.3 million. There are no ongoing examinations by taxing authorities at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-567">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-568"
      unitRef="usd">-154002000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-569"
      unitRef="usd">-145375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-570"
      unitRef="usd">-460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-571"
      unitRef="usd">-165000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-572"
      unitRef="usd">-154462000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-573"
      unitRef="usd">-145540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-574">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax provision were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-575"
      unitRef="usd">74000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-576"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-577"
      unitRef="usd">74000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-578"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-579"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-580"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-581"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-582"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-583"
      unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-584"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-585">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision for the years ended December&#160;31, 2022 and 2021 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-586"
      unitRef="usd">-32437000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-587"
      unitRef="usd">-30563000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-588"
      unitRef="usd">3414000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-589"
      unitRef="usd">1662000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-590"
      unitRef="usd">52000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-591"
      unitRef="usd">28000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-592"
      unitRef="usd">2529000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-593"
      unitRef="usd">2672000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-594"
      unitRef="usd">31542000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-595"
      unitRef="usd">41324000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-596"
      unitRef="usd">-46000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-597"
      unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-598"
      unitRef="usd">103000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-599"
      unitRef="usd">-9763000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-600"
      unitRef="usd">-25000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-601"
      unitRef="usd">-7000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-602"
      unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-603"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-604">The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-605"
      unitRef="usd">111709000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-606"
      unitRef="usd">105509000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-607"
      unitRef="usd">2053000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-608"
      unitRef="usd">2272000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-609"
      unitRef="usd">21439000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-610"
      unitRef="usd">16838000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-611"
      unitRef="usd">10705000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-612"
      unitRef="usd">9741000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-613"
      unitRef="usd">279000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-614"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-615"
      unitRef="usd">1562000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-616"
      unitRef="usd">1613000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <advm:DeferredTaxAssetsLeaseObligation
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-617"
      unitRef="usd">26241000</advm:DeferredTaxAssetsLeaseObligation>
    <advm:DeferredTaxAssetsLeaseObligation
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-618"
      unitRef="usd">24224000</advm:DeferredTaxAssetsLeaseObligation>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-619"
      unitRef="usd">9850000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-620"
      unitRef="usd">9850000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <advm:DeferredTaxAssetsCapitalizedCosts
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-621"
      unitRef="usd">23697000</advm:DeferredTaxAssetsCapitalizedCosts>
    <advm:DeferredTaxAssetsCapitalizedCosts
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-622"
      unitRef="usd">0</advm:DeferredTaxAssetsCapitalizedCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-623"
      unitRef="usd">207535000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-624"
      unitRef="usd">170047000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-625"
      unitRef="usd">188141000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-626"
      unitRef="usd">148440000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-627"
      unitRef="usd">19394000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-628"
      unitRef="usd">21607000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-629"
      unitRef="usd">19394000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-630"
      unitRef="usd">20227000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-631"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-632"
      unitRef="usd">1380000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-633"
      unitRef="usd">19394000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-634"
      unitRef="usd">21607000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-635"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-636"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-5"
      id="f-637"
      unitRef="usd">39700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-5"
      id="f-638"
      unitRef="usd">53800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i48f2b20caf244f849a37d4c8e8327f84_I20221231"
      decimals="-5"
      id="f-639"
      unitRef="usd">418900000</us-gaap:OperatingLossCarryforwards>
    <advm:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i48f2b20caf244f849a37d4c8e8327f84_I20221231"
      decimals="-5"
      id="f-640"
      unitRef="usd">57300000</advm:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i85786b5c81d343789ff2c120dd964eb8_I20221231"
      decimals="-5"
      id="f-641"
      unitRef="usd">239900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9a146e7e34f3411f8b40f1773b7e8c0a_I20221231"
      decimals="-5"
      id="f-642"
      unitRef="usd">49000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4c8589134e324d12b0bbaf1468c0b43a_I20221231"
      decimals="-5"
      id="f-643"
      unitRef="usd">17500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5f072761559d486f92055c7cfb714341_I20221231"
      decimals="-5"
      id="f-644"
      unitRef="usd">15500000</us-gaap:TaxCreditCarryforwardAmount>
    <advm:DeferredTaxAssetsCapitalizedCosts
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-645"
      unitRef="usd">23700000</advm:DeferredTaxAssetsCapitalizedCosts>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-646"
      unitRef="usd">24700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-5"
      id="f-647"
      unitRef="usd">21900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-648"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-649">A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to prior year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-650"
      unitRef="usd">21944000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib8adb68b6ec04de6b8475ea4dc7364a3_I20201231"
      decimals="-3"
      id="f-651"
      unitRef="usd">8677000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-652"
      unitRef="usd">274000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-653"
      unitRef="usd">10656000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-654"
      unitRef="usd">2527000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-655"
      unitRef="usd">2611000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-3"
      id="f-656"
      unitRef="usd">24745000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-3"
      id="f-657"
      unitRef="usd">21944000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i0e11c662ebe9427c840584ca1263d906_I20211231"
      decimals="-5"
      id="f-658"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id8fa0f98710e4bf9af1b5718d2dc578d_I20221231"
      decimals="-5"
      id="f-659"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-660">Net Loss per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      id="f-661">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96823e332fad42d4a1f4b9064d27f17e_D20220101-20221231"
      decimals="-3"
      id="f-662"
      unitRef="shares">19320000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iada4fca2d20a473abfe9c9eaec73a105_D20210101-20211231"
      decimals="-3"
      id="f-663"
      unitRef="shares">13288000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i90d6a4e6dcbf4891bbb8bcd22b37a13c_D20220101-20221231"
      decimals="-3"
      id="f-664"
      unitRef="shares">1693000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib724c14cbcfe4412b6c1ae8d4c5cc41f_D20210101-20211231"
      decimals="-3"
      id="f-665"
      unitRef="shares">2126000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idaaa273c85484c7b8335ccf796b65072_D20220101-20221231"
      decimals="-3"
      id="f-666"
      unitRef="shares">307000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80c09039c3df4bae937a95e6a7634f2d_D20210101-20211231"
      decimals="-3"
      id="f-667"
      unitRef="shares">148000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231"
      decimals="-3"
      id="f-668"
      unitRef="shares">21320000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231"
      decimals="-3"
      id="f-669"
      unitRef="shares">15562000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M8/3>')1L>T5K:%&Y^MP+;:K=#4O37D%:![-^$$(?#;M!W[#3OU!+ P04
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M5K#6.XF@4];MJXWV1HFJ>3MP)Y0217.Y9BF$H W@\Y4 )M_=Z!<.^Q=,\_\
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M4YS3ITV M%=:5:\=46U H*?H1?.,)& <E'F.X]=;?<^N,!JBW$$3X)&7TE;
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M/E%:@^EIDG>_=]7^'O+\'D3@&Z_52H)/=4&+PPXF6OS. [3UX H%>[RA^4>
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M,OYPD8'OAVR_B:Y-@VWE(HW)M.17CYX%Z+YT5.##A@WLOW06_P!02P,$%
M  @ =8%^5L=_]Y4O'   4E8  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULM5S;DMM&DOT51,_$K!S!IKI;LL>69$6T;K.:L,<*M:5]V-B'(E D88$
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M^Z=7$P9@[_R3*+NWMW?;NA0YS\Z"3?<0Q]LC@QT=\T3]R!W=0MVA;1.URPG
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M\A-0UD@4#LOPHMB!K6#KNBB8$Z8D-]#"B_::7+//2C^S6(?/UE6E38,#1UT
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M,1LP$UYCPX?3E7\!76GG=.E_YIA=A2$"[*\UE&L^2$#W)'[W7U!+ P04
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M6H81?;"2?D@HY?0BW^?GV<6/Q#:R9T7:1D>"/FJ)7F6Z7GEFM&VDIO6A%7C
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M\7/H/Y2G9Y&>YODM>+JQZ'_K]R1T2:^_-'*+CO0)_0JQ1W?\<*=Q5QCTK0.
M69.OF-9&H?^EWIP1TLKUBFV?VO"3T8MW&I*F<4!S+R.'QD.J!XYFG%G[G;!,
M)Y0EHWP2__-\3._%RECAC=T?:63C9#3/*<N3V6Q.;QJKI4>B(]):WON8]/ET
M#HQL-*7WC/ZNC"I)UEMK[KB.,1@!!;?Y-)FE&8AIU$C3#A6I"8(;P#A@I%E*
MD%U,Z)/Q0H6K)P)$DRQ9P.'Q-,E'(!YT15$T==,69,G(2R%%.[6@*6ICO?S:
MOGB139/%8OP2AU&2S7!X+@TG@?PBGX7#*$FG*7U",D)LA=X3U,)8ATVA@\M"
MVB[00NV1/F3-4@%L#'=23P58.,>(4)B+)1D=4RU+W,BU+%K"*( C:*G+<&&L
MH[*QJ(>HLF>!1(>Q\=_J.(V4>THEHR@P""'J*^';X@(ZW0G5\*'<6EX)[2I9
M5+03C_0:%^P*C%'[&3$26^1)%%42Y5"E, [HUIE"6+L/XA'^E"Z1*WR,'(;^
MP1:'J^AK\J\X%I6PF\CI)#_-,+Z5"A$)9I!AL]'R*^B$(']G$-IH=S$,:7.=
M.9Q!FVEGI?>LJ30[\#<!%Z%AYV4=%1XB!5>*PC9X]_H>7WB'1@CU\QLT+%TW
MU@8'WDNQDDIZB=N#.!^+FRA>=.+J2+P; /^K_V&GK:'.)JIXGLS09">T2/)T
MT7-" M=H(XBBZ]8,\Y-13I-)VDMHHPM,0L1-@5H83&CY*4PG<[3K0:H7";X!
MM B]6?(==I>VWEO523)=!-5T,J=;C\"2%_<PNA5[L5),^60<IE,V[\(YSF9!
M&K_M7! _%DJ,.(R>:6CB;)ZDXQD]]4$9'BT!-:/NPJH3\M!HW^X#_=M^F[IL
MEX@'\785^X"RE1J]P&NHIJ<S+"^V76_:!V^V<:58&8\%)1XK;(1L@P#NU\;X
MPT,PT.^8RW\ 4$L#!!0    ( '6!?E:OQ+UQ#0,  -T&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;*65;6_3,!#'O\HI2+R:FC;;8!IMI74#@032
MQ.,+Q(NK<TDL'#O8EW;]]IR=+!1I3 +>M'ZX_^\>;%^6>^>_AX:(X:XU-JRR
MAKF[S/.@&FHQS%Q'5G8JYUMDF?HZ#YTG+).H-7DQGS_+6]0V6R_3VJU?+UW/
M1ENZ]1#ZMD5_V)!Q^U6VR.X7WNNZX;B0KY<=UO2!^%-WZV663Y12MV2#=A8\
M5:OL:G&Y.8OVR>"SIGTX&D/,9.O<]SAY4ZZR>0R(#"F.!)2_'5V3,1$D8?P8
MF=GD,@J/Q_?T5REWR66+@:Z=^:)+;E;9108E5=@;?N_VKVG,YSSRE#,A_<)^
ML#TO,E!]8->.8HF@U7;XQ[NQ#D>"B_D?!,4H*%+<@Z,4Y0TRKI?>[<%':Z'%
M04HUJ24X;>.A?& ONUITO+YV;:M9JLP!T)9P[2QK6Y-5FL(R9W$1#7,UXC8#
MKO@#;E' .R$T 5[:DLK? ;G$-@58W >X*1XEWI":P>GB!(IY43S".YT2/DV\
MTW])&&YT4,:%WA-\O=H&]G)KOCU4AL')V<-.XDNZ#!TJ6F7R5 +Y'67KIT\6
MS^8O'DGA;$KA[#'ZWY_9?^#@K5;R! FN:D\T&'UL2(S:#NT!M&B@0\\'8 <[
M]-KULC09GT#GM9 Z-.8@K]A@9$=;,X!+8%*-=<;5@FB0Q>A'KZ5J4/4<#Z+#
MP^#W6-UJ0_(XK)@Y#]X=T' ,5Q[Z* MHXKR"T)'2E19/G7=EKZ2)20K>]74#
M<KNHW9*?;M@)6(%&&4N6M4,3H,$2MD2QA32:=@+JY7+[9#%F<91QJJ']+<(]
M23RHE.]%*^%*1K@U-(,-*>Q%'4DC/#)&][)Q!)%*6\=0Z3N!1!\E,7EI"1%U
M(EU5-:".CK+!'25%"EW.P/1E=&^3M_'\GCZY*!;/7P11VN",+I'%9HL&K9(2
MQK829@]=V?RHY;3DZ]18(Z:W/'2?:77JW5=#R_IE/C3^=^AK;0,8JD0ZGST_
MS\ /S728L.M2 ]LZEG:8AHU\?\A' ]FOG./[270P?='6/P%02P,$%     @
M=8%^5B^5;58\"P  !2$  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
MM5II;]M($OTK#4T\:P.TS$-G#@-VDIG)8B<QXDP&B\5^:(DMJ1$>,INT[/WU
M^ZJ:IRY[LMD/EBBRZZYZ5=WTZTV:?3,KI7+Q$$>)>=-;Y?GZY<6%F:]4+$T_
M7:L$3Q9I%LL</[/EA5EG2H9,%$<7ONN.+F*ID][E:[YWDUV^3HL\THFZR80I
MXEAFC]<J2C=O>EZONO%9+U<YW;BX?+V62W6K\C_6-QE^7=1<0AVKQ.@T$9E:
MO.E=>2^O![2>%WS5:F-:UX(LF:7I-_KQ(7S3<TDA%:EY3APDON[56Q5%Q AJ
MW)4\>[5((FQ?5]Q_8=MARTP:]3:-_M1AOGK3F_1$J!:RB/+/Z>8W5=HS)'[S
M-#+\*39V[2#HB7EA\C0NB:%!K!/[+1]*/[0()NX! K\D\%EO*XBU?"=S>?DZ
M2S<BH]7@1A=L*E-#.9U04&[S#$\UZ/++VSR=?Q,WD4S,ZXL<#.GVQ;PDOK;$
M_@%BSQ>_ITF^,N)]$JJPR^ "FM3J^)4ZU_Y1CN_4O"\"SQ&^Z_M'^ 6U>0'S
M"PZ9MY*9.K]&V$)Q(Q^13;FXRC*9+!5?_^MJ9O(,J?'O?=9;WH/]O*E<7IJU
MG*LW/=2#4=F]ZEW^_),W<E\=T7Q0:SXXQOVIP!PEWJ]:BZ/XE BX6L4SE0E_
M1.YV\9FOE'B;QFN9/ H9INL<7J-[]%2\ORMT_B@^)',X#I7$G!RQ6>GY2FRD
M$1(>11:(V2,3S5*9A2)=B%!G*,$T,P)5^#&]MU*](4E%!IW2XI]_FOB^^XH%
M$5_^[;TZZXLOE7RZ+60$%($,H!$+62*4N4Z6)$?7FAFV%/JC[HTX+9E_N/UD
M*KY")J%(TN3\KI"17FBPW$_TL4V4IRQ4Q>LH?53*.")F8PR)/V S"9J#(U "
MJM8K2S?W!6DE-BHK;8$B:1(]5J+*9:2!-WYEVJ)A;E2$UO:%GJM25B-YLTH%
MLA\^,VE#V!<?=R3FK>?;"D/#1/R]@$J(UL#9J]4!LS7,9:^NTBAD_=;K#/&W
M2:5,+F>1-BLNQ-(M)&,WTZXVQ)\3H)LM6-S-ED]E^&+YB/"**$6A [:5T,84
M$%P@0[,FIVU.+7+<8Q,#EY-RP$;+,-3$S6DTX_5D@P[A*4I"F23(( H&6J+!
M39WP\J3@+(=9AB (MM]+'<%@Q62DCH1]M#935JO44BYT9G(Q*PQJVA@1PA)P
M41)5MM!F#F&/2F8.C%KJ)*'X;W2^8E)Z(&P1UM5MP92J35&N4ZP7:9&)M<K(
MO>)T<')6>7]'Z6ZRUO&>IW$,;<N**7)$,N%,E$QB"N@:REP)<I"(8 :X[GH$
MQBFX'EVM08VG4XMC\PF7C%VN-SZ&6]X8J\-B;M%^)X.VGG51I^)8 F@H1J[K
MN*Y;Z=^)X[K(Z"HG_W:1A"KA\^T?II5[6V*M."Y[1,40D8KT4E.R@!WL5E0%
M7*W6P<<$;-M+$* 1'N0LXF]AP<A<FX7U. </3BX-:JA+>9;K1VE">2>6A0[+
MO)4YK'?$4B4J RP_.@BU51^5EZ-*U+U."P.CH$0%+Y01523)DJOP7F5%[-#]
M14K@SFF$L"<2Z1XJ8JE3S@"":\N'U',H?\"YI3!F-"RV.4Z6-5;_#1Y-Z"&8
MZZ2&.Z;BZBGUV&HW3JOJR<O[7(LA4F69!5$,8SQMWBNRVK 2W&_[XHH#MU65
MOD].R],<.N-I,':F2+'QU&_57Z?6&+7K?.PD(.D7..#I3(-Q1<_KN\BS*/(B
M4]W@MO2T0T(%H[>=1&N#9]LM>U*: 7C6=!B2;"/)1A5K<I?G,F+9#):4,FAC
MAG&;D \IEF"->U+!$#J&IAB#G=29N)=1H:IGE<,LAEKP65CQ^X%F%UB<"ME#
M1ZPP92 C')OG+/P!@*F-LEH2(;1#\V;ET5+;S51"[9-VZRO[44XN:=GF_<^V
M];="=+"C-\5#=^JB%?<0+#))K1A]!B;;[L!QL=70E&7.262W;_H_RG1PR.ZO
MJ&\W:;(-YG;]FB=04BI3$9NL$[N[!)N7XO0#V0GDP K$1#W,U3K?<K\E9R7/
MZF3]DW=@*CQO75TMEYE:DL<^)#G*W^BY^,J^/95GXEI&MG;RG<IT$4)G$/CB
MA1CWO:F8].D2#T?^2/Q:>GGB^(&'YRYFEE*_4)Q.S\2P/QF)M\0;@!!>P+J%
MTD1Q.G2"T>@,S/O@?42^)SQ4\V0"H6 6B%%_BDMO,*R%0[]I$ BO[W>D>\,S
MX9+&>\4/G,ED1/KYTV/2?>%-G0!.@,G]8 +KZ1(T7Y$NX$/>5P]KU(W--<XB
MN1_B&E;#_GC:L"IUYIS:J\+(\5QRNN?U77+ P-)1X"@O91U:78?6EHW&A"*C
M>6&3J\3A4"\ U(H,GJE\HU12=K]6"F_5>(5M\R@UE/]UY3\Y$T'F79':81YH
MD'!J ^21S"O:>]K*LL"_K?U.?U=U<,.".U@UZIG]LQY<1YIS$M&^[(4WX;&%
M;KY :HA81Q'/M4"5==6OFMFYPI M:0>%V8T(FD)_6+%N]2^@/A<W''\^XWUX
MUSINO[,4'ZV5K"MU.7(X)1<I@DV)'<@K8.H )0_(G6B6(S^YH$'7$LV[#:(P
ME:'7D9Q_.[^= [:A/C'GT(DX#574#-H-)FXJJ)' 3KF$YI :6]M>UBY]7XT_
MY1Z\R) 'QC9=\<]#H3SX@-W.\6VNWE?E>)\B[W5$2#R9GHBI=R+&XQ/A^?Y)
MLXBZH3C%7J7$T!&JDOZ )OQ7+^0)2A'8:A6%/#=[_JN#WY^U^7:^R!07)<K-
M-A?*C1%4Z*/?!?2!+#SA&.ZXKPDJ9\]V7_N."J 1"&D_#6P!#/LHAZW,/SB<
M\>[,%E'@ H"J]*81)L'8D"X3-,(RI<OT!A"L56)DB2ATK>I.M[,[*.?H#IK.
M:'W-FYNRW/54,QC#N57#YGT ?]!LRE4HY(:G>Y9$&^H\XFVG*$>3U@Z# D=G
M#YD,;:M__BZP6..RK-1]Y<DZP4[K(U[=AE8CJ=Z>#[ EN2U?*N;2]+WSS]:T
M4SK49\[>JX%%-^O.)T<>D@I)_^=II[&K[<;6S/.QWDSOFWJ.SC7# 35@M%,/
M93BIQPG?&4Z&J,ZIVV[RT%EQQ$X#=\ASPTC\THP3H^F ;HXFQT<9W_% %_3'
M(V# H!F?AF/Z'>P7. D@," U6P('0[X)GL>G%V>$>L>X0.80GG62XZ\VMG;E
M[VUL50TD=.+U?0WMW5\%-J<<'_:4V;UU)\.6CQ!7NC/^>0"+ P/ E\X14)M5
MZ0ES:%]:[Y*J,Q-RPHH:!I;,U$I&"^[1=4EB.V@ /W;3?&]1J'TH@:V:CHN8
M#B?R ILSW)4/EBO(R%.9NBNP<Z,=Y['M=0O!6Y;O '@'M.<IM:T&L8ND= .[
MY$<@MH=1J43L][<W-X>/6)]]9'ILP&B?>)&X)XZY?'?B3+"S:&)-:=V)]\[)
M0[5S_B%GHM]]$ HY6T>=Q*<\?Z1I(E'-N:>W[]SSR<93.>6I0\\?=]KY[GEH
MY8C)9.RX(Z]S]K-S[$WQ?]YI%)@- F<P\8X>1NT]7*HC^6RYK3)UO[=,&S%<
M!.5;O[=MDL\-JS(GWP)]TTB'S.06:*.JVOJ$3)'-"2OQR=2*7D=C4OI'BHS<
M-RKPZS8Z63LX$1P9$U\^9^3O3 QG,,F !KG'+W\4D#Q=LPDO$$'/I0,$E/-X
M*'ZU4Y ]; L)8.G-)[]?\7QG.O:$-W(";RJ^< 9PT(^-M.BNKN..Z5C"'SK>
M="#VO?6\:+V:CE6VY!?P5%-%DMNWU/7=^AW_E7VUW2RW_R#PN\Q0Z ;UO "I
MVQ\/>R*S+]WMCSQ=\XMN--\\C?ERI20RD!;@^2+%EKS\00+J_WRX_"]02P,$
M%     @ =8%^5GV'=4_I @  9P8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&ULE57;;MLP#/T5PAN&#>CB2]*NZ)( 3;MA>R@0-+L\#'M0;"86JHLK
MR7'S]Z,DQ\N&MMA>$HD2#\^A2'K::7-G:T0'#U(H.TMJYYJ+-+5EC9+9D6Y0
MT<E&&\D<;<TVM8U!5@4G*=(BR\Y2R;A*YM-@6YKY5+=.<(5+ [:5DIG] H7N
M9DF>' RW?%L[;TCGTX9M<87N:[,TM$L'E(I+5)9K!08WL^0ROUA,_/UPX1O'
MSAZMP2M9:WWG-Y^K69)Y0BBP=!Z!T=\.KU (#T0T[GO,9 CI'8_7!_2/03MI
M63.+5UI\YY6K9\EY A5N6"O<K>X^8:_GU..56MCP"UV\.Z:(96N=EKTS[257
M\9\]]'DX<CC/GG H>H<B\(Z! LMKYMA\:G0'QM\F-+\(4H,WD>/*/\K*&3KE
MY.?FDRQ_??<&5FS'U=;"4C U31T!^^.T[$$6$:1X B0OX$8K5UOXH"JL_@1(
MB=% JSC06A3/(EYC.8)Q?@)%5A3/X(T'F>. -WX"[Q8=-TC%Y&"!"C?<6?AQ
MN;;.4%G\?$QQQ)L\CN=;Y<(VK,190KU@T>PPF;]ZD9]E[Y]A.QG83IY#_]='
M^6^0+S7"E98-4WM Z]A:<*J<"IBO8W*OWI;TC(:OV] QMG=MR!5:>ED#J[Z9
M>G"] 1<P*QR!1^_M/AB4>H?& A,"4#9"[Q$M=+4&Z8=-']'7-)>M!)H P%0%
M/I>\1&KX^[9_,GL23@A(=\2&&<=+3B+H#9WV0$2,0:--H!8Y<3(IU3)!-"1-
M,,OBH?(W#3KVX)N9VTB;2=U2:9#K<0((OF:N5QBS)EF%/JC[2VO5&DI5,.^1
MD6KTC0!4QBC7:&)E'.HYJ*%%#AVS\#(?Y90%(<*0HA,R9 ?#">7!-AA&E]B/
M'JNM]*CY)9IM&'&6A)"B. <&ZS!%+^/P^'T]CN ;9K:<9 O<D&LV>G>:@(EC
M+6Z<;L(H66M'@RDL:_H2H/$7Z'RCM3ML?(#AVS+_!5!+ P04    " !U@7Y6
MJ:[4[ L$  #:"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-5EMO
MXD84_BM'WG05)(+!0!(E@ 2DJZ92JBC9W3Y4?1C&!SS*V..=&7/IK^\Y8W!)
MEZ5]P7,YE^]\YS*,-L:^N0S1PS;7A1M'F??E71P[F6$N7,>46-#-TMA<>-K:
M5>Q*BR(-2KF.DV[W.LZ%*J+)*)P]V\G(5%ZK I\MN"K/A=W-4)O-..I%AX,7
MM<H\'\2342E6^(K^2_EL:1<W5E*58^&4*<#B<AQ->W>S <L'@:\*-^YH#1S)
MPI@WWCRFXZC+@%"C]&Q!T&>-<]2:#1&,;WN;4>.2%8_7!^N?0NP4RT(XG!O]
MNTI]-HYN(TAQ*2KM7\SF%]S',V1[TF@7?F%3RPY(6%;.FWRO3 AR5=1?L=WS
M<*1PV_V!0K)72 +NVE% ^2"\F(RLV8!E:;+&BQ!JT"9PJN"DO'I+MXKT_.0%
MG;>5])55Q6H4>S+)%['<J\]J]>0'ZKT$GDSA,P<_%RFF[PW$A*4!E!P S9*S
M%A]0=J#?:T/239(S]OI-@/U@K_]_ @11I/""6GA,8<H%H;Q"!W],%R1%%?+G
M*0IJ!X/3#KAK[EPI)(XC:@N'=HW1Y..'WG7W_@S\00-_<,[Z?^?GO'JOVX'W
M##P6\&NE=X'>-O@,86[R4A0[4'FID?J-N1'4<,=:9@DT!ZS@3G)M4(745<H7
M%M,J])>C0U@8GT%&LT&:JO"!;=S2_'!(2MY :96Q1/E?",H[D 172:&IC=8T
M'DIVSJ[4UBS0FA46",Y84PJ[-FN4</GQPVV2=.\?M^:*]F'7NV^U@:<36@J+
M>AHM@6)OPL'TX>O358B4L2P-=53P7*H2F2O@M'M<[8 FA$3K:8Q!1IU,IBB;
M:Z$#)%EI82%5#FD N Y\H6*W@;SW-)5:%.])#?P0'';*\XF 2H3%#FZ&@$2X
MV2'5WZ4H2VNVBJ8,DN?^S4\M1D]4A%Q=U]W0@3!$03G*SWZ*LLQ[#-(X\I76
M&X:R0\*.W)Y S84Y4=LTV!V\$O56% 2*&9H1Y4O&.@]67KV1;U<S"CH-$5$F
M0PG 9^,I;9=43#XSE2-5UX)Y)NR*HKF 0?NZG]!WV*\WMT.8"Y=!*7:<8T<3
M+$6X#&(MX#3VDOMF_YLIKB2+-Q?#?JO^F0E=8_7?QT*N#@JG5@'K>3;^G3II
M+,M=##HW-'NUYLA/\]WF\TVF9 87_2/IC> J%\ZII>*V<JQ,"$B.Z3ZN^T.C
MA(N+7J=[Q@AWAJ4$L*A(Z5E0H8[I?6O,=.#S42S2<'-S9W]?M*HF9FDJ2]W[
MK1+6$R<43ZBY4S,L/GIOJ.U6X54EC-ST]=/3G#8/][1^K_X1KU_])RH91<-#
MXY)4NYV;802V?DGKC3=E>+UHM-!;&)8\8-"R -TOC?&'#3MH_LY,_@902P,$
M%     @ =8%^5@M4UC)%"P  L1\  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULK5EM<]LV$OXK&-7MV3.,S%=1LA//)$[;2Z9-,W'2FYN;^P"1D(2&
M E0 M*S^^MM=D!0IRR]M[XM-@=C%ON^SX,NM-E_M2@C'[M:5LJ]&*^<V%^?G
MMEB)-;=CO1$*WBRT67,'/\WRW&Z,X"41K:OS. PGYVLNU>CJ):U]-%<O=>TJ
MJ<1'PVR]7G.S>R,JO7TUBD;MPB>Y7#E<.+]ZN>%+<2/<E\U' [_..RZE7 ME
MI5;,B,6KT>OHXDV*^VG#KU)L;>^9H29SK;_BCW?EJU&( HE*% XY</AW*ZY%
M52$C$./WAN>H.Q()^\\M]Q](=]!ESJVXUM6_9.E6KT;3$2O%@M>5^Z2W_Q2-
M/AGR*W1EZ2_;^KU),F)%;9U>-\0@P5HJ_Y_?-7;H$4S#!PCBAB FN?U!).5;
M[OC52Z.WS.!NX(8/I"I1@W!2H5-NG(&W$NC<U3M5Z+5@G_F=L"_/'7#$]?.B
MH7[CJ>,'J*.8_:R56UGVO2I%.61P#J)T\L2M/&_B1SF^%<68)5' XC".'^&7
M=/HEQ"]Y4C_V5MJBTK8V@OWG]=PZ Q'QWV,Z>X[I<8Z8)1=VPPOQ:@1I8(6Y
M%:.K[[Z))N'E(_*FG;SI8]R?],?SJ=GGE6 +74':2;5DCL\KP4ABY2PK89]U
MLF!<E;#+0/0J!L0;K>B]7C"PE65S@2^!3M]*2D3XR:0_QN$Q%^S?@AO+! 8
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M/VYK*\J#ZM=M'C]>;"U86RYDP<&)3U>E03X?E_Z"O2;RYP7TV_L,+]@'L"]
M.X@!%)@2B:P'&FZY*;&T1E$4Y.$,GT*HJ_#TNBA,S2L;L*;SD6":W!\'89;
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M#5BV D.;&F<.-#?=9;":0L+7-RI(? LA_[:F>L79^QH42$(J.>$]&P;HI5)
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M%J\V"]0F3_#B9);BS>0TF.0Y7GW[)M5#&1N(.^/W#^XT+8OS%*^J)MGD*.$
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MN!P$H-OVU$ZLJGU+6"M+#<8/2^KHJ)T![1=*V</$!>C^(V9_ %!+ P04
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MSC$%3N8N>)\H-L2^"TH+W74T/_DL9\7-L5.)55WB91&F"1'%[UVU9MH#T<"
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MC&&5*NZ,ME6O"A)FQ9Z"Z1,0>B68$*H3^PL-KG&6E>UQNIAD+P\(7AIKNPH
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M/7CS5!(1/8C87\%$+GT,/A9.BK4FR83I[D356R,V*'I KF*;9$?&OPH(R9J
MV:1M5$TRJ =@!@:N/Q2-4>YFX>%CQ#:E!1>IJ6XQW1!WU<MUO[=^5!=^\R*B
M$*\.,NF<7#>>^@S:U$M__'&;7X]\Z;W6$)ZJB<^7''M]AZO8^^VR-L1F!N4<
MDQA.W6F+Z:XQ?#.PY*BOJ3NDA'_!P1%)Q34<[!8X<-0%_W]8-M9%\>"(<&#M
MPM, K"90=2F%PTNQ%8,NBQ.D-/Z>WO34U6EXLR;K2<;E?%;X($YG9M</7[0)
M<!\!"RZ\$Z#6AKJZ1&5+%T'LF@.8:^Y_[&V=-[H=!R.SQMI@R_+\8(C]FLWM
M^>VS KWBV:3[CIHV^L1O;J^SUQ1=2CM&-^CH <+;%-)EW[?.P@W&-PJ.XC4X
MT: E!9GH: GZ)LD]U<@OIDO;;S16I/4>3'66.U&.!GG_Y))H=ORS T][<3&7
M[%GJ[,EFW>(UD@?ZRJ*C'WMU7MYFW4?HO%3CTS[L*'H2YKV\_1"GX=:GV$.1
M=GZ7]7D2(\XO0\/H>VI">9;'K+-VTO?2?MT<62SLS_GS1XLGO<B,JKT-I_"I
MT4/!W$KRRU9*\ RQSQH?L )</BO@0'B0IZ?SGV;ACY].+W[(_WC,!!]_F,_9
M5_&"I3SX@,&Z> (Q:_)(WK!C/]9!\N<@@B3'. @92-V-%E]IVT=E'"QU@=+V
MDSNQHV\OSF*4.#WH%UH3X[N*U#?+C7'A 1LQH?-'+ON%06=%O"Z^HE@+$TL0
M,(6,L,OUDDH\1;/D-#;7AR=RLMI=XNG,"1EYZ&7X,@^_ENA;3&6M;-D)M04#
M+R__HPZFM)GI5_BH'+T'K8A@&X;'X]B 2@EXE=MZ*)'[US3^7LWP&.#BQ.<'
ME#RI,L!7#KN4?: 5'U >GHDX? !N4/!567H\-UTA0/A/U72XQ3RT,K'ON%%H
MK*>66X2@;(^%FXZ^2!K,QO3JZ;@]<IZ]=;W58,SCB][4_MNT_.QU_#6^&OZ2
MW\I.P_G)\5_ %\":FEJO8.K%V8^/3[A>-?S1VAV]G+VT;6NW]$],AVJ' ^#[
MRH).EC]P@_B6^HO_ U!+ P04    " !U@7Y6:3BM\,L#   P"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6RM5MMNVS@0_15"+8H8T$8B=75B&\@5
M+; !@B9I'Q;[0,MCFXA$NB1E-_OU.Z1LQ6F=%%WLBTT.9\Z<F2->1ANE'\T2
MP)+O32W-.%A:NSJ)(E,MH>'F6*U XLI<Z89;G.I%9%8:^,P'-77$XCB/&BYD
M,!EYVZV>C%1K:R'A5A/3-@W73^=0J\TXH,'.\%DLEM89HLEHQ1=P!_9A=:MQ
M%O4H,]& -$))HF$^#L[HR7GJ_+W#%P$;LS<FKI*I4H]N\FDV#F)'"&JHK$/@
M^+>&"ZAK!X0TOFTQ@SZE"]P?[]"O?>U8RY0;N%#U5S&SRW%0!F0&<][6]K/:
M?(1M/9G#JU1M_"_9=+Y%$I"J-58UVV!DT C9_?/OVS[L!93Q*P%L&\ \[RZ1
M9WG)+9^,M-H0[;P1S0U\J3X:R0GI1+FS&E<%QMG)-1>:?.%U"^0&N&DU8,>M
M(5S.R-Z:FI-K(;FL!*_))VFL;CN_HWL^K<$,1I%%-@XSJK:9S[O,[)7,E)$;
M)>W2D"LY@]E+@ C+Z&MANUK.V9N(EU =DX2&A,6,O8&7]+U)/%[RZ]Y<"E/5
MRK7'D+_.IE@_?DY_'RJZ@TP/0[HM=F)6O()Q@'O(@%Y#,/GPCN;QZ1N$TYYP
M^A;ZY ZW[*RMO5P7W"S)U;=6K'G=*WJW5-K^84$W*.(:C/4B'BKCS42'R[A?
M IFK&K>YD LB,.-NJSL^%E<O5+/B\NG#NY+1XM20RG&$'SB:9X[BF2,Y$A(Q
M5&O0QPQ."(H-S11T+S@Y:S!0_ ,S\B#Q?*I_'%X9*W ;X^A/6$--J/O^X EW
MDW[$TV_>(C!Y3V@<LB3#@:?)3E^,MHL= ",/QW?'9*'6H*5CZ?GC42:K)V*@
M:K6P C^8;!BF9=&C')4L'9"L#/,\<2UI0/MMM>(K+(?&+"RPFMZ;I?G 6],B
M1W>]4AJ+(%/EZ+(PSH;/ODDV<":6DGME$?)W&DR+-,SBY!F,AC1&/%HD83(L
ML69C3KK/:A_Q*,M#EB'%71S-.UL:#[8L7DF(W:0E^A4O.HQIXW(X\*M%2+/R
M)Z7I_ZAT0NGK2KO%WU,Z9R'+RSWM:#EPQCB+#RA=%"&C&;([RNG 3VF6_21Q
M6H0)VY,EP>:@C97_160VQ"2T<#D3QXT-\[",XU?%91DNEWOB;DW%+[5E!0V3
M>.@ZZ51-:#'PUC@<#A-RZ+"+]FXQ[-3"W]5X2*A6VNY"ZZW]<^"LNP6?W;NW
MQ W7"R$-J6&.H?%QD05$=_=S-[%JY>_$J;)XP_KA$I\TH)T#KL^5LKN)2] _
MDB;_ E!+ P04    " !U@7Y6T[E>^AL#  "=!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q]5=N.VS80_96!&A190%E=K(OMV 9VDP8MT"#&[J9Y
M"/) 2R.+#44J)&4G?]\A9;O>P/&+1,[E\)PA.5SLE?YJ6D0+WSLAS3)HK>WG
M462J%CMF;E6/DCR-TAVS--7;R/0:6>V3.A&E<5Q$'>,R6"V\;:U7"S58P26N
M-9BAZYC^<8]"[9=!$AP-#WS;6F>(5HN>;?$1[<=^K6D6G5!JWJ$T7$G0V"R#
MNV1^G[EX'_ /Q[TY&X-3LE'JJYO\52^#V!%"@95U"(Q^.WR#0C@@HO'M@!F<
MEG2)Y^,C^CNOG;1LF,$W2GSBM6V7P32 &ALV"/N@]G_B04_N\"HEC/_"?HPM
M9@%4@[&J.R03@X[+\<^^'^IPEC"-?Y&0'A)2SWM<R+-\RRQ;+;3:@W;1A.8&
M7JK/)G)<NDUYM)J\G/+LZF\D209>/K&-0'.SB"R!.E=4'0#N1X#T%P!)"N^5
MM*V!/V2-]7. B-B<**5'2O?I5<2W6-W") DAC=/T"M[D)''B\2;7)7Z^VQBK
MZ11\N21RA,@N0[B;,3<]JW 9T-$WJ'<8K'[_+2GBUU<(9B>"V37TU2/=M'H0
M"*J!C[+FIE*#M%C#N\$.&L$+@#7[09?!&ABHSAH^]*B9Y7([NB]INKKJ94UW
MQI&@'<!N0XL<=R$$+BLQU&XYVR)@T]"M<J&VY89N],;@MX'8 >[H&_J@X5Q*
M,TJ12KZJF*SH%KH#!\)+ZY]+<\FC@VTUXNABE,T,-$I0'Z$#RR7%J<$P69N;
M^7/*/]7&P..P$>=%A <*YSM/@?1-X 4D29A-,QKDX33+G#5SMFE>0A'&R<Q9
M<DC2,,U2LE#3<Y;"68K)C"R3:>XL)223,,YCLN1E"4\M4J]L+#%+XBS,DAC*
M(DS*#)Z49>)YD7ZJ1E+D83%-*;$,D]F,Q!@SA[7;+)*P8V*@DM3_4I,8XU^6
M65@6Q<T!^@7,XG"6%'#IB$9G+:-#O?6-T8!G,G:/D_74>^_&EO-_^-BXWS.]
MY=(0^X92X]LR#T"/S7"<6-7[!K11EMJ9'[;T?J!V >1OE++'B5O@]"*M_@-0
M2P,$%     @ =8%^5KENRO36 P  W0@  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&ULI59M;]LV$/XK!RT84D"(),J2Y<PVD+>B!=(M2+KMP[ /M'2R
MB4JD2E)QLE^_(V4K+N :'?9%(J6[YY[C/:?3?*OT%[-!M/#2-M(L@HVUW644
MF7*#+3<7JD-);VJE6VYIJ]>1Z33RRCNU3<3B.(]:+F2PG/MG#WHY5[UMA,0'
M#:9O6ZY?K[%1VT60!/L'CV*]L>Y!M)QW?(U/:'_O'C3MHA&E$BU*(Y0$C?4B
MN$HNKS-G[PW^$+@U!VMPF:R4^N(V'ZM%$#M"V&!I'0*GVS/>8-,X(*+Q=8<9
MC"&=X^%ZC_[>YTZYK+C!&]7\*2J[601% !76O&_LH]I^P%T^GF"I&N.OL!UL
MLUD 96^L:G?.Q* 5<KCSE]TY'#@4\7<<V,Z!>=Y#(,_REEN^G&NU!>VL"<TM
M?*K>F\@)Z8KR9#6]%>1GE]>\X;)$>/(*N%%MIR1*:^#\,U\U:-[-(TMAG'%4
M[B"O!TCV'<B$P2<E[<; G:RP^A8@(GXC2;8G><U.(MYB>0%I$@*+&3N!EXY)
MIQXO_:&D'['A%BNX%:9LE.DU&OCK:F6L)LG\?2S_ 7UR'-VUT:7I>(F+@/K$
MH'[&8/GS3TD>_W*"^V3D/CF%OGRBMJSZ!D'5\*"I.;5]!2XKN/O:BX[:Q8;P
M*]ICM$\"'Z?]301\BR#IW$I%K6E(*L3$;A!JU5"+"[F^!"H8MBO48]'<)8'S
MCY(L56\(S;SS:NLM68W /HQ1M=URC7 &29BRS-\9F\ ]7RG-K=*O!Q[))$P+
M!@D+I],"WO=:"DLE]$BU>+&^G$5>$$:2YG"/U,(;U50@VDZK9VR]VE-"H;<L
M#Z=Q0L0D5;\?OAM" AFN"<801IS$0+:S##XKRQOWZL@!09:$,TIXDH<L)>+.
MEY=EW_:#U"JD(RX%'SY,Y,E;I:WX9WAPGN3A;#9Y1XLT3*:T.%6&,T=^QJ9N
MD89Q'L,)E66CRK(?5ME56>J>2-^]T"0P=)J.Q&]4<0TWO=8NW7O!5Z(15J Y
M)KR3L8X+;Q\4#X,J'[3<!6W>@NZU^+^D2'&&\]_%I ,MPBG5^PQF(8MGXT%0
MS6NJ*)F2 &JD\%G*(,OBT4(J65*:HB2#4KD>(?7E%#HL2#E[J]'$Y4:@I9-)
MA<\T*0<5#:Y9F,^<:YP5\&1)/V#Y"P7M^*O[1 /+)JY1DF)7E$DR==9T'23*
M_]M14K=1%^1.3TD1QI/I43U%!R.G1;WV@]75H9=VF#[CTW%V7PTCZ\U\&/R?
MN%X+::#!FESCBRG)10_#=-A8U?D!ME*6QJ%?;NC_ [4SH/>U4G:_<0'&/YKE
MOU!+ P04    " !U@7Y6]R&";L(%  "X#@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6RU5VUOXS8,_BM$;CTT@.OX)7:<7AN@[7I;/]Q6M/>"8=@'
MQ682H[;ED^2DW:\?*2=."J3>[<,^))9E\2$I/B2EBXU43WJ%:."Y+"I].5@9
M4Y^/1CI=82FT*VNLZ,M"JE(8>E7+D:X5BLP*E<4H\+QX5(J\&LPN[-R]FEW(
MQA1YA?<*=%.60KU<8R$WEP-_L)MXR)<KPQ.CV44MEOB(YDM]K^AMU*%D>8F5
MSF4%"A>7@RO__'K"Z^V"KSEN],$8V).YE$_\<I==#CPV" M,#2,(>JSQ!HN"
M@<B,[UO,0:>2!0_'._2/UG?R92XTWLCB6YZ9U>4@&4"&"]$4YD%N?L6M/Q'C
MI;+0]A\V[=HX&$#::"/+K3!94.95^Q3/VWTX$$B\-P2"K4!@[6X562M_%D;,
M+I3<@.+5A,8#ZZJ5)N/RBH/R:!1]S4G.S!Z-3)_@OA"5AM//8EZ@'EZ,#"'S
M]U&Z1;EN48(W4/P /LG*K#3<5AEFKP%&9%)G5["SZSKH1?P94Q="WX' "X(>
MO+#S,[1XX5M^KH3"LVN*7P;WXH5H9>!**5$MT8[_O)IKHX@C?QWSOL4>'\?F
MO#G7M4CQ<D")H5&M<3![_\Z/O0\]EH\[R\=]Z+-'RL.L*1#D MIH_5XSH35<
M,:-S\W+,XG[,SRN$A2PH(_-J"8;#ODW+_&_4H*T:6>_SAK1 0Z%58$CT1I:U
MJ%[>OTL"?_)AM[ZV)!)51LE:"$,;G5=MU2"8<SB]JTA8-II6: ?P.<7:T -5
MFFN$6N4IMN(O*)0>=FY^LYF%V=G!Z&JY5+@D)7!7&953C4CAJR@:A%,QA&M!
MIJ0(P@#Q",LYV;WED@>^YXS# 'Z"B>M/(7%Y2!_C((9?B ]L=^($H4_?O3'<
M;NW+X'0ZA,A-8KAA[*+ ;$3>+3!GB=/(">-X2. N8??H]\$/G2!)2"F!A1"[
M4QKZXZA33O9-PQ!\-WBEW8^&X+'%1]6/G22)V;Y@VJ<] '_JA+0)Y+(;)N0]
M#TGF*VK&X=W'YYHJ)KT8"6N:!J&9>CU0D3N9[J&V-EM.'34A=GR/-]WW78\W
M8-S*<>"8EZ(+;=Z%=FU#FVM(19$V+;G(+.9BEB\6J) =GJ/9(%9V^A6%7Y/,
M>LEKTD)JYG\[2SX>XW8JRY(@6CS2^;V1K)T3 RI+;5$PF5=<2MR>?(^Z?(]^
M.-\_BEQM>4UO;4+ G=8-6<#35C]<T439)LNQ4M"OSI8"5K/>J4&1KE[O7]YJ
MW)#[1(B\;/??M/O/D2*I)=,7&KNA/']=B/3IC)R1U%(L>&ML*3/D)F=6=MF^
M"FUVR2W6J.@\0)O=N77>%8/;LB[D"^*V%-XWBG:>(LL=#/[@P@'(+>@U[][\
M8 EITW(_NMTEP%H2T_*":U\R/8&I?P*3R0GX07"R7V10E7":5[NJ%5,>\(_R
MU_ZZA1E5T0RYO.589& )%GQX\_F0ZZ>SA4*;!D1P2D3%6QVX,9G@>B>4P?1'
M)>&DAW1Q1[KXATGW0+HH(]CF=I._5+GI[S;]X/_2;9@&#X]?_N=&T_+3LO6
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M#@4N2-1S)]2+5'M/:E^,K.W=9"X-W73L<$572U2\@+XO)'7;[0LKZ"ZKLW\
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M OQX7G^\D&Q?''FOF)0L*3[N*-E0GANH^UO&Y.-%?HI>_6IB_A]02P,$%
M  @ =8%^5BU*.5GS @  *@H  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULS99M3]LP$,>_BI5-$Y. //0)6!N)4J$AP81 L!?37KC)M;%P[,QV6MBG
MW]E)LVI+@X:&1%\T?KJ[W_]L)S=>2_6@,P!#'G,N],3+C"E.?%\G&>14'\H"
M!,XLI,JIP:Y:^KI00%-GE',_"H*AGU,FO'CLQJY5/):EX4S M2*ZS'.JGJ;
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M'.%;256%2=4QLG#%P%P:+"U<,\-B#I1=@/,+*<VF8^N+ICR,?P%02P,$%
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M2+\GXM W'@:*5TVOMN)*=W[-Y5;WVB#, CV_YEP]#TS[UW7OR4]02P,$%
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M+0.%!1<TK9,E@S3.JF_R7 O12<#NA02[3K!_-L&I$YRRT(I96=8#$228,WI
M3$5+-'51:E-FRVKB3$WC6C#Y-)9Y(K@G"<E"0.O2,TN:YC2#3'#T'JVE9:(B
M 40W:,6D<9AX022+T!\_BCB74RENT">9]/8!!(D3_D[F?%T_H+=OWJ$W*,[0
MEQTMN$S@<U-(JNH'S;"F=5_1LB_0>H#P%CGX!MF6;6O2ES^?COOIIA2H4<EN
M5+)+/.<"WK'\&[22<HF^"NB?1QF./@I(^;^Z4BML5X^MUND=STD("T,N1 YL
M#T;PZR_8LW[3%3X26$\&IY'!&4(/OE!!$I1WO0!'%72%5VA^B:;VDWTPP3,U
M(?MN1>=1KF<[;A/5H^HV5-U!JH_ N=PCPB(M$B(@DDM;"A+&I-H\)'.24B;B
M_\H;.O(5OM>A]1Y[LYE[PEX7YF#_ OU)0W\R2'^EU?@&9: 5>G)&PG%GMG]"
M51/E6)ZE9^HU3+U!IFK+* 2PEF7)F=.-.! &.K:#@->NAY' >K7[3>W^*VX+
M_I@RC 36DV':R# ==5N8GOD0._;DQ*R:(-N^L*IF#='9\*9 GB@C@K*788*#
M*-?.S$A@O8*QU?Z]6Z]HT1I\)"7&0NM+T>ET\*@VK>%Z%G2=J7UB5%V8[?M3
MO55QVW+@P;_RX$/!LE@4#$JFF_A97>M;J5$;C+'0^F6W+09V7M.P@PW,U5*,
MA-:7HFUA\' /<[5ASWN1J3<]M>MY$,:.=\&M;;^"AQN61Y#O4CN:1"A.)>,]
M*))ZMPX"73U%(Z'URVZ;'^R]IEM'[83&0NM+T?9">+#'N-ZMOJ9I=3I.K*LZ
M#[,]W\(7#-OV+'BX:5G2C M65(<)\F55$M]*6?26'82Z>IY&0NL7WO9 >/::
MEAVU-QH+K?]2WS9']F#'<;5E:[CNJRJVL'7B6$V4Z\PF)X8U.V<VZL#L+\*V
M<<91 AN99MWZ<F-CU1E4-1 T+X]QGJ@0-"TO=T B8"I /M]0*HX#=3+4G 0&
M_P-02P,$%     @ =8%^5F4W/D O P  1PD  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&ULK9;?;]HP$,?_%2NKIE;:FA^0 !U$:F'3)FU:5=KM8=J#
M"4>QZL29[0#][W=V0@8D(![V G9\W_/G+N=SAFLA7]020)--RC,U<I9:YS>N
MJY(EI%1=BQPR7%D(F5*-4_GLJEP"G5M1RMW \R(WI2QSXJ%]=B_CH2@T9QG<
M2Z**-*7R]0ZX6(\<W]D^>&#/2VT>N/$PI\\P!?V4WTN<N;67.4LA4TQD1,)B
MY-SZ-^.!L;<&/QBLU<Z8F$AF0KR8R9?YR/$,$'!(M/% \6\%8^#<.$*,/Y5/
MI][2"'?'6^^?;.P8RXPJ& O^D\WU<N3T'3*'!2VX?A#KSU#%$QI_B>#*_I)U
M9>LY)"F4%FDE1H*49>4_W51YV!'XW2."H!($YPHZE:!C RW);%@3JFD\E&)-
MI+%&;V9@<V/5& W+S%N<:HFK#'4ZOJ.<9@F0J2V9L4ASD4&F%7E/IE@Q\X(#
M$0MRFR2R@#GYN,'R4: (S>;DNUZ").-"2E20KXS.&&>:X>KE!#1E7%VAFZ?I
MA%Q>7)$+PC+RN!2%0JT:NAKI#8.;5*1W)6EPA'0"R37I^.](X 5!BWQ\OMS?
ME[N8LSIQ09VXP/KKG)6X!^!48WXF3"5<J$)B$G[=SI266*>_VX(MO7?;O9NS
M>Z-RFL#(P<.I0*[ B=^^\2/O0UOH_\G97B(Z=2(ZI[S'IF:P)J@]E5#61UO
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M ](8X/I""+V=F,NT_G:*_P)02P,$%     @ =8%^5N61AET- @  /@0  !D
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M^28M^8719?5NJ2?*&,VJCPN"9Z00!_"_SREEVR^B@MW[S";_ U!+ P04
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MQJGD^#3&/.E/)0L>R22AF2!G9(I5$BX2(&Q&]),S95%(QBS%NA%4.W_UI,9
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M1^B">B/>H=0+,$^#J<-MZ?=[0W-90ZA7$>H=3.@8<Y0!"X"(NAP<-R(>2JD
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M&G$$<P >,"2*JO?@SOLH;-Y3X?H_?*/?4$L#!!0    ( '6!?E:7BKL<P
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M_ZEW+J==RM>>[S4^_S^I+N=[T_7QE^7WR=&K<L$YP&_[QR]02P,$%     @
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M/@%02P$"% ,4    " !U@7Y6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '6!?E;(VRTT[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( '6!?E:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ =8%^5G3^\+SF!P  ZR\  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( '6!?E;-W_%*.P(  +P%   8              " @2D0  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !U@7Y6= Z6&"8&  !L&@
M&               @(&:$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ =8%^5M?+7&[Y @  4PH  !@              ("!]A@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '6!?E9%71C*\P0
M $(2   8              " @24<  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " !U@7Y6,Z])J$4'  !C,P  &               @(%.
M(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ =8%^5E:0
MB+9A @  U00  !@              ("!R2@  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( '6!?E8SPAI_'0@  .LC   8
M  " @6 K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !U
M@7Y67C'S'",$  #U"   &               @(&S,P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ =8%^5L=_]Y4O'   4E8  !D
M         ("!##@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " !U@7Y6N:H/QJ8(   >%P  &0              @(%R5   >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '6!?E8)'22FD@0   \*
M   9              " @4]=  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ =8%^5A@"8(L+"0  Q!<  !D              ("!&&(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !U@7Y6Q ZB
MUYX$  !O"@  &0              @(%::P  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( '6!?E:OQ+UQ#0,  -T&   9
M  " @2]P  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M=8%^5B^5;58\"P  !2$  !D              ("!<W,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " !U@7Y6?8=U3^D"  !G!@  &0
M            @('F?@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( '6!?E:IKM3L"P0  -H(   9              " @0:"  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ =8%^5@M4UC)%"P
ML1\  !D              ("!2(8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " !U@7Y68 !@W^ "   O!@  &0              @('$
MD0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '6!?E:#
M'?E1A1P  %==   9              " @=N4  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ =8%^5FDXK?#+ P  , D  !D
M     ("!E[$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '6!?E9S[)X *P8  "$1   9              "
M@=?%  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ =8%^
M5FN_DB0& P  ? 8  !D              ("!.<P  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " !U@7Y66H+$9)("   ]!@  &0
M        @(%VSP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( '6!?E8?]MO)RP0  . >   9              " @3_2  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ =8%^5FVH0:W]!0  02$
M !D              ("!0=<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " !U@7Y6+4HY6?,"   J"@  &0              @(%UW0
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( '6!?E:@Y6 E
MU0(  %D*   9              " @9_@  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ =8%^5B2E,@0(!@  ]BT  !D
M ("!J^,  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !U
M@7Y6O;74TE,#  #)"P  &0              @('JZ0  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( '6!?E8?%G;E"@0  !44   9
M          " @73M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ =8%^5F4W/D O P  1PD  !D              ("!M?$  'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !U@7Y6Y9&&70T"   ^
M!   &0              @($;]0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( '6!?E9JRJ?38 D  -M,   9              " @5_W
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ =8%^5N4)
M$@U9!0  Q!T  !D              ("!]@ ! 'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    " !U@7Y6,^C$]Y(#  #[#0  &0
M    @(&&!@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M '6!?E8<+\ZA2P0  ' 3   9              " @4\* 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ =8%^5F0)11$Q P  O@L  !D
M             ("!T0X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " !U@7Y63\=-.6X"  "[!0  &0              @($Y$@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '6!?E;49LL$/ ,
M " -   9              " @=X4 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ =8%^5@G^4F5+ P  NPP  !D              ("!
M41@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !U@7Y6
MA2!M+[ "   -!P  &0              @('3&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( '6!?E:/^43!R0(    )   9
M      " @;H> 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ =8%^5A:6Z'/) P  6@L  !D              ("!NB$! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !U@7Y6."6CG"0$  #F#P
M&0              @(&Z)0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( '6!?E:?Z3Y2&04  , >   9              " @14J 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ =8%^5EGJ7"'Q
M @  /P@  !D              ("!92\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " !U@7Y6/YJ^2XH#  #D#P  &0
M@(&-,@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( '6!
M?E8_W=-\-P,  .X3   -              "  4XV 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ =8%^5I>*NQS     $P(   L              ( !L#D!
M %]R96QS+RYR96QS4$L! A0#%     @ =8%^5B!(*QU+!   +R,   \
M         ( !F3H! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '6!?E9\
M?ND;U $  ,8?   :              "  1$_ 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( '6!?E8J9-*FR@$  )L?   3
M      "  1U! 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     ] #T HA
' !A# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of the business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Descriptionofthebusiness</Role>
      <ShortName>Description of the business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/StockPlans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Restructuring</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Description of the business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails</Role>
      <ShortName>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansAdditionalInformationDetails</Role>
      <ShortName>Stock Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Stock Plans - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails</Role>
      <ShortName>Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock Plans - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Plans - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - 401(k) Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401(k) Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Restructuring - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringAdditionalinformationDetails</Role>
      <ShortName>Restructuring - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes- Schedule of Components of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="advm-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtSecuritiesAvailableForSaleTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife -  advm-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:SubleaseIncome has a value of -300000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:SubleaseIncome fact are: Context: i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231, Unit: usd, Rule Element Id: 7095. advm-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="advm-20221231.htm">advm-20221231.htm</File>
    <File>advm-20221231.xsd</File>
    <File>advm-20221231_cal.xml</File>
    <File>advm-20221231_def.xml</File>
    <File>advm-20221231_lab.xml</File>
    <File>advm-20221231_pre.xml</File>
    <File>advm-20221231xexx104d.htm</File>
    <File>advm-20221231xexx104e.htm</File>
    <File>advm-20221231xexx10lgxadve.htm</File>
    <File>advm-20221231xexx211.htm</File>
    <File>advm-20221231xexx231.htm</File>
    <File>advm-20221231xexx311.htm</File>
    <File>advm-20221231xexx312.htm</File>
    <File>advm-20221231xexx321.htm</File>
    <File>advm-20221231xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>advm-20221231_g1.gif</File>
    <File>advm-20221231_g2.gif</File>
    <File>advm-20221231_g3.gif</File>
    <File>advm-20221231_g4.gif</File>
    <File>advm-20221231_g5.gif</File>
    <File>advm-20221231_g6.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="592">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 592,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 105,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 461,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 23,
   "keyStandard": 296,
   "memberCustom": 10,
   "memberStandard": 32,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.adverum.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.adverum.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.adverum.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock Plans",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.adverum.com/role/StockPlans",
     "shortName": "Stock Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - 401(k) Savings Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.adverum.com/role/A401kSavingsPlan",
     "shortName": "401(k) Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.adverum.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.adverum.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.adverum.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.adverum.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock Plans (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.adverum.com/role/StockPlansTables",
     "shortName": "Stock Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.adverum.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.adverum.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Description of the business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails",
     "shortName": "Description of the business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenue - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.adverum.com/role/RevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i8d10cca15a0a461eb8300e1d2fb5a723_D20210125-20210125",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails",
     "shortName": "Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
     "shortName": "Stock Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i0e11c662ebe9427c840584ca1263d906_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails",
     "shortName": "Stock Plans - Schedule of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
     "shortName": "Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i0d65268f8ad743689e8f2f494a584f50_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i5f966046784044f3987ed481b7a376f1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails",
     "shortName": "Stock Plans - Schedule of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i31eee3dbfa2f4f2ba64c8316b7d087fc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock Plans - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - 401(k) Savings Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails",
     "shortName": "401(k) Savings Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "idd9a1719e37e4f70a2a084ceacc62892_I20220706",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Restructuring - Additional information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
     "shortName": "Restructuring - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "idd9a1719e37e4f70a2a084ceacc62892_I20220706",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails",
     "shortName": "Restructuring - Schedule of Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails",
     "shortName": "Income Taxes- Schedule of Components of Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "id8fa0f98710e4bf9af1b5718d2dc578d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i0e11c662ebe9427c840584ca1263d906_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "ia2adc237b17e4a0a91ee3139a8e40c15_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "ia2adc237b17e4a0a91ee3139a8e40c15_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "ie36098bd65274595a8505fad4f3f88e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of the business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.adverum.com/role/Descriptionofthebusiness",
     "shortName": "Description of the business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20221231.htm",
      "contextRef": "i51ba6dd490624052a7b8a2055fd377e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "advm_AccruedClinicalAndDevelopmentProcessCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and development process costs current.",
        "label": "Accrued Clinical And Development Process Costs Current",
        "terseLabel": "Accrued clinical and process development costs"
       }
      }
     },
     "localname": "AccruedClinicalAndDevelopmentProcessCostsCurrent",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedNonclinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical costs current.",
        "label": "Accrued Nonclinical Costs, Current",
        "terseLabel": "Accrued nonclinical costs"
       }
      }
     },
     "localname": "AccruedNonclinicalCostsCurrent",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.adverum.com/20221231",
     "xbrltype": "stringItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Amortized Cost",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedLabel": "Less: Cash equivalents, amortized cost basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Gross Unrealized Gain",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "negatedLabel": "Less: Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Gross Unrealized Loss",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "terseLabel": "Less: Cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination",
        "label": "Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination",
        "terseLabel": "Decrease in right-of-use asset and lease liability due to termination"
       }
      }
     },
     "localname": "DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_DeferredTaxAssetsCapitalizedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Costs",
        "label": "Deferred Tax Assets, Capitalized Costs",
        "terseLabel": "Capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedCosts",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_DeferredTaxAssetsLeaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease obligation.",
        "label": "Deferred Tax Assets Lease Obligation",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligation",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options And Non-Qualified Stock Options",
        "label": "Incentive Stock Options And Non-Qualified Stock Options [Member]",
        "terseLabel": "Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)"
       }
      }
     },
     "localname": "IncentiveStockOptionsAndNonQualifiedStockOptionsMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deposits and other noncurrent assets.",
        "label": "Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable",
        "negatedLabel": "Deposit and other long-term assets and deferred rent receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseLeaseTerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Termination Fee",
        "label": "Lessee, Operating Lease, Lease Termination Fee",
        "terseLabel": "Lease termination fees"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseTerminationFee",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseLeaseholdImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leasehold Improvement Allowance",
        "label": "Lessee, Operating Lease, Leasehold Improvement Allowance",
        "terseLabel": "Leasehold improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseholdImprovementAllowance",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseNumberOfRenewalContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "label": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "terseLabel": "Number of renewal contracts"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalContracts",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "advm_LesseeSubLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Sub-Lease, Monthly Base Rent",
        "label": "Lessee, Sub-Lease, Monthly Base Rent",
        "terseLabel": "Lease monthly base rent"
       }
      }
     },
     "localname": "LesseeSubLeaseMonthlyBaseRent",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LexeoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexeo Therapeutics, Inc",
        "label": "Lexeo Therapeutics, Inc [Member]",
        "terseLabel": "Lexeo Therapeutics, Inc"
       }
      }
     },
     "localname": "LexeoTherapeuticsIncMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "NOL carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporary impaired investments available for sale securities.",
        "label": "Other Than Temporary Impaired Investments Available For Sale Securities",
        "terseLabel": "Marketable securities other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_RemeasurementOfRightOfUseAssetOnLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement Of Right-Of-Use Asset On Lease Modification",
        "label": "Remeasurement Of Right-Of-Use Asset On Lease Modification",
        "terseLabel": "Remeasurement of right-of-use asset on lease modification"
       }
      }
     },
     "localname": "RemeasurementOfRightOfUseAssetOnLeaseModification",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum",
        "terseLabel": "Award price as a percentage of grant date fair value, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage",
        "terseLabel": "Percentage increase in shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold",
        "terseLabel": "Significant stockholder threshold ownership percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.",
        "label": "Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan",
        "verboseLabel": "Number of shares available for future issuance (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_TerminatedLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated Lease",
        "label": "Terminated Lease [Member]",
        "terseLabel": "Terminated Lease"
       }
      }
     },
     "localname": "TerminatedLeaseMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen equity incentive plan.",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandFourteenPlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen plan and inducement plan.",
        "label": "Two Thousand Fourteen Plan And Inducement Plan [Member]",
        "terseLabel": "2014 Plan And Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenPlanAndInducementPlanMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandSeventeenInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen inducement plan.",
        "label": "Two Thousand Seventeen Inducement Plan [Member]",
        "terseLabel": "2017 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenInducementPlanMember",
     "nsuri": "http://www.adverum.com/20221231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r264",
      "r268",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r290",
      "r432",
      "r443",
      "r454",
      "r455",
      "r469",
      "r480",
      "r487",
      "r526",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r290",
      "r432",
      "r443",
      "r454",
      "r455",
      "r469",
      "r480",
      "r487",
      "r526",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r283",
      "r290",
      "r319",
      "r320",
      "r321",
      "r408",
      "r432",
      "r443",
      "r454",
      "r455",
      "r469",
      "r480",
      "r487",
      "r521",
      "r526",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r283",
      "r290",
      "r319",
      "r320",
      "r321",
      "r408",
      "r432",
      "r443",
      "r454",
      "r455",
      "r469",
      "r480",
      "r487",
      "r521",
      "r526",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r264",
      "r268",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r486"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net (accretion) amortization of (discount) premium on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r13",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r140"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r143",
      "r439",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r103",
      "r400",
      "r444",
      "r445",
      "r503",
      "r504",
      "r505",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r512",
      "r513",
      "r514",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r88",
      "r89",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r37",
      "r63"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r121",
      "r142",
      "r159",
      "r199",
      "r208",
      "r212",
      "r223",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r364",
      "r367",
      "r377",
      "r486",
      "r524",
      "r525",
      "r571"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r136",
      "r144",
      "r159",
      "r223",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r364",
      "r367",
      "r377",
      "r486",
      "r524",
      "r525",
      "r571"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r218",
      "r230"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r54",
      "r217",
      "r230",
      "r434"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable and current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r138",
      "r456"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedLabel": "Less: Cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r40",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "verboseLabel": "Deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r44"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r105"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r113",
      "r125"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r249",
      "r250",
      "r451",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares available for future grant (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r486"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2022: 100,117 and 98,381 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "terseLabel": "401(k) Savings Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r146",
      "r148",
      "r153",
      "r435",
      "r440"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r118",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r511",
      "r559"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r349",
      "r357",
      "r511"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Marketable securities term (in years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r221",
      "r231",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of marketable securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r511",
      "r560"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r37",
      "r99",
      "r350",
      "r356",
      "r357",
      "r511"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r109",
      "r119",
      "r343"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "auth_ref": [
      "r129",
      "r130",
      "r133",
      "r570"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease.",
        "label": "Deferred Rent Receivables, Net",
        "terseLabel": "Deferred rent receivable"
       }
      }
     },
     "localname": "DeferredRentReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r95",
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals, reserve and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r97",
      "r558"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution by company"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r37",
      "r64"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r280",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic tax authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r154",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r178",
      "r180",
      "r182",
      "r183",
      "r184",
      "r188",
      "r371",
      "r372",
      "r436",
      "r441",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r154",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r182",
      "r183",
      "r184",
      "r188",
      "r371",
      "r372",
      "r436",
      "r441",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation, weighted-average period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and Benefits Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r134",
      "r150",
      "r151",
      "r152",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r190",
      "r224",
      "r270",
      "r325",
      "r326",
      "r327",
      "r352",
      "r353",
      "r370",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r400",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r373",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r374",
      "r405",
      "r406",
      "r407",
      "r467",
      "r468",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r284",
      "r289",
      "r374",
      "r405",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r284",
      "r289",
      "r374",
      "r406",
      "r467",
      "r468",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r265",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r405",
      "r406",
      "r407",
      "r467",
      "r468",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r234",
      "r266",
      "r269",
      "r369",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r466",
      "r517",
      "r518",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r29",
      "r53",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Losses incurred on deposits"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets and Purchased Intangible Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r131",
      "r132",
      "r564"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "verboseLabel": "Lease incentive receivable"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r160",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r106",
      "r114",
      "r127",
      "r199",
      "r207",
      "r211",
      "r213",
      "r437",
      "r465"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r160",
      "r358"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r335",
      "r341",
      "r348",
      "r354",
      "r359",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r162",
      "r176",
      "r177",
      "r198",
      "r333",
      "r355",
      "r360",
      "r442"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r331",
      "r332",
      "r341",
      "r342",
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income tax expense at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "terseLabel": "Impact of internal reorganization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses, other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r508",
      "r568"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r222",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Future Lease Payments under Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments to be Received, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Payment Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r159",
      "r223",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r365",
      "r367",
      "r368",
      "r377",
      "r464",
      "r524",
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r110",
      "r123",
      "r486",
      "r510",
      "r520",
      "r563"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r137",
      "r159",
      "r223",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r365",
      "r367",
      "r368",
      "r377",
      "r486",
      "r524",
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Facility"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized loss on marketable securities",
        "verboseLabel": "Net unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r38",
      "r115",
      "r126",
      "r135",
      "r145",
      "r147",
      "r152",
      "r159",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r181",
      "r199",
      "r207",
      "r211",
      "r213",
      "r223",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r372",
      "r377",
      "r465",
      "r524"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r199",
      "r207",
      "r211",
      "r213",
      "r465"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r388",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r396",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average IBR (as percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r395",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Descriptionofthebusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r238",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments made"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r31",
      "r52",
      "r155"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r486"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r33",
      "r86"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r52",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r86"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r139"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r67",
      "r124",
      "r438",
      "r486"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of assets (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of BPI loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r91",
      "r128",
      "r579"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r450",
      "r499",
      "r509"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r238",
      "r241",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "terseLabel": "Number of employees (as percent)"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r37",
      "r242",
      "r244",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Charges",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r237",
      "r238",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r238",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedTerseLabel": "Total restructuring costs"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r238",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Non-cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r74",
      "r122",
      "r447",
      "r449",
      "r486"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r134",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r224",
      "r325",
      "r326",
      "r327",
      "r352",
      "r353",
      "r370",
      "r444",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r196",
      "r197",
      "r206",
      "r209",
      "r210",
      "r214",
      "r215",
      "r216",
      "r279",
      "r280",
      "r433"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r394",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Option Issued Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r484",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Awards granted to employees and non-employees vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares of performance units both performance and service vesting conditions (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "periodStartLabel": "Beginning Balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair values of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contract Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair values of options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "periodStartLabel": "Beginning Balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r297",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Stock options granted period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted- Average Remaining Contract Life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r75",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Stock Plans"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r111",
      "r112",
      "r120",
      "r500"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State credit carryforwards"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r73",
      "r134",
      "r150",
      "r151",
      "r152",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r190",
      "r224",
      "r270",
      "r325",
      "r326",
      "r327",
      "r352",
      "r353",
      "r370",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r400",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r190",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "verboseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r51",
      "r486",
      "r510",
      "r520",
      "r563"
     ],
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r392",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Negative sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r384",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r384",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r384",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "State taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r266",
      "r269",
      "r369",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r517",
      "r518",
      "r519",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r237",
      "r238",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r330",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits as of the end of the year",
        "periodStartLabel": "Unrecognized tax benefits as of the beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax provisions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax provisions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized would effective annual tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r191",
      "r192",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance due to net operating loss"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r391",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r179",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r178",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001628280-23-009899-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-009899-xbrl.zip
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M!CIKC@O^#@AJ@8?W2RW2-O\Y2SODLH/PQ>O/SKW.S?5$XKF)Z?+0=3V'QZ8
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M4.<VG/WE[*?R4E0%_G)25HNRHEKI^KC@QQ<";A5U7TFX)S@D/!?L/Y[&CN>
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M@GH3!X/Y81HR'KB.'T8B3.W4C5SFA6[JF7N$,]=0]+OY(B^70@PX_W,$9 "
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M&E91HE55=P4BYH&T'HJTKF:"PK$K]/6=];T\R1D(*J0L;K \[\AK2'>Q4!?
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M+D+&MQ0SO XZ!V:XB\P0P?8!;C'.6"J:I?$VJS$IOZT.^N$>$=YM+/$0Y'Y
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MC-S,LCAK"'![^Q(KU81=W;9QELP$;_.#ZKI/O.16(73@\]N!C2Z?L;;?9?/
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M,7>C65,Z8Y%GXG+M:U$WV7S#Y5*LKSVR$M@*86W70GQ=/P=8 43WAK47);*
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MMD5O?^F$A6$P4>G -_OJ58W)K4$]F7DIF9%\O I%'K#Z(2,Z.DXC8SE=T=!
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M?/R/HV >(I^JJJ4L61\=6U*2O5N+WUH54=5C0!4A2Y8Y?,2 G7;<CYBFU(\
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M?1='QALJB"(TUK[H2S%$1)R.V+FU!TW*._N/]!\=MM9L:Z6C^3!AA5:C#!M
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M[CFJX:7<WBXS=]A%\VZY@C1**]?C.E4ID,X\'+6!PD)'?!'J0UC>R6_@'YC
M37A\S4@;69:=X_\T9 <E:_4HH6S8LU'Z);$"HZ!&.*J-K\YD4]GQ,G^,;VQ9
MN\U^<%0RCAETW4S7/]0\MI^PW7=& ?3&' +JTKK:)G88 <!VSRNQL/Y9K!X!
M@V&45K71W7;;64R5K95SMZMVT9GOTS*=JCF>8Z@C<Z&BCHZ=/"Q2=2/-R<4N
MOND4^G^S'"-61].?"6KQ6*6"?U !Y2$5<$ DWB$5<!>V\NBI@#LI-"F!>KM"
M$[:P66B^554V@T;UPYYMF\<9]%X\J@3ITKWT( $L:U,=E"<="QPT4%;I:=3;
M_GYM[8^VU7JU2X)?T2[EV-5AC^SUJ1'C\OWN$/LHKHQT8O\8[!LSKAF[ATJJ
MH_Q:<M6CHJUUX83"9JH&I/$U4:77UEVQ^Z;8 TCJ)'\<73%LV:YN!@DO!SA\
M8QC4GHQ+PMG:CCM9.QQ>04^O^Q,AG*/.J"O#(^0,;"U%=1<V+)E9&N[44EW4
M5G(46=//W1BC-6_)CZGAIEY?=0;2Z$O-/*AJ1E4^=@,8,@E74D?K9@#?$33Z
MVL NI14/X ++CF&K/P/R8R2YOW$3%"39]4<T&:PQ46F:=*QJEE US-^D'V0_
M$'C@%R1[28[B4JE_]:R\JL>=YO235(66)ET:<T#[79T4DA7#"B)]T+VRJ>I.
MM;HY'CNB^QQNZL8^#.:M9-)@>PJ@,52.50MM2C)8.T#=6N7(>"]K,3 M>#(<
M;K+: 7Z<UW#SS)2^_12ESN!A4IFTS"9:R] KUA"I.U1LV3$.<G:.^KLRGXT=
MB]<GT?0MY149;&;NUP"DZQBS,CRFX"O?# YN1%0:FS;/,CD8T(]D0'_&EBI=
M5VS9I44:6'D.^ER:C;(2*1%[T*:,87+$%5FBNL779)C9+>7"()2/&4M'V[2<
ML8AZV)]$31K(I2W*BL%)&%US=*I2[4\!Y''&U[(*NL)JFO*@&H9.-IB4X[$D
MV#FWY"I[11_XZAD?C;8][#N:D:R5#DKJ)[3RM!4]9,R$L6L#XJ49_8 U>5TW
M"=WR=1QD& Q;&O:/T[/JL/,41PI6_>1XGV>Q,LE*#YZXIKW%@=8?B=:/!_4K
M73@_Q@K*2UTP21W[U-#$KMDB@;&6U;VK9;?=.HA/V/RVPEOQJK64GDUI/*H[
MB6QSH;%ED+:S75X!5(?)X[(0"M^)VFL/YR!NW+0J(2K*2]T?Y4)FDW<I_]<&
M:3?FN9'=H!U#9!=,M:V$/3.HW1N 8I#Z! SC#<TQTZDT\,RUY!JX?DK#),G9
M-&CKUCL#&TS,[3J0*0-DU$NNNQ%YE2ZW[=,J8SP<N$7E5G8O0<<E:RJZUG+*
MDZ[34F/5[B3)X8R)1?0OMZK-D\-]T-MCY<15)8>.)Y")J?0.;K1Q!M9&4[:J
M7SL*OBZ0BKTV2SP%U8-9*2MXG@/8)%3.->!\" J-&E*5V9"N1*^!B?]4T56+
MOF"^3V D"(X)MBMREEA"IG*R3*3;1+8T7(^(')CJ8S'5DZX7C% -\G0Z/<XU
MOY$A#AA@#_5!HTWUVVHKEWZP)*GPRQ%CW2[#E/TG\I)R[3$.WA:2W6-)#592
M#CKG7'9%4,/BI:O!^2%ER^80!>A%C2Q1E#TM!I)DG/4[EBNC_L"5[C1!?$T.
M.,%V2GKVO.P80,X=Z<GH*KX.]L>CD<^[ 8=;ST,:0QKK350S:.P1JV<[K^2J
M;8[1;W5\TZ<UD:_?%1A^K MVD)N_05NYI'%.+\_22-,Z36$CD=N78ZANOA2-
MDG/5BI;:*F-K,);(GLS28.MU!.T@&S@SM>F@2F>QX1ME[WTX[GKV#H:?R@W1
MR!.*N<IJB49UO0+2J^6DZ2XLKD+YRN6\FG2FFV[!X:HN&H@)JH8#D\THR0R#
M@_WYD8-+6ATR.4H6<^>KC1^'D7F--VS ;$:5(G<C\2UF<?R$\OQ<.8$ 3;[B
MS)V[I1=M+Z'CIZ'G2C9]Q]$]:9L/'*_SDC.M26GON.; ,O.>\A692BM63=9%
MYUF\8JA*H2 9I_1T;E;M.=:Y<J)00X&'.?YX+^"5GOU+B#7\75..<GX/YSRB
M&U./7I^WC>HTK\:NGQ9 MG+X%2]E"X61FU]=2/6\J_WH*K&@#M8@*.4X>>EZ
MQJ2GDH\SF'2K>.GH0U=,-[%#/;94_E"=I-)Y_B:=,UP)6B1AZDJ@M]KWY))C
MCLE9+X<@]].H<3>R;+^_JB,V; .O;(#Q6,NR<S5N.FSD:W(^Y&[C^5D_RP98
M4=W('&KJ*Z28IL8=74HR@+)N@T@M0?-2-AYOLKCD6KW!Y+2I^H[R;O^G1>]:
MO8("Y.BEKFU#62 G;^+.L )<-7I@O77?E&6N6C]BTU&:7BE%*!@<<EK;&JD>
MJ?23@8N;-%UJXB@G%)*K@>S\,56.:^=E23A\.J1(/9:&==;&:/63R!NUNM^N
MJ?"9\DEP0$?7PW]<B[>BUO6HULTM(*& [0E4OYB!$WN(9S,Q+Q<S' >!2? 4
MYYRWJC\Y:\@!,3'.6(&S"4%+ $6KX+ =8&9E!>;+C$9((;M+6!6S^3)G5#XA
MQ0_&2R[R98(%2G"&)5E[6GHU.*?1PL=FR==<,D;]X\3XS+ A1%T6'7OM?D("
M? ML0138*EAOEB]KO=W!)%9->2OAX<$!Q!E-Z0.F\^7S.]^3,@I.:3A!M(L
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M,&L<T5!,T:20W1\,<HOKZ\ 80S(9N8W>?CS&I$/M;T.! /<P&0SM^[UC4Q_
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M-C24J?/088?#%G9S2)!Y5*P!$T=.@2PN=@]M$$UHLND@S-UM6(V]+-L&3$2
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M5RC"TK6A ,B\F%@1QM "_O*,Y!?4E\LV6)2$ 9&.35:,8AH4]TZ\*5;-/-S
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MW7V2_7SZ[O#!MP^_^_:[AW>H=7\\O[\+<^_#4/X88>[H?*A)1!%+F*",0AZ
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MHD)9((<GYXU6GQ>M6'%85(\U1^:FB9XA9D6"NUB2AO*&AO*@87'GXY5J,K>
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MQQBC<B2G!?T*^K5R4TSFB+FCE?U<S0-?VKZ/:*_#ME74MH?0]5'-?.&FPD&
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M6JXQ%5+3X>6@V6P]Y]FON2>E#5#'(?DQ?0,'KB8752G-BJ?A%!(660Z\1+*
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M'1?(/I69OJ_13%<VCR!E05O45?'%C_8G$KQI!:ENDFW)E_3V_PR^#6XX<?0
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M83T/?T"UN$/^Y00JA1]#^\T\U.%01D0"_UO&+V7EF[@8_:6@ %+87/@HQ-P
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M&UC6YV&V=6QB74B;(S\V]76NKVO$Q@GH(VZ7PK^NV:^#+#:/(&B+X#QT#5T
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M-E'2_^%38RT+M!V!C];%^)D(%1._S1KI2'[7'>]S=>2A6H1YJ6?;ZQ*AFF\
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M5F9_<BM#WT0@Y;Q6[^STU5ON.Z^/2S;H]"*HTS!_((/"R((&IPJ6\)=W(S?
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M1[G+V:R7= F&@:Q;HHX#0QY*2VRWLR9I>1UNZ+5U?@N.P[K<*4[L#C61] Z
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MMFEEKI17.I(,Z[4LCV+5TJU&07MCSA%AH3!K9?OFA H/,9=/Z48AB@P@//R
MDU-"(8B:-3_*P<D_+(LEW;7KCLG)!!>6.UQ=AVMVCMP^PQ#%NG75H+$#=31P
MW\5F@(/,021(*)D62O<4"\O=(7ST2*W8[5W1_#U#63HJPM[> \_.(94VF?54
MQHH7_S 6!S%:PQRT^,/Q'.VD,W(,1EWI"WJJ3O.P/$[*F3;2P4S[D,%+CLNH
MD^8J6LTA2E,GAFG"=+(>X')5) >/.AF6=#34])HID5.1G1/V=7M;(BU]XA7C
MX'6;CIE1MDA_>*X;<:ZG:PYDT?+%'(O@3J&4VVH,5N4D%S7(+E5T$; *?T[Y
M.LI"6F-KJP\#L8J!R3O)&QDT#6KSP_MH4+&!G!76#,@GK"-F8B*K?5W6D_(&
M292;!\3N%A3NRJ&GB_#LI%6ZEE+) 4(><#3H.[:7GY^:6518]:U8"CIU)2P#
M(>N4ASEN&,%J]?WBDO5?#2L 4NI2VZ8(>K01#.SKSSP>K3@6R[H+$3OY!DU-
MSA362/N5*L X/2?TJ&+2-AV?LN?/3R3 Q<P7,$H,0H0HJB;0>PNRU#;4L+2V
MIFZE1Q*$A )E/44/6C4 YR;6GY$DJ'[RXWQ/M\;.3>;7^9MF7&I@(M:<V%;4
M36W+=*\\.#^(=W ./2!5_&%T])W[X:?@;7"4+^DV<FD&"N:UHL/NQD'AO\MW
MIOG.;^_RG?LPE#]&OO,=+CR<5G<1HOP"I[510D:Y%F$*U*X[[+!]%F_O2.X8
M[O5@<UYJA.9:7L MI4:^D#7%,N@%T;*'G6N)/E6*/;QVX=P%*"D!F":#.!E\
M-!?*"N8!W5_HK#-5MBP"9E<=YTHYSR'U))S16*&?233V$F![9-Q""2MA1)=<
MN"(?,V-,L*;;II8Z'F:/(W^ ."!+@$H8ZC2M.M!=P/&D;L#Z@<M,E$H0-:]F
MY8A;@P##S7J90+N1\F8E";\N/+^;@6N7%A)$==EU6TP 6:31MFME@U\1G*<V
MK9@E<(L\+C:P3E>Y:8=7E:,)P0FJ..) %C$0BL7_S]Z;;KEQ)%G"KX)3\\V,
M=":2Q4522:69.B=%4BJVBB);I(JG?P: 0&:(0 0J I%)U--_;M<6-X\%F4F)
M$MC"C^ZB$D LOIC;<NU>A=:O?"][<I<R.E0]B1V$71/^?GJ-D:!!PW83=EV&
MTRC%^1@O5]H<)ADM01>MIS1.T:/D?\G+4AL]PH!B3=Z;G:.7BA-S:]?VU^OK
MT=ZRK)?)<M&JAL"#E(\&KIRFE *I=%5H@8273N+! :I=,),3'_L: \"O<0I!
MU+ B@#WQ;54LW/K4:/,X$T&->[N$^<"H$8@W5MY*GI@QKDM+L!)9<TZ6J5C3
M?3F@, 8I_6370'J3;MP$VX5 6.F!@Y4YPSU$TRH84_WO@;]]W F:UR/,#M8^
MZY)Z([W/?G%."!P/L3#21,E-(;<:FZ-B+Y$V!0EOHXSU<4_RL[0AU;/\)3FX
MZT)%Z*D_+9^30U0W,7A)V.E<Z4^[(/V%(V&DA18[PE7J"K \+[<P 8[@]Z(8
M3H%H2GGUC90KF,?845Q]^^2\I\F-GTR_$C,E2R.Y_5!).SAK #/KT[FICZ)O
M'5-"<RHX<%Q7H  P>/>$ZE/\'%1Q, ^US_R(\%Z\^EC&TRIEAMWBS@3'<MJ*
M!S07[2W.X-B#42OT7AGK,/(;0-O*M^PZ/?OAB3!'6RLSWJ[0"/H2->KD>GCZ
MUX=ZG/DAM+8ZEKZ1^FDPIUZLE0\0;OFF&;0*W-3Y[UZ,PW9[ ATKK&,K/W J
M"KE5_#,*)U(M0=/QXN"0GW9)"GAHDZF286=_PZ]+OG_279NRJIHV^ZJ_;BRE
M*J@\.'/3F22@8"[(L],4QO#%COQ<NMEDA97A.?9^)^MUP&;=3$#W6XWTY"%W
MU\C\=<$-2>B/=ENY)\WWTJ) G:K?CVG\3W^[-\/&D_4"UN%!]ME$2[VQ$9)9
M8G],%;"85Y)U9>%,]W)HS!&NZ\:-&9**I8C(C]!O12_72/05F:')9O:UL,.O
MB9I[>H//'O>6;MPXL)USLSA<5.2Z0L(.FUJK&)?;E5_SE9\P,N**"_*]8J4O
M<7#'^63>4D041A]EY+;1_Y(4,+5,;@K/OUK'9/>#1]H0IE,AW[FH:S=?BDBC
M1ZJ6>;-,0XN=*9\;>6?,T*[ 8 D (5>%Q@\E(=GEZ 0EY2)25EPR/U1<)^EO
M$0;*%)_-]V<Z\1(.OE9^H%SA;Y3(;  N6BJVS=62*&&"T*SG'S <ZC;'JFZ*
MIQU)ZN8"C@">[)S:+AED_O3YN5"0%/1O;CBEI^3D+&%.MF$"%/+Y]#&;;<3N
M],+Q)2:?:2<%YK"12E[0ZY',.)\9))JKFO=DLNWAOZ5/7E/H-SMOD?IFB(Y9
MB4^>+4*H7RVSV3_*8D'=\<$E$3:B'^KF.M]_R@>]?^0XX&7K]%@]!_M8_2K&
MTG6SI74QDF@;L.N>$3CU:C0K)QU3DC_C* X]JG[=0#?56OZ*VRV?1'A@55*^
M!S)/L(9QK;0>)SV8FF!ENW78= 4GOM 2.R3!P33#5E,(L"]VPG 6<U4B9=V[
M/N]Z?;%-)YCB17U1E0KOOOGM[.:1*"=?!T]KN>\] 0%&^D] G@>7E6IIK.ZM
M8*G3X)G^'8O$XVE2RX%\A"D'12*04[UJR&9K=JX@ 07':9^8FGB".>WOJ7WV
M\,']V3+? P41(1.RW2R/K(H>]>)M&(AZ2RFURO)I4[9&<XKQ@<SPT(NLR*"A
M'2%3^'-57$/;S>5&TE?%<5NV;\^<7BAVDD$8)&WY@HY%7)#(1%#Z[Z<\%9$1
MGR@,9%>A>YV&B?OU!:>?5.R'2VVO/4+!)E,Q#\)&1/K1DI 0-5 H[4'-XV_%
M]JKPR#4:DS-@3F4PCGR9NC._] NQ@C7JT87EK(82T=?!5N5:.%$B-(95,$%:
M.JFRG"NB%G?L^:V"+F*^7LK,UKMA\&5V#RD?SM"G*S9X5_3RI60R\A84 DG6
M;E[88IY:[&(R^1E= 285]+BG!O3\QEUSPY6F]Y(/X2JESJ'W\B5]-WR,R38[
M^O3QB0P\*3-_>2HS'\.C?+ R\^_#LT8'_$_?6]L+'0;+)K_V"=9P8-9]&-+#
M^],\/]\TQ;MREZ$[::U:I9!0H0Y7J<H@-/^>6=B2M&%1794-:[2TEM!C)Z&=
M(.T&@51,S8&]8Y<"[N16\CH3MX.-Q:->1(1_#R9/B&O]2+Y*1SS8G(-GZ74.
ME@+WSX<:.O.N65(SW0O/[?29#JS+F(7G1@ND]$"8=@Q7 [GQ1H\N^&;@>!'_
MK+3T%AO&FG1PMWK]LW!M#I[H1H\=(NQ<;\/!D?TGZ*;AJ\ 0PJ6B$():RN@A
MGN="W?3P0?^7$/%#M7I5+[J6W1*T+"-RID .-;QD??BLX?=<ZER;\TV)@"3L
M&@.@G;M>F=F\7MI9?NY&$GV>!H% N5K5YDQ2:2P^0]*V "<Y\6H1:UE!A=6S
MJ(3.@7/91E< \4Y8157QSEK)>\.-SPRBE@_GU4="]$+?/7])K#-;Y2<2LDO9
M#(JRIU6XH%,<J1I*?R*/$5Z)?K\,TX)-H)GO"TJA*T]R1KTR# 5A;AQS(#F7
MHM#E>;X#S@!M._!W4OW*[VC(@H$HX0=]\K2ZX/#\U:+>K?&$X?_>4)'I4R '
M!/  TE$N-%O"+,3OM FKV;-&8GQQW@GQ28\7]SF3,2G"CL/>&NB3H3T ?Q38
MFY.&=IVB;&1A(OEA@>!@-A9YT\#7ZW;JVW H^!(U<[W0;>9&J;^&E^GO-V8&
M4GW8UN4F2\=^7<^#7R,L=." +X1(NT(C"(*"JE:@S39JO)"1VV$C%(E5]FW(
ME.1 3L'GZI$RU+%Q*RB,.&"H& FRG@@HYVTAXS%, 2"MQ^O-9VV3%2C\L-^G
M<\\C39-XP\\S=+M=@JUMP;U.,0F;ZS#)ZK;>:S&Y'&Y<</X@O1$W:'T]VUW7
MT@=/0J^+R'EOUD*D(=RP"O<V7Z*'T IOE+XHK%?XZU!-\88WQ[M0?R+(J5SD
M'.Q=V+QULY<N>>)/UV:M8;[+F#?I1H*_L)Z^TIP S7 W1?*],_OJ=8C4^,S1
M,S[BVSBU;S6>CF;]O!4[T$Z%-V%'I+8(3/E1$L*7%F*VU5!C@\(DYZOLYQ:B
M3]Q^:+["UG9&5MM7PT:_138UPJ9B[*0K/R9X\U2QQ2;IQ_BJG /6+@;LFV&&
M(1Y"EM#'VZ=/1#63$:2ASOF]V2M"<T6_$.,OR3DP#<R$?'-#>/6P/X(G+2_W
MDWFKXWX<+XE>/<5:Y0UQ/F MF:Y83+?0\K9'NY2ZG>Y0("$R9@BEFF6Y:Q-;
MZ*HE43M9 0/?PQ"3GC2@DC?\'OZGTLE$%@G.1[86:4OYJS\V<2>2W=UR&&ZD
MX3&=GK-(M#($AI$4.G:\YW1=OX= \@EB>4C!; YJZ6G12Y?.[YZ+^M5JM,\C
M#YY1BF#''%U5UF78<D??-S+9&C::#1Q!Y9@?GJ3<R\I%;.D])AO+O'=5IJS]
MCF1PLCOET)MPGR"?3EZ?6=O_DGIK6^SX&2I?K92S-TOV+5E+U6!6<H#D6BK=
MTY>J#%<C=]!JG7PNIJ^0U)HX!CQ_^2P)E.B__> L^VBE<!^S+>@=TD"#4G2-
M=FIN./I3 ]8#@3@OCQON617*T7IS@7_<8FB+YI#=H*=0BRI\&EN'A;Z0(SZ^
M<]NU$)C@]S@PZV S6>3"BCLAQ(J4R+"6HXS?J8!L7 W)F@QW_OV3ZK^:(7N2
MBRS0<YO1IY&Z['AL5RE,#E>CK7KFK[H%-[5$^R=7B-,[TF,C H6P(OX5PA7B
M"0>%/_10X.GK$D')P9&[S;HMH?FF*OA5GP+#0@>]H'C#[I+W9D_Z-]E"(W37
MCIEDJ5+*ZH855U"X.MTR>+73 :,[(.O7P@LVN0E?"*3X)U+6^4]Z@Q//#G(.
M,*CID*_\8X"QAF<N$Y422=K84Z1WO@T^0G >#%4T 8 #+R\6RO#S_:Z9GOY&
M[Y%LY<6B$3]E4JYDC*QF'6/4B,0HWER:7U&KIPQ6Q<4[J1W*,W+F1L".\7KX
M)G!VQN&[FCUX(/<H5]ELV5G<M2J;<!KZ.<.D$!B6VF>E],/G]R'3+G#3UG>N
M.&?1$3A0;^G.MT&;0)TDZ9+G:P',0?+-56P])K8<PK:(2:M8<R<.GPAI4J/?
ME0I)) (=DYAX3T-AI\(Z8]L/T\&"4#&4P&-353U<-HU)<[<CW;+BW!7=3#/M
M%JT149/D^["-NB8V;4P]#1?X*+B(X*_(ZG8JPB5%N*].1;AC>)0_K"+OTYCF
M(/851S_WBK$*'TN;RYNB[VA5W:8 \Y)@O#/5R5%!+WK+=;V G$4R"I=Q% 2Q
MH=PD3QWY'I*@CJ4&)XC3;$_)Z39Y./X!8PA7A')"7]Q!3_1V5Q#)$Y?6DB=S
MHA$JDUDMUPP1)#"ZVC^TF(X "?E<3?L.N$K%EVR#-P)N4;TNT;M0.K\)$T,Q
MEWS/TMG2N,-<$=0.DO\[/#F-.<'WE!-PO7<?*,4Z" ]89.\Z;W=RL;*"=$OR
M14GM&3W*Z+BC/J'):)9EE084;II@E: M=8[NM";!_E,7W .M5+: J5X7)FSC
MPW1F?0932^-E*/UW=I<) %GNA_8$/DQ7E/Z&IEK.?(DKY%(Q7,*4%GSJ.O9&
M(L\ECTUD/83BTI3H@'=^ZJ54[DBNY[B4%!;OPU<"$*G_?E6OKPKE?AF=1;05
M4YUU78;+TC^9:FF0;>B-3;JR!UF-+ X>]JG,HG-;K@T:)5353+[Q]U?ARSPF
MI9)AT)?DI?OU=WQ_=$4UDC IWF7J ZT:ILJ5[G,D2!T52@&J&'B9U!@2?D&@
M) @@@HLLJ1YS+;^WQMSXC#U4VF&;9'ABZ=$,D&353?+/L?C$F92UN"BD(UBM
MAH%LD>36^?:C'H(_TOWB8,88&FE]S8-+J.J8Y&Y3>" ,?KI_>C4\7Y22=P'I
MN'K!J$!S'6QRLDPJB_O"A9HV1%P5I>_#B41D6KQ2KHL!)XML:*2C1<PJ!QF>
MY/]&S,@1=+ >/-N90/9QB!YHASV'FAXMEZ,]R $@.L>R,12+P(,>8N5=YDLN
ME86X,JS(-='R/$*>Y P=>D782?6^ -&1'A?VMW"=SQ$MSEY>WGMRCR;R.?WO
MLJ J=_CXRZ^PCHKJ(A>A:.+XRIL%NP+.:K)->O19__NV\)/O,B5DD3&3:B9-
MD^':H)L--PZV5\P5I 0)%,-I3\/U\PT54;*QJ1Q@@:BV]*;0<OT%5+:$(V,?
MAT(;L5%N!D:#1&?=QPWO?:,YXU(@^NI(>5IVK:\JFJ;E;!Y6D4A_&;ZHQ5.9
MX!89"0\A$LQP\@R,AR=43OIT\EJ,M6G1?D\H(*57C"3HD2X,^[MK6#DQ''>Q
MUP6>#0VX4;Z#Y,YR$,S/P*\H=Z*<5[Z&96>%>V'A:.5(,(P:+&&!]C P7>2S
MU^'X>1,\/RZ"(UE%;/2L-_4 OP?7;+C9-\'ZG8>(CW95&\+XNMO^_MG=@_MV
MN(*0=6&/ T57Y$_(W%)V3W%LM(%,+%#GB>5SL&:B]J*HRX7=CNX'NEW46+PL
MB<%5SW@^'F#$N2),@H:8,T<9RW('0B"(+ 9E4=;L%KQ1-^9*( UR*K'NE#9*
M 43E*\5P0>@]I?.:(XG,*V/3[;UT]*X@L50F9R%<8CT81RI]: UJ6= *533>
MG B"R1O:4[,#.1CKWF_[O%_=EBR@KO9S(B+I-J:W^(W:K\?B2 ).2<1?;<*V
MRRX+).!TXS[5[?GW\)MY7;_5C;BK+[AO'WR\.VZZHB8H[^!Z)E3'"L\VPS%F
M;M'#1$M$V$3(RVF(P/)ML==N=#GP-@4Y/A%+1J#]BR;?\ML(4H!D4 !*J-J8
M&E<I.N6X5WMS! ?^'</[)_$MGP9'1I;@,U[O1QS2PZ+('ER(HH@'_M(+%?&%
M2GTA"]2?/'UF@;I0Y^58N\9=Q[WBT 7W;G4P)-)@#^$ 61$^8G+K<])7"5]Q
MO'D5T426E59%_*GZQ>?WOOJ?^CAVQ,V!-9M]_M ^(DO#N-AK,A+7(=#@)_O\
M_O^,NZB5UH=\)WSE=7/&:NFPM?/Z2GZ/]#3))=-UPIU2X\U):QMJ-<O7=G3)
MB**=FNBL6:B8X&EU8QR +BAT8PW<]:YA#@5@I(0E6F-3L==$>QNN52E!T3QL
M<FDV,NN<K(RH"(B(EGUX3K[+-3-GZ#6W,S3A8U8851RM":C=;8NU$.+R->@H
MAQ7N62WKB+8+GI&'H/X?LX)%?8>G/W[7QJ5;+;4<MB$3'I;UF0I'F0-I>!CG
M_N(AK"3 @>IU/:.+*W!/%B$/1;<%B3U]1V> 1K>K8KNA7X5_G;UZ<?[C[)-7
M_#L:F3=8DF$6Z1#Z,:_>MG2W3S,!'W+1G.^"&0JWKALX?_KXJV*3KXMX$[\M
M%=\ QO,P][1X6#8BX3O_QW??O/[/_S/[Y&5#\ .^O^;:@-(E<9?TR(^K6@Y_
M'A]YUA9/)I>U)U.4!8:3WR23BV<1)2NF"8>W6TS2G!RB[@OCNRL;>2M08,41
MBV*S8:JHYD0] 47#N<$MC0*OGDR>0M<_YQS-X8I+!;*UZRWC+52"P]T_!.IS
M-B(?WV'WN'^.?R/G^-$><RP5QL8Q6+*-M)FDQ@?J'8+.,QY;R3O:ZSJE7O5
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MZ9.EDC$4Q!V50RLZMFBF5X9X/ S%VA71AQ>^G;A&]X.;Z:J"1T].(S-W+3I
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MWOE^9&A)\/CO8>01F[[,JR*$0^>+X/^1KT,DR$-^KM:_KR<#3!_YX^N(.N?
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M#20PX:[DJ"*IVN_Y2O!=YNHUE"EIP WU#%*YCIBUDIW6@^*Y\</8I_T)IN0
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MX4$6Y18OI=E5Q3>USML/H:O44IGMCA!FJ[K3:(%TBL+?*TJA$2LMN-F(Y%I
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M-C]H^B>#I^^)36_5YJ:F,H1]-$@.)M"2V3+?4*3$C-S;;I?W^8S :&%IE,-
M@#3Y0C"0<B="1@).G1J^A&Y0X!JJ_A</2?VEC$X<LF3BT^)['([3EOY06_K%
M=%P0TP@<V'$A6B)I6LK!>=\Z8#2*9LH]%OY:";[,JHPK5-;(A[PL-MS:EK"%
MA:/M>;A&#=@P*S=.?E5P_I?[-A9T[:N.((+.%4..:$O(A),AW3:$C#?PIE*
MK?=.AO+?R!=(HV :>\'S\,CQ'OR#( YMF]NY:SPG^CS2@NP.:N),J832(THN
MX,O V(=WA1"I6ES5O6>EA7!_4)H0>=0^4X9KH6()<U6'V)\\["VA6'E"ZUF^
M(U38SC.+3))OIIPCO0<<XR^:P7M9HJL@&$*Q9F!];7>,/AYIP-[%<L')&GS
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M) ;<^I2[<<*.P>9QAR&CL(D3]MRZ#\\TV\4@RCR%B88)@GM-O];<"+>=,&X
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M/^'>TY.X@M/8[53S:)-9!X:%+LA="V';@G/9NZKH]?,#KE:6WIK&.0T7OO)
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MSB09B'1TA2H@88=LA?(D,=]3-YW@CXJT@)SF8)83XJ_WTBS^&L ZI>#0:QJ
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MY^L&?OGEXBV7$;A?F_O"R8XID4);])3+($[XVX+JNX9$HI3/=<N:DK3()%(
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MN"%@)Z7R86C" F!S(DC!^*@GOK")L4&7VQ7-[O^1V5V\"<MQCWP_PT-IAJ$
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ME">7%+87Z($Z\137#ZC8M: ?7!"EU.+?GGY*(DZ5U-_&&4.C#% XK3(L*&$
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MJ T+%5X+E)5*TQ'H.VKU@(:<>3"UHYH9ND(>X;TVT^+@YD9!:L!4(?6.H9<
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MF7*U"83L-+PMTDQ4T[Z[E,5<()QZ2GX$(T$JA]& /^J"5HNAQ'1CE[P6)]^
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M2Q88K]*NM)0%NTN>0"'4X:B_AU%XC#4E$X0;E7+'O$&.B&/BG+:_!8ECQ!V
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MI)-G 16^1Z)"BX#$6<NO>MII^.S;EL ]UBRB84K/B+&I&3$A@P(!SH4,R)9
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MG$8RMKLUY__[(H_E^$[X__]+'I#]9GD/2/2I>^!3+^& 06@R31(5?3[%%N8
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MT2>WQ4SB<"\G# .HTJ'R2JX->A**M%2L-P@4V"SF-S0WS]+DJM>7?"^<;F+
M_=#H=XR9AF>2-!Q=,A^A=5?*HG9BI3\=SX^QH)D@TA0O4D&]\-:/0?E*TC&Q
M&\UUMB=C]<D_RN%W:L[?K9)BF^V+Q#*WVZ65&\ES.4; !H6V#K7>=NI4NF<T
MO#1D<@-2^N:X)S\SH:*%.31A.]1T<UIS;.\./;Z&]/Y8&UNF[_K9<==-C\HB
M%4V1?"*0 .#)C;W0WFQAI-F:MDL&G[<0[[#%5:B.U?LX CXB#2J[O*L8=2S6
MZ,$B3P918&/+)X&M#F,+5SN_)4>@^T*64+EW_=?M##HL'/$F(F<PTJ;&!YB;
MU8WJA%-ZU,UI;A!B91IG %A7V+@<:#+-Y]H:5\>K>C-%I]"/E3^-N>N Z+V8
M;SA'(V"<FLG"$"(2?Y;6ZJO.\IKSL] H% A4JL#E5VB+I=9D]<S,F;]TELIS
M'OJ3B>1K"I76N+\,3&UV&FK.!1.4\I/4<XJ]F%5+3% D9.)9QD%6O^A'4CPA
MZX:[!H5ZY"7"TAKFVQ3QAVU5(6K#'(./ ,:!&/$J]&@I''5^9VXL07G'UFK#
M,C?.+=UXP3&/<BN4,PJE$!Q$!L6#)76\VJ""-CD!+LM$P?WKLHQI),^3FO-E
M97!&!81F<2#G(9AH^@9'RD("CO/D6$74$1? =59B!JN'V?V!:%!.\(A'HI()
M?B(_27RWJ?LR'M>J@=J6@AY\0/!.ONHVO(F%K0O!3R,P67@O8=TPI[%K1V"8
MO,YR,E='EK 42YI&T'II#8Z 5*#G 500&!TT?*D\8S$BU@:7R&O0NT'=-F?7
MM^26+AM8<-ZL7"8%':&7!$\XX+*)50$1'5CLW>DP#3A?-U'D,QAP?(==& C0
M19[CRE=F/4=897J.A\5#$R#PH5HJ.SFDWP!724G'AIXUS+4'6;'0K4@*RS"4
MERP^>%WMPOG13%"'-&\FM$,<-EK[TTG$U=MZ8^M-G6GM5@=-HC%M2*E *QNW
MCY&)!&>&2I=2DL-0FRZ-+U 9E2R52Q:KEHCI1Z,8,RX\3@YJWUL?S]P)J):"
MB$X9U16O/DYYJ>8C5?;;, &A2\C^)LZ53[EB;-BC9U.^R'XQ61O6B:J\$##D
MTY!I:Q*5BE=QU87^'L;54\7*:6QEO?'@E=\O?"L1A7_&,0V]"9X)R2W4/J-[
MA;73:GEM.CT36^-*3Y@Q=KQU=;<Q[1&9C.:*@HIC,Y=\,N0G#G,2B;'MU6<0
M%IR.?B+=);9D,G=PG"))F\8E*/FA?CIGGCSY4 KT26\A D/,D]:?G.%%5D"(
M1,+5<PO6EC2W"/@1#W^%<L<A"0/Y )AQ MQ$R/%3.!6YE9<JC:,'DBM4GF$E
MTO(1]N58(H:AEIX$EO.MG S E% .IKLRC(QS!#.HF0FBH07MQ^-QEPV4PA'1
M9 &6WHHR#YLN8?_<,85(C-50OI05;#W"G/E^.&3V!WC9#]BETX0)AK' XB*(
MHPJV>I'LT?:9I%S)@X894[WO6G^Y.W=#7*O/Y(9GP21J],>#EL"+[B$6K.NL
M"$5BO1-'H:B;#6:8L?IBQ/B0CV9G@(XO3L/ZFA[^.^+'PF$Z,240="^57J@X
M+SP*., \(&$9Y3-3AD5U(Z?#SAH7JYY5:DSET73TQL;I0&T+1PR16:"18H]_
MJ3(.(SCA340.M@6'JX<0S%!_V<&NW'!L+%$U=]9I;;5?H#2ZBI044_$ZO3;F
M<24N)?.@#24QG?,H7@0?:<F@E,QI .0=U$Y%W##T1C0Y<".5_#25%MX_4JD.
M=/(G@",.5@R[_@&D@.2-[9)LD$_%-3 BIRMP$%0:]C>"0]A>=.)26#.(H'6
MXZN%)Y=\U>7WZ/A.C!C# EA?,R*A46#@:.)$ Q^- /6,F1,GPK(]J $$N=
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M'900J-9:[C3AA(.)0RG 9ZAYT=$G9 -;6" $NA2&2_I=9KDSOFP8:1,U XQ
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M1G_RG'56SMDA1#2O5W9N5=TZ3U2)6@_[P9UZ-C_B&*Y_W^BKAP2A+V7T_?$
M!_D:<O Y5G!6V,OG.C^LVZ^?17Q]Z\5B)S;DY:=?"NA%:#0HGI^]^"J^GGMS
MX2,OJWD[G\]UO9F[Z_7,BG$_SK#8Y;A[1R?UFESAY?#STA^<F1<[=_ \UUGY
MK0F\)WD^\A?K*_&3DM-T?AO%4N#\;4VJ_IHE*_R,'5(H[? S!L2>M)S@7EY
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M&\91F/R,RTC7?85%O/@^CSVY&$'HQ8O+N9@F4@7 <.-H,D$E,!>Q2+8&$VL
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M>">/5^56F&6+"JIRSRI%W#9II-[DDP]JZDZG4;JF6^E1@O6"EU8M> =^924
M!WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924
M!WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924
M!WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924 !WYE)0 '?F4E  =^924
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MJ.IIO*_[U _IHQU.:3BE0Y_2(>V.C5QHZ'<AQG?9X'O?^3]G<1X7_(9G]W'
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MZ%HE5Q_#EM51G+ DB-D$U@=_H&X69Y4C<7ZO\@NF?N98L(IIFM-$W7<9QR+
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M_W>UF1J]$X_8FN0QQ\0>V=[.#;J'*%IO,1.4N="W7=_F@6J&W/9=T[$X,\/
M,6R3&829:M\PTSPYMXV1V5'QV3?,'$R[O0H=#G]>*FZ>5VWM&^#^_?FV_UJ8
M6^A&3(T\U]%4;OJ1QR+-MQS-#?4PL!PW).;VW";KULP-)WNI(\_8UP3&8[%
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M8)"/TZPXQ<P[62M"<O#E\&%ME11-0H0U8M;&5;W"K='! .7#M5:@PTAY&,<
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MCDZSYB;T<A.4.(^>KQ\999D\-E8]:BWE.Q!<=L_K)<)'E7_@9S 7'_8PH[)
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MLH6IJ6DK/_@_YS*#6T7;DG'.OX'R_V2&85CZ:64'@UI-DL) /#QECX)9BBQ
M<C1/Y+A7-"Y1YZC3S(5[!8!?^T\R6:X8EQG29;<,$3* ]U.V'K6):(3I9;R
MG(-U-1@Y#V1&8]%P"5"23B+\ %0@28G/U)F=DI;+3<LLT67M*=JGU.CY /MO
MQ>9',GT\;V3*RDL5XTNJWJ="!I5[$%$4'Y8[QNBM3$!JK:,*;:8^!GU(Y7N,
M^40 1*A"],?Y'&LP.6/ ;>"XPDER5<C>)Y23VD0T61A7CK8K.K"EG2&?/ KU
M(PY%YJ5TJV-88+YI:".'M>FS*8]LX;"$.BDRE441NLC1A7?S!SBD=%I+Z,;,
MX/KO6:/9"JFL%+8B#0E3MQ8\RWV+MGYO*BT([7GV4?HPB6F$@BK:#DQ!%)5?
MK0EUT6VV57M0O;[JI5-65CRE; /[X0BCJLTR%@H\1;N@NSM</QQ8V^F6E T@
MZM6A^[?OZ?\W..]!\D.LE5EV?.T2*";X::G)9W-:Z^(!"4B736\"#/\5#Q@!
MS.>^W\B9EK: #$ W6TW,? )[(=H!B>ZDK$W4\C$\US/E8]UI::T^-R_JI 49
M2F&3^I4\BX@KULD?(MN]>PU=BZ^PO8ZY">&+?81+N,PU3VXN1GZ]D<WA<U%J
M3SGC8JVR[5.#^EBKO0=V8BX[MJW> <&X'-0E'=[M%\V=Y:C1CT*44I#HDK/6
M2R\V*0LA+"#.*<WNGG=VR%JOAV.(LVG=4:3C"1L=+>#DQK: B//7W75?V,9:
MTJRX)''1]F1K(\LX.5?/C-5&EB3O%:BS-!V'$ "'[A#PGKV);T=Z]T>Y[.]4
MJU N.O_*BRU2'ESSY!PO+28]X/ZV0025:UI@VSKWN6?J3N "-KAFP#3=-D+
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MB[WU@-IJ2FO3W=8*H]=#A7%PUTP4?1=W35_\",,[-GC'6W"=;)3QL13C]>V
MT2D@CUJ*&*[J.YYF!IC9X1F6%X;,-,W(\U3+]6S6$_>#H:HGYY8W,EVG1])D
M3RK:@(TOC(W[MM<-57O%%L0K1\_?C@@_YRS<13S43\Y=W5S P=\'].LK^O4
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M[P(8I%*DRAUG&)I4 M!Z 4X*'!J6%J<@-3 ]:RK:1A:+BHW0RE#,RE>$[=M
M=\0EBZZJ!HB:Z:P@$<=0 )UF>%"T*1^C#\CV\*SRV:0HCS4-A H8D'0M%UB
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M (@(B@B/45>M50N)&#E@BG0*L& <PRF5Z%(2$^P%%#G O?Q,N:B>GSRV/_@
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MR S-#;FGZI[* ]"*I>Q6=?N@_A0/S'^P<=8(=,P-IZ! Q+.L]JM4AXE@1^?
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MI+VO*"=8+7R[VUZHJ_)[-U*S>@>AI8E7^X-#OSE-GRR:KWQ[YF&12]_3MVW
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MV;,4C02&PL]\Y/+,1]YH)L*[;#P,M921ECZ)GFG:51?(6;"Q9$6=6<TA@$(
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M4?\CN"(!#4_/K=P['*[I5W[A^]9/1VII:;]2QW%+FCFMF!8'U 8;YL?)M\<
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MHUII3HP91D"\JS3%^>?%;*4E,<.9:=\T:-:@R(EHE+>Z61;4<-J<W%+5=0:
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M\CK4!W/K/IA!Z,<DBKYP'&&NR#/\^N<(#+H1[1R^]>!Y4/\*24X<P[9M$+5
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M+2.W+4*B<>-[7'A7GJ]54CAZ:9BD_$00(7V8!R*F7FVM,F1142VW*WMDN3I
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MQ-=G!KG+?7]29EFS]"1,N@X9)=#<'%12TWC2Y61.[[!DCQ%LZ"V/CO''#":
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M G^K^*O( ,!JY1"7 >^WI"TIK(/V!C#YWLN3X6 $H\7_'U27(0!: /0Q[JD
MZ"'>;.ED_'@16A4 ?=( [<BR:6CF"*!U\V]'MCE W_[PHGZ&'1OGX/(KB4CL
M=:CT.4S8<$P@R@L;47P7>^WA<(M'^L([+O"NL'_$K.UJ,:FR.@1BW+V.J:18
M3+%I^X#ON=Q:WM^ ;DJL*<$TMB]*I(/053N,@1_4MO/HN,F$9/FM/SH;0-^2
M!72\-H!VVC8 "%&S;8#Y"]R&#6#][2CJNU'R$OD9+I\VE>88/W^&.#+K._^D
M-E(A*2I3WHJP<(2%TP05W+1M%Q;.N(6SX;*[X[=P]*MF"):P;7:-VK:LRH8B
MCU!;_5N1BR(R/JZSQK#A8V7F8/JL*:Q[S$YFBK*UKZ1UP6=S^&PJHJ7:#,KL
M?;/+5I/9#]WH.'9;\^3/RX9">*)DP-,?84@N:4A^/E%#\G0/RH;%&8IA6]9'
MEL02A&F6#^?EP1I(E'<XV'_!KXI)\*,$E_5-R_'(T54O#2-)X>7@>XD;-4@X
M9\#UH;^6 .H"J(T3+_S Q!8!U$L"];4 ZM,$:E66+=.QAU642E%%J<BZQR'Z
MB>)$WPHZ8^(I ^P/.+(.1X3P?SY3'+;+EOCSQB'\6_+*1WL7=6TX.5>@^-&B
M^+X+./?=,+!H7;2[XO:FD6&+H'3$,'XC8/R 8;S$8+7L9  @[',0?NZ$Z=XQ
MN%!-K(!3W7Z"J;AT&RJ]&_I^1/>DH_XYII^.2_=N:8B.T+U[T[VTB%$F_33O
MU"E?H6!/YU*A8/>L8(U3S4HZ#@6[7J<O1W5&G;X46=,4#%$9$:KA.$D7RU#Z
M=LUTKO2!2&^=)(H&4O(6@_+-^FX6^B%)!V6]U772A3T>_,QT]]7C[?FW:^GQ
M]I>[^V_2M_NVI"HUROLW$O?Q$;8X93K^^-3IGC+]3@8\M_BTCY@,$9M:DF B
M%^1$X7O6$1,"N%N<,?7=:$'P1D3^C;P U$J_T)CB@/>4].J\J;)>2#4%(A\_
M(HL3(W%BM"V,F4;ECSD!C56JD4H^=K$D76U;!BR[EV0A4Z@IC4"SOM)/Q2!U
MMN3JC<4H3GET"W&S).KGLV\9 XRLW^V"^S&]0[O?#I5OAS6A:RO_[:0C$K_0
M<S>EY/LY"6"U%R1Z(X/L[./8FW;#^'R"LLL0938)MH6I:M-!?_X""]#_*50U
MDSJ&XU##570]4!W/<0Q+,TW?T@P ^+^ML\MG% 7>81OX+<ZS&IR=%!/8E1?8
M4S:B3:W3*T C)F(C\6 SW8 R$>EE]*+\XY,?9KV(#"["F+T?N^E3\?A"II!=
M)M44_A[_NN DQVGK#")+B[OXX8+/VHS/2ETQ]IW5MJW9W\IM9<7O#,U8Z<YY
M:]7,MBX?RF*=MKF%I^IM1W4.A **UC;EU1Z[^\5:;67%I^Z#M61CL?4LZ(3O
M_7QBYJ6*O;HUM\^IWG??KN\?'^X?KYYO;Z3/_Y(>;[_</MY^N][2.>LRD9>C
MFIXN1LTO3RSIYO;I^O'NX?GN_MMNJ;79H;_[).67NZ^WTL(,=T)TN7_\?5.C
MPP7#50A[ T@B""L09+_$>GB\__/NYO:&4>M7L&C^NGO^]7BS-LRK#S_]?*(G
M/Z?;YJ.82*[(IF:IQD??5!Q9]^D/IYPFH\*UTEWL]SU^VO,0D;B%YS:D,JH\
M+4:5BW.;2TW3SE4#B+E,,ZMFOQ?3$$_GI]M10LQI0RHX3EO;OT=_0 1#4/TL
M0/54056Q--E2=?NCKYN:IF@,5=4R4SWMXD$,FW$JW?/1I[^DA,V,@>WC\V"*
MST>I%FQU+.^Q#I9//&V"R1R#7U6V'5W [[&\^["=,$-@94M=0@^ $(# HK/5
ML@A\+1!8(' %@;5Q!'X$US4-/4Q&Y&!\]492?QJ+9UPGL%E@L\!F@<W".UX!
MFRT!S:<'S<-: U7538?UG=1QS#C->KT>(&415RY&J<ZMU\;;I-MN+TH&E!:P
M_-"'W\<"A;F!:@''QUQA<+HU?T5G28[&IUUBL(R1*= 8"&:+ ^#3A6/X2]4T
M]6/Q2HIL,TP.>XOC\+_[./44/@#6QMFJW$$6,"Q@^.3VM(1AF<'PEH9W'P =
M$%4$#"]),'%D?((P/!RW).N&61FWI.A_ Q9;RYP:CWT[(SX]%ZX%*A\S*I]Z
M^;TIQB,IPC=>%I3%*;( Y1$HFPC*SCL'R7_$8;[P:7+EXL4A6^"TP.DCW%.!
MTR5.FP*GE\3I&X'3IX?31;:7KMJRJ>L??4MU-,WP&53;NTCW$N[T JE?BF,I
MVC(Y,@?P7D_GRL?==;MNVMO_UH\&DLK&&&[+I3P *B!0BRCWLD!]>[I +?K,
MSNXS:]-QO'Z@:0!_$L#5!=SJN5<+[!8NMG"Q12?:22 2T+T<Q1R!W *YIY%[
M(AQ^W2'Q"Y7"F#6;39.(GTU3V$L&SR,T!L26Z _J]1GV)D$ :)YF4@+XC" -
M&XQ(#<NCP?1U J %0!_CG@J 'L*-P.<E@Q&R .B3!6CXTS8T?0C0,DY@^\$B
MX>/X? <_VHU# %$RD2B&>.R'*?7R!& 847L:G07L'C/LGF[B-LY,4VV1M;VE
M+F='#+J* -V3!=V98T^M.(E_T&XOXMC[+8G/A^7*-P7$LA&F-,XX##\D4>@-
M&+H*LA5D$\:&,#:.<4_%@%;>!438&D@PIVTL;&RH)URJ??+6QE2IMA*1?@IL
M&H29U^&0R:T,YL[/'M1:7\R-#O]7_D#I"SZ1IA/CT_LQ+3M,R *;!38?XYZ*
M"FX1"U@#GX^VAGLQ*NP3H-=>X1806IU&:'X^7D5/84<U;Y<6R5]8TJS:VI8+
MT=S0IL="*IN]05..B9"IIF\9R810-7N'A&LO7/N3V%/AV@\=53%-9&G77CM6
MSU[ Z+N-8!Q95RS;&C6"4?]6=64C$?<'"JPN/24]DGXG$P'WB1D+C@!F <S'
MN*??DE?:14:W.)^?+"$$,J^"S+I YM-#YO?KTA1G(P#].0U?PEQZ#",Z&(=G
MEC-<# <6T'S,T"S*T40YVK;,DF-&9D,@LT#F:616-^,Z/]&<I+0#_S^@_G?R
M']H-QP'ZAGK<K] $2 N0/MX]%2 ]])Y%SMK2(&T*D!8@70/2ZD9 ^C'T.MA4
M[3/UOG=Q(E@]0,L"H05"'^^>"H0>(O3. MP?<^)&M%0C\)_REF))NMJV$"5[
M218RQ9K2B&"SBT]OH9]WBB57;W23/$^Z%_+H%N)F2=3/9]\R!AQ9O]LEZ6!Z
MAW:_'2K?#GM"UU;^VTE')'ZAYVY*R?=S$L!J+TCT1@;9V<>Q-^V&\?D$99<A
MRFP2; M;U::#__P%%N#_4ZAJ)G4,QZ&&J^AZH#J>XQB69IJ^I1D ]'];9Y?/
M* JL.QO\(+!<5H.SDV("N_(">PK: I92IU> 1DS$1N*1PN+.@3(1Z67THOSC
MDQ]FO8@,+L*8O1^[Z5/Q^$*FD%TFU13^'O^ZX"3':>N*@<Q46-_%#Q=\UF9\
M5NJ*L>^LMFW-_A:,X!6_,S1CI3OGK54SV[I\*(MUVN86GJJW'=4Y$ HH6MN4
M5WOL[A=KM945G[H/UI*-Q=:SH$.^JC6Q_4L5>W5KCFO(35L0]@0X6;7VW-VW
MZ_O'A_O'J^?;&^GSOZ3'VR^WC[??KAO06K< HP)>X#X)++70ETJ:'!2=;__Y
MZ]WGN^=_N.G'RV]__/[Y]G&S!#Y&8DDWMT_7CW</SW?WWW9+K>)[9C@=-BF_
MW'V]E19FN!.BR_WC[XL39/X+"X:K$/8&D$005B#(?HGU\'C_Y]W-[0VCUJ]@
MT?QU]_SK&+V.[ C($FV%FAL&VOX9D*KJIO.1]0HF_YN2[\E;$@3P?)H#JV[D
M%.BWI!-+C_CDB99").Z3=""ILB@]//[SG].M<"A+#Q5Q *1L:6SB,:=H6'MO
M*S0TQP1$[QNB70[1O33I)OA+#*8Y2C^4GTE?&79O J%QU*=BB/0, <_'NZ<"
MGD=8\UG \]+P?+UO>!;N<S.PV9O YNRUMT5DCJFD<XTE@%D \S'NJ0#F$<I<
M"V!>%IAM@<L"EP&7-0^@N!_EL'.DC%['!3)?#[]:*;+]C<3>0+IM2P_P&CFI
M@>@RZUM@M,#H8]Q3@=%#P-$$1"\+T8XX>CYEC)Y=?BAOIORPWX/=EF[^YRGI
M_V<"G8=MQQ15A+>/'Z%%]:$ Z&UU_3UJA-[[X;- Z$9XT:J?(8AFM$?X+S%?
MFL/TT_##"DPC /]"8YJ22'JD$85;60UB1,)NMB$09RZV)3SLX\=OX6$+#UNT
MQUW>XA'H?=CH73K'ZL@YCEY^P*=T&, .0A\X+P2873.:_>7K+](#27/ ;/CX
MZ]?K&1ZSJNX(<<6EQZ7"_WEH930+OI>J;&M<JM"R^]&RJE)T*?T:@NT%RB_K
MNUGHAR0%E2G47H,N/0#U<+1J3Q-J[\C4GJ:,\B+0> 3-=P=W]6B,-J;T2%]
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M52B$GF[$>RS[RE/=<^8W91\GSXFU %=FMP#_Z";^ /ZODW>CR_\?4$L#!!0
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MCO#0'^W,ZH" WWL$)EXR\$=Z_]5GSN346=SJ;_TS=8[0R),"6_*F-L:..F%
MG3.B]KEMI&(TV/-U4Y-"?4--'XYT#;A3;@_UP0'!D3(RNC4*]G[<U"S(!Z@Z
M%\4'P13R0M#]1\']V4TM:$DA :RAX/2!X JX"2 K%EVXHYC'QY1D.@MQ3@0;
MWH+_=]GJ1K@G=9!5?_S%(T$ZDMO_\HS,)K%]H:'*V,0FHV]IDCLRXQZ5K7"+
MC]I*&.RK";H"UZ/$38$-N3Z!L0D]*V&L[47L8,;7=:T[,I(# MW0VXY:<P@U
M2L][+@80N#YC57B3BY;CJ(-WB U='("SQ'?NX&IK+(GH,S*<@EJ3Z?"9_T:P
MR/?"5Y6Y_1A^57_MD1?"A^ T>$: M>6!=WTF[HB(I)D"E:-8E4]1QIT*]6=Y
MK-NUS5U,68$>A1O:U"" N*Z^)ZVKL^%FMESP362'&H/U;'R;?OS8$@*SB6YZ
MNXB;A+N%6\]8V)T7(BSJD4=!+0BK+9C:+34U3TA__"-02^7.\:LK8!/7=W/-
M]ZW5>$5/FP4:[,/V4:CNL@=?C9#^6)-X3Y %B3FQ(;2HC1O*3^)^?U$[N8.O
MO6UK[%WE'H1U@Z1H-1&(N@/S&'E60Y1I^^3']'),]M[O\ J39$)$L?0!?D/"
MOK*OC*FP]%-TEF3RUN90O2VW0PCCZG5&4'7U'4P0X'EJ"0W*PP+Z1V"5BWQQ
M!H<:VM?YKOYGRAV[Z\X$GVL*E9$\!P=1EA@%!DZ':I0A$2YE*O\*UDH;!T!.
MXT/P[TQ-N(UG5 9NJ3./#6FJD?) D\WT*6FML(-Y\.6W?Z5 K3;4L4GQ)+,=
MIHIZA34G#M=OVSP*;L& *Y-VEF!TJ -SZPPPNYY=35J"K:UQGK+_'+2\!B5
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MSW%*N\Q 2>&$3AZ<UIY4B0W@L*:H,HQ*,F,P=W  W=5PFCE"/S .?&$AAA+
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M//F LVH\&S@!26;TAQRG@4AJ! E2XKB5\#QG[^J' G<ZP,=-Z</ERHJ9T?F
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M9<I=^YA+JY)$&"_]F)*0S->^1[@9LKU5ENV'%9/>M=-#A&CEV<9-O&?U43<
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M]>K;*8RG,'#@2RT%26Q;H<.$3)R(0*)6WL5DK8O]TF8)Y#%SXSZRODD UY4
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MYB#N\;8<>DPSJ0/!^CK*OD^RRI66,5<+_P]2E#11'TF4!CTVAH9!,(HBU4T
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M_"C.1VW*QB2_+'\&:?GH#\M'=TC=W#W([DF@>Q;LM7129K+0D#B3PDH7F95
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M)4*#DT#1MY*R]C'."AB/C 5=!;WV['=-&'_Y[?(A^"G\]4__'U!+ P04
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MJ4N42+)D\@[-) $>UQFNE>#QK_:TI(4W=W4HI&(RISV++;^0SG.[*$BD4^Z
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M\E@)_>E+]<$-N3LI*! SI,&"._$,]0#G$9C&/YN0\)XKQG@'$'ZLTR^Z:*%
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M[F:(;--SA!-I8]KT<C?.APO_/7WX;^G7K6-W@_QY]^ET?B.W_KW-S) 5C%0
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MN!FTH BZ]]%$O0*9A-G"U-[6&[]]ZI'[AR;AL/!&6RW,%4*(-DBM0UD1W$_
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M/V%:R#Y\.TD%>I2Y+?T$0IF"V4Z$\B $8:D"!?+(PR9T(,"YI4!-TD2((#)
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M4HJF^1C(&G-<YKRF-<!YV"4W4S1;%8<(GO_02-:8]ASFT$$Y3(MN<539G2&
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M^\CO)[2"8Q9)T]X@$U2G7\2EJ]*H+G CMA+BM@ ),TQC4B:FDBKFARH)9]Y
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M<,+!+OF6IF7:IB.$4]OWLZ-M;C+E<$*48L<1?W3_6D3TUQW4F$0R%AY(]<Z
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M'%*99,]C+%.1H\@RA;^87-+0&M)YI-&W_+G$!+[_RQH5)5)+55*,'(#"(\M
M'<@A1<A8^Y[((-3JFP%CS+XUA5.*)/^&-\@9^]Q3I/32JHL&/YE'P%/4]03,
M27P -*5(57&_$[7+"23/E*LYU4R P]11H*N[E".#JM,'/Q'2>JO/9 528 75
M&:7%=%G 2MW).BLZ386_P@/ HQQ2XS- (X73+H4,.!!37+7629A'.)T!%*7(
M- A!FP35FNN^!'@#R,#$*[I0*UJ7U#.U,S+82>I!S6(B]5N5-A4MP5HLY&,Y
M>)DY[QLA7]DYRXL@!ZU3"1R !Z!(M!2 !"!1X]G6U[R9FF.5\JM3 Z35?7"
MHV3+X;'3>;G*94#6V_/ ' A (65/!J35>DB[D"/9,?B!3GLE($6 <Q6 FDL#
MB41(*P5 65W_UY7MNP<0 +H$N@2PR;6C60 T/J!S@#'0@000@!^ 5ZE%R: %
M6I"SOK<-2:.LR#HUTZSLPW@++5:910%02YV4337]/95C0HE<,^NSS_14@P"$
MC#&P4F_EG1\H1/OLS(K,V6CPKQRH7 08@)<M6;V42,$35M(%/OY3EP6T4K9D
M%2!]VWV @P&(35M, (1D6XP,P.&TT_14N044U0<XP[\]QAEP/ZK]O<G4JC&L
M3=CET=2DSI2#W1P8@$3\/Z^%UU597>-[.HG, ;5]6[N339N[7ILKWO5\7.#;
MQ=_[2?\;@T2%6_QC70'06MGL664#4?_KW+5E0M;<5]]+@^GLW*"U_[VAFR$$
MT-?95=P!$%B=S-N@O5D$.)?;\[U"0UFG<V !*+Q]W4!6 8)7'-H96#,&/-/8
M%5--0%D<"Y]E2>'*.Q8?0Z(2:C'*<ZR#8R,=BD(Y [@! [75*M56&C1TK"76
M\UF=18"O9+P,/KY9FS4K+<BRA4S)C4W_D]5#1 "T-,:>]=FC',W"4X-/50;\
MG94-?(#9K<CR:Y?"PUS@LQDA;964,QX-%H UV]*;=>"F20--Z%>VG,0I3KD9
M"%[]Y!W^XR;A%-N1VL"!K%'CW=8"!EW(,$8_59>O/-JI)$O6794C;N*1@KE'
M;=Q$II\<4(,9W0<;W82G(=7#C)>*K+E6 ?]:5WR_XE/!]#1/C PUF/-)R85+
MO#4:HPOA7@;D]XM-1[8YE6U.66:?2G9/X=S>HC'< 2!1'F4>QJ5-D9M;[H33
M6))95=G"7 N[-7X ,M!4W[U)5IED? S-FC/ FE.;GS,><K5&FID!.""&>23)
M4_U-$KOEJB0IKH6FRHR&!/!  $3+MB3(5SXZ==%G.YW;4D1-G4UE5AEDH0LF
MUHO?'SZX"R6I8WNU.KNVC':5C;Y&MM'H>U&E?I6-F?PS/FO'2KHRCT,S#]LQ
MD@N@YN&?=6X7BJ2$=ME"E$4 $E6#3) ,^"N_P#O:G*4,.*UE$7,_'GW3!'"Z
M=@EJFW-.I(3=R+C_NMKY7=;=UJ-+SX(\X7F+V56QC'CMU%J#ZJ#,VV.TNAS(
M/(1^&LMPW'DIP![*1GC%H!G8PN$UTU"\W/D,.;T>R,6MR"Y>E<)[@*_D0E>Y
MR Z=Y;W>MN#L5Y%$PZG)O)[]W;$V.D9V%Z"U:-O5;)HU-,@ @@P^:<.CV<E<
M4[:#U_B4C!+<45;Y6NZ<C.#I+]L;+?L<@"M68S3<Q7N)395U7?C-292,7-D$
M6ZHV.\+,QL">/KW\HK&4SKZ3@9O16HET3F5HZDY"[,B8V.[3A$C]9JWYU,A@
MU7296U7UZ9#3X%>F6G694LU68Y2$C&)X +=N6E=9P!EP *M=%0_D4>Q-_^B0
MZV<,TKJODS$#SSD$OQ^:TB[)*\+:;CP&#40+E4%B<]"14KY_C)<AAMK(0,8#
MCF^OSDL I$N!N+T!V$ O7O'.%;S6NMM]$,RH<6M(=AJ@14@X6'$ GIHQ@(-E
ML-?HL=96-4;*]M20:]L)QJ0D]5,Q!6,U8/'/-K^K/-SU?N/"RP2N)A^;%+LG
M]^)EXVS(Z"3AY.,6XN"\[3[; V ^AEW197+G]CNS\T#*-MQ:+B?[' .3O$G)
M_.M],&"1+4%6KN,F-]1V,6.49!K^NVV<EN7_-E#X4]P2Y&#CS1?&%>ZD)!Y0
M6'$O1EI8EEXY?_(T4(-HOD #C6;KU>I9W5")F_]55ZY?50E>3373H,P "4#V
MOUEER/%0!V#!U03W-?269=9#?Q6AK;X2Q-/>Y#PZ[<Q8-T]WF<4<H,VB['%Z
MQC[A<3]0<%^K-1L\=9K*K(?T?&*5ZUHXQ%$15O/JH_6>$@!2Q>)7*;S(W64B
M/V.^#4AY?[U'C*R(=<!Z?T3[HW<Z4Y?PAHW^&\"=:Z^.[D\;A#U\L<,[%+"4
MBJX:LA>H0=S,M,FC \\:K5-!K495C<_1HK[7G%V(^&K#%@@9,EP8[^U'SMY#
M7T !0  =H(B4SH$M7ZUK/T/Q]3;P7 :RU=UXF?+=L=H,'E)5,;RNG57B ;H"
MG &:I00!\/CZ% @XB-D,5H9-$/\YKI'B1,_<MSE*5DWKV"S.+WVZ=685L?UJ
M-<9JM69 >TG=RRUL7R?E=^)I0YT:5.?UIEGE@1U( TSF6(93-1;MP0VY8-=Y
M)/=6H]SM,\QKLOS<-R"&JF=-'1A(:,@!_D/9LLS('\36-2[/SZ9;.;?C=;%>
M.$QQN"TJFQ]$7^]9MA6(N"Q<Y<[[I]9+L)G5SXZ&&>"_$/S1<?8[TW?QID%(
MHAMMFO%*R*@7#T1SK7^5&7U?/RUL:PW F#UH*W7O-NU9B5>&98A7(>VT5D]K
MR(C5=B'1A_RM*1*_&30ID(XA\W\X4L>KM4&7 70^.U10A%6LH&*7_]3P"\5P
MX>%&@$C_@"!! @<""0X<J&G?LAP)%N[+ 6??/C4(<E!L"%$3PHX**=9[,' ,
M14T_EC%,, "B&HS[E,TX*! BG#'12B;(<;/AQ(H72]K<1PR!&HIP<J3!.?"@
MLI<Y?N[CZ%(C18LZHXYYX!&ELH,D]]6\J6E@O9(Y4.X3N3!:CJ)@T]R,2M1L
MTWT)W&J"*Y<@P@?$**8A0[$K@K)C/1)L6NSCOA\"7,)!H(,BL1P0';JL##%D
M LHYE2;XNO?@0)?*S@Z>"U;  XB(Z_Z :!>UT\L/*28L>;%I/<L4*2%X0/&I
M0*X"W5KLO"^-\F5 _K[\7)'T P$;KT9-D#3J#YS=EQ\?GJ#I_[+8PQ%LU[%T
M*<6H.LC/-!HTJH#M:GXD%'AUK%N'MT^3-X9O$=U640Z9Y0#?=B:A)15E X:4
M7X(,F>?4 RA1M1I+$T8C($OK%:B&6\L)%A52-Q%VT':@T+:,03)M)E%5JJDA
MW6D0,8< 3E,]-]@,PNT3RH!D(/#7,FD<" U#,NY#24$H<9202]&!V)%62QWT
M8GX)B-0105I2)]-!5_(U$)A+=2GFBZ05A!B7(&Z97UWMT5FGG7?BV5Z76XXI
M$Y;Y#90FG#(9!">9^>W9T9J(LFFFFX7R)1"991[:UY\0/;#@12CI\\  :<RY
MS%A5)N169 C!4=9@73H@VSXL-CK@2_]*C8$68'QI$I=3.;D:5:("[4202X>E
M86LTD^#:'G&E*990:W2>!JQ0<1V9V'!^M5=,4U&.N"1CE%5:FJN:. 1DE)%>
MA&)\^XPA78U$Z5IM<-VB%(T,+H$RP!LS2HJ60X&N)]LRY,W04W)U55EL>W4A
MB6%[T3#W0%T##%225K15Y<  +ODW7DJJ_3NCJ_YN]\8 8,JZ47#C/N46<]:)
MAS'$!%T&J&GM-52:K75Q=&%[?!GT%1PKG>=Q6A@;I=_"#]!+7*CDS0OM/M'$
M)%.W-4_87G+?.64KO^MA3!,"J=)9F9<%[E,/;X0F8.2<' G04QH#J1%J<LII
M(M+5%%6G,$7_,ZN6'=)J&#3#US0?GBBB@U8J*9N./P[IXH@U'MSCEAOZ**58
M&I2GYY_G29R@E;,YJ:$ GRUFG)=[N?J?9?K9>NR-RFYI3C\PUQ9S"3SV QG$
M':@&DJ]#KMWN8 .!I']+(05$N\[*], 8SC] Q@_+!W^@S=-G15H.OB.IIK#A
M(S!#\O]R.<8/ GJO>^QM$7<0_.\25-6!Y.>$E+!M9=76#PA]SWK+RPGWR"0H
M+N7@?!U1'_H<E9/P/9 ,(GD 4I85//SIYS[W*Q?\+J*#X2%D(3GSTHM^\,$<
M,"UB8X"@_V2'E-\]X(0//-#ZT >_%Z6A)5+RW?4 IH:L)$2&%SG?_T ^R)<-
M5N]Z"?!=_-8C/><A "7TRT$! Q68+B6P>Q?1W?)FH EH6.DX!_H>"/4#/QK^
MBXM;>H#SGD)& %*/-<UC'_-PE\8?M"1^VCDA4H[GOPW&[B(K= @>_4-%!<JO
M@P_,X^0>N#X*LH^ A31@?GB(0O5I)9%P(%>Q+'*4&2B#7,*+FT;&D@-*9*I:
MY$H0N3312HO4;0RNS D<M*.,HU "A:&4I6.$EX992F0W9M%.F )9NT$9$TN/
M,^;L!N7,LP$*,<I<#^BJ:<T!LLYR;2H=]&2'.4DY$'6'NM*D7@0F<T8/=>!L
M$_2T*4X^'81BW#2F !!S)M;1CE212B;MEO_YNBKU,YK>A!TR^71/?AY$'\N1
M9S.C*=!H*HZ9#JT=I"0*.]G5DU3RG*CJ[E*2>H(IGQG-Y\F^--"'6M1US;12
MG!C*402H-'K$B,9IGA419 ;4=1N=23V>R9=Z;I-/+OVG0/XT@)3BTZ4[?>A1
M0034@!*4=B.%JC+[.=!\7E6@C)C$)%XQ"4J\HA&:".M8&:$)6]CBK(4X*RPT
MT56N>A6L8GV%66%A5EL8XJR&@(,M7J&)7GAU$K!H1";"6MBYBM46C* $6C-Q
M"UM0HA?@H(<["C$)31A"FN5T7#O'"3G4+:I+HT.= T/[V3>QDR"BY1QU\F/-
MUWH.?>L\+4J)FLW_CC+SF+6[+4JAB<^8AE2?8VJG--'5N)4ZU'1N*FB:+,HV
MS15TN/P<'58U9A3A$@^@^M1N.G5KU=5!=9Y!W29N 04DI_@41)FT;6U]*Z;?
M7A2YRXW= 5?JISUU"R?RG9WL!#696J:6H,IE4W!/*U[;)M.SQ&-;;[5YT-JM
M]J)$+52XKOK>;VJW2S(HA"%D8(A";!C$'Y8!%U[! AF8F N%X ("7E&%#0/"
MPR NQ!](7.,2LT#%7$#QC@OQXA$#N1 Y!G&)K8#B%7CXQ>!H!SW,T>%"I()/
MT85O5">*W:C:=\I:[NAZO ;;+]_TPFX"FDGM6>;G$EAVDLN29J4\*>FJOM?-
MI"(G>*^<92YAE:BL4E1Y?:LETMFYHN'L,V[]:5_WYE"V2SGG2>]KS$6ME,+$
M@_25I5Q<R@F7(+]L"0EMQ\_LSC<_]]SR2^?;ISG?N;QMT80O]QOGYU9)?W^*
M:*7ENUW.<KDOIG861\^\9OHV.)!I^O4TETO)^PKTNP2105$1$A,$,#L!S(;V
MLJLM[:(^^]G33LBTH^UM9PM$V\TNGT"F/08XZ)#!!QQP1 .,)F@>T%$&5?/E
MZHMA72\:7?7_ S._PYS:X+23V&QV9KQ1VVG*"5O"OQHTF>/47%Z[2;GK5F>5
M?KUG/D]Y<](5-(0[6]K2L:YR$99<)BD,.TA!JN @XGC%*:5:UV6RM1C7-YS7
M24Y<!VJ=X53PP%&;$(H15\S%_//'42M:8^XIDQ%V\,DA-^QY"O3/;/YW1P0P
M9XJ7&>*K6[.E*1UAX_)7ZNQ-K;VS#CNE/W.-O34IQ*G,V7 =F[\X;7MX]PO5
MF*LSOHWN[9M?9/5<XQO9JJOPGIRX]?@2N[X&9^G9$D7K+BFIWU\>X((K?^;4
MW?/QC*NWY@8O;(".>KV^U;KM'(YKP7ND[_I.%*7US>ADWQK"_:SH_S*1"NE'
M"SCA/9>W[F%_9F1R'*'OMG161Q_X8R8=YW*_M#Y%G^<JDW?MJ-Z]16^.:M-G
MVO 2OO34:1=\=(*WHE__/*8;I7TR1]SAZGUNV7UZV_'2WN2LQ9QRLQ_]\<+<
MRN[-MY_R[40T0]7M =S9?!^\197B%1C7N9O.C=D 'H3D@5D#F1U$\9[,<1R[
M_1/A15V]'5[DT([H^1_53>#V<52!V1K^S<Z# 10*7AFM*1_;Z5L%JE3+(=BK
MS=:"%1/VJ1S;D<["05_XS0YU,0H'SAQ6M8X/-MI!N=/@$9^E#2#OV1_Z55^F
M15KYF=J++%T#IE[&95Y[S=87=I-P.<#I]/_7EGD@.S7.Q9%=;]%>VI4A#_;<
M%X94&T+.'+X=L&&92J4<:Y7?RG64O3W>!VX@PJE?'L*@GZ@*!%K3PX7)O2$4
M5>D6J$6B(1H:/O6?%C:<HS4BXB%7O W8_P74G@W:JUD?G:%>IT63I*T>FDQ3
MV3W=$WH7_TW.E@2? YW>>X44&MJB^,F@"S)8S:$9=\T6I(GBS8V@ W93&TK<
M.\47:>%?(#KB_YG7-*9>/IGBE+WB^!'7,SD?XSBAQO7A_FF<(RKAKH513/E3
M^VVBL;G:]C7*Q,6@=-W9^=$6]!DA\0G?)-J=^S7AT.FC(L+6 )E@SK6<SXG)
MKX#?VTT.F!Q=-U'_5X!AH?8Q(L^!6MM!'.V)U]2]&C+"FGO]8G2M8"N&9#PN
M8"HR(?<I4SE&5/#]RO+=F@*NH*'UX^(IWC*5G4(NGANV8T[F8YJY(=81FMF%
M'#?:8"4:V/#U9*HA)2.2HJ-M8TJ5G,PAX3KNH=&%5TS!4W"]V1(FGT$&G?*5
MXTDIWI7)G^ Q"BR*WM-%GRC"X<!M%I[Q7V@YXS6BEOAU'O]!'D!>4T$^4X&]
M6X!YI3O&'DB^G_Z1GQYJI/-U5U0E9 X>W^;9(''%'U)I).=]'%&I$R/RF4S*
MW%/&)#H.8$(J3L&5&=>%8.MQY$0)7"'669N=8ZC5'^/](9]H9K&EV>FI_V3F
MB!H)>A,(+B SH5,[AF9QT>(]'AK_V5RQ5>0A8F8\0A1.WN$VP:1K0N)RBB Q
M8ITZJB)IU29<&E]5E9JR<:8YMM?<!26@1!=,ZN5>CM<ZW=X+)H1.KF,(?J2G
MS=_!B4_(!2-O&N9N&EH7WIW,52>625=#5DI98N7IM2;1$2)!XEVHX9LRGI^6
MI266W*0C(AW@O90+_B0FMF<8>F)Z7=PL)F91F2+NF>3T<=<@CN+]^23I,%AG
M&5]7/N<2$IS^T> ["ET1DB&AQ<FMW:?T/9]_MF:C=69I-B-*?AHA(@0L:M-*
M^: &'F$*OB'JD2@KGITE8HF7K>>=4-[^55A@_O^B?59FF1(DV,U;[!38#K)>
M?[TFTTB@8.IC'>[:E4B$0/Q ,<!*97Y34A9G-E5*@FQ"CA1F1[U!,9Q+O6G"
M,D1&#H2",MS-Z] AE26H8;9&#CQ&*!##J01,* F*9=Q2W2PJ*!"#IH;"80B$
M#FB",FBJ2?2%GHH*JQ(#K$3D17#J;1JE- I/4/Z:EJ+BG?XA1_ I'MXI @!!
M*$5JQQU<ZRU@,.7$,NPIW^4:4X:1?H#",K3+<>R.*^4-;\+E@:HI8H#*)BR+
MRZ6FEX!",9P*;PE+NK8&J6H%JZRJB"C#)H22J,0J$*Q'W0B)>?E)&MBK8N:C
M0710#J3K_\"@&H+6(=[_WFC>X82>6C6:)!XZY<&IG0?^J2P*1)>"3A,)9;")
MTRW"HHOVZ6,RX%,R8!R"HGFV**+\17(D)'?Z84>:H;$R!-T4361:&'TVDS%6
MR7<<!M/1U]3]1300H7)TA4ML D?FVF1*Y\M!Z?KE1%-@!FAT"42HQT%\QR_A
M28KT2DD0+)XD1WY,1(K\WI'*X&T(*\>QY$;>9%$LPZ!,"%-N5D*0@3[DC*ED
MK'+5XFXEQ$14AFH0JJ12*IE&$V2LC%Q$$=]X7)/Z+0.N28@XXZL%IXX(A:=%
M) #QS5><BV1414_<2>?BR&E!2D^4JZ!MI5?05-7N!7B5J5+F6I$RY^R2[("M
M_ZF*+F88BN7&<FQLR:.\B5[E3J(PMBC5,5S>\:S(?JCRGND0)L17[,Y51M54
M65F%R<E+4$QLD(M462.1\L[)#BEIE$@MZ=]T@D)TL)/->(9EY,7W0J$(%@2@
MN)3P.11,U4QKL%JLZ== P,=&S*HF$(,F )AL@,*BMH<F/$9& ' !FTU'#,M2
M3:% 0+!NA._S/9\#& ?_N89#44SJJDO<5,5(]:<TS6!'E 4H\([V4MX,-M+/
M&>^8N%*[?$6-&$VR?99**5=&#<0O=2L"0#"<3+"OZ&1I4(2-!$P1_U( _TT
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MPM:\\'SV1U22PA()BGLT0A\@,+Z<)*".J0?SIPV/159L):+T3$R699ZTT'\
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MLF[;VHTZHR]<VH ]E$D-IA9MWL^$WJSCS\V[.8),)_K (1!#&(*-)Y),$9-
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MO_+D,P]FS"_;\IO_O.>+B]W;/CNZ*M<Y=X>,\^YN&IWJQ+9[[^Q>=KI5<YH
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M25CD-1+TP%?1!-WZ 8Y8AGAY )I* P?8A^"L2IM#MEM#2>I*@WWX@26C*6C
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MMZD!!0S-/F&(*[BJ+^20"[G 4'+MRVLE-&&Y5JX340)+/JI@B:# QG)=T7F
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M;]XZ0:=5/3Y]835;WS*+X7HN(GL9HDQ3AJ_<2BQ>)RD:MWOZA'B8AV1(AF#
M&#U+T%RE)V+0A,IEQ\'&G(:IFLE1BT8G!F& >G;,AW4P"SHAB+<X=*](='?
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M[>KU*]BP8K\J(Z9,JSYZQ'KYZO]%#%U;=V[=FE565J99F7:%Q4LV+YF\3,1
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M 'NP5 5A^[VO'/:0@3[IE_[0L'9AW,*UB_4F]S;7$WR>\[/83[8S+Z+MF[T
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MEWO)EWWIEW\)F($IF(-)F(5IF!&'B9B)J9B+R9B-Z9B/R2L! 0 [4$L#!!0
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M4^,_2O[#]5_Q/RN  !@0& ."8T (# B% 6$P,  &!L; X!@8 @-#86 83#@
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MWIY@1EPGJ\0+4OQN6WR@7O]049W-$/GY/$67=-O>C__2S/$CL\3\0[WN%?^
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M[^G.^'7AD91MV/$*)%].=1_X<K+B5RMD(A+U\5?7L.CQJ]PLOX=#?98C:/!
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MFJ"F(8!%R^G:VJZ]&TQT^;OI'*:1AIN46T=CJJV'[4] I5CV),@$V$7H54Z
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MA\2[_#V2,TU:0>"8[5S9Q<=A#2;\*R!]\.+O(E;:MSDV_ZJI"A:G7T.M=H%
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MH%#>[0;0#Q0"=WG]]PT@EA-T0G+'!>Y =))"HR6WI]8[9E18D-98;[*0_GI
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MBWY_YM'HH&)"8ONJ)JE5M6HN[2BL$BE"TB*R<FRNV@%O]6[ \J&>@BTY_2L
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M&Y*)!B?44"(U:$&CT:F(EM28&>FD4//S66E-] 9J:LAO]#$3Y7SD([>N4(%
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M$*'PO#$Q,*"@0=$ #9JPT#&993'1938B/ALS?BD9T+!1-7_SXQA,$(-Z$'#
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MZ)R^_\13AL#.R:.C0/$P@2;VSS6,K[WX,('=='U^'V_X"8=_4'D)YVB#^C8
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MJ.*CQWKDJ-<XCMTC'+[ALY+:'(=<J<#5V_>8G=[!4L[Q4C"-/IN:/D^ '?V
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M\:F0/$7Z$'\_^AN> \P1OAJK@$Y4OC*"%QG*3M5GK(=*!@I "I2KIER3(\%
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MS,62<2?F!B\H T#8PQR%LY9FYCB\"3V>XO8P3)M^"?A\QAC] Z:(P#ES8FZ
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M5"#E*Q6%4DJK=H>(!F&W5$H0B3:EMB05!_<M5-ER4P:.6)PE5*EH!T-U>-L
M+YL+N::+XI!K5K>KC9R+(.XHDKI0,??97,1HNQ(F,D%S"QVB?MDKCS!IO2!3
MOM80#X5B#[&UE(QU-C=&NRA:,T.IZ5")-:D5)9+3*,S"8_Y"D\H57/4P*!AL
M*E*"ZNY".TXBC/=&)PRO9G@V$;&8\1:XF!Z1[N+B_X:]6#M'D2WV;CAH)IIJ
M9A?!S*71[L',;(*;#'C:ICWQACC$!AQM1L]^HQ1Q&"NR^&/YT_ Z,3YIT86)
MECP0]$'"^#,6,:WCCH<E)V0;A,(@9/E"9SQ EC'V\YT@MA^IL<\L@_$F!(+G
M*46H<3VB=D(8K6CK(_?J[$&0+WG&D\DL;T'N6)ETZB&U^'BP0Z>V>/?.D\\0
M\GI<#:C<[WHB$CKDYV[#-I'+UM7HATG1ITI;1#U6#6[)5DK'YTHC68!@)ZV*
M#6[9!).=I'P>]TN\9T=LF6_7)$:<;2=MV=GX#T[[BF\=$(,HZ'\@MP(3ZP(U
MMPT"9;*:,H7*FP-?Y88>Y?_=JE(%%450=LB]@ZBS:G#=T,UVL3(LP3DL%6Y5
M1,4(^QM:C.A2>:O@^&T.G(@(&:Y1BC!85M6>GW==D.OB]D5:XHAYD_ )!X*-
MZHA;ZH7CQ/ AJDOE'(*@V4M?-.:-\/ ,$0E<?"Y^5<)@."8-)\FCO:*3A*Z_
M\NMB'D* \Q 0*9I_D8XA0D(NXC!B68)<CSS <%,1Y468A,9=\]>"8>EFFIPC
M#K8//T<^^1$4FY/MFI'%9JQA?8.6FK&;KF;+*Y@63PRLBT9@]29B5;2;)COM
M@OC-6,1"I"9 S@/N6(<X*&,O'FPTT@PD'$1?VT->JR8\SXEF)V]J=^-U K&G
M^AC_>E!Q<!3V<U@40-VB9_?8<S0;^*@F2&=TINP#1:U,-#;4=" *=CH,/I48
M'D>6^$Q#0P?T=:38T*+'(!7MH:8'S( V0Q M9Y]OM7-4D;''2+''DW';-Y84
MDF--)I%]V5*9J^CG_'[-N(,DDKNDKMSVV>9J;,M'2F3[1*;[K.BJ3:ZM34^2
M_@2KNOEJKVQY<;V=NG,-3^2D@GYYNX$Y \'[NQGE _V4O%GH3QXKW)PYWL)-
M4USH4=]MAY1H1UJW!C<K5EB%G&DK!RLE5L0RBNSRMD0E6(A%=XO06 [NP$F%
MY'_KBH9K+]5H>5'U,&O5"3$."OG978HU,7O5YLWE5@=3_UYHE9$8@@O3B[U"
MSK_@T)("& Z]ZR >Z23(BS+],),R9B*.<Z+WMY/D<&4JN ]?VBNF@I;,XF(0
M.*8K$<HG^*:A?-"_C*1]VNVB+L9L5),L@[Z>FJ-X4\*@[H:/5B- 4:EMYFN6
M>LD01_.HTU]#K#Z+=HGM[C):!_#+L>U0C&8ZP[-M)D$Z*HF[H_:^^/(SSZ?T
M[L6D1JT#]*N'0U]95OHDUHG!4<[1"8QE3Z;(8T?%T<?>F,D0DK3A7'KF8D&T
M^&\X#W0*:M$%;=@5S;)=;T(U#6V:X_)=!*H!*M:W5J56KVN+BFL)Y&M3/ZE6
M!TL'C:LFLD@F[7V6]$<X3=7V#ZA]KG3_>/M(__:W1Q(EN?VLB.0ST&36D.39
MH62#Y'V"P!T@BK@I@J8(D8)N?+PA0L0-PX0+'S8DXL/A1(MH'OZXV+ BQX$3
M,SI,Z&;DR(XG338T67+EQ98P2SILXU)FFYDKW=P<(I,.3Y8E>=*\J5,FD9M'
M2])42J=H23HWH2IU>I-H&ZMNYDPMJE5K&TPW+V4M>G,.)JV==(*5^M5K&[9F
MO8+->E:GV3;_9BT L?!#[P8@%0#O%1Q8KX4B>@-7,,+7@I' '/KV?0R$\E_%
M@!\;Z5N$,!#$H!?_"+Q!\M\B@5'_H%P!\0_5D7^4/BQ[-)#2MSG71@UD]&;5
MJ(N,#CZ\^/#6/W3_K5U:>'#DI:,#)EX:>63@R(4C1_ZZ0G?AS;V#WPV=_'CB
MSLE_7]^< O77[K.W+D^$_0\-KWUL\/$>_W/4]1%7GP;HN;=1!0&^)MMS]1&!
MX(-%\">A</Y%&%V PA%1&H$; 5A:@QMM""""^V68(8*O.4BA;/RAB)^#&FYT
M7X1%N$>CA3?RA]^'*=8&(XT&!JA?C0;E5V)]&R#98H J#H@C?QT._^F>BE *
M6021/[JG99%%<KBC?AA.""**&O)WHXU5ML8DBT42@>6!;J*8XXD6AJCC:R]^
MN(&%#2*X8IE%>!DBB'&Z22.3/!*XI(Q'/@F@B5-FV".5;5HXX9#\-<AGAV@6
MD:2,+[()IHR:NC>AJ30J:A"9-))*9*9TNBEFE ;1.*JLE>)JYJZKXJIIIK0Z
M":RFOWX**+&'1N@F195FVJ"S&SUKT++1=J@K0V_X\.NR&4U+T+(@#5311@II
M^P-(F2K$+$C8\I<1$0LY))) ])H[TJ%I<-3@O1(YI"V[#6V4$+P2O3O1P0<9
MA%"_!FD;44$=160120\9-/%'&,N;L4HXP?]TT4\O-;143B*G)!/(-JU4%1%0
M)=643$$5)9537C%%%LTZ-1756SFW-=5;8FDU5UDER7536E61)55<57GR51MI
MB=7&)5!%??33=PGFF&%[,?8#!X.1ME=?80,166) ""998X)=YMEBJ1W&%V _
MM"T8;XH]5G=ILDTW=W6;M?9W=[5UUUMXVA$W7^)]_\===(6']YUXQ5'.=W7.
M66X?XLP1SCGFR2$.97.[&0BYZ*@3GGF==))IWN@*HH=BB:(&!^#DDOH'(8O[
M\8AD[ E>F!U^_BT)X>CZR8@CJ\HK_Z6)K';*Z94*(DEGG<_W+FFAK0&[XI52
M2FKIGO!YRJM__BG_N7WO'3;OIGLO=@_^IURZR2;SN,+IJ?JR[IGI@_GSE9SZ
M9"D*M<I^@OH1KZI$JOQLKT>]$M^$;!6H!O[(3Q.L4K.*="1KV6E]I%(3J$S4
MH4,I#T8.I""A_ >^6@7H15>:D@>I14%>-6I6_1M6BDS(H5_9RG^?*E&;9C2L
M336H@[X*UA"3R$05TBI=S5I(PVJ5J86XBUAN>E>]E"409GDQ0FZ(EJVDQ1!O
M,80B$8E(M!SF+%EEBUC:HDC%'#(M?S&D0P.A8Z;">,<\_NM<%3M8OBK6+8<
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M_^\WL@Z.<(,G#&$*,[C"&+ZP$?J[X0O#E[T<)O"!X0#B 3O7O"B^[1$BN]W
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MF8)[9ZRPQY;)")X%;'=L&;LRBKA!:H(:NX,2Z[_\B;6'R'8H:)L).YQ[FY;
MN960R<"?BH+M.XS8Z,"3B(RG2;\I&[,$Z7872[*6&Z>-MZ<(B*Y#['PJZX+8
MJ+V 51G!.J# _VNUG1N<[>I[0LRK2SJR/(BW>V>WFUF<G#J<JSJ(Q.>)'=R
M@*C!<,N_4?MX(FNE!DB9%7J ;UJ,%6B>&HNT,+BB5!RHHPBU]XN)G1NL7$NK
MD7>=YPNL(/B9#5N^/XN''3J).FR"M]F,;WO(J=C%(AC%EJFA:KO)F?S&8UJ#
MBIR,.=BLM*? TLFCNOB F"S)1XN8Q6N"HXR/^SA-C 5[CMBINI?+;_>S>^R!
M3ZF!)BRSS/B9HGC),CF"M5O,#MR,+"BZ?!?)OP>WO8>,MZ?)G:D,DX #,!
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MA0P*[IS?]]W-,8#AR]"XWT<,!W#6?OG2LM>Q?^R"B#N_\/W$U$EW:! #]GT
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MP&G,B7>^8]#A&N_.WAP#H!!XFAT#&RZJF=#PG(V]8B_NRO\>=Y-@  > V=&
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M$<.B$C,!4Z!0#5 A!C0T?4@, P#0)),8.A5#$S&CF:33 \18IJ852H5FDAL
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M9W-2)@";\-UTA6&]C"833 _ *7+5)PDW<V0-#T",OC01HZ(8)L'N(&5&A &
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MORO**<>AKG6RNQ-I+_:"$*';AS&*D)MT*05Q')<P@*HZC,$,):F,Q:_9&?\
M4A,*U0]4+*&6D8Z4*;L'Q0@00YN4B5?Y,"7B?-B=.::C,M A$8])U<^1)5E?
M H(XV(_D")DFT[PK.T<9"A 3^BIHL[=/539+XA@+%),)O)+8 Q+KJ-EI,IOQ
MX!/Q&,S7,%H#+32"T(2_@8$9DHB!J!.6T"ZL :D#.(B$[#A]@".38P@ZF@J#
M8:(T")4(\=HTJ(DP<IDPS!S;#$FX2POE$5=:,HC)T:(=30-"K1Y(^A29BLGB
M&M%^#2.+!".9Q4.HB$G\FZF*LA=1X;F66Q B8J*H"*,-@:8.TRLPX0ZD/4
M,\=K)%AWJQ&1F-FLVIJAM0^RD1K54XD'+:4AB5?_]3DJ<2JLNYA!4429E$@@
MSPB",L$;>R/=H9 8C,TP3$46KN'*(X.K #%:X8V8 CDFLCBL^61>JP+4YFW
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M<\!-0HX#M"8BG%.(M?"[. ^M1%"/8;\_K[;-PRH/#)'*9(_8.YMUB8IQD0U
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M:);)/C TFJ8;#V]D4@8@0.]E*@86+;HP!O5,9'.6I,SQ]<,5-]#4!KR0.@[
M"7>#)D--) 9U!;8TR0VRW9#&4"5UI(D8!@A'6X2*P?8<<>NM (I9R@20W69/
M*8/&0S'@T-]1<TDGDTQ\W5391X9QI)-C="464U(VT@@37J,9.%-%/0%U56&:
M5677?"KMQ%A*C[6DU7Q.C=11CF8QYMAE6S%DQ!%OB3DFF66:>2::::JY)IMM
MNODFG&K"8010:16V4VD>%38544)B5B-93 (9U%<L<1529%GA5!J4+LU87TN4
M)?9G6E?I)/^=5R-I*=A/4D+FITM\5N470W9I$H,! 93%D5<X"#0,H:<B--,D
M!JR QDZN!H!&0["IH E0:.AV@R3+"!? 1),@E$:+KCT7PTY6/HF3,FGD=D!U
MD]2XD+(P:#*)J\HI@Q,Q!P @AD[[O":<N)QVE$E^#R:VCZPDIO&<&#$9A@9!
MT3TU%&XIHL&<<4S-9*AH,)JDF&UWM>084IYEZ=F+AP'V5&2A2IE:-#DZ9K%D
ME4F(<,>L,L<PI ]3&RV3K#G*&5XJ\?E528=Q5?,R<(0YYIQ9U3F?9P5OYAAE
MOB69$H^42=7H94=K17&@1_XLLEZL#;953!EFC>3-5.:8+M!12M3_4)8,PQCD
MJC,-]=U2-'WG8F)$MD<83FB5>-13"W>-TTMW5U75PGHWS)EX 8!RI%GMD;SP
M7"JM;7=K8@ 00VV:NGA78&L''K?F$K;-ZG<O_L5V<6.?M;==@>$4E<LMGTTQ
MTD.[39>$5_94]T(0([Y7Z4MU5:?9?>6.U8UGFZ[37X&-&IEE2-4N=TQ&J!$G
M]=5;?SWVV6M_!)V"!2F3;_9%FU2.?2K5-ZN-SR>2;YVRK]K@BN;=I.47YUU[
MEIP9'^7):#\ZM]54]KN[S21P2&G*5=B6ON\ [U^,VTH!]:25G;1M;11C2:UN
MI1D@@85^Q6F/4[X"P<MH @;HF5&)HF2E_\XE26V-*V#B7 @JG(4E:[C3#/C&
MHI2_[(1+1 D:JP W'RK=97UM&Y]>,N6;JMAI:D:4B=CD)JWG2<M%K:&8\N2F
M(Z/5;B%L(=,1X+"^YN5$*7J2VM%<-#O4%(='76P?GJ:$LR729WXT\TUB5G@V
M+)UQ?KK[T0*/,J^0-01)5IK*J&8'MO"-+W%6$EZD$..X)T9J)J-[GT<NE;YH
M2$Y%8=%3T=AG1H8-CXT4*Q=&)O4OE/"(+!X!'Z!HLIB0)-(LR^ 38=P6M^=]
M)I%3^]<"S6;'3:)Q5$6TBA5+)*HU"LID=CH=%*&)FL09C"A?"9FDHJ0S[7&S
MF][\)CC/I 8CE/^N;Y#9EC.Q-"7Z":UIH!D<*4_G&;N\J&3^X<C7'-F> \I.
M,G8:BXT2B)G,W*EI@:)472 UMB1RS*#"4T8]#OI,$!HL;:<Y9T<P<YF/0#*1
M>G*2A%!Y@$S,48\^.MF+,N9#53($10<00ZFD4C_"<+"51"))_?94O(74*31)
MY"(RQV<PCF9*?EVJIT?*MYJE$2IA5*-=\O@XO$/AD'DKPZ6B'&.II&824EUR
M*B1+PQPDC8:/Z(O=JARSS3$9P0B%G",0OQ*T2_9MG@N]$K7$4M2AVDQU4A1F
M5GR6M\)4:J!"+%DA^2K5=>JN>;3[D0WK"9H8CD5X0[0<\V06T"/9YC'_J3,-
M03>6%90)5*$9.PW%'KH/@CQ+/HXJTDTLJQ. CC*H15N/"6\ JK'DK902DZH-
M(5;$OB3/9H.A(%$W^4]E3LN>5_'A;(F"OQCECDJQY9UHIH;+_/WN+^(#HMS
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M81%:N@\]J5H680TU&BZ_"II1HNA/\J@JT=9*\LA><9K6S1\2Y5F_+5/*7 ;
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M05>Y)"&I92WE #C@"#$.@(;D3(1>$#EA&M)@K1)&8Q)N08.YQH*G-)3* ),
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M$)#UHDVRN@*C6"ISO+,B*;52DR]+^N*5_BJ# L1O3L;1KNW+BK)=/&0,^ 5
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M,,80AEDXK& 63UX-%,-KFN$0Y)%PL0G  ?K)ML]T."KCD%%!G0G12)F(I0D
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M@!LF$5H3 P+H' ;5Q5#FJ@BQ BJ3&U;H/HPTE&&,^C . &"%[+<2 X#.U0\
MAOFQWP<4%6AO,_ IG\ @0I-I!>M7_AF-GHAC(M H"SZ%VMC)__XDGY1U+%4Z
MRY'/.M6@R24-/'QS%5MTPZ+6&.E@-MH0:A#SL@NQ)QIO^E<-;7A#'.90.D>
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M:QJI4^8^W*Z[K\S:&HZXU6PI(6IGSIMN=5QNM7IJVCZ:6G6UC^CAH$2)V0L
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M%>M=*XRA5>B*\&4C++E&<Z&#Q):JG';BO<0*&Z+#3X5N$"NACXG4<;+_5B#
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MHT> @+9L7[1ET32MP+%/6;1] PTZC!:M7AH8FC(%0#,QFI@#8@@6C!;#(D$
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M/'MIJ#3\0#-'%1&?8TE4/J?1.11& "O)ITR8 -P W\W;(<9Z=9&4^%0UO8,
M0"&\J1C)#+ "TO#,,NFAEGE,M!'Q#*0X.#$,MN0S&FN-QCBL"Q7C^A*1<O]-
MA3Z/6QJ!0B4\ %%K@H[+E>E<MZQDJ9!>\HE6?IH#']<=KC:I*HO[*.><'XHP
M4HR#CP]Y$Y<7"F\YXFJ.@:)3+M"U*G#JF4V(J!9"&HKP.H[;HGV,$ <''0$.
MV1FCK<)W1/>MT3(D;(Y -"%  B%G4C>HB0+Y8K+QE29,)%F& (\2 Z.@[0 /
MQ,M)1"1(LJPE+% R#EKJ)1AHN*0P<@( U\["F)!,Q2U66<$;ZO,\@T7$?C$K
MS0%@("-]:*)EMQ$+3[[CDO?,137$.(#]&-*MC>SR)&8A1LO$\"6'B0DE4!&1
M0Y21ADS6QSAKVV6+]O:4L< *,RHH9?X,U<BZ421; &]HH79P<#"65 <^)J+5
MI&@SKDNJ!E2'&XZL$(4;LZSJ8WC$#J18I4$4M6<_2N2B;8*8P:7-2H<XR>"V
M]O,Q>SK.7*0IUP4W=9MRJ; Z)-14Y1ZB(KZ@ZW8B'?\I24MJT@C!P0B/ V!(
MJ A!W>3*/>]\E4%N)(D7 2 3B,+(3?>!$9FD807-0T,:T# )%KE,9](*B</B
M1!BP!4U #5D! !Q"F.;LPV0N*M<^BK:R*"6)3)>,3S0RYB+:/,4FEL$!5AHE
M$I?9+P!NP:9(.B87G_6L14>51!INY#+]=0PN]MGHV]Y340#9QYYO!)R\(!B@
M>$*G.0^-TD&Y!2*V-#$YS@HA.F>Z'QSJ;3GTNV0$-XNJZO '@T:D%FU655C>
M5=$Y7M,=GK8D6\^!QS60(@VG#(LHP_JG/E^,)S]Y0\/;1C [%DQ.?%+JH)02
M483[F<YK(>BJZ)K'/9?R#S7_<1 &''@7!S?H4V BDI+[]:4T-T@@7_'U)K#L
M RH-85(,V@L5 U0F!BK  1K&X-ZQU/0 -T##*H'6O#2(Q28NC8CV6I0&H 45
M9=0+0%H@<@  \&5F%$8P#,"K@DI-(@ W4-)08D#A_M(L*PUAJXP(TC)F@L)H
M68ROD#9BGFB*)"FT 4681O;=&!@@1JY"""]Q((8;Z"0S*NX/K21"C!N,3 R3
M./+(,@%'GYK8P7V"2L 6%8V*I $XAKT*M:1ZFW1J37#1(-#E0*@:$CI*+WL#
MUVM<JCB76E!%KE4==YJCJ<J D5%-9%1_MK@;0.-*6[;][9@@*.9J40W'ZZ&/
MG[M(_],0PN$()]TTISOM:0F9\;8=954*>7NZAYBG/&/;B,E:LT>P"*@C^#/9
M&Y;Q%T6V+-<.W)I,>A/!I.'FU=^+&:LX21"V4B8D<5N)^N8"E^^@X6X3R9A6
MG+@,L<AH-CC@I##Y4KY5O@8&;P%:9ASHMO^Q-41M,K$#6WD CAU$Q!HUHG :
M)=-.#<C7JENJ86Y%-1+MK<FF<M62+HK8W1)Z<GY6G&[3"\XF-BNZO%4HOSS(
MP2QRR3PII*@'2YU$, J46<!-W=GB;,3?4FIMNA-Y84^=1=+YAW$==&<3"1K=
MNN46U>/:AQ&"@$8X:,ZW7]/+;H.^N<CU6\-N>9C!'M8\Z/\LPP!F6YHF^C2R
M,&?B,]<QFG]8E!D7B84MH.A(3;!>S:' 2&,+2<-5I$YB0+^610\3 UC"%+"G
M]"^$J)1()LB-@ZQTQ,JEZ8@*$$:,6W-Y(@9YM;,,<(#S.(PN(9&$E:B[-BE9
MZ429*!]28C &+RIC9HH,<LOX&[!G8TYT?3^  __^P]<H PUL#9,8LG(XF)YF
M):NNAR:RQ)SKOJ>XEAL@Z,"(55UAU.%T)JY'MW6<"48NYOCVJ.* 8UJS)%_-
M9SJ/:G?HP9:;$'#[*G5^!NY2EWZHC?:Y5NJA!2 $?3K^\I__[8Y@A/P,75)P
M)/[O4IXI9D[)BX#/C$Q)0TQ)5\'_B40 A0+:T<[\RD" F6$,#%YDPM3LTM%X
MANV9Q@$\3:5<S<D\SHIAQ8IA6)\%"(R 1G/$AL0(C)544-'0R8QLT5$8$PCR
MW=DMH(6IP.\9ESOQH+"4#A*=D!BI$T(9QN*TB_3UAT"QQ LME*A%2\L]44=1
MEJ_@%D%!%N=,E&KXSF1]A[B\"G^@'*>PF1Q587*4X9]MRN,LR7J4"/5]4::L
M34(QDYAEE)[5RW9Y"[DLT>4!B$SA44@U"+JL5!<ED:/=B325BP\%FGX(Q7S-
M%_W<"@1MA@)"XL6]T7P-!P\^XDSL!Z&YRGS9X1I98E#(H )&2B*JG"@N8&U4
M(A?J2F>Y_^)MQ0VX#0^NL)(8 !\76B)R",4O/HZU#!IBF2(?GDH.7HYA):*F
MH(&8^(<,P9!]1-$QUHH5VMA*/5^_Z0VOS,9':<4J<E;U6:$/I9/O]$4WQF*R
M@,IY:,J<O5;R,6%&/<X5L5S%W5:H %PP2DH]V!_]^>,_ J2$J(&'H%RIZ",/
M8>%_G >IQ!-KU(_Y"$:K.42;K(0R2-W:$$E93$^V_$5@!-4;; 3CI8$*N(A6
MC*26U,-7O(?)N($:OE5Y!%)>+ 2UU<I,2ELSA8DFQ)+9] 1J4 J8O1-_X$M*
MK 1?4%-!/,1OT!BQ&<0P9$01$9\]6HOWL52A)4?><&&JX",/3O_EYT139'F+
M6=1;/-;-C6T4_>SAQHV5J*V97KP'.]E33&T.CFE<L6S'J#QAX3R*M9TCTW 4
M97&*.\V3FIF6J?$9\5W1VLCE<.V;;;'45B*48)C1ST&A;DT*$2XAJBECQHD?
M>PB&/KI6>#A'G!7$DEB<H_V?HYW>D%@E<NDC]$F4F2"E?<@F8M;A0A:+O:QB
MR_698:FE5,!'D%187UY>,_H&.6:DOD7'=R3E](U<77ZF@&C7!['$$,$*K00/
MKP3,CV@%[PS0Q44<9647]=66YM2-I1W<>?29"A7'8B:FI]1;W9"F<.W6F:&(
M:<Z91(E6<:0:^TT'Z0Q+B?S9<9$5%L7_7*1EW$80J',%9(,Z*/UUR)M%(>5$
MU+=H(4/@$<\$E4: S0@V1P'*B<]PQ#(QU7X-!!I83428F&D80".DATYH D.8
MV)Y0SXJ^R,$$2-P\C;5A! XT6C2,P2?AU( 05(?V&E[D2%916$C$P CR!8\!
MS*B)SKKQ2&VTR4F81VPXQ<ET68<B#&39V\5AS^D04.8<WT*QGV, #E=52CQQ
M5+YI2JA Y8REYF_43:E=%&Q5VW24SNH@5G3-H>&$$&E:GGGF$#P!9G+ %%OF
MS8E8T&BYR\(MHQ'R4[G("G)H1;WA6'+4F9KRG!&H"] 9IGTF5/!)$V?)"S[=
MR9>8);[M&Q7._UNF&&%%.0L*L:)D&5J3V>=7 N$.F<44UA9KL>%=$B'TJ:-D
M)9129@K^&58T-,(>F8]]F@IU<>>[\)^E"A9F0@9\:)'T#6%J-=PD(B;[=<N2
MW$B/0*/K?-9A/J$9,N$.Q1#P=8U81HD77B-&VMR-Z2-Y?@L0>HUTJ49,@1]]
ME-R?NJI2F&;D. ?A)%%@+L=F'*?[T9R;,M-HP,Z#8FS&GI01@&I4JFE?%)PQ
M)NRV*!:R+EM!,)Y24%Y1-B.SH8V(30(:I)UOH$U"H(')G-.3- ]8?%MI*I(8
M()C4V5[-@@6!!)66;!Q[_,N(_46'?>?Q:-1Y[)&6R(6(?8?^-(E 0/\IT(J!
M6PRM8WF0_GA$'BK#58S8)%Q%#-027L1 S(9)G!S?JUJA&1*L$)T''%T*3$).
MG#9KO8UG1 7A#V;''-UFK+1.I%!7LY(LJG(1OG[LHZ'9NHZFQ656"'FE>UQ4
MLLHB':[K_@5KG;D?* $/.DH$_F&10^&MUJ3<KY+G7V::@P!!'#3.%Q['ZLR6
MLCQNFK;KID:)-?I:%L*IF>&F)$:JP?+*FXEA<<EJM+1F/P%4^H%K;+Y13'D,
M0I+=Q5@7<!'(8H";]$5F;O[6;T:6K<21EY&..II<FPKN\Y37"NG0%%HAI!)<
MO;:C$#X.^0&7!BULT:'.]NU<:9!1&/%+GI[_RN1>H31E"G*%9CZ-;Z(N5K&D
M87]B8X9"%.W.6SB&!(-J[ 9S\.RDD?DZ,"9"E$2)86V<QM,$GF4$8#2\00(:
MQ23@0)"-EYPN ]L93.UIZ$B<Q,"X#^*) 2@ 1^"IAB0< )686H!H I2577:(
M18%VAM-<1Y-:V9(4C=F("(N(VP_/G.@\Q+9A;W2\@:&,#!HD&T1DPO&<S$]X
M;X8B,' 1Z?$.;K1$;J*=(>Y&2\&BZ3I.6MV@+G"46DB0$VSA(6()A^ 0B]TZ
M2FB-[P:-2NGR2^("'PF#)V#:I:^U,?'N4#P"3\PA(:^<+_VZ7/-IA4"H2-(B
M% W!U(P,9*CN&PUG_Y%AZHY7KFFXR*-XPNI]'BR\L+%P_2<[#JSH3N69%LZ5
M,?!I%O.^X:(E#? UFII[#,L?BJ-TW&UWTM&[>(UHTB>R2A4.X5,<59#XU6IN
M^0VRVE.&)N8>MM;D&M1$[8V"PB%96C*;^=N__LYUN='2K V?=A##ZFL?[^EA
M;2-UDF\GVYD;3V*J)21"+5<0DA/1T2OGYAP(\X4::%H'6_1%6P@0 -V$[DO\
M4J\('6>Q4B$D[L;'!(4RG,9J[L4C>M O#J]$?**WGD=H&B9(J",>T0:=B6(S
MGZ)K-!Q(V(<F*N&Q^"#C+*!AD(Y6K!.W?HZK"NL;#8X5C1%\\D=[$B$] ?_F
MQ_R*O*;3\/76$ODR!?_3<@4J.A%N]DKC;SRN\"R:J.7*8_"KW5*E:W$<.><*
MFCD?YA1'$^K0$1UF$XZ:=IIC""+O&#+LZS9(&J$(KP)0Q^UA?."J7OBQ<A2(
M%Q6:+P7F_?JU:E PX<S<+ <N&XEN'[[>,WL+9E5?$#TL:2,A2QFN"3VU;"86
M9<,0:L5*"6^+8-89F-I<.],SMP;(GB7JG<[M7_:RHAD'<K;3[X)M'$/N<ABB
M7^.O9 ^C!#-N-!KTR$66GHXV^Y%:B@B4=[]>I>P97P1RBI1C>(^VYL9'^+"%
M(&)T?,LW@WPPPKKS92$1^/[EZ2;EXGC1W[Q(DWC_Z@I!VI#X1L4:,FF%T0+_
M8+:D9T&%H!NNXI)4QJ%QE*!09X63860^QKUV<VWJ)B>3*5DA2J%FT2]AYAE.
M*F/W1V;=I<S)[6E9LFC>T]]4*J)Y#J;\]_ZNX0NY<1+MI3Q586,A-=CB6#*3
M*0T3*_2.XK@D:[ <3AORQZ.*BCWGII/#'*OH[?;%ZGI&@P8O2$H!\@J)=B1+
M:)TFU^W6=IN"4W>76?D:KLOU$+$ VGU?4?[IY9JG9;N$BRA[GUD3LZ/Q"^*
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MP W0T/J#O-Z6LX=EP%=P@(9G8KGBU?UYF_D3X)=.#-!WUD[2H )-I"$&!P"
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MYG1?<,#[)J(Q/^DV#Z(J5W T4I#9+BX:WJ#YD/\)(<0@ -+ -W8ONFQB2\7
M-\+/ Z,!URCU)QI**O=A-.4.(4!A!5AS(&!0#&S"(G8GNJ(!)WO28 0D$U2
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MT$[(Q^XD]'/HKEAVIJDDK6>GAHM,!M7^YE0P:3$"A<G0Z-6.3.^D"&5U%(M
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MA90CCW)[ZFZ_S(?O[E:>I9.(@MOL8DI\)]!*"SZHL=(RC1.GBX_+AU(6Z&9
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M.F%G<\D-S4"+5L4 !\2 X5^/<^$K$Q90=T]BX@$2?ANSX2 ,X\5 ="8>  \
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M+35!;$*"&"&()YJ5+5R$+O;_YED.U!Q\A$;GHX&*5"]""$>#!S":M4#<ID*
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M^[H?^U:O_*E/^&7OYFB._:;_]?]?/_L]GO1K__B67__LO_7$'_:##\KE#_L
M<<0(G"-PC,0Q&.>@D34+U12$^)"@Q(4*+2Z$R'!@QH87%1($N3%A19 %#Y8T
M"'&D1X<1378<>+*BQ",TX00)J;!A12 62ZHQ4O"C2Y V<1;$J7,AR(8357)L
MB1)(SJ4D,UYL>I5JR8H;@2K]";&GR*Y#<XZ-@W;ATJ=E19H<:A,IU8LU5>(\
MJ):EPJH?C\(9BU*E6I XG0H.N6G?8L:-'3^&'%GR9,J5+5_&G%GS9LZ=/7\&
M'5KT:-*E39]&G5KU:M:M7;^&'5OV;-JU;=_&G5OW;MZ]??\&'ESX<.+%C1]'
MGESY<N99S9T_AQY=^G3JU:U?QYY=^W;NW;U_!Q]>_'CRY<V?1Y]>_7KV[=V_
MAQ]?_GSZ]>W?QY]?_W[^_?W_!S!  0<DL$ ##T0P00479+!!!Q^$,$())Z2P
M0@LOQ#!30PTWY+!##S\$,4011R2Q1!-/1#%%%5=DL4477X0Q1AEGI+%&&V_$
M,4<==^2Q1Q]_!#)((8<DLD@CCT0R22679+)))Y^$,DHIIZ2R2BNOQ#)++;<^
MY+)++[\$,TPQQR2S3#//1#---==DLTTWWX0S3CGGI+-..^_$,T\]]^2S3S__
M!#1000<EM%!##T4T44479;3_44>/*Z*"#22E=%)+*\7T4DTSY7133SL%]5-1
M0R5U5%-++;6(1U=EM=7T-H#54E@EG3566F7%]59=;>6U5E]S[1787W<=-EAB
MA47V6&6-9=959Y^%-CM)1X0U6FNOQ3:Y:D6<-%MOO[52&0  "&#<<I5Y#8T8
M&LN$7'/#@"P&8D*;Q%Q[T=AL6A'U!;=??Y>D)X!,V!6XM4P"6)>Q26Z@C)@8
M!C8-C14XZY;;#?[%.&,BE3E@$L<D1E>U&U:((>'%Q!"#LDP.")FT@UO.;-L0
M^=6X9IMS! !BQNHQP.-]E"F77'S%39FQ&(JV3(P5H,'!Y'UB2&.R3%8P8 6&
M]VFWYURG-3L WL7JU9FRBD,<^V:SSWX1Z+ 7 R!E8@P89C%E5A@8C0 8.QB:
MS<2X^N<#2@:@8\B #KG>D&_8^K)Z/:/Y,4D H%J% &  8-[2Q%4ALW95."!N
MQL* W #)*?\<<L<V5R8& #AG=_4#UC;:=<=4YUR2QD"G&NG(9*Y9]7+Q?:Q=
MV/<! (?&Q 7 L;8W,[RRK,=-'++G)Y/W-7&'UZY>=P$ 'OER+?^X\L;$ ,#G
MQ=   .;+RK?,]W&QG_U]R2;1G;48C.=N7)C=5W\?[?M7'=*RYC7_Z6\S\JL,
M^=RUO@52#WZI0?]@?_3!/L?<P'CJ:LP-4J8, UA.$M%+H,DTH0*(O:U^/^O@
M8@P0M<4L0P4LS,S]/,.[QTSB # XP-\09H 3?J9D!\B,&&)P@!4 [V0ZO*$.
M!S:,''IN,9+XV]-TZ$0A$G%XJANBZN0& X3=,  ^XV(2CS:9LF4L!GVSVF-&
M-CST-682,2B8W.*8&2;VSS&3"$#+R&?'\?6P,<1XW6L"]L#KH.&$Q(CC]1Z3
M.A@2+XJ,$2)G F!$R2Q/CG[$&P"B09D84)(U8B!@=L2 L);]$ 9P5%\.8]"_
ME27O:S$PP-W.5S+.6+$R:.!<%M-'F2K2,C) RYEL;.D?M3UFC(QY6P#_5H"_
M3BYFCIEIFF3RYAA$H@N13MR'!C73+CY:IG%W?.3Y5L RT0P#80  X> ")S$@
M,@8'*J DX)P)@T8B;& E,T SV78 SF'SB0A;3,D\)H8;+B8-5?,?*?V7SV[2
M\%\C;-G!P+>/479.>BMHV0T,:40H<N9@^J!,,!LC..KA3S)UM)Y%P://QF#0
MG=$[YCX B5)G$C(R!B!D&K;6+LK@$:34\^1J<(#)Z(C+BWK#6@ ,4(]]X  &
ME!0#YY;V&&*@TW)#I-I5#Q!4RZ"3D$!3:=6XVA@<6%(RJ0N /UOCU?_PS'Q&
MPQ\Z)YG-HAWL9WD,7]#TVC>*IK.J$_W9+H=A_X#]F52FV]/K+O<A"5EVQJ%N
M]"4D ^ UY 40:^ALC.ILQZX;-LV5/UN!2&M(2W[JC*">Q*''U/793' 174,<
M9<*8*,1G'A%X[3*>$(LV-Y:A@8>+@496)5/&FP$M&<CL7&T70X^M,F8%FGBC
M.Y&VO?T%31.+,6?(R'?"(DYF>QL,'!<')JZ@+69E =QC)ON'OO(&U)!!BZBY
MS&G3Z@3@NI1Q:?CPMJXXOLUR>!R7[I[7MR\NIJJ?Q1M>(U,O^#:5<RK '_J$
MIL)Q5LZL3SNA][AG7@"8,\"-<1?*^%J=$1Z H"I8QF(886+L M3 .71MO (9
M7!XVDV,JN"][-\P8QO]^.* % ^8)EX%#RZG+I.YSY>2\"#'JRI2+.#RG^=J%
MX-BU%WF:"$.#O^8NM-)7/L7\8\^RZ;1CIBX3ANP,#D;,6?7Y=Q^@H%MFQRH9
MEG+FFRT-IWFU"#3 #=%CJ@O9VV*08G:M*Q-#9 S'8'!?8S:7H$@CWUOWD8;E
M ;)Z% U T4J&AI'IC:"#?9@Q17KHQ$TBG\%3:&3N7#-3,Y5MF1 78"%95P/<
M-63!!%I=T\JVJS%Q8"NC!T7)^1BG-O9X<P0 "X\)R,W:+=AO0U=P=394-9J,
M?#^&V"B_IN!A>D?0JE.I,7L(R& _;6!B )X-SZ?8KAD4QP%-F)C?UDC&,!'_
M!I(^6:W=G>*/GDR6^IAK-H&'AG8F%:G(%!]H/79>.6+BK@//=';>)E.&+L:I
MW7/QTV P!EBZ.GY1.Y@8#K8N/J,KMCCLKK"S^%OBA7IR?D3GJ1WSSK_];5U5
M^UL'^8Q#5&HBGTH.N62#>@.$\9SDNM3E^6Z(="_'QZT?DV5,>692=,>9,Y'D
M<$LSYQC".=.(S,7W9#@6=LP0%[);TP0.)PU/BW=77463V)P/3>6S3FY>K57P
M*#U)\*(=8,<XA!C1#2DXHG>YT3XK,37]+FGFIGQW%T-;ZDR*9D!B;V$G*UHP
M 3FO-,!@?,9[ XH9@\$1+H/@LH:D%\7\-<_/>C':_^RKG.]J.3'@;VYKFQNC
M5X8NQ"4ZA:+E6-.C\T:('0S?-L3>C,5G5[KN ^ Z ]IU';^/@G4,:',&*]6,
M35(4WAT *5:D>3&Z#QGL-N'Y'3U?FSE?2.:6K[#7#EJUR^*? ?JR:<"['=6U
M+B%F8L@L>R-#"X"K&;(\T@0M6@R_FY<A$C3#XCJ$@4"(40;6P1HN.AE+$@.<
M^IIVH[Y%JS_"VH=E0"?UX2T#BR6V\:6I.8 %7*994J[\ +.3"35A"QG82K!T
M"J%$:\&D8C1D L&D\IS(NHRNFR'(BXQV&;&1:RDEPQ= TC>EZB8EM PH,IG)
MR;85<@PABK!Q2BJ3V32'P?^!M]F"#NQ!>/.9E9F81$.G$0,:M9N,5<L8I4HP
MO8FUR""W;/(9E+DL]W*C6JL]=EF:E2$?^H(C+CJXNXJEJY&A?=# T5L7:.,P
MIC*UR2"?&!B_F (D97 SQGBW\B"XTPF S8(,/=0$64*I@NDWQH"!3(!$H\$7
M"),YE5&R^K$;SAD8&PHV=6.,94@AEM(GJX.,9&*QE0$?/82:/N(.0=.N@/.Y
M0:LJ 5PEZ2&E6 (I.!H&'#  ?%FM0OR;3&B7(9*J0 H<J>JFQ0@#+XHIBANG
MUGLT9P*W!P,B#K*Z41H8*,*D9(*ENYI!>50&GSN <B/#_T@==!K'@@LH(C(
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MZ1E?ZKR#>BZ54[+/?"-TBD@82)E\BL@UBXPD>BV_RR)9NLD$1+F: X!Z"*Y
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MU,,:N06XJ($_#K(<C@F UP%&[]"'B/P^BRO-SN1AQY@MQSC'TPF<"P.D#4U
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M&AJ$Q"I51D>55X]B!V'YWO<$Q)?=6]%U*>)T31^>@:$_9(PO_R)LK]5$!\[
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M**;$,,1 VY  F*U)7 LC,AWIE0+[=(.L3<P]>%$&VJ0HHN#0HV,]I!4*N4A
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M# J_ U[1-G51 2__%(&KE^ GKT>NJ\WFX_->XG.O_E.4CWVE4'[[/-4C'-Y
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M/@!3'8EB4NP-/<#?!.H#RJW(F@6<I\4>*C9:*0ZB+IJB(!ZCR2C#&^  #MR
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MD+\!_>/.I_@>BJ:H^6Y2"26A*)S00@DQE"DGH-+KL,(,-\3I0@TY_)#$C3:
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M:NZ[2J8^*FM.4V][G<I>21<ZJU@+#G\).$KAC*8H.T9)$F746MBFUL('*O5
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M>QP)T29#@CC?PV9M<#9Q/T@F83++,B-3FHAWO,U8QB-IX)(RXOP1,8"[,OK
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M?Z53#"C&,U)1-8@*7S_B.<4SRI8F&G& J H6!WP&?W& /0=T80&)["K8(\8
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M,;0JN]K5ZU>P8<6.)5O6[%FT:=6N9=O6[5NX42OBB%O790P  0#DW<L5Z"0
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M)MH $.T$D&*6B0+L8#%PP?_;9?3]OG(A'1"MWC$I%R!.GHL"#E+$*V(@3N3
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MKB,I?HD%Z>#/!AM#[(TU IM_+AK;0(ZN@0$9<*Q81PE5TH>L.&8X2;:6ZAB
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MX4:>Z@H.B69UT= LL11?/";K#>NO-0< PVM^&$N%+&1 '8<O0>I,/' Y3D7
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M+A*B)(C[E>W(<UPDW41G]8:@D4X]MPI'=]*/Y$0H;;R-Y#O,[KO3@W[H\Q3
M#SQ3,<M0S160#L?61'QGJ]-_2 X,S)6:F4[72,;D2'2(;\4W"U:[3FR/FJ6!
M\E%[=$/%CVB"Y.OPV5['U#]%3U-$DQD 6M2UH'7*6P\80VV\X>!:/30)O>6:
MN@_<8N':*QE%9*4(97D$L7_%H_\>9X79/F@_%I^ZZ--__?_+#JOO1*>DVZIQ
MR20!1 P#*P[$$+-OGX$8F1#NBQ& H;(#, (<&(@#X0V(#1U.#*",8R.% !Y2
M!,DQ4XR3Q P0:RCF($>9^S09F(10# ".86)RC'%@ILQZ!F+F#/HR!D<Q 1!F
M K#L:%1E&UG>W(=C1<-,*PP@E+CBI$RB"-&LP+COALY]Q [<Q)&4K,I]DEHB
MC $W:EZ]>_GV]2OF@$N$%1M.DKMOV %)30/(/8#&KTR6@O<9W3?T+!JYR@B&
MC?P9=&C1HTF7+IW#=&K5JUFW=OT:=FS9LVG7MGT;=V[=NWDWU$19[\""!SSO
M:SR0X>"%#2=J:GB79'*',:PR%EC_CZ/P&"0/K( V<^.^3!\;X@BSE]X!  4Y
M2I3>E"O7 !0A<US?$%J &U'?RA0S4*W/)D.(+9+PVD>BG@#8[ZB?5, !C9[^
M"\" 85Y2;[MH"L.PI]YP8XG"%=Y[ P!]"J,P@#"4 < Y%=)H\,"9QO,L#0,H
M;(2C25#,! :H//P12-S4")+((HT\$LDDE5R2R2:=?!(A34*!DK247K.2RBRU
M;)*>L[;\$LR]4 N3S#+-/!/---5<L\G?V QJN=;(>Y/..O7*I#X[]03RQ3W]
M_!/00 4=E-#(- '%S_2 ,^V&Z@I]5,L8?(244M/&1!(- #0-,++MM 2@0]L
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MNN[U[GSCR]WR3I>^Z56N?<'[WOR.%\#G92]_I>M?]&*7P.9%L'/OZ]_LZO?
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MB_N[X!7'^, YKG&&7_SC&_=XQD%.<I&7W.#U&(.2+#>:HX'S(',FBD"9/$G
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M"XTQB@-KC;0\;"HFE2$R48(XQO\#!KK2+QJ#(]  .E\"(U)"$U0 00)C&51
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MYH3W-@__@'OMHO!H5E;<MGD4(A^18D-R1$S[ DJG\ST@&"%: @>DMUY"YJO
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MT9G:]*8X?4U"'5*M , @ "$ER)Z&(IL8$'4G7=N( 2SZ$&(8H%K0B8'"#&(
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MTXT38$?[Y<O=!EF<4%&$_?61710=+@C*"6'R,L.)&T[84@GINF'_"P'S7"%
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MWWU[-%._VEG6&W#I^.V[_S[\\<L_/_WP@U\__OD3I\RKYO>O6N6JMP*GZ:^
M!CP@ A.HP 5RCW ,?" $YU(K\Y4/@)N;V63_(JC!#7*P@Q[\( A#*,(1DK"$
M)CPA"E.HPA6RL(4N?"$,8RC#&=*PAC:\(0YSJ,,=\K"'/OPA$(,HQ"$2L8A&
M/*(04W4;U 7G?K(Q&DFJ(H8)[H9X)N08;#)!0-7X#HE>_"(8PRC&_"G1-E8B
MC@-GHRU  4=R(@R<; ;DFK>,L8YVO",>\[@R.M8&;4T4&&WVQ)8H]N9\(;P6
M;#KTFB[JL9&.?"0D(PF;5'&M(2D3VX0NTI?KN,5H6VS>17+B']-!B'* _%+M
M)K>ZZ,DE>@V!&^VBN+.64.TYZ,J<V_K"-9^8#BE\\60G =">72Y/=A0QT:^F
M137I<8V*JKP*(M>RB4S7Q0N0#N+:N6H'RXC(:R-\E"0XPRG.<89Q1<(LF*B"
MHAUC5JD[BF3BY"2&G+XH3$(7(:2TPH8\A9G(9R[AR'U219>Y+.Y<8QM*M%84
M%H59!"*R&A=,VEF7@C0$CL-R$4,FQ"B,F(A3A%L(/JL%DV6E*$$=I9"- &FA
MMI1*,G)IZ.1@TJ]O28V<_S:]*4YS.D.G2,@AU<P)&D23(NKL9""GK,JN"O4M
M!;D%,/>;Q/]>=);$?&XE >N+17W'214==%61B=0*T)"RO>SJ>"$)%V@^*3RY
ME(HE;6NJ=RR"'M2,=2A24FI2$5I-,67&74D1UH 021,YPE.GACTL8A.[P00)
M9C3/Z@JXVE.HTGBJ@E)TGG+@0PREPF6"\G)FM4*I3[/U)"TD42J&9J>5!&'N
M(!9J+($REY#R?((S@!SL?ZCSF 49):5G.:7I$%3&B$AN1W"TZ#-#EU*^]H]K
M"%%DQ )WR@PJMKK6O2YVX9<@C'%-M(%+K=N:Z:UE.@:*I4E<5F;96:22[IGU
M /]IV+C;76(XD":&["DF;[DJEAA2<G\I%EQ1$I+N:K.21WK)) :<":52;;,"
M<YO<+-?=D^"U6>:%TE[3T[%S)H8FJB,P^ Q0T^R2N,0F/O&=G))9MA!/+HB<
MK>\LTC_4E6;%DSWE42GBJ04#4CN)421%TB(FZF14M4T)W4$W13$"]O0KZ0OP
M18?;$M&6)!,W.$F/'G*O \76:6Z,2%BU0^/H6,:T&N[I6FCB1V5%+ 8C1C&<
MXRSG.>?&I$61D$<$UE.06HJ6AGE1,J\URU1=$JF30%)&US(DF3@P+8+<\K2
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M^M:_/O:SK_WM<[_[.0P( #M02P,$%     @ =8%^5FM9]51_=@$ @78! !0
M  !A9'9M+3(P,C(Q,C,Q7V<S+F=I9D1V9504[A/UTBV-=/<" DMW=\/2(+ET
M-X+2W2RQ=,<2TBE(YX+4(B @W:!(B(KN^_N_[X=WOLV9<V;NW#OW/(^ZIIJ$
MI+T 5B[Z3\#_"Q    $ 8    @!  8   ! $ $( 0!@ B   40 P   & < 0
M !@& ", 8!0@"@"( @&B(( H&" * 8A" >   !P$@$, <!@ C@# 40 D ( $
M 9 0 !(&0"( 2-1_O0$H$  % :!@ !0"@/HO^6\V" 2 @  P$ #Q7PT$!("
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MFO4\2TC!5)KYK-Y,*)2S\G86\8KWT#>U16TF#C3'$/!%)>;O1$I/_))(H2%
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M/U:OA!!=D'3\D8:C&?&AEHY&7_D6QO2<N8E:%:17LT_23Y0)(BM,C<>E?HD
M,6;Z,,E.E>H/,J&UC>8(JMQ.W5 ]Y+BKD)BFM&52G0:[S*6?+!5<U0J_(3VP
M.?JKI$<5 YN8I$E7Z<CK=,>)/)"Z5BM30D6<U <WV;"_\2!4I8<2*>$/>NNT
M'']W"#5-_< "(9OSR^N#X.&=_-EO"F(1*@.CL H<-B"&6TE??]:R, AQ.>L2
MW0K[CWK*(AP19 (H_/<?$NP?>C_(7K6[/CM %"%"Q W!?0?W*=.'4!G!@027
M(=Q7\"$1'P,O$D%#Y(W$?6\<%GRC3.(GD0,+IO\,N5)E2X<;W:242;!ES) %
MV^!,V89F3)YNAL042C"HFS9*?*K,*=1H4YXYYR05NC1GU:D$J4YM:I0.5*E>
MK8*EXS1IU#:8<E[JZJD-V[-FR<[):0$(W0IUZQJQ\,,NWKMT-P !\I<O$ X_
MZB(^/-C(W<%UBP )7*$Q281PBNRM:_F@IL,5-$D$%9AO1X31*/_XX5&BG1]&
MH"V+M@_UC\\>;?_8P'F?ZR(5?IN2B/D'\-]%=/_X/7L?*. 5F.]+?EKY<^0;
MBE]7SCM[<CBLCRO_P1MY>?'8M1?AK0G]<X^?@.L.S3#Y;][1PD=$^"8YD1^@
M:%,&#B+BVT B_'X@$#G_.R12AH(B?#!0(O/0 Q A:,0C0K^#?E-0/=%\^$VW
M"'_0(,$1+3QHF1#C.]"_(AZL@!Z)3MP@Q!I##)&U'5F+YL404]P'LQ A#!(:
M%@D\$$GD9D1H@R*0(R*Z?3H$C@*/-'F1-_XT@/)*B; S\4.$-(&PB-U$.[&(
M(#F$$#LBBC"1"-S@5)/(!,V<4J HBS -H1IA=!/."HB0D,=#]RDT033)],_&
M/AOT#\XO$5)4TB(\BA!('O&#DT@_#YKR1DGQ#%*3+D.4\]$<!0).R@.1Z](B
M,XGXCCI68655U1=_C%+-!XFH9T)6ZY!HF4L?5-+,8AF2M */XL3STA!Y]6@#
M_S@EE0T:4+@4R-:#E"F15MX&%&B^@^@1",\0H0%1H#D1TD==;'GS=%XSI25B
M/6P]=4.@B_YM5Z(W+DIC(#,Q;7#/B["\*,&-/.+(4X>*V.BA<Q,B:,R#)"["
M7S=^ +D@'T#Z)-)9-2*(6LZF;$@@@HD($A0?"DIC)I7T%<V-BRCR")25#&:)
M)9I3=LEHFFY".B>LD+;)Z:5ELNFHK:*6*:JAH"YH+*?=Z(J(I=O8NJFQPM[J
MZK+1UJJIJ*Z^I.N<V&K*[;?<4"NMKMR JXVJ\.ZD;CHNF0,MMAZCRX+,^"K,
M@L;RNNNOS!ASG+&] $OLL,,I3YPNX:@[G#*/X$C-"/^)ZJD@MPV%+.ZPS[(S
M_2[L/(KOOP9-_PWU942$?;CZ:N_]7-F9BT8U0S&4'3OQX@,.VNZPXRVAXX +
M4AGLJ.?=S=DGK(]-XK +$D$Q/=*GNIP16J:]A!$"1;L&ZWLPDP/K$QC<0"-$
M_R#,8LRTO ?)/9-4A($3HF_MPQ3BBI"QQ(6G*9GH6B."4OTH(#T;35!34/+(
M&R:XL7U\8D1/&N#T1D4Z.97H!Z(2U[/<Y1\VU:%#4WJ#K]@TJ@KPAH6$^H'\
M]E'#6K$F0:[R%8RFY)Q!#=&&C^(-[B XI40UT%XG4J'"'E3!!]GO(T[DC1TN
M]0-F'204]"O"E&I$('B%BEK_RO$/JB#D+'69Z%#JJY\8$X0Z.Q"IC.K:T[J*
M@+'GA3%!>M1' P5B+$^]R5?3NB.V3J0!CP"K2*+!%YPD@B%/R6QA4\J2F<IH
M+P)-*1.T A65)(4Q4] JCJ*YE,\F!JD)V4N0"9*4_BRB"6B0I"&DTE!);'DO
M@!%!CZ 42- ^^9&'!-)%!1$(ZAH2HI%$(R( 0X- I/<OWB1S9Q4Y&$4PI@R/
M46P@('$#FRI%-(=\$B7=O A(RADD?7BS8L[+A-!V]K&BP?-F-6')S9+&M:;)
M)&L]<0A5ON83F@3E:G@+2U.*\K:D9(4J> OH0>'2%4S 96UD*1O;+)JWIOBM
M+3GA RA:^/\&4<,ASG!XN=QC_J*7P@2F+QQ *>,RIQG)':8Q Z1-Z." NGU@
M9R\50%TTC("]/Y'&=-A93&!$5,(#2284'@FJB*@8#3C\  Y*Y)UR]B*BX+5N
M(;29#D(*5)WPM =U8ZV.$C51'>5X9!EO (XL$\(MWGDD&J#8#FO8<R,J:K,(
M-MT'[N*S5PR.Q%HD&N-!YFB'%_Z 0>F+%57IJHFWTI5$R,%AARHDD3K4Z(2!
M<I3)RL<B"$725R;B3IT<I2 MN4L\4"(A;S#D)G+QZ@>@G9]RV'@:+Y4'AV]*
MD/-\@T/$GLAY+]3@05*E'!S.S$PR4R9KWH#&$,4(3N]3V*;B^L+_3]&58,&D
MDG*F&RLW:="NJ"WD-,=K*G5=*YOV(J\6^>,?^+U(3*GM$":C!$X.9=*,C#I(
M)UF%1SG9<%+";0Y(^@0*)?[53+D]"#1HA5]5)7=2I+PE0A[YP59YRD5X M6Q
M/.P1OJXI0.J;%YNTN4-!+NN":TH5;SIY1N<IP[C..Q(F(Z;)LEX$Q0/BB/.B
MA$YJD4R3SDO(.XF0"2,WQ& A\T&/LD18B93)(%CJIG731Y&HOI"7*E(&DA-D
MVWU 8V<"@0G1&,::6JILFUU%2(R5/&9ES PD$+.R&PP,BI3PS"$K49E*O!D2
MHN$3*$XCBCYW,M"8%.4F2J@*5IC2$S<@_X5JBHX:$<1&EJ9@&BAC@?1"R=:U
MKV@:+$[!V]PT:C>)ABTL!NW*6#J1EK %#BTE-5QN*"<8RO2%,'UA*5\@Y[B@
MNC0PJT.,Y*"#*#))AME^Q>MD(G,7Y!RN.$#(3%^5S>#48&?!.W+.M,V*[8.<
MYP<;T@WZE%'4[ASF>.B)77J \TD$B<C(/"I/]+*-$-^T*-]C%NL-\QTN[70;
M,Q60H'(@U.T=+5:,HO*5?_?!'C4Y,3DVPI@;6R7"<R=(3P^:XHT82,4G/4@#
M%4P0FVQ(7A,Q\.)>E @]"/78B'50OSSJI(UJOJ-'$6BV;T+="S50;Q[-[$D&
MWI&/" 4<H_,HBO]/JN.+/(*J!G;I1-ZS%PT-6(3&@@L]%+BP1R!<(HGH(^:L
M,KMX(^0I[Q[+LWCZ;;^'==\GP[U93M2XF1Z%L%$Y\7IP<KBDI#?"0I'.4A(\
M9;\SV6\.LG)'9KIB'>%.K3VUTEYN3M2_%*[FA[ *97Q.$-W'_"YL41%1T.@F
M^?(]JX((';H.:2\WW^5-([\!).BL9B]Y](F'N('UK-&]Q@KRS#T?K26#ILF@
M81+/IBEM*%R324(3ZL].+R4H2_DGU33Z%%-;;:%E\7Y2#*K0JYD%;TV)6]VR
M[P:T) 75;A-<6O(&TO5C=&Y1P1Q?8)J77%,NJ(N[RTGW8C$R1Z5BJC#_< UQ
M@"#;S.<QDB/G:&,O2 .I7J<X@@H[3*?W:L,"K6TUE$UX<D<UH J%FB,$4\2N
M-D3BS,-XD(<\>D>M4.PXEB/;[ JJQJ/?.JE '-!8.B0Y,B]4*BY$ZNW&/BQ'
MXJ,'#\*M%$0WA 6LCH-_2F)1.BN S&3K$H*!UHHZYD4$D:L\ B7E?,![?,",
M6LM#+DA<@F2S'J@(MNAYB(12:*.0-"B*'@CNAL2"#F6YZH,W.*BY6N.N^HWA
M.%#9XDL,X<Z0#(M0C,1.2LL.+T-,3*57L.ROID6_A$>^3D.*-DR\LBA0OH@U
MF OO*B@'=T3R) 7B9'"\+!'#Q*C!\$CR8DY:_R"D23AD%4%%FR1O[D*%5C[(
MEGS "(6I[$A/S72IVT#B!SCGO^:%(WQQ7A($%[=04KZ.2JC%NQ9.DR#$7PZ&
M5N"D]P0I1V#&&0419A+$\@X%R2;&%W\&6\1,DLR,()RLFUBCSS9BFU#O4!I"
M^ :"&QL%)N!IG 2-^.@I)!@-T9AOGPK-^0*J^?R);YBB^F@BT[#":XR"T[9B
M*:Z&*[(BHT@-+5R-U4S-*\C/(UDM_-CF+-I@;E8-+_JB %VJUQ+#UPH'UQCG
M_Q0#V ;P=8! J7@DW20#UVP#]_9H,!#'= XC-TR'V8I@='92!2VP"'2*=NHC
M.9Z#L3!,*AF1-<XG>?_"HPAI)-R 0Z>FZGB."W3,BMMX!%1<@X1T0^C@ZB#(
M3CO\<$>T24WB;4>ZR. DHH">I(?JD;O,0TZFY'\J (<*[I$>A7J^4 ?/*!#]
M;>4X#DQ,KDZH#H=.I0L+)>WB\@U+J5%2KN4>A3'I@8$41$_H9P.H<<Y*PK=.
MDS&3*4Y09T",2"(Z20.>LHU4RRD/)1HPJ(D@:4>@ 6-(*%H6QK*FS+. \41P
MB!VOZ(Q@A)+$Q$3(\7EZ\R#JP;S$$+64 UBL"#ST+@W',MN\R(DTP0CK"F42
MB7WL)<"DSI!&J$O^KH\:Q.G,)%).1,RFQXX$8@F/#H/P2!G;2%#P!/?4IQ[_
ML0B/W* VYR>3B.G!TDA=,L5>WJ '(>P6L1&3S/,A1%'W1 ]._*5!E@Z=^$7*
M#@7!^!%"ENZ__JS+FB6>WL68/@:5-$(@*((B'+ A9I1GNBT:(M$D4(+/ +*>
MEL_0:B+X@C2@]BGZGN8@4Z(H+%+Z"HT@Q.;1#FK4<J+\J*\BLX]L0JV@JI2A
MS";]4*VCC&*BT.\MW ;5Z&\D1\K6].(E)\<FF:TO\D]S^D]SCHW9D&TPX. ^
M!.3^&+ HC> ^I@H"<Q([&N,U:L=SD,-U0&&:0@?<<D.L]O1 !*1Z?L/:@ -3
MRP?8Q.,'<&^J6J?BR.TW<".LPN.3PJYZ I6NU$=4_\-# S2!-]1'"U&P0,;S
M-+1I S8$/PI$02;U-'135,_G/N(KFP*H/90#%'!HSL(P3!!.1L!$5&=KO!XD
M.Q&F%JWPL/#C3C9 %JD$83PN#2/FD2;.1-@D4(+$#LK#1-;0%F,%?NS(![RU
MOEI+&>0'&C #+4$.2I0A.G3S3"[K462F1A[O.WEDCA[)#OB4N7)DY#JD+6G#
MKM:03Q9E20K+CA0$C<XU0@IV"ND3O[R'Z)QQ6U?E,R?L7J#NNJ8.CT0Q'C&)
MB5ZF7^F*QF;%L.93MQHVPNJ(5? K1+PUY8B "MU54^C$6Z[K7Y9%9MUR&19/
M07.D47VF& =I&M$+"&53E_]B=DIT$Y$&XD1>CAF) (<TR2(^06D?C&E=J4$E
M)42,"6:(H,DLHE&UEEG7EF#2R!D;(L[<DEL.AFA<:22$2Q_2\6 F1B1L3,_X
M12#$[%CXY9DL8F1B1C8EALW*+"7LE5+1248YE&Q91AD*PI128IOV3'2)AA_Y
MD=!T(DB?="(1;2:RYM(TJG4/<BD6RDB%8@@\;2O*#]*(X&RX@FJ\-/Q:S2NR
M;_U0TJ,^,GE'4BW.M'C;8/]\DBY<"G-4,B=Y[241IR4?(S F8R8CAW$F8S!Z
M*G(0]=J$S7%<IWR%,G,L\%!M4C<&HSCDMP+0 P+E%W%R)WV[ ZO4*G?.!7J.
M SO_JHHAH"2P_FTJH:=UX++=1%4KK4?=*J!9,R2PPBI]M0,QCZ.R*" YNH-
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M 2F 45K2EJC_- =,?$E*9*JK6_6WI05J24M5@F ;X#1"#@*63Y B% :!H*=
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M^L"TY(@1X,&SQH"&8:LI\*",R*FI(@ T:/@.Y'D/.[B0UO W^H@<?>BTUGC
MQQ@LWPDJ^E T.Q">VM@J>0,J%82,":P>X?DT@A.UV^H0#W2/2F.,::N [^&=
MVS&W#\$X\GDLMNJ/8BDA3-,2=7,U@LNW'[A =JL1-6E!_>.A':'"Q_@$ @K
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MLD^9Y'-L\13HV CJ-KE\96UG(POAVC*WMKC!;GB+RN"P,I:WJ"4O70$,6Y+
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MZ+.HE[8@Z'OAYQS5%QX11+X<XL-!&'J%'H ^"IKLR]5]7;>0(RD]D33.5KY
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M:3'%1-"84S.=*3XAKT3\3-!L$]?T!%+ WD0$Y-"P*4GF[NV=DS\!E%;4L]4
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MY$WXI+LF%.O>).RDB+N,EAS]9$(OE+R ENT(I6D-#VC;;D/;L;YH@HQ(!5'
M"+Z %&K_V:A&"3)6]"Z*P(B^[HB=>E3#@M15BH4@* \:N 5M>8\="R^<($PK
MGD)/#?)8=B(@08V.[I9OAW35PH9*\6D=YQ12QJ)*Q197@K+8/F9+4PU.&;*;
MA(I*?:8D,P8O>W(MW>C8;+5332I+X>)D$ ,"B\ D#L)>OJ]P&*J:4'(Q$*IP
MZJA-[?0KRH94>\HHS\8L-@, (P95E:JC)H-W%\V>J,I0.8HI,Z<!ZT__E&(
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M/=9D7=9F?=9HG=9JO=9LW=9N_=9P'==R/==T7==V?==XG==ZO==\W==^_=>
M'=B"/=B$7=B&?=B(G=B*O=B,W=B._=B0'=F2/=F47=F6?=F8G=F:O=F<6=W9
MGOW9H!W:HCW:I%W:IGW:J)W:JKW:K-W:KOW:L!W;LCW;M%W;MGW;N)W;NKW;
MO-W;OOW;P!W<PCW<Q%W<QGW<R)W<RKW<S-W<SOW<T!W=TCW=U%W=UGW=1MB=
MW=J]W=S=W=[]W> =WN(]WN1=WN9]WNB=WNJ]WNS=WN[]WO =W_(]W_1=W_9]
MW_B=W_J]W_S=W_[]WP >X (^X 1>X ;_?N (GN *ON ,WN ._N 0'N$2/N$4
M7N'&G0D D.%BL,_*D.$ @ 8FC>$>/N( $ -BH S_C 8E?M$B?@,SK>(QL,\B
M3N(>;N(H7MPQX.'TL,]BX.$GG>,TGN$W, DE[>$WCL] 3N,V?L^3D.%'GL\B
MCN))ON/ZW.,9_L^98.4 <.+Y/ DW4..9H,]>#N8#;>0SG>'$L,])'N1#;N'8
MW>$9'N/Z/.-$7M)P'N0>'N;]W.0N;M%:_N0NS><<CN<DKN<#K0QB8.BLK>6*
M?L])?M):CN<Q .@,G>4!?><;GL^1'N297L\:SL\]+N>,KN8^WL\S/N)I;L^;
M_NGWO.I;?ND>_][I,)WAC:[JA%[CE([ELN[FO$T,(Y[K^S#J)>WK ) )RG#L
MR(X&*^#D>_[J%0WG/5[G,-WDNV[/Q)[K,P[L_,SLKOWEK([/=PX )_WE-X#L
MR$X,WE[M"JWB??[//6[E^DSNYJX,Q( &0 [B]1SJ@U[L]  )0/:_[.W.#NXC
MWL_$CN_*\.4P$ WY3NOU0,\J_N&V7NP+OP\-C^_^_.Y7+M/<GL]?KNZ(GN'2
M'M#LSNN_#>T.G\\E[O$F#>>I?L_0\.TAC>$X, PK'M."KL]P#NQP7NO^C.:O
M;?$ L SY#.,77](]S@55GO$,W>1R_L\&  #*D.,Z7_3QSO/T3.PZOP_$GO!6
M_P[T^"STXL[/&^_H " )G@X '[\/30X 5+X/*&_/:;_V_-ST3\_O,4WUF@X
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M90,/+A0S42& 2= F#000(Y/$A1T_$AR9<&$,C0-3)E0F$.2-E_LR ;BA$>9
M8CH1Q@"0D:+,@3<B(KP!<B":A/46$C3H4^I4JE6M7L6:56M6($:,=/WJ%2R0
MK1(%II$45&-%,2<G$DLZ4$Q-B9F $A1S,.' ?7!!YJ4J4*C.@6GJW@U*UR9B
MHPF)*>4;6.T^BQH%2[T)0.\^MVMY)A0X*>W@G6TC^WP,P+/FQ3E; NC9FC#L
MJI<ILY[(UZ_<S;?[Q@W:V^7$E1/M@HP!6.)GGP)=Z\S<>S%RY:F52MR=N.QV
M[MV]?P<?7O_\>/+ES9]'GWZ\@QP/<#S(P=[]?.ZI]PED2C'D[9<5(8>4+K/_
M!OL(#<1 .@JURG3" 8 #$/J(* !&2@N'A#(S ++-(E1*L8EL2TVZ @^$**$1
M_TOPH^?VP@TA 2$C<#*=0O0ILV'J^F\IA+B ["C_((M!.O6&)%(\(^* XP@X
MXC@R22>[2RH3_S1:*)/,S,J1+F5(!&DSE_X+<JJD5M1O0H24 4XITB1$[LS_
MJ/)/+Z!(0PHGJ?R+;1\\-?J(I82BG)*X":^4*BTR$5I000"@H2HU1J>*\R<9
M67R1("\G!/-2$>T\D\N!Z%FN18V2HE,BH/SL-$< 0/T1)-"R+#+_5EEGI;56
M6V_%-=?PW&//@?=PZ#4^[J:\"56$'F.J1#TM3=58_P:+:4$!?8Q+R)UHTVB9
MAX3*+(9H]'01@##<Q"FVXW#K]EMK)\KP): 2A!#!,ZL-5UDT!WHTPM?R?!8F
MF?3J\\Y$89KDU&_)A?9?%C?3AZ#8MMQ/5XEI9=+)([VRN+O0]@&*+J X.^TI
M-.K9QZ/A5&+.I@P'0TZOS/)K;E*)3@+U/F5M!B"_U%[*C&>9:XRXK]->+54B
M%7*6B%2-@)($2\,ZGNCCSGQ* P +7_/PSZ"E2LI8H%&U+S=F;=(1T;%?9C'/
M> =[*L],5@YU79L/M4FFFMJ^$.YP21.9_V23S9PX<,$')[QPPP_G+EC%XWMO
MV,@&3HKDDP4*$Z:'7J+\-8!/1JB>@2>*E*)S-Q=UGZJO#F-K/8'*[R2YC0-@
M!9)4/ZDFSW&K7:+;8U-1\U>]OFWS<7UJ5=7*$<I<;$U_?_3,RQ&'OKNOF%1#
M22"H5Q)*CC8BC:V-5%MV>XG20G7/F64DZ,.?3>44.YF$\H^NM !89I_1/BS(
MQ/:G6@'P?1KVGZ3HQB)X$>I:!Y/42#"BGXP\92JI&Y[8X 4[;&$F95+IWTL
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MH8Y>45X9HKC-6\IVJF72W,P@+?897)&XK)+I9R@"F5'F&;-9)"59*]NB8.=
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M+%[CVBT29J1/]IJ4Q:LWF6-0;FU&PB1X%6OZGNR.K.BK&*Z/V:?PE9>G"FM
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M$ZRS)M6D-%.U[+31OU!IO0S-"(?,%<$(]:,N4U.!G&B\#3VUL-9CD=VPT9$
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ME] 9<B!L5.:=9ABLY!%DFCIJ3 C[=Q ''K-U7;SF.;MT&\X1!49Z B2>)(E
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M]6<J;2B4E&JD-4"!LFE-<Y.V@(C;WNXQYBP32)8-%4VJFB0K+_"NOG2^PC*
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MRJ6=O)I ^ B-?H1:S:WPF!\16C8RH:MGWI!H2*L:I'(DW6I%5%:J"EY0:&*
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MP1KS&Q\MMQ;]U:N!5/6P<AAVS* U[GZVM&]R#X+=&B]F(/U!KN.^AS<5XZ3
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MXRSHN%N:R,3UT,>XM$A%I$BP)$:/" ,G!I4 : \<,(!:UB(@3-Y[T8G:22-
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M=ITP>)CXI!58#SNUS7)_B@DM1V*7SKZORY3G.]]4U8#3H,\6)CN7-MTH];X
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M;U5-F29!X[L7#8P 3QVB.1#CAN"?RIHR;BS989K"PWQFBF%@TN3.GC\+!F
M-.G2#@N:3OTS+]ZT;!W$;4GWY>RS+3M20&N;)4?5G3,!K]<X#0 5 #)"9#B1
M"^I]R1<6G)H0NL'("@\3HQYY'_6",:!G=2B&ND2%U+.:-U@O.W7.^XA[]9W1
M=ENU>>GBE=V:M6O8(W_H1Y]>\O&U1@0[1)!@444=>& <@HD1  Q?321A>,H$
M8(!T^TP"P $-"12 &/_9'0# AB&&H4E! 6RWCP$KM!C BH<Y)*,8"EWE4(D
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MVX8H8S#_4X6=;P6D5>+&!)N)Q%='8R/-:R(V3!==[E,=\%&K]2HQDFC0,E0
M@&.E,5SB.PKP,*L<A!$0.'9DR'(>MSJ_X-0A:/C73'?)D/'"=Y_**>SDI,FY
MPXIDBZ]!ZN9<U;DKC02,D>.D0X :KB=21F%N(J6%"$A;=)J5:Y%JU%7.@C>$
MQ&6&$4L+03:4F6%<;,,ZY&5:)+&78-JF41D:IGT#()2?G24&C3H2MDZUV,HQ
M=Z./=&9S[94T74DMH=>E6B9D.V&O02QL'\O?AO%9D)9!",1V$W$ "-*P@FA"
M(&E9K>J80K>0P7BP-).E0@2"95PR"E),X?%Q$ZJ,3.QN.4.A_S-\C+MGATB)
MHTRUTJVNJ-$I.=4DT?12#I2KR-E =+*IHN,1_5QIA1PY:406\JZP6-2H_9C3
MV6N<@6*RG0  0"#=??!B^B9AWFI%K_M K>Q^U*2:H!:M122H."<DD 5JIX#[
M;)10OVI &""0(5,!44-R))"-L<JHGP:R1"-)'\=63]-&SNA))'N;)_EJ$F3%
MK<,\!#:#TGI)-?'9KW_:%EE;AR$B4I%"(OS:_2ZDWD6),;/+UA"57<S2"%VB
M<@S&'0<'7#-]1O@^FLII*BV-)1)YZB*AIT@?M^1 V[3))!:4JNT\;N&6YC1'
MG2;=ZU%ON3]6VG/S(]7YQH08-Q (&O^,<^K%>3GD'WW Y60C\<3Z5].[HD#F
M6-+HE>.*(MAMXC!NHO0F1D,@<<KYU"NM'C1,1SE43XS"$?[CC8::>M:>'K4M
MGD5I/^"C'4RPJ7J:<:T3%]#8_CDDP:X?I%6DX1UY.#67)M7N[40XN6:5,JAR
MT+<OCZ.%KBACPT[V36N[-4.G8D<:JHE)>#"AFJ+TX3D/19BNE^N=9_"J0]Y,
M 6,1[X.65](F_WBB-W4CUKU)QTVUG?J*WK?*98GK25[)E2^>J/.RTI ICF0%
MSYDA,<?P[C:_)B,9 -FX1Z(4Y07\_DZS)+5"]-B+_^/\$!N)M[D:0I6!95=+
M'_T;%.X"-TG_^O0O)/26_KJVO>_ZQQ]]^X;V**0OO_;W_W\FZB]?HNFHH(JZ
M*L?H?F_N*&_4_LY/E$-&E./;4*7\C@+D '!QM@US!"W_>,^:-F+OG(>:**C;
M,"^,\.0 +A #5[#V"L2\LHX%X<_]$.[UI N;4H_0Z.^Y)DKUH*8BW Z*K"8&
MAY!Y HQI"*VHN(1H#FNQ1F[QJJL!;T\P@ <AVH.SB/#_<L"9&@O;)H("$$U+
MQF[1F"MZ ,3ID&CCL 8+UY %[:P*J8(WSB\&XZ_2;-"IS.Z"C.; BFSBG/#1
M2A#\V!#]3N\T*&#^Q/ (>6Z"1/ 0P<3OJ(J^\,)X"DX%I$X0<0__$Q:K$16Q
MN08,!T&- 07N\@+Q$DO_L?.@09?4P_ @:J%R!PAC@@[]3-&@R^@L:M.6\#4:
MZ>(6#T ^*@U-$0"I3]LZ$8OH#NC,+LA*[O02L2(F,%V4 V"V0^H()%QBA!2!
M,>1FT8O&D ^C;0/K3K&<IQF3K.FPT1S1#[@*+A8U#G8F@5CT;"?6D<Z2\.*,
ML.(820.AJ[$<;S32;A3/$?TT,+J6$>7LD!.O[_JT"" 7TE<\+0^?R0"OIYI^
M3A\OZ0JWJ8.ND2$WTL^ RY;V;#?.PC@L42;D\;@4[YD&S3Y"<!\OYUYH)?]8
M0B-%QVK4D".I3@MQ,,B<< .US],P0A<7$!'-\":+4D (3!=;(@3'KAYCTB A
M_ZLBSG"#-H[VC-(J*PU@CBM%[&L&FZ4K+<TB>7(H,PWB*/(@R40_TBZDKC+G
M!%('D2X,I8OO(A('Y6XDV!(O%P,7$RMZDO G#TWNNA NXZ[O$@I-_"\O$U,Q
M=V(W"L,DB<OH1O OIRLE4PX7.Y ;HQ*B?G$Q*TT8Z7(B";'ZOL[W_E*+OF0F
M.U,Q)R^;A(S0B-%S^O(6+>HU4C-57@)K@"43SD(?;%,U?W,C\<0QO[+2]C!Z
M4)(GN3#0L \1HXK_3! X?8O:I.ON:-.1K,@631,?BR\ZN_/2&,\R+<YZM$\L
MDS'OL*B)E&$2+H\]T>3RTB 3@L8[Y[,H=\-<9N(Q?=JK@I:R ('.D532)?GP
M7B@",<-(R>@3HG! / ?2&Y$&BX@O-K<()H>LHZ 00563/Q_T \G0.EWSR'#E
M(I1++C$"BNP,34[T1"]410%R-U9Q] ZO-1?4![V$-6D%J2)R]RI.+:%S19NH
M!C-HV_"/$W70/\KS-7IT,4$'/.M. 043":?S(AP40IW&0-W32N\32;-T"/V*
M)H#J\,2N@IY)2OU01K'(YQPO[(YT,[M)2Y'H$)>S1D73T J,$5NSP'RS34M1
M0??R2>O//"EB3)]2V_ T5:RF@RXO$PHT3_\7M5#4$PW6\U&;K[>VQ46C9:5P
MLC2%KZFN[49]< .Y4))"0RK#[Q\95704T2T[+:.JD[&ZA$][$$BUR52+4D/M
M\',XT"6);CFCYS1S0.#0A!)N0E%GM4V7 JCRLXD0HE*]\O!<M35/D^Z4*D;[
ME$,S=2,(]52:8QDZ3C?/ AJPE5@KX^'J,MJ844A3U5KO$"U1+EPYT@<L1U,[
M8RE'(BA%,R%?[T/1] A'=7+:<S?;=59=T,%@<,^,55)AD3C]+":KK5:;DTQG
MTPOALC1.L#TK]B8N+RL!EE2F50 9-DZ7IB+&=>>F;=!00V,74E4'D^\V53)A
M+P?U$"3J3/PR]F3_D?0Y+/8V*DTXEA4BD/6CI LEH;+L*-3D:A4\<85?&<<F
M3A11$343DK9F+2,G1ZXB@0Q(/[9A=5 UP!4.C, (NO9KO19LQU9LRS9LN[9K
MX^!LCP!MC4!MTS9LW_9LS99LP]9NR19J-79/K9,']=4U^+,_A/)-(<D9FVAI
MHW91,<,F TZ-(N,&;B &2!)A#R\STY0)M5;3[A$4[W*;=+-IQ0]+$5= &,M)
M*Z(6H117$U(@/Q&Z+K(PW!8(U#8.8A=V99=V9U=VW59W<Q<.V)9M=_=K?Y=W
MC\!VB]<(UJ!VCS=YD7=V11<BEI$L[?4&1S1EL:?X^O!Y-C-OG?<W&W/J_VRO
M/8;S\*24H@A0VGBN6D6#50'L: D-7%'%4-O3<+AW33+41JE61EOW5F]U'R?.
M ;:7(=Y6>(,7;GNW@-F6=H] #8Z @ =8@ U8=W47"'J7@'47@A_8@G^7?OTM
M+'O/.'_R93V1?8$6>@!X@T^8,GZ#9]_/9Q-47EAW&T5T-*_67ED/>[NHVS[W
M%5&8,OPR70,T<,,Q54ES2!.#@&GW@B=X@.$@" HX;)$7#H  =K\6"! X>1?X
M@*-8;3,XB[F8APMB:.JU4ZNW-+)$(E@N7N\U=+Z8C04$F'(',FZ "R!W"%NX
MH?:T;TEX+Y447H<TU/;#A#_H1&FVC16#>H_PA9\EUCXBLWGD%'KQUP&&529F
M%X)_MXF-X'<1.)/3]G8;V( =.&Q!&8J7^))+N6M-V0@D&7'/=&B<M "9L7(+
M3#L5*Y(+V98O S/4T:?F,&'WC(P]=G]E^73YEB_3-",@:AG$3SYOF3*,%$P?
MMAMI6'WG=$R,^(&16'B5N(L?^'>WN8+55@TJ^'='^9O+N7?9N%>K=4'I=&4U
MPN@NBI'KA9G_YWGK>"//"'8%[3BAA-%Z?SD< ].&)5+OH/(."Q>*;&*9Z3DQ
MRA5K_V,6[Q#0= ^/B72"JG(GT):!+]@(L)B+:7>!OS8(PI9VH?B22;IK1YF"
M-9J2EYBEHQB=5Z]Z[U>:]NXR%?E5*C1++%JA=]HH]1FA@O0&5;8_^1=6779:
M>XN0>5HGUMDXN]!6_Y/0(/J71>TPU!:E6UIY*SF+?;=K-SF"!5AWL9AVXQ:D
M3[JL8=> V7A#X=7ZQ#%?-S=67S.QE)JN>[J7Z>SD3C=.[]5E_VN(L2^0ZYJX
M**ECF?I<@X^8==)>P96L*5EYIQBL/[F FQBKN;EWPUFCF3BEO7J _R.8C5W5
MZV;8@PV,&?V:>O=#E05[IY6!&%C;M9>HCN_ZN+8QC2TR-D_[24F[3DU"M3GO
M4\>P;QURA'^9T:"9<ZLZK#%9LCL:G)-7;IGXK)$WJS>ZLC,XG#%8;;%9#5XZ
M\6S[<X0[0AU/M+G/,WK;O*O02WF9<HUZ-,38,VB:P,"[8U?.^,Q[ZD84_SCG
ML!\RB,NR>C_"B.$6@R$8>;EZB968B[G8=STYI+,;@TE9P'4WL$TUKN553J4:
M9$VS[N3;\2S4OI7:!<-7O=].:#%<76M;FH9Y.P]0G?_PPT-.+#,48I5Q[F"8
M5T>P'Q'#JLEZI"U8G#<[K W<B5=Z;+LYF_\_&8LO66XY^J4I"#D'5[\_.!$-
M$:8OZL7I^D.F@D?XB0A]>IMFT5/_6P>;U#_UE?@@:7&OW,]\SI&?"[1;7%<A
MN8-E$C'(&JMW5XDQF[*[F+J3%WB)7,F]5F[E5G>Y6G??=U'+[BPUM4A70L99
M.4S] ^/4?*<5UT:((CE4D(5EF[@*F[0Q+8^9\T^]T#_1CM(13H_+O&17<E?(
M%T1K'(BY3<>3.[(5V-"7.'DOVVV-O("Q^9N1F+*#]VT[68._N)%MI="DV@/3
M.3.Q[=056G*2 ^LX7>N\/(SZFA!E^:\I.C"K]ON>7>2(6'^1W3@;&I*U;<*C
M&'C%^II5VL>_.FXJM;F3L7G(!3UXK]O'KQL(V/B=&739"?N"%)M3,9.JT^5A
M_J+YZ.A8#Q;<_W$/(7[".,B"CF)[O</\/$L=D>$T$T\N5QJ^#HT12&'S>L]\
MM,/[DA+#T#?[@(.\:SN9R)4W=Q/<=GL7P7'WK+D9BXN=AT'1@NAR79UK&*%<
M3=/E6K@%(C[A6#%#TST>_:[EO?2+XM_.?D''0?47VYW+<OW](R:<Z2&GG4M[
M+H6^]?H0!]D\B^J[,." D[';")!8P5L>R3.8K#-;YM?V@"?8WBFXR9_9&ULV
MEK'IP/Z8(/D#T16CIY8C=%GG6'>XZQV>,!(D7!(__:P=BLHSA#^"S3DJKC>Q
M#).F\8]K/$E>U.UR95/#U5NR)5">B_?<NC-:@3U9[G5]I?,<>.-^>/]OGKG9
M.*B1$9(G\F5M/*_CV\53Q3O<XEKN#2*2 QX_'P-KY,[$8.DGG]I[2Z!7EWV9
MLA!+?-#&1(;]FB(*G_F9B4+GO.]'OL)EDV\]/.U_/'BUN:4-?8MW7+)OO:O#
M^?4ENXJU&/9?/K5K%B!^.,@QL*! @@]P)%Q( 2$.!PL52JP@L2!!AQ$7%M1X
M$:+$C!6C[1M)LJ3)DRA3IHP! $"FD?H"M%2FLJ2REC=JZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M&?+IE"+8OQ8$:35CQ:S=B2H,&O$@EVW.J#Z8.R#J&C3JEW+
MMFW1BEP3@BT+U^Q#L5_%=IQK5JN#C6$]SB7_&L?(&B-P@L Q4AC.D<5 ',,!
M4IAQ9,.(%2-FO%DRXL></1<&+?KS9C6@01=VR[JUZY,% ?N=2[9KU=IE]=*^
M"CBWQX2O]]U\2I(E )H[6<8(SKRY\^?0AV::A&8DL>C1B6-O>M"OV-MR"?+%
MBGLB[MD.?W?5M[V]^_?;O?<^GS[N0XYVU?/^'MYKUWI#D:::$:@M5MB!GQEH
M1&H*(JC9$0521N" DQ6F66./24@A:/!U^%X.Y]4U55;ER1977U0UE%]>=O6W
MS&O# 5"2&"U-LA,Q+57GX8X\]NAA)BT1!X"./JJE79% C4<7BWB5UU]Z7_47
MF'U7/8GDE5AF:5)'__B)I:)6*E9YWY3S<42!?+4-1)2"G(4&H8"6>5::9HDI
M*-F&:G#6&&>H):A:9! NJ(:6A$*EGE],_M87E28.I&*3OEGE5V#!X7CD#2V]
MI),!1Q;JZ:>@HF1ID"-E&NI1G9Y*$FX^X(<??2V2V&69=PF6:$<OJJKKKFD)
M)&5_\E&)55RMIFF?8+JY6BM!T 0HF6:'C=;@91@6B)F"&RYFFF<"EE9GAACJ
M:02OY*K$:++D25H?HE3M9FQO63D07(PSMB2)3IFL ( 8Y?;K+W8TWC#<2#0N
M=ZHR,1#Y4ZJZ3G7KHOF=RU='9,DJ'[SBY?#OQASOY*23$+OKV[$.R_<K>#P%
MK0FHG=<>0:"X;MXIV<K7*@:NGWU^F^!F&"[&9L?EDFG;DRU^G"C*8DU,FW>5
M L!I29@&H*E*-!X']-7_6#?5$H#:,4PHC38&Y?6I)PZ]VT X5("Q0?JE^>ND
M(UM,$'M9U]WOV2-F'"RR:R=$4=Q<+DMK?P *]9C+W@ZX9V$Y:_8R@HYM>WCD
MAWEK&8(,&G9SX79_VIW)P\IV\MKHQIW1VA7EVAJ])%6=1DW0D-KY[+3O)*2,
MI>(.:M53+ZP[N7MK!%Z(_15O=.C"MGU6[<Q[&KB2L@K^?/(4OUUQ]>RN^5F>
M@39VH:#9,G9X@C8KF*=CY_\9^>* 6MLS8\T3RBY(APH;:6##+TU]T:=?-"\
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M5::0Z:V.PO/-]0HY)J(1$I?0=(U EODW_2F2(AODC_]9?* ?$F&S9)P#"H4
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M!L?!D#@8&@?#X6  S@R$,X/CS) X,S3.#(<S W 1(%P$'!>!Q$6@<1$X7 2
MPX)P6#@.B\1AT3@L#H<%<$L@W!(<MX3$+:%Q2SC<$H #0#@ C@.0. "- W X
M /A?(_QCXQ\D__+Z9_S7"C 0 (,#,"0 0P,P'  # #,08 8'S)" &1HPPP%F
M ! ! B+@0 02B$ #$3@@ @"P(  +![!( (L&L#@ "P!+(& )#BPA@24TL(0#
MEOX7[%^C_6/['^3_ZOZ_P?^_</\DP .!?H-$_J?\;R9 8  D"H)H^90-1A'"
MF$Q1N_%*<9212IZK&=&J\>J"R.':%N@8)RNO-[F5 ^\H*9>)M^&$7Y5.GKIV
M7HQ0&WBZ0.;I7G%=]A%5L5!D$]W=@L!<I4;VH4@OG9M)E7(Y9>Z=?^T2UC)Y
M9Y-4LF8::I%,+605$[7,R>)'4W>J6K\&5909(-SH;%CN]G^P&)[<U6C7%7QP
MU_CPQ_TG'UY=TR@V,%WN]61PZLB0AS9:%JD)VLS\YO$_>%W\:&4KQ4KD^&.%
M6+!,>.C-:4^YE6M0R?.@LXU._P\R)5;?U[?[7GT^?&3;_=_26&37EU2%D.N#
MX6S&9Y1O[US.5M]X?)P)[_M^L=.?##3JOWP;"GVW\-HB_678W?>+SY6O#?K?
M__GUX_HLV.3UX^> V@_BL@B GLD^DN"J9B>23&9\)YI26- A@K:7>S>6SKIV
M-XXMZ%B#E34*59[ FX;:B^>/JH4FP3K']Y+OC_YP2!8.NLE49_",<=)0BLFI
M)-0PM1].9Z;_Z91!<UN R2#]8Y^I I.FJ])3^6MXD*N>P#M/I>VWAE%[S'2)
MGP_S153I"='G(G4?6TT@3<0)Z8],#9:8<TL"MNM<2\,D.UQ=%3K,LLH\_I@I
ME\=$+>99^8J2KA!YN(%0F.R@N+PJ)R/L27FN]AVJ*NA)X5JY3-72FG:E'U(8
M4CN*$48V9@%)# WU["RP^HZ]PM/&MX?K'M:=,RR>UL@3/HN6$'0@"C&9YK+2
M^E%^0Z2MR9CL2_N\QHLO-5E(UOS:Q9<;7MVP5%8L)@YZBJV(K^J[CSGOG1)Z
M^^J/-*RLF@^Y7)<WY+%24_=WW^UIE=7DAKN7:/R)+2E9_M=!$AN62VM:P/!R
MQ =1+#'":K-Y^:P@COQJG 0P]W,5H+ULIN*%D^=/B%6RM4W":S:9(6YEWZ-9
MQ?H'6S_B!1WZ0[S!7SZPJOU("9C1$0AO7]#2++E9-+[VO%VTH$WML%0@KNU8
M(7/T*HNFAEH&Q5"8H[BCW4U6B6)54YBX$M3>>@5OA40S=6UY#P,E%7'0"L&0
M1*YY[CTV%NA%W%Y"E\.//4Z6O[)[_O8J/0?> :T_^.)>S,<=%<9?$!$3YY;.
M*D&,Z#)5&L1.>E58N4\P^8^>"R%5K2IR,+E*$8LOM+SW**N*%$3-E-'WRZ6R
MM)J)7\_KBI2;'EXO5LIE7ZW^"OUC[*9_X/I:G[#C33F(*LF]S(<R=\G -G3D
MI>'3:3K PHOFP*UHAN6\P>7'\@@#4A=A6EO,-Q .\7F"ST9WCZ)VX*]#=21Q
M0!D!C];@Z_81>\;]3^-JG<UQ@T0.PY=E8%4M-NJ7S3&=<N4^NK7B=!JCL?6)
M#I[B*";FJ-$H:?)IBL?'XAQ1S0Z/%0J\@(B"/ UZ!UOT6GZ=PD%=EV"+Z;U?
M$[2N@</&;NH6?@AZ2R1^G7 GGVB#M3YC>6411-Y3!K5)$; LR[&_>2Y_X$85
M]'RAHVX-XO;D,Q7+<"O;#6A:(7P1O7+HW_;S;8.B2!'55-A.G#H-'H54-"_/
M0Q[$7W%C%SQ'*QYX8NDC;V.7D-]K/!UY\.:2+SD0QR)AL<6RKG!4KL>"89R"
MFLZ D:"2?P$K^^]163*A-$HQTNID(F)=^M 9BOP(2(HXA(>^@QO!8<2NGG/#
M(T 1HZE2 <[R">A+/A_7X(@L(1QFSN8B/('R3CS1C1C@YVW<1SB2(N2VI![>
MS2%>/I[(_&^6 ,B3F% /1=VY6FS>\+_^C3 P5>8B8 7G_%RB>JT/R:?#0S60
M:;O;WV\1[./5KDN.(T\ZMM9KXV<1:8F9,CMPQU6!1IMR7^H\N:]NIB.Q_H;<
M^\9(YHNY'C-23.]+CM')/<:J;;."YY!),ZW<)6S&Y!N+@R1SVQ@]!-1E9$C\
MLDX?QVCFZK(DR#^'L?T]_50RUJ2Y5-CA*[0> @]<?M68:^(0MOA,Z]:\I2*P
M294."KJ]:\[LP;W!3=0/W9VV#+[,:$[(K1\9)1WBD.]L\2;W9,;OD\RF\,HJ
M<[::4<MKS1KDA_]6MGK!U0._V6_(Z1=:CPPB8OPK2.%J^H)E7LE#$P#"&CVT
M%@J]?[9MX/\YZB2Z:N2 3[3IJ$CFNJD>Q-A:=5ENS^<Q7-E\VJ_FZK<*[NTA
MR-QCZX(.HFM[)F.*/T,MNJ]4[J.][/DEC19EY7G;_+PBWNROE_5,<NL'W+LT
M.M'ZSK-80JFME)$ "5JA7LET1ER0FV0'#?.F1-1I-;/:%137O >G"[TX<E[0
M[LS_>,1,)4"!H+VMUN23CJ4*,T5DU[@/T?UL^6'E7S?1-1XO)C?]WXB,/@FP
MF)]-QE'%]^ENDC"^-;O'WIU_C13]SCP0!I/)K=-]>?HNP$S<7OU6M&UOZO&;
M, 9'0J*Z%W)3%MS7#"T:&N)4SM,ZON-">93-0!6$;;5(PGT!?]DJ,CAH+?,V
MQ8+RCLY9G5>_2Q&L04WY/+8WT\'-[@?S6K'&W!NTKC?+E*ITG(]#>B-EH$SC
MB?[3([FW#N<8S3]K11/G#UZZ,'OVFJ\OUVHN?=T5?7;0S;"1M9S>'FC Y39U
M=KGZ33$10\7S<WQ#9Z@S&YAS=A-SLVT),<XN5EMO9CUYO<8/]BR4NEA;S]L\
MG<SJ;1O>Z"(\DK$/0GE_?&2T3Q1?X?B\JT]24FSO<*IBK.[8]]@E\[E'.S5>
M%R44XS0O_>=%)H_$1#&C<DBD#2/?]AHEG^#:',(]GR?'618A=F*4E^&ZEW5,
M&[*]X%/D+FG0@[+EDP5.)M#'$[XQ?L]&#)A_%B6XUC%.K>K_),MML2U$EMDE
MA2GE"C[9,1MN+Y4S.<#2N:8M?6S$:H\9$C#EE,O?"L!R3P<+=XUKSIUKGK\[
MLS^ZRQ&X$]>0)GI3)3%5MG$:T)= [Z!1<^8@\^%6G-$]-A)Y#GGM'MPBUF)O
M+=7:Y"/[;13\$FO;,<6H+L_89KADE Q@*SG>A%3D+UUB2.^V/Y,NC@4;74?+
M5!P#]WX&_F%N\J%PK(9Y:6@_S%L45W5RSFP;GQHBSU(?"/<^%K36IM'S:'@G
M?9$>M[:9/I_=<,#,6R7CF7O)D*5\;2#D^D+SCAK5*<>SL63LYF7ZO#_WY&43
M\ G)W.63G:"2]#!C.PI=\:0WDG(GU49B.OS9U5W6N_?#!/NG6U!<.:-_8;:=
M_XYLL3])SK7<S0'17VG>/T2\"\/4B^WR2A$\33QZ;RIYKQ:IP:Z0DT4^!HF'
MYBK\SO?X#?SX^U7]KS *W9\-1([Y.ZX=)%<>B83P3RY$"8X^8M.D>S7OI%.N
M*-;"("- %W7E]-W?B2+7:>>S$[6+DV2F_P^X82Q4V(O&>'-(D:<CF)_>*6]0
MR5K6B'(1:5N@O.BHY+P2F]IE@1102HL20P;'CE\))>*))H_!_EX+!W+#? F#
MPB2"N2)1B1+Q0]S!G,X!7)C@2"96CN$@HL\A]^'FQD"5!5% 7!2Q4FBNNZ)I
M(GM XJO<1!D,4DXM!'.I\D:9Q8"!72*'87@71>D4 ,W1F+I,XET4KR.R%E%]
M\?H67G$CY=/.,9X)G^V$AV-LCHV2/VAIHIRUTF-2OLV%%9AJMGZSF40A2+.\
MT+Q>\_RV;7/28^JIJ6I2Z]5<UMG:*'';&7J=K3SNCP<R'JH/F(8XMVY?LE00
MS!UX<[>^^LJ?SD>CF]ZFFU/Y;(-0+C7ZE624W>]OU @:G]D8WGFIAV K/26H
M/KE<5(,_!.CD[?&/^I#-T^%/\YB;9K==_Y2 G\/"&5(=S2OAP-KI)_J=1O30
MD#O?<'6![O/UHQB+&+][)J0 G_,13PS"U9D[5A"CZ70_TD+ A>'7E1)Z/N:'
MHQB"D35SW/]1E9(.4EE2.E?$)=>#P12T;V2F):3,;&*<<!^EKLIY*U[EP)R(
M8I/"A.95F 1I/ >W(SU=&)T%75EB\QX22\KRF80(Y7M-W*_KBE49OM\3Z5K=
M(CQ^&=^<:7X1%4N\J&XB8Y;BH&35KEJ)%U)&9)F;YY:::XZ-%^?:#RE+3+0?
M?NZEYHXD2(YJ?R%'R]:G*=6I!1>/MJHRU0J/D7JVB!!S"G.4L&DC9&^ZE?++
M"1]>D;K>14R'P+N[$),/M)XL,'Q<#2<SMG;YP&4=K;F:8#M,R$T_5'+PW6N:
MT&X3^/GD)_C!W,C+E]=IVR/>7Y!VHE>RW[YQWXT].>]XAMNWNT)$Q)D\!17(
MD0KZ$.Q2D\OJ\4K84PO:,\[QD9T\ [M#6"WIE/TR*8+U.VA]W8RCX D0$<UL
M]DY:=G2T"*1\(YMN/3H:/NY@+!%C5,[_\YKF^V*TT5R%2:W XVIZ$8981<O'
M5<&55'S.XN:/B;*?QQ08J7('$'PV-W-C+FU]',ZD;A42K-_[.$%3+.]2T-6<
M)00OV );96!FS!A+ZRO!X+J4_:Q;U%R;"75HGN.+2=X5$I9R&;VJ3A!D^GL5
M%-K-9A(;HO\3\X?&PF#%) @O?P8J] K-C!E3N5\IKLXK&0^<2#PR#8HG82R>
M%[W9P[=5#RCQ"[4W"ZV3,??K2JIWM5 @L,CC9ZLX2>*ELZQ:U\RKL&YV<<?&
ML@8%L ^M%7X8T]R6Y5!236Z-EQZ63=%JTYS4XGRSQ!%Z\V)ZU?IZL'CM).PE
MKW;K-ZDMV4:G:ZYRM;3\Q1(4O@X9%+K'J .]*AFXL4UJ*R6ED7T&;TK(+KWH
M2O^L+GL]YOW?<[L]EU=X:^E>S=#\'5V1*&J%"GF&2/D_<3R$C)%$KF5:4!_Z
M1)I[@P]U:1XRU#P<,.&[X_6AR,\ROGHH8&E(U5$A8F6XR4-W'E-QXE\A0=S*
MRJ(X"Z>_M^\82.-LIV6R-H\4OA0_!. "R0FT&B3JZMKYD2RJ9B?Y?E5*)&I*
M;DO(:/["E,2:S-Z0HG65"FQ!TDFUOD>-:4U"@R"24BW8H>JQ=[OP5!3*E2DQ
M1#X_R=H<0ZJ2O8[145,U3,ISC5?-=D4+N["^$.Q,WE56I.O*BH_UDF?T&PW1
M7\$\HDNN=DMTSDFLE'F1S8"J#\8^OZTM%68?A:BDC6C4!OU;*#UE4BG2JAY%
M4YK=<>[/]K';!9I4)EY)P])5'9H?.QNF1A&S(5P]73:SH9Z-1.'S":E(5:^)
M6DUK?]O)V_#/1VGD>]KNE=PC.@07>:7'X[9I;0\^R]N=?T__,?8J(OH=P)0A
M."3'=65W1I9K]^G,[EK]/1%*#O 2AS!9R*_QVE/5\M+)0K9-?4B([36,]2VB
MRBA&(SE.'(;PR\VA_)(%_/0KT3:2?$XJM.I&#[E6HA@<LJ1"'05(!?%R!.0U
MLQ]L5 AC_2#D&+TU1Z-NY1,5!JND6'=EAO_@%@C"+M\DEU0\4:YVXWB\MJ?,
ML2[T=!KMQD['E:F2N0$RN>IW@_^^>U25@J]:,-+JBBQT-<K(O$!9L<!:?V93
M,\E;%8V'(Z$ZB?:C^78C(T7?XW6J+547A2F<1 +R&1[EAJ!76&JSF(JX@TUP
M017'-?69H_*F&A%'*.)*EDYNU;]^Z%C?;N-NY=A#R^[![I95UH(7&GT]DGU"
M13V9O<!*9-%6[?@KC'77B?3@M_%<7<YNX>*_+1ZCUEIM+%+]&\R@BKX3B S9
ME70;7T/J8G@E;&JENH1F2(L4^I:5YN5"8.EQ"/3XA^Q.1SI;5--I7OI_W[RS
M_:$3[;*_-.PN1I^<+J7CK[[;G8).2%'C/Z<F)+-GSVP^LRF[J?<Y)N GJ+;O
M4(V""BKP;#SD!"O\U\!/I:"@OF=@,^1 U,#/(/)(QK("QM)Z0U#-=V:H5$['
MBD/Z7-%%H6GTAMOT-@T4@@3N0YQ<\>CD7(-H.]JTK00%1$(TBG.KA6<?I""1
M-4JUW^F]$N:UZBH?!H>P#!LZ:RE[5<<Q'\Q9"0;[D0E)D74!I15B@%^27F#2
MDY6J:(]X7G8FGQ=*NL_'PA*K*I8378B"8XUJ<X[11?FUT2=Y$60LD5;F#MAN
MLF@UX-[S$DFAW >A'N1JOAWF<?PN)7D=]<?CZ-%QCIR>\,7"6>84OW:VHJJ)
MBTC)EG76+"F;GB2/4FG/H9^:<Q9]0_5P++VVWD+X>Z9PPCV/NI'>X25XY7X#
MKCI\_HYKJ'YJEREMXZ1O8]VKH5U[3XB[B4[V\#CMW?E;3FAZ)OS!?Q:R\R_^
MO99VEW)VVZSO?]0]^<G\OM1)-M__:?("$1FBF1*EA_=<OA;.>WOVE'4.P@J9
M:5NPATS.\&7RG@W[&CM^)"^BM8'Z :?7ONS\M*)U]E(H R;/"@YKYQO,]N6T
M8UA%A> +6E[Z0(EU?@7^Q_"XQPXOQ/#]*SU@)N*:;8]>Q+NNBCUV%??NW-&M
M"7B@EF"]J*)U'JB)4]35Z;!H3 CP'#+("PFZ&Q1."9"Y'7DZ;8)<"Y7,J8EA
M6Q3:%TS23+0-'[7^G9_;M>09.\QJ9ZX:J/0J-\B\H2:YVL5_?2RU;TR6PTR,
M;QSGD-3"W9FWVE%=@%7>SWNH-EYEC7W=TVW_=_RU;9\!;4K#<\\(WJ*:T,.N
MOOK/RF$GOO#!:K;%>,1_NV'A^]93O6QCL9/C,GT.3B7$CEZ?,\,G#E-=HDO*
MGZR_W2S9/O4"($-ID?AVXV2EPO.V-Z[>711/MCH>"+1"?Z'>Q5?JWH0^@T6]
M^9'W>N_7.^\(:J*Y#*+1,A +I%YUAJV9JOL]%9G,PR-;>XH'_0)X6:#. 0I;
MQZO-C[Q%-#P;OB_G:0!<N8(Y05G&63<EQ:32[%_=VH?H5OOC[1EC@JDR$B,F
MBIXFDNV%V0<;;5?X N+!<1J0G?OPG1GHL*F5N%5WV^,5AEFE+[^W_V,I(^GA
MH'A)C(R8$T[J''5/"GC  >-O""(3<_ERS\T2G.]<3>^A25!(3?'4F7;QI4IL
M>7ZPZW_^M>2+E!1W3J;JS?_A 40+:6>3(+']M+,R>V9V,3<)ML/P@R @IF\D
ML#JV^KLJ:KFF#%J@>4,T94@LLV6QV(3RFZYU_X..0192J%JP]^][-F+UGA),
M4E]W<U!,9M@T!Q^FDQ_&B&JJ5))/1FC8?U(.7&1>5+P>2JS_Z*Y9J=[WQ$0[
M]4F?^0<MT.NS^%+K>KRT7-&&P3O.VI3)R=[BZO.^)>S1S,_PC#>-:=YI_;^G
MWI.?LM&4^CGA?G6=?$79G9.<#CTZ_15O-QC^^CC6;DPJXJ#^]:6ZWM*3,_+R
M#(KQ,L)U>:SJ%]+Z&>X6FB-,) 61PP7;@(BE[]A,_W8;30>M@3M-.2FN9>:3
MW^&6[Z/5[W_N7RM*T'['5WSI]UBQG%$(CYBWGPHH\WETEW'V;. 30VH,;^YC
M?:U8.\']$",:[T)Z;::ZGZ7Y3W=WZ7S^@%H,=@8B'Y^3IQQ6CE-1/)81_*V,
M4<E,I&.@\3UVPO^0POB*SL@2STDUG?>Q>TK(%?=X+"^]>YC5L*-N @6?X_#/
M2^18#M,#YR3^KQ5:40RBDC?=F9CI= 8+ZV&KF#*E3$FQUF)A4V:5A%FBH1Y$
ML\MP+O2ARH%ES+YVAT!R\S"*'IK9Q:+DW5TOCMW.A>S>+9VM>.M"G^61$*@7
M>-I'!4QKB^S1'JF]%K/8QOUB$![ICCRQ3OEMV;88F71RFGK.*+6[J*;DP@?&
M'FV/^_B^GT#L!^QO/OKD"6P1B^YY<_8&ULRQKQ%[0V^)D,9-Q7):O6I)FFI-
MO^*+\D=M&)6=-I_?&A#\H?&-M@N^N_GP(5KWS7;(MQ^;2]?Z3VT5?T$W??U=
MTQ.^@N@,WX&HI,25'U"R923(K-I0#W$S!%"_(TXL^*!R \7,ILK,%GT=).0L
M%A^B.J&>4Z4WH[M4IML*F4N54\"HCN@P%%^.$C\K]M5@W B!C!.';\ZIZJ[+
M7HU#14%#49P%,5?$E!&HJPG.0@PX 5HL57&/ZVW ?-3]R(RK"6@A&XH9)O>C
M7(>GX;<?+G6UH4Q/[.S\BCC^_>85CU@;1LL@B0%;-A4K I::>RQP%VFDL889
M-P3B?[?[EZ<R403PJ),04G9&.B_D1"&(V0--==79<XST=&ZUN60OA/?$ATT/
MW);BO+W<N9^(%H*K9K[>HZA#_$J"K: ;:.H:RHT7I'G'H32)<V4*TTE@O:36
MT_MI?I.>][LJ.H2K4H,<3RQCTVZSJ_R+V!=;4^X<)X1M ?>I^QB6RG/BEK_0
M/<F2 ,EDNZ=/B[0[B\VC\&4XJ[<TT;E,1(0"46__Z)<O7TWK-74*_VIZD"RJ
MZ,7W]+$C]FFLVBB,/Y5Y>?A^_5Y4"O@ZJ/*GPLM/A6?"'Y_?40H5NO.D<&7"
MWC-WI)!4![U.\&*E%"^K'"))7<8N)#?IYP[6R4/G:_4> EB>9%&Y"\S"E]2]
M IVFT[^D-OKO3S.<]$]UB:*(WNU9^E6Z_25/.7]4=Y8\GMI!AOLUT#%H(W;9
M$:[4++[%HD9]A<<M]56)0'VS695R[==L*HF'%$2#S"'%9W1N@;9EF-E--WQD
MB3/FG<:J"R93?2,X[)*&3N+$2&,[GL#XN\SACU;$9S*7*WV> F?XS\^?]Z]F
MA,<:LKG42D2VI^1NU1:G-#X%^%4J/-C)-H");4G.RT^O^"_I;M2T&Q@+8!?F
M?[ OY?Y-9]'KFH-FZ*\K;L\^5ED3X\EF8<#3/,"WECBG!?/FMG+1"!N?8$TI
MYNC4C$?0?S+W)4ZP6MU7P;EI*;J D!8)DVX 'R2<8%8AL&R#]'JD(1Y#+D8[
M:(_[2U]8NN8B_0"3K.HM23/3CDD0B$YN\J9O<KQ-YF%-(+5',KP9;":PY22C
M<%8B:NS$C)K((*R<F_BS'_Q^QC5Y3*(GX\C1=SYL%^V0/"DUU#BS2"2,UZ9C
MY@G-SA%/EJV+W.M'539UW21SX/\DX.[*I2D_J;)@>:%K9KHJ5MQ\8&FVR3QM
M;**>HBLB&;F_WVDYE//(>"!6Y9*\7_*;M+D&QAURLBB);6-_%^#Z\*O13$@[
M7.;F:YR\Z8?IH.=NKW=3B!42%B@^A^ /]!'6>EX)48I]RN8:6_N"]DBFVC@W
MYXS=KU%< M0,G^/R2B>\M)13%C(.9$RA^($SQ1=TD&,&J7(2KV.5VNO9$],;
MZ-JN?\#CUB>/S?8K(10W6@'4'/^EJ,U"3Q("-26-60M<^8^4A5Z8%1J7OY7B
M@TDDANWC+^2E*'4]K*+27X?9W0VYUESI#8<EN&>C?W0IP^DG7\GP/<7>=4$
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M%"2*OHU"$\40H4%<_FY*+\_O:\R!&(@0O7/69=D5$G:(US',2R#>\M#[M&P
MF$^A^5OEQH[X0IP#2;5CHMDW%PP=B3=YF@0O2VUY#^NM5O&Y5JD3">)=6J4Q
MD2R.Q3+JL ^2SEFVGKC&<H]^R<]I:\$G>G<I==3R#2L[&+FQN)O 1V;27*_#
M5ER[I'93U,8JH*56HTI._2<IW8&O.#QN^*5BC5$#VS=1B-Y-'WCNJ9'N/9+=
MOFDY"(<'Q*1]>1VGL,F[LHXNV<;;L;ZAM@VHE5'*(@C"#WZRXN#,<=R3E?'<
M_E@NF[2S-)O%2%GGW:?/M&)ULZ<3I-)U$?H(X3+*')/U>&F_M1IA["%/NUJY
ME >O%(O,YSI)R_ ! WY]1I$TAN>_'*H0:U@,9X("8*#DOY8RX/AOS,)8L?IX
MF^537<AZ9]^9I"X](\\7O!FT%:0^[;9MC)@M8@=NP\>47,<_\ IN\?K?]].?
M\^0UDK_]=^-#*&O#/&-KU^I1ZRG4+*_]9WQ;N O*R2O5;5X3D*OW=;OYG[V?
M3W;I(\MO&Q)]<0BZ4WXC)>*16#X0L7#HPVVEW5F=5&%QX='!U(N!B90D-A9.
M))IH=Z<.4P I"8+%I$4^$TB-YG6^BNNHA3>P?J9&VWGZA.>R3PPBB9"J%"6-
MFXM/E!OQM,:$>G[>;7 'EO<R5_XJ&[\M?$-]733.]90LF>K5A9WZ6]QMF3C)
ME)G-EAEDP[5OZF%04D;T!<#63S;-Z/$5'Y')="9AB#D>@"ML^+XUU1U9YZX=
M@]<FD-)LND7?NW^RQB9)_)*&*,WMLZE^"O1=<JLD7*CTZ&Q'!KX;795]'ZU_
M)4'KKSNJQ/N:-%?9S.%"BOEQO;<BVX70[W+ZR[><J%IBE_$'T88'I%"5EXM.
MHI*.>JJ\=]Q1+M$I1CP]1\<'%<M<?W_C54_&E%]&MGE_"3=\D+DJ*;,-TMBR
M7M/+^W-"'B=!DL>T;RMA670;65B5]VT#Q',__S)%Z?V7<^TFGCB'^XQ)_>=T
M*I41;9WV-LL=+B:B42 %[W*]>OLFDXKWX*_94FW'="81#%%:AM^:X,GVI'R*
M?!<S@%%D6?QRV=67EY6X'^>@UH+(,F)#O]MP2[&#N,J)LF0AR>11=SD$9PJI
MBP94\N*TH,*R/.^'#K+NO+"%GJNW=M;*^,/[V,U6MG2YUWR5,3*:R2118-=[
M>JP;&BG^>3>IPRSO?/#?/\$IAXEWR57OS[ZY!\GXFU#=V=/[Z[Z/5ONP.D8W
MREQ QY;Z;7U&J.-3XO(,@_V,>+O, )9II.@T,7KYQK*$R:J%Y:QFZ3)SHFV$
MYUK/QT5P&ZT7#3V!7E/':Y_L!7#D<3P*>J0?Q*?/SIE 2A05ZH\M8' "'USJ
M*%LA=;-U2-KA\Z]-H)J/7N8$1 J!'<>"1.YV5NL>Z:_C%P%&U.X#]H^O$DSI
MFTOIH-]H"P[:4Q;H&AC.HO7H-9TZE>*E'E0.I8IK6>ID!_U*[1?A*?M#/XY*
MF"NI3-PY&X7.#DAJ&X3F0D$><DVWQ]^@U+9;)#?<M;8))E#GKA1&A%G^:E2%
M4E=")8^65Z8CSQ5S*?OX5O=FGSVV2]=?K9?17)]",SD%^F8#NG-6V4R&^)(Z
MF!2^0J1MH4]BWPE.B/FP.N*L=\3\4;8JL\\I)$>JF N1ZZP1*$1>8&/RGSO"
M/(V4XC@'\^)HU^?CQ8_7R.K YS64$B+!96UI@AS?GBU3$&-_R[ YEIJHB2U2
M49#]>$8$YGR64,:M,CRM' V&,"@#M<WE*E$0*A7=XVKP2/1C$3_;U<LRJG0R
M]9=LH;,8UAPOXUYF24F^3)D RUXK1/9X<:&(Q95NC^0A+E=NB^"V9^&8KT0F
MMG>BI]5$3U?_Y,;S,P(Y7VR8C0Q<J*.@)E.2B1&U&4Q8)75XU=!AOQ\?"W6<
MP'9\C<:G[O#Y?F_M*'B-JE?I_(?HN86);?<D:?0D['M\)BIVUU30L;NY=9(^
MS^'^;YFO5!,O81'\[W;C#Z$5WP>%C)EOTZ$M)OEY?^YN3@:2R3SD__2"CX9J
M1!G_LMN8[*)RPYGXOUC?.J^QGDI4<[&&[#YHE982V_LLU3ZAYLBZ3/VK;U>^
M15EB>\?I%T#U83V\869_^Y>[RX=&XI=OW+J>EHD$/X4LIQZ5>*HU!*U'?AZ,
M7-.X\+)??4%U5_7IQ7)X5V8P:T,U211A4YX]X3,Z(CV7PXGOVZ%T^L<64LQ!
MW0Y)H-,N(\+=)]WLOI7LX[8.8!;DDX3_>C34HL#> <S9^9>::CZ_CA]PY*3P
M=;.P:=T[84Q4][%8?5'_[OM6 4W:&$?*?T9KGQ7_@_Q@SW6$:@T7?*YSLX2$
MLB"X->KK@LM"F43'#JE8N! NY6S\%M546BQ,K%FHB\K/BL^8$)P%3%[M1B6$
M+-55I1>0\D2,<9-<=76<4*50;=Q:)":U[!XXM7![[N0)>]7H,7O5+,!&RB68
MZCA\I!X7'@4I(O+"&CB\YK):E21"Z!RUCP]JJ;$$].+92[&X31BJT$IC^%FH
MO6(RE+B8G84@^'+[&I5@%QCD+2=]N^%;DJT7QHC?0S=B Q+<-PL&>%T!.0/B
M'=Q?E;T$YQ8&'@H-9NG(6YW3&)A*FV6/2OJ^O=1FAXU<:B,D7"0-'AU(Q9MY
M@7,M;%Y4Q2X_"9WSM+!6&G 9MGH^XL+X4>&!JW_8+,LW<UN&N]@ ^^4T<S6[
MVAXB%JO])]7%MJT(TJ2 EM _+!%3J&_X#E,15VN+'^2^LWAY7M!.L^J9"!]X
MRE2SLSBU,1]V>"S^O)WPR.DD8JDJBSBLV$X!S#0BPPZ]=FX4[S$X.&:P_S7$
M!M*+LY8%>*J8H+)$W UC,),1UO;YRP@M@VJ:E]\G,E;HOS!&OW@FODV$,!?G
M.,/#_MT^_(72OMLFQA;V!68%_8K>$1$6@B'MO.D.%+][K2$AWR]_[GTJ<B_3
ME9H*B_H<$ND.ZHFK[7=E6IEPBG,_.?CU+IU_5/--]<(<'?C\HJA4/M3A5#GF
M 3._#ILCE=2I!9X]]T28 DLZ%LDKA.(5U.:"TM;+!CQBV&TR_P]O5BDIANLZ
M)=X/PK9%S*P:LT5":I5$.E]).<)->TIE5%EI7&?I+ZB'FS96+Z"/3U"J>V[O
MK!<_-'Y+?O7AEZB$$A ON:N8HTX 6GIC%*8][JYD1$W-4&Y[<@K5*)/-4&76
MX+S6!FN05H@2#))!*2<L^L@K1B4JDKD/DIS4A/<@2>)JO-PG^8/RK>+I=+BG
M/'6K7":2M,F"*?P,_AB]S8R8RI"&+#42]$C>7G:%DH@ ?S*IF5JGY(, =9A>
M9M*$+C^];KNR2),:&;4LB+%@-R7/CUD'9Z_!4'Q)CIS(9*ZJB.SJ[^87BTO4
M>):B]$BO]D#J79BNHWY;(6B:7UQ[0U/0&3\>I:;*'%T_()U[R6"X3_R \)P%
MU6L>R2:3J/-&B'Z%OXO%@7),G&8=G(>!/_Z#<BV0)R<O=71BOS^*E)Z:!=9=
MR,$EQU(22N05'!I-S')K;R.+:9>0>-)M0Y2)S67BN(50,'XE<\N$7MOD/$TY
M'NF7<V_IZS7]'/.E6<3M?SIS/';;&B.*UUP^51][D'^VQ:?-O-HCODS2EO[^
MH/A] *XF:UV;(T\@>*C^3"%V:N$BHJIFZ:U[<'ZB:]WI=WS!R46U+7(&C2M7
M7OS!:]US_++<T=[TYX(?*"OZ4G0_8*M$:/"J_E/>S5R?P(C$!@:,1\8]2)5=
M2,36J4%B/!QC<X3F8S69U]TL7OXM5.;MT6O>NDK3^I.5.&&4;KZ--^)X*I'1
MXN>AV[BD3Q4.XNIG2P*/:ILY8'Y$[Z3F@:O\\IXY?6\A=UGDYG8)BV:->:X;
MC3NS<T@9[ZO=;Y)RQ*2OJQ@'/&I](_=7PF9NBQ&QOY3YF*CU+='#_[AHOV6C
MR5,H&:R8!I.NM"J/,0XW%&B]N*Q/F2[DSD:ADZ^41[5+"E*$+4Y6V0#Q%GB'
M>+>H^(=D:V<TW/;B*F\ZQNHCN1,CI5*:Y J!NNV T"K9A.0#SQ>4[J/W>L)3
MIF7:O(R?!< =E]^.1KF?K?LXJKX+HJ1\((8TWMPVB7P7.#WZG\,1JU2-[-KJ
M?=]%V]UTM'/W@E(+8D[KM5I1N[!N:D%4@O"\&]OWDFV']+!T,BZ21WQL$\^#
M3*P"3$A=R7O72&2L(XUF4[R6K/A%J1[K&L/SU:2G^<OUPS],SE1:$O90QJ9J
MLX(W"EJ[ZYC[I^>,@I8T5,X.]/"LFP_Z O1/-O7_E%^,U7O-D@E-2]\G8[!B
MF>2.<B=T[_]!;V"""8CZ73,89-1K['$JK;$Z 6"V:;C;4R8(JJ1WXTXDJHTZ
M17'L$!H^0Y10R)<4UC="7\Z3V;!V4^8,*C.!6SY+E]PTEWF]HUJ::<?U/-X!
M/%P;?]YD\+;R"]2M#D*_O8EB;WTOSZRM#6KZ3PY$F%FT_R:LWK&E>)9;B)WU
MJRFVHD4')3)8^=N9U= JN[A'4J0KIGG:78BI>/KJ?EA=X1-] D89$BW712<=
ME\XU?9=50O='K&0V24*L$2HZ[MQ!TVEK^3.DY-:*/;O;BN>&TW5KAW)G;+Y9
M:#MFPW[NX#<M I](:]#";438/VK/RX;H2B;/K;376MA6KI<[A"40];G,+>)&
M MR+OEK1AH%/HHJ_]1P!"AMB*A<>)9FFM?Y-@1^W%!X^E[\^$K/Y);F.R&C&
M,Z7"%\U G!5Y>K*\9E-S.PG:)%WZ](16F7/X1M'T-EE(Z4'_E!]5F)[Q0O7A
M-S.&P0NQ5XTO(,Y4C;PE[Q&+[\NQ!;Q*J_Y/E,J>F[[Y[O!ZZNFO4*U&]R9B
ML+N[9H+!NV?&8'J;>B@7ZVE-D@+21];1W:3N/P%KSPA3%/6'&QFK ]?^]IP7
M7]S=F*WI$O.;QY^HQ>](V#RQ9?177@&XAWOK(&\M&57.=;HC&$-+"$(3AP=_
M)!.HE'%3X(93AKG4YQ'G1?T#C"-LZB:K*V,_\G7/\U]=,H[CA@5*L@2$8DTQ
MY## 39W$6U<@)];&<U4DLQ@V;1R-8)I7RI[83;%%K5(9IELKC+F,&R]&J.0$
MT++)9KO]5K(_3GFVJ9=C.!HHJ^DY,)@<J>)1O$KELRO1..E%5[Z'(TH+U?/.
MF/%4_Y!#4>+%I,SZOIR%R/2P83M08<9="9\MPVZ[FS@SDB@"E!;<H.G7,+E\
M0VQ>OLP]NAY^GJ;^DU#J;>2\R(>JLF4IOMGK8LW3LID+M<2=@\3 Q<A'N50E
M:(X&75K)0$-5MZ'C&X-2J5R2\H1@*6*>]WI(MG&>;6B*#\5/ @U^)KJ=8DZR
MGTJ\[RFXD*0'EWL;!#I;D/&,6)9Z7G"76M(?;JT3%&D5D&(@:J>E3L(.ZXUG
M#W#8W,R87S3TS)A%&Z:OC<^2WM++_067E!CLLHV#+PW]&O)NP*4_4U=_H$C@
M6-/2W^F>B<3QP]1PC30J-X1Q5>Z9-!3K8]? K:,B_ &KQP,A^)QH6-08.Z<Z
M-,[[]R.KCT[S#_.7 9\5C_&CQ*G?KK)TJ4^T;&9ZOEL5Z";C2.5%^CA[2R?U
M(F*"R=6T0L;4F>PY0FW4BN=8(5P!W!/OAG4"4Y/UXBSZRR)-*PAXA' (3#Z/
M:,R8_<[@.>,PFRW_%[6A*H+WN_E&]H03Q?/CNH2C2\.1MP0C=7P&MK$3OU-P
M!80B""9GD-Z,%%,T<Z3H"9<M8,L4#4$29F@X-K%%ZZ4Z:NBY['"AAF.=5M7_
MW;<NLD0;.42>W:,VID3> QIT0^6.%0LL&MQ)3ZH7:\OI#E>)! ^I?B@QEQ[&
M;:X^>ZM18>I@+[7E);^E4>X@+P%V9QM_YDSIRR$@(L\>1N=XN+E6(DJ9A*[X
M>:-9(.<JF$3]JD"S+,. T"=#26Y/PVW\(N (M%N:$L9\E'ID.HV0FL^##G&0
M^+*<HL#Q=)6"%3,/Y3F/Q;5WP\?4H FWH..7^LYW;RO][S%4G!]]<:[)&A;(
MK765U]"*<P8_UL>DV%/7#FPW_O@8* A!LWWZRJ:M)[U<SL4>.8,@'V'!7E;>
M;J8U 6O4&M:UC;R3H$$KR-QQ,7DM%0:MEH?X:5D+":4*\:O-,TPL1-5"RK5+
MI+35C'4RB>: +<$.MKIL84C'ZF2Y[(:&%EGV.BF0^ZF=B2!;GZPFIJY]<:H=
MY-(')@/45_Z6)'=O?5+WW-";G.O]BOEK=G#/6@W?G$^[($9O>)A(A6N0%Z=B
MCX.VJ!'JI^@FE(UNYEO-YYNT'Q@=K_0/5@VESF.0L:;M?)-2ZL8!MF.9A'%X
M>/>7LNQVU*>+"2=NYR=WYZV*V7#*%%89ZK/#1+,91/?1;%8*&@M\&LPJ%*B<
M41M!@250S3HY;.& B>UJNKF7WT.[Y'R3PLU.\PA#&PC(>P149Y^&I.Y(C)<Q
M"0B4$G=;4UZ4.0"_D2L*Q*^TXCWU/YN0'$4J(&Z4CSQ_@]-]6 +^SO TU?H<
M)G[V7.PYM"XG6;L^IXS.J0^*&DUO1U4T(R[HMK,Q)F&M1VK59Q]F8(CPFB+!
MB:\$I)FV@M%<X$Q,>@IJMC]I[<L^ZMB9ZCP670H2J?$UQ&G7WL0<@Y6U79A0
MP[VHR.:*S.;9ZN[CI%'/AO"DZ2&[A&J>]('$+3=4S&_!]PS@GSL" MYYUXV(
MK8.:K3^HQM_IE4)"K:A/JS0G4L^I6VL1/RDPI<7Z:MHGV=9UI>R0FN;)\LVY
M/,<8P"'_X:%HKO,4E8_-.C!OI$K7I!3FU5-KU(VQJ01YWS-?01/M:((.\/;F
M@O5BC*(LWOYQTR375>'-XGZWTD]^JKRS\3ZWBMA]WJ(7KU+RE._=1:5C%K^>
ML) 7SE)^Q(R R33'?K0=;^1)E&&#,8FCI=C2B,B7^>A&MK%+KH9U<ONKE"M%
MHJ>.!3@M/7A'-=TW\J;"XH_T"RU[;-1?D9ZRHRN@&@:6>J^D9RA*]E_:'EX$
ML$YAUV863=0W U0%4Z_C66H+$D5)G+2[^JG\+&53LVP@'ECF_T#9".5 N!=L
MC[ZOJ,8]B;3SVB(4(5,6Q$(:T1GU(]X"C^5=T_)<!=>/=H0JQTC/Q7I1$4,-
MF8"I./CHG%A'E(RO\!4+2<6/!HKLDDI?01&[I!7,VC IA_VT9T*.",+,TTF]
M.=C=*^^^:&TW#];TG.#AL=_Y]#$!9+3",.*EU=WF.>A6D'Q,Y CR9>&")Y[A
M>$VC@:D&]D*QQ=07I38DL9SWE)GXI''_4R8#Y$C(?+/)G%4(TAU6Q/&:I8=K
M#KB$A)ZT&)9NA."$.MI/..DSJWY<_G6X0+\?,Y0\4/WJ_/[K:W\A>_[LX5(-
M%\1-':?0Z?$]K':9I&%867CN_0'JD?<M!"^4R0<Q!X.WWOQFQ0;#+A$2ZF;[
M%^8-+E$]."&78HJXD>EAFNM3KH9OQF^2BN]+_^?T@]P&6!1NFM1(A$Q/N[V9
MUIMNO""4U70 [*[;W ]=YT_;',5:FOB3YHC:J_E;-6!>LZ-QXNR$X*\F)_^9
MK(DE;])NX=W$L8U_<,P8W(8)?#M\]SY.B)(8:ZA'TW6FFDZ9J98 D"<!Y\3X
M\:[308N/1@0BPP2B[ -2);\.'IX]S&I.EHE_9*U9IM4X0YG^]F6-K\:G3:L;
MT-Q6/L47BBDP95]M]/N:J4/!J&UBTJ>^(W%?IHD"/[E/TC\^!G1K*FTU[R(\
M!2@#5T[;EQ1UO#L:4N.:K^L0$8HWQ/CF;&\$)WM):C<S6+Y_H=T08?(X5A.6
M7NS];#O5 N$3TD!*$[LAP!)"?<!QRZ?GF9E02">3T"?MUO9SEGH"%]ZIV?S1
MS&KP_;_J36PGC?P\$'8YFV[+28YR';9&&[:JJ7LJ,<&#&P+1,6;FWJ',-,<:
MPMR).V8:-'HXKE&%>:_7+@-?.L_WKH92JX:,V"9TV<BN+$A:YR,<8@W;::B3
M")_.J(_GGE[-D#\5=,!>J,^J5=/15#\I\&]2(7)3>H9,F_X39RD=SN\LZ)%L
M9M+Z_/#W_+7\@Y+;F;9?I8>A;S7*<LI[):7<LT:?':X"+/$*;V!J_SU#M5:\
M.Y42>>F:YD6'<J3VT<]=@MR$!27^82C,V+/[P)\T&;28.3!F\I^(_MEY(9<G
MS:\:,H_F1N"V^2" !.OLNS#:L) 6V%2U%H>Z9'HF*F"GC=NF),O,N:N58#UC
MF<JB%JFP)DO\.N/8 #ZJ_2CIN](J@7"IK:>@6J<)O&QV!/M#\?HE+#EYI]Q1
MO?<"HYANDTO'_@\ "T#TOXL>^8""K: T4$:C[:D0;9MWK5&?K2'7]9P@Z=P>
M=I&.K5]W2OYUFV(/LIC.Z*UPVQ_?4992[A_]N9HJ[A^%4+AI\AA%[@ "8!Q%
M6_S1R4"X2R=W,D>LFW9M;N>6^DLP4NC&\I_RA+]@3 4"S"1M96_3EU)HC*V?
MS.M&' IF'# 3F('1Y<JT3*=FA0W"4EV410[N!5XH(5W\(,D]=Q!&.\Q,X6G_
MR%+6:.];G$:(A>^%3:9L4.;8@.]EWLUK<#O3+9T6@N']*O2Z9Z%\P^_\#GB\
MLR^ F^^YIF]N[O-OBIGL".>_ZG>THKCK-/C#$OES@/1O/FB%)_3'<IIUA"R(
MYZ;66KGT^+@0SVRY/HF](LF@N D1GZS"7T\!^R?$T^M >_F+X\[4UK#%7P?-
MZK@:S_B/^O._@OQ_TNR3C"SEZ6?G7>@F_B?$;SC8VN^/<@C6AO6;6*V#"N>G
MR*N9YZ=9;R*+)FV5=UZ0@C59SPE8<];MO?43,WD0V5VB@6W7PKG_L+G:YKG=
MAK#9<WJ3(LNDOP=A^X^2-C+?<EN79L1HC]'8@A'__SDE=ADN2$#N&P7@M_%?
M<Y';&AGEN/WQ:#N$&FFNXI-Z>+%VNP6J5C9,JP.,5G(E463EQ8B,4CR,[=[R
M4L0NI *W4;#23*Q,IQXW@#F%PNTNQ/%$,7.W\\92[DMW,RL[\<9JKCIOUI"<
M\UYS\=?<];)-.C/F]J*OSJ 8SUS[%#X'\J=A](,A>;.S^PYX?-LOWV _@6NT
M +>K<6P4!\7[/;<K:&PG;AAL +.KY?SKVL$S @<H0O,(0UNK?Q;COV<P0/C8
M4,1'D2(_BA#YH7###PU%*!2I0*3"084))R)L^'"A18L-B7Q<N+ A08(;*!;1
M@/"DR9,C+4[,>/)BRHH,"_\BC+BAH,*0!7<6-,G3H,"41(A&G(ARY,">"'V:
MC&JTHT"(!I,F9"FPYTV$!5=2##FSYLV)5U,^51B6:<B($:MJU;H68=B%9^&&
MO!ORHM""/>>._%F4ILF_!L-J3:S68\3#+H$&CHK1[<'$9WUD'&S2X<?#@WU"
M%3UUKN&$4N,28:PV--^J@]T 5DV0+]^>K=%(?4.$;T(WO(O\WMW;!V@W"7?_
M51WR=T$TP'G//D[D3?'8RXE,S_[T^._?T=TL'$Z=]X_IVH5G)T_>N_KAN\\K
M_/W<>_#M[;W[P*_>^Q W^[W[CX@V!/S/#?\$))".[/XCT(TYO'.0B 4;+) .
M-QPOQ##!!B]T@XXV&-3P00P_))%$ N? I(T2";Q$0P<A7)' %A]4D8Y+6/2$
MQD[<<''_CC: L, ("X+\@0,@BK3@!R*%K  (#I8T$H@*ABS" BNG!,+*'[+<
MH,LLG0S3""-_<-++BJ8D<\LEBYC2B K(!**ABLH\"$J$E/RAH3/U_ $A/QOJ
MD\X]@>C34(E^>//0/B5JU-! 2ZH(3D<C10A.2"T]B*='_XSTH$;A:G101@<M
M:%1-'?I3HM!*8E1/4U'EC">0]#0IHHM,>Y6HC;YJZ:U58<IHUH)FA4F@5%<:
MZ-8_]?J)5TT/ZTRIM&(RS*FK(K)(IZONNDJH7SOJ-J?%T*HKKHJ.)<I6;RWK
M-2=<W]6SM5<;M0JNE5S23##,3E++W;8\&NDAJDI[#"R2PNTK_^"!G6K+JYI
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MLE #-%L/%Z,Q\WJ"5CR(.___[+*X"JED=5U\!OG4JB=V)I#($V6,;2$4B3;
M<6GXXKA(*QZQQCVC(Y"R9FNLSY-\(AXCJ6F22Y'<!FS\KSG8HY.\[=GR[[6V
M;96@2QU1:=W"AE\#5D+_@V'Q T FUKH<,$$.L  1IPTXE '!ZP SY)D(+D5'
MDG)*!$),$KZ82>).I)I0LKY2Q)G<(&4OP9DTCG64I'5L$@A\E$B89W?>Z;^.
M4)^(#A26-$P:K (TP4N784OFI,&,P$OAP*&6P4NCH6G')*$JP$NE4"*(;AFJ
M9P.6]BR-0"V7P5+H02O?@.BB 0ZP!\7@(!IDK&O5$A1*#%]<C&DEHDBCP<8T
MH0L7_RP:T-(M(V)L&4P?FO8NH;!OO=1N-^ -Y-;!Y'0,.[-;.+58G*H5,S'O
MZ&4RX86E.(9S?Y720NCQ'E5CJ%4C"A$5T^Y70!</X8I:\.<E]((C]/"I"D_1
M[) SZ@@M4A%S\4IA:)=79T*(^$R%V +0<FA?DB\:$\UBE'<P1)$B'!4I:$TN
M-M.FV(5<N@77-&.,K.6N<&TZ,^@PT&X3M[/6,*,Y3W4YHY,Q2N\95U4ZHW6S
MTI/[.N(_MT@\Q6\J:D.TH$,YSE64?$+^5BEO"*FT.HF0U@/:$F+9D&8]_I-?
MXQ,?H8NV6"F3SJ.TZ 9MS&VWTLU  U A"; AU:.["I"$__^C0C7D0S64F&"8
MWR(P)$-$06R8EUKV AW$188I93-GF2K'<RHN<RH.9C^'Y+II288DB6%'9[,D
M3F[RB6''28H4#I GYUHN3E6NYZ $"FTP+!M"+5-."ONDP8R.3KQ4&3K,2QDL
M&M!T'TP!C<]2Y;I6HGY I"J"Z-Y@"*\'(<C42/_X#8(,<%..+>7X!JU8)A@L
M;7O,"H'2+3>J-4OS4R2(^9;*#MFN5V8B6Q(OAAXO%34E$8-*]II"B,),5T71
MRI11-/SPK<JE\QYQ,$H96&+O8 SB.6//=8VB46[*T0A#@I(,\M8%5VDUJE#(
M70B#L%@3T-90$_T%&L\B@\ZJBEBJZ&1$9I6O-34,,8ZVUR6T\]/L3+$BS8OD
MB%PZ;\JNR"_?9>VFL8E.H_@H*V6>+]?.BC4^JX#-$[6T[QJKCQ^%AH^&C1^'
M+8 UZ_ZP)F^L+=J" [;$DR ;^#^YS=N RSX0>C@>-&T"=I32PV[0S8/KYD'M
MXVY@"> 6LG NUKLHDMX^UM\&I$/<("-'!$%L:2,_Q+M0E$,6SF1O^"0?;N$.
MKD9JM$9B5INRB4;_?B1(EK@F?U0&=99,KL0FX8D&1ZZ>0D$KTPEIP?)LYR0K
M4VX9O.2-;S 4#(5K!\J1%^QL#T*,;[!IX82-;Q!1AJS#/D4M^W8*V?1PT]A3
MOMC!U'0#VK2KWX>0&PPM__@&?Z4238U2N*+(.B5WV^7M*,@T"89V1?66Y8*R
MDV7VOA=9A@CO:"W.Y/ J0NADGLRG,.A7?M70'#7XK$*(6@UTAX)8,M&L<@KS
M.M%D6CM330.737E8MX4T"FM7NI>6E\4TE#?S((TQ@B\J.H]A%$V./%%AA(AU
MN]>*[H6VY<BO7LW6IO-TK5,Y92:YM_4SOM=E5L,;ST\:00/8-NDSK$:-_WHF
MDWP"'),#:.B;V4()D+2/M>81VB0V^^#Q:9)C-Q#:D\0-H\T10?\1_^Y#0!5T
M(#FZ/1 28D<XA0U$IO6M(BW</UJ:F#34EE0ZF8;) M%+9#%GX'@:=,K+))E)
M9(=8FJP)14+G!%U'B0>,G9A8B3\.G.R)2'AR=RJ@:%6P(8Q <JFD39/2 B37
MQ!IL&<02#MHTYW[ 2^T@4HJ6R =[3.# P;3P(-AX<L4XD:_259;.P4K,4]C0
M(-[:?< :#@JB2)6AC!GL#?;6Y?KDRYVL2"=7;/>!QM04?#@B5IR*4-DE$/N,
ME$4B$3LY)3Y9AXX1,F,F7,)N= D#7,;*K_SP*?]:^3&*6R8PB"HP-\RD!5"S
MJA"3<5?9XA9#9EOB#(JX[)A+XXE4R%K;"),CK=&0UUA6M1EK_;4' XUJFY=7
M[S%W&WN1.=&:,[&N9=:7;WQE+9R#Z*P2@_8T-66XJOF^VX3FV;VM<3IUYAIK
M[1NE#]D4*=PIB3W#+SK2O6P"^F@2>CS^#V$7:6SDJ"?:8V4*DD$I6D$)7+[I
M!A_+K3CF#]OB S_RICT('D C5"'/X'!JR=]@.+T8D' $+D FY\(CD$07[H95
MU'.RR64E_F57=D1^I"5-\'-@'$4T[D@Z3B93<.,29<"4.': 5"?-B7F*5!.,
M1R>GKE"F1 <1A9"C@4W_RJ2J U=Y-H!M 86K]T$3H-2OV]A/Z#I3X/2LNT<?
M&*QI[WSE_E1^K+S!!!E1P,Y5&F++<;#$O%1[B*XDW@ 4!!=5O/1/-(#IG2ZM
MU)+.\XS4 [/L?HKOU70/WPXOUR<O=-75<6H2+>J%D(RX Z.: 5%5+H-=3',I
M?BJ*YE#R0=66E^\E)/$P;F_UYLXE**:K+/N+*L.!(J.6&VCQHX4M1O]0=<^*
ME$A9\ZJ I!M9I;L713WT'%'VA2];:-W9G>@PVF)_[%=^70:TM;/9$:M@5OF;
M*4V<G^^Q6F:.=$TYMNBS1.O^[HC8<&TZ&/B1W)'8V#V]R:- 34LZ4@;\!=:3
M_]Q&_^X=-GI"VI0KW^U3:OQQN1A4@P&4MP#"#1$B @D:%(CPH$(W"1$Z1-B&
M($2)!(<\7$@DHILV;BQN/$CG(\.-;I*09$B'HYLY)(FP%*B28TR&,DFV2;G2
M9DI,+%E>RLE2)J::/XNFG,-SY5 +/Y@Z;0H$:A$+1BH L0#$JM4-0+ANS5HU
M*UBM8HM46+8OK9VF/WYP^+$A;=JJ9HU$DUO![8^[:369U2MWWYL?1G[D+1*X
M0I&]<NTL7HPV+2BXD??Y5=R6[SY0BBL$YKRX@C*YFC;\,(L:KN'4T +OBT9A
ML6G5LGV8-MM:+NS3J@/S7@R*M ;>JC=DTKQO^&+-?O^+CPZL#-2;Q[$7:ZC]
M.#61#3Z*U.9N>@.1TQ7&<_?^8WOZW['7#Q>ON+WZZ^45VUYO/3WJ\46ZG_^A
M7'?X"4A$$;$).%R!I_U'1'F+F3=>@-YUI]QY_J5GVG@--IC?>1H:6 2'_(GX
M6'>VG9AA?"$ZV-V']UT'5W?]A:B??K%Q6-V(-8[(XH3]I5B@B30.F6!Y )[6
MXFDB*FDDA*==]V.-U]G&GX0; OC@>BZ&.".5()[XHY :GG>>@Q'.>)V&6M(8
M87J**:A<F]N)V>6$&?HH(X5*PO7AC6OZEV2"^E&IWYE)!LEED"Y^J"&B!:I)
M4'I$I/%HG8JBP66+;B1*A)#_/@P48J63@CK0&P-U&FJ(GTKJPZ:H%B10?VY\
M2NF,;A1:1$&/IC=K0@7&>BL1IH;HZJ@^F-HJ$6@,-*M"IL:ZK++,8I00I0(M
MV^M!V#9$$4,'>7200]V*E!%-(XTD44?FJI33$"&=RQ*X[+Y4TT8AW<312TCE
M9!-#G?1;4U!N_(04OIZTT9-,;0RUT;]M= ($!U==9013$EOEE%A<65#$55!A
MS%996#4UU51-/6>9529;Y1M;%=0C%QRFO=Q85J$%5E5QC*7UEV9P%!=<6M'D
MI=E:?VV <C2\^4Q>$95-]E=H4O.VP<]%H+S,;;2MUI;6@:%W&P6NC9T6-$"C
M[)IL_S_DML]:&9Y&]FO*@,V;<D>>UQZ(>?-F'GZGQ;;W==79!N* =AH.(H1&
M%F&A61P"ZKAI[RD^(X@S'DFYAF\.N$&469K7G7QP59YG$<KE+9]B$H;.>.DS
MZNCCD84[BKF1YTDHY=^7PYA@?DOR^&.8CO.M))M-XG?@BK1OF.F0_-&Y)H8C
MEJDFC",^B'UU@[-)HX27?SBHC]R+B1^D,][XI?&/>AC^EA^.SR:NA[[>?OAT
M'KKEH9+2_VAWRZ;ZJ4P)"U4F"E:N0-6J]!SK4XI28!$P-1!*'>M7K5+5 1'%
M0$X1A($#^1^FLN6J4/V@6<TRB+0V"*M2@4H@S[I@LI*5D/__"62$ \06M6YX
MK89HQ%L\]!9'*/)#B* +(1910DS>U4./C,0B'%%BOACB$97HRUQ4K(D5[V4O
M@FWD8!L9"DX$1I0M&HPCG>#(4]Z"%:>$Q6)B>0I5ON(6L#S%*U&QV,[:UA6P
M&"8QA>$*VWY6E<"4AF2>P0M<HF*6Q)SF:8?Y0664 1>8]>4VBGF::C0#&KB@
M3!F43 TE=6::K]$F-IC16BCEPC7EQ,TURE#,&UP3#65H9G&:R4243/,&Y+A&
M$VWZ3I;"]A@W;>@VA"N/UO16(@;Q244] H_?IH0>075N>XM[7NSB%",[)0Y+
M0CI>>.3DH-B QU*;FY/I_/8[X;7_2$7<,U*15O2ESB6)2^U1#NF&I"=SSJ]'
M_,%2^,+YNN_1;TIX$Y^?=G7/U3W(/O$,DGBPI#X;!11RGF+?\K2$T>8=M*!@
M.BB:!B4>^@7/4\W+'_<\:K\?N2BDYM.?^P[%'0S"#U4(K%0 W8<H3.&O/X]B
M5J),-"Q2%2A:S^KIJ'IZ4UE9,%NFPM8"0V0J2IGJ5#WE5:N2-< :C@=8CW)5
MM&SX*8%\JH4FG&I1?95";JG5(&C@E@W%E9 @JJN'#%$"3% RDB 2)"(SH>*Y
ML'@NCN#D)#,)RKUP\D6&+8Q>.?G)$X,RE,5>(B4'VPE'+I$OF4 L8UC!6!NG
M4D<@F.QB_W5D"QI_D$>.J=9D%@A:RK*"6JX$QHYWO,P=UT*>'R1&:GFI#'GT
M$;.FN39K:XO9U%P+2=.@# ZH$8U<EM&TMJ0&%/JXRV+(PYQ.ZDYGB$%E:A*Y
M2KF8K;N3]$$%Z"&7YJ)7+;2Y3Q'@($NRT0U&,\*,W4"DF&02CD!8JHY$.\3?
M[JF&1^9$TGFL<T\'W0U'K3L<G)#D.0&1:;_"RU*=A*D=V2VNO^IC:'XJ=Z [
M82BEFBO0FZHI41&=&';Y?!OHMOEB:T:)>0YJ$O;<<T_9F=B:S$M?G!:*3_<4
M+WKNTP\T/[2X=1;HH0\]DTP#>M'&08I%+"W?0@MTT#U9KWV+@_^F2R',/#JY
MCW\375[\-@741O'443WEZ0,S]09/J;E3! Q6 X-DYU!!$%FN"JNH2!6J#5)U
MJZ.Z%4)2E=427G!6N7JAJS;%51I>ZR /[.!!_,S42ZL5K@N!JT7&!>J6[!!=
M?'T(NTA"AXRDNM2E_HC "#M8?*V+L+#.B4QP<NN%7?:+ --UPBS+1:R0%K0;
M^UC$H-+9U()6*V&Q"EN8HL?*V"&/IF&*;ZKMM,8P)=N3U*//*M!'T>ZVD))1
M#%,TT\H[3B8\=PR%; 1Y76YOII.840RZV?V9SJ@--0)23&!2A!KQ,E,U>4&:
M7$"1-\T@2)#*P<R53 ,*M$VFG\Y\J'?_C$F@^F3'!S$B9H<&G%] 33.86#[G
M+ZFT8@,O.)L9E9%\'&>?SH$4QA"VYY'HHQYS^DZ9+ZZ1Y?3CSH_RIZ# \Z?%
MA;0>,AD.Z3NN,8_+>4T0P_,^"E(3Z3BJ3"^G3Y]X*NF?$)QS]9UOZMX1'8V:
MK#S'?4ZD!&K<Y6#:HOH6B'\8+5"1$%JE.@64FS\-*/J4;*DFFVE^1=X5J7 U
M9TE]G8 :ZK,%:PK5"#YJJB(D2* A.-2MJLJHP_H4MM+SU<CGBH89'#0)23^J
M1JO0A,1B%@-A:)#6=VJJOIK@H6/H4X1,\*WA"O5#P-7#<2WQKN?:*Q%"DI'C
M[_5<;GA7K-\E_U@IYA6P]#JLO69RZY]<GR1@3,IDV\!%R.J:)T*9@U@\"[*+
M5>S9)(-VQKAB,FKG42]H=*TF#%/:N,CEM.2VC,F8QFZNI3114QG+T#.D,1OD
MM0^G<!J:\&^\ 0?0H1J5P5R=@5Q14TH-^!D_\ 9LLP\THAJT47#DT3()^ ,H
M\P;VI3MF@3*7402OE%Z8P1R,DW1-TQV*@5SA43CUE3YU0W(:1U\,AE$!(CG$
MHSS_$2;RA![6Y$RPPSSBA"5)QG-18B7V-3S*LR/;A87.<V)L B1=XG:$DW3@
MPV!?-B/@\3L8 CEHR% ZLF,2171/8CB.XG2)4TW8(W2Z(U-Q9SO\(?\Z3&92
M?B@^I4,HCW(\<E(_7'=W>E=R7O)R][--EF,H=&=21[9X5D92'A5W)&5UD_A2
ME*@A+6(BCD(CKC)"B;(F-#6*4R4FJ[)5W>%XF.=FIU)!D1(L894HIO@K=,9!
MIA)GU])HN2)[B[9Z,I0L;\9"EC=[KF=Y#3%6E"9HSKA6N-<0ZJ)I"B%7Y:*-
MUCA$!W%JWYA7Y=)$YK)\VA@3Y4)K-P$P;L P L-8#H,)2D%&MM8O!9,4<X O
M-_%];2!L<M1&QJ9:>306>406;O1L)D,RTL8QX 88J'1(&R!)^U"!\L894>$6
M"A@-<% !\"5*9E$9$ED!=L!*^148RY""KB7_&>]V<)@A;\M0;U/3.>&U#Y#$
MDAGX&$;R@,U5!"BY;L&A#":Y&*:@&]/A@(EA'NNU#W5 -1P("G<!"H\1@3%C
M=1J''YW!(1WW&Q)&=;+!(0>6/,+$3C[H7PPF3ELY8L-Q7VTXA@ZG=&3H<"/V
M8%6BATSR/ 4UAGQB.)M#=CAF(B)6=9*#8&7I(TYR3Y8S3R&&84OW.5HR81;&
M=#=V)8*"37-'=4IH8^YS)T)"A,+3)]RSA]ZQ),Z34I!3*/XD)W6B/[Q#8JA)
MB2$B97_R4%YV.V,HFHAB*>WS>.U#>%"6B&SRBJ&RB;.H>9%B4Z\S$*<(:)_2
M(@C40K7X>*?2>1L47RJZ%WG($FA&-4!A95695VG**$,F=$+9(BV01F?-<D"P
M GMB-8W4,HUW%6K&%WS,IQ'U8A :48Y0Q'SHZ 9&E%?F\GS2UR^VQFL+TT6R
M]D2Y5J!T,%F.E5D#XZ#_@EG@_\>/;206;Q$Q8K%&[)=L*F-';Q$6K*47%M""
M4?$66A$8!'E;4=%_/\,5LU&4J_24AQ&5X66 >8&2<0-=RM487?,#%RB":O,#
M+THV1G!QJ3$<W-5_;K)0=Q0WC".D<;-NM54X&B"3KZ&3J(,:7]F#:)FEO\1R
MNT,U',(_]6%-VV-ACZ.$ J)2N>-B1I=T+_)1C>--+_8B^*$<]D1A-3@YPN1B
M:'@:AFF'5B<DK!E@[\$Z3.<@0O<@\/&7_A&:U6.'KLDZ6*(C%H>F)$4X6Q)B
M= =---<]=>).$'9.*]69LC.9\>.91.8CITHGR7,F4N(=5F*IV.-2S5.K@4).
M%[4\A?\W*(V"F[M)4PZT0J+(* NT0H06*A*DC*-"0\=Y*K+"*UNE0,1)+&)2
M0K8G+=8R0;C(>BED>5AE$ P$08_6>E-%:0F1+-'2$.=YGBB$0R#4:<+G>]PH
M$:EV5X)%COX)$X,5H$?DG^ (H'U56/1HH+;6CC:ACPHZ,$>Q$MFW$?^8;&?T
M613S%:D%%1K*6ADK;<[V%E.A2!W3?X/$ 4B92>"F&$\J2'E!%TPJ%R@#-41#
M-BY[&]FE&FP#"J:46XQS-7$S&#992A(&-W)!;X\1D6,S&)I$-JX%"@+"-D;#
MDC+).;+Q&!0GAOMAA' )='-2A*.J.^$Q3R#R'X(SI2K7E2C_!SH'=B%5EV(0
MEDUR!W3X5*3 LSV8DYBT8W)]"9E2>#F :'0N1X-B>R55MZCYI*0R<CR?&CYO
M"JCEP[A6USOS,Z@4UI=P^3EUJ*H*YH9PJW7DHW.WNG-]22"^ V-D9G;Y-'8M
ME:MU"YJ7.:9F9HFD^'<SQ2CR4WEJ%D#W\R@Z!66/5WG!Z8H89*YU,D/FZ:S0
MV5.,MHN54BQQYU/-JYV"%F<AHJ[$PBO$B%7_,Y[1.BUFY9WN*HT*P7O5&&H[
MU'L_)%<B,5=#E+XX$45#I(X2H8[Q2VO;1["X-J"QYB]=Y!/79UD*"T8X410+
M2S#@5S$7"FZ=5< 90Q8%:5KM-UH-_ZQ'K44:=/$4.+,5*0JS:0$'A;&0A*$8
M\247[J9=)ZL9)CFC-4H>FL 7L50!H;"CAA&1G,$;+IP6T)4:&;@:</"1+[MO
MAU&3).A=+'DW$><:3]DYF(&2<T-N2F,:F)0Z!D+$@0$-2UN$6K,A^K8]8,),
M6KL@5,<W>3L[2JHB=NHWAJF$B<L?E:,[R4.F#)5-O:.D0[=.("(HO61-S?2F
M6VMC%!9B,A)F7*NV7C@_>W)CO .95HM!(\=?IT-FIBI1M4-V8"),<=PC\R2X
M:BB:9U=B8Q>I8++)F?HV==([D9EC@JN)K(F(=E>::ON9[[.;9GB:L3N9B?B:
M9I8_,D6*YO]#4Q]B0&U&*Q^R+"TR59*R>NEAKEHR+<N9K)(79P/Q5,Q8:<&L
M+(T&C)V"9H?6K<W[:'X6KF0UKEAU>Q64KM."S6AE$&<%5^GIO>P)?#ZD0T/D
M$4K$C<57$\OW$N985R3!GP?:G_P2$_$8,.EHL K36&(DH?B2$OCB6&[D,1MZ
M;%2!%5RQ?FA41ZQ56LV6,QR3%190;6S1HH8!TB4*6WF!&27:7+S1P4Q!TB#=
M%B:M;R"] ?HV@M_EPXO!-J5QTADXM#7]HSI3 3ZKI#U]E>QV@U>I-C/S Q30
M%G5#<#KIQ85C&NUQ3#$2']*57P;F7ADETV57(AEF-X;JM5LKB!;_A5]IC'$.
MMDQ@2SBDQ#Q[8G'8TR,QY\5-EDUJ6DR":);>,\@/]DMI/*E](Y>6\Y6".,D$
MA:D MRKPT<B=&G>FR4\K:,D@16!X**B=<Z>3W+FC.KJ7F+DR1HB>B6('1JJ:
MC5*=^D[74U&,28=+1KA;LK:&EX@DQME>IZL3!4"O(T'4^XG.*B2Q\JPWI;O$
MZ4"QXHK @BL>U&;.+(RGTLN^'7G/VE7'NV80%"U7%8V11T,'Q,TIY$+< KXF
MI'N3]KWB&Y]P)43O25=Q-1)(Y$2N5B[0=Q+].FOQO7SXJ[_;5S#<9VM<]'V4
M%3!A)*%&L5@#,S%O=!7+MGX.[48/G&PE__,4(F,8A5'1#,FQ\\>0IN&ASJ88
M97'!6W,;.OC25AU=+PG2=E /T2 =(;@!%-A((PR3T:5=.-O#^Y9-/KL8-Y@:
M3<.2A*.S[':&1;V4IB0C((=?0\)N;2)S'W?$D((\-'@F+&FF 5;4H2R$9P<F
M?HNU</MU;0RFG>N7BYJ$55ERD$IA5X),M@.6@B@H=/RGA7BW\;-C:L=W".;6
MZ<3C8A)SX1-/D@UF:JEB,4;(O:34YM2)=3=0D#F$JXN%9N;FR4,H/\:Y=?=U
M"#*:M.WGG+HG9(@F@WOHIDMX:S+*H\NYKV,FQDEBBE)2HR=Y/+4_=[8>NAAH
M<5<LPJJ+P.W+P__[C'06O;K7*-4]>I-&0]+LBZ0":<22*>K)C A!0TW5>LM2
M5-'*O0,$0@=T5A@1OO%*ON9]GR)A$O1<$75UOH'5$4B4ONI(18SU:@$M:_/+
M$@JK:_IM16(DP"EAOP@S,)FE6L@&%:25[V'A%48 L2![?O)'%EYAL@?9%6UQ
MP3D#6[-A&CGS%V]Q2(>$&=O62":+@=?E\-$UH_O@DMZ!-D>=LT!]PR^NXKQ1
MDS3NLWTSXXM#2M>5%SC>U#]*Z4(.9'Q3<-WDU0.FU33HM8M*/ 4&UFH=RG5*
M)'+(@_)Q)QI7ENRV95Y8(W99<O6$.(5(Y$NH<C\^F(&>Z7U=/ICK<>__T;=P
MSNF@JX1.@BC:0ZLSAKF%"_0?\IK<4SNGV=AO..:,\X;?@SGRE*94/JJV<RAM
M2.5:TB.8C+9GRG:F0ZAH]SMAV)J?38:$/$]Q<H=,%]N,SB:>ZZSV<V>H;E/-
M7%60QVB;2&?(F9T\Y2K-K"IY%GNOLGF,0E87="J2XMNL:,W2(JYX5E:2EU6G
MHJ[2,HR\#J^P!][KO)[!MT,P-!'H"[_I A/.+^[DJ!+RK"XOD1+-SUCV@FK1
M5T4"&N\'BFOR_B_NN!&7M5A#$5G 5N >LW[_.#'HU] #^14F6UIO8:$,N5HH
MNEHN0Q=C 1!&*ORP4*0"D T_?G!0F+!"$80__S8 D0CD8<,? HO\N)C0X ^#
M!J/M(UG2Y#Y0$D%RW)A0I<J0,#LJC.EQYDR917Q<S FR A&?,4/^+.+QAP:0
M(7T8!)K0*%"D0S<6H1!R*LRE/IR";"H5*5"P(+4J)+)AK,>H%X%2W4B$Z<.E
M.C=^_?FC*=BY8IGJE6M7;MT-1!["9;L49-6H2\T6::I8J]S%:WT(%ESDJ\X-
M?=?^Y%Q9Z]C*4$$F9FOW:%N_2]V.M7Q8+MO765%7KBI[*=+ ;6=GQJO:;UV\
M<!<OCNN[K&G*R/=*UOLUL%^YQJ,S-AV;,6S5TZ47SZQU+=C%5<LN)9K=<.B'
MO>6J/YW]+ENHZU/GEO^]FKI]WQK6MU:_^CF1RR:3SRVPPB)P/[R(L&\U-^PZ
M$(WU&EPM0:#<<,L-QHC(JD("[1)0PS<(= L-L):R4$,B0BS"0C<$G(Q$']Z(
M,48B+-3)PLDPM%'!$%5D4<$4<U3P1!G="#%%'H=4DD0B:U3RQQ!;_)%%'Z:<
MDDDBF+32C39J9)'%+MWXLL8AQ!13B2[##/-'.L0LLTTWRFS#3"+F=&,.+LUL
MHTT[^\S33CSO%-//.>? 9,\Y$\6$CC8\*?1/-SIIXU Z+F&442X1==32-MJP
M@* B/K7 (B L$ @(A@H:-52$+#*"H!]0)8@BAEH]"-9:#PJ5HU@GFHBCB 3_
MZE6A6VT"8J/!=D5VI<&">L@B9 T2-B:>BCCII&4^VJHGE[H-JJ>96",OKYJ<
M;6FG<J=2RR>?*ONAJF^5:DDFR1**RB[.,(/)-+,2 NLBJ1["35_=QE4M7\-P
M6PLIW![C2J*_*&N+L-;Z/:VJU^"USU^F^L*LK\B.TJLNMBR6[-R(^_TNJ>(&
MY*JP[A@CRBY_)0)MNK5L+N+CL?03+[V7B2)N+LP:@\RQY3HN[[[1\.59YHSO
M:RLRZTS[ZC216[ON9_P64VXIC-VBJ^BOI?;+P.G"DUHZFF4+,#JU^_-+O-2*
MQFR[K==V6;_ZZI9;0;_O4ZT^G#V\SC8"5:,PRPR1_\MN1PZ1+()$QJHD(@T%
M&<-0P\DSM-RO$Z\#$D@3,T<RQQ]P5-!RU2 D<K(0+5\=1]HG#])))$D,<G/:
MG;002PM#!-YW+WV?DG@QBW<S>3KC-//Y&A/-\_DU]9S^>3SGK)//0<7$5/I$
M^?1$T.GG=/3[/RF]Y$]&#W5C_3DL73_\]3LY:%13[S]5U%D/\I^B41TD5:#B
MGZA"M2M?P2I4PBI6JX"5$%6UA%0JJ<"K/O41AD!071LI"$L&$A.0=+"#R0*%
M,DZB##OL*UHR^99-V/61F*1E7C:95VEBTI25Z.0B"-L*#5N8-<(,9BWPDLI*
M*@,PM?3+ALERC6VN$A71V/^+7W$!B1(-XS7J4*=A^G++2BY3%8WI1BQ2E)G1
M0*,2GV61;C8\XW.LLY@ <<PP7*S+%J5HL3>>!S@QBYA$:-.AJ^'%+W4[8U\"
M69TA:N9A^JF.V]IEG;!,9SHBZ^*_QL.8Q3Q-/9_9V7E@TR&WD$PPYWD9X0[F
MEMI YF3XZ:3>.!F72)KG.G[3BR!#F2!:7C*58?G/?OJVH, 9YVS( 67C #<A
MT3DH0SH)D6E.A#F_'8DQ)#+<ASR4.=TIDW$H.E*%1*<ZS$FI1JE;$8A8%SP@
MZ:B<Y3Q1EI24I"JM$YTGHJ?F9#>E>!Z/1>Q$GO*,]\\Q:8]Y 5W>\RRD)N\5
M;T[_9>K>$!A5(S[5B4M>LM-$,96]0?&)>^"CU*/ 5RE!8=10>)H?GN+'ODL8
MJ@W9DY6H2M4_(^"/51-1E:U.]:M/,80AIQH(J?QW*HX(A*<-B4A$#O(KI]"*
M)16!H5&%Q1"A/.2"S5*)"ZO**V])9" N3-=,-@BN>5V5A47<2A&CJJY$J@2'
M* /8N-H5Q"-&## YO$@@29:L+28,8H,L"GF2,[&[O45KOG$CP[#6,:N)3&WS
M\2+1VI9%?-4K:N#)BMI@(YR'#8=M9GL;>"+[FRX69F=T<\O0 'L7G?6L:93E
MSVA=*S'NB*:2[:D9T^AR2_C C&P2RZ1LZB:?__#1.Y&-L Y1Q%.XLD22D:11
MSM)N,QNXR=:55*O-T(2IG[^B;;:]Z24PBWG*82YH0#H1+^>LN<G[>%<U,BH0
M>0^DN,K%#BP2RM"1V'LA\GY3FQ#B)NE:=)W0@7)U&2*0BK@Y&0WUSB[2_*\X
MD>1.U;WN1[K+W9-\5SIZ]E.<8^)P] #JO"]Q.'EA8FB;R-0][UG4H(GR4J#L
MA+[K/:I\;KAHGC ZO_9A=%)SXA3[>,PE1CEJQW<Z_Y2E7(H_@NQO(?U[Z4L+
M""M5Q>I_$ZE@!9<,98@,1".V.M:M&/*2+WN+(1\LR >7"L.!?'DHYL(("&F(
MDQKN,*S>\J&W5NB2.-?P!V/QB5OWDJZ<^)F(=<T)$>.U$BRNZ[9!\8@<4>,4
MA\G5:%[,6E3$V!A(YR5GK#W-0W1#%%!/S#Z3]%>^'+O%KBB&KZG\)=#D J]^
ML6:-5ZPL=^9#V,JFMI4:&V07&<E*K%628G/T)*^S.-SOP*R2K22EUT8-2^2(
M,MB161IRK'T@Y5CGN,[ES]?<B)=46OLY]+%.>7JIG&33=KNV95IH.B9,[Y9-
MEA+KC7>U(SKSB,A!=L$<A__(ZQYM&HYS_ 5XYN(Y&652LT;DE="%/G0Z9HJ(
MFABJDN7F2:,6S:Z<29)<C7)T3]/I;G.ENQSN2L=/)QTIXU3ZDL4MKKR7LV@(
M:-B2\L#D8>8QU*#1,RA#&0H^$*.84'K:*)Q\_+[N86IZ.CYZ]MS7"2YQJGV=
MPH1)2\HEF>:45#Y]::VH?*I:A1U7!)0R3Y6:P"ACN2+-2I6R<BKE$'Y$)2.L
M:I=?F!$SJP2J52[7#[-J%*^^\(.#SW-5R>-W1">^7(N9ZUD5VV<]W^LM$NM,
M4%*9K*DLY[-;86Y>F)M)Q#RL-(;]S\..$\K6Z(=D87RE&)U#:R4N33Y\DX]H
M;_;_$Z^I3(C\"DW3I*8QW!/6UYF%)="636NMH9:YEX2CJ.M6W?C<;+B&C9HG
MK:;ID.'ED-E]&:]/KY?'EB7YA/&.YFV)2#_Z;6F7Z74OG2C+0!:LV^!N]V_+
M;Z#<H*UOL.%:&0^'W%Q:#_= +L: IF*R-_O@+WXSG9(SG<K9G/SB' O1I@F1
M+]MQN ;LIM01D73Z/P3SG'(Z$MBIN-G9)@CDKP:A)R'9IW:*DB51D'!*,"0Y
M'I73L ^[P1$3,9NKGH,Z,8$J$R* $SM1'J/+GC9YDS7!*"#[DSV9,:9[%*?#
ME$J9NHM"%"YQE*@+J2R<@QVKNE9QJ5FAJ9B2,B=S%5)Y_SLP'" N.Z#_Z:F!
M6#*H,B!=N2"6L(B7L*HMNX@,.A9BR;.M I67X(F_PP@YVQ>O8B(?DB&9<"N;
M:(S$BRMT88U *[72, H9PBQ]D;QX>0A#6PY.W(NRTK4J\B.2H9GT@YHQ.D5I
MZXJJ@*OJJ(ZH&)LK8@MI@P\C:J38$PU:M*'$&)K?4@Z(\2W:TZO ^K23.9CU
M( RLH3VB6!G:6Z1N>PU@5#VW&"_&FJW_RZ3XH"2]D(V2B22,P9CI&Q#>4 [V
M.P[92"72R(_=HJXL6AC1HS]X"[^ZX3;Z4P_K>@W_,!#TNS>\\+^_(20$\0L-
MD [2B@Y<FI!A:KC\4AP#3!P1L?^=\*J2LT$P]DJO%<F*S2FP 7LX]]K &RDY
M&7E )PDGC/,<'0&2%5DGW,$2=_(=QHB2D/RX"4N2?>HG%X0PY-&G"V,>&P0Q
MB9*H+R$Q@_H2(9RH@Z(QH&,HH303C I"/XDQ,5'")FP4.YD?+G&?\/FQ(9.4
MK#0II(.?*T043W$R)0L@5QD5FMH5-(05H;J5*/L487F[MWQ+6-$5-\0@0'P6
MOGL[.S.S/S26A( 69VFS9ED\FABK/X0AC. 6P?NAKIJA0^.J0=,SM-K$G/&A
M><DKHQ LC%F7EH";*[(97^RKS+@KSRB97!L^I]"_F+$7_FNE] L,::--:70.
MB!''28+_&NZR/EJLC+&!K8XAHL?0S5?CHF\DC-0<+LT@#DI,)"@"/[Y9+&P,
M1TTSOF 3CG2$KN%T+2?*/F 4-ODXI>JKO6HDG/"4O\#:3N,@&5S+HE\[-9SQ
MSGM;FGT,K 29FOZP#+F(/R=:F7H1&WF3&O&:MWF+0%;BG/92R"!!D T1'6\J
MD/MB+[L8N7_#+QL1N8S,'!M!L"&!T&7R+QH!' S1G1$DD(WD'89C'=Q)2<W9
M0)6C28^;49X<GN'1)X(*,1P,,1-S@R1 ,:8LRH+R$A2#%.N)RD QPCY!'S\!
M2[#D2BVT0K)$NI7:D_5)J?>Q2EPI%5+A %>Y'R9CLJ-J*3+\_[HJ(Q6# ""%
M^)2Q8T.\VQ6*&$PJDR#%[#*C4A>\4SPF*A<DXB#$!+0WB[/'C$S([%.W<LQY
M<9>0:,4X4U3 \"M_Z4R8 "/42%3#V\6@$*1%92/G@XR1 2S=!(VM0"U>:C:_
MJE1.XCW F(TI0HNLJ1?0Z@S=.)FL::*K2,W/LK10K514^C0U@IJX6!N.B3;D
M/$COJ"-K@R31*[^6Z:WGZ"SH> S?6IG2ZRRBB,ZA =!LO<Y>!<?QLD_HVL8#
M(:VR21#@")QFA)M&8AHMNC:R^27;2Z;RJK\";3><^1OU6H]Z R4:0= 'M1$)
M41R0%!"&-#@474D4B<!KBLG)$)+.>?^1DF.2BC,P&,2=#\TPW>$OD7,2S7DP
MDVS1=,JG=W+!W^$GDMW)*OD2(!PH?QH4F_LYWZDH@+(3.2&"0+$QB=*H[7&>
M.3E*-.F>H9M*-Z@Z(),>2'%2]YD?]1G+(!LR+NPHK.-2_?D?M?S2F&H5)2,5
M,U53K473,JO+BKA+88$6J5JJ*L,(.[RII9J(-'VS.XP5#WH5*Y,6.#O,P6.7
MO_PJHZ@S'WA;=A&,;V$B&?*KM76-NV(KM *8;PD*U?H8<[D\@FFLZKK4.1*9
M@?&T5OR7_I3.4Y2^FCG-7YV91++-R%)&^_C,UG(:S=7-F3$D9*$,.7)6X>R]
MUZJ.JNB.Q<+_).%#O\4BC9\A4)V9S9.Y#N/R/\NM&WK47%+RC%*SCR]JK=MX
M&5,\1O4,O6ZS35F*KM.()/50-N<+"X'T3TGR#>RPU_SD).&45]E;I;/A3TYZ
M/9U M[D!7@&S5[PY)GQ#6$)ZK\1!6/):6(K3-X,=D<BAT/YRIR+!+]DQL U\
M,)7$BPS30 O!' 3K-\WIV!5QD!A\N91#8"?9V(7CR>,!G@T487]J@YA;$X7J
ML#R)6: ]DSPQNJ;4$Z&,2O1A4CA)4D@A%$P0%/C12A^[%.E1J4PI6JA#E/II
M@U)A%:IU("1S,BA;LIIJ0YORLBAFTT\IEK#=PSS]E3&#"*2Z4\54_XEI"5LZ
M>TP\(SQ=H2 T^RIJ6:&NTE-RZ=-]F=0Y:Q<5HI<7DL3?=(U$TS/&RTQ3+*,_
M[D;.RQI6_8YD<9?CB$_5G2+Z/-58':QDW!G0RK1SQ5U>JJ7.U:R.V;32Z%4]
MHF1.RL1H6[;/6D^BF37XO#2><31:]8^^Q4;"/9J^ BQI)5X!?<=4M"74N!KM
M=;?MA:->TXS"*3U>#E"=$<Y3A:7F>^3KL*Q=:D9NE"W@ (YDCE]A/MV\"8M?
M*AOL*M=<,HYYV[=C$D@#&1$ 4U@&[5<!+KG2 4D%K5^.55 "(TEDDIW\DI $
M;B<(:5B95)(:S%@%H3 57#@)]% G@1V.D__8WZG8G]Q)B18Q'>0P@6J>[O$=
M)0 3@GHQB:HHD 9:GI-*H",?(RQ:E.:Q'*/2I 4I1!FI(O/A.?%*EZ*I,^S2
M,$S+)*/B ^*RLQVS5CF@KSW380&5@2B(.%4(N;TJ/W7+NUV6M@V*B(#J/B4\
M-I/,E] 6C'"AO-V70+TJU@@BQ=M$-F,\4+SJ/46C7CY<TF3<O5WFQS.;3K*8
M._(DT%#&AHF9AP"]J>%&VEP9?;'-^'!/Z["KJ4%&2@VV\D47RDBBZNBMOG:C
MFYE>/V9.;+VD,6+>L(@*XBP8W(U>A5DMCDG(:PL96UY>=6LNZ2KFSCI.[C4]
M[/BV:K9%]:"]US[R3U<RW]3(MGGLCV'%;5]&-GH-P&*6C@0=T/Z@9GL[+P<U
M)OSH7Q=9)_@R+_IBP B\D0RAX Q-0 Q,G0JE#H UN!]!L- Q$0<)8139IHHK
MP MI[XR4IXYEP90480S6IYBS02U!GANU:)9-2J&L$R*-RI >*#FQ$.[9Z#;8
M:/)90D!A<*7<X?0I:1<36BO,'@L_%*V\,2O%E$ZX%@__<! /<1$?<1(O<1,_
M<11/<15?<19O<1=_<1B/<1F?<1JO<1N_<1S/<1W?<1[O<1__<2 /<B$?<B(O
M<B,_<B1/<B5?<B9O<B=_<BB/<BF?<BJO<BN_<BR0SW(MWW(N[W(O_W(P#W,Q
M'W,R+W,S/W,T3W,U7W,V;W,W?W,XCW,YGW,ZKW,[OW,\SW,]WW,^[W,__W-
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MNO]^Y =_L@=^WL_[ZE?^])?^[7_ZI']^IH_^^9=^^,]Z[A?_I"=_@,"1PX%
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MDXJQHH>FHMJ,WD59HVB.AE_@LF-0QO_*-D_.[<OT;E"#6AQF+F:;UK7VYL[
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M?6!ZM\%L^VRO)48Q$(\>PJ$ @8<MN</0SPKSE\\,QR5U,(M",+*9"!+.4QK
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MTS<7TT]A)*D6+2:,*/9TGRSE0ACE?"M</33)13 )_QJ%+ -==!N)8C23)N4
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M$8R?,\[(-+U00QV \(U$MNFZ$Y"G7Z\#D:.QU3 )=0VDR12BUS2L@^HLV]R
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M2()@F']ON(5:*(8H.(6T*(A9"(+GB'X'^']W>(*-*(K]V(XEF(E5*(=/TH
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MK>JJZZ"C-WJP!INP"+NP"MNP#/NP#KL.KZJKYEJQ%GNQNXJN2#FEN"F;+ H
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MX34?61@6@_6\,W@9#1^AT-/@N++A0&<^*)O@?J#P'#BM;#E0@Q$F+F1-!)G
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MJ !V+0(?*((-@%<*4%<6JB! S=4 ]50"-:RN&E(N4J.=V4_Q_]!2HX =OC"
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M,JA,@OZ%W$Y8PXT*7W1ME1@68LU*)![PRI#J>L1,':S= &]PJ'AO<$P" ,3
M0ARM24S"/A!#YJ[>97 1V;'P"LO7U%($VI&<21C!_OC<#T3_@^[*&QHY)>+A
M)%^=I/QR<%NT+6:-#IA\+!%_RDKAVJ=V2:P,KM(L,16[F0<#1W((BPD[A?L.
M1'(X!P!D0CV8[PF*,1F'\4/$<$0LVA!31'2%F+.&JU7&23LV!!@%:A5[1$Y@
M21,9!6BP!!*9:AZ'BHDT8@8*#6Y EF,X\" WLB==<7#T% #< .5R<0J?;PM7
M3R:[+QH[A#=^,BB'LBB#\M<",)ETXRB/\F@%[5J%#3^^R3"2"3V@!#WXAC>B
M\M=BA#"D,B_WLB__,C 'LS /,S$7LS<20V(0DFP@AB9<42VGA$OLVB<_\_=1
M<RI;LS%GLS9O,S=WLS>#,BWS,C8___,LS[(R8#,R)T8ENL82)2S'CDPW=\?'
M?#,]U[,]WS,^Y[,^[S,^ TGDJA *0QP8I^] LZ_3]E@E(]DU_:53(&[=[,?2
MZ)>3X+$C"P36F=S9\,4A000M'6]%JU!=X$3/, A(X49Z[,3@,/) I"T0J/1'
MO_1P_#-P5 _L79S%S5Y)=/% O!XF+P1/K^]/7[)!>/1#L'%YNK)"58!<H%T;
M$S&D[*5/\(E;7A(<"#),6]9A'6QX2<Z7H'3-3$Y@7;58^XI,;X8(AZ2P'"\*
M3X\8<&[H[D-;DR[GPK5;S[5#J#%$H!U%T\5@^D!8ZY?([37N<@>E_+%N6?58
M;^*B2HI$46].82!V8D?V"9:U9H@Q[$W"3EWV\28'AMS %N\#6WI*:.\TD;CT
M/MSKU<2O:*G!/A4!3"RUVW$PIF'6ERB%9+^TG"D/M@P%4=^V(T.R"BG#9TL&
M#"KTNSH%GD&V103V8(L'5//E1ONV= ?N7RBW=+__-'!KQA7)]0WT]D"(@7<;
M!%X7]4(W-4=[!\$Z!5,'+&$CL:!=-WR?MGC%-WT31'9CAMB129&L -6@]EQ0
M&@V7!&WD0&WX=T<LFF"CWFS#BFO(A'77=QY'E&&$-X0/\'U+1D(00WY;+LX4
M-V98VS69]T,0C]H&B('+<&R#8GN?36((<(5_-%4_^(M3\87/1; H0T+LPXWC
MS'@;&'.K1>1<QE>WQ(D7M<@%.->U#X/'Q$S,N),_^8S7N%PD!)7KN%"'2I&O
M!96).$1<TGOS%GOI@";PIW6$.-<Y=Y811HM#.9NW>7U+>5N@,)%,1 R8XLQX
M^.[]>'#<+Q!D.;[J>;&AJOE@Z(:,N[FA'_H&PWD1H\%E#+?,]+@=I[APZ+!/
MC'E$K/>L1<.>U,:7%#JB?SJH*ZZBGYB?JS>@'T<]R-V7+S>"N9EXN%#H=+J+
MA_I Y-[UTCJNH]ZHKP6CPS61)'3,X/E<@/A[^H>W575#8+J)6:;N;EO*Y3I;
MR"!Z0CNUZSIE;P8(7Q$ & "14 VD,P2 ^YNWJ<&\(KAV[3%ZWUBUMT7D55\%
M:,6ZQSO3_^VZ4]PX"(,V&<M,J9L$&"&#ARA#XZQZF1?[8#&[=\0$3LA[0U2@
MJGYKM]I?6:B3W[V)DBHIS#Y>-+1.H@[LOBM\HM*[25CN#?#WCM\Y<(@GHW5(
MZX90*+2GR'%<1:%[QWB:IZO0:O@IR![E6_!?&O%ABY8AKC[KHR4>G:@6/]ZD
M@ZW1AA&DW2R@XP54B17;7JI!S7O\Z8%\23C3"BB'E6\OLWS[0>CU P-9")6R
MDCF4<\,!OL2$;:,8\50]E)2/;WU3XD5? H*AHT5?'JG+]KFL//H6SZ'+;\[C
MNER8_B&A(T6K%-XFC<81&[V5TV=5!*(8V5>&U2?ZM=,5D1C 0O]P 1KT-_QV
M#1/'1BS*%K24VW%<R=3;:RVZV;CC1NU A;KE7,RAZ%K9C7)]GW.N!1Q(5SV=
M94G0F\[W*-WKSU(Z=&WAZM['U6OYU4/.^N5??>9OQHA0>' (.VP?=ZB$PDMF
M!";$P;.O!:IIA?6WS\';3,+/VO*TA/6S184U4IL0E[7>1^3C#3AF1Y-]1<?+
MA7,>)4!HL@/GS9LB!XM4*.)CP\$*1'YL^*'A!P6$;PB"TJAL&;1]'T&&%#F2
MY,AH^Y;M4Q9M&4>7H91M B53TR9--^%H@K,3CIJ>/8&H"0J$#!"C0#255+J4
M:5.G3Z%&E3J5:E6K5[%FU;K5*@"N7KG_1H66:9(R96'1EB265N0\8.K4L=L*
MI\@/.&GEP04FZ:@:32FM&IPXN$C6EIN ZC J-&A-P&PA.TVYLF5ECJ"6:0JE
M:>9-SSE!\_P)M&_?GCZ%G@:J&O5HGZ)U@O9L4W-M4)QU8C2X<(./(KV+$*E+
M1&$1C'4T8CX9F:HF(#\2%@G*/*N^9=',:M14IR!"WS^$+QPND2%TX[IWZE0O
MNK50QD9S -'QXZCBHT;M#[U_7X?0_/M+$^HQZ@@LT, #$4Q0P<C TJI!!-$
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MA#:UHAW&RB@#9\2J4T%SJ-9&!6[PAS)W ]<",#O(AR11$Q2\DT-9M$47]-R
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MH\.R!E4O8<1/:C8R\4DEG$O[4$DY4Y+3\Y]ID,*J-#UB/!5V6D.N"@!E@Q"
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MD^/2L9- D:HZS8(SZ=INH6W25W9'%EFRJHVL6!*H82$V6EEJ18P:^RY0\KA
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M?W[TIU_]ZV=_^]W_?OC'7_[SIW_][7]__.=?__OG?__]_QY_  Q  1Q  BQ
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M% "#@F%0& R*@$$Q,"@.%@> Q8%A<3!8' (6AX'%X6!H  P-AJ%A,#0"AL;
MT#@8%@##@F%8& R+@&$Q,"P.A@/ <& 8#@;#(6 X# SW'X+_B(,1 !@"@$
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M7ZVK0:4E=9 .%T=J6_--:'OIGV3!<K28:^*K=HFF8/!Z#,C1%@M#L<U#1[O
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MJQ'"4XBY<[/LE;V>:F*YM2ZGFX _F.$!M =:2NSE0/2\2LC'I @R30:=1_B
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MU7QQ-(; 0VAHF>2$L&-T)M-8C98J+I&8C..=885M5UDF&T=69P5_P<.55I'
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M M6*)"2KDNH4HT5EWJ9,!< $!JJ"**P@\U)XD$V]01G1T%4T,H&MIP[(5V_
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MXH^^(MOF8BWD3V;6#;<$<@ AZ9!^QO\:R6<XZ?[H#2,M8VB,H/]D/19&,6D
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M3(JX#TT$95[K,LI,GGB5@OC%B31A2A/]9;&9&(9?;V&7OWZ21<9(12]Z49G
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M<!*.?=)4<TTU_Z.1TLP?$ )B@R2+F%+*-34)*224^OP!E&767 84A/K<X(U
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M8T/J(;).(>,]UKJP=LR3 JDIB9\DDQ3 )9_S&;SY<4S$_+*D4C._VQ1B&43
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M=8TDV)5G;!739&(>KFW;T\K<N?$G&-X4MH;5IS44FZH2U6D" *@M)J&!VL9
M=/8G<6920>'A)J6!VN(M * !E&5"WA)#-*0M .!6W[YM-+0M &A"RV(2,0#
M)"P2WHI!/D$N<.&M@8F!X";2<>5M)BR4VBY#WV8"M7W1W8Y!;![CNLY1W^(M
MY]YF$]ZM&&Q=6$DM^)41 /C36$8FYVF=HTX" $1N+Q%N&3&NWFY2\)ZJ1L;4
MV@;KIF*8]SG2AB(BCM9M.(Z@=J97^M'2,K9DWYTJOUGJ$![?YIWD$S9=N.D:
MN9WB"P:A0QY4L(V8\-GE, %LI?(<>R63_Y?^:"$>GVTQ%.U]H+4";3-"%1_Z
MU[\1WA[J85$N:C,V7>'M9Z;&7B,R7D]-;2"))@&OH*.I*-,:JC\EGR\-UUYJ
MF21FV;7!7-<M9"S"G>@^U^G]).@5H_\IFDZZI4\Y&1S^E;U>)=9R(^%II"K2
MUHS^9URNXW92HR^E6KE%6*4-T\NVW$Q!6?FM8$5AG,5YY]'MG&E^X$FY85OQ
MZQH27WSY\"L=I!G&+%*E(9)UXDU>I,Q!GY$V69INET:JWL9Y68=9:\E5\7 =
MDS2I+N*Z40RH[0ULWCN9Y@,*6/NETN7FK=J&;C0P<MYJ@CX$  "$+AD)<NC6
M ^0FVS@)\N/F;?\:F)(*;.XRQ, -1 , I$$T,.[?SIT9]6XCHP'# D ,/"XA
M@V?;2L*C'3 #9]S=-O(E(UB:M:WC@B*965GI59+:BB<$KR(A$EP7]:X8A"8
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M[1G.LNC:8ZOXGVJ]'X@ +.5<M[#P$+/[G/S>(O5?MN,YG_R,8W\\EF=]-!&
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MF,EJE:,%M%PM<D2-%ATJ]&=0H[N\.=WU35>M;\+H\8PH,LB%39OBQ%DS,<+
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M;7PQ: 6(<KJ^S=MG\"#"?<N6;;H0),+#( !NR(@1XT;"C!HW<NSH\:/'6N5
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M&D\0R;VBH0_O_3?.EWH,<KG:B@OIUB8/'K:XIU)=LJ/7\<@MJRE'Q/*- \8
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M&75A1C26\8QI7.,;W=A&-JI1CG6D(QSG&$<\VC&/=]PC(/4HR#\.TH]Y5"*
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MHO653D;*R_\!H"D^8U&FI5KVER7NHG=!)/@E'&X!C3ON0Z'M I&1 R^T72V
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MQ0!JE&M7KU_!AA4[EFS9LL3,IE5;\T9'@2K%$FQ;=B'+L%--XO6*)D9!CC<
MV.6Z$*U> SB]IBRHK*->KT!))E7J-2E!A"O0? U,=2%0 &ZY3LJD<]^-S&^]
MR@6MFO)H #OW0=OL%4",V0?1K.@JQC8 RU,#ZP[==O;6I31K @<@7* RXT;_
M!J9I&W37G@AG:D8KD*)TRH$7 ]CNV&A@Q)E<;P\-WJ!DKV*4PD<. ''->O0+
M?B9VV'SHOON,F\FXDUHR#*>YFGMNK049;-#!!R'T"KD(*>P*032J TL,JA 4
M2PSA #CM+JH.&O]*0XSD U PG_ +B<05W/@J*8.4(L\HP@HRH*/.P)IQ(\O
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MN 8HO+>EY[4O[/E_EP$&OG6DDSGPH'U-T8YNL#W'11$:DEW$MO=;@0(-.LT
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M[>??_WWV]9>?@?R1ER"" 1[(X(,+$MA@A ,*^!^$%$I88'_1=8=1>]$0 T
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MQW+<O,R+Q'\,R($LR#@K)7U+QBZ;2S"R K(+(Q"Q7%>,KT\[NE6"QGZ<KRL
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MG"<J&!;%A2M1AB:4,2LXOA$A?<)?#6.2)TP0*BC"^V$?_?A'0 :R(H8*8L8
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MDBF'L?0M)H4;/._.47C'"TYP@3L'\ XW5K.><WAE45W:S6+\XAV_<,*3*>\
MYSOE16[YO5]>\P4'^,G)L?)4#H0>O6+Y8[SQ_QQCS5WUJX^+SAD.<:/S?.BR
M-[K6S7Y[9U\<ZH_7?>//=/7#FPGB3;=0W1\^<=LG/^FQ+SKN/W3[LCLK[4.Y
MS@T"$.B3 .#P&&)]][U/EM/S?N!C"KS)^]YW\WN^2XI'O-/;OWO#LU_^[E?6
MU0>??O3?7__I-SG^03^4>D #+A SL**X[SM !%2*6J@XB>LVYZL]9%D^9*FZ
M9\,X<AB^B[LZW^.]#8R_X,.VW)N]!X0VYLL]"5R^Z4N0B!"3!&Q!%_R)"V3
MS9@XYS 3]3,X@L._E.N,UW,XK'L]&;RZX[.[(*PX(;2[A].X&_P[_A,\'<1!
M__N)T@N)&\FIW (  _!\02W<PI18P".DP1]DON@CP:%S-C 4$R-$PQ_T01DD
M0JS[P@9\CC/1/1$<P^0301.,ON7CC!3\B5%R*DTAP),* $EHA&7@0D1,1) H
M!S@<0AHLA[P8B(XC"'WP.PTQ!TKL/5J0CF*906_PG(%@AV<K"*JSOV_("WH
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MUR 0!5$"U>VXS@8IUW:W6U.$FK)VPV5EE :1\8:+3.Q&SB7+P>&'>/H#Y;1
MW+F2\GKW.6L\Y]8\UTT6%SM!8 2S3X*W,+VW'(1(%#NU!R>4JRB7NT5K52]$
MAP>6BW2ZG_M2E#37CT5'3\609X6V6WE]6#U1-)WUH#Q/C.<N/"\NM3V8PT;<
MRX1TUGU!4/*ZNNOQNMJ/K(TYUU[+;\5\3VE6BR]*]#U.U,/P2#E> 6TEDMJ'
M/12S3:U M^[_]:(.HVK/0E#5%,EV<X6,D(,AL?,;PL:(JY[0OZ"O TMG.YL[
MCO8]SV,*-4?@.(<5]TWN1[W4%P1)],@<J_Q$E/LN%X8PM\JXX\19B.SP(T3Q
MXP2TM\IRQ_%P._]!2#]:-+?U*C]L7[_?[T?WMX2Z6P75R[U0/#[WB#]"W-?!
M@H7D'_98!+*7KW]?UC\*9??0(^AP8@90 T0Y6@++>=ME\)NNA L5*CSXT&#$
M<K7(4:Q5:R"MA14G<K0H,.)#A@M%5B3W#>(NDB%1LE2X#V9,F3-IUK1Y,Z8R
MG#MY]I1)#   -,0R30I*;*<R ,HR 8 I1LR^3#&>1L49=*9!CCYG_VKDRI/B
MUYT#Q>Y$6?;F0;0WO]%:.S/"!8-QW\JLY:TN3;5Y8X;E"_/NWWT:%;K]*U P
MS+."VR9^F=A@8I6) U,FEYCL7WKS_/+51Y&>X,>"]_[MG!AUS)$.$;).V;JE
M2-?>6!/\.-"BR5JV"6;LN-LW[H+E1+Y.N5)E0Y3+.>+67;#D[I#>)MJ^G+HL
M4NQKFP;UCL:FF!M/G=9;NN^\>:3GKSJE&21"V;N[$/_U5BMQ8\EX!5=$G3FO
M"W8X*(@=[-L%-?\$FR@Q!?ER3;1O4"N-+P#SBN"@"^+[B\*\ZON+%@3_V@'#
M;R+8,*]=#.L//\9:/&Q%#E_D:Y<9MV.1H/_58D-(MAV3\_&;WGZS;K?;?FMN
M2.&<JZ4P(8&K;DDD;].-2B.?].W)W"RZ\2N=N"RKGJ(F 0^G&X(R(*;NK)(J
MJ#5OPHJF"((HBTK2^.-00LA$-.TZQG31TS+!3A3H L$LS.NT+]%*2- @-"KT
MPB H.I&O(!+: 5*^$JWKT+H8_4O BH*8\\)OR*'+M#L?S)-/U"(3[#Y%!;/R
M)(B@)&@ZE8P#4KE>=702R>"$'"BA6X7%\KDEDQQ22RF3);)/66_23MIJWX)S
M)OC6TI8O#172D"\,O0$7Q@9MS,M!&E6MZX*!* W0T7(,1#0BC,+]%D5K>XKU
M+SDGK30"44G-:[28O]+U,$:"66T55%'SK:N6/?GZ\,%SZZ(88G(.2EA?GV;[
M\6/8>JRM65JS].A984T62"5DGT0.N>F&/=+(*+5TLN.:O,R9YYVPE4G.M8+F
M:P=+=2FZ4H,PG;6<0)W^:S&B!0HBT[P^1??)==$R>NF><>H0X?S^]!.U386>
MM.JWS'X+8T_'#C<(I6>-UNJW4X55)*_UWIOOOKG_HM9OKW^.B=NR"E]U/U<Y
M?NO@M[PUT4['%LX8.,&ZUI0CK?MNO*Z"%98<M6\L1NL"4>>M:P>%WD4\0L'@
MRY!%RB9_ZT1=RGDX\-QUWYUWG';NW=K!81JZ+.(Y_<WNMUXE;7:U-4>KZ(32
M5EYB3EL:_2N6!!,0;X.PUWOMM:[F:_RZ4?/<;4,[:AKJY-,7F[+GBZ^(>W2#
M[!3X_/7?7U_ ^>=2>/LXW%<&N)8C-4\LOY$?5YJTN+*0Q(%?$<D")4A!KAQ)
M=W*2$[G^AQ:+Z(=U6*L("#N'P+6H:$'$BN %+;)""9HP@;BQH,=@*!:51.-
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M_?!"2P6KM[G][WVX\S9KUIH]L_?,.6MT]77D%5SY208(OP'^GT$!  0 @ 8
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MT*!^MTB55SN\1;. H8FY0"+3/-U%V+TY7J_ 1G+0W<9=OCVIKME8=4_0J,K
M+U1I&NWW.\?Z2DYXGE_4[2(W0Q:OX.E6_5K/C#!-%D?R;IWU-ROZ5>(9W3.%
M12J_&T+3A;//4?WQFX2WBG_9G54?%2]]3F0C,616PNTS8>'WWX8T*K\^;8GB
MT[YP-C=8^(#LBA*9; WN2.;P\=S\)++9.M>:;*MLG\:TQ\ON"1V.N%CT1@2D
M7G0-OU.1BY4[\__)Z6G[U7(NZ6%PS-<?Y5/ATU??(Z,C_*._CW?F5J:R.18X
M"4<>GK9B07 O- =,F>S";K'J0:C+;;-9_+4_-M%:*$5T@H<N;GWQS>L84TF1
MP;RQOW7!_MDUCS$*_]&\@-6EK;P_]UM)!IM&S,I=5-<%6''9_8PLSP0V.,!4
MP2I+JQ<?@'CKL%KB!I."U5;.U1:'/T-M8_8Q34EXF_\"Z@#.C5M]4\\+Y^;X
M[04;8W^'4,"E;#CY:$FV;,(2;3BN_.(9;,$Y@OSK @&:0LSMPHHPN].O0BE2
MP@R5=$7Q6E(:=NF:,.E1S32<5J:4H#)/O%6[OU:5L/VZ]C>$B+DKL=XA,-"5
M,3@(U+S*X QCZ)1)(-G448L06:D6^<$8@#V"R06)/\H'/;8*EF,R6*(3U]60
MDG=/9+5D.,B78! (9R]D7#IB?-6.E.<5=>65XNL-]I%+E'PG[6\;$D@>$MP0
M LL+Z9%.?/(]..B=491\2$AQ\K-SHSA;E-FAH5.OF+2 K,#74"D\(IQ[(YR#
M%+6FF9P8(5U'@(J7=BD4>D"P$4H_E2+_C1UAE2IOX]03FAS[*&P&F1I#YFP]
M[BXBZPY\XO;@B1O+F2O$VKT?E<B"T-GC"W_HE58 3'^#2ALC%Q-+2AO8>O+>
MTV#O5,_9,JQ#/GRTG=T$$?EVQ8 !CF#P5"3BET7(AA\R*X!)%!U(%8 X[L($
M\Y=%YBIW"-G$J%(HSR@3<V$-HI@HLZ53,4U#J>:195T"MRP\:W53B7Y,H>Z1
M5]29TC"9E2BAU[26%ZY7^4"7M_+,:H'^F62N][L;;\U@_@->^/&Q2DD][\<:
M*TN2Y^XR?,*-\&\W:KTZO@\H^ F8K2?Q4VKPW#R\G!^YAQI1K?J 0.SGA.>$
MY/F>JW[,KH\%/03)>&R907$6*8\-6?S/$ 3G/?E)8'_&+T"4MJWHJ!#WN98Z
M@7\!84"]IEW#M59^M;8*7X++.DQ%P\[6'*D)M']8J_UJ+* +7J0YHQUM!UG
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M-F6A,4_>XUN9@MV6[>!^<0.87)_8Q;W\CK+%VB9886FUUTKA+BO*Q$.\]K5
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M@!^E'\9WXYC7'W<![]8+5'J*V8H ];</4X#0G<<50V>L?B_O$+#'Y>B-7=_
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MBR<Q2BRR86'$C: \I@2U#YHR.#(U;%06%../K0<_E86V,>+$I3P/SCQK$.O
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MV!^,3=8("W[@ -DBF$T6VF,M,"+8:)&U5MAGL74VVB* -:)99,==]@W6F*V
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MT*$UQ4C\'!$JIZPFYE.&G8N0Z(ZH9$(EH<JF&[T4CRZ.-2Y[96LNLIQ4/B^
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M"G<5LDLY:F,9F12ZQA4Q?KGD)$CY5Q89MB]@0=$J A-6H206KI-(JR4WG-C
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MI0<,H:0TIO\,E\(I&0?>RK@U 6QQK3 %O@#>T(&<:"T_ +:+_ONTTM'G#B]
M^O^0P-X A1B":/H30 _DBRE)P:S0#2]I5OE51-9<SKRL@,^" V4@OPT\K/HH
M>JT (%;WJ_)9(B7,( 11=-:J#X S'=QI./LEDE"ON1)V$JJ&G1H1+3S$_!4V
MD+&O#H+#5BX$H!ZAKBND6+F6#")PP2#IJW\EUS2,.K4BN>":(!)6_,$>H" R
MK.XB+-2\GHA-(A1V-P/BSKN*32,T5NDD++\V(Z(;.G5[S"L6]>]$0KB>."*"
M+YXC$_%?SZ1U4$*AI%K,;%BIEF(1(Z;5+^](ET&J%Z+U=5!I=G(I%-+>%8!
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M]S5-D.QR(M(4"41>Z;%G*L0C"P%R1H:L$IC@6&0H0UK/>KP3)@\MRD+CB=;
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M5:Z9KJ14R*E0P)/:G$U,JLU/ZE-"B5]-ILU=U!E-*@7L]MGJ(M1"&11"Q8U
M$<6A@12CD9122FJF4@:G2B5J7%JHU0:GBBH!RD9KP X<).!Z2$;HG <'>.5T
M")L=]-2H%2$#N8ZTGO].K:65#V:;]^(:L-(E]J1J-&B/K]&@?>P@O(UO'GJ5
M7OT''B:F>[Q!] J(OA:![#@(C_SO=&A"?YR5!C75M/%6K6Y'GDB;5C*;!VW
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M'Z,21NT2PU$N6N]^5./T7_Y]:E,*H/$^#O+V5&@T+V_$1N<PX63%FC(80>W
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MEK/@FF<Y_UBYEHLY56W(3F.7O%7)& EU>F4;FL-FI-C:L#BA$ :2OJJ*DU
M?^7_:Y70E8&YX-8]]BP:<=JAZQBU%AL?,:+_2<K1ZY'T;PYCUW$]T6>AD7*U
M2LCIYF.]%Q$7ITX5$74ML0V+G!45US1*Z- Y2<2J.JGG7*XWU]+%7,7^H5VG
MR[^6%VQG(PBG]1OQER_6\*/,%2TRY\OEMC&>)[;4%\TZG#&:**:HG-)E'=]U
M<-GIM21UZ'1^>[_4,+U$TF>K]AY9;2RK$;Q;V,),\HE*#.1)"]XRS$>HTN)!
M-\?4$LK8#.716"H3#,O8F":-M\E,$T)XQ(OEA"F]V$<P/)$!KD2<Q+[,J$&&
MQ,3/A"TOD]#L'C.)/$_@<GT[S47ZLN5>&=:$!1T 'X'S_S)!P+R7J20_&=]:
MO 6"4X7.LV1>"([8*/A<J*Z@_21=Q*Z>J1]<] 6A*7U?_$U!"4[<$ 9C[$4Z
M0VK_5:K_29I* 6#F^&Z,<[WE9(ZH/2IK@#U+/9IJ(&^HG0=-\49,;<YK7"7L
M>#D%%D^O@:^._VJL9MO?[R6P5I65/TA)AU6X,?F5_ZI*1WFQ?E7T_!6(8,BA
M"_!W_M41O69^('%NX=O)MAOT@$?/G3E.9Z)[<#Y(O$@3^8AWA@CFO]R$F'Y^
MO)>N,*=S@,(@?7X;/5 S%I#!RK0>EPJ5U ^@1Z>3!%<.K7"G%%#,]?ZJ_V)X
MZL8*\5'KZY;)*>>MIQQW9C\0@?]*$/40%:O^<ZGF7F/1Q@FB+PX[R/J^%/GG
M=$V_;(&*AHSGTX&7S\G<$+UVO,LQL43C,P)$$1\;?!3Y0:1"$2('%?[0(' #
MPX(%%Q(A*+!A1884,%)DR+#"PH<^#B:D&/*@0X,:&%;$V%'AAH49(9XD@A'A
MS8$W.>:4J! C2YTX?VH<2L3C4!\W738M2B0-TY1*@2ZMZG+B&R)-)W9D^G6K
MPJ]7#S*EJ!4J4JT4=6YU0]$'6B)HQ/IP@U3ATJU(PU8DXJ;(W;!HMA(F/%?@
M7;H+!;]9NE;P7;N%]P+^JY!PD<-OB6B]JW7Q7<%11?_].[FT:-2FWZIV(SKU
MZ[^R7P__H3T;MFW<NMN\[NVF#>[>;>@ -SZ<SN_@M'\;=^Y<N6_IO>= ?YW<
M3?7>EXY+UXY]>/<YPS$AOT2'NWG@Z(=[(MZF$_#X;=S'GU.^C3(@%GY8 %)A
MOP K,,*_ O?KSP@ .>BO"/\ M*#!'Q9,$(@%+:"0O_^ V "(_G[04,(/.>00
MP CY(_'#"A@$$,"(%@RQ"!5_B"BA&3^,T<80@8@11R-^@)$_@Q8LPL>(-OR!
MQX14Q#&B'Y0TZ$D;:WPRRBD-BBA)*'$TB$<G#<H1RQI9LO'*'\,L,Z(TD:QQ
M2S*51(A+AY!TD\LEQ2331BR1Y*@@CM;L$DZ3"(H(3HY02O+'_YG83,C/(G@L
MJ$:+9AP(R8$LK:F(-&>B]"&4(@)EGU"5X;(@B%1*J=.%-GBI5$.'^H@EHC 2
MM" Y94)RIIE<+2+4?:()":6A@L6UTE4G)71&8;$BU:!<Y0RJTB)Z0A(CE4*J
M5E61I%4HI(L(Q>BBES[:E"@X?9+I6ELA%:DD3/F4:5MM5:*T(D*O?;>KC2 R
M*J.BQG6TSR*$VK8A@*O*M*"+3M6(6VZ'DI6D@H]",M9ELWUVV83);>A63#.F
MJ:EFIX*IWJ1&KO4A?DVFRJE7+299(JDF-NO@I'#RJURV< +YA[L"$V@LM@Y"
MR[+.)G)CJH.BFJ@OP.PJB+.RZH*L,_^7!&-,+,L$\BRPG@-+2S2@TT+K:X7D
M*KJTR4RKNNR[HJIZ,[4CVXIHM^Q>K3'6]"8L-KUO@\TNQ5ASPS;8<"/\KMX.
M7SPVX)2@S7#(?2LN/.P*=R,Y(HA;CW#LLI/..]_"*P\[[*K3KCSC[CL=D^K2
M,_TXZEH'CKA+>NODO=3ADZ^-[>:PW3UE'@S0P@8#)%%#"S7DS\$#!5S^0^89
MO)#%#:TGD4(53_SO!PIG/-+"[A/B_LC_?%QP1PC_BW%'$;T$<$5$Y5=1Q3"]
M9!#/$==T\T_\Z^R_1DUJTI8"2"<#"M!,?RI@C%1%)TB5:5M6RM_][#6K!BJ*
M2Z[:4Y?"!*?_@$6*3)1Z5)WJ52B,\,E1<FK@2J+5+!!N:X.UDM1-4M(0#?@@
M&KUZ"$<&54,>UK BP!)8M#QEPFU%A"47D6&Z9B(4)/Y$&;W2Q$Q,U3$/#@I3
M'K$@2*X(IR3FI%D*FR$#+\(15I%1AEQR5D:0*"NA%-%:V<(6$&M8*BU:C%JU
MFB,-^?63?^F+(2<$V+?\-$,E7D0I2L14K 9RQFG=I&(CJV._+!)$;76E*\ZR
M6$*:*+)*)@V/FQQ*(56RK)Y<ZX[-BA>V#$:RG8T+5J_TB<Q6"9=;L6QG25%9
M1F16EH,L)BU&@9I1L+:4J3!M+%7;"UH<@S2\)/,FDI'+54Q3$&!._^:7ILG+
M7OQB%;W(A3*)08K;MF(7H%E&:X<AC-KTQAJ%?.8TH#F-T5+SEY[IS9SUC!QK
M^#8;?Y9&<<!A3>%FHYO7P$:@CEM.=!!7F^F$KC<$[4UQ&HJYX#0G.AA]S7?"
M8QS89103P)G=>]#3'>I\CC[;04]RW+.=E+KA/-O)#GQN)]*7:B<_%V)>@ K4
M'YX:[WD4HA"'^(.^XD&HJ"G2T("JU]3T%6&IV<M>AP;DI!1!-2(02@A_F&I5
M#DGI1?KK4HE4]"(E(2DB/JJ16LLDI2_IB8#]HY'].)C +/%/2WA=T@%_9*JZ
M"L1*@NJ?J>!D(PS2:8%1BM5@YP17Q@9J5O]A1.NSNJ3*"<:*DP=16!(;::UJ
M,?*)$30BDMX@19A A)5"3 A,%C8I5=(KD(U,5TV0Q4!<O2F'OLH)$S?(Q=1N
MBY&.0F%*PJ7%WE[282UDE[FBQ5G1/FNX)FR5P22IJR$.L8N8NI=P';5=:=WD
M(F\$[[J>%:M38D61,$GCI=:H*CLZBB:9-(G#'+4I1,X+6A99%R7[)3 VED1>
MF@3PR8B2,OR"D5Z>+' -!R8Q8O&D7 2>5LIL"S/]EBN7_+79AH%2$5T";6=^
M>0K(;B:UKYA8Q,GL<%2RB4F<A44RSG3F6?"R3LNT9"]1R=I5"*,5TERF-(ZQ
M)SRU>1F[$4TLZES_)MT0<Y>#R'@ISIR+W?Q&-W.NK37MS+(^J\SEY40.<O^D
M#4$1>M#![<;,N9&<YQ#7'.T<='.<FUQ'E4,Y\$#TH]-)G>NPDQ[=O8<\-<5I
M<MK0ND(7.CO<65WOW,.=^.BG0,:K7O.&5SWE[=0_R-OI@Z*'H!9U*$-?G5#U
M.!0AZWTO1@D*T8)0]"+^A,A&%,)16'-T)!CM-=;?>Y^6"G@D"/%O2#4*-@0I
M:%<)5C:Q>Y*K 3U%)C\AL+(Y0C8$F]U!U_Z)O#!,$\J.-9$>FA"$>L+2N];$
MKB0:=EODA>R?JB5&,OJV770<U$)RNX^'V BTVRID1U;%*!<"Q;-V#.UT_V.E
M2A3"E@APZ!4<UL@1H6BVAL?RXZT&QLG,\OL@*"SL!5?"0E4)<B?1TN1K#>:L
MXL+K6B@9"<EI@C$_&B5:>C0NN5SR$RV:$84>PV_%/*G93.(7YXZZ=R^-<BW6
MCC>^'!,X'2\F%9J,!%X4P<FAR&6S?RVW838KNBF3WN"0,R7"1X'7(P^VW*+<
M=V89EOK*<GD4$#/-,6]OV<_?$ABVT,4NV2Q+7\2B%;/AQ9@G[LLZE7F5&&M&
M+/8LIY'%MA5?MN5J0,L,W_2RF*?%D\E56\WBL1S-=B+Y,IOG<FGZZ9G3N.;,
M8!;SZF43T,LE#LZL^<T0+$?1XWB.HA>%?7/NO"S1AZXG.IZK3G<X]Y[7<$<\
M,+5S=&(*N_BDQSW)>;.C89KHSXVG=KT#3DM;9_\[96!Z/P2J$((R'7Y.ES^I
MD4[_4*T'/PZ8CZGPUQ#R5*1JZ265?/#[*E,CI*->-PE]HN37QB=-CB39$ 7:
M]H=]F 2 \BI*Z*J P*38_JJ %F)1B&V $LNO\H0DSF39-O!,'FB!#"M/Y@1-
MJ*51_HU6(FM."DO<O(U.5LC;8%!AOJU8YF3H>BBX-*NT0N4-4"GKU,A6/$AB
M,NM0"L*Y&&R2+ 5+FHZ!BB"*]@$:*.;:9F)0$N;KVN6TF ZU#$5<Q@CA@-",
MIJ()L:210NXBA.B(8'"4>LYE],WCD 7"8 CJ]F5>*(YBL/"ZG,CGN(MAYG"_
M^K KODBYY@N3 "9I8L7_O.J+##UB8,8%[1#)OPXQ7U8NNHC%#H&B)\[H4I!P
M9/B%N5H&P/IEY6".CPC"7W3B5GX.PK3.YC",PT3"8J3N*#:,EN#B*CJ,%MNB
M[&Y&+#H,\8[F()8"[C)/QYS,9\R"GJ()Q[:"Q:SL;"Z#+E#/9^)BRM &[.;F
M[RHCRL:I+3S#,^Z)G=#I&B=#;DQ#G;X&;+K,;_0I<#2''?4)S/H&<?XBH X*
MH0KG<=1LHO Q]N[1-I2#""C''D'GI#P*.6S*]XQO/DQJ^XQ/INX#.0Y-IG9G
M/-8C/22R/-S##>(#=SIRICJ2&)[G_GQJTY:'0'QJ0$JRIYQGTD(D0P#$?#P$
M_ZF<Y'P\9$A^;4$^K0"WRB!>;2=YA'EZQ$Z*9'W.*JLD$($2)$(,@BG?1P'9
MY'X"JZV@38(\,*XH<$X"R <.\ 'UJ( :Q4T@Y8$:J[?.Y (II0:C15TRJ$XB
MZ-^R9%TLSKH>2(:("U4,2TT*9K$@:[<VD(9T,.;2\(+H<K5\R%0JCH9V2)6Z
M!;_\C4W^LE:^)=SN<H@ZQC*]39#*B(&$B)2&@B56+L%"CH5L*-T*)@LWYF,6
MQJ^::$90BPBGCM_FJ+_>ZXP8YNAB#EPJ,8ONBS:)T"9.4XY0"5Y8<^T(QB6"
M!>1NB>06HBMZ(EP0[#;O\+THD3/5CI(,D=_<2Y7X9?\Z_6M9^+(/0XED@/#A
M*.PX!R864_'Q<,(:W\YI<E$CG"8MG@QHI,8J/,PKRH)L^,[)'.^9 %1 K='$
MV,*9WL;*N*EGIF(O:/')N"EK_&*=M*)GS!$TW@E#_48OK@8P>BS*K%&93*]#
M/6_TJJR?Z@D-2C3-U,RA&FIP*@H?9V,Y"J<Y9!1T6D^@AF,@X8S-:+3XI*/W
M.FKXPN/-Z&SY5BH\C*](2^IT/J<A"TTBJV,^+N$B=Z=WV*,-SL/[_./]#,1
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M=I:==EK'T)+C2;442J'O2O?6/F JN+^O0LZ42\-/E1_$1# $3<']U"PD08Q
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M!CDM9Q(,S+,-KN"A^]NT#='$J2G135,(UJ+#81D-6U&.#^4*WK,5ODRFK1%
MZ$,(/LPK!,A44A,VW/!+,A3-%,--$>367QG7TD-!>*.7<172+UJ/!6F/\0PW
MA,&-JEDL<>VF&?'&"4K:J\D=-$E-'>6NB0T:8_\5/IU5%J]:H?'9K;V24E>M
MD (%6Z^(D1#)@01CQ#]M5.G(NZ[I*^;)G25552 !Q1:!D4<!GVPZO2XJP<_2
MJK+IH(&3QX&8A,@I7-7;58Y[V;_]$F<Y3TMBQD&9C5(=.H2 1>'8&U!],E23
M*SX-QD(+IK.-/A(M"/#K&03$G[9U+,W=W%^S0!=150:JVRQIVT^;JDEK*[V(
MT\H;EI4%42<3GA3<LQUM(TH5PF\<287 5;RPE1+LTT)T29*4VG$B*:M*6[&!
MPR+#IKS@TVKBEQ^Z7.9IFK1]%TZ<*X8KLO@D%/BHW 3:-%"MF*Z12 JSIFSR
M-<%]DPB$W;%=,_Y5"T7_\1#X<*%)%-N"+(AZ  +[Z0S:VB,@XJ9C.\Z#J <.
MO"_ ^1Z-1*.]N% U=5YB^(&X:HP+0A#V<E_-R"/9((85N:VNF1003K,5<3H
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M#.(&W_'#,^VC\P32VEL*9W-2-"B,;2@&*_;0;VF0I$;=\%LQW)7'8BAN#].
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MK"=T@B=X@M-V[1P0P?JV@1(0 1T0 1'\@ _\@/P2P?L201'H;Q&H@0[D@ Z
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M#AF5":=H:(>\-B1A4:9)T0_D.#@;RJ@^[JK*0S"G4(7RTI@)A>9P@!*KXQC
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M_SNX)R"UB :E.>-1E]$)=L5)8GSIEW^Y79' "(;0EWVI785TEU\C+UPX!#W
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MN[2^X0"_%1WSX6OJEL.N\'!QP#B0$R*CW2:1"7JUH'4K(O/B*)/0DA92&7,
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M&0:*F,5,F29E5':1&#%E(4&"[%B27DAERU!>S"@ID[),FC)-1#.IIL:,D])
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MJ"^QFP^MD CD@!Q6LA&A4B@ZF3P;/ M!NHWI\RSSB(T(^9L7F@/[DX1=X!X
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M]0 L'IFHG6 $1V2=Y5@E-?$2YR"3\E(V@?2@H@N4AH ?-# *^!@UPAFUY+/
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MD;#<@#@R^0]E@*8,6Z:=J9^HD(F<&I82B[&1^1&+.)Y@;*[F&@D=09*]#!X
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M,()'J.BC'OI5.2 !C,D6LDHJ0<+LJ*S7V XB.38UZ<&-72(B)*HR6FDYFS*
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M6"<[T[F-QY1$N<@YQI%^!>QPB1L8O@(3N<D54P/G,]#]$4-U;2,A8:A+*(E
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MDA"U556,L114A,EH=!A+_VU%^-F-..9XUFTU9C3ACT &N4]@0FG&0 P&W'!
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M*M"L1'E/KX8'B M*7+2\>D.]J2^);OUD5W%(5[JBLDTKH2-.]]K_KP+R]:^
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M0BTE:\(3H<]<VS1<(C5QO8&UXX\>>DR?_\#XQK#)C%K88L+#BB@-SK54<L9
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M&(U Z_X:" L*@?1()8D#'AW2;.#%J?BD)AWK*CT$[VWW=G]]/J!]+UT$0/
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MH2%0@F)SG"5AMHIHO(8(0U-:$A1!M^93-OTAK YC$@H[D;3C0,7[0>A*'1S
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MQU+*[1_^P9P &7%TJL#Z 5]:PG7P;:B=0VA-J_,P3>_[BYQX2H//U=6]T54
M:[73I1%Y+(*UA@,C8&1=:5W4I9LYZ*1SQ DB:# T;6BDN'0-3J;J;D]S[C8"
M=O^N"S2AD92,)RVS-!-M4-GTX[K-;22L-E<[HU\=<<F8&^ "IZF-)H4<-0,U
MS5YXL&D_H2TDZ*D(I#PN5++V(2 <PNE)^VV;0+7V@BH"B)U)%*KQT;AFV\YF
M<S(GEQ8[=<M&\.MBXD,WQ3V_ -7 Y2/NR0TG&WLV<1:^5 UL.9IW,88,(IL>
MJ\9JO"9XA\K=83=3%[;\S+\:"G6P&K;IH,"DD:!)0R?=UN.%2*@%,:C?JEL]
M6(-V6\/:?E&83S*2E<XPM60OH+T(K':PZW[WXX-7"B0O=5NO1>DI-@$ONX!Z
MXBRZ90J.535.90QNOP9M>#/QX+KU:,AU]>RE& _'?&W_B  00.^_:,NPB]C.
M70T)66&5ED"&=7C=FE@"M;:#7]$5\B$?TGTMDT?Y<RRHHYBE=@((4,0TA<$1
M1HP8-&)N+$3H\"%#APH;.C2(XV'"BQ-O<+FQ!4>,&PP5*@QS(X9%DQ<Q(C2(
M$ U)A!QG?N38LB!.BPQ#GJ0X\<VD29DT#5.FB9C 3\249MKG]"G4J%*G4JUJ
M]2K6K%JW<MUJU"A28I,6QA SEN08(D.&)*'39DX;3Y<P7:H;[-BE-FZ&%,F4
MID@1(F_=M.G4!DV;-D.(9%A+8;&/BQ%W+M24C*A F \+,HR8L"++SXT23ISX
M<HPDARH;EK7H,V$:H9G\2E*8!HVDVYK_Q:S<6+:SR!L&=]Z0<1 X1C2RE1%3
MYIQ8IF%#,\G.%%8IJ*[:MW/O[OT[^/!6E8DO[[T>-//JU[-O[[XJTF&6CV(2
MFKOV&#1S+G4*ALP3,L<$X\DQPKCAWR6[+,+((L'4U09_#C*"23#"](<)79WD
M!5<2BLU!A _Y29+?6)/@AIE\SSTW&XN3U,?B0-)EHIPD)J:FD$N:Z2C&;3+E
M]%E,"C&D$45 &KG0"@:$5*1G#\%DFI,LSM8<<\Y9R1QT4K:(R4!@O=>5=4II
MHLQLN9DX21IIN,&?)YXX@T^ PAR#S##"R",/,I@(@XPS;=*AAR> OI&,,WP*
MDXDGG7CRUAQN_\Q!!QU*$$$4I<,(--]E$ZTD4V<-B>10DY_AY-E!,8D1AI"\
MX13#;Z NU!&K.&P144F?'7FJ2YVVBI-QO<801JL2F47=;$(10^52R8ZY[)?-
M.OML5&$F^PE9,>2F4&YB)$$$7(UJJ"%=P3@83">8^$ $'&.H\<,;/G1H6%V$
MK37OO"!"A-!Q72Z;6DOX;CJ9:I*]9AK &''VJZ=+GOI29[/B&YJ31@I7D$P8
M"0S:06:Y4=V85THI%,A!H1'6F$U!>S+*SYKX+#$INX>0RS'+/+-68AIE*9KW
MI5';#T- F&BAR%PR+H;B1M)()(M$LDM==D42C"22W%6?@)? E5@;;O\E,80/
M)NZL6[9?E;S/E<[1HTP]5BY#3S1LLYVVV%DJ]Z2+(HJXVZ:D):3SJ9W*9&II
MO,6P0J@2U68B3$'-AMO&4UI')=K0P,V<C,7R6^-L22T%'WG0+DNF4??AMC,:
M;I2KJ#//(!-@G'H>,XDP>\I9*("D\)F),'!BLKJBC3[ZNQM]26M=)G$3RR(:
MF4AD8L6?=AK1IBX)C$;&%%6/T*_2AR$#<1_AQ%N0JKH6FO08%2P&:LII213D
M4NH+.E$T3Z6\_#0O2[(8K/)8FT,Y##''$-P"ES9=P@W"&!J%^.,#(Z0A!SE0
M@PZ*X(8D$,8PB%%,#^@U :[A("4+6<E\R 3_G31D0A+%HHX)93.W'>'*)!3Q
MS/,:XA+>8(0G1#*(#$(2DM[,,'RA\1NI*E:]V#BN2F?#DG7.A(:=!>4--0*%
MI2S5LOI1L8I44<ZS.F?%[C!GBU[\XGI*)K;ZD"XAC2@=7,K%.G$%XVEHH(LD
M%E&+6BQB%T]SD!V9-B&H7>(8=,G+_Q2S%B+\0 S7&E'.)@'%^4!.&?18!MF6
M 0UE+,.1SB&;(YU"'K=5DCG$HX[BB"6R( 5E$KF)#K'2\!*Z$4MTMJ(8OG:$
M)AA)AQB7D0]T**D/*TEN15FB#A.9!QN0*4N+4E'(R:2XK&'$YFO*P1 F% 4@
MVB'#/WGBA21X$;MU_PB#'7*2AS/ >3MD9&)UQY"+6](Y!TFY82CRD:) BE<\
MLVF2/&2:)W0"9ZN-D&:%4"()27HT-QGF!%B_,4YO8-D98-$0)LHSTFUJL\*7
MB(%%\IG2L:X$G2R=29XDNXP7J0-&:$41BE!DU4A6B88QT"&06-/07"CD(+RX
MP0<_ $(.R) #'1B!"(Y*3 ';((0A#)5>1,C;#!D2EN)UK&S1L"?9ZD&V@2RE
MA/>J6)%L1=%57NNJ-S"H_HZCTAU][TE:58@IWP"XG<&H2AK51(MFM+PWN.]^
MGQ@I7O,:GBGJM:]^_6MW4G04I; U#8S0C1M,UZU.,+9<=6$L3.J2M,E"(O]I
M2E/:)988S6]UZW];VQH1[J,Q4\XH+ (!194RFEJW-J>U36VM,GJ)GK5UTJUP
M(X:,Y),,Y@B$&+6%3F[CPQSVP;4ZN'$B4,XDE%JJK6QFTZ@(/Q8;Y:C02::\
M%$BI@IZ3B9&I)?R:1-V (<:VB76KB]TD&B&,<O"BO=VTTSSDD0]DX,,90EG=
MZCSQ.T@I@0[!R\1EK&12DJF(/,VIAS[6IHQH.,4ZGJR1COCW29 E;VY"8>)T
MA/D:$E+X1A%[E0='^9))U'*CS3D*\2#7R)O]TI0[J^BR+A-@30"VQMX!RZ64
M<8"R'*XT8U""HQQ%ATXXJBX4ZH\P@B$O(A3!"&__*,(/N#6':!(F,?/:X" [
MV,*4W""$3;UM@:^$'K?M0Y)&H0YNS*J^B:*!5J-37*I"!2553425"LG>2X )
MX>.-*6W060Z5Z#%)*U&U112F*&X4I\B2\M7&COZK,1\MZ4GC57/8H;!R$M(&
M'S!J#HKB#W\T=)@T7**R8%!$)!2AM E) M61@$DT0_V6_[%E#DGPP0<LK+CI
M)HNINX3.(M])J0!;YY9$(728+^E<0B-KV4=,[9B0I92RP5:U[5LQ>K#4I=8.
M)#IP%38*YP;*TECX?MFA8BZ/ L78]+@1A!%RFU ')WD$@Q>FM 4O=L$+]KZ7
M'?3%1S*B@PDW_>=1;5#"_SK=P.1/!+@HPQ6A4O1ERV.7S#H.MU*9!]W:XNWC
MD?0@F["E.(P5-^>3N+72LU<T#"?.V33)0W-;E9'@V+)MEYBD=G,J!\I]*@['
MZ:8TT*GB43'!H#>P2<T8?/863] A47GQ1-&$AB'^M,&G2OA?8LF5V;PH9JA%
M'8(&+D*Q[;WJ!EVR#A3#XE85P1;:95O;4X\USRJU*'G&@LXM812FCBW%2B?D
M'[]6@BIVJ^]QDM/'/B27>.>D#1J=Y/;'=&;5P)D(A>8>1M SCY79L$SSR-0\
MZ)-I;F)0=X6-T(M@$I.A"@7#CHR@XQ@8P8AL*N[;F7C%@I(LB=WYT3!MZ- @
M??^P,3.]_#XYCK9SB2*E2L5S^2*W/6RM0_%<HA9R1;%E6*@4\J&KF#F#ABYO
M<8E;YB?CEQ\[GL5/^#$=?:VDF*?*)3T'%NP<[C:H(8Q/NU7>U<EC$OG&9B/@
M&R^8 R^  SNPPSP(@W3P"3YDPL"1@G[1P8= RALH0?%0R3+H0\F8ED7-QIG-
MAK!ME.'!C5,P6)DA6]L\5>+-5H+I0]I 1><LV,>U326ES6PMV]QYTFHY1R_U
MDC*,W-H=B_FY$XJAF=TES\T,&!1YT<J$7E>\SYB,Q&T(DT((AK<D"B;L1UV@
M@;CLGKC$&ERX!2:(5P'1A95ET!!@F0_X@*JTX4X,V+1)4<X]U9*PW1(4(1L&
MHHT]Z>'WZ:&51(,^1$/:"*(?MF#C30[</=(]$1& H=C:D0TD^I(?0MM%38ET
MA,P)?09X?0W$#803?J)3C/]%%FF>=8"B*;)'/$%<10W46$"(#_A.7 S-)=#1
M(3 "*E&"&FC"MRF?)E""(7"!'77AD0G08E 0$?@4A]6'XN3&M.22;3D'\2S'
MR%T&S.%6L3@1R(#@E-Q2EE0.=,"5"%H*-&K)1HE0WC5;:S$%<%G&=)1<1G&4
MA15>EL!57(F,C9#.R.18523$R2@%=@S$_J39&-!%8G&+HR1*@.".,! @>]E"
M #*"+?3"+4Q"+]0)/N!#/J0.HC =I#R*I!3!&\0AH9U6BI 8/99<*4D)Z,A3
M$/[@.A+/E9S-5#W''5Y))2GBBJ%<F;E-"B*8)+T--'#;<%4B.,X&/=+&UPS+
MA('_$A.AP><,%E)X$1:=XN:M)%*4"B,<2>G\7M8HBH;(A1_5AM3((EXT%INX
M0>EPG5 -06.HA0:LX4&(G>#%@,]IPO=UFSNAEB?IW0^FV&Z!'Y5,#MHX1=H<
M4<H)IF >43T\E<?)'-QATMG<)+.)$*%]$G6\"/$<Y?F!5SR:B&EM#E6&)GLT
MFFB6IFE.!3R%14P@CABL24UU2Q\-S2)P02'T0E$.PR2H 2[F)B50@B:\7BWL
M0NP$@P,>0Y !WQ!$F1M V"0 Q<;L3-P(A(IH'"V5C/*54CPID6TH1S/)QE$:
M2P=Z8(K)G?GQ8B5ZU"?1W2<=Y3!,&WJ*4ES5(WRZF(6A_X;FF,Q4!.7)4-4B
M)0.0Y <C5%EB26"B  @F#,,!=E-[#6![161[M8,\S$,^X,,SU!<IO$$=_$FD
M0 I(*L$GY* R,,57&.7V?09X*E$H75\(72"SG=C:72 N45+*%1@GJ4@G"6:R
MS8>4T"&RH!!LC$X*S0CBS WQ&84=QLAI0II=$8-U!4D&$,%G)<$<3*FG:<AM
M- V6=H*%)$JC],R4)L'6- 9;KH4&#(%</@Q(0.6TP4W:E6,N_=E0W)-L9*-N
M==\D+IN8,1CC6<EB*B+9&*:>WF0&UI;;24MTB5(V5H>,)"HHH>C1.26C):FD
M<D>D3:JEFN(&TE]"C 5I8 VG>?]+N(S!'-E"9KZ345H4+RR"+>@;&SF@P6U+
M$D09,H),C53>)&#*F%R<'F[4]EEF=(A@L="(*:59=1 +I7Q,L6I)*842.?J=
MBO!==-724&0)M9I<BL&G95Z8BS%G/H9%%6$'/+U$;>S,FL"%3Q&9HAA0.,V#
M-Q$@ =H"OIF#O"(@/LA#A2)#*7C"A=9!AE)@$=!!';P!GZ+-,IV6LJ(06QV:
MR_&(C22K-CJ."/[2L3E7LS$>-#R;KB)1CY8<*DT'BH&"ELSG?"I7<P;%QHC!
M9_[CI>(5VBE32_@0&G#-,0Z!HV""'^&%)$0"-BW-+NB;OO41,I2+:U:9("T&
M9+!AQ(C_'5V:FZ!13DVR8Z^]D]S)%75AJX-1Z\9%+&SM$K(M6VV!64Q6TCRB
M4K-=X"?)"#U6SIS6G9 *!8U\#8'AY\KZ52DZ"VE.&OW,K=Y>QF?&QBJ-!28,
M!F+ E"<P0B380BTP@JD>:_I!QRW(T=,<4("\P4^YQ3%6'1'8XXR,VT>IFVHY
MAW1H E-8YCQJU$5QC/N@4J4<J[:FI/J52:,6T9LRAU*4GWA^X\.2H\55BCN=
MT-JFU9F 5RK*;514ZI>DFVHNK'AI2&+]5&(!"'TAPP'R CN< SN8@RT0(/4B
M SAEY#,X RGH@1Z I(;^*Z30@8,!8;)H3J(F*E"@WRB!%Y L_Q=1,.)>L@B&
MI6XN^:K'QJ@F-<?W51+74HXF,.K:HE_'BE)]6%B-B,Y\*!.9A!3Q2BHC)07U
ME,89?8;,&NU;\(<P2$*270(VR9XM1$)P:A,F[%XTT8$/^,S6K$4/'&,%^ "J
M[%-<QD 4A1";7E2R;)28Z-;-*-_!&LOH4JQ%+=+C.%@22RV6=(XAJLT XQ:P
M7BM+9I^W?:-\%*NBH6B0-".-Z:U??5ZS&.^CB108KVQW+86-N-R#Z,6:;*%L
MRI'BPN1Z@B!PKBKK"2T16.ZY7-UR;N(D;,S(_&--NE7:DJC>>=L/2J<0K^[B
M4K'O;DD2#V%UAFXE]MHN5F+H6NO^]O\:%A\/H[+;)M;&^^PC&IP,29H4(YA*
M&D3"@Q!90;K!D.$7,L0..S#HN^*;G2##?/D)P')H8OVK&RB!$H0DL$U<?!P%
MF5#8; 23[J+?>9HGL:C6XYPNR" $*@6%")82YF3)5U3LR0TEF= CK8(2L>!F
M$E%'<0&3$M&&6IV%:47J%HFQI5Y'ES345B6$S[1PAWA+3+&>'=F"),A>(\@>
M" =M@:*>41$!!9P+HDD$L)R6VCW'F^9=M.4@;!UKQ*;8VA':Z!ZKL'E,C/ @
MM8%?:IF4X[15]"W%185N==BF/2J'(#./G8F!V$3P&>?T/MRM3O>T7PF6:J()
M\RC$'T$(&I7_CH8HR"L4@BTZCJG*AR3@'N0RC=# Q5860='"A,X<3D+DF*%:
M'^Z.K7>BDB?UZB]ILA!?(BB?ZEZ*1290@O2!&[7F,!VB"!971[("JQ 72_N2
MCG8RSWU611=!RY&."8^LD(O(6@%%V:/0@>U<Y)T(@[ZUE[NRPYUD)"F$;Z#P
M*X>:[_G6P=4^QS]^@B8HXYZ9;#;ZPL%>Z]K2XR&?==VISUX:J<063U$H7S>R
MCU%NG">5,PFE4#8.,;%TYA*MLD)L('9]L4_3S"(9J28L3*T B6+,K  =AIS4
M<KWU[!S)42WP@C45Z"6TU+G,[%K\P+D@+:[(4 Q 90X61:G:7G1E_U0R"(2Q
MQ6B(4@D^/:OX<33H)AO;,0>A3D[*N6-NM_0#>Q+CHC/(*"/=#-16,944+;?>
MDK&$5[@561I2B(X290B$;-H/%(;3T-$K,(*]=6 !\T(A;+>#'%"Y&!PA$8&D
MT(%/Y<QTG8DD%-,NSIWMR0B<JC6*]1J+X/92NK;(+BHNC>X)O5.P]>ZP#=9)
MYFXFJ/9LJ/9>GU\IE=X]\@]:O<3Z\G3,+"DH $D&TP5= ,\QRKAC<^\SR,,!
MMGF;V\GWYJL>? *_UL$>9"CE\JL2U/D#2S13-0>:8,)MV.(2,2IUB$4H[36<
M+A?_;C&'[7;:C7.)%9@STIUS[Q:,4"/PUO](;&R,HIES-KYM^)@&_$"PA<M,
MP2)%Q>!(J9R!E7&:IYJ..279X>["Z_%"<"897B3*8+SX(%& 6I@IX#0$#$BT
M=/I2[4JS;D4;;@F$>]M2;_6:1DV<='0B8(99(SE<(S6'V(+._H9L,DOZ^37J
MUYR)61B)RPT$W][5J5?18#>+ESM:$[;[*=K,LAA2C?-(TW3+IM6LA@0#'8FX
M'-D"B3<"+S "[I6P<&I=)S3*MLBJPAVC&W!F3&/X4-CNQGFL[ZYS=*AC- :Y
M^O4"*BTJGYFD!U:K;-#U="SN4UMC9F)K<"=RH@HZXBB1)AY)<E=1?$CT0:1/
M1(5:X )0\,!;9JO_.9S$ES#$5S+( X62 L#J@9WSZQN\P1+4N=4[&/-=!US=
M1WX0'G.N]3D/A:&#)Z*2T)8H#O;%:70,K[258U&NHSOV+IK1.*>?TJ?3O2KQ
MRUF=RO&MI!=!Q]RFFPBE"D51#-9< J?)K!8*2(7T;+X%_"+T41;JEZ,L!B&M
MQ1H.DJ>DA$$$@!VFB)44)>-VV_Z6^MM;9<2I"(0?&XLN6T[2I)UV].-\M+%*
MAZFV&*+6/)OITU81<KS3.\K0\WM0N(U-)?"#HKJCR*9* E#@1IEC38><"X3(
MHH+0D2VD>"$L N[-T1R-BX5D(92^.),1P1(\V1N8!6+;'11Z(S42B\C__^X)
M?3)'??QLP'7]BWW[[BCO+M^U5BM :!J625DF300S)3R8:=(DA@P=1GPHL2'#
M-)/02$HC"8T8-&,D>10IAJ283\1 $=.TCV7+EB1=QI0YDV;-?9E0$B.H*0R:
MCB$W7KHTIXVG-G22$"GBADY33YU((<.7#YD\J5+S.?-$9\^G.G7LV(%3Y.O7
M-V7AG,PT4)E 4,,T*=.)!B-'C!?38)J49F(FN@X-#J0(.&'$O!4?)L:9D%A!
MG7#E*BM8<.!CMW#7RDVX>))&NV@89N1;$6/GC!U]IB'9<;48'&'B[LRYTF9M
MV[=G=L2]FW=OW[M/OHVKJ>0-UJS/7&JSO V1'X1%B RAT\D3LDO!+NU:I'U7
MI&#!,'5:/F0.$?-#AOCPH6$(D0E$>H@)(__U:S$&9K>-/+#RYH$)^XML+>'6
M.DBG PV2;#*=%M-,P<CB&B:ER"B4K#$+%;Q0,PG_ZX4A!@TJ,!F%*/*K-)\\
M8@2UDCRZH;6V.*3MMQEIK-'&&W%L29EH<K3_C9@>@0Q2R"&)+-)('),93K^.
MW&B(+C'<Z$2Y.=QH(XGTB"BJ$^RZJ\7+16HIY)5%QN1%$O""D?*H(=[XP;PW
MBGC#O*7J2H.NO]"(C1BU##2(&,$VFP@PQ 0*,3'"$!MTLQ(3TR09!BD91J(&
M%P-PH8$$.JA$T@KK5%&'+OI,I(U6+*FC,\30\Y.:"CHRIK:2G,PU%3>"\I).
MPK.RC2&8BI,(.N:@PY-AG2D6&6>R0N894DBI8X\]X(@6CCWLJ.,-)L!:XBQ+
ME1E&O^$LTN@C2>JZ,Q-))MKHHL(BPLC$04=S=U")4(++6TP!?"LRE3(1;D00
M#1WTC4G$4-<S@S,:_UBCN\3 B$47PZ@OXE@=K3@95S'.6.-]\G-4)!='\DBY
M\=1K;]=+GO+D&&&N"T887ER^+E@ES)NSYAR(\*%F'%R+F"07<5 AI9-.>C0E
M0S-E3"%*_SP(,[7LU7>8QOXD$*X]B=&PV_TPS/#1KK,^24',#O5T,YT*?8C<
M$U-4#0VWQ3#.5))PD# G4#;.6^^]BU2&[[\!#UQPC37!>B=)QJ#KW(TP&:I*
MHMHKSP<WA!(JF$BZLP7,16RI!7/LTL1DCO:>BW,)Z(J(LP@["S[8LV]1"A2N
M$=M=JR_$\/T/HKYXEW0B=#]<#,% '<(,8( 76G11= _;G=-V]9+DC8]0 _])
MI!4[ EF,E%*24?"*9Y.O]8(K7X[*\I0XJP[5FZ*#E&%)2>9]4MK? RPX@("C
MVOV_@B/;-W!R-%A=1AEW\H@!+_*74)D(-!*ABUX:,HF!040O=U+41LY6D-C8
M+E,6^@2 *N4TP.B$(AQ9T8G4=:(ZJ6A%+@):Q,(@ ]CHI"VS&=P-<7@3K 5'
M?'%K#1K",*4A["IGYDD*E6Z%B94=XSO". ;*Z%"SU*7..16H61'K$[>(;>$U
M :@A]QJ#*?XHSS_"ZQ<'"\08M=!P: C"FM$R))FXZ,=;<KE0Q22#$[%9*&V;
MXIW9&C(]C'0$;L<)&:K$ER?'G"2'C72D,NB1L1__.7)&":'D)3%Y(]ET;Y#D
M2F!XA$(4*[6'"&[(F1L\@9WK7&<7EP/==:0D'J64#DYN2!V<;LF(C1#L8)@H
M'-&(,2FR?2H3&*Q='YUW.]Y%9(*$R9?Q%%,ILS'$=Y/X#VD4UI"\8/ O?>%+
M&G09$C2HR".)FUM)?""&V3D*AS542P&O]Y'&M4%-HTN"&Y20NJ_8P0AR.DO[
MFE('.ECK#=+2GQWX$!:P_,]:<G$4#0L'1@MVA&"H&>2Y!M80ST1D80/S26<<
MLK &*HY1(.(7@_YS(!(J1'<58=!?Q-4P XX3>^)R&.LZ D,<;.$&,9S/#92$
MD#T]<I*9/-+=<@(T^H@$_P=H$,IXT..<F@TA"6V8PZU0)A0I78(.NXK3#YX#
M5C<5D0+F@:$,9>!#,0  (8L<WMDZ18FEB3%$NJ-K!XGQ*!HJ[:$5NI"W<C(9
M@JP3L)KYZT(D<I':3:I3=-%(.$=2*J:ZQB,\<TSWC)K9C<$$8W[3[&T\\EG1
MCK8EL1%L:"ZBES1H=3ET&*(4B2 Y-U"N<I:KK5!,Z8/GP.D-IUO?%)7R-HZH
MRX)XC MA^A3!VI$K-($*V+L$M4QVH<LA IE$GSQ5W91."KG1#>E>3,3<=95H
M;:?!'O;FQIKMJ:0M-=&-QG;RK<@V @V-FU*5NDJ$].US?V-1'6]_8 0C1(L)
M;_\02UA $1;^P6$)8,G03I)D-TU0-)Z\+)@N3_11NMCI1,PE*08-]A"2@A G
MM%O:7J?9%\4Q1".84(TXKX?3@LE47# N#A=N@(,8^# &8<":D@KGR/>2%DA"
MY>%\>*8],9R!.5 E72E?2U4W$&4HN1J=4HH UAR 52D^@(Z7*>!#%^H4 -^"
M4=HR(5=A=DHE_5$F7$M\D(K92R U3 :$8K2@-0;&+3ND(8/:M4L7DZN9."&-
M0X2+(M3\)&1 ',E\N,<A(D\Z1]#PK*N*2FE-;]JH%%N2DVP*RJX2)0E*,&4=
M2FEJ\TP.#;-E3G3<H#.=8;D(_L4E;V])781A!'9FN^;_&Z37D":I"R+/@\A&
M@-T0O;RY,\7L'8D'0SQE>J@OU"V-9SS:&60C&KP;1@-]9UPJ<<\'#1QZ2TTL
MJ;&<M+71&;GJ5:UJU?*LC[_5*@L=R*(_.!14+&,Y<%A, 19[G^4-#WH+4AU5
M4=20,S6?*<VH,E*NNRAP<9YY6[OD%:+J1A?.)-W4H#;,D8*M",:\_,F+1TX2
MG_5TQS>0(0Z JA\]#K61]8 &IV]D9H%0%LGD]H@EE,.&79'2.<_1[WFL-.6A
M7S'+.BA=S2CP92+HF,<]6VM>"]=6C=\N@K:S5-DD<BF%Y/6M(<+ZA<@NG-EE
M+3 LK?-B[*8\ZC9)@LU6E-IV_TF]ZZDH<>BEC\_6V5Z<#[Z1ER;\X1&?MZP[
M1E-/NE/CZ*"<KKK69D1 M2F)F![UZ%8]5[QUZL:"2Z4$-X$J5-Q>E4$138$T
M-$X*:?-N)QIW*;:;%,GF[>0<[64RJD07 78Q\>1ZF+;>X@ZCZ0\_UIKU8O:&
M,Q^.9(-".:OBEU=$>,-9_.>_L\0I+ ;.OH$5K&\%\Z_!<*!0U<PMH9#-5\,9
M%DE,=YV1UF.$OAKQR[ON7DVX2BJ"H/%N X5/^:IGT<I)(\I)O7K&Y5RDY<1@
MQR#JBS(M\39MYG;"T5BC)^+&J9@#/:(JRU('"(SN/**#Z7Y !W)@R\"J"+Q,
MJLK*!_\@1F+2Z@;*S+0R!5"(:2(6(GF4:[P>PFDJ1IKX X\0HD_6"40PHS^R
MCD$ #51*0]OLXGFX[4Y*3N\0T.]ZHGLF0P*UD"5L3I(.3R>V, R')#CNAKF,
M;Q(P@9[4D"AF!I_D))^68*I("75&;XJR[ ?\JPBT15M01UT@*.26+R=&##"R
M;:1* ]AX,"( <&'(I4GN;S V3)D^9=DV3L22:5.8AUQL2K@,9F!2J_2N)Q3%
M;;)V0D+:*:B4836 Z#5(10I]POXR 8 "98(,(DGDK%_JI6LD0Q_RR&CJZ.RZ
M1Q!#II"HI_@B:WQ\PGHX[$Y(9>1 2H6*;?X6*]L<"!H'20S_#+ *E4\5?P)[
MYJ/E<"QNN"@,8B#2+,9[;D@RQ/ VD"HE1I%GEFQDA"ZJ:"U.W@ $Q4JW*@"L
M'@ %?^ !Q HZQDIG-( (6.3EPL!% *#/CD9YVB78&(L_!J5),.&/W*X_*K$&
M'RJ-'D/M<A AV")$-,-L-@R"^**!&(+N2F\9&<WOU L-> 8'ZH7YUI'PANQ(
M#(_3;K(F>?(WZ@6/),@S5@,3,,$-BK(H9VNVKL\-WB -W  -IB?6T( (G%*W
MT, '["0KFQ(KKZ\KGW)Z.-$G5,0SSK& 2F.Z2F^B7,_:=N>C?B^%S)"!B&\T
M=F=W\(*ZG$?8P,OV.B.CEM$).1&D_US,">V$G% . =5*?-H('5T"(S:FK2+J
M&*^G-/ "#7>)1 S#4H;!7AZD,_UF&1S#0FA(0":C8D;"10Q)Y&H%;@ZHHJPG
MT=A&7%1$F]J/(5SL(;8)+XN)7$@*3^3288QO&X_1)>E&S,81(67@!K &C.+"
MD4*K)VG"R/8$^=0*#=I@'H>.E,!*#8H ".SP#G]@R\03(,7JZ31@('\ 9""&
MLF)@!I>3,UBL[NSNS01E+]!0(JB-;*3-ZR!C,=+&,D!(=X@0[BAHE_*">LZE
M_Q14*,?I -'+D.QC/DPB)Q@).CDM:[S00C5T0_?A)()*V[3M.'2I892K(4 B
M[UA$.$O"3O\HRK$B2!+HB[BPT3X3" VPL' \8I< XX%"A1HMB"]:;"]X4Z-Z
M]!"%[V#NTYC4)N,HPH+N,S-!-$&ED%0,AKCNXK'>YGK,";WD!B8A@YUH@BXV
MIH8LYH>NT50Z8Z,4BS P2$#/AFKB"))"\_SD0FQH,!69RN=$-$M1)$4.Z(#
M"7OJY'I<!S:%=#>CM!K;+_@F2KA$HN?.20!7H^=V"N9BH*>2DZ>&PW!:I9&@
M(0(W]$;;0A0[PCZ:K,ER)G7 *@U^@%5_0+>T[ 1/D/->%:R\;-8Z3ZU>*&X
MX"V",3'H(ME @]@6*[&D)RX'Q6G@,UE9*HV@J:YN<1(>X^MP K$<0&5Q0,I<
M% <T-G'BL#'<3M.0* L-?K)3.?1<<?\C)]%U71/O)V,E[X!4-5I3;6RS]5KQ
M3T/Q@#8JY.+5L:J4(S9*#-P5%,;I+ ES$X?+=>23@68/79R4T$#47/:"$EN/
M8?&.@1+(1" (V)@Q8>VD_MHOPQ1-%"55^02(,?\&PB+J4E51IA3M;2QBV?R/
M2.O*Z[#&,R\$)SR3,0P$"PF"9R2TJ5@D-5/4(\#M^,8EY3PB)'+4+D;%,IE+
MI R6;3+LX?H/&V4,:(76AUXR7Y?J!H[3A71L.9&*72^I%+DGGK:Q:Q>-$?X4
M,4OB#%Y#O> 1'EDC)E4.:'NF/2ET3]BE">T56Y=-4,R0+AG+(1/E/Y)&=Y2F
MI<*N4O2S[CS_Z6#4,O@VD60-2;U0Q3[00#DW%6_,-G1C E0U32Y$=UV3!*D.
MJ/4,2!7M,Z.DT)Q(0N3$=9S@TEWNA%\-D'(5!W;ZKDJO]-M$0RV3S74,1OCJ
MHA#KQ#..#3=5:*.RB5L/54A3:*)&5#5U::(>"YP.D^%*EC[L)B5P2#B^A:=8
M%C@M2!6Y[A+]DS$< TX-BQ<;XV@81%^<3QDD5(OR5E)](F(6#<8R=Z8B2^%
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M LB\QQN_/30GNAL+X32^P3L8"V=!P(@,)X1L2W,F':5[DB3"0&$X8N70.36
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M L%25P[7*DYA\9YW*U-"(MDD0W6E5.<;'*)J9)Y+5C ' :B@0-K6T1L)H%;
M>:D<'RF0 P;N-5B<8PSYN8^/A@ML"LDI:ZH#O)+>:S7#VXZM]N%"X0B)C.FY
M5:BD-D^(_VCPIELEC7":&L943>\@<?F!CBBS2'ER+J)-7>N]# /(6 6K6U)$
MGFHN([HH709R*_P4^DI&432Y;Q]K:!]!;/FF/MU2?_SC$_N,N8SYX<^#6/VC
M"O<!&2^9\))@JYT\Z^/ +EI0#2R]Z'O,":EW"C&,AO$.#U-:+O&Y*RYU :5X
M/E)4ZZFFFP>9W(M*=3'XO(B*#/DJJ_;Q4X',TJ8"@<:L5.,>P?!MJ0*IWF&J
MIQS#V&=L%+/L0*SE2?AP1(H'X:DW=;,UQS4M5Y6\SXD2&J9[>@=<3XW5EN+2
MEX+"L#67C9L0E^I5ULS7=UH$H:0PI57OBF<U!\*MVPY"X!GQZ_^T)[24??-B
MJ?7V<Q]Z0Z!G@[<=L#JDD5PE\69BF1[KC??!6WO87B\+4X6\E:\]>R+$$"#>
M5^IEH)21JSP'!";MX/ [%D&9?D9VRWW83["^W$$HX,<^E0%P?CL(T\L,HLQS
MFG0@%QUN"V.HW549)SR](998"])C!;U&-3/HSJPZ!="OOH%8><FO<;[J&%3*
M9:&O_ @H96.<!RG$4[<JCN4(G#B%5+""(/HR/?%"TH$*Z<^3W%'G;,O0P!$C
M4M5978@?'+C <609\AIQ0C/DXLK14\#._'%<@@9FG"*T((G<ARDI5ZQ#"RY2
MT4BNE(Q:L4QQ\:;(C?5!*3LU'<+N19C_>J6G%=)9T][ZKK8UV"3X2U+ZBN%9
M0EK8;@WI;.K*Q=L+07")S;V6*$7T-6A%")"(D6&X!6[57J863H<J$""]:%.N
M$B'TE,L:8B!5A_N=2/SV 4"-$7 ?H<B8:.QW 80L@WV"53*@"FNG""S/X#II
ML*;&_;DTIMN=Q1). 1%2OA\WC3GCIA1)P>DX[)ISND#-;:8PI5U=<5?%&-EH
M@3/1983D*JHL4K3K'B+L%^H*.0>:.0B+Y>?T',6JUCK, 0-<7GJFIY'" ?76
MF$?4&/[62]1LIT+@UAKG_#&EN+8>1QTSTPI6V'I?]^J '#.#>5:/M.=&<[*U
M.YTA]]KH^X #_[4%PBR'E,IK=\3HX1NMN1EJ]RCA/6ZF]KK&D1.LGD2_ZX09
M4NISAUXLZP1J1]=</+$N58JH6Y):D[?EW #)HEBMM1M92)!!:XIOQZ(QS?$X
MD.+(=")%%F80;AE8BQ<334@^2/LBP/P!CBP",'/^Q'L"]?3038\'(9:U4[T/
ML>O(]8+OK^X9LUQ/">E[OP;H@JI>=$89AM/R#0FM#08'RS(G6TN%*8 5;7)[
MTK(SL[GFT)3S^;JU&:O-<[^4JK?W8J>F>R@SF2Z XA<702NKRPL 1(B@VC\!
M."/ZXIM\,QSCX+#M&)X2"J,38XW7X+UTRCX2VY*N T$9Y!*"*#PI*O^.\ZD=
M\1) B$ J8MD. %P-:PLH&^2OV0A"O; ZY;B]ZI*0\;L>T9O"M1"X?4@ KQL\
M^AJJJ<*WU*J\W[.+Z0(2@C$7,KP>NVDG%Y*BPKL83:H\O4 JRC,6'WR(^)F3
M(Q (^/FK]1DFA0@F@HB&D2F@ZA.LG>BYS)(4*]RB)SE#_TH/AU*(S"F(NOFX
M%S.3 WNJ9M.\SGN_,I(46ZL.5/(.T),(1!PY:W._'VH[6(F\RQ$68HG"8CN(
MS(G%F+(AYS(GY#F6I0$>'@0_\2@O=[,W;(.VD\*OQX,G"VD,*9JT"-R5MI,D
M3GJQBXFC!MF<?7"<2*1&BJ(8D2N(0B,OXWK_I+,;HD L(Y-#)2]<+F\Q#D<I
M*XD@O9;"%0&PE%BSJG.YE?0Z#+%)()OB'MK[/"H<R+%H&Q23HEC2*6F,E1^(
MQEJC&&QZJ-;(I"5!E3AZ$16IH%7)"V68'&110HI9ITDKMWQI)H-Y T2+D/W+
M#0D"L#(JQ5;!-L4;NZGI.WH2$J2+J0-AP,NY%^R!P("T"$P;#L=#L;ZB+[L9
MJ"*$/+.I0!@9&_=KC09)FR ,O%D*N+GHB_20BP"1L;5+I15SJ 0Q#!(9+TKI
M/S/ZI.W;%<,;"&M<1\)0C4C<J#A"(HK1FMYP*D_I2L%Q0?%+'I@D2-$C2<$L
MS*C@NB7AG24!ER4B_SH'U,%+I)Z\H!;XJ,-U[ IFN[&!B!).PKM8B3J7<LBH
MG,9'$C8@X9':6$7;@)5ZS"-U<XA)) AC1+QHP,=$G+Q9J17'LQQ?M!O=#,5U
MS(SPP+:*:)T*\K83&S=MH2XPF1%BR#V)(+;*#$-/H1> <SH!P,D$N1R$M!N,
M^D*)'$GF7"4?]*JE*:TF62#B)+?FO,?!*"GW8,+0#"*I%!MQZS7+L8]56D_#
MG,+ [$\ #5 !S8@Z*R-#<I*C3)>NL,T7TXN4?(B1RIGT0!5,"9JN.Y!.4X98
MTLI5<HP1C+7%'-"/T!KRU$R#N<Z"X$@=<J*]$+-D=(BWE!L3G;5YBDIJL4+!
M6/(M%I2A\QA%6131FR),(!U2(BU2V#L4B,$+Y=Q.X> =,@0C,W,(SW$Z!KJ@
M OS*SQJREL-2@8C1/+I2(PU3,2W_S/\<4S,]4S1-4S5=4S:-"B%M4SB-4SF=
M4SJM4SN%E#O-4SW=4S[M4S\ML3?]4T$=5$(M5$,]U*<H4T1=5,41F6(:".EC
MG^DC"$#$$_IA5$S-U+6H@C_@U"IH"8'H!4_] ^<PA%$]U8@0548@"%'MU%5M
MH$Z-54XU!+ (5$V]50Y9$Y+A&$")U.6[(.0CB#DQ1%PM5F.5BE:M D#8@C^P
M@E>EFC_@@FCMU&$0"$:85FG-UC^ "'JP@C^@U<YIUD+P5EI=ADY=UFG= K!0
MU&,M5%.-U6J%%%GMA8%(5EGMU')[URJ(G$(XU940U5G-B3T\BU!@D^,SOH00
MF37)0SU$_Q->;=>;4(9[-8AK]52".%59?5:'8(0JH->!F(1.K0)P!=B0[=1&
M@-C^) 9.7<IWS8Q^O05K!01P50E.M=6/_8,M (1G-=55)89^)25_P==:1=EB
M)89.'==Q%5D*:=9IK8*3S4:FU59I13!#8%9I[5B!J >15=:<Y8A&F-4JJ()"
MP(E*92Q;JI,=V(&*.[C XB6BG8E&.->MQ5J!B%MOO=J5:-IWE=:9;8AA (0_
M6,J*!5RQA=9E/=PML 6L, 19=5)9C==]J-A[Y51%5=FQ18R0O5PO:=QBO5:-
MW8<_J [&+4*5K8*"@ 9 J()X#5N/58A;4%:._5R!^%O3+0A#*.:$IRV(3O78
M8>C4??A:0Q@&BZ4'3[79DF#7M]U3L9W9N*7;N'W55@75?3!5F,6,FOW=0GA5
MX95=G#U9H[4"XP6)9?C5C2N(-<A#D0D9_'D38HT*B1U5BI75BYU<5XT(CFU=
MJ W;OIW=*I!=MA#>/X#<:>4(XBV$S%#6W,4W3N6UB#!5L?58E275!E)6R W5
M!;8*X=5?3OV#9[5<;U76(FP$I+6"$?Z##4R(3IU9 )96$N9?=+W>6ZT"\%4(
MCNU4Z1T(K95@T+4"_$4(1K"VYS6(=VT0@$4(&.X%;]T'6]C:U/U6KK7AG_\(
MW^2]TUY(7=MM75$%5]3= MZYW5?UW(6XUJ>=!$#HX7V@8(%@UFK=W=GU75$U
MX+ -7=!E78P #?=!&4EEGX)@WSU^V*FPVQ2FX[K%5BC>AW'%673E6XCXV\ =
MB(IEW,)5"7+M#,9-8)4%6M3=5PO^7-I-B0@64E,U!$.P@B(<!E,="%-=RGW(
M80V*X*Y8XE4UU5YH7EH%X-JUB6[E8$>V M6U5EW>AU8U"#:.".$-94=6VCD^
M"L;]XE_.U&4H!!U.B%#FU 3>7"NH8(B0!)T58F:M9A@VB-2-5Y\UW58]BF$@
MX9-5AM25XI! WBFVT_M5")!EUGQU6FMUUMU)84?_EM69%6-HM8*4$-EX]05.
MA5IO/>2]%=J*6),FRQ__09-B(M;(VF.WE8K>[66!&&"7@&&1K>8(9F"(<.!"
M@& T_MYXG01.W8)J9@ME4%;0.]K])0CA+02,Q%DA-6!#_@,SWFA J.#8/9I.
M!=H@[M>C)6%33=U"B&F3N-;]C69&L(+JM5R3$]DB?%F&:%6F/AJQ)249CM<L
M-HBP]>JP!6:1C>!//6-J;5/B/>N%R.+E+8@"]@6*>%W_/>-"@-QSWE8C+@2Y
M)FM ^-U?!F 0_&:>8.=WGM/170A 1F;;W8+J_;QI/6!"ON47EN,Y[FM3)F=Z
MWH?,7E5ZD-:==H@U29F!_SA;A>!C2O5#J9!62V;K9];D?:#K@NAD:(5MA0CE
M429=W[56K(W;/XC;F95E!0[=-S;:L WH888*X[YA?TG:M+Z>U&7NAI!6549E
MQJ8:3@7:ZY'6KOAJ4:[=BCT*D*T"=[8(X4X($0[;<AOF9;[J5155+HA?VR:(
MK^7>/\!LQLW?H]U:IIWO-$W=T#Z(YJW@90AGQ8[C6X9:I8YM*PANW$T( Z>:
M?LW&_IW=U 7:?@UPFRCOPY93T&:(<8Y5D[/JAP!@E_!67B->0Z#7",[65Q7;
MS!#5OY;QX>Z*\Y8(]F&^?9@3'3^((V 9@D#MJ"!>RT8(<5UPSG9I":\"=V (
MG/^&YIV6V&N.7"!NY@S'MZ"6<4XE5TZ]6L/6"9\%:(:X5A967%;EU!-FB!NW
M;IP>"!&NZ][= J!EA&T^;^#&<C&O"8%>",8E:O\560U7B*\N"([=YH(H9[#F
M@H$>ZRPF)&K>!WU0UD W4C"^6'%&<^O&7R(G3%MH6H+PYXW684;(7I90<B-N
M9 K?5EO YWT@Z$+H"C0VB@Y'5(Y=Z83H!6G]7$,P](=89XJM\%A'8P#'MPFO
M8G4]<1U.;!S_)8( F840<C?Q8^4>5^DF=@3'YMJN=CY'==N];K+>6;HE!E.E
MA_$V9YYMH#5OBFA0Z(9@5O*6Z7'G<T_MVW1O6=WU;TG_MFQ5G5ZZ16EP=0?N
MMHE.[6O,(.$/!FMNCPB07? U;U5;YU3>E59@WFUB6-;,4/8U%7=[%@C&Y6&!
MX-17->[(>>8IGXA]Y_@*-U>/7W*%Z%=PW77377@LKP*@97>>X/!9;]->P%E"
MS]UO?O."H.ZV9FP8#^:8O06)E7-?/EFQ+4*4_FN9Q^XV3_>&&"!C(KX\'AF:
MF>@@KVCEQO0P/MPJ>.Q0)>$T7X@/[_8V=V1>/^^/?N,:Y_B$=XHUE]@89VRM
M-83(^>B%Z-=EU5B,Y_>UG]TD;K=.M?$*/^\E!E?+U>Z9,%5L1^]Q[>%F#?3Q
M!GNR7O!!SWQ;!UTNB''?!=F0_R]DJD=3D"W9*G#L>OU@G/U6N.9HNFV(()[Y
M/\!9YG7]A'CBE-[6V1=>0(#UX(WBG#_4U&5>D/?E6WYT@FAOS$CK*OY491!N
MXQX&XZ;7]Z77XI=[<D;F34?Y23<(.;GZLY@3CI$^FH%VMFW?IJB'S78(=Y>/
MY4;[D*7W*JAN>R\(V?9^:Z>'00=X@/A#;-\^0U5Z$4RH<"'#A@X?0HQ(D%B5
M/Y,2 JHXD-B?@P1[=:2GD&,5D1(;&D1(D)%&AHW^,'I(;,N?1OOH;0$4TY#%
MCU4,$5364=G)HD4;Y5QH2*70*@-7PEQ8R"-$D%4RFMS7ZV?"CL-\ M5J):K#
MCBI[<?_YHY7KOID"":8T*G<NW;IV[^(M^O-/VJ<)A::U$G.ALKC[_O0L>JO*
MX*!6"@E6N+5QPZF],@[+N'8PL:DFS>8-_5<TZ=*F3Z-.K7HUZ]:NYY+L^&=J
MV+8_*]ZNIY2J0<H)&66LN$7ERXII!S,:>Y5ME:FRTZX-2]'04X-?7V//CI(J
M07I.P2:L]]/OOF$_B4*<"J@099[7X38G_]M0;</#QB[;*KTB>L/:2=NB7$<T
M9?);<']8L<4M"VT%"%$DR0>1=1,AZ%Q%*K&TH$,<*9=15(:])!V"66%'3T>-
ML<3;'V%Y!\A[!%UU45WZ_69%6!5=9%YB#EU5"'QJT=C64/#-O?B?D4<BF61=
M5Q6I9%T1.AFEE%-26:65I[%DD!4J*=2106HQ9)!-^S"RHD.3K/A=0ID 0M.8
M']&T16T9^9)3)AV5]UA0'3U5YIM7 @K1,* 1Y.%&A%I%8F8EV966C&2VU-!B
MC?%4Q4K\@126.S15QUV@$.F34TY5Z"899)8Q-(Q!(KD%I4.&+7;J8U;(R-.C
M# DUW%3W[435),U-1!-ZVG4F8$6-N5718Y9*Q1MC1IE76VRWP<67;&QU.6H5
MU ;I3E_5_OFIN..2RR>Y$/\->ZZZZ[+;KKOOQO>NO X5AUM.[P&W;4=<:)@0
M17\L8]M;11G&H85_<$FF(90N5Z$5^_RZGX/5WCJOQ11:02*Y!AD$B'ST+&LF
M0TS"EW!$:-:VCW@<3X0;Q]@F=-6=2U4$L<@4%5+=<!?SW#->\<[KJL]#$UVT
MT>L2>C2[H@+R1[I:T>8I08NR.I7085(5ZZR0W;I8?55D-EQ(W7):LM+MNA7P
MV>+NNK;;;Z_]--QSTUVWW1']U.3=>Y^&*M\\DZ3/WTY>=?7@AR/NFN&),]ZX
MXX]#KJXA@%0<N>6)^WVYYIM')#?GGX,>NNBC%R0UZ:>CGKKJXBZ^NNNOPQZ[
M[+.=TUZ[[?-Z?KONN_/>N^^_ Q^\Z*W''@, QR./O&ABB/$:,0#8=3P:":$1
M T%B &#]7=A+?SQ1V&M_?(%49@+]0\D#,'Y"QB=/C/':MW4\_.4#D+OP]^.?
MO_[[QPW\#>@G+S3':UYKT' \NQA/1L:[P?4 P$"[T$]\WML']AXH/BJ!SR$&
M!*#Y" ) 94SB@ 398 <SR+\3HC"%*ESAE?^(-SME7) TQB,@:T+80;R8T(#P
MHPO]'G2\4BDDAE+B7D.>E[TU#7 B1U0(# 'P%/8YD2 S9"$5JVC%*V*Q+O;3
M73UB^#_NU6\?4%3?/M#GP?9]D83QF^ (D4=#\8%Q(& $  WWH4."T&]\,S0
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M8NLYHA/RX")>X1(67>2Y81&NHBI:(2JRXBNV(BRZ8BK2XBW.8B[*XBX&H0_
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MYWFJYWJR9PJ-9WO6US)L0C3 9WU"9GK:9WT=P0Y 9W[ZIPO_ON=_<E4<\*>
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MOEQ\?FE" RC8@3(T_NX;?Q;5?MOK9C30G!%8X@880>\?__1SCO07Q>]O)BA
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M#:L(Y4KC(WP= S_\HY6%KG.93=1M'O[XEWQ,;<D_PKXASX'GRW.Q6H0P1G;
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M*(/'"(F!&/*"Z8-H6LA(#K6H1TWJ_D0WO_^-(*KK\UQRD>8!9VEI=W]24NJ
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M6WW ED+U9LNJ!(TH#TZ7('V-I!M[#CL^/1.J%?_F^*!LB0^^5 KT$U8>#L]
M+!M H$&)-QR ^UP<L.6NKF'&FET)NTF>?S7_4,LG-=$Z37$>([MC-;:FX@G,
MA<(PSM(X8ZG03.+)01IH![>?P[XZ6)6G\EN'OT];;@OLDRGW++IN)-@9K*'\
MFK:A:>0+Z7QT6OM@#D-'NAC8R>>TDH>..6>>[3;U;X58KM1^4'31)#:;9 FG
M+.,IS'2J# F0&.8D$Y"2),%1I"/)O<ZNSG<W-HMJ)Z6 JB,"_.;^!7C=6" <
M:#WS02/H0>8&F]FY%C8<.;B!$H@F+G0V*&&X*;Y/'8YO=2.1*BF.V4]6QHHA
MI:FPD3+ZM^F<S<64S=[-+6_5=HOIH3C^JS>+!S:=3V@J,Q8E!'*42(@E1<;N
M((:!1!+G5*N(XLR'<D(*-S:"6DL*MD0%7VIA/4_7@PZB&[&]U-#T3(,=1\6;
M ON +Q!A!A5M4'KM ]1],NZE#S_J+I;EY)/Y:-7OZH&KY81I>X&0IU!(9G=[
M"$&>2 JC.(DQCTFFF5/2AKUVQT:8GZTW1%%.A9F<ORMFKW+<KPOV,3M/<E<@
MT3,_G0 A($.=T/T<N9A7MHC%_&M#*ONM#<(')U1HI_*I7W<\'[<!?^^*PEAH
M;ZK-75-<K0H!K'YY]U@%';_]H99B6B@Y02A3A&8YS"),(4XR,V%QRF$2<Q3A
M+%,Z\HH+]A=A;'/;[-8>S#ZMBA,&TTH3L'JL=FZUQ/9@O/[MHE9E'4W<.8*X
MR\ ))2)!.20Z,0-'(P0IDQQFB!*1\U10*?SN<'L:ND&O<=>B#3H6CE<1O4Z-
MOLG^5(K$V^72\E?%_/QY)Y5BDQ0:W-IH+9O]NYDMK7XVX@C4( 2\H.B,<J@+
M"7\!AKV Z S0P85#]Y:N]G.IZTYMW3E_4.5$YHS%L9"0,Q5!S&4$>8ZH=9PG
M4:(S\VOL4\#@0G]>*]< =0N,2$"V/A<E^P%8)71G)Y:C&+MQ74#D>B:VHP7D
MC(B]>*&<PR*\U\G1WE[*R^2<ZF>\2LZ^UH.57-V-3$799,^HEB[3I=DZ+Y9:
M34NSR2DF,8YCI+FQO8@V/),@":DD-B^VU)KF"38&=3"CV46B/XT-O51U)15C
M0B_7>C7/K>8V)44_=IO3L 8PXT(/5N];> M\K0RHM6D,LC:ISPW8J%2G^VG-
M.;O:F&'<4FP@(\X'XR%L.B=YQF/B^<#G9?%Y-=R-NG>KS_R'FG[]9@,TGLQ/
MOZHW3;FF3V:?:>02]F:4HHS$69)#F:8"8I3ED,::06;=3U*%TCS5/DSM*\#8
MB+F5&+):9/#NU2?P$RO 8RVO)^=ZCX<;Q?:)<L^,>E#BJI4>-.*#5G[PJ0I2
M:U0(QYU=P0M$E=[=#\J,7<'9)\+.[70(,/^D'C:GZW?ZD^WK3O]1J,HVOIM7
M(OR^D%,]%758*9>,9E&$(<49AU@8UN-22I@R)I(DY4)'S#ELW+O[L7'>C@*5
MY6E5@ L-5\82K?;(-J%+;9@^;"GB$3+L/T;GF;!_Y'OFP5W0[S2HI(=W&AKY
MZWTVN)O7) E^'PITC^CK7L$?**8Z_"#XA4=WQO!LT+-_J\.%,G?6>"= N7LK
MG=,A":5D\9M1QH9 W\YE&^M\IS>Y-#8QTY.$\13S6$'S?YLAB2601L;")C%#
MD3*6=1QYA=%X2S"V1<8*7=C%Y:%[ZI'NP^%F5O<*<L_K22L[L!,.6.FKL)=U
MQ@>#_%;2E\^7D>^2<*D;>N%R,'GV/W1:IF[P',G4U+&ACI=*ZVCL.[U]L_E)
MS>R%]6L;J5$=<'![J=D6NEUG#,@8R0F)4Y@19FUME<$<91A&.9=9A"@F*?$J
M07&5.*.CQ>HZF.]>!V_=&'?-X7#EH#E>8@TV% ->WG<<!?];KR#@A;H4NTZ8
M8>_,@@!W<*46IM6.T4%23FUG;&;KN[^;OV:/TY+-ZENBZK!X8NQ(BI#((,=2
M01R9/W(6<4@2RA7&@L44>44(7>QR;%2YD1@\&I'A= Y$+;1GK-!EL-WH+RR$
M/5/<%GI66NM9U,AKJ_!4MY&5R $CAYSA"14]=+G#82.(G $XB")R?[/#>>G]
M]\7]M\6J8-8K_LG0F%+S=W.Y$M5B9W-2-([7,A9*9T)!F3(!,<UCR(5 ,,TY
MHRRC/%=.IIM7KV.CG3A"&=@(ZE&YV@]LA_/./B#LF79L0L%69K 6>A]/\*46
MW-'(]?R*W<\T^P!XH*-,"W39 EVL@9YN@'XTS_\2Z.#2%ZBSYY7.C0UW3.FK
MW\[II/?+'??E"_,UE%/QVEZE+9^;KSW),$>$Y1#E.H&8QQ12PV P2K(82:(B
ME"BO[?:Q7L;&T:V0M5/GRLP#>QKBN6,^"J?C1OA:D'IFX34^E0]GB\]EUO7?
MU)X#(M1>]6@?PVY!SZEYL+,\^W#73#*/S0[T3MMLK9,XSQ3EFMD2T,94DRJ'
MC& )F6)8*!Q+3:1?M,M^%TZ?\Z"Q+&L)[>'VJX_OP&SA:IJ=Q-%MOG?"9JA[
MY58TBXH5+F2BF.-J!TL2L]?\P EBCBMWF!SFQ',=/?;:JO&L^%8G0&U*HDZ$
MBK7 @D$140YQRCED68HAP3'A/$-("^TWI4_V-;ZY78GJZ6MW$DFW27T=.@-Y
MSUD902-D6UOYIT;.T[Z)_CYRE[ (Y0QWLI]AO=XNJ7O@WG;QA0[G,J:AI75<
M>*/J_[^;[WK1[;DY%!.4"4,"9KU'><IL+;88\L30A(JI3A*=1GGB%)O<J?>Q
M[0$VCJ6UH]JA$YM/B0OOL7 XOND3X9YYIQ4=M+(;[@%[KKRU\Y3UHEH[3_6*
MN,>Y3I_(#W2^LQZ!GV2CQ,_V#']Q^:L/=>;3%<2S9S_>C0YW!M15WYVSH,Z-
M=+,F/ZBR7HYL0<!)EF0IUTD*DRA%$$<B@DS&&4RQCHF(DIQ'PB?<=Z=U+_X?
M*+AW=JZ"G -@":529X)"C!(;MT@9Y-+^$458"\)BC:G/X5EWP 98,$, YF99
M=X:AYU7-(M#:T'7=TMNR7$[YJG:2*Q?@(PN;3?$H$H%LZ=VV![6?CZJU;S,?
M?Z@;S[U7ABW5^YI9"[&<5GD4JF3-DTRK2$O#>BK1UBK&'%+",JA($JN4Y!G.
MG6H".O0UMBE=BWK3AE9MB=OD//?T(CL'L]O4#P1>ST1P!6[>%." 2"!".-?3
MH/3@H/(^6;B\TM'7:EY.Y72V*J=/6SZR=9%U):U3K77_6I5-4?:W;&E+K=NJ
MZY7[U_OI7+TKU4,Q89R@2!N;*J&80)S+&.8Z32'66425SKCBB9='5B#!QD9*
MVWIM.9Z#5K/:8WU+-WMPW6IGPS_K2'OPQ6H(*A4]:2S8D+MQWDL,9,\$.>@8
M^GN:!08\E#]:*+&&]5H+#.:!;UOH]E]D&;A]L+>Y$Z8I0YI%D&.:0,PHAKG*
M$4PRD@F=Y&F2^'GEAI!JU N V,Y\H[:*]*@=*A%L)E:S-954KYO?S9L]JTW'
M4&?!Z9X/)\P7,,B2X#^N?X[UX ;4FHUF*=@%>ASK0"/3GVD1V(4Q\ JPUWC'
M'&<K7ACV,<SSUGKHV?3?MS^FQ82J!$<"(9AB*>T)(+65/QE,68Q%A%.AL%^Z
MW^/]C(VB-V*"2DY@!?5,+W8"43>"#(!3SY1W%"+PQ4H9LGS<>1Q"I>LZT<NP
M2;C.JWJ06NO"XR$29FV7Z&R<?-ZL-L6O!<-$YXF (B;8WA&DD)*<V*!6SA(1
MISGW(@>?SL?&&'N7OYZW"%ZPNS%(7V .=/1XD!>KU>#YQEY$<%6';?41B=H%
MN5Z285WH^@438;F!<CX)EF,;UUR('._P>;L[;<CA;XHM?S/&UX1(3+E,%,Q2
MBB!.\QCF(M(08R*8,'_ETBD/UE52C(W9[K^II6)6PBZ7);Y#X'.-TB.PHV*Y
M&U#!#ZPBP&H2^O:E(Y!![V5\97B!&YN.,!V_R^G:6#<^M)5]RV>[CUS,3?--
MN32!<Y$IP6",LPSB&*<PEYS"/$YTIN*$Q\JKS.;17L;&9[608"VE'ZL=!]*-
MM:Z&IV=6VD>FA]IQ9R$(Q"?'^QB4+\ZJN<\'YQ\.=I[3?*HZ$@GA5$+$$8=8
M1<;&45I ,]EUK#-*>.8UYT_V-+9YW\^9CA<!!,'J9<YU@C/!12SZ.]MY"4:X
MJ*[#^4X09JA]SN[9CT_*BFZ,CNI<^?4WF]WIW?R@E,:_L]FJ>N)V-EM\9T;9
M28QB'7%"(6$VIIK0"/(HHX9"<I%' B=)[)7"['J1QL8UM>C6(?VIE16P5E@_
MS@DP7F[D-.PH]&W*:*U$=1O7.+3:2&^;7QOL:G<#-D-UI+(/6"L)UEJ&OZ0+
MAWP@S@P@T*#D&@[ ?18.V'(WNOYCOC0]?YU/_ZOJI2V@WL91V"(:JYG=1E;W
MA'59];K(AGGZXZ*H\B85$\$(R3#)88KMR9:,&614F9T>(0CG/,IE[.6<%T:L
ML='V.JAH66>YLV<PHA8>/-O#%YM/XW&Y>)H65GP_(@\TDFYD/OSX]$SHVPI5
M!-VJ= /6H[96JG&W:$:NUJMZ::U9./(.BW0@ @\DU* D'A;(?2(/W'JX6XGB
M7OTH7\ULFD65$QE3KJ#B9E>.<Q)!QN($"IGI7*0\CJE3,72W[L9&OEWN32\
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MKW BYF=\M1I7+7["5>O.L';)YO;V8\]%ZY.RIT?FYWOWK/$D41K13&50L(1
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MUWS"E>8L80AJ8\9"S%!L5A0<0ZSC1$G"8N57TB"L>*-;2AKMK#OMMGY;>>U
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M<Q3E$&.LB6:<JBCUX:VN@HR-R\PGF7@6Q>DZ!&Y$-02P/9/7R9JK:SUN0+D
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M=XA:*U&5U=ZJ6&1CC,"N@E5F\HV*[=7YS?&XN^V,YK</BU7(@.V@(Q"N1%P
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M*\>21O0;H)IAD4#;8-0JF:9GJ@_G 7'CCK @#Y3BP^):Y?:P?WF[#?#1&-^
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MMC>]R$#_\^L;H,<N16W&TK1QO 4LH^;I3>K09RK]%6\JWXU4X\[[.U#[#RH
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M-BG<>02T2^!A6?WZX293Y*#C.>)4C23M.<:4N2E_>L*X50RT[QCCZ8-Z0N-
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M)-H#NG?/G!/N_"O."FG#,<=S"5\3:GF$,>8DC73:T9B8ID]W8.=5,4=-O^[
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M[+[641=AM7R6J\V+.8[<Z$#K[?^WS9]-X/U1;F8(I0R'7$(N0PD1BQ',,I'
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M<SG7EYGKE?P7O7:?91%/:))$4*DD@RC.(KWF"QF,"$N)_CT5;E5J(]@\M7=
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M2L LP10*BM-$",1BXK0YWS+6U%BMN?=Q5P7<@.[,[1Z&M^%M1VV>4!R8P2H
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M:CH3$6:13$,8D\ D'F6F<T<20Y4E64)(*BAURB XN/HTLP=JA5U:F.JXEW4
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MRWNNV6TEC\?8CVYLF64T(%FFEWE93!%$*F"FDXJ" E.F:!;')+4,%#M:,+W
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M==H4ODZF\USWV\:.2'^)FV%@KO;9N:YQ3[UMW%/_+.ZIGJT-1V]PUWMR)](
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MDT[7C?R8VA[-+B=N%_Q\D4\T+Y9/9C/,V+RE<_ @5T]%!/TBZ<HU&>Y6]\S
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M)$ 094Q!IB,U2$6$$\;#@,=.1S*MHTV/YBIC =/6.HJ8M.-J1U_>T!J8J/9
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M*[27CZ'\-N/UL.K+-[K]]WJW$N\>]5NR?:.4-*T;@:9/1D>12"RE3"D@22H
MAFFJ1P&9@%A1EC ETU0Y<7\_,^9&\1>/ NZ"I0I:?_O3^!3(QAV],LUW=%5>
MLK$6NAS8A8..#SQVS*U.%X*M]B$HG0@J+X*]&^47/WE5 AX&Y+@G%%U&S.$
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MCTB%+$X9 W'".< B92#-< ((0HF4$')!K$YR.UN:V]M;IT>9@>[8W"Z1#4>
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M%-,_J,^F4MFW]4I?7%0!F/LWA:0H52A.@< F9S2",<@2F@'&!85QFI"$.16
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MKB-2& K<Z!7 V_7F75'LJ$;@H]P857_Z(+_FNGFS(%L@B42LD%'))D9^B5#
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MQ*!-S.FX\.&AU??#1O=WD U$VP5$7L[ITT@<TR_X+*S#!5L3H7C164B*AYP
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M*!TIMDXU99XV#\7!027>^DC<@ZRQ;[(&QEEKQ?2%M>_.^22$#8Y'8*&RHJ(
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MZ;_.ITM\\B5,9S7>>K%8UD?UZWX:SS"2-(/1UNH:==7&+49$<H4] ^L0"YT
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M_?H/B>HRP#X%YHY746>8N]Y$VRZ ?\Q)=R_I"W.288W)[J_+W,X%X%FAT#:
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M%F9K;W(;V:X;ZSVYL]X];]&U-4L1#.N(" LJ"P5!$/I$*MDX532+K3N</(K
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M:UC>?+ZH?WFY">;)&=U4OESL*QTR,\4HD-GD>O&8(%I)IEMQKI Y'V1KO^P
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M *#WYP1_HO_E/"W.<&)S\%G6 (37 *0P#E$+LIJ6*9&$\?GNR-ZC@7.;@OT
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MH[;E3VYAP_8AHI')^HZT7TNM#M#%N/KF^OI=18#O/Q&> U[E=/LN\PZ5K,A
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M)U:95AM$3HG.SU31H+Q5X#,Y!&BLT[:0B>>MNP]>.-+I%#UV@L+V8?;.<ND
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MW)!H7,RU$%(S5_"@452KS^[#113)H*:[PZ-61"K]*D2.(!469LCUE;SUC7S
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MJ>EJ%R'0K1X8<&T#XT+'(-16U]E.G^WCGCL,-@,SNP,C]'0D<6-/7=*J").
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MY*UV$&+$5I8]S&*BSC4T9\#.=RZV"C\;WB\D^VH)H5'D3\NK?:'7 Q"=OAJ
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M7I0S<44S\1@%V $%>?YJ%.0CP[ OUI'$UMW9_LD^,W-16/+TAC^A0JADCJR
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MM45P!.1'I]L8F=.@BYBF:(:M5%,QG''(=5P(!NF%20_6A2U?D.MQE9<_AJ>
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M)D<J@^$H.D$'KE@I63 Q#>0W*.#OKPZ.SG 3 P'3 \0!:>/K<8]P%]C3Q.Z
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M;P]&^1J>YY>2=!Z8?[P:^^'.R.  WE7*1Y/T_<SWTA'\7?[;J\*#J?F:[NC
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M$$H,7YO&W'8<08<E@^4 "15&$*#Q4;LH!!V&Z&Z"?T"$C!,=SZVDN&A'Q6,
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M84".>FA\0$YV6/#Q,Y"J:C?A ^P._N88 76-VYJ1W 9GI=\.R;^Y?*K90BJ
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M)_X0^XG$'""D+**3QVS[$?<R*;;.UQT1F@.H_AR%X(<W!HAEB+HI NJ0&RK
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M6&MRB;4E*8T #"0'E5<@5+F[Q=U/25QZ,@F<VWQARKGHB]L3_=B7Q"L EX)
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MW5-HAHP3,E[.8%/1VJWD>"_87,FJF ];+-#DEC.8<C 72?/:_HQ8!(7D0A?
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M*<B]P[YVKDV4SXU>3(&^EUG!$W].0\>O&$B(@ORE*'O^!,-ZY"(S[#( -5#
M%XAD-F,^$7DLGS%?DGB)I(>^-HG_6?:3Y8BXE+,+8VD#C'V@(@/P5>R E@:V
M.#KGY5ORRQ\\%V>4/_!Y?"+@BM9UFJXX"\M[[1GF=UGPLI95\1.!3'8A4?2]
MQ$X!WX[(ELRD21>33I>>!DKPQVZ=:#]PB5=@$ZQ:Z>6%+N5Y[_<OVN["<?B[
MG!0)=X&[ T;:%X$.+[%H&M/&9BZ\@C"U#,%40#XHH0-B)/'7R\;U^C:+EL
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MO3_0E:.>Z54J^_L'55/1Y?^I5-Z^LF_]%3P9BMY\0919%Z+,<A#'[56?UG0
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MFI$.Q;%UQ'ZM0I&MUG'-95(2/@[F.&!)>@;O"^:V9$=B05$LXD_6H87!^DJ
M?'VSB$3%KAEH9N1/&*V/QU_"7&C[IZW\P>)9AN,G4(9\[R<6DI'38KE4 M<%
M]Z2Z51%QQ;8B0X39+A^J%_?=*O?=B[/MQ=GVXFQ[<;9]ZSJ].-M>G&T_U=EV
M\/C.MM>]R)O#/Z-T''S\_U!+ P04    " !U@7Y6_Y+T*!T#  "K#P  &
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M%SQ3E(D^".V%H*K, V5$,&<FY.;-7O?P>.N%DG+?QS16BR P_6ZG7#HB\7&
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M12:-Z*(K$CN,[72ZZ3;>&YAAL0)^D_]*:Z'OFO,K!6_>5$^\$[Q58!3\9\7
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " !U@7Y6N1#GQ7,W   *8@( %0
M        @ $S30, 861V;2TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @
M=8%^5G86,OP<#0$ (0T! !0              ( !V80# &%D=FTM,C R,C$R
M,S%?9S$N9VEF4$L! A0#%     @ =8%^5OE?FOES,P( :3," !0
M     ( !)Y($ &%D=FTM,C R,C$R,S%?9S(N9VEF4$L! A0#%     @ =8%^
M5FM9]51_=@$ @78! !0              ( !S,4& &%D=FTM,C R,C$R,S%?
M9S,N9VEF4$L! A0#%     @ =8%^5E\$3:4!( $ $R ! !0
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M+FAT;5!+ 0(4 Q0    ( '6!?E9NX<)7'A8  )^^   9              "
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M;2TR,#(R,3(S,7AE>'@R,S$N:'1M4$L! A0#%     @ =8%^5AV&>'Q_"
M\2H  !@              ( !4XT. &%D=FTM,C R,C$R,S%X97AX,S$Q+FAT
M;5!+ 0(4 Q0    ( '6!?E8D2%4FB0@   LK   8              "  0B6
M#@!A9'9M+3(P,C(Q,C,Q>&5X>#,Q,BYH=&U02P$"% ,4    " !U@7Y6RGKY
M?>,$  #:$@  &               @ ''G@X 861V;2TR,#(R,3(S,7AE>'@S
M,C$N:'1M4$L! A0#%     @ =8%^5A39:.;6!   H1$  !@
M ( !X*,. &%D=FTM,C R,C$R,S%X97AX,S(R+FAT;5!+!08     %0 5 )0%
(  #LJ X    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
